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“I	  have	  walked	  that	  long	  road	  to	  freedom.	  I	  have	  tried	  not	  to	  falter;	  I	  
have	  made	  missteps	  along	  the	  way.	  But	  I	  have	  discovered	  the	  secret	  that	  
after	  climbing	  a	  great	  hill,	  one	  only	  finds	  that	  there	  are	  many	  more	  hills	  
to	  climb.	  I	  have	  taken	  a	  moment	  here	  to	  rest,	  to	  steal	  a	  view	  of	  the	  
glorious	  vista	  that	  surrounds	  me,	  to	  look	  back	  on	  the	  distance	  I	  have	  
come.	  But	  I	  can	  rest	  only	  for	  a	  moment,	  for	  with	  freedom	  come	  
responsibilities,	  and	  I	  dare	  not	  linger,	  for	  my	  long	  walk	  is	  not	  yet	  ended.”	  
	  
	  
Nelson	  Rolihlahla	  Mandela	  (1918	  –	  2013)	  
Long	  Walk	  to	  Freedom	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ABSTRACT	  	  
Despite	  widespread	  roll	  out	  of	  anti-­‐retroviral	  therapy	  (ART),	  cryptococcal	  meningitis	  
(CM)	   remains	   a	   significant	   cause	   of	   morbidity	   and	   mortality	   among	   HIV-­‐infected	  
persons	  in	  sub-­‐Saharan	  Africa.	  Host	  immune	  response	  is	  central	  to	  the	  pathogenesis,	  
and	   not	   only	   influences	   susceptibility	   to	   infection,	   but	   clinical	   presentation	   and	  
outcome.	  Animal	  studies	  suggest	  that	  macrophage	  activation	  is	  a	  crucial	  component	  
of	   the	   host	   immune	   response	   but	   human	   studies	   are	   limited.	   This	   thesis	   aims	   to	  
characterize	   the	   activation	   state	   of	   CSF	   macrophages	   and	   blood	   monocytes	   in	  
persons	  with	  HIV-­‐associated	  CM,	  assess	  the	  effect	  of	  ART	  on	  the	  immune	  response,	  
and	  identify	  immune	  correlates	  of	  severe	  disease	  and	  poor	  outcome.	  	  
A	   prospective	   cohort	   study	   was	   conducted	   in	   Cape	   Town,	   South	   Africa	   (Innate	  
Immunity	   in	   Cryptococcal	   Disease	   (IICD)).	   Persons	   with	   HIV-­‐associated	   CM	   were	  
enrolled	  and	  the	  immune	  response	  in	  CSF	  and	  blood	  examined	  using	  flow	  cytometry	  
and	   cytokine	   analysis.	   Soluble	  markers	   of	  macrophage	   activation	   (sCD14,	   sCD163)	  
and	   the	   ex	   vivo	   responses	   of	   whole	   blood	   and	   monocytes	   to	   TLR	   ligands	   and	  
cryptococcal	   preparations	  were	   also	  measured.	  Additional	   CSF	   and	   serum	   samples	  
were	  obtained	  from	  the	  Cryptococcal	  Optimal	  ART	  timing	  (COAT)	  trial	  (South	  Africa	  
and	   Uganda)	   to	   examine	   the	   immune	   consequences	   of	   earlier	   ART	   initiation	   in	  
cryptococcal	   meningitis.	   In	   this	   trial,	   earlier	   ART	   was	   associated	   with	   increased	  
mortality	  in	  CM	  compared	  with	  a	  deferred	  ART	  strategy	  (8	  days	  vs.	  5	  weeks	  post	  CM	  
diagnosis	  respectively).	  
CSF	  flow	  cytometry	  showed	  that	  CD8	  T	  cells	  were	  the	  most	  common	  cells	  in	  the	  CSF	  
followed	  by	  neutrophils	   and	  CD4	  T	   cells.	   Both	  CD14+	  and	  CD14-­‐	  CSF	  macrophages	  
were	  identified	  and	  expressed	  a	  range	  of	  surface	  markers	  associated	  with	  different	  
activation	  states.	  Cryptococci	  were	  identified	  using	  flow	  cytometry	  as	  CD45	  negative	  
cells;	   cryptococcal	   counts	   using	   flow	   cytometry	   showed	   a	   very	   strong	   correlation	  
with	  quantitative	  culture.	  There	  was	  no	  suggestion	  that	  raised	  intracranial	  pressure	  
occurred	   as	   a	   result	   of	   a	   pro-­‐inflammatory	   response;	   instead,	   persons	   with	   high	  
intracranial	   pressure	   had	   a	   greater	   CSF	   fungal	   burden,	   a	   significantly	   reduced	   CSF	  
cellular	  infiltrate	  (particularly	  CD4	  T	  cells,	  CD8	  T	  cells	  and	  double	  negative	  T	  cells)	  and	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larger	   cryptococcal	   cells.	   Contrary	   to	   animal	   studies,	   there	   was	   no	   association	  
between	  macrophage	  activation	  and	  fungal	  burden.	  
ART	  appeared	   to	  have	  a	  more	  profound	  effect	  on	   the	   immune	   response	  at	   site	  of	  
disease	  (CSF)	  compared	  to	  the	  blood.	  In	  the	  IICD	  study,	  ART	  was	  associated	  with	  an	  
increased	  frequency	  of	  CD4	  T	  cells	  and	  decreased	  frequency	  of	  CD8	  T	  cells	  in	  the	  CSF,	  
along	  with	  increased	  expression	  of	  CD206	  and	  CD16	  on	  the	  surface	  of	  CSF	  monocyte-­‐	  
macrophages,	  suggesting	  an	  alternatively	  activated	  (M2)	  phenotype.	  These	  changes	  
were	  closely	  related	  to	  plasma	  HIV	  viral	  load,	  even	  in	  subjects	  not	  taking	  ART.	  
In	  the	  COAT	  trial,	  participants	  who	  received	  earlier	  ART	  initiation	  were	  more	  likely	  to	  
have	  a	  CSF	  cellular	  infiltrate	  by	  day	  14	  compared	  to	  those	  in	  the	  deferred	  ART	  arm	  (8	  
days	   vs.	   5	   weeks	   post	   CM	   diagnosis	   respectively).	   This	   primarily	   occurred	   among	  
persons	   with	   an	   initial	   paucity	   of	   CSF	   cellular	   response,	   the	   same	   sub-­‐group	  
identified	   in	   the	   COAT	   trial	   to	   be	   at	   highest	   risk	   of	   mortality	   following	   early	   ART	  
initiation,	  and	  the	  same	  group	  previous	  shown	  in	  cohort	  studies	  to	  be	  at	   increased	  
risk	  of	  IRIS.	  Furthermore,	  participants	  in	  the	  Kampala	  earlier	  ART	  arm	  had	  increased	  
sCD14	   and	   sCD163	   concentrations	   in	   their	   CSF	   at	   day	   14	   suggesting	   increased	  
macrophage	   activation	   in	   the	   central	   nervous	   system	   (CNS).	   These	   findings	   are	  
supportive	  of	  the	  hypothesis	  that	  the	  increased	  mortality	  associated	  with	  earlier	  ART	  
initiation	  in	  the	  COAT	  trial	  was	  immunologically	  driven.	  	  
Finally,	   immune	   correlates	   of	   fatal	   outcome	  were	   examined.	   Persons	  who	  died	   by	  
week	  12	  in	  the	  IICD	  study	  were	  noted	  to	  have	  a	  lower	  proportion	  of	  double	  negative	  
T	  cells	  and	   lower	  concentrations	  of	   IFN-­‐γ	   in	  the	  CSF	  at	  baseline.	  Non-­‐survivors	  also	  
had	  evidence	  of	  increased	  immune	  activation	  in	  the	  blood,	  elevated	  IL-­‐10,	  decreased	  
monocyte	   HLA-­‐DR	   expression,	   impaired	   monocyte	   TNF-­‐α	   response	   to	   LPS,	   and	  
decreased	  IFN-­‐γ	  responses	  to	  LPS	  in	  whole	  blood.	  These	  features	  are	  consistent	  with	  
those	   of	   monocyte	   anergy	   and	   the	   compensatory	   anti-­‐inflammatory	   response	  
syndrome.	  The	  cause	  for	  this	  immune	  signature	  among	  persons	  with	  HIV-­‐associated	  
cryptococcal	  meningitis	  was	  not	  clear	  and	  warrants	   further	  study;	   the	  downstream	  
effects	   of	   HIV-­‐1	   induced	   immune	   activation	   or	   the	   immune	  modulatory	   effects	   of	  
cryptococcal	  capsule	  are	  both	  possibilities.	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CHAPTER	  1: REVIEW	  OF	  THE	  LITERATURE	  
This	  chapter	  reviews	  the	  current	  literature	  regarding	  HIV-­‐associated	  cryptococcosis.	  	  
The	   epidemiology	   and	   pathogenesis	   of	   HIV	   infection	   and	   of	   HIV-­‐associated	  
cryptococcosis	   are	   discussed	   with	   reference	   to	   disease	   in	   sub-­‐Saharan	   Africa.	   A	  
comprehensive	   review	   of	   the	   current	   available	   literature	   regarding	   protective	  
immunity	   is	   presented	  with	   particular	  mention	  made	   of	   CD4	   T	   cells,	  macrophages	  
and	   monocytes.	   The	   limited	   literature	   regarding	   immune	   correlates	   of	   clinical	  
outcome	   in	   humans	   is	   also	   detailed	   along	   with	   the	   epidemiology	   and	  
pathophysiology	   of	   immune	   reconstitution	   inflammatory	   syndrome	   and	   the	  
evidence	  surrounding	  optimal	  timing	  of	  anti-­‐retroviral	  therapy	  (ART)	  initiation.	  	  
	  
2	  	  
1.1 HIV-­‐1	  infection	  	  
1.1.1 Epidemiology	  
In	   1981,	   the	   Centers	   for	   Disease	   Control	   (CDC)	   received	   a	   series	   of	   reports	   of	  
pneumocystis	  pneumonia	  (PCP)	  and	  Kaposi’s	  sarcoma	  (KS)	  among	  homosexual	  men	  
in	   California	   and	  New	   York	   (CDC	   1981b;	   CDC	   1981a).	   By	   the	   following	   year,	  more	  
than	   500	   similar	   reports	   had	   been	   received,	   detailing	   a	   variety	   of	   other	   unusual	  
opportunistic	   infections	   (including	   cryptococcal	   meningitis)	   related	   to	   a	   profound	  
depletion	  in	  CD4	  T	  lymphocytes	  (CDC	  1981a;	  CDC	  1982).	  In	  1983,	  groups	  from	  France	  
and	  the	  USA	  isolated	  a	  retrovirus	  from	  a	  patient	  with	  AIDS,	  later	  to	  be	  named	  Human	  
Immunodeficiency	  Virus-­‐1	  (HIV-­‐1)	  (Barre-­‐Sinoussi	  et	  al.	  1983;	  Gallo	  et	  al.	  1983).	  
	  
Over	  the	  three	  decades	  since	  then,	  the	  WHO	  estimates	  that	  almost	  75	  million	  people	  
have	   been	   infected	   with	   HIV,	   and	   approximately	   36	   million	   have	   died	   of	   AIDS	  
(http://www.who.int/gho/hiv/en/	   -­‐	   16/10/14).	   The	   vast	   burden	   of	   disease	   and	  
associated	  mortality	  remains	  in	  sub-­‐Saharan	  Africa	  [Figure	  1.1]	  (UNAIDS	  2013).	  	  
	  
	  
Figure	  1.1	  	  Estimated	  numbers	  of	  people	  living	  with	  HIV	  (2012)	  (UNAIDS	  2013)	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South	   Africa	   has	   the	   largest	   number	   of	   people	   infected	   with	   HIV	   worldwide:	   6.4	  
million	  people	  are	  estimated	  to	  be	  infected	  (12.2%	  of	  the	  population)	  and	  antenatal	  
seroprevalence	   is	  29.5%	  (HSRC	  2014;	  SADoH	  2013a).	  KwaZulu-­‐Natal	   is	  the	  province	  
with	  the	  highest	  prevalence	  (16.9%)	  and	  the	  lowest	  is	  the	  Western	  Cape	  (5%)	  (HSRC	  
2014).	   Overall	   prevalence	   has	   remained	   relatively	   static	   in	   the	   last	   12	   years;	  
however,	  a	  significant	  reduction	  in	  prevalence	  has	  occurred	  in	  children	  (5.6%	  in	  2002	  
to	  2.4%	  in	  2012)	  (HSRC	  2014).	  
1.1.2 Origins	  and	  evolution	  	  
HIV-­‐1	   and	   HIV-­‐2	   are	   both	   lentiviruses	   of	   the	   Retroviridae	   family;	   phylogenetic	  
analyses	   suggest	   they	  evolved	   separately	   from	  strains	  of	   Simian	   Immunodeficiency	  
Virus,	   found	   in	   a	   variety	   of	   old	  world	  monkeys	   (Fanales-­‐Belasio	   et	   al.	   2010).	   Both	  
viruses	  appear	  to	  have	  crossed	  species	  in	  the	  early	  20th	  century,	  possibly	  through	  the	  
practice	   of	   hunting	   for	   bush	   meat.	   While	   HIV-­‐2	   has	   remained	   geographically	  
restricted	   to	  west	  Africa,	  HIV-­‐1	  group	  M	  has	   spread	  globally	   (Sharp	  &	  Hahn	  2011).	  
HIV-­‐1	  group	  M	  is	  further	  divided	  into	  different	  subtypes	  (or	  clades)	  which	  reflect	  its	  
spread	  to	  different	  geographical	  locations:	  subtypes	  A	  and	  D	  (west	  and	  east	  Africa);	  
subtype	   C	   (southern	   Africa	   and	   Asia);	   subtype-­‐B	   (Haiti,	   USA,	   South	   America	   and	  
Europe)	  (Sharp	  &	  Hahn	  2011).	  
1.1.3 Viral	  replication	  and	  pathogenesis	  
HIV-­‐1	   infects	   cells	   expressing	   the	  CD4	   surface	   receptor	   (CD4	  T	   cells,	  macrophages,	  
microglial	   cells,	   monocytes	   and	   dendritic	   cells),	   which	   it	   binds	   using	   its	   envelope	  
glycoprotein	   gp120	   [Figure	   1.2].	   Following	   a	   further	   interaction	   with	   cell	   surface	  
chemokine	   receptors	   (CCR5	  or	  CXCR4),	  membrane	   fusion	  occurs	  and	   the	  viral	   core	  
un-­‐coats	  releasing	  RNA	  into	  the	  cytoplasm	  (Stevenson	  2003).	  Viral	  RNA	  is	  converted	  
into	  pro-­‐viral	  DNA	  by	  the	  action	  of	  reverse	  transcriptase	  and	  integrated	  into	  the	  host	  
cell	  DNA	  by	  the	  integrase	  enzyme	  (Fanales-­‐Belasio	  et	  al.	  2010).	  The	  HIV	  provirus	  then	  
uses	  cellular	  machinery	  to	  transcribe	  messenger	  RNA	  and	  synthesize	  viral	  proteins;	  
the	  viral	  particle	   is	  assembled	   inside	  the	  cell	   (a	  process	  which	  requires	  the	  enzyme	  
HIV-­‐protease)	   and	   the	   infectious	   virus	   is	   released	   by	   budding	   from	   the	   cell	  
membrane	  (Fanales-­‐Belasio	  et	  al.	  2010).	  Once	  integrated	  into	  the	  host	  DNA	  the	  fate	  
of	  the	  HIV	  provirus	  is	  dependent	  on	  that	  of	  the	  cell.	  In	  an	  activated	  T	  cell,	  replication	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is	   rapid;	   many	   viral	   particles	   are	   produced	   with	   an	   ultimately	   cytopathic	   effect.	  
However,	  if	  the	  cell	  is	  metabolically	  quiescent,	  the	  HIV	  provirus	  will	  persist	  in	  a	  latent	  
state	  providing	  HIV-­‐1	  with	  a	  long-­‐term	  reservoir	  of	  infection.	  
	  
	  
Figure	  1.2	  	  Life	  cycle	  of	  HIV	  and	  site	  of	  action	  of	  anti-­‐retroviral	  therapy	  (L.	  Chen	  et	  al.	  2007)	  
Although	  HIV-­‐1	  does	  have	  direct	  cytopathic	  effects	  on	  infected	  CD4	  T	  cells	  (especially	  
activated	   cells),	   this	   does	   not	   account	   for	   the	   total	   CD4	   T	   cell	   depletion	   as	   the	  
majority	   of	   cells	   that	   die	   are	   not	   infected	   (Moanna	   et	   al.	   2005).	   This	   “bystander	  
death"	   effect	   appears	   to	   be	   driven	   by	   a	   state	   of	   chronic	   immune	   activation,	   the	  
cause,	   or	   causes	   of	   which,	   are	   not	   fully	   understood.	   Current	   theories	   include	   the	  
persistent	   anti-­‐viral	   response	   against	   HIV-­‐1	   infection,	   a	   direct	   effect	   of	   HIV-­‐1	   viral	  
proteins,	   the	   intracellular	   accumulation	  of	   RNA	   in	   abortively	   infected	  CD4	   cells,	   or	  
translocation	   of	  microbial	   products	   through	   the	   gut	   wall	   resulting	   in	   activation	   of	  
monocytes	   and	   production	   of	   pro-­‐inflammatory	   cytokines	   (Cadogan	   &	   Dalgleish	  




1.1.4 Anti-­‐retroviral	  therapy	  (ART)	  
The	  first	  anti-­‐HIV	  drug,	  zidovudine	  (AZT),	  was	  introduced	  in	  1987.	  Although	  effective,	  
it	  was	  associated	  with	  significant	  toxicity	  and	  resistance	  quickly	  developed	  (Fischl	  et	  
al.	   1987;	   Richman	   et	   al.	   1987).	   Over	   the	   next	   decade	   a	   number	   of	   other	   anti-­‐HIV	  
drugs	  were	  developed	  but	  suffered	  similar	  problems.	  However,	   the	   introduction	  of	  
combination	   anti-­‐retroviral	   therapy	   (ART)	   in	   1996	   revolutionized	   the	   treatment	   of	  
HIV	  infection.	  This	  resulted	  in	  a	  sustained	  suppression	  of	  viral	  load,	  improvement	  in	  
CD4	   count,	   reductions	   in	   opportunistic	   infections,	   and	   improved	   life	   expectancy	  
(Palella	  et	  al.	  1998;	  Hogg	  et	  al.	  1997).	  By	  using	  a	  combination	  of	  anti-­‐viral	  agents,	  the	  
risk	   of	   viral	   mutation	   was	   significantly	   reduced	   and	   lower	   doses	   could	   be	   used,	  
reducing	  side	  effects	   (Gulick	  et	  al.	  1997).	  There	  are	  now	  6	  classes	  of	  anti-­‐retroviral	  
drugs	   targeting	   a	   variety	   of	   steps	   in	   the	   viral	   lifecycle:	   fusion	   inhibitors,	   CCR5	  
inhibitors,	   reverse	   transcriptase	   inhibitors	   (nucleoside	   and	   non-­‐nucleoside),	  
integrase	  strand	  transfer	  inhibitors	  and	  protease	  inhibitors	  [Figure	  1.2]	  (L.	  Chen	  et	  al.	  
2007).	  	  
	  
The	  massive	  global	  burden	  of	  HIV	  infection	  has	  prompted	  an	  unprecedented	  public	  
health	  campaign,	  the	  main	  component	  of	  which	  has	  been	  the	  widespread	  rollout	  of	  
anti-­‐retroviral	  therapy	  (ART).	  There	  are	  now	  9.7	  million	  people	  worldwide	  from	  low-­‐	  
and	  middle-­‐income	  countries	  who	  are	  receiving	  ART,	  7.5	  million	  of	  whom	  are	  in	  sub-­‐
Saharan	  Africa	  (WHO	  et	  al.	  2013).	  In	  the	  22	  high	  burden	  countries	  prioritized	  in	  the	  
global	  plan,	  it	  is	  estimated	  that	  63%	  of	  those	  eligible	  are	  receiving	  ART,	  up	  from	  54%	  
in	   2011	   (eligibility	   determined	   according	   to	  WHO	  2010	   guidelines)	   (UNAIDS	  2013).	  
Large-­‐scale	  rollout	  of	  ART	  appears	  to	  be	  having	  an	  effect.	  In	  the	  latest	  global	  report	  
(2012	  data)	   there	  had	  been	  a	  33%	  decline	   in	  new	   infections	  worldwide	  since	  2001	  
(to	   2.3	   million/year),	   and	   a	   30%	   decline	   in	   AIDS	   related	   deaths	   since	   2005	   (1.6	  
million)	   (UNAIDS	  2013).	   South	  Africa	  has	   the	   largest	  ART	  programme	   in	   the	  world,	  
UNAIDS	  estimates	  that	  coverage	  in	  2012	  reached	  80%	  of	  those	  eligible	  according	  to	  
2010	   guidelines	   (UNAIDS	   2013).	   However,	   many	   patients	   still	   present	   to	   hospital	  
with	   advanced	   HIV	   and	   a	   variety	   of	   opportunistic	   infections,	   amongst	   which	  
cryptococcal	  meningitis	  is	  one	  of	  the	  most	  frequent	  (Jarvis,	  Boulle,	  et	  al.	  2009a).	  
6	  	  
1.2 Cryptococci	  	  
1.2.1 Classification	  	  
Cryptococci	  are	  a	   family	  of	   saprophytic	  yeasts.	  There	  are	  at	   least	  70	  species	   in	   the	  
genus	   Cryptococcus,	   but	   only	   Cryptococcus	   neoformans	   and	   Cryptococcus	   gattii	  
produce	   disease	   in	   humans	   (Kwon-­‐Chung,	   et	   al.	   2010;	   Mitchell,	   et	   al.	   2010).	  
Previously,	  these	  two	  organisms	  were	  considered	  varieties	  of	  the	  same	  species	  but	  
were	  reclassified	  recently	  based	  on	  differences	  during	  molecular	  typing	  (Boekhout	  et	  
al.	   1997).	   These	  medically	   relevant	   cryptococci	   are	   further	   classified	  depending	  on	  
serotype	   (surface	   capsule)	   and	  gene	  analysis	   [Table	   1.1]	   (Franzot	  et	   al.	   1999).	   The	  
vast	  majority	  of	   cases	  of	   cryptococcal	  meningitis	   (CM)	  worldwide	  are	   caused	  by	  C.	  
neoformans	  var.	  grubii	  and	  are	  associated	  with	  HIV-­‐infection.	  	  
	  
	  
Serotype	   Current	  Classification	   Previous	  Classification	   MLST1	  
A	  
Cryptococcus	  neoformans	  	  
var.	  grubii	  





B	   C.	  gattii	   C.	  neoformans	  var.	  gattii	  
VGI	  
VGII	  
C	   C.	  gattii	   C.	  neoformans	  var.	  gattii	  
VGIII	  
VGIV	  
D	   C.	  neoformans	  var.	  neoformans	  
C.	  neoformans	  	  
var.	  neoformans	  
VNIV	  
AD	   C.neoformans	  AD	  hybrid	   	   VNIII	  
Table	   1.1	   	   Classification	   of	   medically	   important	   Cryptococci	   (Pukkila-­‐Worley	   &	   Mylonakis	   2008).	  
1.	  Multi-­‐locus	  sequence	  typing.	  A	  genetic	  typing	  technique	  that	  differentiates	  strains	  according	  to	  12	  
unlinked	  polymorphic	  loci	  (Litvintseva	  et	  al.	  2005)	  
1.2.2 Biology	  	  
Cryptococcus	   neoformans	   has	   a	   global	   distribution	   and	   is	   found	   widely	   in	   the	  
environment,	  particularly	   in	  soil	  and	  pigeon	  excreta	  (Emmons	  1951;	  Emmons	  1955;	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Hajjeh	   et	   al.	   1995;	   Granados	  &	   Castaneda	   2005;	   Agha	   Kuchak	   Afshari	   et	   al.	   2012;	  
Soltani	   et	   al.	   2012).	   It	   has	   also	   been	   found	   in	   the	   excreta	   from	  other	   bird	   species	  
(including	  domestic	  chickens),	  and	  decaying	  wood	  (Irokanulo	  et	  al.	  1997;	  Litvintseva	  
et	   al.	   2005;	   Randhawa	   et	   al.	   2011).	   Reproduction	   occurs	   asexually	   as	   a	   budding	  
yeast,	  and	  sexually,	  through	  the	  formation	  of	  hyphae	  and	  basidiospores	  (which	  may	  
play	  a	  role	  as	  an	  infectious	  particle)	  (Perfect,	  et	  al.	  2010b;	  Nielsen,	  et	  al.	  2010).	  It	  is	  
characterized	  by	  a	  thick	  polysaccharide	  capsule,	  consisting	  of	  glucuronoxylomannan	  
(GXM),	  galactoxylomananan	  (GalXM)	  and	  mannoprotein	  (MP)	  (Heitman	  et	  al.	  2010).	  
Although	   the	   cryptococcal	   capsule	   probably	   evolved	   to	   protect	   the	  organism	   from	  
environmental	   insults	   and	   ingestion	   by	   soil-­‐living	   amoebae,	   it	   serves	   as	   a	   major	  
virulence	   factor,	  allowing	  cryptococci	   to	   resist	  phagocytosis	  and	   intracellular	  killing	  
by	   human	  macrophages	   (T.	   G.	   T.	  Mitchell	   &	   Perfect	   1995;	   Casadevall	   et	   al.	   2003;	  
Steenbergen	   &	   Casadevall	   2003).	   The	   production	   of	   melanin	   is	   another	   major	  
virulence	   factor	  protecting	   the	  yeast	  against	   the	  effects	  of	   reactive	  oxygen	  species	  
(Hogan	  et	  al.	  1996).	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1.3 Epidemiology	  of	  cryptococcosis	  
1.3.1 Cryptococcus	  neoformans	  	  
Although	  first	  described	  in	  1894,	  prior	  to	  the	  HIV	  pandemic	  cryptococcosis	  was	  rare	  
(Hajjeh	   et	   al.	   1995).	   About	   half	   the	   cases	   were	   associated	   with	   a	   predisposing	  
condition,	   the	   most	   common	   being	   Hodgkin’s	   disease	   and	   other	   haematological	  
malignancies,	   diabetes	   mellitus	   and	   corticosteroid	   use	   (Littman	   &	   Walter	   1968;	  
Collins	   et	   al.	   1951).	   In	   the	   early	   1980s,	   the	   incidence	   of	   cryptococcosis	   rose	  
dramatically	  as	  cases	  were	  seen	   in	   individuals	  suffering	  from	  AIDS.	  About	  5-­‐10%	  of	  
people	  with	  AIDS	   in	   the	  USA	  developed	   cryptococcosis,	   typically	  with	   a	  CD4	   count	  
below	  100	  cells/µL	  (CDC	  1982;	  Snider	  et	  al.	  1983;	  Zuger	  et	  al.	  1986;	  Dismukes	  1988;	  
CDC	   1993;	   Powderly	   1993).	   HIV-­‐1-­‐infection	   rapidly	   became	   the	   most	   common	  
predisposing	  condition	  among	  patients	  with	  cryptococcal	  meningitis,	  accounting	  for	  
85-­‐90%	  of	  cases	  (Powderly	  1993;	  Hajjeh	  et	  al.	  1999;	  Mirza	  et	  al.	  2003;	  Dromer	  et	  al.	  
1996).	  During	   the	  1990s	   the	   incidence	  of	   cryptococcosis	   fell	   significantly	   in	  Europe	  
and	   the	  USA	   following	   improvements	   in	   anti-­‐fungal	   prophylaxis	   and	   the	   advent	   of	  
ART	  (Mirza	  et	  al.	  2003;	  Dromer	  et	  al.	  2004).	  However,	  in	  sub-­‐Saharan	  Africa	  and	  Asia,	  
incidence	  remained	  high,	  driven	  by	  the	  uncontrolled	  HIV-­‐1	  pandemic	  (Chariyalertsak	  
et	   al.	   2001;	  N.	   French	  et	   al.	   2002).	   Cryptococcosis	  was	   recorded	  as	   the	  presenting	  
illness	  in	  almost	  20%	  of	  individuals	  with	  AIDS	  in	  Thailand	  in	  2001	  (Chariyalertsak	  et	  al.	  
2001),	   was	   responsible	   for	   44%	   of	   HIV-­‐related	   deaths	   in	   a	   cohort	   study	   of	   South	  
African	  gold	  miners	  conducted	  in	  1998	  (Corbett	  et	  al.	  2002),	  and	  has	  been	  the	  most	  
common	  cause	  of	  adult	  meningitis	   in	  many	  sub-­‐Saharan	  African	  countries	  over	   the	  
last	  decade,	  comprising	  33-­‐63%	  of	  cases	  (Cohen	  et	  al.	  2010;	  Scarborough	  et	  al.	  2007;	  
Békondi	  et	  al.	  2006;	  Heyderman	  et	  al.	  1998;	  Jarvis,	  Meintjes,	  et	  al.	  2010a).	  	  
	  
The	   CDC	   estimates	   that	   there	   are	   between	   370,000	   -­‐	   1.5	   million	   cases	   of	  
cryptococcal	  meningitis	  each	  year,	  and	  125,000	  -­‐	  1.12	  million	  deaths;	  the	  majority	  of	  
the	   disease	   burden	   being	   in	   sub-­‐Saharan	   Africa	   (144,000-­‐1.3	   million	   cases	   and	  
101,000-­‐900,000	   deaths	   per	   year)	   (Park	   et	   al.	   2009).	   However,	   there	   are	   some	  
concerns	   regarding	   the	  methodology	  used	   to	  calculate	   these	   figures	  and	   it	   is	   likely	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that	   the	   disease	   burden	   lies	   towards	   the	   lower	   bounds	   of	   these	   estimates.	   The	  
disease	  burden	  of	  cryptococcal	  meningitis	  in	  South	  Africa	  is	  more	  accurately	  known	  
because	   the	   National	   Institute	   for	   Communicable	   Disease	   records	   laboratory-­‐
confirmed	  cases.	  In	  the	  latest	  available	  annual	  report	  (2012)	  there	  were	  6,817	  cases	  
of	   confirmed	   cryptococcosis	   resulting	   in	   an	   annual	   incidence	   of	   119/100,000	   HIV	  
infected	   individuals	   (Govender	   2012a).	   The	   greatest	   number	   of	   notifications	   were	  
from	  Gauteng	   (n=1,976),	  KwaZulu-­‐Natal	   (n=1,906)	  and	   the	  Eastern	  Cape	   (n=1,109),	  
with	   the	  Western	   Cape	   having	   the	   fourth	   highest	   (n=592).	   However,	   the	  Western	  
Cape	   had	   the	   highest	   incidence	   at	   212	   cases/100,000	   HIV	   infected	   persons,	   with	  
Gauteng,	   Eastern	   Cape	   and	   KwaZulu-­‐Natal	   reporting	   162,	   151,	   119	   respectively	  
(Govender	   2012a).	   Although	   it	   is	   possible	   that	   these	   figures	   may	   be	   a	   slight	  
underestimation	  (given	  that	  the	  system	  relies	  primarily	  on	  passive	  surveillance),	  they	  
remain	  the	  most	  accurate	  data	  regarding	  the	  burden	  of	  cryptococcal	  meningitis	  in	  a	  
high	  incidence	  country.	  	  
	  
Cryptococcosis	   due	   to	   C.	   neoformans	   infection	   can	   also	   occur	   in	   HIV-­‐negative	  
individuals	  but	   is	   far	   less	  common	  and	  usually	  still	  associated	  with	  another	  form	  of	  
impaired	   immunity.	   In	  the	  USA,	  a	  predisposing	  condition	   is	  noted	   in	  almost	  80%	  of	  
cases,	   the	   most	   common	   being	   glucocorticoid	   therapy	   (28%),	   solid	   organ	  
transplantation	   (18%),	   hepatic	   or	   renal	   failure	   (18%),	   rheumatological	   disorders	  
(13%),	   chronic	   lung	   disease	   (12%),	   haematological	   malignancies	   (9%),	   and	   other	  
malignancies	  (9%)	  (Pappas	  2013).	  However,	  there	  are	  recent	  studies	  from	  south	  east	  
Asia	  reporting	  cases	  of	  cryptococcal	  meningitis	  in	  HIV-­‐uninfected	  individuals	  with	  no	  
clear	  underlying	   state	  of	   immune	  compromise	   (Chau	  et	   al.	   2010).	   	   The	  majority	  of	  
these	   infections	  were	  caused	  by	  Cryptococcus	  neoformans	  var.	  grubii	  subtype	  VNIγ	  
and	   it	   is	   possible	   this	   strain	  may	   have	   developed	   heightened	   virulence	   (VNIγ	   was	  
isolated	  in	  84%	  of	  HIV-­‐uninfected	  CM	  vs.	  38%	  of	  HIV-­‐infected	  CM)	  (Day	  et	  al.	  2011).	  
1.3.2 Cryptococcus	  gattii	  
Cryptococcus	   gattii	   can	   also	   cause	   human	   disease	   but	   is	   less	   common	   than	   C.	  
neoformans	  and	  occurs	  only	  in	  specific	  geographic	  locations.	  Disease	  is	  not	  restricted	  
to	  individuals	  with	  impaired	  immune	  function,	  and	  more	  than	  half	  of	  cases	  have	  no	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predisposing	  medical	  condition	  (Lalloo	  et	  al.	  1994;	  Fisher	  et	  al.	  1993;	  D.	  H.	  Mitchell	  
et	  al.	  1995;	  Galanis	  et	  al.	  2010).	  Previously,	  infection	  was	  thought	  to	  be	  restricted	  to	  
tropical	  or	   sub-­‐tropical	   regions	  such	  as	  Northern	  Australia	  and	  Papua	  New	  Guinea,	  
where	   the	   organism	  had	   been	   isolated	   in	   certain	   species	   of	   eucalyptus	   trees	   (Ellis	  
1987;	  Ellis	  &	  Pfeiffer	  1990;	  Ellis	  &	  Pfeiffer	  1992;	  Granados	  &	  Castaneda	  2005;	  Mazza	  
et	  al.	  2013;	  Randhawa	  et	  al.	  2011).	  However,	  over	  the	  last	  15	  years	  there	  has	  been	  
an	  evolving	  outbreak	  in	  Vancouver	  Island,	  British	  Columbia	  and	  the	  US	  states	  of	  the	  
Pacific	   Northwest.	   By	   2011,	   288	   cases	   had	   been	   reported,	   linked	   to	   novel	   strains	  
with	   increased	  virulence	   (VGIIa	  and	  VGIIc)	   (Seaton	  et	  al.	   1996;	  Galanis	  et	  al.	   2010;	  
CDC	   2010;	   Byrnes	   et	   al.	   2010).	   Affected	   individuals	   in	   this	   outbreak	   were	   not	  
“classically”	   immune	   suppressed	   (e.g.	   HIV-­‐1	   infection	   or	   solid	   organ	   transplant	  
recipient)	   but	   often	   had	   other	   chronic	   conditions	   such	   as	   cancer,	   smoking	   or	  
corticosteroid	  use	  (Macdougall	  et	  al.	  2011;	  Galanis	  et	  al.	  2010;	  Byrnes	  &	  Marr	  2011;	  
CDC	  2010).	  	  
	  
Given	   that	   not	   all	   cryptococci	   identified	   in	   clinical	   samples	   are	   speciated,	   it	   is	  
possible	  that	  the	  burden	  of	  C.	  gattii	  infection	  is	  underestimated.	  Studies	  from	  South	  
Africa	   have	   shown	   that	   2.4%	  of	   cryptococcal	   clinical	   isolates	   are	  C.	   gattii,	   the	   vast	  
majority	  from	  individuals	  with	  HIV-­‐1	  infection	  (Morgan	  et	  al.	  2006).	  Furthermore,	  a	  
retrospective	   analysis	   of	   strains	   from	   AIDS	   patients	   in	   Los	   Angeles	   prior	   to	   2005	  
showed	   that	   12%	   were	   C.	   gattii	   but	   were	   not	   linked	   to	   the	   Vancouver	   Island	  
outbreak	  (Chaturvedi	  et	  al.	  2005).	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1.4 Pathogenesis	  of	  cryptococcosis	  
1.4.1 Primary	  infection	  
C.	   neoformans	   infection	   in	   humans	   usually	   occurs	   via	   the	   pulmonary	   route.	  
Desiccated	   yeast	   cells	   (or	   possibly	   basiodospores)	   are	   inhaled	   and	   pass	   down	   the	  
airways	   to	   the	   alveolar	   spaces	   [Figure	   1.3]	   (Nielsen,	   et	   al.	   2010).	   Given	   the	  
ubiquitous	   nature	   of	   C.	   neoformans	   in	   the	   environment	   it	   is	   likely	   that	   exposure	  
occurs	   relatively	   frequently,	   but	   is	   controlled	   by	   the	   pulmonary	   immune	   response	  
and	   does	   not	   usually	   result	   in	   disease.	   	   This	   is	   supported	   by	   data	   from	  
seroprevalence	  surveys,	  which	  have	  found	  anti-­‐cryptococcal	  antibodies	  in	  up	  to	  70%	  
of	  children	  by	  the	  age	  of	  5	  years	  (Goldman	  et	  al.	  2001).	  However,	  if	  host	  immunity	  is	  
impaired,	   C.	   neoformans	   may	   not	   be	   contained	   within	   the	   lungs	   and	   may	  
disseminate	  around	  the	  body,	  often	  migrating	   to	   the	  central	  nervous	  system	  (CNS)	  
(Figure	  1.3)	  (Bicanic	  &	  Harrison	  2004).	  
	  
	  
Figure	  1.3	  	  Route	  of	  infection	  with	  C.	  neoformans	  
(http://bmolchem.wisc.edu/labs/hull/research.html)	  
Cryptococcal	   preference	   for	   the	   CNS	   is	   not	   completely	   understood.	   The	   CNS	   is	   a	  
relatively	   immune	  privileged	  site	  with	   low	  levels	  of	  opsonins	  (such	  as	  complement)	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(Truelsen	  et	  al.	  1992);	   in	  addition,	  the	  ready	  availability	  of	   levodopa	  and	  dopamine	  
(which	  the	  organism	  requires	  to	  make	  melanin)	  may	  improve	  the	  organism’s	  ability	  
to	   resist	   intracellular	   killing	   (Hogan	  et	  al.	   1996).	  Mechanism	  of	  entry	   to	   the	  CNS	   is	  
also	  poorly	  understood	  and	  the	  subject	  of	  much	  debate.	  Two	  theories	  predominate:	  
penetration	  of	  the	  blood-­‐brain	  barrier	  by	  free	  yeast	  cells,	  or	  entry	  inside	  an	  infected	  
phagocyte	  (the	  “Trojan	  horse”	  theory);	  supportive	  evidence	  exists	  for	  both	  (Chrétien	  
et	  al.	  2002;	  Charlier	  et	  al.	  2009).	  	  	  
1.4.2 Reactivation	  of	  latent	  disease	  
Whether	   cryptococcosis	  occurs	  due	   to	  a	  primary	   infection	  or	   reactivation	  of	   latent	  
disease	   is	   not	   known.	   Genotypic	   analysis	   of	   clinical	   strains	   from	   patients	   with	  
cryptococcal	  meningitis	   in	   France	   showed	   that	   the	   strains	   from	   individuals	  born	   in	  
France	   clustered	   together,	   as	   did	   strains	   from	   individuals	   born	   in	   Africa.	   As	   those	  
individuals	   born	   in	   Africa	   had	   lived	   in	   France	   for	   an	   average	   of	   10	   years	   prior	   to	  
developing	   cryptococcosis	   this	   suggests	   that	   the	   initial	   infection	   occurred	   prior	   to	  
their	  arrival	   (Garcia-­‐Hermoso	  et	  al.	  1999).	  The	  concept	  of	   latency	   is	  also	  supported	  
by	   experiments	   in	   rats.	   Following	   pulmonary	   infection,	   these	   animals	  mounted	   an	  
effective	   granulomatous	   response	   and	   did	   not	   develop	   disseminated	   disease	  
(Goldman	   et	   al.	   1994).	   However,	   histological	   examination	   of	   the	   lungs	   from	   these	  
animals	  up	  to	  18	  months	  later	  revealed	  the	  presence	  of	  viable	  cryptococci,	  contained	  
inside	  macrophages	   and	  within	   granulomas.	   If	   previously	   infected	   rats	  were	   given	  
corticosteroids,	   reactivation	   of	   pulmonary	   cryptococcal	   infection	   occurred	   with	  
dissemination	  to	  brain,	  kidney	  and	  spleen	  (Goldman	  et	  al.	  2000).	  
1.4.3 Pathology	  
Cryptococcosis	   can	   affect	   a	   single	   organ	   or	   be	   disseminated	   throughout	   the	   body,	  
with	   the	   pattern	   of	   disease	   strongly	   influenced	   by	   host	   immunity.	   In	   immune	  
competent	   individuals	   disease	   is	   often	   limited	   to	   the	   lungs	   with	   granulomatous	  
inflammation	   a	   common	   finding	   (Baker	   &	   Haugen	   1955).	   Cryptococci	   are	   usually	  
found	   contained	   within	   macrophages	   and	   giant	   cells,	   surrounded	   by	   epithelioid	  
macrophages	  and	  T	  lymphocytes	  (Baker	  &	  Haugen	  1955;	  Lee	  et	  al.	  1996).	  In	  immune	  
competent	   patients	  who	   develop	   CNS	   disease,	   cryptococci	   are	   usually	   confined	   to	  
the	   sub-­‐arachnoid	   and	   perivascular	   space,	   contained	   within	   a	   granulomatous	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response	  (Lee	  et	  al.	  1996).	  In	  contrast,	  immune	  compromised	  individuals	  with	  HIV-­‐1	  
infection	   (or	   other	   significant	   immune	   suppression)	   typically	   have	   disseminated	  
infection:	   fungal	  burden	   is	  high	  with	  numerous	   intra-­‐	  and	  extra-­‐cellular	  cryptococci	  
seen	  throughout	  the	  brain,	  spleen,	  liver,	  lymph	  nodes	  and	  lungs	  (Klock	  et	  al.	  2009).	  
CNS	   infection	   is	  not	  confined	  to	  the	  meninges,	  and	  gelatinous	  pseudocysts	  may	  be	  
found	  in	  the	  basal	  ganglia,	  thalamus	  and	  midbrain	  (Lee	  et	  al.	  1996;	  Klock	  et	  al.	  2009).	  
Despite	   this	   incredibly	   high	   organism	   load,	   minimal	   inflammation	   is	   seen	   and	   the	  
tissue	   response	   comprises	   mainly	   of	   macrophages	   with	   very	   little	   granuloma	  
formation	  (Lee	  et	  al.	  1996;	  Klock	  et	  al.	  2009).	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1.5 Clinical	  aspects	  of	  cryptococcosis	  	  
1.5.1 Clinical	  features	  of	  cryptococcosis	  	  
Meningoencephalitis	   is	   the	   most	   common	   presentation	   of	   cryptococcosis	   among	  
HIV-­‐infected	   persons,	   occurring	   in	   82-­‐86%	   cases	   (Dromer	   et	   al.	   2004;	  Hajjeh	   et	   al.	  
1999).	   It	   is	   less	   common	   in	   HIV-­‐uninfected	   persons	   but	   still	   accounts	   for	  
approximately	   60%	   of	   presentations	   (Dromer	   et	   al.	   1996;	   Hajjeh	   et	   al.	   1999).	  
Presentation	  is	  usually	  sub-­‐acute,	  with	  a	  median	  symptom	  duration	  of	  approximately	  
2	  weeks;	   the	  most	   common	   symptoms	   are	   headache,	   nausea	   and	   vomiting,	   visual	  
disturbance,	  seizures	  and	  hearing	  loss	  (Jarvis	  et	  al.	  2014).	  Altered	  mental	  status	  is	  a	  
relatively	   common	   finding,	   affecting	   approximately	   a	   quarter	   of	   individuals	   at	  
presentation;	  decreased	  visual	  acuity,	  cranial	  nerve	  lesions	  and	  papilloedema	  are	  all	  
well	  described	  (Rozenbaum	  &	  Gonçalves	  1994;	  Jarvis	  et	  al.	  2014).	  Raised	  intracranial	  
pressure	   (CSF	   opening	   pressure	   >25cm	  H20)	   occurs	   in	   approximately	   50%	  of	   cases	  
and	  is	  thought	  to	  occur	  due	  to	  impaired	  CSF	  drainage	  (due	  to	  cryptococcal	  blockage	  
of	  arachnoid	  granulations)	  rather	  than	  cerebral	  oedema	  (Jarvis	  et	  al.	  2014;	  Graybill	  
et	  al.	  2000;	  Loyse	  et	  al.	  2010).	  CSF	  analysis	  typically	  reveals	  little	  or	  no	  inflammation	  
and	   cell	   count	   can	  be	   normal	   (Jarvis	   et	   al.	   2014).	   CT	   scan	  of	   the	   brain	  may	   reveal	  
meningeal	  enhancement,	  nodules	  or	  other	  abnormalities	   in	  the	  midbrain	  and	  basal	  
ganglia;	  mass	   lesions	   are	   also	  described	   consistent	  with	   cryptococcoma	   formation,	  
particularly	   in	   patients	   with	   C.	   gattii	   infection	   (Bicanic	   &	   Harrison	   2004;	   T.	   G.	   T.	  
Mitchell	  &	  Perfect	  1995;	  S.	  Chen	  et	  al.	  2000;	  S.	  C.	  A.	  Chen	  et	  al.	  2013).	  	  
	  
Visual	   symptoms	   are	   commonly	   reported	   in	   cryptococcal	   meningitis	   and	   often	  
ascribed	   to	   raised	   intracranial	   pressure;	  however,	   it	   is	   likely	   that	   infiltration	  of	   the	  
optic	  nerve	  by	  cryptococci	  also	  plays	  a	  role	  in	  the	  pathophysiology	  (Duggan	  &	  Walls	  
2012).	  	  
	  
Pulmonary	   involvement	   occurs	   in	   approximately	   20%-­‐40%	   cases	   of	   cryptococcal	  
disease,	  either	  as	  isolated	  disease	  or	  part	  of	  systemic	  infection	  (Dromer	  et	  al.	  1996;	  
Klock	  et	  al.	  2009).	  Isolated	  disease	  is	  more	  common	  in	  immunocompetent	  compared	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to	   immune	  compromised	   individuals	   (29%	  vs	  7%	   respectively)	  and	   is	   also	   reported	  
more	  frequently	   in	  patients	  with	  C.	  gattii	   infection;	   it	  usually	  presents	  with	  solitary	  
or	   multiple	   pulmonary	   nodules	   of	   varying	   size	   (Khoury	   et	   al.	   1984;	   Dromer	   et	   al.	  
2004;	  Hajjeh	   et	   al.	   1999;	   Shirley	  &	  Baddley	   2009;	   Fisher	   et	   al.	   1993;	  Galanis	   et	   al.	  
2010).	  In	  immune	  compromised	  individuals,	  pulmonary	  disease	  usually	  occurs	  in	  the	  
context	   of	   disseminated	   infection;	   presentation	   can	   be	   with	   bilateral	   diffuse	  
interstitial	  infiltrates,	  lobar	  infiltrates,	  pleural	  effusions	  and	  lymphadenopathy;	  acute	  
respiratory	  distress	   syndrome	   (ARDS)	  has	  also	  been	  described	   (Khoury	  et	   al.	   1984;	  
Sider	  &	  Westcott	  1994;	  Shirley	  &	  Baddley	  2009;	  Murray	  et	  al.	  1988).	  Given	  that	  the	  
symptoms	  of	  pulmonary	  cryptococcosis	  are	  non-­‐specific,	  it	  is	  likely	  that	  the	  condition	  
is	   under-­‐recognized,	   especially	   in	   countries	   with	   high	   burdens	   of	   TB	   (Zuger	   et	   al.	  
1986;	  Shirley	  &	  Baddley	  2009;	   Jarvis,	  Wainwright,	  et	  al.	  2010b).	   Indeed,	   in	  autopsy	  
studies	  among	  South	  African	  miners,	  cryptococcal	  pneumonia	  was	  a	  common	  finding	  	  
(589	   cases	   out	   of	   8421	   post	   mortems,	   7%	   prevelance)	   but	   was	   only	   occasionally	  
diagnosed	  by	  clinicians	  prior	  to	  death.	  Of	  the	  263	  miners	  with	  post	  mortem	  evidence	  
of	  pulmonary	  cryptococcosis	  who	  had	  been	  recorded	  to	  have	  died	  form	  a	  respiratory	  
illness,	  cryptococcal	  pneumonia	  was	  listed	  as	  a	  cause	  of	  death	  in	  only	  7	  cases	  (2.7%).	  
Instead,	  miners’	  deaths	  were	  often	  incorrectly	  ascribed	  to	  tuberculosis	  and	  bacterial	  
pneumonia	  (M.	  L.	  Wong	  et	  al.	  2007).	  
	  
Cutaneous	   lesions	   are	   also	   described	   and	   occur	   in	   5%	   of	   individuals	   with	  
disseminated	  cryptococcosis.	  They	  typically	  manifest	  as	  umbilicated	  papules	  and	  are	  
similar	   in	   appearance	   to	   molluscum	   contagiosum	   (Powderly	   1993).	   Isolated	  
cutaneous	   disease	   is	   also	   described	   and	   occurs	   more	   frequently	   among	   HIV-­‐
uninfected	   individuals,	   it	   is	   associated	   with	   outdoor	   occupations	   and	   minor	   skin	  
trauma	   (Dromer	   et	   al.	   2004;	   Neuville	   et	   al.	   2003).	   Other	   clinical	   descriptions	   of	  
cryptococcosis	  include	  colitis	  and	  pericardial	  disease	  (Osawa	  &	  Singh	  2010;	  Zuger	  et	  
al.	  1986).	  
1.5.2 Diagnosis	  of	  cryptococcosis	  
Cryptococcal	   meningitis	   in	   HIV-­‐infected	   individuals	   does	   not	   usually	   present	   a	  
diagnostic	  challenge	  due	  to	  the	  high	  fungal	   load	  and	  systemic	  dissemination	  of	  the	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organism.	   CSF	   culture	   is	   the	   gold	   standard	   but	   requires	   a	   diagnostic	  microbiology	  
laboratory	   and	   takes	   several	   days	   to	   perform	   (Bicanic	   &	   Harrison	   2004).	   India	   ink	  
staining	  of	  CSF	  is	  a	  rapid	  and	  simple	  test	  but	  diagnostic	  accuracy	  varies	  depending	  on	  
operator	  skill	  (reported	  sensitivity	  in	  HIV-­‐associated	  CM	  is	  73%-­‐94%)	  (Chuck	  &	  Sande	  
1989;	  Rozenbaum	  &	  Gonçalves	  1994;	  S.	  Chen	  et	  al.	  2000;	  Saha	  et	  al.	  2009;	  Antinori	  
et	  al.	  2001;	  Boulware,	  Rolfes,	  et	  al.	  2014b).	  Consequently,	  cryptococcal	  antigen	  tests	  
are	   often	   the	   preferred	   option,	   they	   detect	   the	   presence	   of	   soluble	   capsular	  
polysaccharide	   (usually	   by	   latex	   bead	   agglutination)	   and	   are	   both	   a	   quick	   and	  
accurate	   test	   that	   can	   be	   performed	   on	   either	   CSF	   or	   serum	   (Bicanic	   &	   Harrison	  
2004).	   In	   HIV-­‐associated	   cryptococcal	   meningitis	   they	   are	   very	   accurate	   (CSF	  
sensitivity	   88-­‐100%,	   CSF	   specificity	   86-­‐100%,	   serum	   sensitivity	   83-­‐100%,	   serum	  
specificity	   93-­‐100%);	   however,	   in	   immunocompetent	   individuals,	   sensitivity	   is	  
considerably	   reduced	   due	   to	   lower	   fungal	   burden	   and	   more	   localized	   disease	  
(sensitivity	  approximately	  60%)	  (Diaz,	  et	  al.	  2010;	  Chuck	  &	  Sande	  1989;	  Tanner	  et	  al.	  
1994;	  S.	  Chen	  et	  al.	  2000;	  Antinori	  et	  al.	  2001;	  Saha	  et	  al.	  2009;	  Boulware,	  Rolfes,	  et	  
al.	  2014b).	  A	  recent	  development	  has	  been	  a	  point-­‐of-­‐care	  dipstick	  test,	  based	  on	  a	  
lateral	   flow	   immunochromatographic	   assay	   (LFA).	   When	   compared	   to	   other	  
diagnostic	   tests	   this	   has	   a	   reported	   CSF	   and	   serum	   sensitivity	   of	   99%	   and	   a	   CSF	  
specificity	   of	   99.1%	   (LFA,	   Immy,	   Inc.,	   Norman,	   OK,	   USA)	   (Boulware,	   Rolfes,	   et	   al.	  
2014b).	   In	   the	  same	  study	  serum	  specificity	  was	   reported	  at	  92%;	  however,	  as	   the	  
authors	  used	  a	  composite	  gold	  standard	  of	  positive	  CSF	  culture	  or	  latex	  agglutination	  
this	   likely	   reflects	   the	   reduced	   sensitivity	   of	   the	   older	   tests	   rather	   than	   a	   lack	   of	  
specificity	  of	  the	  LFA.	  
	  
In	   pulmonary	   cryptococcosis,	   the	   gold	   standard	   diagnosis	   is	   fungal	   culture	   of	  
bronchial	   washings	   or	   lung	   tissue	   (Shirley	   &	   Baddley	   2009).	   Cryptococcal	   antigen	  
testing	  is	  not	  as	  useful	  due	  to	  low	  sensitivity	  both	  in	  serum	  and	  bronchial	  washings	  
(sensitivity	   50-­‐80%	   and	   71%	   respectively)	   (Singh	   et	   al.	   2008;	   Vilchez	   et	   al.	   2001;	  
Pappas	  et	  al.	  2001;	  Kralovic	  &	  Rhodes	  1998).	  
	  
HIV-­‐associated	   cryptococcal	   meningitis	   is	   frequently	   preceded	   by	   a	   period	   of	  
asymptomatic	  antigenaemia.	  This	   is	   reported	   in	  approximately	  3.5-­‐5.6%	  of	  persons	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starting	   ART	   in	   sub-­‐Saharan	   Africa	   with	   no	   prior	   history	   of	   cryptococcosis,	   with	   a	  
higher	   prevalence	   among	   those	  with	   CD4	   count	   <100	   cells/µL	   (Jarvis,	   Lawn,	   et	   al.	  
2009b;	  Liechty	  et	  al.	  2007;	  Meya	  et	  al.	  2010).	   In	  South	  Africa,	  retrospective	  studies	  
have	   shown	   that	   despite	   starting	   ART,	   28%	   of	   such	   individuals	   developed	  
cryptococcal	  meningitis,	  a	  median	  of	  35	  days	  later	  (range	  8-­‐188	  days)	  (Jarvis,	  Lawn,	  
et	  al.	  2009b).	  With	  this	   in	  mind,	  antigen	  screening	  programmes	  are	  currently	  being	  
piloted	  and	  evaluated	  in	  a	  variety	  of	  countries.	  	  
1.5.3 Treatment	  of	  cryptococcosis	  	  
The	   optimal	   anti-­‐fungal	   regimens	   for	   cryptococcal	   meningitis	   are	   detailed	   in	  
guidelines	   produced	   by	   the	   Infectious	   Disease	   Society	   of	   America	   (IDSA)	   and	   the	  
Southern	  African	  HIV	  Clinicians	  Society	   (SAHIVCS)	   [Table	   1.2]	   (Perfect	  et	  al.	  2010a;	  
Govender	  et	  al.	  2013).	  Amphotericin	  and	  flucytosine	  combination	  therapy	  has	  been	  
shown	  to	  lead	  to	  better	  clearance	  of	  cryptococci	  from	  the	  CSF	  and	  improved	  survival	  
compared	  to	  amphotericin	  monotherapy	  (van	  der	  Horst	  et	  al.	  1997;	  Day	  et	  al.	  2013).	  
Unfortunately,	   flucytosine	   is	   not	   available	   in	   sub-­‐Saharan	   Africa	   and	   access	   to	  
amphotericin	  varies	  (Bicanic	  et	  al.	  2005;	  Loyse	  et	  al.	  2013;	  Govender	  et	  al.	  2013).	  In	  
many	  countries,	   fluconazole	   is	   the	  only	  available	  anti-­‐fungal	  drug	  but	   is	  associated	  
with	  poor	  outcome,	  even	  when	  used	  in	  higher	  doses	  (Bicanic	  et	  al.	  2007;	  Lightowler	  
et	  al.	  2010;	  Mwaba	  et	  al.	  2001;	  Rothe	  et	  al.	  2013).	  
	  
	   IDSA	  guidelines	   SAHIVCS	  
Intensive	  Phase	  	  
(2	  weeks)	  
Amphotericin	  B	  (1mg/kg/d)	  
+	  flucytosine	  (100mg/kg/d)	  
Amphotericin	  B	  (1mg/kg/d)	  
+	  fluconazole	  800mg/d*	  
Continuation	  Phase	  	  
(8	  weeks)	  
Fluconazole	  400mg/d	   Fluconazole	  400mg/d	  
Maintenance	  
(until	  CD4	  >200	  for	  6	  months)	  
Fluconazole	  200mg/d	   Fluconazole	  200mg/d	  
Table	   1.2	   IDSA	   and	   SAHIVCS	   guidelines	   for	   treatment	   of	   Cryptococcal	   meningitis	   (Perfect	   et	   al.	  
2010a;	  Govender	  et	  al.	  2013).	  *Flucytosine	  is	  unavailable	  in	  South	  Africa	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Both	  the	  IDSA	  and	  Southern	  African	  guidelines	  recommend	  a	  proactive	  approach	  to	  
the	   management	   of	   raised	   intracranial	   pressure,	   routinely	   measuring	   opening	  
pressure	  at	   initial	   lumbar	  puncture	  (LP)	  and	  performing	  therapeutic	  CSF	  drainage	   if	  
required	   (Perfect	   et	   al.	   2010a;	   Govender	   et	   al.	   2013).	   This	   strategy	   has	   not	   been	  
assessed	   in	  a	   clinical	   trial.	  However,	  observational	   studies	  have	   shown	   therapeutic	  
lumbar	   punctures	   to	   be	   associated	   with	   significant	   reductions	   in	   mortality,	  
irrespective	  of	  CSF	  opening	  pressure	  (Rolfes	  2014).	  	  
The	  timing	  of	  ART	   initiation	  has	  been	  a	   long-­‐standing	  matter	  of	  debate	   in	  CM.	  The	  
trials	  addressing	  this	  are	  discussed	   in	  section	  1.8.5.	  Southern	  African	  guidelines	   for	  
cryptococcal	   meningitis	   now	   suggest	   clinicians	   wait	   until	   4-­‐6	   weeks	   post	  
amphotericin	   treatment	  before	   initiating	  ART	   in	  patients	  with	  CM	   (Govender	  et	  al.	  
2013).	  
1.5.4 Outcome	  	  
Without	  treatment,	  cryptococcal	  meningitis	  is	  uniformly	  fatal	  with	  a	  median	  survival	  
of	   only	   10-­‐14	   days	   (Mwaba	   et	   al.	   2001;	   Heyderman	   et	   al.	   1998;	   N.	   French	   et	   al.	  
2002).	   However,	   in	   a	   well-­‐resourced	   setting	   (such	   as	   the	   USA	   or	   Europe),	   with	  
optimal	  anti-­‐fungal	   therapy,	  survival	  has	  been	  reported	  to	  be	  as	  high	  as	  90%	  at	  14	  
days	  and	  75%	  at	  10	  weeks	  (even	  before	  the	  availability	  of	  ART)	  (Chuck	  &	  Sande	  1989;	  
van	   der	   Horst	   et	   al.	   1997;	   Antinori	   et	   al.	   2001).	   Unfortunately,	   the	   majority	   of	  
persons	   with	   cryptococcal	   meningitis	   live	   in	   countries	   whose	   health	   systems	   are	  
under	   strain	   and	   outcomes	   in	   these	   settings	   are	   considerably	   worse.	   In	   an	  
observational	  study	  conducted	  in	  South	  Africa	  between	  2002-­‐2003	  (prior	  to	  ART	  roll-­‐
out,	  when	  fluconazole	  was	  the	  mainstay	  of	  therapy)	  survival	  was	  68%	  at	  14	  days	  and	  
41%	  at	  90	  days	   (Park	  et	  al.	  2011).	   In	  a	  study	   from	  Uganda	   in	  2006,	  where	  patients	  
had	  access	  to	  both	  amphotericin	  and	  ART,	  80%	  of	  study	  subjects	  survived	  to	  14	  days,	  
but	  only	  56%	  survived	  to	  initiate	  ART	  at	  5-­‐6	  weeks,	  and	  only	  41%	  were	  alive	  after	  6	  
months	  (Kambugu	  et	  al.	  2008).	  	  
	  
In	   a	   combined	   cohort	   of	   501	   patients	   (taken	   from	   nine	   trials,	   conducted	   in	   South	  
Africa,	  Malawi,	  Uganda	  and	  Thailand	  between	  2002-­‐2010)	  survival	  was	  83%	  and	  66%	  
at	   2	   and	   10	   weeks	   respectively	   (and	   59%	   at	   1	   year)	   (Jarvis	   et	   al.	   2014).	   Factors	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independently	   associated	   with	   higher	   mortality	   at	   2	   weeks	   were	   decreased	  
consciousness,	   higher	   CSF	   fungal	   burden,	   higher	   peripheral	   leukocyte	   count,	   slow	  
clearance	   of	   infection	   from	   CSF	   and	   fluconazole-­‐based	   induction	   therapy.	   Factors	  
independently	   associated	   with	   poor	   outcome	   at	   10	   weeks	   were	   decreased	  
consciousness,	   high	   baseline	   fungal	   burden,	   older	   age,	   low	  body	  weight,	   anaemia,	  
raised	  peripheral	  WCC	  and	  low	  CSF	  opening	  pressure	  (Jarvis	  et	  al.	  2014).	  Decreased	  
consciousness	   and	   increased	   CSF	   fungal	   burden	   have	   also	   been	   identified	   as	   poor	  
prognostic	  signs	  in	  other	  studies,	  along	  with	  high	  CSF	  cryptococcal	  antigen	  titres	  and	  
illicit	  drug	  use	  (Italian	  cohort,	  1985-­‐1999)	  (Antinori	  et	  al.	  2001;	  Kambugu	  et	  al.	  2008).	  
Although	   high	   intracranial	   pressure	   (>35cm	   H20)	   was	   associated	   with	   increased	  
mortality	   in	   one	   study	   (Graybill	   et	   al.	   2000),	   this	   association	   has	   not	   been	  
consistently	   reported	   since.	   A	   study	   in	   Uganda	   showed	   a	   trend	   towards	   higher	  
pressures	   in	  patients	   that	  died,	  but	   in	   the	   large	  multi-­‐site	   cohort	  described	  above,	  
low	  intracranial	  pressure	  was	  associated	  with	  mortality	  rather	  than	  high	  (Jarvis	  et	  al.	  
2014).	   It	   is	   possible	   this	   is	   due	   to	   effective	  management	  with	   therapeutic	   lumbar	  
puncture.	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1.6 Protective	  immunity	  	  
1.6.1 Overview	  of	  anti-­‐cryptococcal	  protective	  immunity	  	  
Current	   understanding	   of	   anti-­‐cryptococcal	   immunity	   is	   of	   a	   coordinated	   immune	  
response	   involving	  macrophages	   and	  CD4	   T	   cells,	   and	  has	  many	   similarities	   to	   the	  
host	  response	  against	  Mycobacterium	  tuberculosis	  [Figure	  1.4].	  	  
	  
	  
Figure	   1.4	   	   Overview	   of	   anti-­‐cryptococcal	   host	   immunity.	   (A)	   Cryptococci	   are	   opsonized	   by	  
complement;	  (B)	  dendritic	  cells	  (DCs)	  take	  up	  opsonized	  cryptococci;	  (C)	  DCs	  present	  antigen	  to	  naïve	  
CD4	  T	  cell;	  (D)	  antigen	  specific	  CD4	  T	  cells	  proliferate	  and	  migrate	  to	  the	  site	  of	  disease;	  (E)	  CD4	  T	  cells	  
activate	  macrophages	  with	  IFNγ,	  promoting	  intracellular	  killing	  (Boulware,	  Bonham,	  et	  al.	  2010a)	  
Alveolar	   macrophages	   (AM)	   are	   the	   first	   immune	   cells	   to	   encounter	   the	   yeast	  
following	   inhalation,	   and	   phagocytose	   the	   organism	   via	   complement	   opsonization	  
(Voelz	  &	  May	  2010;	  Johnston	  &	  May	  2013).	  However,	  cryptococci	  are	  able	  to	  survive	  
and	   proliferate	   within	   the	   harsh	   environment	   of	   the	   macrophage	   phagosome	  
through	   permeabilization	   of	   the	   phagosome	   membrane,	   resulting	   in	   the	  
accumulation	   of	   capsular	   polysaccharide	   within	   the	   cytoplasm	   of	   the	   cell	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(Feldmesser	   et	   al.	   2001).	   Following	   antigen	   presentation	   by	   dendritic	   cells,	   CD4	   T	  
cells	   become	   activated,	   proliferate,	   and	   migrate	   to	   the	   area	   of	   infection.	   They	  
interact	  with	  infected	  macrophages	  displaying	  cryptococcal	  antigens	  on	  surface	  MHC	  
class	   II	   molecules,	   and	   through	   the	   production	   of	   interferon	   gamma,	   are	   able	   to	  
activate	   parasitized	   macrophages	   and	   promote	   intracellular	   killing	   (Wiesner	   &	  
Boulware	  2011).	  If	  intracellular	  killing	  is	  not	  possible,	  macrophages	  undergo	  a	  variety	  
of	  morphological	   changes	   such	  as	  giant	   cell	   and	  epithelioid	   cell	   formation	   to	  allow	  
the	  development	  of	  granulomas;	  CD4	  T	  cells	  are	  also	  crucial	  to	  this	  process	  (Voelz	  &	  
May	  2010;	  Johnston	  &	  May	  2013).	  	  
1.6.2 Macrophages	  
Macrophages	   are	   phagocytic	   cells	   of	   myeloid	   lineage,	   they	   differentiate	   from	  
circulating	  peripheral	  blood	  monocytes	  and	  are	   found	   in	  most	   tissues	   in	   the	  body;	  
they	  display	  marked	  heterogeneity	  and	  have	  a	  range	  of	  functions	  (Mosser	  &	  Edwards	  
2008).	  In	  addition	  to	  their	  role	  as	  immune	  effector	  cells	  (able	  to	  phagocytose	  and	  kill	  
invading	   organisms,	   and	   augment	   the	   immune	   response	   through	   antigen	  
presentation	   and	   secretion	   of	   pro-­‐inflammatory	   cytokines),	   they	   have	   important	  
roles	   in	   tissue	   remodelling,	   iron	   recycling,	   and	   regulation	  of	   the	   immune	   response	  
(Vecchiarelli	  et	  al.	  1994;	  Mosser	  &	  Edwards	  2008).	  
	  
To	  enable	  macrophages	  to	  perform	  such	  a	  variety	  of	  functions,	  they	  adopt	  a	  variety	  
of	   activation	   states.	   “Classical”	   macrophage	   activation	   (M1	   phenotype)	   was	  
described	  more	  than	  50	  years	  ago	  and	  refers	  to	  an	  antimicrobial	  state	  of	  enhanced	  
phagocytosis	  and	  intracellular	  killing.	  In	  humans	  it	  is	  associated	  with	  up-­‐regulation	  of	  
CD64,	   CD80	   and	  MHC	   class	   II	  molecules	   on	   the	   surface	   of	   the	   cell	   (Gordon	   2003).	  
This	  activation	  depends	  primarily	  on	  the	  influence	  of	  interferon	  gamma	  produced	  by	  
activated	   CD4	   T	   lymphocytes	   and	   natural	   killer	   (NK)	   cells.	   Classical	   activation	   of	  
macrophages	   appears	   to	   be	   vital	   to	   the	   host	   response	   against	  C.	   neoformans	   and	  
other	   intracellular	   pathogens	   such	   as	   M.	   tuberculosis	   (Mosser	   &	   Edwards	   2008;	  
Gordon	   2003).	   “Alternative”	   activation	   of	   macrophages	   (M2	   phenotype)	   occurs	  
under	   the	   influence	   of	   IL-­‐4	   and	   IL-­‐13,	   and	   is	   associated	  with	   up-­‐regulation	   of	   the	  
surface	  markers	  CD206	  (mannose	  receptor),	  and	  CD200R	  in	  humans	  (Gordon	  2003;	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Ambarus	   et	   al.	   2012).	   Although	   their	   exact	   function	   remains	   somewhat	   enigmatic,	  
alternatively	   activated	   macrophages	   appear	   to	   play	   an	   important	   role	   in	   wound	  
repair	  and	  host	  defense	  against	  helminths,	  however,	  antimicrobial	  activities	  against	  
other	  pathogens	  are	  down-­‐regulated	  (Martinez	  et	  al.	  2009;	  Gordon	  2003;	  Mosser	  &	  
Edwards	  2008).	  There	  is	  evidence	  from	  both	  cell	  culture	  and	  animal	  experiments	  to	  
suggest	   that	   alternative	   activation	   of	   macrophages	   is	   detrimental	   in	   cryptococcal	  
infection,	  permitting	  intracellular	  replication	  and	  spread	  of	  C.	  neoformans	   (Voelz	  et	  
al.	   2009;	   Stenzel	   et	   al.	   2009).	   Although	   sometimes	   classified	   as	   “alternatively”	  
activated,	   the	  effect	  of	   IL-­‐10	  on	  macrophages	   is	  different	   to	   that	  of	   IL-­‐4	  and	   IL-­‐13,	  
and	   has	   been	   shown	   to	   promote	   an	   “immune-­‐modulatory”	   state	   of	   macrophage	  
activation	  with	  profound	  down-­‐regulation	  of	  pro-­‐inflammatory	  activity	  characterized	  
by	  surface	  expression	  of	  CD163	  (Gordon	  2003;	  Ambarus	  et	  al.	  2012).	  
	  
The	   interaction	   between	   macrophages	   and	   cryptococci	   is	   central	   to	   the	  
understanding	   of	   host	   immunity.	   If	   activated	   to	   adopt	   a	   M1	   phenotype,	  
macrophages	   are	   able	   to	   kill	   or	   contain	   C.	   neoformans;	   however,	   if	   instead	   they	  
adopt	   a	   M2	   phenotype,	   C.	   neoformans	   will	   survive	   and	   replicate	   with	   the	   cell	  
(Stenzel	  et	  al.	  2009;	  Voelz	  et	  al.	  2009).	  Not	  only	  does	   this	  propagate	   infection,	  but	  
provides	  protection	  from	  the	  immune	  response,	  allowing	  dissemination	  around	  the	  
body	  and	  the	  establishment	  of	  latency.	  The	  dual	  role	  of	  macrophages	  in	  cryptococcal	  
disease	   is	   illustrated	   by	   the	   differing	   effects	   of	  macrophage	   depletion	   in	   different	  
species	   of	   animals.	   Experiments	   in	   rats	   have	   shown	   that	   macrophage	   depletion	  
results	   in	   impaired	  host	   response	  to	  cryptococci	   leading	  to	  a	  significant	   increase	   in	  
pulmonary	   fungal	   load	  and	  extra-­‐pulmonary	  dissemination	  of	   infection	   (Shao	  et	  al.	  
2005).	  	  However,	  depletion	  of	  alveolar	  macrophages	  in	  mice	  (either	  before	  or	  during	  
infection	   with	   C.	   neoformans)	   results,	   paradoxically,	   in	   an	   improvement	   in	   host	  
immunity	   and	   a	   significant	   reduction	   in	   pulmonary	   fungal	   load	   and	   systemic	  
dissemination	   (Shao	   et	   al.	   2005;	   Charlier	   et	   al.	   2009).	   These	   data	   suggest	   that	  
macrophages	   have	   an	   anti-­‐cryptococcal	   role	   in	   rats,	   but	   facilitate	   disease	   in	  mice.	  
This	   is	   supported	   by	   ex	   vivo	   experimental	   data	   demonstrating	   that	   rat	   alveolar	  
macrophages	   have	   significantly	   increased	   phagocytic	   activity,	   oxidative	   burst	   and	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lysozyme	   secretion	   (i.e.	   an	  M1	   phenotype)	   compared	   to	  murine	   cells,	   resulting	   in	  
higher	  intrinsic	  anti-­‐cryptococcal	  activity	  (Shao	  et	  al.	  2005).	  
	  
Macrophages	  express	  both	  CD4	  and	  CCR5	  and	  as	   such	  can	  be	   infected	  with	  HIV-­‐1.	  
Compared	   to	   CD4	   T	   cells	   they	   are	  more	   resistant	   to	   the	   cytopathic	   effects	   of	   the	  
virus	   and	   are	   considered	   a	   possible	   long-­‐term	   reservoir	   of	   infection	   (Alexaki	   et	   al.	  
2008;	  Coleman	  &	  Wu	  2009).	  They	  are	  also	  implicated	  in	  trafficking	  HIV-­‐1	  to	  the	  brain	  
and	   thought	   to	   be	   involved	   in	   the	   pathogenesis	   of	   HIV-­‐associated	   neurocognitive	  
disorder	   (Cobos-­‐Jiménez	   et	   al.	   2011;	   Gorry	   et	   al.	   2005).	   	   HIV-­‐1	   infection	   of	  
macrophages	  appears	  to	  alter	  cell	  signaling,	  possibly	  resulting	  in	  increased	  immune	  
activation,	   T	   cell	   apoptosis	   and	   progression	   to	   AIDS	   (Herbein	   et	   al.	   2010;	   Kuroda	  
2010).	   It	   has	   been	   suggested	   that	   macrophage	   activation	   alters	   as	   disease	  
progresses:	   from	   classically	   activated	   in	   the	   early	   stages	   of	   infection,	   through	  
alternative	  activation,	   to	  a	  deactivated/immune	  modulatory	  phenotype	  when	  AIDS	  
has	  developed	  (Herbein	  &	  Varin	  2010).	  	  
	  
HIV-­‐1	  infection	  is	  associated	  with	  impaired	  macrophage	  responses	  to	  C.	  neoformans,	  
but	  it	   is	  not	  known	  whether	  this	   is	  a	  direct	  effect	  of	  the	  virus,	  or	  a	  consequence	  of	  
CD4	   T	   cell	   loss.	   When	   assessed	   using	   an	   ex	   vivo	   cryptococcal	   challenge	   model,	  
impaired	  alveolar	  macrophage	  (AM)	  activity	  was	  noted	  in	  individuals	  with	  advanced	  
HIV-­‐1	   infection	   but	   not	   in	   those	   with	   early	   disease	   (Reardon	   et	   al.	   1996).	   Similar	  
impairment	   of	   macrophage	   responses	   were	   also	   noted	   in	   experiments	   using	   SIV-­‐
infected	  rhesus	  macaques	  (RhM)	  but	  not	  when	  healthy	  RhM	  AMs	  were	  infected	  with	  
SIV	   in	   vitro	   (Brodie	   et	   al.	   1994).	   Furthermore,	   significant	   improvements	   in	   anti-­‐
cryptococcal	  responses	  were	  observed	  if	  AM	  from	  SIV-­‐infected	  macaques	  with	  AIDS	  
were	   incubated	  with	  cell	  culture	  supernatant	  from	  asymptomatic	  or	  SIV-­‐uninfected	  
animals	  (Brodie	  et	  al.	  1994).	  This	  suggests	  that	  impaired	  AM	  function	  may	  be	  due	  to	  
soluble	  factors	  in	  the	  inflammatory	  environment	  rather	  than	  a	  direct	  effect	  of	  HIV-­‐1	  
on	  the	  cell.	  However,	   in	  vitro	   infection	  of	  healthy	  human	  AMs	  with	  HIV-­‐1	  has	  been	  
shown	  to	  result	  in	  significant	  impairment	  of	  anti-­‐cryptococcal	  activity,	  particularly	  in	  
cells	  positive	  for	  p24	  antigen	  (Ieong	  et	  al.	  2000).	  	  This	  is	  similar	  to	  experiments	  using	  
monocyte-­‐derived	   macrophages	   from	   healthy	   human	   donors,	   which	   have	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demonstrated	   that	   infection	  with	   HIV-­‐1	   results	   in	   significantly	   impaired	   control	   of	  
Mycobacterium	  tuberculosis,	  M.	  avium	  and	  M.	  paratuberculosis	  (Pathak	  et	  al.	  2010).	  
1.6.3 Monocytes	  
Monocytes	   are	   the	   blood	   precursors	   of	   tissue	   macrophages	   (and	   dendritic	   cells).	  
They	  differentiate	   from	   the	   common	  myeloid	  progenitor	   cells	   in	   the	  bone	  marrow	  
and	  are	  identified	  by	  their	  bean-­‐shaped	  nucleus.	  They	  constitute	  5-­‐10%	  of	  peripheral	  
leukocytes	  and	  have	  a	  half	  life	  of	  approximately	  3	  days	  (Yona	  &	  Jung	  2010;	  Gordon	  &	  
Taylor	   2005).	   Monocytes	   migrate	   to	   areas	   of	   infection	   where	   they	   undergo	  
macrophage	  differentiation.	   In	  addition,	   they	  are	  phagocytic	   in	  their	  own	  right	  and	  
are	   potent	   producers	   of	   pro-­‐inflammatory	   cytokines	   allowing	   them	   to	   greatly	  
influence	  the	  immune	  response	  (Serbina	  et	  al.	  2008).	  	  
	  
Monocytes	   are	   classified	   into	   subsets	   depending	   on	   the	   expression	   of	   surface	  
markers:	   CD14++CD16-­‐	   “classical”	   monocytes,	   CD14+CD16++	   “non-­‐classical”	  
monocytes,	   and	   CD14++CD16+	   “intermediate”	   monocytes	   [Figure	   1.5]	   (L.	   Ziegler-­‐
Heitbrock	   et	   al.	   2010).	   The	   terminology	   “CD14dimCD16++”	  has	   also	  been	  used	   for	  
non-­‐classical	  monocytes	   by	   some	   authors.	   These	   terms	   have	   no	   direct	   relation	   to	  
macrophage	  activation.	  
	  
Figure	  1.5	  	  Classification	  of	  monocyte	  subsets	  using	  flow	  cytometry.	  	  Monocytes	  are	  identified	  using	  
forward	  and	  side	  scatter	  (FSC	  and	  SSC	  respectively)	  and	  further	  categorized	  according	  to	  the	  surface	  
expression	  of	  CD14	  and	  CD16:	  CD14++CD16-­‐	  (classical);	  CD14++CD16+	  (intermediate);	  CD14+CD16++	  
(non-­‐classical)	  (Han	  et	  al.	  2009;	  H.	  W.	  Ziegler-­‐Heitbrock	  2000).	  
Non-­‐classical	  monocytes	  are	  smaller	  than	  classical	  monocytes	  and	  have	  a	  more	  pro-­‐
inflammatory	   role	   (increased	   expression	   of	   MHC	   class	   II	   molecules,	   increased	  
(Fig. 1A). To characterize the phenotypes of circulating
CD14highCD16+ and CD14lowCD16+ monocyte subsets in
healthy individuals, we analyzed the x ression pattern of
additional surface molecules that have been reported to relate
to immune functions in monocyte subsets, including Fcg
receptor I (CD64), major histocompatibility complex mole-
cules (HLA-DR), and B7 molecules (CD80 and CD86). Com-
pared with CD14lowCD16+subsets, CD14highCD16+ expressed
similar levels of CD86 but higher levels of CD64, HLA-DR,
and CD80 (Fig. 1B). Of note, CD64 and HLA-DR, which are
closely related to the differentiation and immune function of
monocytes,21,22,24 were the 2 molecules that showed the
most dramatic difference between CD14highCD16+ and
CD14lowCD16+ subsets (2.98-fold higher for CD64 and
2.64-fold higher for HLA-DR). Therefore, CD14highCD16+
cells resembled the CD14+CD16+CD64+ monocytes with an
immunoregulatory monocyte phenotype and an intermediate
henotype between that of monocytes and dendritic cells
(DCs), as described previously.1,21 Because CD14highCD16+
and CD14lowCD16+ subsets showed different phenotypic
characteristics, they might possess distinct immunoregulatory
functions during HIV infection and AIDS progression.
CD14highCD16+ Rather Than CD14lowCD16+
Monocytes Wer Correlated With Dise e
Progression in HAART-Naive
HIV-Infected Patients
HIV-1 may lead to an incre se in CD16+ monocytes;
therefore, we investigated whether there was an increase in
CD14high and CD14low subsets of CD16+ monocytes. To
FIGURE 1. Phenotypic identification
of monocyte subsets. A, Gating of
monocyte subsets. Monocyte sub-
sets present in the whole blood were
identified using light scatter charac-
teristics (left panel) and CD14/CD16
expression patterns (right panel).
Three monocyte subsets,
CD14highCD162, CD14highCD16+,
and CD14lowCD16+ were gated for
further analysis. B, Surface expres-
sion of CD64, CD86, HLA-DR, and
CD80 on monocyte subsets. Left
panel shows representative histo-
gram. Right panel represents data
for mean fluorescence intensity
(mean 6 SD) for healthy controls.
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phagocytosis	   and	   production	   of	   pro-­‐inflammatory	   cytokines)	   (L.	   Ziegler-­‐Heitbrock	  
2006;	  Martinez	  2009;	  Aguilar-­‐Ruiz	  et	  al.	  2011).	   In	  contrast,	  classical	  monocytes	  are	  
thought	  of	  as	  a	   resting	  cells	  and	   intermediate	  monocytes	  a	   transition	  between	  the	  
two	  (K.	  L.	  Wong	  et	  al.	  2011).	  In	  healthy	  individuals,	  classical	  monocytes	  make	  up	  90%	  
of	   the	   circulating	   population;	   however,	   proportions	   of	   non-­‐classical	   and	  
intermediate	   monocytes	   are	   increased	   in	   a	   variety	   of	   inflammatory	   conditions,	  
including	   bacterial	   sepsis,	   rheumatoid	   arthritis	   and	   HIV-­‐1	   infection	   (L.	   Ziegler-­‐
Heitbrock	   2006).	   In	   HIV-­‐1	   infection,	   the	   frequency	   of	   intermediate	   monocytes	   is	  
particularly	   increased,	   especially	   those	   expressing	   the	   haemoglobin-­‐haptoglobin	  
scavenging	   receptor	   CD163;	   these	   cells	   demonstrate	   a	   strong	   positive	   correlation	  
with	   HIV-­‐1	   viral	   load	   and	   inverse	   correlation	   with	   CD4	   count	   (Fischer-­‐Smith	   et	   al.	  
2008;	  Han	  et	  al.	  2009).	  When	  monocytes	  are	  activated,	   they	  shed	  CD163	   from	  the	  
cell	   surface	   into	   the	   surrounding	   environment.	   The	   purpose	   of	   soluble	   CD163	  
(sCD163)	   is	  not	  well	  understood	  but	  there	   is	  evidence	  to	  suggest	   it	  has	  an	  immune	  
regulatory	   role	   (Moller	   2012).	   Serum	   levels	   of	   sCD163	   reflect	   monocyte	   and	  
macrophage	  activation	  and	  are	  also	  elevated	   in	  a	  range	  of	   inflammatory	  disorders,	  
including	   haemophagocytic	   syndrome,	   acute	   liver	   failure,	   rheumatoid	   arthritis,	  
tuberculosis,	   and	   bacterial	   sepsis	   (Moller	   2012).	   Similar	   to	   the	   surface	   bound	  
molecule,	   sCD163	   is	   also	   elevated	   in	   HIV-­‐1	   infection	   and	   correlates	   with	   HIV	   viral	  
load.	   Furthermore,	   it	   is	   elevated	   in	   individuals	  with	   HIV-­‐associated	   neurocognitive	  
disorder	  and	  with	  non-­‐calcified	   coronary	  plaques,	   suggesting	  a	  possible	   role	   in	   the	  
pathogenesis	  of	  these	  disorders	  (Burdo,	  Lentz,	  et	  al.	  2011a;	  Burdo,	  Lo,	  et	  al.	  2011b;	  
Burdo	  et	  al.	  2013).	  	  
	  
As	   the	   precursors	   to	   macrophages,	   monocytes	   have	   a	   number	   of	   important	   anti-­‐
cryptococcal	   activities.	   They	   migrate	   to	   areas	   of	   infection	   via	   CCR2	   dependent	  
chemotaxis	   and	   can	   kill	   cryptococci	   through	   phagocytosis	   and	   intracellular	   killing	  
(Miller	   &	   T.	   G.	  Mitchell	   1991).	   The	   importance	   of	   this	   has	   been	   demonstrated	   by	  
experimental	  infection	  of	  CCR2	  knockout	  mice	  with	  C.	  neoformans.	  When	  compared	  
to	  wild	  type,	  knockout	  mice	  were	  found	  to	  have	  reduced	  accumulation	  of	  monocytes	  
and	  macrophages	  in	  the	  lungs,	  impaired	  fungal	  clearance	  and	  marked	  dissemination	  
of	  organism	  (Osterholzer	  et	  al.	  2011).	  In	  HIV-­‐1	  infection	  the	  anti-­‐cryptococcal	  action	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of	  monocytes	   is	  also	   impaired,	  most	  probably	  a	  result	  of	   reduced	  respiratory	  burst	  
activity	   rather	   than	   impaired	   phagocytosis	   (Harrison	   &	   Levitz	   1997).	   Circulating	  
monocytes	   harbouring	   viable	   cryptococci	   are	   implicated	   as	   a	   possible	   vehicle	   for	  
blood-­‐brain-­‐barrier	  penetration	  and	  development	  of	  CNS	  disease.	  This	   is	  supported	  
by	  experimental	  data	  from	  mouse	  models	  showing	   increased	  CNS	  fungal	  burden	   in	  
mice	   infected	   with	   cryptococci-­‐containing	   monocytes	   rather	   than	   free	   yeast	   cells	  
(Charlier	  et	  al.	  2009).	  	  
1.6.4 T	  cells	  	  
CD4	   T	   cells	   (or	   T	   helper	   cells)	   are	   lymphocytes	   whose	   main	   role	   is	   coordinating	  
cellular	  responses	  in	  host	  adaptive	  immunity.	  They	  are	  antigen	  specific	  and	  will	  only	  
respond	   to	   a	   single	   epitope,	   a	   consequence	   of	   post-­‐translational	   gene	  
rearrangement	   during	   thymic	   maturation	   (Murphy	   2012a).	   Naïve	   CD4	   T	   cells	   are	  
activated	   when	   they	   encounter	   their	   respective	   antigen	   bound	   to	   a	   MHC	   class	   II	  
molecule	  on	  the	  surface	  of	  an	  antigen	  presenting	  cell	   (Murphy	  2012b).	  Following	  a	  
variety	  of	  additional	  co-­‐stimulatory	  signals,	  CD4	  T	  cells	  are	  activated,	  proliferate	  and	  
differentiate	   into	   memory	   or	   effector	   T	   cells,	   with	   several	   functionally	   distinct	  
subpopulations.	  	  
	  
CD4	  T	  cells	  play	  a	  vital	  role	  in	  the	  effective	  host	  immune	  response	  to	  C.	  neoformans	  
infection.	  This	  is	  demonstrated	  by	  the	  marked	  increase	  in	  susceptibility	  of	  individuals	  
with	  AIDS	  (Kovacs	  et	  al.	  1985).	  Post	  mortem	  examination	  of	  persons	  who	  have	  died	  
from	   HIV-­‐associated	   cryptococcosis	   have	   shown	   widespread	   dissemination	   of	  
organisms	  with	  a	  profound	  lack	  of	  inflammatory	  response	  [section	  1.4.3]	  (Lee	  et	  al.	  
1996).	  A	  similar	  appearance	  has	  been	  noted	  when	  mice	  that	  congenitally	  lack	  T	  cells	  
(nude	   mice)	   or	   those	   depleted	   of	   CD4	   T	   cells	   were	   infected	   with	   C.	   neoformans,	  
namely	  a	  paucity	  of	  cellular	   infiltrate	  and	  no	  evidence	  of	  granuloma	  formation	  (Hill	  
1992;	   Salkowski	   &	   Balish	   1991;	   Mody	   et	   al.	   1990).	   Compared	   to	   wild-­‐type,	   both	  
these	   groups	   of	   mice	   were	   shown	   to	   be	   significantly	   more	   susceptible	   to	  
cryptococcal	   infection,	   have	   increased	   fungal	   burden,	   systemic	   dissemination	   and	  
reduced	  survival	  (Graybill	  &	  Drutz	  1978;	  Salkowski	  &	  Balish	  1991;	  Mody	  et	  al.	  1990).	  
The	   relevance	  of	   CD4	  T	   cells	   in	   protective	  host	   immunity	   against	  C.	   neoformans	   is	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further	   emphasized	   by	   murine	   experiments	   showing	   the	   benefit	   of	   prior	   antigen	  
exposure	   (Hill	   &	   Aguirre	   1994;	   Kawakami	   et	   al.	   1995;	   Buchanan	   &	   Doyle	   2000).	  
Immunized	   mice	   have	   a	   more	   robust	   cellular	   inflammatory	   response	   against	   C.	  
neoformans,	   with	   significantly	   higher	   tissue	   levels	   of	   IFN-­‐γ	   and	   TNF-­‐α,	   increased	  
expression	  of	  surface	  activation	  markers	  on	  macrophages	  (MHC	  II,	  ICAM-­‐1	  and	  Fcγ-­‐R)	  
and	   increased	   phagocytosis	   of	  C.	   neoformans	   (Kawakami	   et	   al.	   1995;	   Uicker	   et	   al.	  
2005).	   Depletion	   experiments	   confirm	   this	   protection	   to	   be	   dependent	   on	   the	  
presence	   of	   CD4	   T	   cells	   and	   IFN-­‐γ	   (Hill	   &	   Aguirre	   1994;	   Kawakami	   et	   al.	   1995;	  
Buchanan	  &	  Doyle	  2000).	  Furthermore,	  transfer	  of	  lymph	  node	  and	  spleen	  cells	  from	  
immunized	  mice	   have	   been	   shown	   to	   confer	   protection	   in	  C.	   neoformans-­‐infected	  
SCID	   mice	   (lacking	   T	   and	   B	   lymphocytes);	   this	   protection	   was	   maintained	   if	   mice	  
were	   infused	   solely	  with	   T	   cells,	   but	   lost	   if	   T	   cells	  were	   depleted	   prior	   to	   transfer	  
(Huffnagle	  et	  al.	  1991;	  Hill	  &	  Aguirre	  1994;	  Aguirre	  et	  al.	  1995).	  Depletion	  of	  IFN-­‐γ	  or	  
TNF-­‐α	   during	   challenge	   also	   leads	   to	   a	   loss	   of	   protection	   and	   an	   inability	   to	   focus	  
inflammation	   at	   the	   site	   of	   infection,	   resulting	   in	   large	  macroscopic	   lesions	   in	   the	  
brain	  (Aguirre	  et	  al.	  1995).	  	  
	  
Taken	   together	   these	   data	   support	   the	   vital	   role	   CD4	   T	   cells	   and	   the	   pro-­‐
inflammatory	   cytokines	   IFN-­‐γ	   and	   TNF-­‐α	   in	   protective	   host	   immunity	   against	   C.	  
neoformans.	   There	   are	   also	   murine	   data	   from	   T	   cell	   depletion	   experiments	   that	  
suggest	  CD8	  T	  cells	  may	  also	  play	  an	  additional	  minor	  role	  in	  limiting	  dissemination	  
of	  the	  organism	  (Huffnagle	  et	  al.	  1991).	  	  
1.6.5 Polarization	  of	  cell-­‐mediated	  Immunity	  	  
As	   previously	   mentioned,	   CD4	   T	   cells	   have	   the	   ability	   to	   differentiate	   into	  
functionally	   distinct	   subsets,	   a	   process	   influenced	   by	   surrounding	   cytokines	   and	  
stimulation	   from	   antigen	   presenting	   cells	   (APCs).	   The	   presence	   of	   IFN-­‐γ	   and	   IL-­‐12	  
during	   T	   cell	   activation	   (produced	   by	   natural-­‐killer	   cells	   and	   APCs	   respectively)	  
promotes	   their	   differentiation	   into	   Th1	   cells	   –	   a	   vital	   component	   of	   host	   defence	  
against	   pathogens	   that	   parasitize	  macrophages	   (Romagnani	   1997).	   These	   Th1	   cells	  
are	   able	   to	   produce	   large	   amounts	   of	   IFN-­‐γ,	   TNF-­‐α	   and	   IL-­‐2,	   resulting	   in	   a	   M1	  
macrophage	   phenotype	   (classical	   activation),	   increased	   intracellular	   killing	   and	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granuloma	  formation	  (Murphy	  2012c).	  In	  contrast,	  the	  presence	  of	  IL-­‐4	  during	  T	  cell	  
activation	  (possibly	  produced	  by	  eosinophils,	  basophils,	  or	  mast	  cells)	  induces	  naïve	  
CD4	   T	   cells	   to	   differentiate	   into	   Th2	   cells	   –	   a	   crucial	   component	   of	   host	   defence	  
against	   helminths.	   	   Th2	   cells	   produce	   IL-­‐4,	   IL-­‐5	   and	   IL-­‐13,	   which	   results	   in	   the	  
promotion	   of	   eosinophil	   and	   mast	   cell	   responses,	   the	   stimulation	   of	   B	   cells	   to	  
produce	   IgE,	   and	   a	   M2	   (alternatively	   activated)	   macrophage	   phenotype	   (Murphy	  
2012c).	   Numerous	   experiments	   have	   been	   conducted	   in	   mouse	   models	   to	  
investigate	   the	   effects	   of	   T	   cell	   polarization	   on	   host	   immunity	   to	   C.	   neoformans,	  
these	  are	  summarized	  below.	  
	  
The	  effects	  of	   IFN-­‐γ	   in	  promoting	  a	  Th1	   response	  during	   cryptococcosis	  have	  been	  
investigated	   by	   adding	   exogenous	   IFN-­‐γ	   during	   C.	   neoformans	   infection,	   and	   by	  
infecting	  mice	  with	  an	  IFN-­‐γ-­‐producing	  strain	  of	  C.	  neoformans	  (H99-­‐γ)	  (Kawakami	  et	  
al.	  1995;	  Wormley	  et	  al.	  2007).	  Both	  of	  these	  scenarios	  have	  been	  shown	  to	  result	  in	  
the	   skewing	   of	   pulmonary	   cytokines	   towards	   a	   Th1	   response,	   an	   increased	  
pulmonary	   cellular	   infiltrate	   (neutrophils,	   MHC	   II	   expressing	   cells,	   CD4	   and	   CD8	  
lymphocytes),	   reduced	   fungal	  burden	  and	  significantly	   improved	  survival	   (Wormley	  
et	   al.	   2007).	   	  While	  pulmonary	  macrophages	   from	  mice	   infected	  with	  a	  non-­‐IFN-­‐γ-­‐
producing	   strain	   displayed	   markers	   of	   alternative	   activation	   and	   contained	   highly	  
encapsulated	   replicating	   cryptococci,	   macrophages	   from	  mice	   infected	  with	   H99-­‐γ	  
displayed	   markers	   of	   classical	   activation	   and	   evidence	   of	   enhanced	   macrophage	  
fungicidal	   activity	   (Hardison	   et	   al.	   2010).	   Furthermore,	   prior	   infection	   with	   H99-­‐γ	  
resulted	   in	   a	   dramatic	   improvement	   in	   survival	   following	   re-­‐challenge	   with	   the	  
normally	   fatal	  H99	  strain	  –	  significantly	  more	  effective	  than	  all	  other	   immunization	  
strategies	  (Wormley	  et	  al.	  2007).	  Deletion	  experiments	  showed	  this	  protection	  to	  be	  
dependent	  on	  T	  cells	  and	  a	  Th1	  cytokine	  response	  (Wozniak	  et	  al.	  2008).	  In	  contrast,	  
IFN-­‐γ	   depletion	   or	   knockout	   led	   to	   a	   Th2	   skew	   in	   cytokine	   profile,	   a	   reduction	   in	  
classical	   macrophage	   activation	   and	   a	   significantly	   impaired	   response	   to	   infection	  
(impaired	   macrophage	   phagocytosis/killing	   of	   yeasts,	   increased	   pulmonary	   fungal	  
load,	  marked	  neutrophil	  and	  eosinophil	  infiltration,	  dissemination	  of	  the	  organism	  to	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the	   brain	   and	   dramatically	   reduced	   survival)	   (Hoag	   et	   al.	   1997;	   G.-­‐H.	   Chen	   et	   al.	  
2005;	  Aguirre	  et	  al.	  1995).	  	  	  
	  
Th1/M1	   signalling	   can	  also	  be	   induced	  by	   treating	   infected	  mice	  with	   IL-­‐12,	   a	  pro-­‐
inflammatory	   cytokine	   produced	   by	   dendritic	   cells,	   macrophages	   and	   neutrophils	  
(Trinchieri	  2003).	   	   This	  has	  been	  shown	   to	   result	   in	   significantly	   improved	  survival,	  
increased	   IFN-­‐γ	   production,	   increased	   pulmonary	   inflammatory	   response	   and	  
reduced	  fungal	  burden	  (Kawakami	  et	  al.	  1996).	  The	  beneficial	  effects	  of	   IL-­‐12	  were	  
negated	  if	  mice	  were	  IFN-­‐γ	  deplete	  or	  treated	  with	  IL-­‐4	  prior	  to	  infection;	  however,	  
they	  were	   improved	   if	  mice	  were	   treated	  simultaneously	  with	   IL-­‐18	   (Qureshi	  et	  al.	  
1999;	   Kawakami,	  Qureshi,	   et	   al.	   1999b;	   Kawakami,	  Hossain	  Qureshi,	   et	   al.	   1999a).	  
Conversely,	  knockout	  or	  depletion	  of	   IL-­‐12	  in	  mice	  prior	  to	  C.	  neoformans	   infection	  
resulted	   in	   a	   deleterious	   Th2-­‐skewed	   response,	   with	   reduced	   levels	   of	   IFN-­‐γ	   and	  
significantly	  reduced	  survival	  (Decken	  et	  al.	  1998;	  Hoag	  et	  al.	  1997).	  The	  effect	  was	  
even	  more	  dramatic	   in	   IL-­‐12p40	  and	   IL-­‐18	  double	   knockout	  mice	   (Kawakami	   et	   al.	  
2000).	  	  
	  
The	  deleterious	  effects	  of	  a	  Th2	  skew	  to	  the	  immune	  response	  and	  the	  presence	  of	  
M2	   macrophages	   are	   further	   demonstrated	   by	   IL-­‐13	   overproducing	   transgenic	  
BALB/c	  mice.	  These	  mice	  were	  found	  to	  have	  reduced	  survival	  and	  higher	  pulmonary	  
fungal	  loads	  compared	  to	  wild	  type,	  and	  had	  significantly	  worse	  cerebral	  disease	  and	  
large	   pseudocystic	   lesions	   bordered	   by	   foamy	   alternatively	   activated	  macrophages	  
(Stenzel	  et	  al.	  2009).	  In	  contrast,	  blocking	  Th2	  signalling	  though	  genetic	  knockout	  (or	  
depletion)	  of	  IL-­‐4,	  IL-­‐13,	  or	  IL-­‐4Rα	  (IL-­‐4	  receptor	  α	  chain,	  required	  for	  IL-­‐4	  and	  IL-­‐13	  
receptors)	  resulted	   in	  a	  beneficial	  Th1/M1	  response	  (Nelms	  et	  al.	  1999;	  Kawakami,	  
Hossain	   Qureshi,	   et	   al.	   1999a;	   Blackstock	   &	   J.	   W.	   Murphy	   2004).	   This	   was	  
characterized	   by	   a	   switch	   from	   alternatively	   activated	   to	   classically	   activated	  
macrophages,	   a	   reduction	   in	   eosinophilia	   and	   fungal	   burden,	   and	   significantly	  
improved	   survival	   (Kawakami,	   Hossain	   Qureshi,	   et	   al.	   1999a;	   Müller	   et	   al.	   2007;	  
Müller	   et	   al.	   2008;	   Zhang	   et	   al.	   2009;	   Stenzel	   et	   al.	   2009).	   Similar	   results	   were	  
obtained	  when	  lox-­‐cre	  mice	  were	  used	  to	  restrict	  the	  IL-­‐4Rα	  knockout	  solely	  to	  CD4	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T	   cells	   or	   to	   macrophages	   (therefore	   creating	   Th1	   cells	   or	   classically	   activated	  
macrophages	   in	   isolation)	   (Müller	   et	   al.	   2012;	   Müller	   et	   al.	   2013).	   IL-­‐33	   is	   an	  
important	   driving	   factor	   in	   the	   establishment	   of	   the	   Th2	   response	   and	   is	   up-­‐
regulated	  in	  murine	  cryptococcal	  infection	  (Flaczyk	  et	  al.	  2013;	  Liew	  et	  al.	  2010).	  Its	  
deleterious	  effects	  in	  cryptococcosis	  were	  demonstrated	  by	  C.	  neoformans	  infection	  
of	   IL-­‐33	   receptor	   deficient	   mice,	   which	   had	   a	   lower	   fungal	   burden,	   reduced	  
dissemination	   of	   organism,	   increased	   M1	   macrophages,	   and	   improved	   survival	  
(Flaczyk	   et	   al.	   2013).	   In	   addition	   to	   adding	   exogenous	   cytokines,	   the	   host	   T	   cell	  
response	  can	  also	  be	  polarized	   towards	  a	  Th1	   response	   through	   infection	  with	   the	  
gut-­‐restricted	   bacteria	   Citrobacter	   rodentium,	   with	   similarly	   beneficial	   effects	  
(Williams	  et	  al.	  2006).	  
	  
Th17	   cells	   are	   another	   CD4	   subtype	   and	   arise	   when	   IL-­‐6	   and	   TGF-­‐β	   are	   present	  
during	  activation	  (but	  IL-­‐12	  and	  IL-­‐4	  are	  absent);	  they	  help	  to	  control	  infection	  with	  
extracellular	   bacteria	   and	   fungi	   through	   the	   production	   of	   IL-­‐17	   and	   activation	   of	  
neutrophils	   (Murphy	   2012c).	   There	   is	   evidence	   to	   suggest	   that	   the	   Th17	   response	  
offers	   some	   degree	   of	   protection	   against	   infection	   with	   C.	   neoformans	   and	   it	   is	  
interesting	  to	  note	  that	  C.	  neoformans	  has	  been	  shown	  to	  inhibit	  the	  production	  of	  
IL-­‐17	   during	   Th17	   cell	   differentiation	   through	   the	   production	   of	   prostaglandin	   E2	  
(Valdez	  et	  al.	  2012).	  Blockade	  of	  this	  has	  been	  shown	  to	  result	  in	  increased	  levels	  of	  
IL-­‐17	   and	   improved	   survival	   in	   mice	   (Valdez	   et	   al.	   2012).	   The	   effect	   of	   Th17	  
polarization	   in	   cryptococcosis	   has	   also	   been	   explored	   by	   manipulating	   IL-­‐23,	   a	  
cytokine	  produced	  by	  APCs	  that	  promotes	  the	  Th17	  phenotype	  (Langrish	  et	  al.	  2004).	  
Following	   infection	   with	   C.	   neoformans,	   IL-­‐23	   knockout	   mice	   had	   preserved	   IFN-­‐γ	  
levels	  but	  significantly	  reduced	  IL-­‐17	  production.	  This	  resulted	  in	  a	  modest	  reduction	  
survival	   and	   delayed	   fungal	   clearance,	   along	   with	   reduced	   hepatic	   granuloma	  
formation	   and	   reduced	   expression	   of	   IL-­‐1b,	   IL-­‐6	   and	   MCP-­‐1/CCL2	   in	   the	   brain	  
(Kleinschek	   et	   al.	   2006).	   The	   fact	   that	   IL-­‐12/IL-­‐23	   dual	   knockout	   mice	   had	  
significantly	   worse	   survival	   than	   either	   of	   the	   single	   knockouts,	   suggests	   a	  
complementary	   action	   of	   Th1	   and	   Th17	   responses	   in	   anti-­‐cryptococcal	   immunity	  
(Kleinschek	   et	   al.	   2006).	   However,	   no	   difference	   in	   outcome	   was	   noted	   between	  
wild-­‐type	  and	  IL-­‐17	  knockout	  mice	  when	  infected	  with	  the	  IFN-­‐γ	  producing	  strain	  of	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H99,	   suggesting	   that	   the	   Th17	   response	   is	   less	   important	   compared	   to	   the	   Th1	  
response	  (Wozniak	  et	  al.	  2011).	  Similarly,	  although	  the	  addition	  of	  exogenous	  IL-­‐23	  
to	  mice	  prior	  to	  infection	  has	  been	  shown	  to	  result	  in	  an	  induction	  of	  Th17	  cytokines	  
(IL-­‐17,	  IL-­‐22,	  IL-­‐6	  and	  IL-­‐1b)	  and	  improved	  survival,	  the	  effect	  is	  not	  as	  dramatic	  as	  IL-­‐
12	  treatment	  (Kleinschek	  et	  al.	  2010).	  	  
	  
In	  summary,	  it	  is	  clear	  from	  experiments	  in	  the	  murine	  model	  of	  cryptococcosis	  that	  
a	  Th1	  response	  is	  beneficial,	  a	  Th2	  response	  is	  detrimental	  and	  a	  Th17	  response	  has	  
some	   minor	   benefits	   in	   host	   immunity.	   However,	   a	   degree	   of	   caution	   must	   be	  
maintained	   when	   applying	   these	   principles	   to	   cryptococcosis	   in	   humans.	   Mouse	  
strains	   are	   inbred,	   each	   harbouring	   specific	   genetic	   weaknesses	   meaning	  
susceptibility	  and	  response	  to	  infection	  can	  vary	  significantly	  between	  strains	  (Chen	  
et	  al.	  2008).	  Furthermore,	  although	  the	  Th1/Th2/Th17	  paradigm	  is	  well	  characterized	  
in	   mice,	   evidence	   that	   it	   is	   relevant	   in	   humans	   is	   not	   so	   clear	   (Rook	   2001).	   In	  
addition,	   it	   is	   likely	   that	   the	   model	   of	   macrophage	   activation	   is	   also	   an	  
oversimplification,	   and	   more	   resembles	   a	   spectrum	   of	   activity	   rather	   than	   a	  
dichotomous	  state	  (Mosser	  &	  Edwards	  2008;	  Davis	  et	  al.	  2013).	  Finally,	  although	  the	  
benefits	  of	  pro-­‐inflammatory	  cytokines	  such	  as	  IFN-­‐γ	  and	  TNF-­‐α	  appear	  to	  be	  clear	  in	  
humans,	   there	   is	   less	   evidence	   that	   in	   advanced	   HIV-­‐1	   infection	   host	   immunity	   is	  
skewed	   towards	   a	   Th2	   or	   Th17	   response	   (Jarvis	   et	   al.	   2013).	   These	   differences	  
between	   human	   and	   murine	   experiments	   may	   reflect	   inherent	   differences	   in	   the	  
host	  (human	  vs.	  mouse),	  infecting	  strain	  (clinical	  vs.	  laboratory),	  the	  presence	  of	  HIV-­‐
1	   infection,	   or	   simply	   the	   timing	   of	   infection	   (murine	   experiments	   are	   typically	  
conducted	  days	  or	  weeks	  after	  infection	  whilst	  humans	  may	  be	  latently	  infected	  for	  
years	  prior	  to	  developing	  disease).	  This	  is	  discussed	  further	  in	  chapter	  8	  [section	  8.2].	  	  
1.6.6 Antibody	  mediated	  immunity	  
Although	   the	   majority	   of	   evidence	   supports	   the	   theory	   that	   protection	   from	  
cryptococcal	   disease	   is	   largely	   dependent	   on	   cell-­‐mediated	   immunity,	   there	   are	  
some	  data	   suggesting	  antibody-­‐mediated	   immunity	  may	  also	  play	  a	   role.	   This	  may	  
explain	   the	   reason	   why,	   despite	   widespread	   evidence	   of	   environmental	   exposure	  
(Goldman	   et	   al.	   2001),	   not	   all	   HIV-­‐1-­‐infected	   individuals	   with	   low	   CD4	   counts	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develop	   cryptococcosis.	   Indeed,	   recent	   work	   has	   shown	   an	   increased	   risk	   of	  
cryptococcosis	   among	   individuals	  with	   specific	  polymorphisms	  of	   the	  Fc-­‐γ	   receptor	  
3A,	  and	   it	   is	  conceivable	  that	  HIV-­‐1-­‐induced	  B	  cell	  dysfunction	  may	  also	  play	  a	  role	  
(Rohatgi	   et	   al.	   2013;	   Casadevall	   &	   Pirofski	   2005).	   Although	   the	   effects	   of	   B	   cell	  
depletion	   in	   murine	   models	   of	   cryptococcal	   disease	   are	   conflicting,	   passive	  
immunization	  with	  anti-­‐GXM	  antibodies,	  or	   vaccines	  which	  elicit	   a	   strong	  antibody	  
response	   to	   GXM,	   have	   been	   shown	   to	   confer	   a	   degree	   of	   protection	   against	   C.	  
neoformans	  infection	  (Monga	  et	  al.	  1979;	  Rivera	  et	  al.	  2005;	  Dromer	  et	  al.	  1987;	  Devi	  
1996).	  In	  addition,	  anti-­‐GXM	  antibodies	  have	  been	  shown	  to	  offer	  additional	  benefit	  
when	   combined	   with	   amphotericin	   B	   therapy	   in	  murine	  models	   of	   cryptococcosis	  
(Dromer	  &	  Charreire	  1991).	  The	  mechanism	  of	  antibody	  protection	  is	  thought	  to	  be	  
via	   improvement	   in	  phagocytosis	  and	  activation	  of	  complement.	  However,	   the	   fact	  
that	   administration	   of	   IgG1	   anti-­‐GXM	   mAb	   is	   not	   protective	   in	   mice	   that	   have	  
additional	  cellular	  immune	  defects	  (depletion	  of	  CD4	  cells,	  IFN-­‐γ,	  and	  inducible	  nitric	  
oxide	  synthase)	  suggests	  its	  main	  actions	  are	  to	  potentiate	  Th1	  mediated	  immunity	  
(Casadevall	  &	  Pirofski	  2005).	  
1.6.7 Neutrophils	  
Well	   recognized	  as	  vital	   to	   the	  host	  defence	  against	  extracellular	   fungal	  pathogens	  
such	  as	  Aspergillus	  (Neofytos	  et	  al.	  2010)	  (Lin	  et	  al.	  2001),	  the	  role	  of	  neutrophils	  in	  
anti-­‐cryptococcal	   immunity	   is	   not	   well	   established.	   Although	   neutrophils	   do	  
demonstrate	  anti-­‐cryptococcal	  activity	  in	  vitro,	  produce	  pro-­‐inflammatory	  cytokines	  
when	   exposed	   to	   C.	   neoformans	   and	   are	   seen	   in	   association	   with	   infecting	  
cryptococci	  in	  about	  50%	  of	  pathology	  specimens	  from	  immunocompetent	  patients	  
(Miller	  &	  T.	  G.	  Mitchell	  1991;	  Retini	  et	  al.	  1996;	  Baker	  &	  Haugen	  1955),	  the	  fact	  that	  
cryptococcosis	  is	  not	  a	  common	  complication	  of	  neutropenia	  or	  neutrophil	  disorders	  
suggests	  they	  do	  not	  play	  a	  major	  role	  in	  protective	  host	   immunity	  (Antachopoulos	  
et	   al.	   2007;	   Neofytos	   et	   al.	   2010).	   Furthermore,	   neutrophil	   depleted	   mice	   were	  
found	   to	   survive	   longer	   in	   pulmonary	  C.	   neoformans	   infection	   and	   had	   a	   reduced	  
pulmonary	   fungal	   burden	   compared	   to	   wild-­‐type	   mice	   (Mednick	   et	   al.	   2003).	  
However,	   knockout	   of	   myeloperoxidase	   (an	   enzyme	   which	   generates	   reactive	  
oxygen	   species,	   found	   mainly	   in	   neutrophils)	   prior	   to	   cryptococcal	   challenge	   has	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been	   shown	   to	   lead	   to	   increased	   fungal	   burden,	   increased	   dissemination	   of	   the	  
organism	   and	   markedly	   reduced	   survival.	   This	   was	   associated	   with	   a	   skew	   in	  
pulmonary	  cytokines	  towards	  a	  Th2	  response,	  suggesting	  the	  balance	  between	  pro-­‐	  
and	   anti-­‐	   inflammatory	   response	   does	   not	   simply	   rely	   on	   T	   cell	   differentiation	  
(Aratani	  et	  al.	  2006).	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1.7 Immune	  correlates	  of	  poor	  outcome	  in	  humans	  
In	   contrast	   to	   the	  wealth	   of	   data	   from	   animal	  models,	   there	   are	   very	   few	   studies	  
examining	  immune	  correlates	  of	  poor	  outcome	  in	  humans.	  A	  summary	  of	  the	  current	  
literature	   is	   presented	  below.	  A	  discussion	   regarding	   the	   reasons	  behind	  observed	  
differences	  in	  humans	  and	  animal	  studies	  is	  included	  	  
1.7.1 CD4	  T	  cells	  
Although	   low	   peripheral	   CD4	   count	   is	   strongly	   associated	   with	   risk	   of	   developing	  
cryptococcosis	   (Crowe	   et	   al.	   1991),	   large	   observational	   cohort	   studies	   of	   patients	  
with	  HIV-­‐associated	  CM	  have	  not	  identified	  peripheral	  CD4	  count	  to	  be	  significantly	  
associated	  with	  mortality	  when	  controlled	  for	  other	  factors	  (Jarvis	  et	  al.	  2014).	  
1.7.2 Interferon	  gamma	  
Similar	   to	   murine	   experiments,	   data	   from	   clinical	   studies	   suggest	   IFN-­‐γ	   plays	   an	  
important	   role	   in	   determining	   outcome	   from	   infection	   in	   humans.	   In	   an	  
observational	  study	  of	  patients	  with	  HIV-­‐associated	  CM	  in	  Thailand,	  survivors	  were	  
found	  to	  have	  higher	  CSF	  concentrations	  of	  the	  pro-­‐inflammatory	  cytokines	  IL-­‐6,	  IFN-­‐
γ,	   TNF-­‐α	   and	   IL-­‐8	   (Siddiqui	   et	   al.	   2005).	   Levels	   of	   TNF-­‐α,	   IFN-­‐γ	   and	   IL-­‐6	   were	  
negatively	  correlated	  with	  baseline	  fungal	  burden,	  and	  G-­‐CSF,	  TNF-­‐α,	  IFN-­‐γ	  and	  IL-­‐6	  
were	   positively	   correlated	   with	   faster	   fungal	   clearance	   (Siddiqui	   et	   al.	   2005).	   In	   a	  
multivariate	  linear	  regression	  model,	  only	  IFN-­‐γ	  remained	  independently	  associated	  
with	  clearance	  rate	  (Siddiqui	  et	  al.	  2005).	  Moreover,	  when	  assessed	  in	  a	  randomized	  
clinical	   trial	   among	   persons	   with	   HIV-­‐associated	   CM,	   IFN-­‐γ	   therapy	   resulted	   in	   a	  
significantly	  faster	  rate	  of	  CSF	  fungal	  clearance	  when	  given	  alongside	  amphotericin	  B	  
and	  flucytosine	  (Jarvis	  et	  al.	  2012).	  No	  significant	  difference	   in	  mortality	  was	  noted	  
between	  the	  groups;	  however,	  the	  trial	  was	  not	  powered	  to	  detect	  this.	  
1.7.3 CD4	  T	  cell	  phenotype	  in	  blood	  
An	   immunological	   sub-­‐study	   of	   the	   IFN-­‐γ	   trial	   described	   above	   examined	   the	  
relationship	   between	   peripheral	   blood	   CD4	   response	   and	   outcome.	   No	   significant	  
association	  was	   found	  between	   the	   total	   cryptococcal-­‐specific	   CD4	  T	   cell	   response	  
and	  baseline	  fungal	  burden,	  rate	  of	  clearance	  or	  2-­‐week	  mortality	  (Jarvis	  et	  al.	  2013).	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However,	   significant	   differences	  were	   noted	   between	   patients	  who	   died	   and	  who	  
survived	   in	   terms	   of	   the	   CD4	   functional	   phenotype.	   Those	   who	   died	   had	   a	  
significantly	   higher	   frequency	   of	   MIP-­‐1α/CCL3	   producing	   CD4	   cells.	   Conversely,	  
individuals	   who	   had	   a	   detectable	   IFN-­‐γ	   and/or	   TNF-­‐α	   response	   at	   baseline	   were	  
significantly	  more	  likely	  to	  survive	  than	  those	  who	  did	  not	  (Jarvis	  et	  al.	  2013).	  In	  the	  
same	  study,	  the	  number	  of	  IFN-­‐γ-­‐producing	  cryptococcus-­‐specific	  CD4	  T	  cells	   in	  the	  
peripheral	   blood	   was	   significantly	   associated	   with	   the	   CSF	   lymphocyte	   count.	  
Persons	  with	  an	  IFN-­‐γ/TNF-­‐α	  predominant	  CD4	  T	  cell	  response	  also	  had	  significantly	  
lower	   baseline	   fungal	   burden	   and	   a	   non-­‐significant	   trend	   towards	   higher	   levels	   of	  
pro-­‐inflammatory	   cytokines	   in	   the	   CSF,	   more	   rapid	   clearance	   of	   cryptococcal	  
infection	   from	   the	   CSF	   and	   lower	   mortality	   at	   two	   weeks	   (Jarvis	   et	   al.	   2013).	  
Although	   exploratory,	   this	   study	   suggests	   that	   it	   is	   not	   necessarily	   the	   number	   of	  
antigen	  specific	  CD4	  T	  cells	  circulating	  in	  the	  blood,	  but	  the	  nature	  of	  their	  response	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1.8 Complications	  of	  Immune	  Restoration	  
1.8.1 Restoration	  of	  immune	  function	  
It	  is	  well	  recognized	  that	  the	  initiation	  of	  ART	  and	  reversal	  of	  the	  profound	  immune	  
deficiency	   is	   essential	   to	   improve	   long-­‐term	   prognosis	   of	   individuals	   with	   AIDS-­‐
defining	   conditions.	   This	   is	   illustrated	   by	   the	   dramatic	   drop	   in	   HIV-­‐associated	  
mortality	  in	  North	  America	  and	  Europe	  following	  the	  introduction	  of	  ART	  in	  the	  late	  
1990s,	   and	   a	   similar	   improvement	   in	   prognosis	   among	   persons	   in	   sub-­‐Saharan	  
African	  in	  the	  2000s	  (Palella	  et	  al.	  1998;	  Floyd	  et	  al.	  2012).	  However,	  the	  initiation	  of	  
ART	   in	   individuals	   with	   advanced	   HIV-­‐1	   infection	   can	   lead	   to	   inflammatory	  
complications,	  known	  as	  immune	  reconstitution	  disease	  (M.	  A.	  French	  et	  al.	  2000;	  M.	  
A.	  French	  et	  al.	  2004).	  	  
	  
1.8.2 Immune	  Reconstitution	  Inflammatory	  Syndrome	  (IRIS)	  	  
Immune	  reconstitution	  inflammatory	  syndrome	  (IRIS)	  or	  Immune	  restoration	  disease	  
(IRD),	   is	  defined	  as	  “a	  paradoxical	  deterioration	  in	  clinical	  status	  attributable	  to	  the	  
recovery	  of	  the	   immune	  system”	  (Shelburne	  et	  al.	  2002).	   In	  HIV	   infection,	  this	  may	  
occur	  following	  the	  initiation	  of	  ART,	  and	  manifest	  as	  inflammatory	  reactions	  at	  the	  
site	  of	  previously	  treated	  or	  previously	  unrecognized	  opportunistic	  infections	  (M.	  A.	  
French	  et	  al.	  2004).	   IRIS	   is	  also	  described	   in	  HIV-­‐negative	   individuals	  who	  suddenly	  
reduce	  or	  stop	  taking	  potent	  immune	  suppressive	  therapy	  (Tan	  et	  al.	  2011;	  Pruitt	  et	  
al.	  2013).	  IRIS	  is	  split	  into	  paradoxical	  and	  unmasking	  forms:	  paradoxical	  IRIS	  occurs	  
in	  an	  individual	  who	  has	  received	  successful	  treatment	  for	  an	  opportunistic	  infection,	  
but	   following	   the	   initiation	   of	   ART	   experiences	   a	   clinical	   deterioration	   with	   a	  
recurrence	  of	  the	  original	  symptoms;	  unmasking	  IRIS	  refers	  to	  the	  scenario	  when	  a	  
sub-­‐clinical	   opportunistic	   infection	   becomes	   clinically	   apparent	   following	   ART	  
initiation,	   often	   presenting	   with	   unusual	   inflammatory	   features	   (Lawn	   &	  Meintjes	  
2011).	  A	  range	  of	  opportunistic	  infections	  have	  been	  associated	  with	  both	  forms	  of	  
IRIS	   including	   Mycobacterium	   tuberculosis,	   Mycobacterium	   avium	   complex,	  
Cryptococcus	  neoformans,	  Cytomegalovirus,	  Herpes	  Simplex	  Virus,	  hepatitis	  viruses	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and	   JC	   virus	   (M.	   A.	   French	   et	   al.	   2004);	   Kaposi’s	   sarcoma	   IRIS	   is	   also	   described	  
(Letang	  et	  al.	  2010).	  	  
1.8.3 Cryptococcal	  IRIS	  
Paradoxical	  cryptococcal	  IRIS	  (C-­‐IRIS)	  is	  reported	  to	  occur	  in	  13-­‐45%	  of	  HIV-­‐infected	  
individuals	  who	  start	  ART	  following	  treatment	  for	  cryptococcal	  meningitis.	   It	  occurs	  
at	  a	  median	  time	  of	  4-­‐9	  weeks	  following	  ART	  initiation	  but	  delayed	  cases	  have	  been	  
reported	   more	   than	   a	   year	   later	   (Boulware,	   Bonham,	   et	   al.	   2010a;	   Bicanic	   et	   al.	  
2009b;	   Shelburne	   et	   al.	   2005;	   Sungkanuparph	   et	   al.	   2009;	   Jarvis	   et	   al.	   2014).	   The	  
usual	  presentation	   is	  with	  a	   recurrence	  of	  meningitis	   symptoms	   (headache,	  nuchal	  
rigidity,	  vomiting)	  along	  with	  other	  CNS	  signs	  (raised	  intracranial	  pressure,	  decreased	  
consciousness,	   seizures,	   focal	   neurology).	   Non-­‐neurological	   presentations	   are	   less	  
commonly	  described	  but	  include	  ocular	  symptoms,	  lymphadenitis,	  pneumonitis	  and	  
soft	  tissue	  manifestations	  (Haddow	  et	  al.	  2010).	  Diagnosis	  is	  based	  on	  internationally	  
agreed	  criteria	  [Table	  1.3]	  with	  diagnostic	  workup	  targeted	  at	  excluding	  other	  causes	  
for	  deterioration	  (Haddow	  et	  al.	  2010).	  	  
	  




Cryptococcal	  disease	  diagnosed	  before	  ART	  	  
(positive	  culture	  or	  clinical	  features	  +	  CSF	  India	  Ink	  or	  CrAg)	  
Initial	  clinical	  response	  to	  antifungal	  therapy	  	  
Clinical	  Criteria	  
Clinical	  event	  within	  12	  months	  of	  ART	  start/switch	  after	  failure	  
Clinical	  disease	  worsening,	  presenting	  as	  
Meningitis	  
Lymphadenopathy	  






No	  evidence	  of	  non-­‐adherence	  or	  suboptimum	  antifungal	  therapy	  
No	  alternative	  infection	  or	  malignancy	  diagnosed	  at	  affected	  site	  
Failure	  of	  ART	  excluded	  if	  possible	  with	  HIV	  viral	  load	  testing	  
Table	  1.3	  	  INSHI	  diagnostic	  criteria	  for	  paradoxical	  cryptococcal-­‐IRIS	  (Haddow	  et	  al.	  2010)	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As	  with	  other	  neurological	  forms	  of	  IRIS,	  C-­‐IRIS	  has	  been	  associated	  with	  significant	  
morbidity	   and	   mortality	   (13-­‐36%),	   and	   has	   been	   identified	   as	   an	   independent	  
predictor	  of	   fatal	   outcome	   in	   studies	   from	  Uganda	   (Boulware,	  Meya,	   et	   al.	   2010b;	  
Jarvis	  et	  al.	  2014).	  Management	  of	  suspected	  C-­‐IRIS	  is	  based	  on	  expert	  opinion	  only.	  
Current	   guidance	   from	   the	   Southern	  African	  HIV	  Clinicians	   Society	   emphasizes	   the	  
importance	  of	  excluding	  cryptococcal	  relapse	  by	  performing	  a	  lumbar	  puncture	  and	  
CSF	   fungal	   culture	   (Govender	   et	   al.	   2013).	   Raised	   intracranial	   pressure	   should	   be	  
controlled	   with	   therapeutic	   CSF	   drainage	   (repeated	   daily	   if	   necessary).	  
Corticosteroids	   can	   be	   considered	   in	   cases	   of	   severe	   IRIS,	   preferably	   once	   other	  
aetiologies	   are	   excluded	   and	   CSF	   fungal	   culture	   result	   is	   known	   to	   be	   negative;	   in	  
patients	   with	   life-­‐threatening	   neurological	   deterioration	   they	   should	   be	   started	  
immediately	  (Govender	  et	  al.	  2013).	  	  
1.8.4 Pathophysiology	  of	  C-­‐IRIS	  
The	  exact	  immune	  pathogenesis	  of	  C-­‐IRIS	  is	  not	  well	  characterized.	  C-­‐IRIS	  appears	  to	  
be	   associated	   with	   a	   cellular	   infiltrate,	   which	   in	   some	   studies	   consisted	  
predominantly	  of	  neutrophils	  (Bicanic	  et	  al.	  2009b;	  Boulware,	  Bonham,	  et	  al.	  2010a).	  
On	  the	  rare	  occasion	  tissue	  responses	  have	  been	  examined	   in	  patients	  with	  C-­‐IRIS,	  
necrotizing	  granulomatous	  inflammation	  has	  been	  noted	  (Skiest	  et	  al.	  2005).	  Studies	  
comparing	   C-­‐IRIS	   to	   individuals	   with	   CM	   showed	   that	   those	   with	   C-­‐IRIS	   had	  
significantly	   reduced	   CSF	   fungal	   burden,	   increased	   CSF	   cell	   counts,	   increased	   CSF	  
protein,	  and	  increased	  CSF	  concentrations	  of	  the	  pro-­‐inflammatory	  cytokines	  TNF-­‐α,	  
IFN-­‐γ,	   VEGF	   and	   G-­‐CSF	   (Boulware,	   Bonham,	   et	   al.	   2010a).	   In	   contrast,	   those	   with	  
cryptococcal	   relapse	   had	   CSF	   features	   similar	   to	   CM.	   Further	   studies	   have	   shown	  
that	   persons	  who	   develop	   C-­‐IRIS	   have	   significantly	   lower	   CSF	   inflammation	   during	  
their	   initial	  episode	  of	  CM	  with	  significantly	  reduced	  CSF	  white	  cell	  counts,	  protein,	  
IFN-­‐γ,	   IL-­‐6,	   IL-­‐8	   and	   TNF-­‐α	   (Boulware,	   Bonham,	   et	   al.	   2010a).	   Cohort	   studies	   from	  
Uganda	   have	   also	   shown	   that	   prior	   to	   the	   initiation	   of	   ART,	   individuals	   who	  
developed	   C-­‐IRIS	   also	   had	   increased	   serum	   levels	   of	   IL-­‐4,	   IL-­‐17,	   and	   cryptococcal	  
antigen	   (CrAg),	   along	   with	   decreased	   serum	   levels	   of	   TNF-­‐α,	   G-­‐CSF,	   GM-­‐CSF,	   and	  
VEGF	  prior	   to	  ART	   initiation.	   Following	  ART	   initiation,	   these	   same	   individuals	  were	  
noted	  to	  have	  significant	  increases	  in	  serum	  levels	  of	  IL-­‐6,	  IL-­‐7,	  IL-­‐13,	  G-­‐CSF,	  IL-­‐1RA,	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C-­‐reactive	  protein	  (CRP)	  and	  D-­‐dimer	  compared	  to	  time	  matched	  controls	  (Boulware,	  
Meya,	  et	  al.	  2010b).	  Similar	  studies	  from	  cohorts	  in	  South	  Africa	  have	  also	  identified	  
paucity	   of	   CSF	   inflammatory	   response	   during	   the	   initial	   episode	   of	   CM	   among	  
individuals	  who	  developed	  C-­‐IRIS	  (Chang,	  Dorasamy,	  et	  al.	  2013a).	  These	  individuals	  
also	  had	  lower	  CD4	  counts	  and	  reduced	  numbers	  of	  cryptococcus-­‐specific	  activated	  
CD4	  T	   cells	   at	   baseline.	   IFN-­‐γ	   production	  by	  CD4	  T	   cells	   following	   stimulation	  with	  
cryptococcus	   mannoprotein	   was	   also	   significantly	   reduced	   at	   baseline	   among	  
individuals	   who	   went	   on	   to	   develop	   C-­‐IRIS;	   however,	   contrary	   to	   expectations,	  
persons	  who	  developed	  C-­‐IRIS	  had	  no	  significant	  increase	  in	  IFN-­‐γ	  response	  following	  
the	   initiation	   of	   ART	   (Chang,	   Dorasamy,	   et	   al.	   2013a;	   Chang,	   Lim,	   et	   al.	   2013b).	  
Further	  analysis	  of	  blood	  and	  CSF	   cells	  using	   flow	  cytometry	   in	   this	   study,	   showed	  
that	  patients	  who	  developed	  C-­‐IRIS	  had	  a	  lower	  CD4+/CD8+	  T-­‐cell	  ratio	  in	  both	  blood	  
and	  CSF	  prior	  to	  the	  initiation	  of	  ART	  and	  a	  higher	  proportion	  of	  CXCR3+CCR5+CD8	  T	  
cells	  in	  the	  CSF	  compared	  to	  blood	  (Chang,	  Omarjee,	  et	  al.	  2013c).	  	  
	  
In	  summary,	  current	  evidence	  suggests	  that	  C-­‐IRIS	  occurs	  when	  there	  is	  a	  paucity	  of	  
CSF	  inflammation	  during	  the	  initial	  episode	  of	  cryptococcal	  meningitis	  (possibly	  due	  
to	  reduced	  CD4	  IFN-­‐γ	  production),	  which	  results	   in	  poor	  clearance	  of	  organism	  and	  
persistence	  of	  antigen.	  When	  ART	  is	  initiated	  and	  immune	  function	  starts	  to	  improve	  
the	  high	  levels	  of	  persisting	  antigen	  drive	  an	  inflammatory	  reaction	  resulting	  in	  tissue	  
damage.	   This	  hypothesis	   is	   supported	  by	  data	   from	  a	   variety	  of	   additional	   cohorts	  
that	   show	   IRIS	   risk	   to	   be	   associated	   with	   higher	   CSF	   fungal	   burden	   prior	   to	   ART	  
initiation	  (Jarvis	  et	  al.	  2014;	  Chang,	  Dorasamy,	  et	  al.	  2013a).	  The	  pattern	  of	  elevation	  
of	  serum	  cytokines	  prior	   to	  development	  of	  C-­‐IRIS	  suggests	  significant	   involvement	  
of	   myeloid	   cell	   types	   (such	   as	   monocytes),	   a	   similar	   finding	   to	   studies	   of	   TB-­‐IRIS	  
(Tadokera	  et	  al.	  2011;	  Andrade	  et	  al.	  2014).	  	  
1.8.5 Timing	  of	  ART	  initiation	  after	  diagnosis	  of	  cryptococcal	  meningitis	  
Discussions	   regarding	   IRIS	   risk	   invariably	   lead	   to	   the	   clinical	   dilemma:	  when	   is	   the	  
optimal	   time	   to	   start	  ART	   in	  patients	  with	  HIV-­‐associated	   cryptococcal	  meningitis?	  
These	   patients	   are	   profoundly	   immune	   suppressed,	   if	   ART	   is	   delayed	   for	   too	   long	  
they	   are	   at	   significant	   risk	   of	   developing	   further	   life-­‐threatening	   opportunistic	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infections.	   However,	   if	   ART	   is	   started	   early,	   it	   could	   increase	   the	   chances	   of	  
developing	  C-­‐IRIS	  -­‐	  a	  condition	  with	  significant	  associated	  morbidity	  and	  mortality.	  A	  
number	  of	  trials	  have	  addressed	  this	  question	  over	  the	  last	  10	  years.	  
	  
The	  first	  trial	  addressing	  this	  was	  the	  ACTG	  A5164	  trial	  (2003-­‐2006),	  which	  recruited	  
282	  patients	  mainly	  from	  the	  USA	  with	  a	  variety	  of	  AIDS	  related	  OIs,	  and	  randomized	  
them	   to	   early	   ART	   (within	   14	   days	   of	   OI	   treatment)	   or	   deferred	   ART	   (after	   OI	  
treatment	   was	   complete).	   Early	   ART	   was	   found	   to	   be	   associated	   with	   a	   reduced	  
likelihood	   of	   AIDS	   progression	   or	   death,	   with	   no	   significant	   increased	   risk	   of	   IRIS	  
(Zolopa	  et	  al.	  2009;	  Grant	  et	  al.	  2010).	  However,	  only	  12%	  of	  the	  trial	  participants	  (35	  
patients)	   had	   cryptococcal	  meningitis	   at	   entry;	   analyzing	   these	   patients	   separately	  
showed	  no	  significant	  difference	  between	  the	  two	  study	  arms	  (although	  there	  was	  a	  
trend	   towards	   reduced	   AIDS	   progression	   or	   death	   with	   early	   ART)	   (Zolopa	   et	   al.	  
2009).	  Following	  this,	  an	  open	  label	  trial	  in	  Zimbabwe	  was	  conducted	  comparing	  ART	  
initiation	  within	  72	  hours	  of	  CM	  diagnosis	  against	  initiation	  at	  10	  weeks;	  initial	  anti-­‐
fungal	   therapy	  was	   fluconazole	  800mg	  per	  day	   (Makadzange	  et	  al.	  2010).	  The	   trial	  
was	  stopped	  early	  by	  the	  data	  safety	  monitoring	  board	  (DSMB)	  after	  excess	  deaths	  
were	  noted	   in	   the	  early	   treatment	  arm,	  these	  occurred	  mainly	  during	  the	   first	   two	  
weeks	  of	  ART	  but	  no	  cause	  for	  them	  could	  be	  ascertained	  (Makadzange	  et	  al.	  2010).	  
The	   third	   trial	   was	   a	   small	   study	   in	   Botswana	   (n=27),	   which	   compared	   early	   ART	  
(within	  7	  days)	  against	  deferred	  ART	  (after	  28	  days)	  using	  intravenous	  amphotericin	  
B	  as	  anti-­‐fungal	  treatment.	  No	  difference	  in	  mortality	  was	  noted;	  however,	  early	  ART	  
was	  associated	  with	  significantly	  increased	  risk	  of	  IRIS	  (Bisson	  et	  al.	  2013).	  
	  
The	  largest	  trial	  to	  date	  has	  been	  the	  COAT	  trial	  (n=177);	  an	  open	  label	  randomized	  
controlled	  trial	  conducted	  in	  Uganda	  and	  South	  Africa.	  ART	  naive	  persons	  with	  first	  
episode	   of	   CM	   were	   initially	   treated	   with	   IV	   amphotericin	   1mg/kg/day	   and	   oral	  
fluconazole	   800mg/d,	   and	   randomized	   to	   early	   ART	   initiation	   (7-­‐14	   days	   after	  
starting	   amphotericin),	   or	   deferred	   initiation	   (after	   5-­‐6	   weeks).	   This	   trial	   was	   also	  
stopped	  early	  by	  the	  DSMB	  after	  significantly	   increased	  mortality	  was	  noted	   in	   the	  
early	  ART	  arm	   (6	  month	  mortality	   45%	  vs	   30%,	  Hazard	  Ratio,	   1.7;	   95%	  CI,	   1.1-­‐2.8;	  
P=.03)	   (Boulware,	   Meya,	   et	   al.	   2014a).	   The	   reasons	   for	   this	   increase	   in	   mortality	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were	   also	   not	   clear;	   excess	   deaths	   all	   occurred	   within	   a	   month	   of	   enrollment,	  
reported	   rates	  of	   IRIS	  were	  not	   statistically	  different	  between	   the	   two	  study	  arms,	  
neither	   was	   drug	   toxicity.	   Risk	   factors	   particularly	   associated	   with	   early	   ART	  
mortality	  included	  altered	  mental	  status	  at	  time	  of	  randomization	  (hazard	  ratio,	  3.0;	  
95%	  CI,	  1.0-­‐8.8;	  P=.05)	  and	  failure	  to	  mount	  a	  cellular	  response	  in	  the	  CSF	  (CSF	  WCC	  
<5:	  hazard	  ratio,	  3.3;	  95%	  CI,	  1.3-­‐8.4;	  P=.01)	  (Boulware,	  Meya,	  et	  al.	  2014a).	  The	  fact	  
that	   paucity	   of	   CSF	   inflammatory	   response	   has	   previously	   been	   associated	   with	  
failure	  to	  sterilize	  the	  CSF,	  and	  increased	  risk	  of	  IRIS	  makes	  it	  plausible	  that	  immune	  
pathology	  may	  underlie	  these	  excess	  deaths	  too	  (Boulware,	  Bonham,	  et	  al.	  2010a).	  
An	  immune	  sub-­‐study	  of	  the	  COAT	  trial	  is	  presented	  in	  chapter	  7	  that	  explores	  these	  
issues	  further.	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CHAPTER	  2: HYPOTHESIS	  AND	  AIMS	  
This	  short	  chapter	  outlines	  the	  hypothesis	  and	  aims	  of	  the	  thesis.	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2.1.1 Introduction	  
It	   is	   clear	   that	   host	   immune	   response	   is	   integral	   to	   the	   understanding	   of	   the	  
pathogenesis	  of	  cryptococcosis.	  The	  animal	  studies	  discussed	  in	  the	  previous	  chapter	  
confirm	  the	   importance	  of	  CD4	  T	  cells	   in	  host	   immunity	  to	  C.	  neoformans	   infection	  
and	   also	   demonstrate	   the	   influence	   macrophage	   activation	   has	   on	   determining	  
outcome	  from	  infection.	  This	  thesis	  aims	  to	  examine	  the	  role	  of	  macrophages	  further	  




In	   HIV-­‐1	   associated	   cryptococcal	   meningitis,	   macrophages	   adopt	   an	   alternatively	  
activated	  or	  immune	  modulatory	  (M2)	  phenotype.	  Individuals	  in	  whom	  macrophage	  
polarization	   is	   most	   skewed	   towards	   an	   M2	   phenotype	   will	   have	   a	   more	   severe	  
infection	   and	   worse	   outcome.	   The	   initiation	   of	   anti-­‐retroviral	   therapy	   results	   in	   a	  
switch	   towards	   a	   classically	   activated	   (M1)	   macrophage	   phenotype;	   extreme	  
polarization	  towards	  an	  M1	  phenotype	  following	  ART	  initiation	  will	  result	  in	  IRIS.	  
	  	  	  
	  
2.1.3 Aims	  
1. To	  characterize	  the	  activation	  state	  of	  CSF	  monocyte-­‐macrophages	  and	  blood	  
monocytes	  in	  HIV-­‐associated	  cryptococcal	  meningitis	  
	  
2. To	  assess	  the	  effects	  of	  ART	  on	  host	  immune	  response	  	  
	  
	  




CHAPTER	  3: METHODS	  
This	  chapter	  details	  the	  research	  methods	  used	  in	  the	  thesis.	  Information	  regarding	  
the	  study	  design	  is	  included	  along	  with	  the	  methods	  used	  to	  identify	  and	  enroll	  study	  
subjects.	   Details	   of	   the	   clinical	   information	   recorded,	   samples	   collected	   and	  
laboratory	   techniques	   used	   are	   also	   provided.	   Broad	   mention	   is	   made	   of	   data	  
analysis	  techniques;	  further	  details	  are	  included	  in	  the	  relevant	  results	  chapters.	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3.1 Overview	  of	  studies	  included	  in	  the	  thesis	  
The	   data	   presented	   in	   this	   thesis	   is	   obtained	   from	   two	   studies,	   both	   of	  which	   are	  
detailed	  in	  this	  chapter.	  
3.1.1 Innate	  Immunity	  in	  Cryptococcal	  Disease	  (IICD)	  study	  -­‐	  overview	  
The	   Innate	   Immunity	   in	   Cryptococcal	   Disease	   (IICD)	   study	   was	   an	   observational	  
prospective	  cohort	  study	  conducted	  in	  Cape	  Town,	  South	  Africa	  between	  2012	  and	  
2014.	   A	   comprehensive	   assessment	   of	   the	   immune	   response	   in	   CSF	   and	   blood	  
among	   individuals	  with	  HIV-­‐associated	   cryptococcal	  meningitis	  was	   obtained	   using	  
flow	   cytometry	   and	   cytokine	   analysis.	   Details	   of	   the	   methodology	   and	   laboratory	  
techniques	  used	  are	  given	   in	  sections	  3.2	  and	  3.4	  respectively.	  Data	  obtained	  from	  
this	  study	  is	  presented	  in	  chapters	  4-­‐6,	  and	  forms	  the	  majority	  of	  the	  thesis.	  	  
3.1.2 Cryptococcal	  Optimal	  ART	  Timing	  (COAT)	  trial	  -­‐	  overview	  
The	   Cryptococcal	   Optimal	   ART	   Timing	   (COAT)	   trial	   was	   an	   open	   label	   randomized	  
clinical	  trial	  designed	  to	  determine	  whether	  early	  ART	  initiation	  improved	  survival	  in	  
persons	   with	   HIV-­‐associated	   cryptococcal	   meningitis,	   compared	   to	   deferred	   ART	  
initiation	   (1-­‐2	  weeks	   vs.	   5-­‐6	  weeks	   respectively).	   It	   was	   conducted	   in	   Uganda	   and	  
South	  Africa	  between	  2010	  and	  2012	  (Boulware	  et	  al.	  2014a).	  The	  original	  intention	  
was	   to	   nest	   the	   IICD	   study	   within	   the	   COAT	   trial,	   allowing	   a	   comprehensive	  
assessment	   of	   the	   effects	   of	   earlier	   ART	   initiation	   on	   CSF	   and	   blood	   immune	  
response	  in	   individuals	  with	  CM.	  Unfortunately,	  this	  was	  not	  possible	  as	  enrolment	  
for	   the	   COAT	   trial	  was	   suspended	   in	   the	   same	  month	   that	   enrolment	   for	   the	   IICD	  
study	  started.	  As	  such,	  the	  analysis	  of	  the	  immune	  effects	  of	  early	  ART	  initiation	  was	  
limited	   to	   the	   measurement	   of	   soluble	   biomarkers	   (cytokines,	   chemokines	   and	  
macrophage	   activation	   markers)	   on	   cryopreserved	   CSF	   supernatants	   and	   serum,	  
rather	  than	  the	  detailed	  flow	  cytometry	  assays	  developed	  for	  the	  IICD	  study.	  Details	  
of	   the	  design	  of	   this	  sub-­‐study	  and	  the	   laboratory	  techniques	  used	  are	  provided	   in	  
sections	  3.3	  and	  3.4	  respectively.	  The	  data	  is	  presented	  in	  in	  chapter	  7.	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3.2 Innate	  Immunity	  in	  Cryptococcal	  Disease	  (IICD)	  
3.2.1 Overview	  
The	   main	   component	   of	   the	   IICD	   study	   was	   a	   prospective,	   observational,	   cohort	  
study	   based	   in	   Cape	   Town,	   South	   Africa,	   designed	   to	   extensively	   characterize	   the	  
host	   immune	   response	   in	   HIV-­‐associated	   cryptococcal	   meningitis	   (CM)	   [section	  
3.2.5].	   To	   better	   understand	   the	   abnormalities	   in	   blood	   immune	   response	   among	  
subjects	  with	   CM,	   two	   groups	   of	   control	   subjects	  were	   enrolled:	   HIV-­‐infected	   and	  
HIV-­‐uninfected	  (healthy)	  controls	  [section	  3.2.13].	  
3.2.2 Study	  setting	  
Patients	  with	  cryptococcal	  meningitis	  were	  recruited	  from	  GF	  Jooste	  District	  Hospital	  
(GFJH),	   Mitchell’s	   Plain	   District	   Hospital	   (MPH)	   and	   Khayelitsha	   District	   Hospital	  
(KDH).	   These	   three	   hospitals	   are	   all	   located	   in	   the	   Cape	   Flats	   area	   of	   Cape	   Town,	  
South	   Africa	   [Figure	   3.1];	   they	   serve	   communities	   with	   high	   rates	   of	   social	  
deprivation	   [Table	   3.1]	   and	   high	   prevalence	   of	   HIV-­‐1	   infection	   (antenatal	   HIV	  
seroprevalence	   in	   Khayelitsha	   is	   33%	   (SADoH	   2012)).	   Despite	   a	   public	   ART	  
programme,	  CM	  remains	  a	  significant	  clinical	  problem	  in	  this	  area,	  and	   is	   the	  most	  
common	  microbiologically	  confirmed	  cause	  of	  adult	  meningitis	  (Jarvis	  et	  al.	  2010a).	  
Control	  subjects	  were	  recruited	  from	  Khayelitsha	  day	  hospital	  (general	  clinic)	  and	  the	  
Ubuntu	   Clinic	   (ART	   clinic),	   Khayelitsha.	   Both	   these	   clinics	   are	   situated	   in	   a	   large	  
community	  health	  clinic	  (CHC)	  in	  the	  catchment	  area	  of	  Khayelitsha	  district	  hospital	  
and	  reflect	  the	  typical	  demographic	  of	  patients	  in	  this	  study.	  
	  
	   GFJ	   MPH	   KDH	  
%	  unemployment	   36	   24	   38	  
%	  households	  with	  less	  than	  R3200	  (£180)	  per	  month	   61	   38	   74	  
%	  households	  living	  in	  informal	  dwellings	   10	   5	   55	  
%	  households	  with	  no	  piped	  water	  in	  the	  house/yard	   1	   2	   38	  
Table	  3.1	  	  Markers	  of	  deprivation	  in	  IICD	  study	  areas	  (SSA	  2012)	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Figure	  3.1	   	  Map	  of	  Cape	  Town,	   South	  Africa.	  The	  three	  study	  sites	  are	  marked:	  GF	  Jooste	  Hospital	  
(red);	  Mitchell’s	  Plain	  district	  hospital	  (purple);	  Khayelitsha	  District	  Hospital	  (blue).	  	  
3.2.3 Institutional	  approval	  
Institutional	   and	   ethical	   approval	   was	   provided	   by	   the	   University	   of	   Cape	   Town	  
(HREC	   REF:	   408/2010	   and	   371/2013)	   and	   Liverpool	   School	   of	   Tropical	   Medicine	  
Research	  Ethics	  Committee	  (11/92).	  Approval	  to	  conduct	  the	  research	  in	  the	  clinical	  
sites	  mentioned	  above	  was	  provided	  by	  the	  Western	  Cape	  Government,	  Department	  
of	   Health	   (RP	   46/2012).	   Study	   insurance	   was	   provided	   by	   the	   University	   of	   Cape	  
Town.	  All	  medical	  staff	  involved	  in	  the	  recruitment	  of	  patients	  were	  registered	  with	  
the	  Health	  Professions	  Council	  of	  South	  Africa.	  A	  payment	  of	  R50	  was	  made	  to	  any	  
study	   participant	   (main	   cohort	   or	   control	   patients)	   who	   attended	   the	   study	   clinic	  
during	   the	   time	   they	  were	  enrolled	   in	   the	  study.	  This	  was	   to	  cover	   transport	  costs	  
incurred	  with	  their	  attendance.	  	  	  
3.2.4 Funding	  
The	  study	  was	  funded	  by	  the	  Wellcome	  Trust	  through	  a	  Training	  Fellowship	  awarded	  
to	   Dr	   James	   Scriven	   (094013/B/10/Z).	   The	   award	   was	   managed	   by	   the	   Liverpool	  
School	  of	  Tropical	  Medicine	  with	  a	  sub-­‐contract	  set	  up	  with	  University	  of	  Cape	  Town.	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3.2.5 Cohort	  study	  
An	   observational	   prospective	   cohort	   study	   was	   conducted.	   Individuals	   with	   HIV-­‐
associated	  CM	  that	  met	  study	  entry	  criteria	  were	  enrolled	  shortly	  after	  presentation	  
to	  hospital	  [section	  3.2.6,	  Table	  3.2].	  A	  clinical	  assessment	  was	  made	  and	  markers	  of	  
clinical	   severity	   recorded	   [section	   3.2.8;	   Table	   3.3].	   Host	   immune	   response	   was	  
examined	  in	  CSF	  and	  blood	  using	  flow	  cytometry	  and	  cytokine	  analysis	  [section	  3.4].	  
Subjects	  were	  followed	  for	  24	  weeks	  to	  monitor	  for	  study	  endpoints	  	  [section	  3.2.10;	  
Table	  3.5].	  Data	  were	  analyzed	  as	  detailed	  in	  section	  3.2.14.	  
3.2.6 Entry	  criteria	  and	  enrolment	  
Study	  staff	  identified	  hospitalized	  patients	  with	  cryptococcal	  meningitis	  through	  daily	  
review	  of	   laboratory	  CSF	   results.	  Cryptococcal	  meningitis	  was	  defined	  as	  a	  positive	  
CSF	  culture	  identified	  as	  C.	  neoformans	  or	  a	  positive	  CSF	  cryptococcal	  antigen	  (CrAg)	  
detection	  assay	  with	  a	  titre	  ≥1:4.	  Individuals	  with	  CM	  were	  approached	  by	  a	  member	  
of	   the	   study	   staff	   and	   assessed	   for	   eligibility	   based	   on	   the	   criteria	   detailed	   below	  
[Table	   3.2];	   previous	   episodes	   of	   cryptococcal	   meningitis	   were	   identified	   by	  
questioning	   the	   patient	   and	   checking	   previous	   laboratory	   results.	   Patients	   were	  
recruited	  irrespective	  of	  ART	  status.	  
	  
Inclusion	  Criteria	   Exclusion	  Criteria	  
HIV-­‐1	  infection	  	  
Age	  ≥18	  years	  
Cryptococcal	  meningitis*	  
≤2	  doses	  of	  amphotericin	  B	  
Previous	  cryptococcal	  meningitis	  
Taking	  immune	  modulating	  medication	  
Contraindication	  to	  LP	  
Pregnancy	  
Table	   3.2	   	   Entry	   criteria	   for	   IICD	   study.	   	   *Diagnostic	   criteria	   for	   cryptococcal	  meningitis	   is	  detailed	  
above	  [section	  3.2.6].	  Immune	  modulating	  medication:	  steroids,	  chemotherapy,	  etc.	  
3.2.7 Consent	  
Potential	   participants	   were	   approached	   by	   a	   member	   of	   the	   study	   team	   and	  
provided	   with	   verbal	   and	   written	   information	   in	   English	   or	   Xhosa	   (the	   most	  
commonly	   spoken	   first	   language	   amongst	   patients	   admitted	   to	   these	   hospitals).	  
Written	  informed	  consent	  was	  obtained	  in	  Xhosa	  or	  English	  (see	  Appendix	  B)	  and	  the	  
study	   discussed	  with	   the	   patient’s	   clinical	   team	   to	   ensure	   they	   had	   no	   objections.	  	  
Informed	  consent	   included	  permission	   to	   store	   samples	   for	   the	  current	  and	   future	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projects	  and	  the	  sharing	  of	  information	  and	  samples	  with	  collaborators.	  Any	  patients	  
who	   were	   illiterate	   or	   unable	   to	   sign	   their	   name	   were	   asked	   to	   make	   a	   mark	  
witnessed	   by	   an	   individual	   not	   related	   to	   the	   study.	   If	   patients	   could	   not	   provide	  
consent	  due	   to	   their	  medical	   condition	   (e.g.	   impaired	  consciousness),	   their	  next	  of	  
kin	  was	  approached	  to	  provide	  surrogate	  consent	  and	  patients	  re-­‐consented	  if	  their	  
condition	   improved.	   This	   policy	   was	   adopted	   to	   ensure	   the	   clinical	   cohort	   was	  
representative	   of	   hospitalized	   patients	   (i.e.	   Including	   patients	   with	   severe	  
cryptococcal	  meningitis)	  and	  was	  specifically	  approved	  by	  the	  ethics	  committees	  at	  
both	  University	  of	  Cape	  Town	  and	  Liverpool	  School	  of	  Tropical	  Medicine.	  
3.2.8 Clinical	  assessment	  and	  data	  collection	  (cohort	  study)	  
All	  subjects	  had	  clinical	  data	  recorded	  anonymously	  on	  dedicated	  case	  record	  forms	  
(CRFs),	   included	   baseline	   demographics,	   past	   medical	   and	   medication	   history	  
(particularly	  ART	  or	  TB	  treatment),	  details	  of	  the	  presenting	  history,	  conscious	  level	  
and	  presence	  of	  any	  abnormal	  neurology.	  This	  allowed	  an	  assessment	  of	  CM	  severity	  
[Table	  3.3].	  	  
	  
Markers	  of	  disease	  severity	  
Altered	  consciousness	  (Glasgow	  Coma	  Scale<15)	  
CSF	  opening	  pressure	  >30	  cmH2O	  during	  admission	  
CSF	  Fungal	  burden	  (CFU/ml	  CSF)	  [section	  3.4.11].	  
Table	  3.3	  	  Markers	  of	  disease	  severity	  in	  cryptococcal	  meningitis	  
3.2.9 CSF	  and	  blood	  sampling	  
Samples	   of	   cerebrospinal	   fluid	   (CSF)	   were	   obtained	   from	   lumbar	   punctures	  
performed	   for	   clinical	   reasons	   (e.g.	   to	   measure	   opening	   pressure	   and	   drain	   CSF).	  
Depending	   on	   the	   opening	   pressure,	   between	   5-­‐20mls	   of	   CSF	   was	   drained	   and	  
analyzed	   as	   detailed	   in	   Table	   3.4.	   Cell	   count	   and	   other	   diagnostic	   tests	   were	  
performed	   in	  the	  hospital	   laboratory	  and	  the	  remaining	  CSF	  was	  placed	  on	   ice	  and	  
transported	   to	   the	   research	   laboratory	   within	   2	   hours.	   Venepuncture	   was	   also	  
performed	   at	   study	   enrolment	   as	   detailed	   below	   [Table	   3.4].	   Twice	  weekly	   blood	  
tests	   were	   performed	   during	   hospital	   admission	   to	   monitor	   for	   amphotericin	   B	  
toxicity	  [Table	  3.4;	  section	  3.5.2].	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Day	   CSF	   	  Blood	  
0	   Cell	  count,	  protein,	  glucose	  (0.5mls)*	  
Quantitative	  fungal	  culture	  (0.5mls)	  
TB	  culture	  (5mls)*	  
Flow	  cytometry	  (10mls)	  
	  
	  
FBC,	  U&E,	  Mg,	  CD4,	  VL,	  CRP,	  blood	  culture*	  
Whole	  blood	  antigen	  stimulation	  
Flow	  cytometry	  
Serum	  for	  storage	  	  
Plasma	  for	  storage	  
RNA	  (PAXGENE)	  
1-­‐14	   Quantitative	  culture	  (0.5mls)	   FBC,	  U&E,	  Mg	  (twice	  weekly)	  
Table	  3.4	  	  Inpatient	  research	  laboratory	  investigations.	  Detailed	  methodology	  is	  provided	  in	  section	  
3.4.	  Tests	  marked	  *	  were	  performed	  in	  a	  hospital	  diagnostic	   laboratory:	  FBC	  (full	  blood	  count),	  U&E	  
(Urea	  &	  Electrolytes),	  Mg	  (magnesium),	  VL	  (HIV	  viral	  load).	  
	  
3.2.10 Follow	  up	  	  
Subjects	  were	   followed	   during	   their	   hospital	   admission;	   repeat	   clinical	   assessment	  
was	   performed	   and	   documented	   at	   days	   1,	   3,	   7	   and	   14	   (+/-­‐	   1)	   post	   recruitment;	  
additional	  assessments	  were	  made	   if	   a	  participant’s	   clinical	   state	  deteriorated.	   	  All	  
LPs	  were	  recorded	  along	  with	  opening/closing	  pressures,	  and	  any	  new	  medications	  
deemed	  significant.	  Following	  discharge	  from	  hospital,	  subjects	  were	  followed	  up	  in	  
clinic	  at	   study	  weeks	  4,	  8,	  12,	  16,	  and	  24	   to	  monitor	   for	  any	   clinical	  deterioration;	  
additional	  attendances	  were	  arranged	  depending	  on	  clinical	  indications.	  Subjects	  not	  
taking	   ART	   at	   enrolment	  were	   initiated	   on	   ART	   at	  week	   4	   as	   described	   in	   section	  
3.5.4.	  Study	  end	  points	  are	  detailed	  below	  [Table	  3.5].	  Repeat	  blood	  sampling	  was	  
performed	  depending	  on	  ART	  status	  at	  enrolment	  [Tables	  3.6,	  3.7].	  
	  






Rate	  of	  fungal	  clearance	  from	  CSF	  
Paradoxical	  IRIS	  
Cryptococcal	  relapse	  
Table	   3.5	   	   Outcomes	   for	   the	   IICD	   study.	   The	  method	  used	   to	   calculate	   rate	   of	   fungal	   clearance	   is	  
described	  in	  section	  3.4.11.	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  Week	   CSF	   Bloods	  
4†	  
	  
No	  routine	  CSF	  samples	  taken	  
	  
As	  day	  0	  (but	  no	  VL	  or	  blood	  culture)	  
8	   As	  day	  0	  (but	  no	  VL	  or	  blood	  culture)	  
12	   As	  day	  0	  (but	  no	  VL	  or	  blood	  culture)	  
16	   As	  day	  0	  (but	  no	  blood	  culture)	  
26	   CD4	  +	  clinical	  bloods	  
Table	  3.6	  	  Outpatient	  investigations	  for	  subjects	  not	  taking	  ART.	  †ART	  initiated	  at	  week	  4	  
Week	   CSF	   Bloods	  
4	  
	  
No	  routine	  CSF	  samples	  taken	  
	  
Clinical	  bloods	  
8	   Clinical	  bloods	  
12	   As	  day	  0	  (but	  no	  VL	  or	  blood	  culture)	  
16	   Clinical	  bloods	  
26	   CD4	  +	  clinical	  bloods	  	  
Table	  3.7	  	  Outpatient	  investigations	  for	  subjects	  taking	  ART	  at	  enrolment	  
3.2.11 Clinical	  deterioration	  
Participants	  experiencing	  clinical	  deterioration	  were	  fully	  assessed	  to	  determine	  the	  
cause	   and	   classified	   as	   detailed	   below	   [Table	   3.8].	   Participants	   with	   neurological	  
deterioration	  on	  ART	  (and	  therefore	  possible	  CM-­‐IRIS)	  were	  assessed	  using	  the	  INSHI	  
criteria	   for	   paradoxical	   cryptococcal	   IRIS	   (Haddow	   et	   al.	   2010)	   [Table	   1.3].	   Repeat	  
lumbar	  puncture	  and	  blood	  sampling	  were	  performed	  as	  detailed	  below	  [Table	  3.9].	  
Additional	  persons	  presenting	  to	  one	  of	   the	  study	  hospitals	  who	  met	   INSHI	  criteria	  
for	  neurological	  CM-­‐IRIS	  [Table	  1.3]	  were	  also	  enrolled	  an	  additional	  IRIS	  case	  even	  if	  
they	  had	  not	  been	  enrolled	  during	  their	  initial	  episode	  of	  CM.	  	  
Category	   Criteria	  
CM-­‐disease	   Worsening	  CM	  despite	  treatment	  
CM-­‐relapse	   Culture	  proven	  relapse	  
CM-­‐IRIS	   Meets	  INSHI	  criteria	  for	  paradoxical	  CM-­‐IRIS	  (Haddow	  et	  al.	  2010)	  	  
AmB	  toxicity	   Creatinine	  doubling,	  thrombophlebitis,	  anaemia	  +	  transfusion	  
Bacteraemia	   Positive	  blood	  culture	  
TB	   Microbiologically	  confirmed	  TB	  
Other	   Cause	  of	  deterioration	  known,	  not	  listed	  above	  
Unknown	   Cause	  of	  deterioration	  not	  known	  
Table	  3.8	  	  Classification	  of	  clinical	  deterioration	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Day	   CSF	   	  Blood	  
ND	  
	  
Cell	  count,	  protein,	  glucose	  (0.5mls)*	  
Gram	  Stain,	  bacterial	  culture*	  
Quantitative	  fungal	  culture	  (0.5mls)	  
TB	  culture	  (5mls)*	  
Flow	  cytometry	  (10mls)	  
FBC,	  U&E,	  Mg,	  CD4,	  VL,	  CRP,	  bloodculture*	  
Whole	  blood	  antigen	  stimulation	  	  
Flow	  cytometry	  	  
Serum	  for	  storage	  	  
Plasma	  for	  storage	  	  
RNA	  (PAXGENE)	  
Table	  3.9	   Investigations	   for	   subjects	  with	  neurological	  deterioration	   (ND).	  *	  performed	  in	  hospital	  
diagnostic	  laboratory	  
3.2.12 Study	  deaths	  
An	  attempt	  was	  made	  to	  ascribe	  cause	  of	  death	  for	  any	  participant	  who	  died	  during	  
the	  course	  of	  the	  study	  using	  the	  same	  categories	  detailed	  above	  [Table	  3.8].	  To	  help	  
determine	  this,	  consent	  was	  sought	  from	  families	  of	  deceased	  study	  participants	  to	  
conduct	  a	  medical	  post-­‐mortem.	   If	  willing,	   the	  process	  and	  practicalities	  of	  a	  post-­‐
mortem	  were	  discussed	  with	  the	  next	  of	  kin	  and	  close	  family	  members	  in	  English	  or	  
Xhosa.	  It	  was	  emphasized	  that	  there	  was	  no	  legal	  requirement	  for	  the	  examination,	  
and	  the	  possible	  fates	  of	  organs	  were	  specifically	  discussed:	  retained	  for	  teaching	  or	  
research,	   replaced	   after	   examination	   prior	   to	   burial,	   or	   returned	   to	   the	   family	   for	  
burial	  at	  a	   later	  date.	  Only	   if	  a	  family	  were	  in	  full	  agreement	  would	  a	  post-­‐mortem	  
examination	   be	   performed.	  Written	   informed	   consent	   was	   obtained	   using	   a	   form	  
from	  Groote	  Schuur	  Hospital,	  Department	  of	  Anatomical	  Pathology	  (Appendix	  B).	  	  
3.2.13 Enrolment	  of	  control	  subjects	  
To	  better	  understand	  the	  abnormalities	   in	  blood	  immune	  response	  among	  subjects	  
with	  CM,	   two	  groups	  of	   controls	  were	  enrolled:	  HIV-­‐uninfected	   (healthy)	   and	  HIV-­‐
infected	  controls	  [see	  Table	  3.10	   for	  entry	  criteria].	  Potential	  control	  subjects	  were	  
identified	  through	  liaison	  with	  clinical	  staff	  at	  a	  large	  local	  community	  health	  centre	  
(CHC)	  located	  close	  to	  Khayelitsha	  hospital	  [see	  section	  3.2.2].	  HIV-­‐infected	  controls	  
were	   identified	   from	   patients	   attending	   the	   ART	   clinic	   (“Ubuntu	   clinic”),	   while	  
healthy	   controls	   were	   identified	   from	   patients	   attending	   the	   general	   clinic	   (“Day	  
Hospital”)	  for	  HIV	  testing	  or	  other	  reasons.	  HIV-­‐infected	  subjects	  with	  low	  CD4	  count	  
were	   specifically	   recruited	   to	   allow	   closer	   comparison	   with	   individuals	   with	   CM.	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Particular	  efforts	  were	  made	  to	  enroll	  only	  HIV-­‐infected	  persons	  with	  no	  evidence	  of	  
opportunistic	  infection.	  	  
HIV	  uninfected	  healthy	  controls	  	   HIV-­‐1-­‐infected	  controls	  
Negative	  HIV	  test	  within	  last	  month	  
No	  intercurrent	  illness,	  meningitis	  or	  TB*	  	  
No	  chronic	  health	  problems	  	  
(e.g.	  diabetes,	  hypertension,	  asthma)	  
	  
Positive	  HIV	  test	  
Not	  taking	  ART	  
Clinic	  CD4<200	  cells/µL	  
Negative	  serum	  cryptococcal	  antigen	  
No	  evidence	  of	  TB†	  
Table	   3.10	   Entry	   criteria	   for	   healthy	   and	   HIV-­‐infected	   controls.	   *determined	   clinically,	   †Subjects	  
were	  screened	  at	  enrollment	  with	  TB	  symptom	  screen	  and	  samples	  sent	  if	  appropriate;	  subjects	  were	  
excluded	  at	  a	  later	  point	  if	  any	  sputum	  samples	  sent	  from	  clinic	  were	  positive	  for	  M.tuberculosis.	  
Clinical	  assessment	  and	  data	  collection	  	  
A	  short	  symptom	  questionnaire	  was	  completed	  on	  all	  control	  subjects,	  including	  a	  TB	  
symptom	  screen,	  and	  a	  sputum	  sample	  was	  sent	  for	  TB	  testing	  if	  clinically	  indicated.	  
Limited	  demographic	   and	   clinical	   information	  was	   recorded.	  Control	   subjects	  were	  
not	  followed	  up	  but	  their	  laboratory	  record	  was	  checked	  3	  months	  post	  recruitment	  
and	  any	  subjects	  with	  a	  positive	  sputum	  culture	  for	  M.	  tuberculosis	  excluded.	  
Peripheral	  blood	  sampling	  	  
Control	  patients	  had	  a	  single	  blood	  draw.	  Investigations	  and	  assays	  were	  identical	  to	  
CM	   patients	   at	   enrolment	   except	   blood	   cultures	   were	   not	   performed;	   a	   detailed	  
breakdown	  is	  presented	  below	  [Table	  3.11].	  In	  addition,	  HIV-­‐1	  infected	  controls	  had	  
blood	   sent	   for	   viral	   load	   and	   a	   serum	   cryptococcal	   antigen	   test	  was	   performed	   to	  
ensure	  they	  did	  not	  have	  asymptomatic	  cryptococcal	  antigenaemia.	  No	  CSF	  samples	  
were	  obtained	  for	  either	  control	  group.	  
Day	   CSF	   	  Blood	  
0	  
	  
No	  CSF	  sent	  for	  control	  subjects	  
	  
FBC,	  U&E,	  Mg,	  CD4,	  CRP,	  	  
HIV	  viral	  load	  +	  CrAg	  test	  (HIV-­‐infected	  only)	  
Whole	  blood	  antigen	  stimulation	  	  
Flow	  cytometry	  	  
Serum	  for	  storage	  	  
Plasma	  for	  storage	  	  
RNA	  (PAXGENE)	  
Table	  3.11	  Investigations	  and	  assays	  for	  control	  subjects.	  Only	  HIV-­‐infected	  controls	  had	  HIV-­‐1	  viral	  
load	  and	  serum	  cryptococcal	  antigen	  (CrAg)	  sent	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3.3 Cryptococcal	  Optimal	  ART	  Timing	  (COAT)	  Trial	  
3.3.1 Overview	  
The	   COAT	   trial	   was	   a	   multisite,	   open	   label,	   randomized	   clinical	   trial	   designed	   to	  
determine	  whether	  early	  anti-­‐retroviral	   therapy	   (ART)	  was	  a	  beneficial	   strategy	   for	  
patients	   with	   HIV-­‐associated	   cryptococcal	   meningitis.	   Study	   participants	   were	  
randomized	  at	  amphotericin	  day	  7-­‐11	  to	  receive	  “early	  ART”	  (initiate	  ART	  within	  48	  
hours)	  or	  “deferred	  ART”	  (deferred	  for	  ≥4	  weeks).	  Primary	  outcome	  was	  survival	  at	  
26	  weeks.	  	  
3.3.2 Study	  setting	  
Three	   trial	   sites	  were	  used:	  GF	   Jooste	  Hospital,	   Cape	  Town	   (South	  Africa);	  Mulago	  
Hospital,	  Kampala	  (Uganda);	  and	  Mbarara	  Regional	  Referral	  Hospital	  (Uganda).	  	  
3.3.3 Institutional	  approval	  and	  funding	  
The	  trial	  was	  sponsored	  by	  the	  National	   Institute	  of	  Allergy	  and	  Infectious	  Diseases	  
(NIAID),	   USA	   (grant	   -­‐	   U01AI089244).	   The	   trial	   was	   registered	   on	   clinicaltrials.gov	  	  
(http://clinicaltrials.gov/ct2/show/NCT01075152).	   Institutional	   and	   ethical	   approval	  
was	  granted	  at	  all	  sites,	  and	  the	  trial	  was	  monitored	  by	  an	  independent	  data	  safety	  
monitoring	  board	  (DSMB).	  
3.3.4 Enrolment	  
Patients	   with	   first	   episode	   of	   HIV-­‐associated	   CM	   were	   enrolled	   according	   to	   the	  
entry	  criteria	  detailed	  in	  Table	  3.12.	  
	  
Inclusion	  Criteria	   Exclusion	  Criteria	  
HIV-­‐1	  infection	  
ART-­‐naive	  	  
Age	  ≥18	  years	  
Cryptococcal	  meningitis*	  
Amphotericin	  therapy	  
Previous	  cryptococcal	  meningitis	  
Inability	  to	  take	  enteral	  medication	  
Immunosuppressant	  medications	  
Cannot/unlikely	  to	  attend	  clinic	  visits	  
Clinical	  need	  for	  early	  or	  deferred	  ART	  	  
Pregnancy	  or	  breastfeeding	  
Table	  3.12	  COAT	  trial	  entry	  criteria.	  *diagnosed	  by	  positive	  CSF	  culture	  or	  antigen	  
55	  	  
3.3.5 Outcome	  of	  COAT	  trial	  
The	   trial	   was	   halted	   after	   18	  months	   by	   the	   data	   safety	  monitoring	   board	   due	   to	  
increased	   mortality	   in	   the	   early	   ART	   arm.	   Final	   analysis	   showed	   that	   26-­‐week	  
mortality	   was	   45%	   with	   early	   ART	   compared	   to	   30%	   with	   deferred	   ART	   (p=0.03,	  
hazard	  ratio	  (HR)	  1.73,	  95%	  confidence	  interval	  (95%	  CI)	  1.06	  -­‐	  2.82);	  the	  majority	  of	  
excess	  deaths	  occurred	  within	  a	  month	  of	  randomization.	  The	  deleterious	  effects	  of	  
early	   ART	   were	   particularly	   marked	   in	   groups	   of	   patients	   with	   low	   CSF	   leukocyte	  
count	  at	  enrolment	  (<5	  cells/μl,	  HR	  3.9,	  95%	  CI	  1.4-­‐10.6,	  p=0.008).	  IRIS	  incidence	  was	  
not	   significantly	   increased	   (20%	   vs.	   13%	   for	   early	   and	   deferred	   ART	   respectively,	  
p=0.32),	  no	  difference	  in	  drug	  toxicity	  was	  noted	  between	  the	  two	  arms	  (Boulware	  
et	  al.	  2014a).	  
3.3.6 COAT	  immunology	  sub-­‐study	  
It	   was	   hypothesized	   that	   an	   inflammatory	   mechanism	   related	   to	   early	   ART	  might	  
have	  driven	  the	  excess	  mortality	  seen	  in	  these	  two	  trials,	  resulting	  in	  sudden	  death	  
rather	   than	   evolving	   to	   what	   was	   clinically	   recognized	   as	   paradoxical	   IRIS.	   A	   sub-­‐
study	   was	   conducted	   to	   test	   this	   hypothesis,	   the	   entry	   criteria	   of	   which	   were	  
identical	  to	  those	  of	  the	  COAT	  trial.	  All	  available	  CSF	  and	  serum	  samples	  taken	  during	  
the	  trial	  were	  obtained	  for	  the	  time	  points	  detailed	  below	  [Figure	  3.2].	  Samples	  of	  
CSF	   and	   serum	   were	   defrosted	   in	   batches.	   Commercial	   magnetic	   multiplex	   bead	  
assays	   were	   used	   to	   measure	   cytokine	   and	   chemokine	   concentrations	   of	   19	  
cytokines	   and	   chemokines	   as	   described	   later	   [section	   3.4.12].	   In	   addition,	  
commercial	   ELISA	   kits	   were	   used	   to	   measure	   the	   concentration	   of	   three	   soluble	  
markers	   of	   macrophage	   activation:	   sCD163,	   sCD14,	   CCL22/MDC	   (macrophage-­‐
derived	   chemokine)	   [section	   3.4.13].	   CSF	   leukocyte	   count	   and	   serum	   CRP	   were	  
measured	  at	  approved	  clinical	  laboratories.	  
3.3.7 Analysis	  strategy	  
To	   assess	   the	   effect	   of	   early	   ART	   on	   the	   immune	   response	   [AIM	   2,	   chapter	   1],	  
concentrations	  of	  CSF	  and	  serum	  biomarkers	  were	  compared	  between	  trial	  arms	  at	  
the	  above	  time	  points	  [Figure	  3.2].	  Sub-­‐group	  analysis	  was	  performed	  by	  study	  site	  
due	  to	  marked	  differences	  in	  baseline	  characteristics.	  Given	  the	  marked	  detrimental	  
effect	   of	   early	   ART	   among	   individuals	   with	   a	   paucity	   of	   CSF	   pleocytos
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randomization,	   additional	   comparisons	   in	   both	   CSF	   and	   serum	   biomarkers	   at	  
amphotericin	   day	   8	  were	  made	  between	   individuals	  who	  had	  CSF	  WCC	  <5/µL	   and	  
those	   who	   had	   CSF	   WCC	   ≥5/µL.	   Finally,	   associations	   between	   biomarkers	   and	  
mortality	   were	   examined.	   	   Analyses	  were	   performed	   using	   SAS	   9.3	   (SAS	   Institute,	  
Cary,	  North	  Carolina,	  USA)	  with	  Χ2	  tests,	  Fisher’s	  Exact,	  and	  linear	  regression	  models	  
as	   appropriate;	   plots	   were	   generated	   with	   R	   statistical	   software	   2.10.1	  




Figure	  3.2	  	  CSF	  and	  serum	  sampling	  time	  points	  in	  the	  COAT	  trial	  	  



















3.4 Laboratory	  Procedures	  
The	   following	   section	   details	   the	   laboratory	   techniques	   and	   protocols	   used	   in	   the	  
thesis.	  	  
3.4.1 Laboratories	  
The	   National	   Health	   Laboratory	   Service	   (NHLS)	   laboratories	   at	   Groote	   Schuur,	   GF	  
Jooste	   and	   Khayelitsha	   hospitals	   conducted	   all	   diagnostic	   testing	   along	   with	  
haematological,	  biochemical	  and	  virological	  monitoring	  of	  subjects.	  This	  included	  CSF	  
cell	   counts,	   CSF	   India	   Ink	   staining,	   CSF	   protein	   and	   glucose	   concentrations,	   CSF	  
bacterial	   and	   mycobacterial	   culture,	   blood	   cultures,	   full	   blood	   count,	   CD4	   count,	  
urea	  and	  electrolytes,	  liver	  function	  tests,	  CRP	  and	  HIV-­‐1	  viral	  load	  [Table	  3.4].	  These	  
laboratories	  are	  all	  accredited	  with	  the	  South	  African	  National	  Accreditation	  System	  
using	   recognized	   international	   standards	   (ISO	   15189:2012).	   All	   other	   laboratory	  
experiments	  were	   conducted	   in	   research	   laboratories	   at	   the	   Institute	  of	   Infectious	  
Disease	  and	  Molecular	  Medicine,	  University	  of	  Cape	  Town.	  	  All	  patient	  samples	  were	  
handled	  in	  class	  2	  bio-­‐safety	  cabinets	  using	  standard	  precautions	  for	  handling	  blood-­‐
borne	  viruses	  and	  complying	  with	  institutional	  health	  and	  safety	  regulations.	  
3.4.2 Flow	  Cytometer	  
All	   flow	   cytometry	   experiments	   were	   performed	   using	   a	   BD	   LSR	   Fortessa	   Flow	  
Cytometer	   (model	   649224B7,	   power	   690W,	   manufactured	   September	   2010)	  
configured	   with	   4	   lasers	   and	   22	   detectors	   [Figure	   3.3].	   Optimal	   photomultiplier	  
voltages	   were	   used	   and	   BD	   Cytometer	   Setup	   and	   Tracking	   (CS&T)	   beads	   used	   to	  
configure	   the	   machine	   daily.	   	   Saved	   application	   settings	   were	   used	   to	   ensure	  
reproducibility	  on	  each	  run.	  Species	  appropriate	  positive	  and	  negative	  compensation	  
beads	   were	   used	   with	   each	   antibody	   to	   ensure	   accurate	   compensation	   (BD	  
Biosciences	  Z552843	  and	  552844);	  ArC™	  Amine	  Reactive	  Compensation	  Bead	  Kit	  was	  
use	   for	  viability	  dyes	   (Invitrogen	  A10346).	  Acquisition	  of	  data	  was	  performed	  using	  
FACS	   Diva	   software	   (BD	   Biosciences,	   San	   Jose,	   CA,	   USA),	   data	   was	   exported	   and	  




Figure	   3.3	   	   BD	   Fortessa	   flow	   cytometer	   set	   up.	   Lasers	   and	   filter	   set	   up	   are	   detailed,	   along	   with	  
possible	  fluorochromes	  
3.4.3 Whole	  blood	  flow	  cytometry	  	  
Overview	  
Circulating	  blood	   leukocyte	  populations	  were	  examined	  using	   flow	   cytometry.	   This	  
was	   performed	   on	   fresh	   whole	   blood	   due	   to	   concerns	   that	   peripheral	   blood	  




































expression	  of	  monocyte	  activation	  markers	  (H.	  W.	  Ziegler-­‐Heitbrock	  2000;	  Tippett	  et	  
al.	  2011;	  Moniuszko	  et	  al.	  2006).	  Blood	  was	  collected	  in	  EDTA	  tubes	  (BD	  367844)	  and	  
two	   flow	   cytometry	   panels	   used	   to	   enable	   a	  more	   extensive	   examination	   of	   cells.	  
Panel	   1	   allowed	   the	   identification	   of	   T	   cells	   and	  monocyte	   subsets	   (classical,	   non-­‐
classical,	   intermediate)	   and	   a	   limited	   assessment	   of	   their	   activation	   state	   [Table	  
3.14];	   panel	   2	   also	   enabled	   identification	   of	  monocyte	   subsets	   along	  with	   a	  more	  
comprehensive	  assessment	  of	  their	  activation	  status	  (surface	  expression	  of	  HLA-­‐DR,	  
CD163,	   CD80,	   CD11c,	   CCR2,	   CCR5	   and	   TLR4)	   [Table	   3.15].	   The	   interpretation	   of	  
surface	  marker	  expression	  is	  detailed	  below	  [Table	  3.13].	  	  
	  
Marker	   Comments	  
CD16	   FcγRIII,	  pro-­‐inflammatory	  monocyte	  subset	  (L.	  Ziegler-­‐Heitbrock	  2006)	  
HLA-­‐DR	   MHC	  II	  molecule,	  marker	  of	  activation	  and	  antigen	  presentation	  (Wolk	  et	  al.	  2000)	  
CD163	   Scavenger	  receptor,	  increased	  expression	  in	  inflammation	  (Van	  Gorp	  et	  al.	  2010)	  
CD80	   Co-­‐stimulatory	  receptor	  for	  antigen	  presentation	  (Löw	  et	  al.	  1997)	  
CD11c	   Integrin,	  involved	  in	  monocyte	  adhesion	  to	  endothelium	  (Gower	  et	  al.	  2010)	  
CCR2	   Chemokine	  receptor,	  monocyte	  migration	  to	  tissues	  (Traynor	  et	  al.	  2000)	  
CCR5	   Chemokine	  receptor,	  co-­‐receptor	  for	  HIV	  cellular	  entry	  (Rossi	  et	  al.	  2011)	  
TLR4	   Toll-­‐like	  receptor	  4	  –	  cellular	  binding	  site	  for	  LPS	  (Brunialti	  et	  al.	  2006)	  
Table	   3.13	   Monocyte	   surface	   markers	   and	   their	   function.	   Additional	   background	   information	   on	  
monocytes	  is	  detailed	  in	  section	  1.6.3.	  
Method	  
Antibodies	  were	   added	   to	   FACS	   tubes	   in	   a	   total	   volume	  of	   30μl	   as	   detailed	  below	  
[Tables	  3.14,	  3.15].	  100μl	  of	  whole	  blood	  was	  added	  to	  each	  tube	  and	  the	  samples	  
incubated	   at	   4°C	   for	   30	   minutes.	   2ml	   of	   BD	   FACS	   lysing	   solution	   (BD	   Bioscience	  
349202)	   was	   then	   added	   and	   the	   tubes	   incubated	   at	   room	   temperature	   for	   10	  
minutes.	   Samples	   were	   centrifuged	   at	   500	   x	   g	   for	   5	   minutes	   and	   supernatant	  
discarded;	   a	   further	   1ml	   of	   BD	   lysis	   solution	   was	   added	   and	   the	   incubation	   and	  
centrifugation	  repeated	  to	  ensure	  full	  lysis.	  Cell	  pellets	  were	  then	  washed	  with	  flow	  
buffer	  (2%	  fetal	  calf	  serum	  and	  0.05%	  sodium	  azide	  in	  phosphate	  buffered	  saline;	  in-­‐
house)	  and	  fixed	  by	  adding	  2%	  paraformaldehyde	  in	  flow	  buffer	  for	  10	  minutes	  prior	  
to	   a	   final	  wash	   and	   re-­‐suspension	   in	   flow	   buffer.	   Antibodies	   and	   antibody-­‐stained	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cells	   were	   protected	   from	   light	   at	   all	   times.	   Samples	   were	   acquired	   on	   the	   BD	  
Fortessa	  within	  48	  hours;	  at	  least	  150,000	  total	  events	  were	  analysed.	  	  
	  
Target	   Fluorochrome	   Company	   Reference	   Volume	  (μl)	  
CD3	  (UCHT1)	   Pacific	  Blue	   BD	   558117	   2	  
CD4	  (SK3)	   PE-­‐Cy7	   Biolegend	   344612	   0.5	  
CD8	   Qdot	  655	   Invitrogen	   Q10055	   0.2	  
CD14	   Qdot	  605	   Invitrogen	   Q10013	   0.2	  
CD16	   APCH7	   BD	   560195	   5	  
HLA-­‐DR	   Alexa	  Fluor	  700	   Biolegend	   307626	   2	  
CD163	   APC	   Biolegend	   333610	   5	  
CD19	   Alexa	  Fluor	  488	   Biolegend	   302219	   1	  
CD38	   PE	   Biolegend	   303506	   2	  
PD-­‐1	   PerCP-­‐Cy5.5	   Biolegend	   329914	   1.5	  
Flow	  Buffer	   	   In	  house	   	   10.6	  
Table	  3.14	  Flow	  cytometry	  blood	  panel	  1	  
Target	   Fluorochrome	   Company	   Reference Volume	  
CD14	   Q-­‐Dot	  605	   Invitrogen	   Q10013 0.2	  
CD16	   APCH7	   BD	   560195 5	  
CD163	   APC	   Biolegend	   333610 5	  
HLA-­‐DR	   AF700	   Biolegend	   307626 2	  
CD80	   PECy7	   Biolegend	   305218 1	  
CD11c	   PerCP-­‐Cy5.5	   Biolegend	   301624 2	  
CCR2	   AF488	   R&D	   FAB151G 5	  
CCR5	   PB	   Biolegend	   313718 5	  
TLR4	   PE	   Biolegend	   312806 1.25	  
Flow	  Buffer	   	   In	  house	   	   3.5	  
Table	  3.15	  Flow	  cytometry	  blood	  panel	  2	  
Assay	  development	  
The	  optimal	  amount	  of	  antibody	  for	  these	  assays	  was	  determined	  through	  titration	  
experiments.	  A	  series	  of	  two-­‐fold	  dilutions	  were	  made	  in	  flow	  buffer	  (incorporating	  
the	  manufactures	  recommended	  volume)	  and	  100μl	  of	  whole	  blood	  added	  to	  each.	  	  
Median	  fluorescence	  intensity	  (MFI)	  was	  measured	  on	  the	  appropriate	  positive	  and	  
negative	  populations	   and	   the	   ratio	  of	   positive	  population	  MFI/negative	  population	  
MFI	   calculated.	   The	   optimal	   volume	   was	   that	   which	   resulted	   in	   the	   largest	  
positive/negative	  MFI	  ratio.	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Gating	  controls	  
“Fluorescence	   minus	   one”	   (FMO)	   gating	   was	   used	   to	   determine	   the	   separate	  
monocyte	   subsets.	   This	   technique	   aims	   to	   reduce	   false	   positive	   readings	   resulting	  
from	   overspill	   of	   other	   fluorochromes	   into	   the	   desired	   channel	   and	   involves	  
including	   an	   additional	   tube	   containing	   the	   entire	   antibody	   panel	   apart	   from	   the	  
fluorochrome	   in	   question	   (e.g.	   CD16	   APC-­‐H7).	   By	   comparing	   the	   difference	   in	  
measured	  fluorescence	  in	  the	  desired	  channel	  between	  these	  two	  tubes,	  an	  accurate	  
assessment	  of	  cells	  that	  were	  truly	  positive	  for	  the	  fluorochrome	  could	  be	  obtained	  
(Herzenberg	  et	   al.	   2006).	   This	  was	   included	  during	  optimization	   steps	  of	   the	  assay	  
and	   at	   regular	   occasions	   during	   patient	   recruitment	   to	   ensure	   that	   separation	   of	  
monocyte	  subsets	  remained	  accurate.	  Isotype	  control	  antibodies	  were	  not	  used.	  	  
3.4.4 CSF	  flow	  cytometry	  
Flow	   cytometry	   was	   used	   to	   examine	   cellular	   components	   of	   the	   CSF	   immune	  
response	   during	   CM.	   The	   antibody	   panel	   was	   designed	   to	   allow	   accurate	  
identification	  of	  the	  various	  types	  of	  infiltrating	  cells	  along	  with	  the	  activation	  state	  
of	   CSF	  monocytes/macrophages	   and	   T	   cells;	   a	   summary	   of	  macrophage	   activation	  
markers	  are	  detailed	  below	  [Table	  3.16].	  To	  maximize	  the	  number	  of	  cells	  analysed,	  
all	   CSF	   remaining	   after	   clinical	   testing	   and	   quantitative	   culture	   was	   used	   for	   flow	  
cytometry,	   this	   usually	   was	   between	   5-­‐20	   mls	   and	   was	   recorded	   to	   enable	  
calculation	  of	  absolute	  cell	  counts.	  	  
	  
Marker	   Biology	   Interpretation	  
HLA-­‐DR	   MHC	  II	  molecule,	  	   Increased	  with	  classical	  activation	  
CD16	   FcγRIII,	  	   Increased	  with	  classical	  activation	  
CD206	   Mannose	  receptor,	  	   Increased	  with	  alternative	  activation	  
CD163	   Scavenging	  receptor,	  	   Increased	  on	  immune	  modulatory	  macrophages	  
Table	   3.16	   Summary	   of	   macrophage	   activation	   markers.	   Summarized	   from	   (Biswas	   &	  Mantovani	  
2010;	  Gordon	  2003;	  Vega	  2006;	  Mosser	  &	  Edwards	  2008)	  
Laboratory	  method	  	  
CSF	   was	   centrifuged	   (500	   x	   g,	   10	   minutes)	   to	   pellet	   cells;	   the	   supernatant	   was	  
removed,	  separated	  into	  aliquots	  of	  0.5mls	  and	  stored	  at	  −80°C	  [section	  3.4.10].	  CSF	  
cell	  pellets	  were	  re-­‐suspended	  in	  1ml	  of	  PBS	  containing	  0.5μl	  of	  AQUA	  viability	  dye	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[Table	   3.17]	   and	   incubated	   for	   30	   minutes	   at	   4°C.	   Cells	   were	   pelleted	   again	   by	  
centrifugation	  (500xg	  for	  5	  minutes)	  and	  the	  supernatant	  discarded,	  the	  pellet	  was	  
stained	  with	  a	  cocktail	  of	  monoclonal	  antibodies	  [Table	  3.17]	  and	   incubated	  at	  4°C	  
for	  30	  minutes.	  1ml	  of	  BD	  FACS	   lysing	   solution	   (BD	  Bioscience	  349202)	  was	  added	  
and	  the	  mixture	   incubated	  for	  another	  10	  minutes	  at	  room	  temperature	  to	  ensure	  
any	   erythrocytes	   contaminating	   the	   samples	   were	   lysed.	   Cells	   were	   pelleted	   by	  
centrifugation	   (5	   minutes	   at	   500	   x	   g)	   and	   fixed	   in	   2%	   paraformaldehyde	   in	   flow	  
buffer	   for	   10	   minutes	   before	   washing	   and	   re-­‐suspending	   in	   flow	   buffer	   [section	  
3.4.3].	   Samples	   were	   acquired	   on	   a	   BD	   LSR	   Fortessa	   within	   48	   hours	   [section	  
3.4.2].	  	   Antibodies	   and	   antibody-­‐stained	   cells	   were	   protected	   from	   light	   at	   every	  
step.	   When	   large	   volumes	   of	   CSF	   were	   available,	   samples	   were	   split	   to	   enable	  
“fluorescence	  minus	  one”	  (FMO)	  staining	  to	  be	  performed	  (Herzenberg	  et	  al.	  2006).	  
This	  was	  done	   for	   selected	  markers	   that	   required	  accurate	  gating	   (HLA-­‐DR,	  CD206,	  
CD16,	   viability	   and	   CD163).	   	   For	   a	   small	   number	   of	   subjects,	   CD68	   PE	   was	   used	  
instead	   of	   CD66b	   (to	   identify	   a	   subset	   of	   cells	   as	   macrophages).	   As	   this	   is	   an	  
intracellular	  marker,	  cells	  were	  permeabilized	  prior	  by	  adding	  1ml	  of	  BD	  PermWash	  
(BD	  Bioscience	  554723)	  after	  the	  lysis	  step	  and	  then	  incubated	  with	  CD68	  PE	  for	  30	  
minutes,	  cells	  were	  then	  washed	   in	  BD	  PermWash	  (BD	  Bioscience	  554723)	  prior	   to	  
fixing	  and	  re-­‐suspending	  as	  described	  above.	  	  	  	  
Fluorochrome	   Target	   Company	   Product	  number	   Amount	  (µ l)	  
AQUA	   Live/Dead	   Invitrogen	   L34957	   0.5	  
PerCPCy5.5	   CD45	   Biolegend	   304028	   1	  
Qdot	  605	   CD14	   Invitrogen	   Q10013	   0.5	  (1:10	  dilution)	  
Qdot	  655	   CD8	   Invitrogen	   Q10055	   1	  (1:10	  dilution)	  
Pac	  Blue	   CD3	   BD	   558117	   2	  
PECy7	   CD4	  (SK3)	   Biolegend	   344612	   1	  (1:10	  dilution)	  
AF700	   HLA-­‐DR	   Biolegend	   307626	   0.5	  
APCH7	   CD16	   BD	   560195	   5	  
APC	   CD163	   Biolegend	   FAB1607G	   5	  
AF488	   CD206	   Biolegend	   321114	   2	  
PE	   CD66b	   Biolegend	   305106	   1	  
Flow	  buffer	   	   In	  house	   	   10.5	  
Table	  3.17	  Flow	  cytometry	  panel	  for	  staining	  CSF	  cells.	  Dilutions	  made	  in	  flow	  buffer	  prior	  to	  staining	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Assay	  Development	  
Given	  the	  difficulty	  in	  obtaining	  CSF	  for	  assay	  development,	  full	  titration	  experiments	  
were	  not	   possible.	   Instead,	   the	  CSF	  panel	  was	   adapted	   from	  blood	  panel	   1	   [Table	  
3.14]	  with	   some	  adjustments.	   The	  amounts	  of	   antibodies	  used	   for	  CD14	  Qdot605,	  
CD4	  PECy7	  and	  HLADR	  AF700	  were	  reduced,	  as	  the	  amounts	  used	  for	  blood	  panel	  1	  
resulted	  in	  fluorescence	  signals	  greater	  than	  the	  maximum	  measureable.	  In	  addition,	  
a	  viability	  marker	  was	   introduced	  to	  exclude	  dead	  cells	  and	  CD45	  added	  to	  ensure	  
leukocytes	  were	  analysed	  rather	  than	  any	  other	  cells	  present	  in	  the	  sample.	  	  
3.4.5 Whole	  Blood	  Antigen	  Stimulation	  Assay	  (WBASA)	  -­‐	  overview	  
Two	  whole	   blood	   antigen	   stimulation	   assays	  were	   run	   concurrently	   to	   assess	   host	  
response	   to	   cryptococcal	   antigens	   and	   toll-­‐like-­‐receptor	   (TLR)	   stimulants.	   A	   6-­‐hour	  
stimulation	   was	   performed	   to	   assess	   monocyte	   intracellular	   cytokine	   production	  
(WBASA-­‐1),	   and	   a	   24-­‐hour	   stimulation	   was	   performed	   to	   assess	   production	   of	  
cytokines	   and	   chemokines	   in	   plasma	   supernatant	   (WBASA-­‐2).	   The	   same	   antigen	  
preparations	  were	  used	  for	  both	  [Table	  3.18].	  Antigens	  were	  prepared	  and	  diluted	  
under	  strict	  sterile	  conditions;	  stock	  solutions	  and	  aliquots	  of	  working	  solution	  were	  
stored	  at	  −80°C	  and	  defrosted	  when	  required.	  
Ag	   Details	   Source	   Concentration	  




Stock	  solution	  (5mg/ml)	  
Working	  solution	  (1ug/ml)	  
Final	  concentration	  in	  tube	  (100ng/ml)	  




Stock	  solution	  (1mg/ml)	  
Working	  solution	  (50µg/ml)	  
Final	  concentration	  in	  tube	  (5µg/ml)	  
GXM	   Glucuronoxylomannan	  
(polysaccharide)	  
Boulware	   10x	  Stock	  GXM	  (1590µg/mL	  carbohydrate)	  
1x	  Working	  GXM	  (159µg/mL	  carbohydrate)	  
	  
CW	  	   Whole	  Cryptococcal	  
preparation	  	  
Boulware	   10x	  Stock	  CW	  (100µg/mL	  protein	  )	  








1x	  Phosphate	  buffered	  saline	  
(magnesium	  and	  calcium	  chloride	  free)	  
	  
Table	   3.18	  Details	   of	   antigens	  used	   in	  WBASA-­‐1	   and	  WBASA-­‐2.	  Cryptococcal	  antigen	  preparations	  
were	  kindly	  donated	  by	  David	  Boulware	  (University	  of	  Minnesota).	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Both	  GXM	  and	  CW	  were	  kindly	  donated	  by	  David	  Boulware,	  University	  of	  Minnesota.	  	  
These	  antigens	  were	  formulated	  in	  house	  from	  C.	  neoformans	  H99	  strain.	   	  CW	  was	  
obtained	   by	   heat-­‐killing	   H99	   then	   mechanically	   disrupting	   the	   fungal	   cells	   by	  
vortexing	  with	  glass	  beads	  and	  diluting	   to	  achieve	  a	  protein	   content	  of	  100µg/mL.	  	  
GXM	  was	  obtained	  following	  a	  previously	  detailed	  protocol	  (Nimrichter	  et	  al.	  2007).	  
Briefly,	   following	   separation	   from	   fungal	   cells,	   H99	   culture	   supernatant	  was	   ultra-­‐
centrifuged	   at	   15,000	  x	   g	   to	   remove	   smaller	   debris	   and	   concentrated	   20-­‐fold	   by	  
passing	  through	  an	  ultrafiltration	  cell	  (100kDa	  cutoff).	  GXM	  was	  deposited	  as	  a	  thick,	  
translucent	  film	  on	  the	  membrane	  and	  removed	  using	  a	  cell	  scraper	  and	  diluted	  to	  
achieve	  a	  standard	  carbohydrate	  concentration	  (7.95µg/50µL).	  	  
3.4.6 WBASA-­‐1	  –	  monocyte	  intracellular	  cytokine	  response	  
Antigen	  Stimulation	  
Whole	  blood	  was	  obtained	  in	  sodium	  heparin	  tubes	  (BD	  367878)	  and	  transported	  to	  
the	   lab	   in	  a	  cool	  box.	  100μl	  of	  each	  of	   the	  5	  antigen	  working	  solutions	   (LPS,	  GXM,	  
CW,	  R848,	  PBS)	  were	  added	  to	  separate	  sterile	  15ml	  falcon	  tubes	  along	  with	  900μl	  of	  
whole	   blood	   and	   contents	   were	  mixed	   by	   pipetting.	   Blood	   and	   antigen	  mix	   were	  
incubated	   together	   at	   37°C	   for	   a	   total	   of	   6	   hours;	   Brefeldin	   A	   (B7651-­‐5MG	   Sigma	  
Aldrich)	  was	  added	  after	  2	  hours	   (10μl	  of	  500ug/ml;	   final	  concentration	   in	  solution	  
5ug/mL).	   After	   incubation,	   tubes	   were	   removed	   from	   the	   incubator	   and	   stored	  
overnight	  at	  4°C	  (15	  hours).	  	  
	  
Cell	  Harvesting	  
2mls	   of	   ice	   cold	   EDTA	   (15mM)	  were	   added	   to	   tubes	   and	   incubated	   at	   4°C	   for	   10	  
minutes	   (final	   concentration	   10mM).	   Tubes	   were	   vortexed	   for	   20	   seconds	   to	  
dislodge	  adherent	  cells	  and	  contents	  transferred	  to	  FACS	  tubes.	  Cells	  were	  pelleted	  
by	  centrifugation	  (500	  x	  g,	  10	  minutes)	  and	  supernatants	  discarded	  prior	  to	  staining.	  
	  
Surface	  Staining	  
Harvested	  cells	  were	  surface	  stained	  with	  the	  panel	  shown	  in	  [Table	  3.19].	  To	  ensure	  
consistent	  staining	  and	  to	  avoid	  pipetting	  delays	  between	  tubes,	  a	  “master	  mix”	  was	  
made	   up	   in	   advance.	   Antibody	   and	   flow	   buffer	   volumes	   required	   to	   stain	   a	   single	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tube	  were	  multiplied	  by	  the	  total	  number	  of	  tubes	  plus	  one	  to	  ensure	  no	  shortfall.	  
Antibodies	  and	  cells	  stained	  with	  antibody	  mix	  were	  protected	  from	  light	  at	  all	  times.	  	  
	  
Antibody	   Fluorochrome	   Reference	   Amount	  (μl)	  
CD14	   Qdot	  605	   Invitrogen	  Q10013	   0.2	  
HLA-­‐DR	  	   AF700	   Biolegend	  307626	   2	  
CD66	   AF488	   Biolegend	  342306	   1	  
CD3	  (UCHT1)	   AF488	   Biolegend	  300415	   1	  
CD19	   AF488	   Biolegend	  302219	   1	  
Flow	  buffer	   	   	   15	  
Table	  3.19	  Flow	  cytometry	  surface	  staining	  for	  WBASA-­‐1.	  
20μl	   of	  master	  mix	  was	   added	   to	   each	   tube	   and	   incubated	   at	   4°C	   for	   30	  minutes.	  
Tubes	   were	   then	   incubated	   with	   2mls	   of	   FACS	   lysing	   solution	   (BD	   Biosciences	  
349202)	  for	  10	  minutes	  at	  room	  temperature.	  Cells	  were	  pelleted	  by	  centrifuging	  at	  
500	  x	  g	   for	  5	  minutes,	  and	  supernatant	  discarded;	   lysis	  was	  repeated	  to	  ensure	  no	  
residual	   erythrocytes	   in	   the	   pellet.	   Following	   lysis,	   cells	   were	   permeabilized	   by	  




Tubes	  were	  centrifuged	  at	  500	  x	  g	  for	  5	  minutes,	  supernatant	  decanted	  and	  the	  cell	  
pellet	   stained	  with	   the	   panel	   detailed	   below	   [Table	   3.20].	   Antibodies	  were	   added	  
along	  with	  Perm	  Wash	  to	  form	  a	  master-­‐mix	  and	  30μl	  added	  to	  each	  tube.	  Cells	  were	  
incubated	  for	  30	  minutes	  at	  4°C.	  
	  
Antibody	   Fluorochrome	   Reference	   Amount	  (μl)	  
TNFα	   PECy7	   Biolegend	  557647	   0.5	  
IL-­‐6	   APC	   Biolegend	  501112	   2	  
IL-­‐10	   PE	   Biolegend	  506804	   2	  
IL-­‐12	   PB	   Biolegend	  501820	   2	  
Perm	  Wash	   	   BD	  554723	   23.5	  
Table	  3.20	  Intracellular	  cytokine	  staining	  panel	  for	  WBASA-­‐1.	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Following	   intracellular	  staining,	  cells	  were	  washed	   in	  Perm/Wash	  (BD	  554723),	  and	  
fixed	  in	  2%	  paraformaldehyde	  for	  10	  minutes.	  Cells	  were	  pelleted	  and	  re-­‐suspended	  
in	   flow	   buffer	   and	   acquired	   on	   a	   BD	   Fortessa	   within	   48	   hours	   [section	   3.4.2];	   a	  
minimum	   of	   500,000	   total	   events	   were	   acquired.	   Gating	   strategy	   is	   discussed	   in	  
chapter	  6.	  
	  
Notes	  on	  Assay	  development	  
This	   assay	   is	   adapted	   from	   an	   assay	   developed	   by	   the	   South	   African	   TB	   Vaccine	  
Initiative	   (SATVI)	   (Shey	   et	   al.	   2012).	   In	   contrast	   to	   the	   SATVI	   protocol,	   cells	   were	  
stained	   fresh	   rather	   than	   frozen,	   and	   surface	   and	   intracellular	   staining	   was	  
performed	   sequentially	   rather	   than	   concurrently.	   This	  more	   “traditional”	   approach	  
was	   used	  because	   storage	   in	   FACS	   lysing	   buffer	   appeared	   to	   significantly	   alter	   the	  
expression	  of	  some	  surface	  markers	  in	  early	  optimization	  experiments.	  	  
	  
Time	  points	  were	  selected	  following	  optimization	  experiments.	  Six	  hours	  was	  used	  to	  
assess	   monocyte	   cytokine	   production,	   due	   to	   a	   significant	   decline	   in	   monocyte	  
numbers	   with	   longer	   incubations	   (likely	   due	   to	   adherence	   to	   the	   surface	   of	   the	  
container	  (Bennett	  S,	  et	  al.	  1994)).	  Twenty-­‐four	  hours	  was	  used	  for	  measurement	  of	  
cytokines	  in	  whole	  blood	  supernatants,	  to	  allow	  IL-­‐10	  concentrations	  to	  reach	  their	  
peak	  (Liese	  et	  al.	  2001).	  
	  
It	  was	   not	   possible	   to	   obtain	   cryptococcal	  mannoprotein	   (the	  main	   cryptococcal	   T	  
cell	   epitope	   (Levitz	   S,	   et	   al.	   2006))	   during	   the	   course	   of	   the	   study.	   As	   such,	  
Glucuronoxylomannan	  (GXM)	  and	  heat-­‐killed,	  mechanically	  disrupted	  C.	  neoformans	  
(CW)	  antigens	  were	  used	  to	  try	  and	  assess	  cryptococcal	  specific	  responses.	  GXM	  was	  
used	   because	   it	   is	   the	   molecule	   which	   forms	   the	   majority	   of	   the	   polysaccharide	  
capsule	  and	  hence	  the	  component	  of	  the	  organism	  to	  which	  the	  immune	  system	  is	  
most	  frequently	  exposed	  (Zaragoza	  et	  al,	  2009);	  CW	  was	  used	  to	  assess	  the	  immune	  
response	   to	   cell	   wall	   and	   intracellular	   cryptococcal	   epitopes.	   Appropriate	  
concentrations	  were	   determined	   following	   discussion	  with	   the	   Boulware	  Group	   at	  
University	  of	  Minnesota.	  An	  additional	  15-­‐hour	  4°C	  incubation	  step	  was	  incorporated	  
into	  the	  protocol	   (between	  stimulation	  and	  harvesting)	  to	  enable	  next	  day	  staining	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of	   samples,	   this	  was	  after	   comparison	  experiments	   showed	  no	   significant	  effect	  of	  
this	  delay	  on	  intracellular	  cytokine	  production.	  	  
3.4.7 WBASA-­‐2	  –	  whole	  blood	  cytokine	  responses	  
WBASA-­‐2	  was	  performed	  in	  parallel	  to	  WBASA-­‐1	  using	  the	  same	  antigen/stimulants.	  
50μl	  of	  working	  concentration	  of	  the	  4	  antigens	  or	  PBS	  were	  added	  to	  five	  separate	  
15ml	   falcon	   tubes	  along	  with	  495μl	  of	  whole	  blood	   (Sodium	  Heparin).	   Tubes	  were	  
incubated	  for	  24	  hours	  at	  37C,	  after	  which,	  cells	  were	  pelleted	  (centrifugation	  500	  x	  
g,	   5	  mins)	   and	   the	   supernatant	   removed	  and	   stored	  at	   −80°C	   in	   aliquots	  of	   100μl.	  
Cytokines,	  chemokines	  and	  other	  biomarkers	  in	  the	  supernatant	  were	  later	  analysed	  
using	  Luminex	  assay	  and	  ELISA	  [section	  3.4.12-­‐3.4.13].	  	  
3.4.8 Plasma	  
Remaining	  whole	  blood	  from	  the	  WBASA	  assays	  (sodium	  heparin	  tubes	  BD	  367878)	  
was	  centrifuged	  at	  1200	  x	  g	  for	  10	  minutes	  and	  then	  stored	  in	  aliquots	  of	  0.5mls	  at	  -­‐
80°C	  for	  future	  analysis.	  
3.4.9 Serum	  
Blood	  collected	  in	  SST	  tubes	  (BD	  Biosciences,	  367989)	  was	  allowed	  to	  clot	  and	  then	  
centrifuged	  at	  3000	   x	   g	   for	  10	  minutes.	   	   Serum	  was	   stored	  at	   −80°C	   in	   aliquots	  of	  
0.5mls	  for	  future	  analysis.	  
3.4.10 CSF	  supernatant	  
CSF	  supernatant	  was	  obtained	  during	  the	  processing	  of	  CSF	  cells	  for	  flow	  cytometry.	  
CSF	   cells	   were	   pelleted	   (centrifugation	   500	   x	   g	   for	   10	   minutes)	   and	   supernatant	  
removed	  and	  stored	  at	  -­‐80°C	  in	  aliquots	  of	  0.5ml.	  	  
3.4.11 Quantitative	  Culture	  and	  Early	  Fungicidal	  Activity	  
Quantitative	  cultures	  were	  performed	  on	  all	  available	  CSF	  samples	  to	  determine	  the	  
fungal	  burden	  of	  C.	  neoformans	  in	  colony	  forming	  units	  per	  ml	  CSF	  (CFU/ml).	  	  This	  is	  





Dilutions	  and	  fungal	  culture	  
0.5	  mls	  of	  CSF	  was	   vortexed	  and	  mixed	   thoroughly.	   Four	   additional	  dilutions	  were	  
created	   by	   performing	   serial	   10-­‐fold	   dilutions	  with	   distilled	  water.	   100μl	   from	   the	  
resulting	  4	  dilutions	  and	  neat	  CSF	  were	  each	  plated	  in	  duplicate	  onto	  separate	  halves	  
of	   Sabouraud	   dextrose	   agar	   plates	   containing	   chloramphenicol	   (NHLS,	   Cape	   Town,	  
SA).	   Plates	  were	   incubated	   at	   30°C	   for	   up	   to	   14	   days	   and	  monitored	   regularly	   for	  
growth.	  	  Any	  new	  colonies	  were	  marked,	  when	  no	  new	  colonies	  had	  formed	  for	  48	  
hours	  then	  a	  final	  colony	  count	  was	  performed.	  	  
	  
Quantitation	  of	  fungal	  burden	  
To	  calculate	   the	  overall	   fungal	  burden,	  a	  colony	  count	   (CC)	   from	  the	  two	  halves	  of	  
the	  plate	  was	  performed	  (CC1	  and	  CC2).	  The	  mean	  count	  was	  then	  multiplied	  by	  the	  
dilution	   factor	  and	  by	  10	   (to	  account	   for	   the	  plate	   inoculation	  volume	  of	  100μl)	  as	  
shown	  below.	  
	  𝐹𝑢𝑛𝑔𝑎𝑙  𝑏𝑢𝑟𝑑𝑒𝑛 =   𝐶𝐶1+ 𝐶𝐶22 ∗ 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛  𝑓𝑎𝑐𝑡𝑜𝑟 ∗ 10	  
	  
On	  the	  occasions	  when	  growth	  was	  observed	  in	  a	  number	  of	  different	  CSF	  dilutions,	  
the	  plate	  with	  counts	  closest	  to	  50	  per	  half	  plate	  was	  chosen	  (as	  this	  proved	  to	  be	  a	  
more	  accurate	  number	  to	  count).	  	  
	  
Calculating	  rate	  of	  fungal	  clearance	  
To	   calculate	   the	   rate	  of	   fungal	   clearance	   (or	  early	   fungicidal	   activity	  –	  EFA),	   fungal	  
burdens	  were	   log10	   transformed	  and	  plotted	  against	  days	  of	  amphotericin	   therapy.	  
Fungal	  burdens	  were	  limited	  to	  CSF	  samples	  taken	  from	  patients	  during	  the	  intensive	  
phase	   of	   amphotericin	   therapy,	   and	   excluded	   sterile	   cultures	   taken	   during	   the	  
second	  week	   of	   amphotericin	   therapy	   if	   they	   lessened	   the	   slope	   of	   the	   curve	   (as	  
sterility	  would	  have	  been	  achieved	  prior	  to	  this	  sample	  being	  taken).	  Standard	  linear	  
regression	  was	  performed	  to	  calculate	  a	  line	  of	  best	  fit	  and	  the	  slope	  of	  the	  line	  used	  
to	  determine	  the	  EFA	  (change	  in	   log10CFU/ml/d).	  Note	  was	  made	  of	  the	  number	  of	  
quantitative	  cultures	  used	  to	  calculate	  each	  individual	  patient’s	  value.	  
69	  	  
3.4.12 Analysis	  of	  Cytokines	  and	  Chemokines	  	  
Analysis	   of	   cytokines	   was	   performed	   using	   commercial	   multiplex	   bead	  
immunoassays	  on	  samples	  obtained	  from	  both	  IICD	  and	  COAT	  studies.	  	  
	  
IICD	  cytokines	  
The	   concentrations	   of	   30	   cytokines,	   chemokines	   and	   growth	   factors	   in	   CSF,	   serum	  
and	  WBASA-­‐2	  supernatants	  were	  measured	  using	  a	  commercially	  produced	  30-­‐plex	  
bead	   immunoassay	   (LHC	   6003,	   Invitrogen	   Corp,	   CA,	   USA).	   This	   assay	   utilizes	  
polystyrene	   beads	   and	   a	   96-­‐well	   filter	   plate	   connected	   to	   a	   vacuum	   manifold	   to	  
enable	   vacuum	   emptying	   of	   the	   wells	   following	   a	   wash.	   Analytes	  measured	   were	  
Interleukin	  (IL)-­‐1β,	  IL-­‐1RA,	  IL-­‐2,	  IL-­‐2R,	  IL-­‐4,	  IL-­‐5,	  IL-­‐6,	  IL-­‐7,	  IL-­‐8,	  IL-­‐10,	  IL-­‐12	  (p40/p70),	  
IL-­‐13,	   IL-­‐15,	   IL-­‐17,	   tumour	   necrosis	   factor	   (TNF)-­‐α,	   interferon	   (IFN)-­‐α,	   IFN-­‐γ,	  
granulocyte	   colony	   stimulating	   factor	   (G-­‐CSF),	   granulocyte	   macrophage	   colony	  
stimulating	   factor	   (GM-­‐CSF),	  macrophage	   inflammatory	   protein-­‐1α	   (MIP-­‐1α/CCL3),	  
MIP-­‐1β/CCL4,	   interferon	   gamma	   induced	   protein-­‐10	   (IP-­‐10/CXCL10),	   monokine	  
induced	  by	  gamma	  interferon	  (MIG/CXCL9),	  Eotaxin,	  regulated	  on	  activation	  normal	  
T	   cell	   expressed	   and	   secreted	   (RANTES/CCL5),	   monocyte	   chemotactic	   protein-­‐1	  
(MCP-­‐1/CCL2),	   vascular	   endothelial	   growth	   factor	   (VEGF),	   epidermal	   growth	   factor	  
(EGF),	   fibroblast	   growth	   factor	   (FGF-­‐basic)	   and	   hepatocyte	   growth	   factor	   (HGF).	  	  
Samples	  of	  serum,	  CSF,	  WBASA-­‐2	  unstimulated,	  WBASA-­‐2	  CW	  and	  GXM	  stimulated	  
supernatants	  were	  not	  diluted	  prior	  to	  analysis;	  WBASA-­‐2	  LPS	  and	  R848	  stimulated	  
supernatants	   were	   diluted	   1:10	   with	   PBS.	   Optimal	   dilutions	   for	   WBASA-­‐2	  
supernatants	   were	   determined	   following	   a	   dilution	   experiment	   performed	   on	   a	  
selection	  of	  subjects,	  with	  dilutions	  selected	  to	  maximize	  the	  number	  of	  detectible	  
cytokines.	  Additional	  dilutions	  (1:100)	  were	  later	  performed	  for	  select	  CW	  and	  GXM	  
samples	  with	  values	  of	  IL-­‐6	  that	  were	  out-­‐of-­‐range.	  	  	  
	  
Manufacturer’s	   instructions	   were	   followed	   with	   additional	   points	   included	   on	   the	  
standard	  curve	   for	   increased	  accuracy.	  Briefly,	  after	  a	  single	  wash-­‐aspirate	  cycle	   to	  
pre-­‐wet	  the	  wells,	  vortexed	  detection	  beads	  were	  added	  and	  the	  wells	  washed	  twice	  
with	  wash	   solution.	   Incubation	  buffer	  was	   added	   to	   each	  well	   and	   assay	  buffer	   to	  
70	  	  
wells	  designated	  for	  samples;	  standards	  or	  samples	  were	  added	  to	  the	  appropriate	  
wells	  and	  the	  plate	  incubated	  for	  2	  hours	  at	  room	  temperature	  on	  an	  orbital	  shaker	  
protected	   from	   light.	   After	  washing,	   biotinylated	   antibody	  was	   added	   to	   the	  wells	  
and	  the	  plate	   incubated	  for	  a	   further	  hour.	  A	  further	  wash	  was	  performed	  prior	  to	  
the	  addition	  of	  streptavidin-­‐RPE	  and	  the	  plate	   incubated	   for	  30	  minutes.	  The	  plate	  
was	   then	   washed	   three	   times	   and	   beads	   re-­‐suspended	   in	   wash	   solution	   prior	   to	  
reading	  [Figure	  3.4].	  Results	  were	  acquired	  on	  a	  Luminex	  200	  instrument	  using	  bio-­‐
plex	  manager	  software	  version	  6	  (Bio-­‐Rad	  Laboratories,	  Hercules,	  CA,	  USA).	  Standard	  
curves	   were	   generated	   using	   5PL	   non-­‐linear	   regression	   models	   and	   reviewed	   for	  
goodness-­‐of-­‐fit	   (observed	   value/expected	   value	   *100	   =	   70-­‐130%),	   extreme	   values	  
were	   removed	   if	   their	   inclusion	   significantly	   altered	   curve	   fit	   or	   if	   the	   observed	  






Figure	  3.4	  	  Experimental	  protocol	  for	  Invitrogen	  30-­‐plex	  immunoassay	  	  
(http://www.lifetechnologies.com/order/catalog/product/LHC6003?CID=search-­‐product)	  
Extrapolated	  values	  were	   included	   in	   the	  analysis	  provided	   the	  observed/expected	  
value	  for	  the	  last	  standard	  was	  within	  an	  acceptable	  range	  (70-­‐130%).	  Values	  marked	  
“out-­‐of-­‐range”	  because	  they	  were	  too	  low	  to	  be	  measured	  were	  marked	  as	  0.	  Values	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dilution	  if	  samples	  were	  available.	   If	  this	  was	  not	  possible	  an	  arbitrary	  number	  was	  
given	   equal	   to	   the	   highest	   measured	   value	   for	   that	   analyte	   plus	   one.	   To	   avoid	  
negative	  numbers	  and	  allow	  log	  transformation	  of	  data	  for	  the	  occasional	  WBASA-­‐2	  
biomarkers	  that	  decreased	  during	  stimulation,	  the	  maximum	  reduction	  in	  value	  was	  
added	  to	  all	  values	  to	  ensure	  all	  numbers	  were	  positive.	  	  Prior	  to	  log	  transformation	  
the	  value	  of	  1	  was	  added	  to	  all	  values;	  this	  ensured	  a	   log	  transformation	  remained	  
possible	  and	  meant	  that	  the	  lowest	  log	  transformed	  value	  would	  be	  zero.	  
	  
COAT	  cytokines	  
Luminex	  magnetic	   bead	   technology	   (Bio-­‐Rad	   Laboratories,	   Hercules,	   CA,	   USA)	  was	  
used	   to	  analyze	  19	  cytokines	  and	  chemokines	   (G-­‐CSF,	  GM-­‐CSF,	   IFN-­‐γ,	  TNF-­‐α,	   IL-­‐1β,	  
IL-­‐2,	   IL-­‐4,	   IL-­‐5,	   IL-­‐6,	   IL-­‐7,	   IL-­‐8,	   IL-­‐10,	   IL-­‐12,	   IL-­‐13,	   IL-­‐17,	  MCP-­‐1/CCL2,	  MIP-­‐1α/CCL3,	  
MIP-­‐1β/CCL4,	   VEGF)	   according	   to	   manufacturers’	   protocols.	   Briefly,	   beads	   were	  
added	   to	  wells	   and	  washed	   twice,	   the	   appropriate	   amount	   of	   standard	   or	   sample	  
were	   added,	   and	   the	   plate	   incubated	   for	   30	  minutes	   (protected	   from	   light	   on	   an	  
orbital	  shaker	  at	  850rpm).	  After	  three	  washes	  detection	  antibody	  was	  added	  and	  the	  
plate	   incubated	   for	   30	   minutes	   (850rpm,	   protected	   from	   light).	   The	   plate	   was	  
washed	  a	  further	  three	  times,	  streptavidin-­‐PE	  was	  added,	  the	  plate	  incubated	  for	  10	  
minutes	  and	  then	  washed	  for	  a	  final	  three	  times.	  Beads	  were	  re-­‐suspended	  in	  assay	  
buffer	   and	   the	   plate	   read	   using	   a	   Luminex	   200	  machine.	   Data	  was	   cleaned	   in	   the	  
same	   manner	   as	   discussed	   above	   for	   IICD	   except	   that	   “out-­‐of-­‐range”	   low	   values	  
were	  given	  the	  arbitrary	  value	  of	  half	  the	  manufacturers	  lower	  limit	  of	  detection.	  	  
3.4.13 Soluble	  markers	  of	  monocyte/macrophage	  activation	  
Soluble	  CD14	  (sCD14)	  and	  soluble	  CD163	  (sCD163)	  were	  measured	  in	  serum	  and	  CSF	  
using	  commercially	  available	  ELISA	  kits	  (R&D	  Systems	  Inc,	  MN,	  USA;	  Ref	  DC140	  and	  
DC1630	   respectively).	   Both	   assays	   utilized	   a	   96-­‐well	   plate	   pre-­‐coated	  with	   capture	  
antibody	  and	  were	  performed	  as	  directed	  by	  the	  manufacturer.	  Briefly,	  assay	  diluent	  
was	  added	   to	  each	  well	   followed	  by	   sample	  or	   the	  appropriately	  diluted	   standard.	  
Plates	  were	   incubated	   at	   room	   temperature	   for	   the	   appropriate	   time	   (3	   hours	   for	  
sCD14,	  2	  hours	  for	  sCD163),	  then	  washed	  4	  times	  using	  an	  automated	  plate	  washer	  
and	   incubated	   with	   the	   appropriate	   conjugate	   (1	   hour	   for	   sCD14	   and	   2	   hours	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sCD163).	  Following	  a	  further	  wash	  step,	  substrate	  solution	  was	  added	  and	  the	  plate	  
incubated	  for	  30	  minutes	  before	  adding	  stop	  solution.	  The	  plate	  was	  read	  within	  30	  
minutes	  using	  a	  micro	  plate	  reader,	  set	  to	  450nm	  with	  wavelength	  correction	  set	  to	  
540nm.	  	  Following	  optimization	  experiments,	  CSF	  samples	  were	  diluted	  200	  fold	  and	  
25	  fold,	  and	  serum	  samples	  diluted	  1500	  fold	  and	  50	  fold	  for	  measurement	  of	  sCD14	  
and	  sCD163	  respectively.	  All	  dilutions	  were	  performed	  using	  Calibrator	  Diluent	  (RD5-­‐
24,	   R&D	   Systems	   Inc,	   MN,	   USA).	   Samples	   out	   of	   range	   were	   repeated	   at	   higher	  
dilutions.	   CCL22/MDC	   was	   also	   measured	   using	   a	   commercial	   ELISA	   following	  
manufacturers	  instructions	  (COAT	  sub-­‐study	  only);	  no	  dilution	  was	  required	  (DMD00,	  
R&D	  Systems	  Inc,	  MN,	  USA).	  
	  
Raw	   data	   was	   analysed	   in	   Microsoft	   Excel	   for	   Mac	   (ver	   14.3.9,	   2011).	   Linear	  
regression	  was	   used	   to	   calculate	   a	   line	   of	   best	   fit	   for	   standards	   and	   this	   equation	  
used	   to	   calculate	   the	   measured	   concentration	   from	   the	   optical	   density.	   This	   was	  
then	  multiplied	  by	  the	  dilution	  factor	  to	  determine	  the	  actual	  concentration.	  
3.4.14 Lipopolysaccharide	  (LPS)	  measurement	  
LPS	  was	  measured	  using	  the	  commercially	  available	  Limulus	  amebocyte	  lysate	  (LAL)	  
assay	   kit,	   manufacturers	   instructions	   were	   followed	   with	   some	   minor	   alterations	  
(LAL	  assay,	  50-­‐647U,	  Lonza	  Group	  Ltd,	  Basel,	  Switzerland).	  The	  assay	  was	  performed	  
using	  a	  pyrogen	  free	  polystyrene	  96-­‐well	  plate	  flat	  bottom	  plate	  (LAL	  reagent	  grade,	  
Lonza	  25-­‐340,	  Basel,	  Switzerland),	  LAL	  reagent	  grade	  fluid	  reagent	  reservoirs	  (Lonza	  
25-­‐364),	  pyrogen	  free	  glass	  dilution	  tubes	  for	  making	  up	  the	  standard	  (Lonza	  N207),	  
and	  sterile	  filter-­‐tip	  pipette	  tips.	  Briefly,	  samples	  of	  plasma	  were	  defrosted,	  diluted	  
1/10	   with	   LAL	   reagent	   water	   and	   heat	   inactivated	   at	   80°C	   for	   15	   minutes	   on	   a	  
heating	  block.	  50µl	  of	  standards	  and	  samples	  were	  loaded	  in	  triplicate	  into	  a	  96-­‐well	  
plate	  and	  incubated	  at	  37°C	  for	  5	  minutes	  to	  equilibrate.	  LAL	  reagent	  was	  prepared	  
when	  required	  and	  used	  immediately	  –	  50µl	  was	  added	  to	  the	  first	  two	  wells	  of	  the	  
triplicate	   standards	   or	   samples	   and	   the	   plate	   incubated	   for	   12	   minutes	   at	   37°C.	  
100µl	  of	  chromogenic	  substrate	  was	  then	  added	  to	  the	  first	  2	  wells	  of	  each	  triplicate	  
and	  incubated	  at	  37°C	  for	  a	  further	  7	  minutes.	  50µl	  of	  25%	  acetic	  acid	  (stop	  solution)	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was	  then	  added	  to	  the	  first	  two	  wells	  of	  each	  replicate	  and	  the	  plate	  read	  using	  an	  
ELISA	  plate	  reader	  at	  405nm.	  	  
	  
To	  calculate	  results	  for	  standards	  and	  samples,	  absorption	  of	  the	  third	  replicate	  was	  
subtracted	  from	  the	  mean	  of	   the	  first	   two.	   	  Mean	  values	  were	  used	  to	  construct	  a	  
standard	   curve	   and	   the	   linear	   equation	   used	   to	   back-­‐calculate	   the	   amount	   of	   LPS	  
present	  in	  EU/ml.	  	  	  
3.4.15 Assessment	  of	  Cryptococcal	  Antigen	  
Semi-­‐quantitative	  assessment	  of	  both	  serum	  and	  CSF	  cryptococcal	  antigen	  load	  was	  
performed	   by	   testing	   serial	   two-­‐fold	   dilutions	   using	   a	   commercial	   cryptococcal	  
antigen	   lateral	   flow	   detection	   assay	   (CrAg	   LFA)	   (Immy	   IM-­‐CR2003,	   OK,	   USA).	   	   The	  
laboratory	  protocol	  was	  based	  on	  that	  suggested	  by	  the	  manufacturers	  with	  minor	  
adaptations.	  Briefly,	  a	  62.5	  fold	  dilution	  of	  the	  sample	  was	  performed	  and	  added	  to	  
the	   first	   well	   of	   a	   96-­‐well	   plate,	   serial	   two-­‐fold	   dilutions	   made	   using	   LF	   titration	  
diluent	  (IM-­‐E10010,	  IMMY,	  OK,	  USA),	  and	  CrAg	  LFA	  test	  strips	  were	  used	  to	  test	  for	  
cryptococcal	   antigen.	   CrAg	   titre	   was	   determined	   as	   the	   highest	   dilution	   where	   a	  
positive	   result	   was	   obtained.	   Test	   strips	   were	   double-­‐read	   to	   minimize	   observer	  
error;	   any	   discrepancies	   between	   observers	   were	   discussed	   and	   if	   no	   agreement	  
could	  be	  made	  then	  the	  lower	  titre	  was	  used.	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3.5 Management	  of	  cryptococcal	  meningitis	  
3.5.1 Anti-­‐fungal	  therapy	  
Patients	   were	   treated	   with	   anti-­‐fungal	   therapy	   according	   to	   local	   guidelines	   as	  
detailed	  in	  Table	  3.21	  (Govender	  et	  al.	  2013);	  despite	  its	  proven	  efficacy,	  flucytosine	  
is	  not	  available	  in	  South	  Africa	  (Day	  et	  al.	  2013;	  Loyse	  et	  al.	  2013).	  
	  
Phase	   Therapy	  
Induction	  (14d)	  
IV	  amphotericin	  B	  deoxycholate	  1.0mg/kg/d	  	  
+	  oral	  fluconazole	  800mg/d	  
Consolidation	  (10	  weeks)	   Oral	  fluconazole	  400mg/d	  
Secondary	  Prophylaxis	  	  
(until	  CD4>200	  for	  6	  months)	  
Fluconazole	  200mg/d	  
Table	   3.21	   Details	   of	   anti-­‐fungal	   therapy	   used	   for	   subjects	   in	   IICD	   study.	   Treatment	   based	   on	  
Southern	  African	  HIV	  clinicians	  society	  guidelines	  (Govender	  et	  al.	  2013)	  
3.5.2 Management	  of	  amphotericin	  B	  toxicity	  
WHO	   guidelines	   to	   reduce	   amphotericin	   B	   (AmB)	   toxicity	   were	   followed	   (WHO	  
2011).	   Participants	   received	   intravenous	   pre-­‐hydration	   with	   1	   litre	   0.9%	   saline	  
supplemented	   with	   20mmol	   of	   potassium	   chloride	   prior	   to	   AmB	   administration,	  
along	   with	   regular	   oral	   potassium	   and	   magnesium	   supplementation.	   Routine	  
laboratory	  monitoring	   of	   haemoglobin,	   potassium,	  magnesium	   and	   creatinine	  was	  
performed	  at	  baseline	  and	   twice	  weekly	  while	   receiving	  AmB	   [section	  3.2.9,	   Table	  
3.4].	   Further	   intravenous	   fluids,	   oral	   and	   intravenous	   electrolyte	   supplementation	  
were	   provided	   as	   appropriate.	   In	   keeping	   with	   South	   African	   guidelines,	   AmB	  
administration	  was	   halted	   if	   the	   serum	   creatinine	   value	   doubled,	   and	   re-­‐started	   if	  
the	   value	   reduced	   significantly;	   dose	   reduction	   or	   increased	   dosing	   interval	   was	  
considered	  in	  patients	  with	  significant	  renal	  toxicity	  (AmB	  therapy	  halted	  more	  than	  
twice	  during	  therapy)	  (Govender	  et	  al.	  2013).	  	  
3.5.3 Management	  of	  raised	  intracranial	  pressure	  
All	   patients	  were	  managed	   according	   to	   the	   Infectious	  Disease	   Society	   of	   America	  
(IDSA)	  and	  the	  Southern	  African	  HIV	  Clinicians	  Society	  (SAHCS)	  guidelines	  (Perfect	  et	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al.	   2010a;	   Govender	   et	   al.	   2013).	   A	   lumbar	   puncture	   to	   measure	   CSF	   opening	  
pressure	  was	  performed	  at	  baseline	  and	  at	  any	  time	  there	  was	  clinical	  suspicion	  of	  
raised	   intracranial	   pressure	   (e.g.	   worsening	   headache,	   decreased	   consciousness,	  
new	   neurological	   findings).	   Therapeutic	   drainage	   of	   CSF	   was	   performed	   if	   CSF	   OP	  
was	  >25cmH2O	  with	  the	  aim	  to	  reduce	  the	  pressure	  to	  <20cmH2O	  (or	  by	  50%	  if	  the	  
opening	  pressure	  was	  >40	  cmH2O).	  Repeated	  drainage	  was	  performed	  according	  to	  
clinical	  condition.	  CT	  scan	  was	  considered	  prior	  to	  LP	   if	  there	  were	  clinical	   features	  
suggestive	  of	  space	  occupying	   lesion	   (eg.	   lateralising	  neurological	  signs).	   If	  patients	  
gave	   consent,	   an	   additional	   LP	   was	   performed	   at	   14	   days	   at	   the	   completion	   of	  
amphotericin	  B	  therapy	  to	  assess	  CSF	  sterility.	  	  
3.5.4 Anti-­‐retroviral	  therapy	  
An	  anti-­‐retroviral	   therapy	   (ART)	   history	  was	   sought	   for	   all	   study	   subjects	   including	  
details	  of	  previous	  regimens,	  toxicity	  and	  adherence	  problems.	  Following	  extensive	  
counselling	  from	  a	  trained	  HIV	  counsellor,	  subjects	  not	  taking	  ART	  were	  started	  on	  
ART	   at	   week	   4	   of	   the	   study	   (provided	   there	   were	   no	   clinical	   contraindications).	  
Choice	  of	  regimen	  was	  determined	  by	  the	  South	  African	  ART	  guidelines;	  first	  line	  ART	  
was	   tenofovir/lamivudine/efavirenz	   at	   the	   beginning	   of	   the	   study,	   and	   changed	   to	  
tenofovir/emtricitabine/efavirenz	   (fixed	   dose	   combination)	   from	   the	   1st	   January	  
2013	   (SADoH	   2013b).	   	   If	   renal	   function	   was	   impaired	   (creatinine	   clearance	  
<60ml/min)	   stavudine	   or	   zidovudine	   were	   initially	   used	   instead	   of	   tenofovir;	   such	  
individuals	   were	   later	   switched	   to	   tenofovir-­‐based	   therapy	   if	   their	   renal	   function	  
improved.	  A	  similar	  strategy	  was	  adopted	  as	  a	  prophylactic	  measure	  for	  any	  patients	  
taking	  tenofovir-­‐based	  ART	  prior	   to	  admission.	  The	   likely	  adherence	  of	  participants	  
on	   ART	   was	   assessed	   at	   study	   entry	   through	   interview	   with	   an	   experienced	   HIV	  
counsellor	  and	  by	  examining	  CD4	  count	  and	  HIV	  viral	  load	  results.	  Patients	  on	  failing	  
regimens	   or	   those	   with	   adherence	   problems	   received	   extensive	   adherence	  
counselling.	   Switch	   to	   second	   line	   ART	   was	   made	   on	   clinical	   grounds	   in	   line	   with	  
South	   African	   ART	   guidelines	   (HIV	   viral	   load	   >1000	   copies/mL	   on	   2	   occasions	   2	  
months	   apart),	   the	   choice	  of	   regimen	  being	   influenced	  by	  previous	  drugs	   received	  
and	  any	  co-­‐morbidities	  (SADoH	  2013b).	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3.6 Data	  analysis	  	  
3.6.1 Planned	  analyses	  to	  address	  main	  aims	  of	  thesis	  
AIM	  1	  -­‐	  Characterize	  the	  activation	  state	  of	  CSF	  and	  blood	  monocyte/macrophages	  	  
• IICD:	   Describe	   infiltrating	   CSF	   cells	   and	   the	   activation	   state	   of	   CSF	  
macrophages	  	  
• IICD:	   Compare	   the	  blood	   immune	   response	  of	   subjects	  with	   CM	   to	   healthy	  
and	  HIV-­‐infected	  control	  groups	  	  
	  
AIM	  2	  –	  Assess	  the	  effects	  of	  ART	  on	  host	  immune	  response	  
• IICD:	   Compare	   baseline	   immune	   responses	   in	   CSF	   and	   blood	   between	  
individuals	  who	  were	  taking	  ART	  at	  presentation	  and	  those	  who	  were	  not	  	  
• COAT:	   Compare	   immune	   response	   in	   CSF	   and	   blood	   between	   early	   and	  
deferred	  ART	  arms	  	  
	  
AIM	  3	  –	  Explore	  immune	  correlates	  of	  severe	  disease	  and	  fatal	  outcome	  
• IICD:	   Examine	   the	   relationship	   between	   baseline	   immune	   response	   in	   CSF	  
and	   blood	   at	   enrolment	   and	   the	   three	   markers	   of	   severity	   (CSF	   fungal	  
burden,	  altered	  consciousness	  and	  raised	  intracranial	  pressure	  [Table	  3.3])	  	  
• IICD:	   Examine	   the	   relationship	   between	   baseline	   immune	   response	   in	   CSF	  
and	  blood,	  and	  mortality	  at	  day-­‐14	  and	  week-­‐12	  	  
• COAT:	  Examine	  the	  relationship	  between	  immune	  response	  during	  the	  COAT	  
trial	  and	  week	  4	  mortality	  
	  
3.6.2 Analysis	  techniques	  
A	  variety	  of	  statistical	  techniques	  were	  used	  throughout	  the	  thesis.	  Details	  are	  given	  
in	  each	  relevant	  chapter.	  Flow	  cytometry	  data	  were	  combined	  with	  biomarker	  data	  
(concentrations	  of	  CSF	  cytokines,	   chemokines,	  and	  soluble	  markers	  of	  macrophage	  
activation)	  to	  reflect	  a	  more	  “complete”	  assessment	  of	  the	  immune	  response.	  Due	  to	  
the	  nature	  of	  the	  dataset	  (a	  large	  number	  of	  potentially	  interconnected	  variables	  in	  a	  
relatively	   small	   number	   of	   subjects)	   traditional	   statistical	  methods	  were	   felt	   to	   be	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potentially	  inadequate,	  as	  data	  were	  likely	  to	  suffer	  from	  significant	  multicollinearity,	  
and	   statistical	   power	   compromised	   by	   stringent	   multiple	   comparison	   tests.	  
Therefore,	  further	  data	  analysis	  was	  performed	  using	  Principal	  Component	  Analysis	  
(PCA)	   and	   heatmap	   analysis	   with	   hierarchical	   clustering,	   descriptions	   of	   both	   of	  
these	  are	  given	  below.	  Prior	  to	  PCA,	  variables	  were	  log2	  transformed	  if	  skewed,	  and	  
standardized	   such	   that	   the	   mean	   equaled	   zero	   and	   variance	   equaled	   1.	   Missing	  
values	  were	   imputed	  by	  K	  nearest	  neighbours	  technique	  (Troyanskaya	  et	  al.	  2001).	  
Specific	  principal	   components	  were	   later	   incorporated	  as	   summative	  variables	   into	  
regression	   models.	   Most	   analyses	   were	   performed	   using	   Stata	   version	   12	   (Stata	  
Corp,	  Texas,	  USA);	  Qlucore	  Omics	  Explorer	  version	  3.0	   (Qlucore	  AB,	  Lund,	  Sweden)	  
was	  used	  to	  perform	  PCA	  and	  generate	  PCA	  plots.	  
	  
Principal	  Component	  Analysis	  (PCA)	  
Principal	  component	  analysis	  (PCA)	  is	  a	  well-­‐established	  mathematical	  technique	  for	  
analysis	   of	   complex	   data.	   Rather	   than	   assessing	   datasets	   in	   terms	   of	   all	   individual	  
variables,	   PCA	   reduces	   the	   dimensionality	   of	   the	   data	   into	   a	   series	   of	   orthogonal	  
principal	   components	   (Ringnér	   2008;	   Coussens	   et	   al.	   2012).	   Each	   principal	  
component	   is	   a	   linear	   combination	   of	   variables,	   with	   co-­‐efficients	   reflecting	   the	  
respective	   weighting.	   Specific	   principal	   components	   may	   be	   influenced	   heavily	   by	  
certain	   variables,	   with	   highly	   co-­‐linear	   variables	   contributing	   similarly.	   The	   first	  
principal	   component	   accounts	   for	   the	  maximum	   single	   variation	   in	   the	   data,	   with	  
successive	  principal	  components	  accounting	  for	  the	  maximum	  amount	  of	  remaining	  
variation.	  Although	  the	  total	  number	  of	  principal	  components	  will	  equal	  the	  number	  
of	  variables	   in	  a	  data	  set,	  the	  majority	  of	  the	  variance	  can	  often	  by	  summarized	  by	  
the	   first	   two	  or	   three	  principal	   components.	  This	  allows	   the	   information	  contained	  
within	  hundreds	  of	  variables	  to	  be	  plotted	  in	  just	  two	  or	  three	  dimensions	  on	  a	  PCA	  
plot,	   the	   distance	   between	   observations	   representing	   the	   degree	   of	   similarity	  
between	   subjects.	   Inspecting	   such	   plots	   enables	   rapid	   visual	   identification	   of	  
patterns	  in	  the	  data	  prompting	  further	  statistical	  analysis.	  	  
	  
It	  is	  well	  recognized	  that	  the	  inclusion	  of	  a	  large	  number	  of	  non-­‐informative	  variables	  
may	  confound	  a	  PCA	  and	   interfere	  with	  the	   identification	  of	  underlying	  patterns	   in	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the	  data.	  As	  such,	  it	  is	  commonplace	  to	  apply	  some	  form	  of	  filter	  to	  select	  variables	  
of	  greater	  interest.	  Common	  techniques	  include	  excluding	  variables	  with	  the	  lowest	  
variances	   or	   including	   only	   variables	   that	   are	   highly	   related	   to	   a	   specific	   response	  
(Fontes	  et	  al.	  2011).	  In	  the	  analyses	  used	  herein,	  the	  latter	  technique	  was	  used	  and	  
variables	  filtered	  using	  statistical	  tests	  prior	  to	  incorporation	  into	  the	  PCA	  such	  that	  
only	  variables	  with	  a	  statistically	  significant	  association	  with	  the	  dependent	  variable	  
were	  used	   (e.g.	   T-­‐tests,	  ANOVA,	   linear	  and	   logistic	   regression	  as	  appropriate).	   This	  
relatively	   restricted	   but	   robust	  way	   of	   performing	   PCA	  was	   chosen	   to	   simplify	   the	  
data	  as	  much	  as	  possible	  and	  identify	  clear	  differences	  between	  groups.	  However,	  it	  
does	  result	  in	  the	  possibility	  of	  more	  subtle	  patterns	  in	  the	  data	  being	  overlooked.	  	  	  	  
	  
To	  correct	  for	  multiple	  testing,	  statistical	  significance	  was	  expressed	  using	  q-­‐values,	  
defined	   as	   the	   false	   discovery	   rate	   (FDR)	   using	   the	  Benjamini-­‐Hochberg	   procedure	  
for	   multiple-­‐testing	   correction	   (Benjamini	   &	   Hochberg	   1995).	   FDR	   reflects	   the	  
probability	   that	   an	   observation	   deemed	   significant	   is	   a	   false	   positive	   result.	   It	   is	  
performed	  using	  a	  mathematical	   technique	   that	   ranks	   the	  p-­‐values	  of	  all	   statistical	  
tests	   performed	   and	   examines	   their	   distribution.	   It	   is	  more	   stringent	   than	   using	   a	  
per-­‐comparison	   error	   rate	   (e.g.	   a	   non-­‐adjusted	   p-­‐value	   <0.05)	   but	   is	   less	   stringent	  
than	  using	  family-­‐wise	  error	  rates	  (e.g.	  Bonferroni	  correction).	  This	  enables	  the	  risk	  
of	  a	  type	  I	  statistical	  error	  to	  be	  controlled	  while	  ensuring	  there	  is	  no	  significant	  drop	  
in	  statistical	  power,	  a	  major	  disadvantage	  of	  using	  a	  Bonferroni	  correction.	  As	  such,	  
FDR	  is	  ideal	  for	  exploratory	  data	  analysis	  where	  it	  is	  important	  to	  ensure	  potentially	  
significant	   findings	   are	   not	   falsely	   disregarded.	   In	   contrast	   to	   p-­‐values,	   there	   is	   no	  
accepted	  cut-­‐off	  for	  what	  is	  defined	  as	  “statistically	  significant”	  and	  typically	  a	  value	  
of	  0.05	  -­‐	  0.1	  is	  used	  (Duffy	  et	  al.	  2014;	  Coussens	  et	  al.	  2012).	  	  Given	  the	  exploratory	  
nature	   of	   this	   work,	   a	   q-­‐value/FDR	   of	   <0.1	   has	   been	   arbitrarily	   chosen	   and	   used	  
throughout;	   this	   corresponds	   to	   a	   10%	   false	   detection	   rate	   (i.e	   if	   10	   variables	   are	  
reported	  to	  be	  different	  between	  two	  groups,	  1	  is	  likely	  to	  be	  a	  false	  positive	  and	  9	  
likely	   to	  be	   true	  positives).	  Observations	   that	  do	  not	  meet	   the	  q-­‐value	   criteria	  but	  




Heatmap	  analysis,	  hierarchical	  clustering	  and	  dendrograms	  
Heatmaps	   are	   a	   way	   of	   visually	   displaying	   complex	   data	   where	   numerous	  
measurements	  have	  been	  made	  on	  a	  number	  of	  subjects.	  It	  comprises	  a	  matrix-­‐like	  
structure	   with	   subjects	   displayed	   as	   columns	   and	   variables	   as	   rows.	   Each	   small	  
square	  of	  the	  matrix	  corresponds	  to	  a	  specific	  variable	  in	  a	  particular	  subject	  and	  are	  
coloured	   to	   reflect	   the	   normalized	   value	   (Bergkvist	   A,	   et	   al.	   2010).	   In	   all	   the	   plots	  
used	  in	  this	  thesis	  positive	  values	  are	  coloured	  in	  shades	  of	  red	  and	  negative	  values	  
in	   shades	   of	   green.	   Heatmap	   analysis	   is	   frequently	   paired	   with	   a	   hierarchical	  
clustering,	   a	   technique	   that	   uses	   an	   agglomerative	   algorithm	   to	   sequentially	   pair	  
together	  objects	  showing	  the	  highest	  degree	  of	  similarity	  in	  their	  measured	  variables	  
(in	   this	   case	   study	   subjects	   in	   the	   heatmap).	   Paired	   objects	   are	   condensed	   into	   a	  
cluster	   and	   this	   is	   then	   paired	   with	   the	   next	   most	   similar	   object	   or	   cluster.	   By	  
repeating	   this	   step	   all	   objects	   in	   a	   dataset	   are	   eventually	   paired	   together.	   The	  
resultant	   connections,	   illustrating	   the	   degree	   of	   similarity	   between	   objects,	   are	  
illustrated	  graphically	  in	  a	  tree-­‐like	  structure	  known	  as	  a	  dendrogram	  (Bergkvist	  A,	  et	  
al.	  2010).	  	  
	  
Although	  PCA	  and	  heatmap	  analysis	  with	  hierarchical	   clustering	   frequently	   identify	  
similar	   patterns	   in	   the	   data,	   there	   are	   differences	   between	   these	   two	   techniques.	  
Because	   PCA	   reduces	   the	   dimensionality	   of	   the	   data	   to	   just	   a	   few	   principal	  
components	  the	  patterns	  revealed	  may	  be	  cleaner	  and	  easier	  to	  interpret.	  However,	  
this	  runs	  the	  risk	  of	  excluding	  more	  subtle	  patterns	  in	  the	  data.	  Such	  subtle	  patterns	  
might	   be	   identified	   in	   heatmap	   analysis	   (as	   this	   displays	   the	   data	   without	   any	  
preprocessing)	  but	  may	  be	  harder	  to	  identify	  and	  interpret	  (Bergkvist	  A,	  et	  al.	  2010).	  
In	  this	  thesis	  these	  two	  techniques	  are	  used	  together	  in	  a	  complimentary	  manner.	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3.7 Literature	  Review	  Methodology	  
To	   ensure	   a	   complete	   review	   of	   the	   current	   literature	   was	   performed	   for	   the	  
literature	  review	  [chapter	  1],	  three	  systematic	  literature	  searches	  were	  performed	  as	  
detailed	   below.	   Searches	   were	   performed	   in	   PubMed	   on	   the	   dates	   stated	  
(www.ncbi.nlm.nih.gov).	  Papers	  published	  after	  those	  dates	  were	  identified	  using	  a	  
PubMed	  email	  notification.	   Further	  papers	  were	   identified	   through	   references	  and	  
personal	  collections.	  	  
3.7.1 Search	  1	  	  	  
This	  was	  the	  main	  literature	  search	  and	  was	  designed	  to	  obtain	  all	  published	  papers	  
relating	  to	  the	  role	  of	  host	  immunity	  in	  the	  development	  of	  cryptococcal	  disease,	  the	  
severity	  of	  cryptococcal	  disease	  and	  the	  outcome	  from	  cryptococcal	  disease.	  	  
	  
The	  following	  terms	  were	  entered	  into	  PubMed	  (28th	  Dec	  2013):	  	  
(“Cryptococcus"[Mesh]	   OR	   "Meningitis,	   Cryptococcal"[Mesh])	   AND	   (immunity	   OR	  
immune	   function	   OR	   immune	   response	   OR	   host	   response)	   AND	   (outcome	   OR	  
mortality	  OR	  survival	  OR	  severity	  OR	  susceptibility	  OR	  protection).	  	  
	  
These	   terms	   were	   altered	   by	   Pubmed	   to	   result	   in	   the	   following	   search	   being	  
performed:	  	  
("Cryptococcus"[Mesh]	   OR	   "Meningitis,	   Cryptococcal"[Mesh])	   AND	  
(("immunity"[MeSH	   Terms]	   OR	   "immunity"[All	   Fields])	   OR	   ("immune	   system	  
processes"[MeSH	   Terms]	   OR	   ("immune"[All	   Fields]	   AND	   "system"[All	   Fields]	   AND	  
"processes"[All	  Fields])	  OR	  "immune	  system	  processes"[All	  Fields]	  OR	  ("immune"[All	  
Fields]	  AND	  "function"[All	  Fields])	  OR	  "immune	  function"[All	  Fields])	  OR	  (immune[All	  
Fields]	  AND	  response[All	  Fields])	  OR	  (host[All	  Fields]	  AND	  response[All	  Fields]))	  AND	  
(outcome[All	   Fields]	   OR	   ("mortality"[Subheading]	   OR	   "mortality"[All	   Fields]	   OR	  
"mortality"[MeSH	  Terms])	  OR	  ("mortality"[Subheading]	  OR	  "mortality"[All	  Fields]	  OR	  
"survival"[All	  Fields]	  OR	  "survival"[MeSH	  Terms])	  OR	  severity[All	  Fields]	  OR	  ("disease	  
susceptibility"[MeSH	  Terms]	  OR	  ("disease"[All	  Fields]	  AND	  "susceptibility"[All	  Fields])	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OR	  "disease	  susceptibility"[All	  Fields]	  OR	  "susceptibility"[All	  Fields])	  OR	  protection[All	  
Fields])	  
	  
This	  search	  resulted	  in	  325	  papers,	  which	  following	  review	  of	  titles	  and	  abstracts	  was	  
reduced	   to	   116.	   Papers	   were	   excluded	   if	   they	   referred	   mainly	   to	   cryptococcal	  
virulence	   factors,	   to	  purely	  cellular	  mechanisms	  of	   infection,	  solely	  clinical	  aspects,	  
or	  were	   referring	   solely	   to	   the	  use	  of	   animal	  models.	  Nine	  additional	  papers	  were	  
added	  through	  reading	  the	  above	  papers.	  	  
3.7.2 Search	  2	  	  
This	  additional	   search	  performed	  to	  ensure	  all	   relevant	  papers	  had	  been	   identified	  
referring	  to	  the	  role	  of	  macrophages	  or	  monocytes	  in	  cryptococcal	  immunity.	  	  
	  
The	  following	  search	  terms	  were	  entered	  into	  PubMed	  (15th	  Jan	  2014):	  
(cryptococcus	  OR	  cryptococcosis	  OR	  cryptococcal	  meningitis)	  AND	  (macrophage	  OR	  
monocyte)	  
	  
These	  terms	  were	  altered	  by	  PubMed	  to	  result	  in	  the	  following	  search:	  	  
(("cryptococcus"[MeSH	   Terms]	   OR	   "cryptococcus"[All	   Fields])	   OR	  
("cryptococcosis"[MeSH	   Terms]	   OR	   "cryptococcosis"[All	   Fields])	   OR	   ("meningitis,	  
cryptococcal"[MeSH	   Terms]	   OR	   ("meningitis"[All	   Fields]	   AND	   "cryptococcal"[All	  
Fields])	   OR	   "cryptococcal	  meningitis"[All	   Fields]	   OR	   ("cryptococcal"[All	   Fields]	   AND	  
"meningitis"[All	  Fields])))	  AND	  (("macrophages"[MeSH	  Terms]	  OR	  "macrophages"[All	  
Fields]	   OR	   "macrophage"[All	   Fields])	   OR	   ("monocytes"[MeSH	   Terms]	   OR	  
"monocytes"[All	  Fields]	  OR	  "monocyte"[All	  Fields]))	  
	  
This	  search	  resulted	  in	  701	  papers,	  this	  was	  reduced	  to	  67	  papers	  after	  title	  review	  
and	  40	  papers	  after	  abstract	  review.	  Papers	  were	  included	  if	  referring	  directly	  to	  role	  
of	   macrophages	   or	   monocytes	   in	   cryptococcal	   immunity	   or	   outcome	   from	   CM;	  
papers	  were	  excluded	   if	   they	  primarily	  were	  concerned	  with	   the	  pathogen	  specific	  
mechanisms	  of	  intracellular	  survival.	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3.7.3 Search	  3	  	  
	  
This	   additional	   search	   was	   performed	   to	   ensure	   all	   relevant	   papers	   had	   been	  
identified	  referring	  to	  the	  role	  of	  macrophage	  activation	  in	  cryptococcal	  disease.	  	  
	  
The	  following	  search	  terms	  were	  entered	  into	  PubMed	  (15th	  Jan	  2014):	  	  
cryptococcus	   AND	   ("macrophage	   activation"	   OR	   "alternatively	   activated	  
macrophages"	  OR	  "M1/M2")	  
 
This	  resulted	  in	  the	  following	  search	  being	  performed	  by	  PubMed:	  
("cryptococcus"[MeSH	   Terms]	   OR	   "cryptococcus"[All	   Fields])	   AND	   ("macrophage	  
activation"[All	   Fields]	   OR	   "alternatively	   activated	   macrophages"[All	   Fields]	   OR	  
"M1/M2"[All	  Fields])	  
	  
This	   search	   identified	   51	   papers,	   none	   of	   which	   were	   new	   papers	   -­‐	   all	   had	   been	  
identified	  by	  previous	  searches.	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CHAPTER	  4: CLINICAL	  FEATURES	  OF	  THE	  IICD	  COHORT	  
This	   chapter	   discusses	   the	   clinical	   characteristics	   of	   the	   Innate	   Immunity	   in	  
Cryptococcal	  Disease	  (IICD)	  cohort.	  Details	  regarding	  the	  demographics,	  background	  
and	   clinical	   characteristics	   are	   included,	   along	   with	   information	   regarding	  
participants	   who	   developed	   complications	   or	   who	   died	   during	   the	   study.	   Clinical	  
differences	   between	   subjects	   taking	  ART	   at	   presentation	   and	   those	  who	  were	   not	  
are	  examined	  along	  with	  factors	  associated	  with	  poor	  prognosis.	  These	  data	  are	  used	  
to	  inform	  immunological	  analysis	  in	  subsequent	  chapters.	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4.1 Additional	  methodology	  
4.1.1 Clinical	  information	  
Clinical	   information	   was	   obtained	   through	   direct	   questioning	   and	   examination	   of	  
participants,	  along	  with	  review	  of	  hospital	  admission	  records	  and	  laboratory	  results	  
from	  the	  National	  Health	  Laboratories	  Service	  (NHLS).	  The	  NHLS	  laboratories	  process	  
samples	  from	  all	  government	  hospitals	  and	  clinics	   in	  South	  Africa.	  By	  accessing	  the	  
NHLS	   computer	   database,	   previous	   results	   from	   hospital	   and	   ART	   clinics	   could	   be	  
reliably	   obtained.	   Details	   of	   previous	   ART	   therapy	   and	   adherence	   issues	   were	  
checked	  with	  community	  ART	  clinics	  when	  possible.	  For	  ART-­‐naïve	   individuals,	  CD4	  
counts	  sent	  from	  ART	  clinics	  were	  used	  as	  a	  crude	  measure	  of	  whether	  participants	  
were	   under	   active	   clinic	   follow	   up	   (SA	   national	   HIV/ART	   guidelines	   recommend	   6	  
monthly	  CD4	  counts	  in	  individuals	  not	  yet	  eligible	  for	  ART	  (SADoH	  2013b)).	  Cause	  of	  
death	   and	   cause	   of	   deterioration	   were	   determined	   by	   the	   research	   team,	   cases	  
where	  the	  cause	  was	  in	  doubt	  were	  categorized	  as	  “unknown”.	  
4.1.2 Analysis	  
Demographics	   and	   baseline	   characteristics	   were	   summarized	   using	   proportions	   or	  
medians	  with	   interquartile	   ranges	   (IQR)	   as	   appropriate.	   Categorical	   variables	  were	  
compared	  between	  groups	  using	  Fisher’s	  exact	  test	  or	  Chi-­‐squared	  tests	  (depending	  
on	   the	   lowest	   numbers	   in	   each	   category);	   non-­‐parametric	   tests	   were	   used	   to	  
examine	  differences	  in	  medians	  between	  groups	  (Wilcoxon	  rank-­‐sum).	  Prior	  to	  their	  
inclusion	   in	   regression	   models,	   the	   distributions	   of	   continuous	   variables	   were	  
examined	  using	  a	  histogram	  plot	  and	  with	   statistical	   tests	   for	  normality	   (Skewness	  
and	  kurtosis,	  Shapiro-­‐Wilk	  and	  Shapiro-­‐Francia	  normality	  tests).	  Variables	  that	  were	  
skewed	   were	   log	   transformed.	   Logistic	   regression	   modeling	   was	   performed	   to	  
identify	   baseline	   variables	   that	   predicted	   fatal	   outcome	   by	   day	   14,	   and	   Cox	  
proportional	  hazards	   regression	  was	  performed	  to	   identify	  variables	   that	  predicted	  
fatal	  outcome	  over	  the	  entire	  24	  weeks	  of	  follow	  up.	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4.2 Recruitment	  and	  baseline	  demographics	  of	  participants	  
4.2.1 Recruitment	  
Sixty-­‐six	   participants	   were	   initially	   recruited	   over	   a	   16-­‐month	   period	   between	   11th	  
April	  2012	  and	  30th	  July	  2013.	  Three	  were	  excluded	  as	  they	  had	  previous	  episodes	  of	  
cryptococcal	   meningitis,	   two	   were	   excluded	   due	   to	   negative	   CSF	   cryptococcal	  
culture/antigen	   tests,	  and	  one	  withdrew	  consent	  and	  was	  not	   included.	  Sixty	  were	  
thus	  included	  in	  analyses.	  Study	  follow	  up	  was	  to	  24	  weeks;	  three	  participants	  were	  
lost	  to	  follow	  up	  at	  12	  weeks	  (5%),	  and	  five	  at	  24	  weeks	  (8%).	  	  
4.2.2 Cohort	  Demographics	  
Demographics	  of	  the	  cohort	  are	  summarized	  in	  [Table	  4.1].	  Median	  age	  was	  36	  years	  
and	  median	  CD4	  count	  was	  34.5	  cells/µL.	  17	  participants	  reported	  they	  were	  taking	  
ART	  at	  enrolment,	  this	  is	  discussed	  further	  later	  [section	  4.2.4].	  
Charaterisitc	  (n=60)	   Median(IQR)/number(%)	  
Age	  (years)	   36	  (29.5,	  43)	  
Male	  Sex	  (n,	  %	  subjects)	   33	  (55)	  
Median	  CD4	  (cells/µL)	   34.5	  (12.5,	  76)	  
HIV	  viral	  load	  (log10	  copies/mL)	   5.14	  (4.36,	  5.49)	  
Taking	  ART	  at	  enrolment*	   17	  (28)	  
Site	  of	  enrolment	  
	  	  	  GF	  Jooste	  Hospital	  (GFJ)	  
	  	  	  Mitchells	  Plain	  Hospital	  (MPH)	  





Table	  4.1	   	  Baseline	  demographics	  of	  participants	   in	  the	  IICD	  study.	  *ART	  status	  was	  as	  reported	  by	  
the	  participant,	  further	  breakdown	  is	  given	  in	  section	  4.2.4.	  
4.2.3 Length	  of	  time	  HIV	  status	  known	  prior	  to	  presentation	  
The	   median	   time	   between	   HIV	   diagnosis	   and	   presentation	   with	   cryptococcal	  
meningitis	   was	   24	   months	   but	   varied	   significantly	   among	   participants.	   A	   full	  
breakdown	  is	  shown	  below	  [Figure	  4.1].	  Nine	  individuals	  (15%)	  were	  diagnosed	  with	  
HIV	   for	   the	   first	   time	  on	  admission	   to	  hospital,	   and	  7	   (11.7%)	  had	  been	  diagnosed	  
during	  the	  preceding	  month.	  Almost	  half	  had	  been	  diagnosed	  more	  than	  a	  year	  prior	  
to	  enrolment;	  one	  subject	  reported	  to	  have	  been	  diagnosed	  20	  years	  previously.	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Figure	  4.1	  	  Reported	  time	  between	  HIV	  diagnosis	  and	  CM	  admission	  (according	  to	  study	  participant)	  
4.2.4 ART	  status	  
A	  detailed	  breakdown	  of	  ART	  status	  is	  shown	  in	  Figure	  4.2.	  17	  of	  the	  60	  participants	  
reported	  they	  were	  taking	  ART	  at	  enrolment	  (28%	  cohort).	  	  Of	  the	  43	  not	  taking	  ART,	  
9	  (21%)	  had	  previously	  defaulted	  ART	  and	  34	  (79%)	  were	  ART-­‐naive	  (15%	  and	  57%	  of	  
the	  total	  cohort	  respectively).	  25	  ART-­‐naïve	  subjects	  had	  known	  their	  HIV	  diagnosis	  
prior	  to	  admission.	  When	  the	  NHLS	  computer	  database	  was	  checked,	  13	  of	  these	  25	  
ART-­‐naive	   individuals	   had	   a	   clinic	   CD4	   count	   in	   the	   preceding	   year	   that	  was	   <200	  
cells/µL.	   However,	   none	   of	   these	   individuals	   had	   started	   ART,	   despite	   meeting	  
criteria	   (SADoH	   2013b).	   No	   results	   were	   available	   for	   the	   remaining	   12	   ART-­‐naïve	  
subjects.	  Of	  the	  17	  taking	  ART,	  8	  (47%)	  had	  been	  started	  on	  1st	  line	  ART	  within	  the	  3	  
months	   prior	   to	   admission,	   6	   (35%)	   were	   failing	   1st	   line	   therapy	   (on	   regimen	   >6	  
months	  with	  detectable	  HIV-­‐1	  viral	  load),	  and	  3	  (18%)	  had	  recently	  been	  started	  on	  
second	  line	  therapy	  (13%,	  10%	  and	  5%	  of	  total	  cohort	  respectively)	  [Figure	  4.2].	  The	  
combined	   information	   regarding	   participants’	   ART	   status	   and	   HIV	   history	   is	  



















On admission <1 month 3-6 months 6-12 months >12 months unknown1
88	  	  
	  
Figure	   4.2	   	   Details	   of	   participant	   ART	   status	   at	   enrolment.	   Information	   was	   obtained	   through	  
discussion	  with	  the	  participant	  and	  liaison	  with	  their	  ART	  clinic.	  	  	  
	  
	   Months	  between	  HIV	  diagnosis	  and	  CM	  presentation	   	  
	   0	   <1	   1-­‐6	   6-­‐12	  	   >12	  	   Not	  known	   Total	  
ART	  naive	   9	   7	   3	   1	   10	   4	   34	  
Defaulted	   	   	   	   1	   8	   0	   9	  
1st	  line	  <6	  months	   	   	   3	   	   5	   	   8	  
1st	  line	  >6	  months	   	   	   	   1	   4	   1	   6	  
2nd	  line	  <6	  months	   	   	   	   1	   2	   	   3	  
Total	   9	   7	   6	   4	   29	   5	   60	  
Table	  4.2	   	  Relationship	  between	  ART	   status	  and	   time	   study	  participants	  were	  aware	  of	   their	  HIV	  
status	  
	  
4.2.5 Reasons	  participants	  developed	  AIDS	  despite	  availability	  of	  ART	  
Background	   details	   were	   combined	   to	   summarize	   the	   reasons	   participants	  
developed	  an	  AIDS-­‐defining	  condition	  despite	  widespread	  ART	  rollout	  in	  South	  Africa	  
[Figure	  4.3].	  The	  most	  common	  reasons	  for	  developing	  AIDS	  were	  late	  HIV	  diagnosis	  	  
(27%)	  and	  a	  failure	  to	  start	  ART	  among	  individuals	  with	  a	  known	  HIV	  diagnosis	  (30%);	  
a	   further	   30%	  were	   failing	   1st	   line	   ART	   or	   had	   defaulted	   previous	   ART	   (15%	   each	  























Figure	   4.3	   	   Reasons	   participants	   developed	   CM	  despite	  ART	   availability.	  Definitions:	   “New	  HIV”	  –	  
HIV	  diagnosed	   either	   on	   admission	  or	  with	   1	  month	  of	   admission;	   “No	  ART	   start”	  –	  HIV	  diagnosed	  
more	  than	  1	  month	  previously	  but	  not	  started	  ART;	  “recent	  ART”	  –	  started	  1st	  line	  ART	  or	  switched	  to	  
2nd	  line	  ART	  within	  the	  preceding	  6	  months;	  “ART	  fail”	  –	  taking	  1st	  line	  ART	  for	  longer	  than	  6	  months	  
with	  detectable	  HIV-­‐1	  viral	  load;	  “default”	  –	  started	  ART	  but	  defaulted	  therapy.	  
4.2.6 Cryptococcal	  antigen	  screening	  	  
In	   August	   2012,	   the	   Western	   Cape	   government	   brought	   in	   recommendations	   to	  
screen	  ART-­‐naïve	  persons	  with	  a	  CD4	  count	  <100	  /µL	  for	  cryptococcal	  antigenaemia	  
(Govender	   et	   al.	   2012b).	   26	   ART-­‐naïve	   individuals	   were	   recruited	   after	   this	   time	  
point,	  10	  of	  whom	  had	  a	  CD4	  count	  <100/µL	  sent	  from	  clinic	  in	  the	  3	  months	  prior	  to	  
hospitalization.	  Only	  one	  of	  these	  participants	  had	  a	  serum	  cryptococcal	  antigen	  sent,	  
this	  was	  2	  days	  prior	  to	  admission	  to	  hospital	  and	  found	  to	  be	  positive.	  	  
	  
Irrespective	  of	  ART	  status,	  a	  total	  of	  19	  patients	  in	  the	  cohort	  had	  a	  clinic	  CD4	  count	  
below	  100	  cells/µL	  in	  the	  3	  months	  immediately	  preceding	  admission	  (median	  time	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4.3 Clinical	  features	  of	  cryptococcal	  meningitis	  (CM)	  
4.3.1 History	  and	  examination	   	  
History	  and	  examination	  findings	  are	  summarized	  in	  Table	  4.3	  below.	  All	  participants	  
presented	  with	  a	  history	  of	  headache	  apart	  from	  one	  individual	  who	  was	  unable	  to	  
give	   any	   history	   due	   to	   decreased	   conscious	   level.	  Median	   duration	   of	   symptoms	  
was	  14	  days.	  Eleven	  subjects	  (18%)	  had	  reduced	  consciousness	  level	  on	  presentation	  
(GCS<15)	  and	  a	  further	  13	  individuals	  had	  a	  history	  of	  confusion	  prior	  to	  admission.	  
Seven	   had	   evidence	   of	   gaze	   palsy	   (four	   had	   a	   sixth	   cranial	   nerve	   palsy,	   one	   intra-­‐
nuclear	  ophthalmoplegia,	  one	  had	  a	   third	  cranial	  nerve	  palsy	  and	  one	  severe	  optic	  
neuritis	  with	   surrounding	   retrobulbar	   oedema	   resulting	   in	   proptosis	   and	   complete	  
paralysis	  of	  eye	  movement).	  Individuals	  with	  gaze	  palsy	  were	  significantly	  more	  likely	  
to	  have	  altered	  consciousness	  compared	  to	   those	  without	   (RR	  4.33,	  95%CI	  1.7-­‐9.1,	  
p=0.005).	  
	  
Clinical	  finding	   median	  (IQR)	  /	  n	  (%)	  
Median	  days	  of	  symptoms	   14	  (7,	  21)	  
Headache	  	   59	  (98)	  
Vomiting	   39	  (65)	  
Blurred/double	  vision	   31	  (51.7)	  
History	  of	  confusion	   24	  (40)	  
Seizures	   11	  (18.3)	  
Reduced	  consciousness	  (GCS<15)	   11	  (18.3)	  
Nuchal	  rigidity	   28	  (46.7)	  
Cerebellar	  signs	   10	  (16.7)	  
Gaze	  palsy	   7	  (11.7)	  
Table	  4.3	  	  Clinical	  findings	  at	  presentation	  among	  the	  IICD	  cohort.	  N=60.	  
4.3.2 CSF	  findings	  
CSF	  findings	  are	  summarized	  below	  [Table	  4.4].	  Median	  CSF	  white	  cell	  count	  (WCC)	  
was	  18	   cells/µL,	   and	  was	  within	  normal	   laboratory	   limits	   in	  19	  participants	   (31.7%	  
cohort);	  protein	  was	   raised	   (>0.4g/L)	   in	  all	  but	  3	   subjects.	   India	   ink	  was	  positive	   in	  
80%	  of	  individuals	  and	  varied	  by	  hospital	  (88%	  positive	  at	  GFJ	  &	  MPH;	  67%	  positive	  
at	   KDH),	   but	   differences	   were	   not	   statistically	   significant	   (Fisher’s	   exact	   p=0.262).	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Median	   quantitative	   culture	   was	   4.74	   log10	   CFU/ml	   CSF.	   One	   individual	   had	   a	  
negative	  CSF	   fungal	  culture	  but	  had	  compatible	  clinical	   features	  and	  a	  positive	  CSF	  
CrAg	  test	  (titre	  1:32).	  	  
	  
	   N	   Median	  (IQR)/	  n	  (%)	  
CSF	  WCC	  (/µL)	   60	   18	  (3,	  103.5)	  
CSF	  neutrophil	  (/µL)	   60	   0	  (0,	  4)	  
CSF	  lymphocyte	  (/µL)	   60	   15.5	  (2,	  89)	  
CSF	  protein	  (g/L)	   60	   0.97	  (0.58,	  1.5)	  
CSF	  glucose	  n(mmol/L)	   60	   2.25	  (1.60,	  2.80)	  
Positive	  India	  ink	  	   60	   48	  (80)	  
Quantitative	  culture	  (log10	  CFU/mL	  CSF)	   60	   4.74	  (3.5,	  5.75)	  
CSF	  OP	  at	  D0	  (cmH2O)	   56	   26.5	  (16,	  37)	  
Max	  OP	  during	  admission	  (cmH2O)	   57	   35	  (25,	  47)	  
Study	  day	  of	  max	  OP	   57	   0	  (0,	  6)	  
OP>25	  cmH2O	  at	  D0	  	   56	   29	  (48.3%)	  
OP>30	  cmH2O	  at	  D0	   56	   21	  (35%)	  
OP>25	  cmH2O	  during	  admission	   57	   41	  (72%)	  
OP>30	  cmH2O	  during	  admission	   57	   36	  (63%)	  
Total	  number	  of	  LPs	  performed	  	   60	   5	  (3,	  6)	  
Table	  4.4	  	  CSF	  findings	  among	  IICD	  participants.	  Pressure	  measurements	  were	  not	  preformed	  on	  all	  
subjects	  due	  to	  technical	  difficulties	  performing	  LP	  in	  the	  lateral	  position.	  
CSF	  opening	  pressure	  (OP)	  was	  measured	  in	  56	  participants	  at	  enrolment	  and	  in	  57	  
of	   participants	   at	   some	   point	   during	   their	   admission.	   The	   findings	   are	   also	  
summarized	   in	   Table	   4.4	   (missing	   values	   were	   due	   to	   technical	   difficulties	  
performing	  LPs	   in	   the	   lateral	  position).	  The	  median	  maximum	  OP	  during	  admission	  
was	  35	  cmH2O	  and	  the	  maximum	  measured	  CSF	  opening	  pressure	  of	  all	  subjects	  was	  
90	   cmH2O.	   However,	   in	   10	   of	   the	   subjects,	   measurements	   were	   limited	   by	   the	  
maximum	   reading	   of	   a	   single	   manometer	   (40	   or	   50	   cmH2O	   depending	   on	  make).	  	  
Although	   maximum	   opening	   pressure	   during	   admission	   occurred	   at	   enrolment	   in	  
over	   of	   half	   the	   subjects	   (31/57),	   10	   persons	   (18%)	   had	   maximal	   measurements	  
during	   the	   second	  week	   of	   amphotericin	   B	   therapy,	   even	   up	   to	   day	   14	   (n=2).	   The	  
median	  number	  of	  lumbar	  punctures	  performed	  (diagnostic	  and	  therapeutic)	  was	  5	  
per	  subject;	   the	  maximum	  was	  10	  over	  a	  14-­‐day	  period.	  No	  association	  was	   found	  
between	  either	  the	  presence	  of	  raised	  ICP	  or	  the	  maximal	  opening	  pressure,	  and	  low	  
GCS,	  gaze	  palsy	  or	  cerebellar	  symptoms	  [Tables	  4.5,	  4.6,	  4.7].	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   GCS<15	  	  
n	  (%)	  /	  median	  (IQR)	  
GCS	  15	  	  
n	  (%)	  /	  median	  (IQR)	   P-­‐value	  
CSF	  OP	  at	  day	  0	  (cmH2O)	  	   27.5	  (22,	  41)	   25	  (16,	  35)	   0.332	  
Maximum	  CSF	  OP	  (cmH2O)	   34	  (22,	  46)	   36.5	  (25,	  49)	   0.613	  
CSF	  OP	  >30	  cmH2O	  	   6	  (55)	   30	  (64)	   0.732	  
Table	   4.5	   	   Relationship	   between	   CSF	   opening	   pressure	   and	   decreased	   consciousness	   (GCS<15).	  
Decreased	   conscious	   level	   is	   defined	   as	   a	   Glasgow	   Coma	   Scale	   score	   less	   than	   15.	   CSF	   opening	  
pressure	   is	   displayed	   as	   baseline	   measurement,	   maximal	   measurement,	   or	   the	   presence	   of	  
significantly	  raised	  pressure	  at	  any	  time	  during	  admission	  (>30cmH2O).	  The	  latter	  value	  is	  expressed	  
as	  a	  percentage	  of	  the	  GCS	  group.	  P-­‐values	  refer	  to	  Wilcoxon	  rank	  sum	  tests	  or	  Fisher’s	  exact	  test	  as	  
appropriate.	  	  
	   GP	  	  	  
n	  (%)	  /	  median	  (IQR)	  
No	  GP	  	  
n	  (%)	  /	  median	  (IQR)	   P-­‐value	  
CSF	  OP	  at	  day	  0	  (cmH2O)	  	   27	  (12.5,	  34)	   26	  (18,	  38)	   0.594	  
Maximum	  CSF	  OP	  (cmH2O)	   35	  (27,	  46)	   35.5	  (22,	  49)	   0.761	  
CSF	  OP	  >30	  cmH2O	  	   5	  (71)	   31	  (61)	   0.698	  
Table	  4.6	   	  Relationship	  between	  CSF	  opening	  pressure	  and	  gaze	  palsy	   (GP).	  CSF	  opening	  pressure	  
and	  statistical	  testing	  are	  identical	  to	  those	  described	  in	  table	  4.5.	  	  
	   CSx	  	  
n	  (%)	  /	  median	  (IQR)	  
No	  CSx	  	  
n	  (%)	  /	  median	  (IQR)	   P-­‐value	  
CSF	  OP	  at	  day	  0	  (cmH2O)	  	   29	  (16.5,	  32.5)	   25.5	  (16,	  39)	   0.944	  
Maximum	  CSF	  OP	  (cmH2O)	   41	  (34,	  35)	   35	  (22,	  48)	   0.324	  
CSF	  OP	  >30	  cmH2O	  	   8	  (89)	   28	  (57)	   0.291	  
Table	  4.7	   	  Relationship	  between	  CSF	  opening	  pressure	  and	  presence	  of	  cerebellar	  signs	   (CSx).	  CSF	  
opening	  pressure	  and	  statistical	  testing	  are	  identical	  to	  those	  described	  in	  table	  4.5.	  
	  
4.3.3 Cryptococcaemia	  
Blood	   cultures	   were	   performed	   at	   enrolment	   on	   46	   subjects,	   20	   (43.5%)	   of	   these	  
were	   positive	   for	  C	   neoformans	   (33.3%	  of	   total	   cohort);	   no	   other	   pathogens	  were	  
isolated	   from	  blood	  cultures	  at	  enrolment.	  Median	   time	  to	  positivity	  was	  52	  hours	  
(IQR,	  30-­‐90).	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4.4 Effect	  of	  ART	  on	  clinical	  presentation	  of	  CM	  
4.4.1 Participants	  taking	  ART	  at	  enrolment	  
Baseline	   characteristics	  were	   compared	  between	  participants	  who	   reported	   taking	  
ART	  at	  enrolment	  and	  those	  who	  did	  not	  [Table	  4.8].	  	  
	   On	  ART	  (n=17)	  n	  (%)	  /	  median	  (IQR)	  
Not	  on	  ART	  (n=43)	  
n	  (%)	  /	  median	  (IQR)	   P-­‐value	  
Age	  [median	  (IQR)]	   34	  (31,	  46)	   37	  (29,	  43)	   0.980	  
Male	  sex	  [n	  (%)]	   18	  (42)	   25	  (58)	   0.311	  
CD4	  count	  (/µL)	   54	  (22,	  85)	   29	  (12,	  67)	   0.189	  
HIV	  VL	  (log10	  copies/mL)	   3.27	  (1.81,	  4.68)	   5.33	  (5.05,	  5.61)	   <0.001	  
HIV	  VL	  <40	  copies/mL	  	   4	  (23.5)	   0	  (0)	   0.005	  
Days	  of	  symptoms	   14	  (6,	  21)	   14	  (7,	  15.5)	   0.666	  
GCS<15	  	   2	  (11.8)	   9	  (20.9)	   0.336	  
History	  of	  confusion	   3	  (17.7)	   21	  (48.8)	   0.040	  
Seizures	   2	  (11.8)	   9	  (20.9)	   0.712	  
Double/blurred	  vision	   12	  (70.6)	   20	  (46.5)	   0.187	  
Cerebellar	  sings	   2	  (11.8)	   8	  (18.6)	   0.709	  
Gaze	  palsy	   2	  (11.7)	   5	  (11.6)	   1.000	  
CSF	  OP	  at	  D0	  (cmH2O)	   30	  (12.5,	  36)	   25	  (16,	  40)	   0.985	  
Max	  CSF	  OP	  (cmH2O)	   35	  (27,	  40)	   37.5	  (22,	  49.5)	   0.697	  
OP>30	  cmH2O	  during	  admission	   10	  (58.8)	   26	  (60.5)	   0.109	  
Number	  of	  LPs	   5	  (4,	  6)	   4	  (3,	  6)	   0.717	  
CSF	  WCC	  (/µL)	   13	  (0,	  35)	   21	  (3,115)	   0.169	  
CSF	  lymphocyte	  (/µL)	   4	  (0,	  35)	   20	  (3,	  101)	   0.056	  
CSF	  neutrophil	  (/µL)	   0	  (0,	  4)	   0	  (0,	  3)	   0.894	  
CSF	  protein	  (g/L)	   0.82	  (0.62,	  1.30)	   0.97	  (0.56,	  1.66)	   0.612	  
CSF	  glucose	  (mmol/L)	   1.9	  (1.0,	  2.7)	   2.5	  (1.70,	  3.0)	   0.067	  
Positive	  India	  ink	   13	  (76.5)	   35	  (81.4)	   0.794	  
CFU	  (log10	  CFU/mL	  CSF)	   4.85	  (3.85,	  6.27)	   4.73	  (3.48,	  5.5)	   0.470	  
Cryptococcaemia	   5	  (29.4)	   15	  (34.9)	   0.622	  
Blood	  WCC	  (x109/L)	   5.10	  (4.30,	  5.95)	   4.3	  (2.83,	  6.14)	   0.309	  
Blood	  CRP	  (mg/L)	   44.9	  (18.5,	  79.3)	   37.2	  (14,	  84.4)	   0.676	  
Table	   4.8	   	   Comparison	   of	   clinical	   and	   laboratory	   features	   between	   participants	   taking	   ART	   at	  
enrolment	  and	  those	  who	  were	  not.	  CSF	  OP	  (CSF	  opening	  pressure);	  P-­‐values	  are	  from	  Wilcoxon	  rank	  
sum	  and	  Fisher’s	  exact	  tests	  as	  appropriate.	  	  
ART	  use	  was	  not	  associated	  with	  a	  significantly	   increased	  peripheral	  CD4	  count	  but	  
was	   associated	   with	   significantly	   lower	   HIV	   viral	   load	   (median	   (IQR)	   =	   3.27	   (1.81-­‐
4.68)	   vs.	   5.33	   (5.05-­‐5.61)	   log10	   copies/ml,	   p<0.001,	   respectively)	   [Table	   4.8];	  
however,	  only	  4	  participants	  were	   found	  to	  have	  a	  viral	   load	  below	  the	  detectable	  
limit	  (<40	  copies/mL).	  Participants	  on	  ART	  were	  also	  less	  likely	  to	  report	  a	  history	  of	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confusion	  at	  presentation	  (17.7%	  vs.	  48.8%,	  p=0.04),	  and	  had	  a	  non-­‐significant	  trend	  
towards	  decreased	  CSF	  lymphocyte	  count	  and	  glucose	  concentrations	  [Table	  4.8].	  
4.4.2 Participants	  taking	  effective	  ART	  at	  enrolment	  
As	   detailed	   in	   section	   4.2.4,	   participants	   taking	   ART	   were	   a	   heterogeneous	   group	  
ranging	  from	  recent	   initiation	  of	  ART,	  to	  ART	  failure.	  With	  this	   in	  mind	  the	  analysis	  
was	  repeated	  excluding	  seven	   individuals	  who	  were	  clearly	   failing	  therapy	  (defined	  
as	  taking	  ART	  for	  more	  than	  6	  months	  with	  detectable	  viral	  load)	  or	  in	  whom	  there	  
were	   significant	   doubts	   regarding	   adherence.	   Subjects	   were	   then	   re-­‐classified	   as	  
effective-­‐ART	   (n=10)	  and	  no-­‐ART	   (n=43)	  and	  the	  same	  comparisons	  made	  between	  
these	  two	  groups	  [Table	  4.9].	  	  
	   Effective	  ART	  (n=10)	  n	  (%)	  /	  median	  (IQR)	  
No	  ART	  (n=43)	  
n	  (%)	  /	  median	  (IQR)	   P-­‐value	  
Age	  [median	  (IQR)]	   31.6	  (27-­‐40)	   37	  (29-­‐43)	   0.369	  
Male	  sex	  [n	  (%)]	   3	  (30)	   25	  (58)	   0.162	  
CD4	  count	  (/µL)	   60	  (45-­‐85)	   29	  (12-­‐67)	   0.024	  
HIV	  VL	  (log10	  copies/mL)	   2.4	  (1.3-­‐3.3)	   5.3	  (5.1-­‐5.6)	   <0.001	  
HIV	  VL	  <40	  copies/mL	  	   3	  (30)	   0	  (0)	   0.005	  
Days	  of	  symptoms	   14	  (6.5-­‐25.5)	   14	  (7-­‐15.5)	   0.631	  
GCS<15	  	   1	  (10)	   9	  (21)	   0.665	  
History	  of	  confusion	   2	  (20)	   21	  (49)	   0.158	  
Seizures	   1	  (10)	   9	  (21)	   0.665	  
Double/blurred	  vision	   6	  (67)	   19	  (49)	   0.446	  
Cerebellar	  sings	   2	  (20)	   8	  (19)	   1.000	  
Gaze	  palsy	   2	  (20)	   5	  (12)	   0.604	  
CSF	  OP	  at	  D0	  (cmH2O)	   24.5	  (11.8-­‐30.5)	   25	  (16-­‐40)	   0.465	  
Max	  CSF	  OP	  (cmH2O)	   27.3	  (23.5-­‐32.5)	   37.5	  (22-­‐49.5)	   0.255	  
OP>30	  cmH2O	  during	  admission	   3	  (38)	   26	  (60)	   0.268	  
Number	  of	  LPs	   4	  (3-­‐6)	   4	  (2-­‐5)	   0.206	  
CSF	  WCC	  (/µL)	   8	  (0-­‐45)	   21	  (3-­‐115)	   0.227	  
CSF	  lymphocyte	  (/µL)	   3	  (0-­‐41)	   20	  (3-­‐101)	   0.079	  
CSF	  neutrophil	  (/µL)	   2	  (0-­‐13)	   0	  (0-­‐3)	   0.309	  
CSF	  protein	  (g/L)	   0.73	  (0.57-­‐1.3)	   0.97	  (0.56-­‐1.7)	   0.502	  
CSF	  glucose	  (mmol/L)	   1.9	  (1.5-­‐2.7)	   2.5	  (1.7-­‐3)	   0.175	  
Positive	  India	  ink	   8	  (80)	   35	  (83)	   1.000	  
CFU	  (log10	  CFU/mL	  CSF)	   4.1	  (3.1-­‐6.1)	   4.7	  (3.5-­‐5.5)	   0.838	  
Cryptococcaemia	   2	  (25)	   15	  (47)	   0.428	  
Blood	  WCC	  (x109/L)	   5.9	  (4.3-­‐6.7)	   4.3	  (2.8-­‐6.1)	   0.080	  
Blood	  CRP	  (mg/L)	   79	  (45-­‐95)	   37	  (14-­‐84)	   0.041	  
Table	  4.9	  	  Comparison	  of	  clinical	  and	  laboratory	  features	  between	  participants	  taking	  effective	  ART	  
at	  enrolment	  and	  those	  who	  were	  not	  (n=53).	  Variables	  and	  statistical	  tests	  identical	  to	  table	  4.8.	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The	   results	   of	   this	  were	   broadly	   similar	   to	   the	   previous	   analysis,	  with	   significantly	  
reduced	  HIV-­‐1	  viral	  load	  in	  the	  effective	  ART	  group	  along	  with	  significantly	  increased	  
proportion	   of	   participants	   with	   undetectable	   viral	   load	   [Table	   4.9].	   In	   addition,	  
individuals	  taking	  effective	  ART	  had	  significantly	  increased	  CD4	  counts	  compared	  to	  
those	  who	  were	   not,	   (median	   (IQR)	   =	   60	   (45-­‐85)	   vs.	   29	   (12-­‐67)	   cells/µL,	   p=0.024,	  
respectively)	   and	   significantly	   increased	   serum	   C-­‐reactive	   protein	   concentrations	  
(median	  (IQR)	  =	  79	  (45-­‐95)	  vs.	  37	  (14-­‐84)	  mg/L,	  respectively,	  p=0.041)	  [Table	  4.9].	  	  
4.4.3 Unmasking	  cryptococcal	  IRIS	  
One	  participant	  taking	  ART	  at	  presentation	  (IICD16)	  presented	  with	  a	  clinical	  picture	  
strongly	  suggestive	  of	  unmasking	  cryptococcal	  IRIS	  (Haddow	  et	  al.	  2010).	  In	  addition	  
to	  typical	  meningitis	  symptoms,	  he	  had	  marked	  proptosis,	  decreased	  eye	  movement	  
and	  decreased	  vision	   in	  his	   right	  eye.	  A	  contrast	  CT	   scan	   revealed	   inflammation	  of	  
the	   right	   optic	   nerve	  with	   surrounding	   retrobulbar	  oedema	   consistent	  with	   severe	  
optic	  neuritis	  [Figure	  4.4].	  No	  alternative	  cause	  could	  be	  found,	  and	  following	  review	  
by	   the	   Ophthalmology	   team	   he	   was	   started	   on	   a	   course	   of	   steroids	   (methyl	  
prednisolone	   1g/d	   for	   3	   days,	   then	   prednisolone	   30mg/d,	   tapering	   over	   8	  weeks).	  
Although	  the	  swelling	  improved	  dramatically,	  his	  sight	  did	  not.	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Figure	  4.4	  	  Contrast	  CT	  scan	  of	  orbits	  (IICD16).	  Enhancement	  of	  right	  optic	  nerve	  and	  retrobulbar	  
area	  noted	  (marked	  with	  red	  circle);	  no	  similar	  appearance	  of	  left	  orbit.	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4.5 Outcome	  	  
4.5.1 Microbiological	  outcome	  measures	  
Fungal	   clearance	   (EFA)	  was	   calculated	   for	  49	  of	  60	  participants	   (82%	  cohort)	  using	  
the	  method	  described	  in	  in	  chapter	  3	  [section	  3.4.11].	  It	  was	  not	  possible	  to	  calculate	  
EFA	  for	  11	  participants:	  2	  refused	  further	  LPs,	  8	  died	  after	  only	  one	  culture	  had	  been	  
performed	  and	  one	  had	  negative	  cultures	  at	  baseline.	  For	  the	   individuals	  where	  an	  
EFA	  could	  be	  calculated,	  median	  rate	  of	  fungal	  clearance	  was	  −0.34	  log10	  CFU/ml/day	  
(IQR	   -­‐0.44,	   -­‐0.25).	   There	   was	   no	   significant	   difference	   in	   rate	   of	   fungal	   clearance	  
from	   the	  CSF	  between	   individuals	   taking	  ART	  at	  presentation	  and	   those	  who	  were	  
not	   (median	   -­‐0.36	   (IQR	   -­‐0.23,	   -­‐0.41)	   vs.	   -­‐0.33	   (IQR	   –0.25,	   -­‐0.44)	   log10	   CFU/ml/day,	  
p=0.717,	  respectively).	  	  
	  
41	   participants	   had	   a	   LP	   performed	   at	   day	   14	   (end	   of	   amphotericin	   therapy).	   CSF	  
sterility	  was	  confirmed	  for	  28	  at	  this	  time	  point	  (68%	  of	  available	  CSF,	  47%	  of	  total	  
cohort),	   but	   despite	   anti-­‐fungal	   therapy	   13	   participants	   remained	   CSF	   culture	  
positive	  at	  day	  14	  (32%	  of	  available	  CSF,	  22%	  of	  total	  cohort).	  CSF	  sterility	  could	  not	  
be	  determined	   for	  19	   individuals:	   14	  died	  before	   the	  end	  of	   amphotericin	   therapy	  
and	  5	  refused	  a	  LP	  on	  completion	  of	  therapy.	  There	  was	  also	  no	  significant	  difference	  
in	  the	  proportion	  of	  subjects	  with	  sterile	  CSF	  by	  day	  14	  between	  persons	  taking	  ART	  
at	   presentation	   and	   those	   who	   were	   not	   (47.1%	   vs.	   46.5%	   of	   the	   total	   cohort	  
respectively,	  p=0.79).	  
4.5.2 Mortality	  
The	  case	  fatality	  rate	  was	  23%	  at	  14	  days	  (14	  of	  60	  indviduals),	  39%	  at	  12	  weeks	  (22	  
of	  57	   individuals)	  and	  45%	  at	  24	  weeks	   (25	  of	  55	   individuals).	   The	  median	   time	   to	  
death	   was	   10	   days	   (IQR	   2-­‐33).	   Overall	   mortality	   by	   week	   24	   using	   Kaplan-­‐Meier	  
estimates	   was	   43%	   (95%CI	   31%-­‐56%);	   overall	   survival	   was	   57%	   (95%CI	   44-­‐69%)	  




Figure	  4.5	  	  Kaplan	  Meier	  survival	  curve	  for	  IICD	  cohort.	  Overall	  mortality	  by	  week	  24	  was	  43%	  (95%CI	  
31-­‐56%).	  Overall	  survival	  was	  57%	  (95%CI	  44-­‐69%).	  	  
	  
4.5.3 Causes	  of	  death	  
Details	  of	   the	  25	  participants	  who	  died	  are	  provided	  below	  [Table	   4.10];	  causes	  of	  
death	   were	   determined	   by	   the	   research	   team.	   11	   deaths	   were	   ascribed	   to	  
cryptococcal	   meningitis	   (44%	   of	   total):	   six	   of	   these	   had	   clear	   neurological	  
deterioration,	   in	   the	   other	   five,	   participants	   died	   suddenly	   (presumed	   to	   be	   brain	  
stem	   involvement).	   There	  were	   8	   deaths	   for	  which	   the	   cause	   could	   not	   be	   clearly	  
stated,	   in	   four	   of	   these	   progressive	   multi-­‐organ	   dysfunction	   occurred,	   with	   renal	  
failure,	  metabolic	   acidosis	   and	   respiratory	   compromise;	   clinically	   this	   resembled	   a	  
sepsis-­‐syndrome,	   but	   blood	   cultures	   were	   negative.	   	   Of	   the	   remaining	   six	   deaths,	  
two	   were	   due	   to	   confirmed	   nosocomial	   sepsis	   (positive	   blood	   cultures)	   [section	  
4.6.1],	  one	  was	  due	  to	  probable	  IRIS,	  one	  was	  due	  to	  cryptococcal	  relapse,	  and	  one	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IICD	   Study	  Day	   1st	  hosp ART	   Days	  of	  ART	   Mode	  of	  death	   Cause	  of	  death	  
1	   19	   Yes	   Yes	   28	   Sudden	   Unknown	  
4	   5	   Yes	   No	   	   Neuro	   CM	  
6	   2	   Yes	   No	   	   Sudden	   CM	  
8	   3	   Yes	   Yes	   114	   Resp	   Pulm	  Crypto	  
9	   2	   Yes	   Yes	   Unknown	   Neuro	   CM	  
18	   101	   No	   Yes	   86	   Sudden	   Relapsed	  CM	  
19	   28	   No	   Yes	   >	  3	  years	   MOD	   Unknown	  
21	   75	   No	   No	   	   Sudden	   Aneursym	  
25	   15	   Yes	   Yes	   73	   Neuro	   CM	  
26	   33	   Yes	   No	   	   Neuro	   Unknown	  
27	   1	   Yes	   No	   	   Sudden	   CM	  
28	   85	   No	   Yes	   53	   MOD	   Bacterial	  Sepsis	  
30	   3	   Yes	   No	   	   Neuro	   CM	  
32	   3	   Yes	   Yes	   Unknowon	   Sudden	   CM	  
33	   2	   Yes	   No	   	   Sudden	   CM	  
37	   13	   Yes	   No	   	   Sudden	   CM	  
39	   18	   Yes	   No	   	   MOD	   Bacterial	  sepsis	  
41	   145	   No	   Yes	   114	   Neuro	   Unknown	  
45	   1	   Yes	   No	   	   Neuro	   CM	  
49	   10	   Yes	   No	   	   Resp	   Unknown	  
53	   8	   Yes	   No	   	   MOD	   Unknown	  
57	   2	   Yes	   No	   	   MOD	   Unknown	  
62	   39	   No	   Yes	   39	   Neuro	   ?CM-­‐IRIS	  
64	   39	   No	   Yes	   8	   MOD	   Unknown	  
66	   2	   Yes	   No	   	   Neuro	   CM	  
Table	  4.10	  	  Details	  of	   IICD	  participants	  who	  died	  during	  study	  follow	  up.	  1st	  Hosp	  refers	  to	  a	  death	  
during	  the	  first	  episode	  of	  hospitalization,	  ART	  refers	  to	  whether	  the	  participant	  was	  taking	  ART	  at	  the	  
time	  of	  death.	  Days	  of	  ART	  was	  calculated	  at	  the	  time	  of	  death.	  MOD	  =	  multi-­‐organ	  dysfunction;	  Pulm	  
Crypto	  =	  cryptococcal	  pneumonia	  (see	  post-­‐mortem,	  section	  4.5.4).	  
	  
4.5.4 Post-­‐mortem	  examinations	  
Two	   post-­‐mortem	   examinations	   (PM)	   were	   performed:	   IICD8	   and	   IICD25.	   In	   both	  
cases,	   a	   clinical-­‐pathological	   meeting	   was	   held	   after	   the	   post-­‐mortem	   had	   been	  




Participant	  IICD8	  presented	  to	  hospital	  with	  symptoms	  typical	  of	  CM	  and	  started	  on	  
amphotericin	  treatment.	  Due	  to	  failure	  of	  1st	   line	  ART,	  she	  had	  been	  switched	  onto	  
second	   line	   ART	   3	   months	   prior	   to	   admission	   (zidovudine,	   lamivudine,	   lopinavir,	  
ritonavir);	  CD4	  was	  45	  cells/µL,	  HIV	  viral	  load	  was	  296	  copies/mL.	  On	  the	  second	  day	  
of	  admission	  she	  developed	  worsening	  shortness	  of	  breath	  and	  hypoxia,	  with	  a	  chest	  
x-­‐ray	   showing	   bilateral	   diffuse	   pulmonary	   shadowing,	   suggestive	   of	   Pneumocystis	  
jirovecii	   pneumonia	   (PCP)	   [Figure	   4.6].	   Unfortunately,	   despite	   treatment	   with	   co-­‐
trimoxazole	  and	  prednisolone	  she	  died	  of	  respiratory	  failure.	  
	  
Figure	  4.6	   	   IICD8	  CXR	  (day	  2).	  Diffuse	  interstitial	  shadowing	  noted	  throughout	  both	  lung	  fields,	  right	  
more	  than	  left.	  	  
At	   PM	   her	   lungs	  were	   found	   to	   contain	   no	   evidence	   of	   TB	   or	   PCP,	   but	   contained	  
abundant	  mucoid	  colonies	  of	  encapsulated	  yeast	  cells	   consistent	  with	  cryptococcal	  
pneumonia	  [Figures	  4.7	  &	  4.8].	  The	  infiltration	  was	  so	  extensive	  it	  involved	  almost	  all	  
the	  airspaces.	   There	  were	  also	  a	  moderate	  number	  of	  macrophages	  present	   along	  




Figure	  4.7	  	  IICD8	  post	  mortem:	  lung	  section	  (mucicarmine	  stain).	  Numerous	  encapsulated	  yeasts	  are	  
seen	  in	  the	  centre	  of	  the	  picture,	  their	  capsules	  taking	  up	  the	  stain.	  
	  
Figure	   4.8	   	   IICD8	   post	   mortem:	   lung	   section	   (Grocott’s	   stain).	   Numerous	   cryptococci	   are	   seen	  
throughout	  the	  section,	  stained	  dark	  purple.	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IICD25	   presented	   with	   symptoms	   typical	   of	   CM.	   She	   had	   started	   tenofovir,	  
lamivudine,	  and	  efavirenz	  2	  months	  prior	   to	  admission;	  CD4	  count	  was	  85	  cells/µL	  
and	   viral	   load	   <40	   copies/mL.	   CSF	   opening	   pressure	   was	   31cmH2O	   but	   improved	  
following	  therapeutic	  LP.	  At	  day	  8	  she	  developed	  progressive	  cerebellar,	  bulbar	  and	  
brain	   stem	   dysfunction	   and	   repeat	   LP	   showed	   CSF	   pressure	   had	   increased	  
significantly	   (55cm	   H2O).	   Despite	   repeated	   therapeutic	   drainage	   (10	   x	   LPs)	   her	  
symptoms	  failed	  to	  improve	  and	  GCS	  progressively	  deteriorated;	  she	  died	  on	  day	  15.	  	  
	  
Figure	  4.9	  	  IICD25	  post	  mortem:	  base	  of	  brain	  Foramen	  magnum	  moulding	  is	  noted	  
PM	   examination	   revealed	   evidence	   of	   brainstem	   herniation,	   marked	   foramen	  
magnum	   moulding	   [Figure	   4.9],	   cerebellar	   swelling,	   effacement	   of	   the	   fourth	  
ventricle	   [Figure	   4.11],	   and	   prominent	   impingement	   deformation	   of	   the	   medulla	  
[Figure	  4.10].	  Examination	  of	  cut-­‐sections	  showed	  abundant	  cryptococcal	  organisms	  
with	  multinucleated	  giant	  cells,	  macrophages	  and	  lymphocytes	  [Figure	  4.15].	  There	  
were	   focal	   cryptococcal	   granulomas	   in	   the	   cerebellum	   with	   diffuse	   vascular	  
congestion,	   widespread	   loss	   of	   Purkinje	   cells,	   and	   diffuse	   vacuolar	   degeneration	  
[figures	   4.13,	   4.14].	   Sections	   of	   the	   medulla	   confirmed	   architectural	   deformation	  
with	   ischaemic	   change	   and	   necrosis	   [Figure	   4.12].	   Cause	   of	   death:	   brainstem	  
herniation	  secondary	  to	  cryptococcus-­‐associated	  cerebellopathy.	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Figure	  4.10	  	  IICD25	  post	  mortem:	  brainstem.	  	  Impingement	  deformation	  of	  medulla	  is	  noted.	  
	  
Figure	  4.11	  	  IICD25	  post	  mortem:	  cerebellum	  and	  pons.	  Cerebellar	  swelling	  and	  effacement	  of	  the	  4th	  
ventricle	  is	  noted.	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Figure	  4.12	  	  IICD25	  post	  mortem:	  medulla.	  Marked	  architectural	  deformation	  with	  ischaemic	  changes	  
is	   noted	   with	   diffuse	   neuronal	   changes,	   necrosis	   and	   axonal	   swelling.	   Numerous	   neurons	   show	  
cytoplasmic	  coagulation	  with	  loss	  of	  nuclear	  detail.	  	  	  
	  
Figure	   4.13	   	   IICD25	   post	   mortem:	   cerebellum.	   Granuloma	   is	   noted,	   composed	   of	   cryptococcal	  
organisms,	  proteinaceous	  secretions	  and	  epithelioid	  histiocytes	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Figure	   4.14	   	   IICD25	   post	   mortem:	   cerebellum	   (CD68	   staining).	   Granuloma	   is	   again	   noted,	  
macrophages	  (CD68)	  stained	  brown.	  
	  
Figure	  4.15	   	   IICD25	  post	  mortem:	  meninges	   (mucicarmine	   stain).	  Numerous	  cryptococci	  are	  noted	  
(pink	  oval	  objects)	  some	  of	  which	  have	  been	  phagocytosed	  by	  multinucleated	  giant	  cells.	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4.6 Complications	  	  
4.6.1 Bacterial	  sepsis	  
Bacterial	   sepsis	  was	   clinically	   suspected	   during	   the	   study	   period	   in	   18	   participants	  
prompting	   further	  blood	  cultures	   to	  be	  performed.	  Seven	  episodes	  of	  bacteraemia	  
were	  subsequently	   identified	   in	   five	   individuals	  at	  a	  median	  of	  14	  days	   (IQR	  13-­‐17)	  
after	  enrolment	   (8%	  cohort).	   Two	  were	  due	   to	  methicillin	   resistant	  Staphylococcus	  
aureus	   (MRSA),	   two	   extended	   spectrum	   β-­‐lactamase	   (ESBL)	   producing	   Klebsiella	  
pneumonia,	   two	  Enterobacter	   cloacae,	  and	  one	  Stenotrophomonas	  maltophilia.	  All	  
these	   isolates	   were	   multi-­‐resistant	   organisms	   associated	   with	   nosocomial	  
acquisition;	   three	   episodes	   were	   associated	   with	   an	   infected	   cannula	   site.	   Two	  
participants	   died	   as	   a	   direct	   result	   of	   bacterial	   sepsis,	   the	   others	   required	   an	  
additional	  two	  weeks	  of	  hospital	  admission	  for	  intravenous	  antibiotic	  therapy.	  
	  
Individuals	  who	  developed	  bacteraemia	  were	  compared	  against	   those	  who	  did	  not	  
[Table	   4.11].	   No	   significant	   factors	   for	   developing	   bacteraemia	   were	   identified,	  
however	   there	   was	   a	   non-­‐significant	   trend	   towards	   lower	   baseline	   CD4	   counts	  
(median	  (IQR)	  CD4	  13	  (11-­‐14)	  vs.	  40	  (13-­‐84)	  respectively,	  p=0.052).	  Although	  80%	  of	  
individuals	  with	   bacteraemia	   had	   inflammation	   at	   cannula	   sites,	   site	   inflammation	  
was	  also	  noted	  in	  56%	  subjects	  who	  did	  not	  develop	  bacteraemia	  and	  there	  was	  no	  
significant	  association	  between	  the	  two	  conditions	  (p=0.130).	  
	  
	   Bacteraemia	  (n=5)	  
No	  Bacteraemia	  
(n=55)	   P	  value	  
Age	  (years)	   33	  (23,	  42)	   36	  (30,	  43)	   0.486	  
Male	  Sex	   3	  (60)	   30	  (55)	   1.000	  
CD4	  count	  (/µL)	   13	  (11,	  14)	   40	  (13,	  84)	   0.052	  
HIV	  VL	  (log10	  copies/mL)	   5.2	  (4.8,	  5.4)	   5.1	  (4.4,	  5.5)	   0.989	  
On	  ART	  (n%)	   1	  (20)	   16	  (29)	   1.000	  
WBC	  on	  admission	  (x109/L)	   2.8	  (2.2,	  4.5)	   5.0	  (3.4,	  6.1)	   0.152	  
CRP	  on	  admission	  (mg/L)	   55	  (23,	  68)	   39	  (16,	  85)	   0.763	  
Total	  AmB	  days	   13	  (12,	  14)	   14	  (7,	  14)	   0.920	  
Phlebitis	   4	  (80)	   31	  (56.4)	   0.390	  
Total	  number	  LPs	   6	  (6,	  6)	   4.5	  (3,	  6)	   0.130	  
Table	   4.11	   	   Differences	   in	   baseline	   characteristics	   between	   participants	   who	   developed	  
bacteraemia	  and	  those	  who	  did	  not.	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4.6.2 Neurological	  deterioration	  on	  ART	  
ART	  was	  initiated	  in	  28	  study	  participants	  (26	  received	  1st	  line	  ART,	  2	  received	  2nd	  line	  
ART)	  at	  a	  median	  time	  of	  31	  study	  days	   (IQR	  27,	  34);	  a	   further	  2	  participants	  were	  
switched	  onto	  2nd	   line	  ART	  having	  been	  deemed	  to	  have	  failed	  1st	   line.	  Of	  these	  30	  
individuals	  starting	  active	  ART,	  there	  were	  12	  episodes	  of	  neurological	  deterioration	  
in	  11	  participants	  at	  a	  median	  of	  84	  days	  post	  enrolment	  (IQR	  42-­‐112)	  and	  61	  days	  
post	   ART	   initiation	   (IQR	   38-­‐82).	   These	   episodes	   and	   basic	   clinical	   information	   are	  
listed	  below	  [Table	  4.12].	  Causes	  were	  ascribed	  by	  the	  research	  team.	  
	  








gluc	   Cause	   Outcome	  
2	   14	   Headache	   15	   22	   463	   0	   1.62	   1	   ?TBM	   Survived	  
5	   56	   Headache	   15	   15	   1	   0	   0.23	   2.9	   NAD	   Survived	  
15	   14	   Headache	   15	   16	   25	   0	   1.48	   2.8	   NAD	   Survived	  
15	   82	   Confusion	   13	   28	   75	   0	   3.96	   1.4	   TBM	   Survived	  
18	   61	   Headache	   15	   41	   69	   5	   1.08	   1.7	   Relapse	   Died	  
28	   18	   Headache	   15	   33	   8	   18	   1.29	   2.1	   IRIS	   Survived	  
34	   99	   Headache	   15	   37	   88	   25	   0.46	   2.7	   IRIS	   Survived	  
41	   113	   Headache	   15	   ?	   0	   0	   0.23	   2.9	   Unknown	   Died	  
43	   52	   Headache	   15	   23	   0	   0	   0.27	   3.4	   NAD	   Survived	  
50	   77	   Headache	   15	   34	   90	   1	   0.51	   3.2	   Relapse	   Survived	  
56	   62	   Headache	   15	   46	   40	   0	   0.79	   2.1	   IRIS	   Survived	  
62	   38	   Headache	   15	   35	   51	   0	   2.27	   1.2	   IRIS	   Died	  
	   	   	   	   	   	   	   	   	   	   	  
MED	   59	   	   15	   33	   46	   0	   0.9	   2.4	   	   	  
Table	   4.12	   	   Details	   of	   the	   episodes	   of	   neurological	   deterioration	   (ND)	   that	   occurred	   during	   ART.	  
Abbreviations:	   “ART	   day”	   –	   days	   taking	   ART	   when	   presented	   with	   ND;	   “Clinical”	   –	   nature	   of	   the	  
presentation	  with	  ND;	  “OP”	  CSF	  opening	  pressure;	  “CSF	  Lym”	  –	  CSF	  lymphocyte	  count;	  “CSF	  Neut”	  –	  
CSF	  neutrophil	  count;	  “CSF	  prot”	  –	  CSF	  protein	  concentration;	  “CSF	  gluc”	  –	  CSF	  glucose	  concentration;	  
“TBM”	  –	  TB	  meningitis;	  “NAD”	  –	  no	  additional	  abnormality	  detected	  (see	  text).	  Bottom	  row	  displays	  
medians	  (MED).	  	  	  
Four	   episodes	   of	   neurological	   deterioration	   (ND)	   met	   criteria	   for	   paradoxical	  
cryptococcal	  immune	  reconstitution	  inflammatory	  syndrome	  (IRIS)	  (13%	  participants	  
starting	   active	   ART)	   (Haddow	   et	   al.	   2010).	   	   All	   these	   individuals	   presented	   with	  
headache	  and	  raised	  CSF	  opening	  pressure.	  All	  had	  therapeutic	  lumbar	  punctures	  to	  
control	  pressure;	  two	  were	  given	  high	  dose	  prednisone	  with	  apparent	  clinical	  benefit	  
(IICD	   28	   and	   34).	   One	   individual	   (IICD62)	   died	   suddenly	   a	   day	   after	   re-­‐admission.	  
108	  	  
There	  were	  2	  episodes	  of	  cryptococcal	  relapse,	  both	  of	  which	  were	  associated	  with	  
interruptions	   in	   fluconazole	  secondary	  prophylaxis	   (in	  both	  cases	  participants	  were	  
still	  taking	  ART).	  One	  individual	  developed	  confirmed	  TB	  meningitis	  (M.	  tuberculosis	  
identified	   on	   CSF	   culture)	   and	   one	   other	   developed	   probable	   TB	   meningitis	  
(lymphocytic	  CSF,	  high	  CSF	  protein,	  low	  CSF	  glucose	  and	  M.	  tuberculosis	  identified	  on	  
sputum	  culture).	  Three	  episodes	  of	  neurological	  deterioration	  were	  classified	  as	  “No	  
additional	   abnormality	   detected”	   (NAD),	   this	   was	   defined	   as	   mild	   symptoms,	   no	  
significant	   neurological	   abnormality,	   CSF	   cell	   count	   and	   opening	   pressure	   within	  
normal	  limits,	  and	  symptoms	  resolved	  without	  treatment.	  In	  one	  case	  the	  cause	  was	  
unknown	  (the	  participant	  died	  before	  diagnostic	  workup	  was	  complete	  and	  no	  post	  
mortem	  was	  performed).	  These	  episodes	  are	  summarized	  below	  [Table	  4.13].	  	  
	  
	   CM	  relapse	   CM-­‐IRIS	   NAD TBM	   P-­‐value	  
N	  (%)	   2	  (16.7)	   4	  (33.3)	   3	  (25) 2	  (16.7%)	   	  
Study	  day	  	   95	  (84,	  105)	   64	  (44,	  103)	   52	  (14,	  56) 68	  (23,	  112)	   0.631	  
ART	  day	   69	  (61,	  77)	   50	  (28,	  81)	   33	  (14,	  54) 48	  (14,	  82)	   0.404	  
GCS<15	   0	  (0)	   0	  (0)	   0	  (0) 1(50)	   0.417	  
CSF	  OP	  cmH2O	   38	  (34,	  41)	   36	  (34,	  41)	   16	  (15,	  23) 25	  (22,	  28)	   0.050	  
CSF	  WCC	  (/µL)	   83	  (74,	  91)	   46	  (33,	  82)	   1	  (0,	  25) 269	  (75,	  463)	   0.071	  
CSF	  lymph	  (/µL)	   80	  (69,	  90)	   46	  (24,	  69.5)	   1	  (0,	  25) 269	  (75,	  463)	   0.079	  
CSF	  neut	  (/µL)	   3	  (1,5)	   9	  (0,	  21.5)	   0	  (0,0) 0	  (0,0)	   0.417	  
CSF	  prot	  (g/L)	   0.8	  (0.5,	  1.1)	   1.0	  (0.6,	  1.8)	   0.3	  (0.2,	  1.5) 2.8	  (1.6,	  4)	   0.186	  
CSF	  gluc	  (mmol/l)	   2.5	  (1.7,	  3.2)	   2.1	  (1.7,	  2.4)	   2.9	  (2.8,	  3.4) 1.2	  (1.0,	  1.4)	   0.125	  
India	  Ink	   2	  (100)	   1	  (25)	   0	  (0) 0	  (0)	   0.261	  
CSF	  Culture	  +ve	   2	  (100)	   0	   0 0	   0.030	  
Table	   4.13	   	   Summary	  of	   clinical	   and	  CSF	   features	   among	   subjects	  with	  neurological	   deterioration	  
(ND).	  All	  characteristics	   refer	   to	   the	   time	  of	  ND,	  not	   to	  baseline.	  Abbreviations	  of	  conditions	  are	  as	  
table	  4.12.	  Culture	  +ve	  refers	  to	  fungal	  culture.	  P-­‐values	  are	  calculated	  using	  Kruskal-­‐Wallis	  test.	  
4.6.3 Neurological	  Deterioration	  unrelated	  to	  ART	  initiation	  during	  study	  
There	   were	   four	   additional	   episodes	   of	   neurological	   deterioration	   not	   associated	  
with	   initiation	   or	   switching	   ART	   during	   the	   study.	   All	   episodes	   occurred	   between	  
days	  14	  and	  28	  of	  the	  study	  shortly	  after	  completion	  of	  amphotericin	  B	  therapy.	  One	  
individual	  developed	  headache	  with	  raised	  intracranial	  pressure	  at	  study	  day	  21	  but	  
improved	   following	   therapeutic	   CSF	   drainage;	   one	   developed	   headaches,	   high	   CSF	  
opening	   pressure	   and	   brainstem	   signs	   at	   day	   14	   and	   unfortunately	   died	   despite	  
therapeutic	  LP	  (IICD25,	  see	  post-­‐mortem,	  [section	  4.5.3]);	  two	  developed	  increasing	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impairment	   of	   consciousness	   following	   completion	   of	   amphotericin	   (study	   day	   15	  
and	   day	   21	   respectively)	   and	   died.	   The	   cause	   of	   these	   two	   patient’s	   neurological	  
decline	   was	   not	   known;	   in	   all	   but	   the	   last	   case,	   CSF	   culture	   was	   negative	   for	   C.	  
neoformans	  (this	  was	  at	  a	  very	  low	  level).	  	  
4.6.4 Tuberculosis	  (TB)	  
Twenty-­‐three	  participants	  in	  the	  cohort	  (38%)	  received	  TB	  treatment	  (TB	  Rx)	  during	  
the	  period	  of	  the	  study:	  12	  were	  taking	  TB	  treatment	  at	  enrolment	  (20%	  cohort),	  11	  
were	  started	  on	  TB	  treatment	  during	  the	  course	  of	  the	  study	  (18%	  cohort).	  Fourteen	  
of	  these	  cases	  were	  microbiologically	  confirmed	  (23%	  cohort:	  7	  prior	  to	  enrolment,	  7	  
at	  or	  after	  enrolment).	  Nine	   individuals	   (15%)	  were	  classified	  as	  having	  “active	  TB”	  
(microbiologically	   confirmed	   TB	   diagnosed	   either	   2	   months	   before,	   or	   up	   to	   2	  
months	   after	   enrolment):	   this	   was	   used	   to	   inform	   subsequent	   immunological	  
analyses.	   Three	   individuals	   with	   active	   TB	   died	   during	   the	   study,	   but	   cryptococcal	  
meningitis	   was	   thought	   to	   be	   the	   cause	   of	   death	   in	   all	   of	   them.	   There	   was	   no	  
significant	  difference	  in	  the	  prevalence	  of	  active	  TB	  between	  participants	  taking	  ART	  
at	   study	   enrolment	   compared	   to	   those	   who	   were	   not	   (24%	   vs.	   12%	   respectively,	  
p=0.256).	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4.7 Predictors	  of	  mortality	  
4.7.1 Factors	  associated	  with	  14-­‐day	  mortality	  
To	  explore	  factors	  associated	  with	  mortality,	  clinical	  characteristics	  were	  compared	  
between	  participants	  who	  died	  before	  day	  14	  and	  those	  who	  survived	  [Table	  4.14].	  	  
	  
Variable	   Died	  by	  day	  14	  n=14	  
Survived	  to	  day	  14	  
n=46	   p	  
Age	  (years)	   37	  (27,	  45)	   36	  (30,	  43)	   0.854	  
Male	  sex	   8	  (57)	   25	  (54)	   1.000	  
CD4	  count	  (/µL)	   33	  (13,	  45)	   34.5	  (12,	  85)	   0.546	  
HIV	  VL	  (log10	  copies/mL)	   5.21	  (4.69,	  5.69)	   5.14	  (4.35,	  5.44)	   0.318	  
On	  ART	   3	  (21)	   14	  (30)	   0.737	  
Active	  ART	  (n=53)	   2	  (15)	   8	  (20)	   1.000	  
Active	  TB	  (micro	  positive)	  	   2	  (14)	   7	  (15)	   1.000	  
GCS<15	   6	  (43)	   5	  (11)	   0.014	  
Seizures	   3	  (21)	   8	  (17)	   0.707	  
Gaze	  palsy	   4	  (29)	   3	  (7)	   0.045	  
Log	  CFU/mL	  CSF	   5.54	  (4.66,	  6.44)	   4.48	  (3.1,	  5.46)	   0.032	  
Positive	  India	  Ink	  	   13	  (93)	   35	  (78)	   0.269	  
Cryptococcaemia	  (n=46)	   7	  (64)	   13	  (37)	   0.169	  
CSF	  OP	  at	  D0	  (cmH2O)	  (n=56)	   22	  (14,	  41)	   27	  (19,	  36)	   0.577	  
Max	  CSF	  OP(cmH2O)	  	  (n=57)	   31	  (16,	  49.5)	   36	  (27,	  47)	   0.308	  
CSF	  OP>30	  cmH2O	  D0	  (n=56)	   4	  (29)	   18	  (43)	   0.529	  
CSF	  OP>30cmH20	  	  anytime	  (n=57)	   7	  (50)	   29	  (66)	   0.350	  
CSF	  WCC	  (/µL)	   5.5	  (1,	  45)	   19.5	  (3,	  106)	   0.258	  
CSF	  neut	  (/µL)	   0	  (0,0)	   0	  (0,	  4)	   0.245	  
CSF	  lymph	  (/µL)	   5.5	  (1,	  45)	   16.5	  (3,	  90)	   0.304	  
CSF	  prot	  (g/L)	   0.69	  (0.46,	  1.43)	   1.04	  (0.65,	  1.52)	   0.311	  
CSF	  gluc	  (mmol/L)	   3	  (2.1,	  4.4)	   2.1	  (1.6,	  2.7)	   0.015	  
Blood	  WCC	  (x109	  cells/ml)	  	   6.46	  (3.86,	  7.36)	   4.4	  (2.83,	  5.79)	   0.020	  
C-­‐reactive	  protein	  (mg/L)	   84.9	  (46.5,	  115)	   33	  (13,	  68.3)	   0.011	  
Creatinine	  (mmol/L)	   61	  (49,	  92)	   60	  (50,	  76)	   0.391	  
Table	  4.14	  	  Differences	  in	  participant	  characteristics	  between	  participants	  who	  died	  and	  survived	  by	  
day	   14.	  Data	   are	  medians	  with	   IQR,	   or	   numbers	   and	   percentages;	   unless	   specified,	   n=60.	   P-­‐values	  
from	  Wilcoxon	  rank-­‐sum	  or	  Fisher’s	  exact	  tests	  as	  appropriate.	  “Active	  TB”	  is	  defined	  in	  section	  4.6.4	  	  
Participants	   who	   died	   by	   day	   14	   were	   significantly	   more	   likely	   to	   have	   altered	  
consciousness	   at	   presentation	   compared	   to	   those	   who	   survived	   (43%	   vs.	   11%,	  
p=0.014,	  respectively),	  and	  were	  more	  likely	  to	  have	  evidence	  of	  gaze	  palsy	  (29%	  vs.	  
7%,	  p=0.045).	  Non-­‐survivors	  also	  had	  significantly	  increased	  cryptococcal	  fungal	  load	  
in	   the	   CSF	   (median	   5.54	   vs.	   4.48	   log10	   CFU/ml	   CSF,	   p=0.032;	   died	   vs.	   survived	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respectively),	   raised	   CSF	   glucose	   (median	   3	   vs.	   2.1	   mmol/L,	   p=0.015),	   raised	  
peripheral	  WBC	  (6.46	  vs.	  4.48	  x109	  cells/L,	  p=0.020)	  and	  raised	  CRP	  (84.9	  vs.	  33	  mg/L,	  
p=0.011	  respectively).	  Baseline	  CD4	  count,	  HIV-­‐1	  viral	  load,	  ART,	  and	  the	  presence	  or	  
magnitude	  of	  raised	  ICP	  were	  not	  associated	  with	  death	  by	  day	  14	  [Table	  4.14].	  	  
	  
These	  variables	  were	  entered	  into	  a	  logistic	  regression	  model	  to	  determine	  baseline	  
factors	   that	   predicted	   death	   by	   day	   14.	   Seven	   variables	   were	   identified	   in	   the	  
univariate	   analysis	   with	   p-­‐value	   <0.2	   and	   were	   used	   to	   construct	   a	   multivariate	  
model	   (backwards,	   stepwise).	   Only	   three	   of	   these	   were	   found	   to	   significantly	  
contribute	   to	   the	   model:	   GCS<15,	   fungal	   burden,	   and	   serum	   CRP	   (LR	   chi2	   =20.8	  
p=0.0001	  pseudo	  R2=0.322,	  [Table	  4.15]).	  	  
	  
	   UNIVARIATE	   MULTIVARIATE	  
OR	   p	   95%	  CI	   OR	   P	  	   95%	  CI	  
Age	  (years)	   1.01	   0.875	   0.94-­‐1.07	   	   	   	  
Male	  sex	   1.12	   0.854	   0.33-­‐3.74	   	   	   	  
CD4	  (log	  cells/µL)	   0.88	   0.618	   0.54-­‐1.44	   	   	   	  
HIV	  VL	  (log10	  copies/mL)	   1.24	   0.436	   0.72-­‐2.12	   	   	   	  
On	  ART	   0.62	   0.515	   0.15-­‐2.59	   	   	   	  
GCS<15	   6.15	   0.011	   1.50-­‐25.14	   14.1	   0.010	   1.9-­‐106	  
Seizures	   1.30	   0.733	   0.29-­‐5.73	   	   	   	  
Gaze	  palsy	   5.73	   0.038	   1.10-­‐29.78	   2.75	   0.485	   0.16-­‐46.6	  
Log	  CFU/mL	  CSF	   1.53	   0.071	   0.96-­‐2.44	   2.31	   0.014	   1.2-­‐4.5	  
CSF	  OP	  D0	  (log	  cmH20)	   0.87	   0.779	   0.32-­‐2.35	   	   	   	  
CSF	  OP>30cmH20	  D0	   0.53	   0.347	   0.14-­‐1.98	   	   	   	  
CSF	  WCC	  (log	  cells/µL)	   0.81	   0.198	   0.60-­‐1.11	   	   	   	  
CSF	  WCC>5/µL	   0.35	   0.099	   0.10-­‐1.22	   0.42	   0.335	   0.07-­‐2.45	  
CSF	  Lymph	  (log	  cells/µL)	   0.83	   0.248	   0.60-­‐1.14	   	   	   	  
CSF	  Neut	  (log	  cells/µL)	   0.84	   0.447	   0.55-­‐1.30	   	   	   	  
CSF	  proteIn	  (log	  g/L)	   0.75	   0.554	   0.29-­‐1.93	   	   	   	  
CSF	  glucose	  (log	  g/L)	   1.96	   0.223	   0.66-­‐5.79	   	   	   	  
Blood	  WCC	  (log	  x109/L)	   4.89	   0.047	   1.02-­‐23.32	   2.91	   0.327	   0.34-­‐24.6	  
CRP	  (log	  mg/L)	   2.23	   0.031	   1.08-­‐4.62	   2.89	   0.010	   1.3-­‐6.5	  
Creatinine	  (log	  mmol/L)	   2.70	   0.203	   0.58-­‐12.50	   4.41	   0.159	   0.37-­‐52.8	  
Table	   4.15	   	   Logistic	   regression	  model	   to	  predict	   death	  by	  day	   14.	  Method	   is	  described	   in	   the	   text	  
above.	  Continuous	  variables	  were	  log	  transformed	  to	  reduced	  skewing.	  Variables	  surrounded	  by	  a	  box	  
are	  part	  of	  final	  model.	  OR	  =	  Odds	  ratio;	  95%	  CI	  =	  95%	  confidence	  interval	  (for	  the	  OR).	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The	   importance	   of	   these	   variables	   to	   the	   model	   was	   confirmed	   by	   comparing	  
predictive	  ability	  before	  and	  after	  their	  removal	  with	  a	  likelihood	  ratio	  test	  	  (p-­‐values	  
were	   0.004,	   0.003	   and	  0.003	   for	   decreased	   consciousness,	   fungal	   burden	   and	  CRP	  
respectively).	  ROC	  analysis	  of	  the	  model	  revealed	  an	  area	  under	  the	  curve	  of	  0.865	  
(95%CI	  0.77-­‐0.96).	  	  
4.7.2 Factors	  associated	  with	  overall	  survival	  
A	  cox	  proportional	  hazards	  model	  was	  created	   to	  determine	  factors	  that	  predicted	  
fatal	   outcome	   over	   the	   24	   weeks	   (168	   days).	   Univariate	   analysis	   identified	   seven	  
variables	  with	  p-­‐value	  <0.2,	  these	  were	  used	  to	  construct	  a	  multivariate	  model.	  Five	  
of	  these	  variables	  remained	  significant	  within	  the	  model:	  GCS<15,	  gaze	  palsy,	  fungal	  
burden	   in	   the	   CSF,	   serum	   CRP	   and	   creatinine	   [Table	   4.16].	   The	   effect	   of	   reduced	  
consciousness	   is	   shown	   below	   [Figure	   4.16].	   Baseline	   CD4	   count,	   CSF	   opening	  
pressure,	  and	  ART	  were	  not	  associated	  with	  mortality	  during	  the	  study	  [Figure	  4.7].	  	  
	   UNIVARIATE	   MULTIVARIATE	  
HR	   P	   95%	  CI	   HR	   P	   95%	  CI	  
Age	  (years)	   1.02	   0.470	   0.97-­‐1.06	   	   	   	  
Male	  sex	   0.60	   0.205	   0.27-­‐1.32	   	   	   	  
CD4	  (cells/µL)	   0.91	   0.556	   0.67-­‐1.24	   	   	   	  
HIV	  VL	  (log10	  copies/mL)	   1.00	   0.990	   0.74-­‐1.35	   	   	   	  
On	  ART	   1.20	   0.678	   0.52-­‐2.77	   	   	   	  
GCS<15	   4.40	   <0.001	   1.92-­‐10.1	   5.95	   0.002	   1.87-­‐18.9	  
Seizures	   1.51	   0.375	   0.60-­‐3.79	   	   	   	  
Gaze	  palsy	   3.99	   0.004	   1.57-­‐10.1	   3.98	   0.048	   1.01-­‐15.7	  
Log	  CFU/mL	  CSF	   1.33	   0.049	   1.00-­‐1.77	   1.64	   0.004	   1.17-­‐2.29	  
CSF	  OP	  D0	  (log	  cmH20)	   1.09	   0.798	   0.55-­‐2.17	   	   	   	  
CSF	  OP>30cmH20	  D0	   1.14	   0.761	   0.50-­‐2.59	   	   	   	  
CSF	  WCC	  (log	  cells/µL)	   0.88	   0.351	   0.67-­‐1.15	   	   	   	  
CSF	  WCC>5/µL	   0.56	   0.160	   0.25-­‐1.25	   0.93	   0.869	   0.37-­‐2.32	  
CSF	  Lymph	  (log	  cells/µL)	   0.90	   0.477	   0.67-­‐1.21	   	   	   	  
CSF	  Neut	  (log	  cells/µL)	   1.06	   0.757	   0.72-­‐1.58	   	   	   	  
CSF	  protein	  (log	  g/L)	   0.97	   0.934	   0.51-­‐1.87	   	   	   	  
CSF	  glucose	  (log	  g/L)	   1.02	   0.946	   0.52-­‐2.03	   	   	   	  
Blood	  WCC	  (log	  x109/L)	   1.85	   0.187	   0.74-­‐4.59	   1.43	   0.536	   0.46-­‐4.4	  
CRP	  (log	  mg/L)	   1.39	   0.103	   0.94-­‐2.07	   1.55	   0.031	   1.04-­‐2.3	  
Creatinine	  (log	  mmol/L)	   2.59	   0.085	   0.88-­‐7.68	   6.37	   0.002	   1.98-­‐20.5	  
Table	  4.16	  	  Cox	  proportional	  hazards	  model	  to	  predict	  fatal	  outcome	  during	  24	  weeks	  of	  follow	  up.	  
HR	  =	  Hazard	   ratio,	   other	   abbreviations	   identical	   to	   table	   4.15.	  Variables	   that	   form	  part	   of	   the	   final	  
model	  are	  highlighted	  with	  a	  box.	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Figure	   4.16	   	   Kaplan-­‐Meier	   curves	   showing	   effect	   of	   baseline	   conscious	   level	   on	   survival.	  GCS<15	  
unadjusted	  HR	  4.4,	  95%CI	  (1.9-­‐10.1),	  p<0.001;	  adjusted	  HR	  5.95,	  95%	  CI	  (1.9-­‐18.9),	  p=0.002.	  	  
	  
	  
Figure	   4.17	   	   Kaplan-­‐Meier	   curves	   showing	   effect	   of	   baseline	   ART	   status	   on	   survival.	   Taking	  ART:	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4.8 Discussion	  	  
	  
In	   this	   chapter	   the	   demographics,	   clinical	   features	   and	   complications	   of	   the	   IICD	  
cohort	  were	  described,	  along	  with	  analysis	  determining	  predictors	  of	  poor	  outcome	  
and	  the	  effects	  of	  ART.	  A	  number	  of	  key	  aspects	  are	  discussed	  further	  below.	  
4.8.1 Characteristics	  of	  the	  cohort	  
The	  vast	  majority	  of	  individuals	  in	  the	  cohort	  had	  advanced	  HIV-­‐1	  infection	  with	  low	  
CD4	  count	  (only	  3	  were	  above	  200	  cells/µL).	  Unlike	  other	  studies,	  patients	  were	  not	  
excluded	   if	   they	   were	   currently	   taking	   ART	   or	   had	   previously	   defaulted	   from	   ART	  
care	   (43%	   of	   the	   cohort	   fell	   into	   these	   categories).	   	   In	   this	   respect	   this	   cohort	   is	  
highly	   representative	  of	   the	   clinical	   caseload	  of	  CM	  seen	   in	   South	  Africa	   currently.	  
The	  only	  difference	  from	  routine	  clinical	  practice	  was	  the	  exclusion	  of	  persons	  with	  
cryptococcal	   relapse	   to	   avoid	   excessive	   heterogeneity	   in	   the	   cohort	   (as	   such	  
individuals	   may	   have	   additional	   problems	   such	   as	   anti-­‐fungal	   drug	   resistance	   and	  
adherence	  issues).	  
4.8.2 Clinical	  features	  
Patients	   typically	   presented	   complaining	   of	   headache	   accompanied	   by	   nausea,	  
vomiting,	   and	  blurred	   vision;	   approximately	   half	   had	   a	   raised	   intracranial	   pressure	  
(CSF	  OP	  >25	  H2O),	  18%	  had	  a	  reduced	  conscious	  level	  and	  11%	  had	  a	  gaze	  palsy.	  CSF	  
white	  cell	  counts	  were	  typically	  less	  than	  100	  cells/µL	  and	  were	  often	  within	  normal	  
laboratory	  limits	  (CSF	  WCC	  <5µL).	  The	  diagnostic	  sensitivity	  of	  CSF	  microscopy	  with	  
India	   ink	   staining	  was	  80%	   (using	   a	   gold	   standard	  of	   cryptococcal	   antigen	   testing).	  
These	   findings	   are	   all	   consistent	  with	   large	   published	   cohorts	   of	   patients	  with	   CM	  
(Jarvis	   et	   al.	   2014).	   However,	   in	   contrast	   to	   larger	   studies,	   there	   was	   no	  
demonstrated	   association	   between	   CSF	   opening	   pressure	   and	   neurological	  
complications	  (impaired	  consciousness,	  gaze	  palsy	  and	  cerebellar	  signs).	  	  
4.8.3 Mortality	  and	  predictors	  of	  poor	  outcome	  
Mortality	  in	  the	  IICD	  cohort	  was	  high:	  23%	  at	  2-­‐weeks,	  39%	  at	  12	  weeks	  and	  45%	  at	  
24	  weeks.	  This	  is	  significantly	  higher	  than	  studies	  from	  well-­‐resourced	  settings	  such	  
as	  the	  USA	  and	  Europe	  (where	  mortality	  is	  reported	  to	  be	  as	  low	  as	  5-­‐10%	  at	  14	  days,	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and	   25%	   at	   10	   weeks)	   but	   similar	   to	   other	   studies	   from	   sub-­‐Saharan	   Africa	   and	  
south-­‐east	  Asia	  (where	  14	  day	  mortality	  is	  between	  17-­‐32%	  at	  14	  days	  and	  34-­‐59%	  at	  
10	  weeks)	  (Chuck	  &	  Sande	  1989;	  van	  der	  Horst	  et	  al.	  1997;	  Antinori	  et	  al.	  2001;	  Jarvis	  
et	  al.	  2014;	  Day	  et	  al.	  2013;	  Park	  et	  al.	  2011;	  Kambugu	  et	  al.	  2008).	  
	  
Compared	   to	   survivors,	   subjects	   who	   died	   before	   day	   14	   were	   significantly	   more	  
likely	   to	   have	   impaired	   consciousness	   at	   presentation	   and	   the	   presence	   of	   a	   gaze	  
palsy	   on	   examination;	   at	   baseline	   non-­‐survivors	   also	   had	   increased	   fungal	   burden,	  
raised	   CSF	   glucose,	   raised	   serum	   CRP	   and	   increased	   peripheral	   leukocyte	   count.	  
When	  these	  variables	  were	  used	  to	  construct	  a	   logistic	  regression	  model	  to	  predict	  
death	  at	  14	  days,	  only	  three	  remained	  significant:	  impaired	  consciousness,	  increased	  
fungal	   burden	   and	   increased	   CRP.	   A	   Cox	   proportional	   hazards	   model	   examining	  
mortality	  over	   the	  entire	  24	  weeks	  produced	  similar	   findings,	  with	  conscious	   level,	  
gaze	   palsy,	   fungal	   burden,	   serum	   CRP	   and	   serum	   creatinine	   all	   significantly	  
contributing	  to	  the	  model.	  These	   findings	  are	  also	  consistent	  with	   larger	  studies.	  A	  
recently	  published	   study	  combining	  9	   cohorts	   from	  5	  countries	   identified	   impaired	  
consciousness	   and	   increased	   fungal	   burden	   to	   be	   important	   predictors	   of	   14-­‐day	  
mortality,	  along	  with	  older	  age,	  high	  peripheral	  leukocyte	  count	  and	  slow	  CSF	  fungal	  
clearance	   (Jarvis	   et	   al.	   2014).	   Raised	   CRP	  was	   not	  measured	   in	   this	   study	   but	   has	  
been	   identified	   as	   an	   important	   predictive	   factor	   for	  mortality	   in	   patients	   starting	  
ART	  after	  treatment	  for	  CM	  (pre-­‐ART	  CRP>32mg/L	  associated	  with	  a	  8-­‐fold	  increased	  
odds	  of	  death	  on	  ART)	  (Boulware	  et	  al.	  2010b).	  Fungal	  clearance	  rate	  (EFA)	  was	  not	  
found	  to	  be	  significantly	  associated	  with	  mortality	  in	  the	  IICD	  cohort,	  mainly	  due	  to	  a	  
survival	  bias	  in	  its	  calculation.	  Raised	  intracranial	  pressure	  was	  also	  not	  significantly	  
associated	   with	   poor	   outcome	   in	   either	   the	   IICD	   or	   the	   larger	   combined	   cohort	  
studies.	  It	  is	  possible	  that	  aggressive	  management	  of	  raised	  ICP	  with	  therapeutic	  LPs	  
negates	   this	   as	   a	   risk	   factor	   for	   mortality	   (Bicanic,	   Brouwer,	   et	   al.	   2009a).	  
Interestingly,	  observational	   studies	   from	  Uganda	  have	   shown	  a	   survival	  benefit	   for	  
persons	   receiving	  more	   therapeutic	   lumbar	   punctures,	   irrespective	   of	   CSF	  opening	  
pressure	  (Rolfes	  et	  al.	  2014).	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4.8.4 The	  effect	  of	  ART	  on	  presentation	  and	  outcome	  in	  CM	  
Taking	   ART	   appeared	   not	   to	   have	   a	   major	   effect	   on	   the	   presenting	   clinical	  
characteristics	  of	  CM.	  Participants	  taking	  ART	  had	  significantly	  lower	  HIV	  viral	   loads	  
and	  were	  less	  likely	  to	  have	  a	  history	  of	  confusion.	  Furthermore,	  subjects	  deemed	  to	  
be	  taking	  effective	  ART	  had	  significantly	  raised	  peripheral	  CD4	  counts	  and	  serum	  CRP.	  
However,	  there	  were	  no	  significant	  differences	   in	  terms	  altered	  consciousness,	  CSF	  
opening	   pressure,	   CSF	   cellular	   infiltrate	   or	   fungal	   burden,	   and	   ART	   was	   not	  
associated	  with	  any	  differences	  in	  terms	  of	  mortality	  or	  fungal	  clearance.	  	  
	  
These	   findings	   are	   broadly	   similar	   to	   two	   other	   prospective	   cohort	   studies	   that	  
included	   individuals	   with	   CM	   who	   were	   taking	   ART.	   The	   first,	   conducted	   in	   Cape	  
Town	   in	   2005	   (54	   participants,	   18	   on	   ART),	   found	   that	   patients	   taking	   ART	   had	  
significantly	   lower	   HIV	   viral	   load,	   higher	   CD4	   counts	   and	   lower	   baseline	   fungal	  
burden	  compared	  to	  those	  who	  were	  ART-­‐naïve	  (Bicanic	  et	  al.	  2007).	  No	  difference	  
was	  noted	   in	   terms	  of	  CSF	  opening	  pressure	  between	  groups	  but	  ART-­‐experienced	  
individuals	   had	   a	   non-­‐significant	   trend	   towards	   increased	   CSF	   white	   cell	   counts.	  
There	  was	  also	  no	  difference	  in	  fungal	  clearance	  or	  10-­‐week	  mortality	   in	  this	  study	  
(Bicanic	   et	   al.	   2007).	   The	   second	   study	   conducted	   in	   Botswana	   in	   2005-­‐6	   (92	  
individuals,	  26	  taking	  ART)	  showed	  no	  significant	  difference	  in	  clinical	  characteristics	  
between	   ART	   and	   non-­‐ART	   groups	   (HIV	   viral	   load	   and	   fungal	   burden	   were	   not	  
measured)	   but	   did	   show	   that	   ART	   was	   associated	   with	   improved	   survival	   using	   a	  
multivariate	  model	   adjusting	   for	   sex	   and	   TB	   status	   (Bisson	   et	   al.	   2008).	   However,	  
these	  data	  should	  be	  interpreted	  with	  caution	  as	  the	  95%	  CI	   is	  extremely	  wide	  and	  
includes	  1.0	  (adjusted	  odds	  ratio	  0.19,	  95%CI	  0.04-­‐1.00).	  	  
	  
Immune	  reconstitution	  inflammatory	  syndrome	  (IRIS)	  
CNS	  paradoxical	  IRIS	  occurred	  in	  13%	  individuals	  who	  started	  (or	  switched	  to)	  active	  
ART.	   IRIS	   occurred	   at	   a	   median	   of	   50	   days	   following	   ART	   initiation/switch	   and	  
manifested	   mainly	   as	   headache	   and	   raised	   intracranial	   pressure.	   This	   is	   broadly	  
consistent	  with	  previous	  reports	  regarding	  the	  incidence	  of	  paradoxical	  cryptococcal	  
IRIS	   from	  Cape	  Town	   (16%)	  but	   lower	   than	  reported	  rates	  of	  neurological	  C-­‐IRIS	   in	  
Uganda	  (30%)	  (Bicanic,	  Meintjes,	  et	  al.	  2009b;	  Boulware	  et	  al.	  2010b).	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4.8.5 Nosocomial	  Bacteraemia	  
A	   relatively	   high	   incidence	  of	   bacteraemia	  was	   noted	   among	   the	   cohort	   (8%).	   The	  
timing,	   organisms	   isolated	   and	   their	   drug-­‐resistance	   profiles	   strongly	   suggest	  
nosocomial	   acquisition.	   No	   clear	   risk	   factors	   for	   bacteraemia	   were	   identified	   but	  
there	  was	  a	  non-­‐significant	  trend	  towards	  lower	  CD4	  counts.	  	  
	  
These	   data	   have	   since	   been	   combined	   with	   participants	   from	   the	   Cryptococcal	  
Optimal	   ART	   Timing	   (COAT)	   trial	   to	   create	   a	   combined	   cohort	   of	   187	   individuals	  
hospitalized	  with	  CM	  (115	  Kampala,	  72	  Cape	  Town).	  From	  this	  cohort,	  30	  episodes	  of	  
bacteraemia	  were	   identified	   in	   28	   persons	   at	   a	  median	  of	   14	   days	   post	   admission	  
(cohort	   incidence	  15%)	   (Rajasingham	  et	  al.	  2014).	  Organisms	   identified	   in	  Kampala	  
were	   similar	   to	   those	   in	   Cape	   Town	   and	   included	   methicillin-­‐resistant	   S	   aureus,	  
Klebsiella	  pneumonia	  (ESBL),	  Pseudomonas	  aeruginosa	  and	  Acinetobacter	  baumanni.	  
77%	  of	  isolates	  were	  resistant	  to	  ceftriaxone	  and	  46%	  to	  ciprofloxacin.	  No	  clear	  risk	  
factors	   for	   bacteraemia	   could	   be	   identified.	   Although	   70%	   of	   cases	   had	   preceding	  
thrombophlebitis,	   this	   was	   also	   common	   in	   patients	   who	   did	   not	   develop	  
bacteraemia.	   Mortality	   was	   higher	   for	   individuals	   who	   developed	   bacteraemia	  
compared	  to	  those	  who	  did	  not	  develop	  the	  condition	  (43%	  vs.	  30%	  respectively)	  but	  
this	   difference	   was	   not	   statistically	   significant	   (OR	   1.8,	   95%	   CI	   0.78-­‐4.0,	   p=0.17)	  
(Rajasingham	  et	  al.	  2014).	  	  
	  
Data	  regarding	  nosocomial	  infections	  in	  sub-­‐Saharan	  Africa	  is	  very	  limited	  (especially	  
bacteraemia).	   A	   systematic	   review	   produced	   by	   the	   World	   Health	   Organization	  
identified	  only	  2	  high	  quality	  studies	  from	  the	  region	  and	  estimated	  a	  prevalence	  of	  
2.5-­‐14.8%	   for	  nosocomial	   infection	   (in	   some	  areas	   cumulative	   incidence	  was	  up	   to	  
45.8%)	  (Nejad	  et	  al.	  2011).	  Although	  patients	  with	  CM	  are	  undoubtedly	  at	  high	  risk	  
for	  nosocomial	   infection	  (because	  they	  are	   immune	  suppressed,	  have	   long	  hospital	  
stays,	  and	  require	  vascular	  access)	  it	  is	  likely	  that	  this	  worrying	  finding	  is	  a	  sign	  of	  a	  
more	  widespread	  problem	  with	  health-­‐associated	  infections	  in	  sub-­‐Saharan	  Africa.	  
	  
118	  	  
4.8.6 Reasons	  for	  developing	  an	  AIDS-­‐defining	  condition	  	  
This	   cohort	   illustrates	   some	   of	   the	   challenges	   facing	   HIV	   and	   ART	   programmes	   in	  
sub-­‐Saharan	   Africa,	   as	   individuals	   developed	   an	   AIDS-­‐defining	   condition	   despite	  
widespread	  availability	  of	  ART	  in	  the	  community	  (Bor	  et	  al.	  2013).	  	  
	  
One	  of	  the	  most	  important	  reasons	  in	  this	  cohort	  remained	  “delayed	  HIV	  diagnosis”,	  
with	  nine	  individuals	  (15%	  cohort)	  being	  diagnosed	  with	  HIV	  following	  admission	  to	  
hospital,	   and	   a	   further	   seven	   in	   the	  month	   prior	   to	   admission.	   A	   variety	   of	   public	  
health	  strategies	  have	  been	  suggested	  to	  improve	  HIV	  testing	  including	  mobile	  HIV-­‐
testing	   units	   and	   home	  based	   testing	   (Sabapathy	   et	   al.	   2012;	   Bassett	   et	   al.	   2014).	  
However,	  major	   barriers	   remain,	   including	   perceived	   low	   risk	   of	   HIV	   infection	   and	  
concerns	  regarding	  confidentiality	  and	  stigma	  (Musheke	  et	  al.	  2013).	  
	  
Failure	   to	   initiate	  ART	   in	   individuals	  with	   an	  established	  HIV	  diagnosis	  was	   also	   an	  
important	  factor	  and	  was	  the	  underlying	  reason	  behind	  a	  third	  of	  cases	  in	  this	  cohort.	  
The	   reasons	   for	   this	   are	   beyond	   the	   scope	   of	   this	   study	   but	   judging	   by	  NHLS	   CD4	  
counts,	  some	  had	  been	  attending	  clinic	  and	  had	  met	  ART	  eligibility	  criteria	  but	  had	  
not	   started	   ART.	   A	  meta-­‐analysis	   of	   29	   studies	   from	   sub-­‐Saharan	   Africa,	   involving	  
almost	   150,000	   patients,	   showed	   that	   this	   is	   a	   common	   problem:	   out	   of	   100	  
individuals	  with	  a	  positive	  HIV	  test,	  72	  had	  a	  CD4	  count	  measured,	  40	  were	  eligible	  
for	  ART	  and	  only	  25	  actually	  started	  ART	  (Mugglin	  et	  al.	  2012).	  Possible	  strategies	  to	  
improve	  this	  include	  same-­‐day	  ART	  eligibility	  assessments	  (bed-­‐side	  CD4	  testing)	  and	  
improved	  integration	  between	  HIV	  testing	  and	  ART	  programmes	  (MacPherson	  et	  al.	  
2012).	  	  
	  
Defaulting	  and	  failing	  ART	  also	  appeared	  to	  be	  important	  factors	  in	  a	  further	  third	  of	  
cases	  in	  this	  cohort.	  ART	  default	  rate	  in	  Cape	  Town	  has	  been	  reported	  to	  be	  12.8	  per	  
100	   person-­‐year,	  with	  male	   gender	   and	   high	   baseline	   CD4	   count	   identified	   as	   risk	  
factors	   (Kranzer	   et	   al.	   2010).	   Virological	   failure	   is	   also	   known	   to	   be	   an	   increasing	  
problem	  in	  sub-­‐Saharan	  Africa	  and	  is	  strongly	  linked	  to	  poor	  adherence	  (Nachega	  et	  
al.	  2007;	  Paris	  et	  al.	  1999).	  Detectable	  viral	  load	  has	  been	  reported	  in	  5-­‐41%	  patients	  
on	  ART	  with	  at	  least	  one	  drug	  resistance	  mutation	  detectable	  in	  a	  half	  (Hassan	  et	  al.	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2014;	  Abdissa	  et	  al.	  2014;	  Liégeois	  et	  al.	  2012).	  Increased	  use	  of	  viral	  load	  monitoring	  
is	  one	  strategy	  to	  improve	  detection	  of	  ART	  failure	  but	  is	  expensive	  and	  was	  recently	  
judged	  to	  not	  be	  cost	  effective	  in	  low-­‐resource	  settings	  at	  current	  prices	  (Boyer	  et	  al.	  
2013).	  Further	   innovations	  in	  technology	  to	  reduce	  the	  cost	  will	  undoubtedly	  make	  
this	   a	   more	   attractive	   option	   but	   will	   have	   to	   be	   accompanied	   by	   	   “low-­‐tech”	  
solutions	   such	   as	   improved	   counselling	   for	   individuals	   on	   ART	   (not	   just	   those	  
initiating	   therapy)	   and	   improved	   community	   support	   (Scanlon	   &	   Vreeman	   2013;	  
Kabore	  et	  al.	  2010).	  	  	  
4.8.7 Cryptococcal	  antigen	  screening	  
Despite	   a	   recommendation	   from	   the	   Western	   Cape	   government	   for	   clinicians	   to	  
screen	  ART-­‐naïve	  persons	  with	  CD4<100	  cells/µL	  for	  cryptococcal	  antigenaemia,	  only	  
one	  participant	  (from	  a	  possible	  10	  who	  met	  criteria)	  had	  an	  antigen	  test	  sent	  prior	  
to	  admission.	  Although	  efforts	  to	  improve	  cryptococcal	  antigen	  screening	  may	  prove	  
beneficial	  in	  reducing	  the	  burden	  of	  cryptococcal	  disease	  there	  remain	  a	  number	  of	  
other	   important	  strategies	  that	  could	  potentially	  have	  greater	  benefit,	  as	  discussed	  
above	  [section	  4.8.6].	  	  
4.8.8 Strengths	  and	  limitations	  
This	   chapter	   provides	   a	   solid	   characterization	   of	   the	   clinical	   features	   of	   the	   IICD	  
cohort	   to	   qualify	   future	   immunological	   analysis.	   The	   demographics,	   clinical	  
characteristics,	   mortality	   rates	   and	   factors	   predicting	   fatal	   outcome	   are	   similar	   to	  
those	   reported	   elsewhere.	   However,	   the	   study	   cohort	   is	   relatively	   small,	   and	   has	  
significant	   heterogeneity	   due	   to	   the	   relatively	   non-­‐restrictive	   entry	   criteria.	   The	  
ability	   to	   examine	   complications	   following	  ART	   initiation	   (such	   as	   paradoxical	   IRIS)	  
was	   particularly	   hampered	   as	   only	   28	   subjects	   initiated	   ART	   following	   their	  
admission.	   This	  was	  due	   to	   the	   fact	   that	   the	   cohort	  was	  not	  wholly	  made	  of	  ART-­‐
naïve	  persons	  at	  baseline	  and	  early	  mortality	  was	  high.	  Another	   limitation	  was	   the	  
fact	  that	  EFA	  (the	  rate	  of	  CSF	  fungal	  clearance)	  could	  only	  be	  calculated	  on	  82%	  of	  
the	   cohort.	   This	  was	  also	  due	   to	  high	  early	   case	   fatality	   rate	   (of	   the	  14	   individuals	  
who	  died	  within	   the	   first	  14	  days,	  only	  6	  had	  an	  EFA	  calculated).	  EFA	   is	   frequently	  
used	  as	  a	  surrogate	  endpoint	  in	  randomized	  controlled	  trials	  and	  had	  been	  intended	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to	  be	  used	   in	  a	  similar	  way	   in	  this	  study;	  however,	   the	  values	  here	  should	  be	  used	  
with	  caution,	  as	  they	  clearly	  are	  subject	  to	  a	  survivor	  bias.	  	  
	  
Despite	  this,	  the	  analysis	  of	  this	  clinical	  cohort	  does	  have	  some	  particular	  strengths.	  
Although	   the	   non-­‐restrictive	   entry	   criteria	   increased	   heterogeneity	   in	   the	   study	  
population,	   it	   does	   mean	   that	   the	   cohort	   is	   representative	   of	   the	   current	   clinical	  
situation	  in	  South	  Africa,	  and	  provides	  an	  insight	  into	  the	  reasons	  why	  HIV-­‐infected	  
people	  still	  develop	  AIDS	  despite	  widespread	  public	  ART	  programmes.	   	   In	  addition,	  
the	   enrolment	   of	   persons	  with	  CM	  who	   are	   taking	  ART	   at	   baseline,	   allows	   further	  
characterization	   of	   this	   understudied,	   but	   increasingly	   common	   group.	   Despite	  
theories	  that	  these	  patients	  would	  have	  a	  significantly	  different	  clinical	  phenotype,	  
their	   clinical	   features	   of	   CM	   and	   outcome	   measures	   appeared	   broadly	   similar	   to	  
persons	  not	  taking	  ART	  and	  only	  one	  individual	  had	  a	  clinical	  presentation	  suggestive	  
of	  unmasking	  IRIS.	  Finally,	  the	  reports	  of	  high	  rates	  of	  nosocomial	  bacteraemia,	  with	  
multi-­‐resistant	  organisms,	  are	  a	  new	  and	  particularly	  worrying	  finding.	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CHAPTER	  5: CSF	  IMMUNE	  RESPONSE	  
This	  chapter	  examines	  the	  CSF	   immune	  response	   in	   individuals	  with	  HIV-­‐associated	  
cryptococcal	  meningitis.	  Flow	  cytometry	  is	  used	  to	  analyze	  the	  CSF	  cellular	  infiltrate	  
with	  additional	  information	  obtained	  through	  measurement	  of	  soluble	  biomarkers.	  A	  
description	  of	   the	   flow	   cytometry	   gating	   strategy	   is	   provided	   along	  with	   details	   of	  
CSF	   cell	   populations;	   particular	   attention	   is	   given	   to	   the	   activation	   state	   of	   CSF	  
monocytes-­‐macrophages.	  The	  effect	  of	  ART	  on	  the	  CSF	  immune	  response	  is	  assessed	  
and	  associations	  between	  the	  CSF	  immune	  response	  and	  markers	  of	  clinical	  severity	  
and	   mortality	   are	   sought.	   Finally,	   the	   immune	   response	   among	   subjects	   with	  
cryptococcal	   IRIS	   is	   examined,	   both	   at	   the	   time	   of	   IRIS	   and	   at	   their	   original	  
presentation	  with	  CM.	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5.1 Methodology	  	  
5.1.1 Laboratory	  procedures	  
The	  methodology	  for	   flow	  cytometry,	   including	  CSF	  handling	  and	  staining	  protocol,	  
and	  the	  antibodies	  used	  are	  detailed	  in	  chapter	  3.	  A	  sample	  compensation	  matrix	  is	  
included	  in	  Appendix	  A	  for	  reference	  [Table	  A.1].	  	  
5.1.2 Data	  analysis	  
Conventional	   statistical	   analysis	   and	   initial	   exploration	   of	   the	   data	  was	   performed	  
using	  Stata	  version	  12.0	  (StataCorp,	  Texas,	  USA).	  Non-­‐normally	  distributed	  data	  was	  
either	   log-­‐transformed	   prior	   to	   the	   use	   of	   parametric	   tests	   (e.g.	   Student’s	   T-­‐test,	  
Pearson	   correlation	   etc.)	   or	   non-­‐parametric	   tests	   were	   used	   (e.g.	  Wilcoxon	   Rank-­‐
Sum	   test,	   Spearman’s	   rank	   test).	   SPICE	   version	   5.35	   (Simplified	   Presentation	   of	  
Incredibly	   Complex	   Evaluations;	   National	   Institute	   for	   Health,	   USA)	   was	   used	   to	  
display	   the	   multiple	   combinations	   of	   monocyte-­‐macrophage	   surface	   receptor	  
expression;	   comparison	   of	   distributions	  was	   performed	   using	  Wilcoxon	   Rank	   tests	  
and	   partial	   permutations	   test	   as	   described	   (Roederer	   et	   al.	   2011).	   Principal	  
component	   analysis	   was	   performed	   using	   Qlucore	   Omics	   Explorer	   version	   3.0	  






5.2 Flow	  Cytometry	  	  
5.2.1 Available	  samples	  
CSF	  was	  obtained	  for	  flow	  cytometry	  analysis	  of	  cell	  populations	  from	  57	  of	  the	  60	  
individuals	  in	  the	  cohort.	  However,	  due	  to	  technical	  issues	  with	  staining,	  the	  number	  
of	   participants	   for	   which	   data	   was	   available	   varied	   from	   57	   to	   51	   individuals	  
depending	  on	  the	  variable	  concerned.	  When	  this	  occurred,	  subjects	  were	  excluded	  
from	   analysis	   of	   that	   particular	   variable,	   but	   not	   excluded	   from	   the	   overall	   study	  
analysis.	  The	  number	  of	  participants	   included	   in	  each	  analysis	   is	   stated	  throughout	  
the	   chapter.	   All	   available	   stained	   CSF	   cells	   were	   acquired	   on	   the	   cytometer	   to	  
maximize	   data;	   the	   number	   of	   cells	   counted	  was	   divided	  by	   the	   volume	  of	   CSF	   to	  
calculate	  cells/mL.	  
5.2.2 Gating	  Strategy	  	  
The	  gating	  strategy	  is	  shown	  below	  [Figures	  5.1-­‐5.6].	  Cells	  were	  initially	  gated	  on	  
“time”	  (to	  ensure	  no	  debris	  at	  the	  end	  of	  the	  acquisition	  affected	  the	  results),	  after	  
which,	  doublets	  were	  excluded	  and	  care	  taken	  to	  ensure	  no	  antibody	  aggregates	  
were	  included	  in	  the	  analysis	  [Figure	  5.1].	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Figure	  5.1	  	  CSF	  gating	  strategy	  1	  –	  removal	  of	  debris	  and	  aggregates.	  (a)	  cells	  gated	  using	  time;	  (b)	  
doublets	  excluded	  using	  forward	  scatter	  area	  (FSC-­‐A)	  vs.	  height	  (FSC-­‐H);	  (c-­‐e)	  antibody	  aggregates	  
excluded;	  (f)	  CSF	  cell	  populations	  displayed	  according	  to	  size	  (FSC)	  and	  granularity	  (SSC).	  	  
Following	   the	   initial	   gating	  described	  above,	   cells	  were	  examined	  using	   a	   forward-­‐
scatter	   (FSC)	   against	   side-­‐scatter	   (SSC)	   plot	   (representing	   cell	   size	   and	   granularity	  
respectively)	  [figure	  5.2].	  Typical	   leukocyte	  populations	  were	  found	  to	  be	  obscured	  
making	  gating	  difficult.	  	  Staining	  with	  the	  leukocyte	  marker	  CD45	  enabled	  cells	  to	  be	  
split	  into	  CD45	  positive	  and	  negative	  populations,	  and	  a	  live-­‐dead	  stain	  was	  used	  to	  
exclude	  dead	  CD45	  positive	  cells.	  Examination	  of	  FSC-­‐SCC	  plots	  of	  the	  three	  separate	  
populations	   illustrated	  their	  contributions	  to	  the	  original	  overall	  appearance.	  Given	  
that	  any	  erythrocytes	  present	  in	  the	  CSF	  had	  been	  lysed	  during	  the	  staining	  process,	  
it	  was	   concluded	   that	   the	  CD45	  negative	   cells	  were	  most	   likely	   to	  be	   cryptococcal	  
cells.	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Figure	  5.2	  –	  CSF	  gating	  strategy	  2	  –	  isolating	  leukocytes	  and	  cryptococci.	  (a1)	  population	  from	  figure	  
5.1f	  shown	  in	  FSC-­‐SCC	  view	  -­‐	  poor	  definition	  of	  cell	  subsets	  due	  to	  cryptococci;	  	  (a2)	  CD45	  and	  live-­‐
dead	  stain	  are	  used	  to	  separate	  cells;	  (b)	  CD45-­‐ve	  cells	  –	  presumed	  cryptococci;	  (c)	  live	  CD45+	  cells	  –	  
CSF	  leukocytes;	  (d)	  dead	  CD45+	  cells	  –	  dead	  CSF	  leukocytes.	  
5.2.3 Cell	  counts	  and	  viability	  
CSF	   sample	   volumes	   ranged	   from	   0.6-­‐15mls	  with	   a	  median	   of	   7mls	   being	   used	   to	  
determine	   cell	   populations	   (IQR	   4.5-­‐8).	   This	   resulted	   in	   a	   median	   total	   leukocyte	  
count	  of	  108,000	  cells	  (range	  80-­‐2,870,000,	  IQR	  30,877-­‐294,500).	  In	  two	  participants,	  
total	   cell	   count	   was	   less	   than	   1000	   making	   determination	   of	   various	   cell	   subsets	  
difficult;	   although	   data	   from	   these	   participants	  was	   used	   in	   the	   calculation	   of	   the	  
broad	  cell	  types	  present	  in	  the	  CSF,	  it	  was	  excluded	  from	  analysis	  of	  cell	  subsets	  and	  
activation	   status.	   Despite	   initial	   technical	   concerns,	   cell	   viability	   remained	   high	  
(median	  100%,	  range	  92-­‐100%)	  and	  no	  samples	  were	  excluded	  on	  these	  grounds.	  	  
5.2.4 Identification	  of	  leukocyte	  subsets	  
Following	   the	   exclusion	   of	   cryptococci,	   leukocyte	   subsets	   were	   further	   examined.	  
Neutrophils	  were	   identified	  by	  expression	  of	   the	  carcinoembryonic	  antigen	   related	  
glycoprotein	   CD66b	   [Figure	   5.3a].	   CD66b	   is	   considered	   a	   surface	   marker	   of	  
neutrophil	  activation,	  increased	  expression	  is	  noted	  in	  inflammatory	  conditions	  and	  
in	   vitro	   stimulation	   has	   been	   shown	   to	   lead	   to	   increased	   neutrophil	   activation	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(Torsteinsdottir	   &	   Arvidson	   1999;	   Stocks	   et	   al.	   1995;	   Stocks	   et	   al.	   1996).	   The	  
proportion	  of	  neutrophils	  that	  were	  no	  longer	  expressing	  the	  Fcγ-­‐III	  receptor,	  CD16,	  
was	   also	   assessed	   as	   loss	   of	   this	   marker	   has	   been	   shown	   to	   be	   associated	   with	  
apoptotic	  neutrophils	  [Figure	  5.3b]	  (Dransfield	  et	  al.	  1994).	  T	  cells	  were	  identified	  by	  
gating	   on	   CD3+	   cells,	   and	   separated	   into	   CD4	   and	   CD8	   subsets	   [Figure	   5.3c-­‐d].	  
Monocyte-­‐macrophages	  (MM)	  were	  identified	  through	  CD14	  expression	  (CD14+MM)	  
[Figure	  5.3e].	  	  
	  
Following	   the	   exclusion	   of	   T	   cells	   using	   CD3,	   a	   second	   population	   of	   cells	   was	  
identified	   that	   appeared	   also	   to	   be	   monocyte-­‐macrophages	   [Figure	   5.3e,	   marked	  
with	   a	   †].	   These	   cells	   were	   CD14-­‐	   but	   CD4+	   and	   had	   high	   expression	   of	   HLA-­‐DR	  
[Figures	   5.3e,	   5.6c].	   They	   had	   similar	   FSC	   and	   SSC	   characteristics	   to	   CD14+	   MM	  
[Figure	   5.3g]	   and	   similar	   expression	   of	   the	   intracellular	  macrophage	  marker	   CD68	  
[Figure	   5.3h];	   they	   also	   expressed	   a	   variety	   of	   macrophage	   markers	   (see	   section	  
5.2.6,	   [Figure	   5.6]).	   They	   are	   referred	   to	   in	   this	   chapter	   as	   CD14-­‐ve	  
monocyte/macrophages	  (CD14-­‐MM).	  	  
	  
	  Following	   exclusion	   of	   neutrophils,	   monocyte-­‐macrophages,	   and	   T	   cells,	   a	   cell	  
population	   was	   noted	   with	   high	   expression	   of	   CD16.	   This	   was	   thought	   likely	   to	  
represent	  NK	  cells	  [figure	  5.3f].	  CD16-­‐	  cells	  were	  thought	  predominantly	  to	  be	  B	  cells	  




Figure	  5.3	  –	  CSF	  gating	  strategy	  3	  –	   isolation	  of	   leukocyte	  subsets.	   (a1)	  cell	  population	  from	  figure	  
5.2c,	  FSC-­‐SSC	  view,	  population	  with	  high	  FSC	  noted	  (circled	  and	  marked	  *),	  (a2)	  neutrophils	  isolated	  
using	  CD66	  and	  SSC;	  (b)	  activated/apoptotic	  neutrophils	  identified	  by	  loss	  of	  CD16	  expression;	  (c)	  CD3	  
used	   to	   identify	   T	   cells;	   (d1)	   T	   cell	   subsets	   isolated	  using	  CD4	  and	  CD8,	   (d2)	   FSC-­‐SCC	  view	  of	   T	   cell	  
population	  including	  population	  of	  “Large	  T	  cells”	  (circled	  and	  marked	  *);	  (e)	  further	  gating	  on	  non-­‐T	  
cells	  using	  CD14	  and	  CD4	  identifies	  monocyte-­‐macrophages;	  population	  of	  CD14-­‐MM	  are	  circled	  and	  
marked	   †	   (see	   figure	   5.6	   for	   further	   analysis);	   (f)	   CD3-­‐CD4-­‐CD14-­‐CD16+	   population	   possibly	  
represents	  NK	  cells,	  (g)	  physical	  characteristics	  of	  CD14	  +	  and	  CD14-­‐	  MM;	  (h)	  similar	  CD68	  expression	  
noted	  on	  CD14+	  and	  CD14-­‐	  MM.	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5.2.5 T	  cells	  	  
T	  cell	  populations	  were	  identified	  according	  to	  CD4	  and	  CD8	  expression	  [Figure	  5.4].	  
T	   cell	   activation	   was	   assessed	   by	   measuring	   expression	   of	   HLA-­‐DR	   (both	   using	  
median	   fluorescence	   intensity	   (MFI)	   and	   proportion	   of	   T	   cells	   expressing	  HLA-­‐DR).	  
Double	   negative	   (CD4-­‐CD8-­‐)	   and	   occasionally	   double	   positive	   (CD4+CD8+)	   T	   cells	  
were	  also	   identified	  [Figure	  5.4a1].	   In	  some	  individuals,	  a	  population	  of	  T	  cells	  was	  
seen	  with	  high	  FSC	  and	  SSC	   [Figure	   5.4a2	   –	  marked	  with	  a	   circle],	   further	   analysis	  
showed	  them	  to	  mainly	  consist	  of	  CD8+	  T	  cells	  [Figure	  5.4d].	  These	  cells	  are	  referred	  




Figure	  5.4	  –	  CSF	  gating	  strategy	  4	  –	  T	  cell	  subsets.	  (a1)	  CD4	  and	  CD8	  used	  to	  identify	  T	  cell	  
populations;	  (a2)	  FSC-­‐SCC	  plot	  shows	  unusual	  high-­‐FSC	  cell	  population	  (marked	  with	  circle);	  	  (b)	  and	  
(c)	  HLA-­‐DR	  expression	  on	  CD4	  and	  CD8	  T	  cells	  respectively	  -­‐	  a	  measurement	  of	  T	  cell	  activation;	  (d)	  






IICD21 D0 CSF analysis Layout: T cells
7/5/14 15:56 Page 1 of 1 (FlowJo v9.5.3)




























IICD21 d0_CSF 1 (5 ml).fcs
Event Count: 4356
















IICD21 d0_CSF 1 (5 ml).fcs
Event Count: 2997




















IICD21 d0_CSF 1 (5 ml).fcs
Event Count: 172647































































The	  term	  monocyte-­‐macrophage	  (MM)	  is	  used	  throughout	  the	  chapter	  and	  reflects	  
the	  uncertainty	  of	  their	  exact	  classification.	  Although	  their	  microscopic	  appearance	  
resembled	   monocytes,	   these	   CSF	   cells	   expressed	   CD206	   (a	   marker	   not	   normally	  
found	   on	   blood	   monocytes	   (Wollenberg	   et	   al.	   2002))	   suggesting	   a	   degree	   of	  
differentiation	   towards	  macrophages.	  Monocyte-­‐macrophages	   (identified	   in	   Figure	  
5.3e)	  were	  defined	  as	  CD14+MM	  and	  CD14-­‐MM	  [section	  5.2.4],	  and	  the	  expression	  
of	   four	   surface	  markers	  quantified	  both	   in	   terms	  of	  %	  cells	  expressing	   the	  marker,	  
and	  median	  fluorescence	  intensity	  (MFI).	  A	  summary	  of	  the	  interpretation	  of	  surface	  
activation	   markers	   is	   provided	   in	   Table	   5.1;	   further	   information	   is	   included	   in	  
chapters	  1	   [section	  1.6.2]	  and	  3	   [section	  3.5.4].	  An	   illustration	  of	   the	  expression	  of	  
these	  markers	  on	  CD14+MM	  and	  CD14-­‐MM	  is	  shown	  in	  Figure	  5.6.	  Some	  individuals	  
were	   noted	   to	   have	   CD14-­‐MM	   with	   very	   high	   expression	   of	   HLA-­‐DR	   [Figure	   5.5,	  
marked*].	   It	  was	  not	  possible	  to	  determine	  whether	  these	  cells	  were	  macrophages	  
or	  another	  cell	  type	  (e.g.	  DCs).	  They	  have	  been	  termed	  HLA-­‐DR++	  cells	  in	  analyses.	  
Marker	   Biology	   Interpretation	  
HLA-­‐DR	   MHC	  II	  molecule	  	   Increased	  with	  classical	  activation	  
CD16	   FcγRIII	   Increased	  with	  classical	  activation	  
CD206	   Mannose	  receptor	   Increased	  with	  alternative	  activation	  
CD163	   Scavenging	  receptor	  	   Increased	  on	  immune	  modulatory	  macrophages	  
Table	  5.1	  –	  Summary	  of	  macrophage	  activation	  markers	  (Biswas	  &	  Mantovani	  2010;	  Gordon	  2003;	  
Vega	  2006;	  Mosser	  &	  Edwards	  2008)	  
	  
Figure	  5.5	  –	  CSF	  gating	  strategy	  5	  –	  HLA-­‐DR++	  cells	  (marked	  *).	  Nature	  of	  these	  cells	  is	  unclear.
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Figure	  5.6	  –	  CSF	  gating	  strategy	  6	  –	  monocyte-­‐macrophage	  populations.	  (a)	  MM	  populations	  isolated	  
as	   shown	   in	   figure	   5.3;	   (b-­‐e)	   expression	   of	   activation	   markers	   on	   CD14+	   and	   CD14-­‐	   monocyte-­‐
macrophages	  (CD206,	  HLA-­‐DR,	  CD163	  and	  CD16	  respectively)	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5.3 Description	  of	  CSF	  constituents	  	  
5.3.1 Correlation	  between	  flow	  cytometry	  and	  standard	  laboratory	  measurement	  
As	   shown	   in	   Figure	   5.2,	   the	   total	   CSF	   events	   were	   divided	   into	   CD45+	   cells	  
(leukocytes)	  and	  CD45-­‐	  cells	  (presumed	  to	  be	  cryptococci).	  The	  summary	  values	  are	  
shown	  below	  [Table	  5.2].	  	  
	  
CSF	  constituent	   n	   Median	   IQR	   Min-­‐Max	  
CD45+	  cells/ml	  CSF	   57	   26,800	   7746-­‐69765	   107-­‐960000	  
Cryptococci/ml	  CSF	   57	   37,067	   2114-­‐160000	   175-­‐1600000	  
Cryptococci/CD45	  cell	  ratio	   57	   1.6	   0.10-­‐20.95	   0.00-­‐707	  
Table	  5.2	  -­‐	  CD45+	  (leukocytes)	  and	  CD45-­‐	  (cryptococci)	  in	  CSF	  of	  individuals	  with	  HIV-­‐associated	  CM.	  
Counts	  are	  per	  mL,	  divide	  by	  1000	  to	  convert	  to	  cells/µL	  (units	  typically	  used	  by	  hospital	  laboratories	  
to	  report	  CSF	  cell	  count).	  
To	   establish	  whether	   flow	   cytometry	   counting	  was	   an	   accurate	   assessment	   of	   the	  
numbers	   of	   cryptococci	   and	   leukocytes	   in	   CSF,	   flow	   cytometry	   results	   were	  
compared	   to	   established	   laboratory	   techniques.	   Flow	   cytometry	   measurement	   of	  
cryptococci	  was	  found	  to	  have	  a	  strong	  positive	  correlation	  with	  quantitative	  fungal	  
culture	  (Pearson’s	  r=0.906,	  p<0.0001)	  [Figure	  5.7].	  Indeed,	  assuming	  an	  intersect	  of	  
0,	   a	   linear	   regression	   model	   showed	   that	   quantitative	   culture	   result	   could	   be	  
accurately	   predicted	   from	   the	   flow	   cytometry	   cryptococcal	   count	   (log10CFU/ml	   =	  
1.041	  x	  log10	  (crypto	  count);	  p<0.0001;	  R2=0.977).	  	  
	  
The	  agreement	  between	  these	  two	  measurements	  was	  also	  assessed	  using	  a	  Bland-­‐
Altman	  plot,	  which	  plots	  differences	  between	  two	  measurements	  against	  their	  mean	  
[Figure	  5.8].	  This	  shows	  broadly	  good	  agreement	  between	  these	  two	  measurements;	  
the	  mean	  difference	  between	   the	   two	  measurements	  was	   -­‐0.1	   log10	  with	  6.9%	  of	  
values	   lying	   outside	   the	   95%	   limits	   of	   agreement	   (-­‐1.56	   –	   1.36	   log10,	   marked	   by	  
shaded	  area	  on	  plot).	  The	  main	  outliers	  were	  at	  the	  very	   lowest	  values	  where	  flow	  
cytometry	  counting	  produced	  higher	  values	  by	  1-­‐2	   log10.	  This	  may	  represent	  over-­‐
counting	   on	   the	   part	   of	   flow	   cytometry	   or	   alternatively	   a	   lack	   of	   sensitivity	   of	  
quantitative	  culture.	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Figure	   5.7-­‐	   Relationship	   between	   cryptococcal	   counts	   (flow	   cytometry)	   and	   CSF	   fungal	   load	  
(quantitative	  cultures).	  Cryptococci	  were	  defined	  as	  CD45-­‐	  cells;	  quantitative	  cultures	  performed	  as	  
described	   [section	   3.4.11].	   Quantitative	   culture	   can	   be	   accurately	   predicted	   from	   flow	   cytometry	  
cryptococcal	  count	  using	  the	  formula	  log10CFU/ml	  =	  1.041*log10	  “crypto	  count”	  (p<0.0001;	  R
2=0.977).	  	  
	  
Figure	  5.8	  	  Agreement	  between	  flow	  cytometry	  assessment	  of	  fungal	  load	  and	  quantitative	  culture	  
(“crypto	  count”	  and	  “CFU/ml”	  respectively).	  	  Bland-­‐Altman	  plot	  shows	  good	  agreement	  between	  flow	  
cytometry	   and	  quantitative	   culture	  measurement	  of	   fungal	   load	   (mean	  difference	   -­‐0.1	   log10)	   apart	  
from	  at	  low	  values	  where	  flow	  cytometry	  counts	  were	  higher	  by	  1-­‐2	  log10.	  Greyed	  area	  indicates	  the	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Following	   log	   transformation,	   CSF	   WCC	   (microscopy)	   and	   CD45	   count	   (flow	  
cytometry)	  were	  also	  positively	   correlated	   (r=0.607,	  p<0.0001)	   [Figure	   5.9].	  Higher	  
values	   were	   typically	   obtained	   from	   flow	   cytometry	   with	   the	   outlying	   points	  
corresponding	   to	   occasions	   where	   the	   laboratory	   reported	   there	   to	   be	   no	   cells	  
present	  but	  when	  some	  were	  detected	  by	  flow	  cytometry.	  In	  one	  study	  subject,	  flow	  
cytometry	   was	   compared	   to	   manual	   counting	   by	   an	   experienced	   laboratory	  
technician.	  Microscopy	   counts	  were	   295	   cryptococci/µl	   and	  71	   leukocytes/µl;	   flow	  
cytometry	  counts	  were	  227	  cryptococci/µl	  and	  61	  leukocyte/µl.	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5.3.2 Components	  of	  the	  CSF	  cellular	  infiltrate	  
The	   cells	   constituting	   the	   CSF	   cellular	   infiltrate	   are	   shown	   in	  Table	   5.3	   and	  Figure	  
5.10.	  The	  most	  abundant	   identified	  cell	   type	  were	  CD8	  T	   lymphocytes,	   followed	  by	  
neutrophils.	  However,	  there	  was	  significant	  variation	  between	  individuals.	  	  
	  
	  
Cell	  type	  	   Median	  (cells/ml)	   IQR	  (cells/ml)	   Min-­‐Max	  (cells/ml)	  
CD14+MM	   932	   168-­‐2,690	   1-­‐32,069	  
CD14-­‐MM	   476	   134-­‐821	   1-­‐3,448	  
CD4+	  T	  cells	   1,909	   386-­‐5,021	   3-­‐65,667	  
CD8+	  T	  cells	   10,476	   3,306-­‐34,600	   11-­‐170,000	  
CD4-­‐CD8-­‐	  T	  cells	   1,360	   259-­‐2,646	   2-­‐17,563	  
NK	  cells	   543	   184-­‐2,069	   3-­‐10,407	  
Neutrophils	   2,603	   245-­‐11,045	   1-­‐660,000	  
Other	   2,161	   917-­‐4,043	   45-­‐24,546	  
Table	  5.3	  -­‐	  Summary	  of	  CSF	  cell	  counts/ml	  CSF	  among	  participants	  at	  baseline	  (n=57)	  
	  
	  
Figure	   5.10	   -­‐	   Box	   plot	   showing	   the	   relative	   proportions	   of	   CSF	   cell	   types	   among	   participants	   at	  
baseline.	  (n=57).	  Boxes	  indicate	  interquartile	  ranges	  with	  the	  line	  in	  the	  centre	  indicating	  the	  median.	  
Whiskers	   extending	   from	   the	   box	   include	   all	   data	   points	   within	   1.5	   x	   IQR	   of	   the	   nearest	   quartile;	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5.4 CSF	  monocyte-­‐macrophages	  
5.4.1 CSF	  monocyte-­‐macrophage	  subtypes	  
CD14+	  MM	  were	  more	  abundant	  than	  CD14-­‐MM,	  constituting	  approximately	  73%	  of	  
CSF	  monocyte-­‐macrophages	   in	   the	   total	   cohort	   [Table	   5.4].	   However,	   the	   balance	  
between	   CD14+	   and	   CD14-­‐	   MM	   varied	   considerably	   between	   individuals:	   in	   35	  
participants	  CD14+MM	  were	  more	  abundant;	  in	  20,	  CD14-­‐MM	  were	  more	  abundant.	  	  
	  
	   n	   Median	   IQR	   Min-­‐Max	  
CD14+	  MM	  (%	  total	  MM)	   55	   72.2	   38.8-­‐87.9	   9.13-­‐97.2	  
CD14-­‐	  MM	  (%	  total	  MM)	   55	   27.8	   12-­‐61.4	   2.81-­‐91	  
Table	  5.4	  –	  Relative	  proportions	  of	  CD14+	  and	  CD14-­‐	  MM.	  	  
5.4.2 Differences	  in	  activation	  marker	  expression	  on	  MM	  subgroups	  
The	   expression	   of	   the	   four	   surface	   markers	   was	   examined	   on	   CD14+	   and	   CD14-­‐	  
monocyte-­‐macrophages,	   in	   terms	  of	   the	  percentage	  of	   cells	  expressing	   the	  marker	  
[Table	  5.5],	  and	  the	  median	  fluorescence	  intensity	  (MFI)	  of	  the	  marker	  [Table	  5.6].	  
Expression	   of	   CD16,	   CD163	   and	   CD206	   varied	   widely	   between	   individuals,	   with	  
significantly	   higher	   expression	   on	   CD14+	   compared	   to	   CD14-­‐	   monocyte-­‐
macrophages.	  HLA-­‐DR	  expression	  varied	  less	  between	  individuals	  and	  was	  the	  same	  
in	  the	  two	  MM	  subtypes	  	  [Tables	  5.5,	  5.6;	  Figure	  5.11].	  	  
	  
	   CD14+MM	   CD14-­‐MM	   p-­‐value	  
Surface	  
marker	  













































Table	   5.5	   -­‐	   Proportion	   of	   CSF	   CD14+	   and	   CD14-­‐	  monocyte-­‐macrophages	   expressing	   CD16,	   CD163,	  
CD206	  and	  HLA-­‐DR.	  Numbers	  refer	  to	  the	  proportion	  of	  macrophages	  expressing	  surface	  activation	  
marker.	  P-­‐values	  generated	  using	  Wilcoxon	  Log-­‐Rank	  test.	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Figure	  5.11	  -­‐	  Proportion	  of	  CD14+	  and	  CD14-­‐	  MM	  in	  the	  CSF	  that	  express	  CD16,	  CD163,	  CD206	  and	  
HLA-­‐DR.	  Expression	   is	  as	  a	  proportion	  of	   the	   total	  macrophage	  subpopulation	   (CD14+MM	  or	  CD14-­‐
MM).	  Significantly	  higher	  proportions	  of	  CD14+MM	  expressed	  CD16,	  CD163	  and	  CD206	  compared	  to	  
CD14-­‐MM;	  no	  difference	  in	  expression	  of	  HLA-­‐DR	  was	  noted.	  Details	  and	  p-­‐values	  shown	  in	  table	  5.5.	  	  
	  
	  
	   CD14+	  MM	   CD14-­‐	  MM	   P	  value	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Table	   5.6	   	   -­‐	   Expression	   of	   CD16,	   CD163,	   CD206	   and	  HLA-­‐DR	   on	   CSF	   CD14+	   and	   CD14-­‐	  monocyte-­‐
macrophages.	   Numbers	   refer	   to	   median	   fluorescence	   intensity	   (MFI).	   	   P-­‐values	   generated	   using	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5.4.3 Co-­‐expression	  of	  MM	  activation	  markers	  
Analysis	   of	   CSF	   macrophage	   surface	   markers	   using	   Boolean	   gating	   combinations	  
confirmed	   that	   their	   expression	   was	   not	   mutually	   exclusive	   [Figure	   5.12].	   Co-­‐
expression	   was	   a	   common	   occurrence,	   despite	   the	   fact	   that	   the	   surface	   markers	  
examined	   are	   reportedly	   associated	   with	   different	   macrophage	   activation	   states	  
(HLA-­‐DR	   with	   classical	   macrophage	   activation,	   CD206	   with	   alternative	   activation)	  
(Biswas	  &	  Mantovani	  2010).	  	  
	  
Expression	   of	   activation	   markers	   differed	   significantly	   between	   CD14+	   and	   CD14-­‐	  
monocyte-­‐macrophages,	  as	  shown	  by	  the	  appearance	  of	  the	  two	  pie	  charts	  in	  Figure	  
5.12a	  (permutation	  test	  p<0.0001).	  	  
	  
The	  differences	  between	  CD14+	  and	  CD14-­‐	  MM	  in	  terms	  of	  specific	  combinations	  of	  
activation	  markers	  are	  displayed	  in	  Figure	  5.12b.	  Simultaneous	  expression	  of	  all	  four	  
activation	   markers	   was	   more	   frequent	   on	   CD14+	   MM	   compared	   to	   CD14-­‐MM	  	  
(median	   23.7%	   CD14+MM	   (IQR	   10.3-­‐40.5)	   vs.	   0.41%	   CD14-­‐MM	   (IQR	   0.13-­‐0.97)	  
respectively;	  Wilcoxon	  rank	  p<0.0001),	  as	  was	  expression	  of	  CD16,	  CD163,	  and	  HLA-­‐
DR	  in	  the	  absence	  of	  CD206	  (median	  13.7%	  (IQR	  5.2-­‐26.2)	  vs.	  0.11%	  (IQR	  0.02-­‐0.28)	  
CD14+	   vs.	   CD14-­‐MM	   respectively;	   Wilcoxon	   rank	   p<0.001)	   [Figure	   5.12b].	   In	  
contrast,	  there	  were	  significantly	  fewer	  CD14+MM	  compared	  to	  CD14-­‐MM	  cells	  that	  
dual-­‐expressed	   the	   markers	   CD206	   and	   HLA-­‐DR	   (median	   0.4%	   (IQR	   0.1-­‐0.8%)	   vs.	  
3.3%	   (0.5-­‐6.8)	   respectively;	   Wilcoxon	   rank	   p<0.0001),	   and	   significantly	   fewer	  
CD14+MM	  compared	   to	  CD14-­‐MM	  that	  expressed	  only	  HLA-­‐DR	   (median	  1.4%	   (IQR	  
0.7-­‐3.0%)	   vs.	   11.8%	   (IQR	   4.6-­‐27.6)	   respectively;	   Wilcoxon	   Rank	   p<0.0001)	   [Figure	  
5.12b].	  	  
	  
Further	  examination	  of	  the	  relationship	  between	  surface	  activation	  markers	  on	  MM	  
showed	  that	  not	  only	  were	  many	  co-­‐expressed,	  but	  also	  expression	  was	  often	  closely	  
correlated.	   This	   again	   included	   markers	   reportedly	   reflecting	   different	   activation	  
states	   (e.g.	  CD206	  expression	  on	  CD14+MM	  showed	  significant	  positive	  correlation	  
with	  HLA-­‐DR	  and	  CD16	  expression	  on	  CD14+MM,	  and	  CD16	  expression	  on	  CD14-­‐MM	  




Figure	  5.12	  –	  Co-­‐expression	  of	  surface	  activation	  markers	  on	  CD14+	  and	  CD14-­‐	  MM.	  (a)	  Pie	  charts	  
show	  co-­‐expression	  of	  MM	  surface	  markers,	  coloured	  rings	  around	  pie	  charts	  indicate	  the	  expression	  
of	   the	   four	   surface	   markers	   (legend	   on	   right),	   segments	   of	   pie	   charts	   correspond	   to	   unique	  
combinations	   of	   markers	   (see	   below);	   (b)	   Dot-­‐box	   plots	   showing	   %	   expression	   of	   each	   unique	  
combination	   of	   surface	   markers	   for	   individuals	   in	   the	   cohort,	   on	   CD14+MM	   (blue)	   and	   CD14-­‐MM	  
(red);	   the	   colour	  below	   the	  bar	   chart	   corresponds	  with	   the	  pie	   chart	   segment	  above.	  Dots	   indicate	  
individual	   measurements,	   boxes	   represent	   medians,	   dashed	   boxes	   with	   #	   indicate	   significant	  


















Figure	   5.13	   -­‐	   Matrix	   scatter	   plots	   showing	   surface	   activation	   markers	   expression	   on	   CD14+	   and	  
CD14-­‐	  MM.	  Corresponding	  Pearson’s	  r	  statistics	  and	  p-­‐values	  are	  shown	  below	  [figure	  5.14].	  
	  
Figure	  5.14	  –	  Correlation	  matrix	  showing	  relationship	  between	  surface	  marker	  expression	  on	  CD14+	  
and	   CD14-­‐	   MM.	   Corresponds	   to	   the	   matrix	   scatter	   plots	   above	   [figure	   5.13];	   numbers	   refer	   to	  





































0.469 0.381 0.465 1
<0.001 0.004 <0.001
0.215 0.027 40.012 0.096 1
0.129 0.851 0.936 0.503
0.254 0.584 0.135 0.066 0.415 1
0.072 <0.001 0.335 0.638 0.002
0.111 0.001 0.301 40.116 0.418 0.366 1
0.443 0.997 0.030 0.415 0.003 0.008
0.311 0.131 0.199 0.341 0.397 0.364 0.164 1



















5.5 Effect	  of	  ART	  on	  CSF	  immune	  response	  –	  exploratory	  analysis	  
5.5.1 Effect	  of	  ART	  on	  composition	  of	  the	  CSF	  cellular	  infiltrate	  	  
To	  better	  understand	   the	  effects	  of	  ART	  on	   localized	   immune	  response	   in	   the	  CSF,	  
the	  composition	  of	   the	  CSF	  cellular	   infiltrate	  was	  compared	  between	  subjects	  who	  
were	  taking	  ART	  at	  enrolment	  and	  those	  who	  were	  not	  [Table	  5.7,	  Figure	  5.15].	  
	   Not	  on	  ART	   On	  ART	   	  
	   n	   Median	   IQR	   n	   Median	   IQR	   p	  	  
Non-­‐flow	  	   	   	   	   	   	   	   	  
Peripheral	  CD4	   43	   29	   12	   67	   17	   54	   22	   85	   0.189	  
HIV	  VL	   43	   5.33	   5.05	   5.61	   17	   3.27	   1.81	   4.68	   <0.001	  
Log	  CFU/ml	   43	   4.73	   3.48	   5.5	   17	   4.85	   3.85	   6.27	   0.470	  
Flow	  counts	   	   	   	   	   	   	   	   	   	  
Crypto/ml	   43	   30770	   2114	   147778	   15	   67960	   1696	   857000	   0.333	  
Crypto	  size	   43	   98240	   76544	   131000	   15	   97280	   64256	   117000	   0.716	  
CD45+/ml	   43	   36630	   7746	   79681	   15	   20840	   2604	   49691	   0.333	  
Neut	  (%CD45)	   43	   10	   2.35	   25.8	   15	   23	   7.35	   50.8	   0.056	  
Neutrophils/ml	   43	   2730	   150	   8780	   15	   2474	   367	   13875	   0.528	  
NK	  (%CD45)	   38	   2.23	   1.25	   4.62	   15	   2.65	   1.64	   3.85	   0.686	  
NKml	   38	   551	   197	   2968	   15	   403	   112	   1119	   0.244	  
MM	   	   	   	   	   	   	   	   	   	  
MM	  cells	  (%CD45)	   40	   5.9	   2.9	   11.2	   15	   12.2	   5.37	   15.6	   0.106	  
MMs/ml	   40	   1407	   654	   4633	   15	   1929	   392	   3650	   0.821	  
CD14+MM	  (%MM)	   40	   73.7	   37.1	   88	   15	   70.4	   48.3	   87.9	   0.985	  
CD14+MM	  (%CD45)	   42	   3.22	   1.21	   7.82	   15	   5.49	   1.56	   12.2	   0.302	  
CD14+MM/ml	   42	   945	   168	   2690	   15	   932	   147	   2729	   0.971	  
CD14-­‐MM	  (%MM)	   40	   26.4	   12	   63	   15	   29.8	   12	   52.1	   0.970	  
CD14-­‐MM	  (%CD45)	   40	   1.24	   0.7	   3.0	   15	   2.19	   1.14	   3.94	   0.151	  
CD14-­‐MM/ml	   40	   484	   140	   751	   15	   332	   114	   1006	   0.835	  
HLA++	  (%CD45)	   40	   0.04	   0.02	   0.09	   15	   0.04	   0.001	   0.2	   0.921	  
HLA++/ml	   40	   10.8	   3.4	   24.6	   15	   4.6	   0.67	   15	   0.086	  
T	  cells	   	   	   	   	   	   	   	   	   	  
CD4	  (%T	  cells)	   41	   8.33	   4.81	   12.7	   15	   24.6	   	  5.3	   34.4	   0.003	  
CD4	  (%CD45)	   42	   5.79	   3.73	   8.92	   15	   9.55	   2.81	   23.1	   0.057	  
CD4/ml	   42	   1420	   367	   4895	   15	   2112	   409	   5558	   0.691	  
CD8	  (%T	  cells)	   41	   82.3	   76.2	   87.1	   15	   67.3	   52.4	   82.4	   0.001	  
CD8	  (%CD45)	   42	   57.3	   36.7	   66.2	   15	   26	   17	   38.5	   0.001	  
CD8/ml	   42	   16234	   3819	   40000	   15	   4196	   1002	   8176	   0.019	  
CD4-­‐CD8-­‐	  (%T	  cells)	   41	   7.14	   4.74	   11	   15	   7.865	   5.29	   11.3	   0.718	  
CD4-­‐CD8-­‐	  (%CD45)	   41	   4.68	   3.34	   7.89	   15	   3.86	   2.22	   4.76	   0.122	  
CD4-­‐CD8-­‐/ml	   41	   1880	   349	   3022	   15	   693	   124	   1615	   0.074	  
Large	  T	  (%T	  cell)	   43	   2.36	   0.73	   3.53	   15	   0.97	   0.3	   4.44	   0.342	  
Large	  T	  (%CD45)	   43	   1.16	   0.43	   2.13	   15	   0.39	   0.07	   1.81	   0.059	  
Large	  T	  cells/ml	   43	   339	   93	   887	   15	   32	   11	   304	   0.024	  
CD4/CD8	  ratio	   42	   0.10	   0.06	   0.16	   15	   0.36	   0.063	   0.639	   0.003	  
Table	  5.7	  -­‐	  Differences	  in	  baseline	  CSF	  immune	  response	  between	  participants	  who	  were	  taking	  or	  
not	  taking	  ART	  at	  enrolment.	  Absolute	  counts	  are	  expressed	  as	  cell	  counts	  per	  mL;	  relative	  counts	  are	  
expressed	  as	  a	  percentage	  of	  either	  the	  parent	  population	  or	  of	  total	  CD45	  leukocytes.	  P-­‐values	  refer	  
to	  Wilcoxon	  rank-­‐sum	  tests	  (p<0.05	  are	  shaded).	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Individuals	  taking	  ART	  had	  a	  significantly	  decreased	  plasma	  HIV	  viral	  load	  compared	  
to	   individuals	  not	   taking	  ART,	  but	   there	  was	  no	   significant	  difference	   in	  peripheral	  
CD4	  count,	  fungal	  burden	  and	  CSF	  white	  cell	  count	  [Table	  5.7].	  In	  terms	  of	  absolute	  
cell	   counts,	   the	   only	   significant	   differences	   between	   the	   two	   groups	   were	  
significantly	  decreased	  CD8	  T	  cell	  and	  “large	  T	  cell”	  counts	  in	  individuals	  taking	  ART	  
at	  presentation	  [Table	  5.7].	  With	  regard	  to	  relative	  cell	  counts,	  ART	  was	  associated	  
with	   increased	   frequency	   of	   neutrophils	   and	   CD4	   T	   cells	   (as	   a	   proportion	   of	   CD45	  
cells	  and	  T	  cells	  respectively),	  along	  with	  a	  significant	  decrease	  in	  relative	  frequency	  
of	  CD8	  T	  cells	  [Table	  5.7,	  Figure	  5.15].	  	  
	  
Figure	   5.15	   –	   Differences	   in	   CSF	   cell	   populations	   between	   individuals	   who	   were	   taking	   and	   not	  
taking	   ART	   at	   enrolment.	  Box	   plot	   displaying	  median	   percentages	   and	   interquartile	   range,	   colours	  
refer	   to	  ART	   status	   at	   enrolment.	   Cell	   populations	   that	   differ	   significantly	   between	  ART	   groups	   are	  
marked	  with	  a	  box	  and	  Wilcoxon	  Rank-­‐Sum	  p-­‐value	  included.	  
5.5.2 Effect	  of	  ART	  on	  activation	  of	  CSF	  macrophages	  and	  T	  cells	  	  
The	  difference	  in	  expression	  of	  activation	  markers	  on	  macrophages	  and	  T	  cells	  was	  
also	  compared	  between	  individuals	  who	  were	  taking	  and	  not	  taking	  ART	  at	  baseline	  
[Table	  5.8].	  Individuals	  on	  ART	  had	  a	  significantly	  increased	  proportion	  of	  CD14+MM	  



















magnitude	   of	   CD16	   and	   CD206	   expression	   (MFI)	   on	   the	   same	   cells.	   They	   also	   had	  
increased	   proportions	   of	   CD14-­‐MM	   expressing	   CD16;	   there	   were	   no	   significant	  
differences	  in	  T	  cell	  activation	  [Table	  5.8].	  
	  
	  
	   Not	  on	  ART	   On	  ART	   	  
	   n	   Median	   IQR	   n	   Median	   IQR	   p	  value	  
CD14+MM	   	   	   	   	   	   	   	  
%CD16+	  	   42	   70.8	   51.4	   81.2	   14	   88.65	   76.4	   92.7	   0.013	  
%CD163+	  	   42	   94.6	   84.7	   97.1	   14	   97.05	   94.5	   97.9	   0.061	  
%CD206+	  	   39	   48	   31.9	   63.1	   15	   70.3	   41	   88.2	   0.028	  
%HLADR+	  	   42	   99.5	   98	   99.8	   14	   99.05	   97.3	   99.9	   0.485	  
CD16	  MFI	  	   41	   1694	   1066	   2328	   15	   2811	   1591	   3882	   0.011	  
CD163	  MFI	  	   41	   14225	   8029	   20641	   15	   19125	   13975	   24438	   0.084	  
CD206	  MFI	  	   39	   2562	   1520	   4670	   15	   5910	   3545	   9907	   0.020	  
HLADR	  MFI	  	   41	   4375	   3507	   6938	   15	   5386	   4522	   8243	   0.064	  
CD14-­‐MM	   	   	   	   	   	   	   	   	   	  
%CD16+	  	   40	   8.34	   5.06	   12.6	   14	   12.7	   10.3	   29	   0.109	  
%CD163+	  	   40	   21.3	   13	   50.8	   14	   29.15	   10.8	   72.1	   0.837	  
%CD206+	  	   38	   30.8	   18.9	   43.9	   15	   49.5	   19.7	   68.1	   0.235	  
%HLADR+	   40	   98.6	   97.5	   99.4	   14	   98.8	   97.4	   99.2	   0.969	  
CD16	  MFI	  	   39	   231	   161	   337	   15	   428	   247	   524	   0.019	  
CD163	  MFI	  	   39	   538	   399	   782	   15	   495	   400	   756	   0.976	  
CD206	  MFI	  	   37	   817	   451	   1555	   15	   1288	   574	   4582	   0.148	  
HLADR	  MFI	  	   39	   4661	   3515	   5826	   15	   5015	   4326	   6307	   0.164	  
CD4	  T	  cell	   	   	   	   	   	   	   	   	   	  
%HLADR+	  	   41	   49.1	   35.6	   56.9	   15	   40.5	   30.1	   46.3	   0.165	  
HLADR	  MFI	  	   38	   410	   243	   708	   15	   273	   213	   685	   0.921	  
CD8	  T	  cell	   	   	   	   	   	   	   	   	   	  
HLADR+	  	   42	   22.7	   13.6	   36.1	   15	   19.4	   15.4	   33	   0.817	  
HLADR	  MFI	  	   40	   423	   235	   641	   15	   349	   279	   618	   0.946	  
CD4-­‐CD8-­‐	  T	  cell	   	   	   	   	   	   	   	   	   	  
%HLADR+	  	   40	   38.6	   29	   47.9	   15	   27.9	   20.1	   45.5	   0.249	  
HLADR	  MFI	  	   34	   306	   223	   415	   15	   292	   183	   390	   0.461	  
Table	  5.8	  -­‐	  Differences	  in	  expression	  of	  activation	  markers	  on	  MM	  and	  T	  cell	  populations	  between	  
individuals	  taking	  and	  not	  taking	  ART	  at	  enrolment.	  Activation	  is	  expressed	  as	  the	  percentage	  of	  cells	  
expressing	   a	  marker,	   and	   the	  median	   fluorescence	   intensity	   (MFI).	   P-­‐values	   are	  Wilcoxon	   rank-­‐sum	  
tests,	  p<0.05	  marked	  with	  red	  shading;	  no	  adjustment	  for	  multiple	  comparisons	  has	  been	  made.	  
5.5.3 Effect	  of	  ART	  on	  concentration	  of	  CSF	  biomarkers	  
Finally,	  the	  CSF	  concentrations	  of	  19	  cytokines,	  4	  chemokines	  and	  2	  soluble	  markers	  
of	  macrophage	  activation	  (sCD14	  and	  sCD163)	  were	  compared	  between	  individuals	  
taking	  ART	  at	  enrolment	  and	  those	  who	  were	  not	  [Table	  5.9].	  Participants	  taking	  ART	  
were	   found	   to	   have	   reduced	   concentrations	   of	   IL-­‐1RA	   and	   CXCL9/MIG	   (Monokine	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Induced	  by	  Gamma	  interferon)	  (p-­‐values	  0.027	  and	  0.034	  respectively,	  not	  corrected	  
for	  multiple	  comparisons).	  	  
	  
	   ART	  (n=16)	   No	  ART	  (n=43)	  
Cytokine/chemokine	   Mdn	   IQR	   Mdn	   IQR	   p	  value	  
IL-­‐1β	   1.09	   0.54-­‐3.04	   2.08	   0.96-­‐3.64	   0.138	  
IL-­‐1RA	   396	   247-­‐957	   733	   505-­‐1416	   0.027	  
IL-­‐2	   3.48	   1.92-­‐5.31	   4.61	   2.37-­‐8.89	   0.250	  
IL-­‐2R	   104	   66-­‐227	   240	   61-­‐659	   0.242	  
IL-­‐4	   0.42	   0.26-­‐0.58	   0.45	   0.27-­‐0.68	   0.858	  
IL-­‐5	   0.43	   0.18-­‐1.35	   0.53	   0.16-­‐3.04	   0.538	  
IL-­‐6	   1162	   241-­‐3076	   1498	   224-­‐4246	   0.973	  
IL-­‐7	   4.45	   2.16-­‐12.02	   2.40	   1.14-­‐5.97	   0.175	  
IL-­‐8	   253	   198-­‐310	   346	   166-­‐722	   0.152	  
IL-­‐10	   20.9	   12.0-­‐36.4	   20.2	   12.2-­‐44.2	   0.759	  
IL-­‐12	   1.74	   1.10-­‐2.85	   1.56	   0.23-­‐2.12	   0.358	  
IL-­‐13	   19.3	   8.7-­‐37.0	   21.0	   7.9-­‐34.2	   0.838	  
IL-­‐17	   0.53	   0.10-­‐7.29	   3.09	   0.10-­‐13.69	   0.149	  
G-­‐CSF	   16.6	   9.2-­‐36.8	   21.2	   6.3-­‐37.1	   0.825	  
GM-­‐CSF	   1.75	   0.10-­‐43.57	   7.39	   0.57-­‐30.13	   0.382	  
IFN-­‐α	   377	   235-­‐479	   395	   336-­‐508	   0.126	  
IFN-­‐γ	   100	   45-­‐150	   142	   67-­‐212	   0.147	  
TNF-­‐α	   3.38	   2.19-­‐5.69	   5.09	   2.01-­‐8.97	   0.264	  
VEGF	   6.53	   2.68-­‐10.66	   10.12	   3.83-­‐15.52	   0.107	  
MCP-­‐1/CCL2	   229	   133-­‐509	   299	   179-­‐753	   0.331	  
MIP-­‐1α/CCL3	   37	   13-­‐47	   46	   31-­‐77	   0.054	  
MIP-­‐1β/CCL4	   56	   34-­‐70	   52	   32-­‐92	   0.851	  
CXCL9/MIG	   70	   30-­‐245	   247	   81-­‐459	   0.034	  
sCD163	   1445	   603-­‐2459	   1140	   501-­‐1872	   0.366	  
sCD14	   1050	   796-­‐1616	   1209	   921-­‐1490	   0.865	  
Table	  5.9	  -­‐	  Differences	  in	  CSF	  cytokines,	  chemokines	  and	  soluble	  markers	  of	  macrophage	  activation	  
between	   subjects	   taking	   or	   not	   taking	   ART	   at	   enrolment.	   All	   cytokines	   and	   chemokine	  
measurements	  are	  in	  pg/mL	  while	  sCD14	  and	  sCD163	  are	  in	  ng/mL.	  P-­‐values	  refer	  to	  Wilcoxon	  rank-­‐
sum	  tests.	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5.6 Effect	  of	  ART	  on	  CSF	  immune	  response	  –	  PCA	  
5.6.1 Effect	  of	  ART	  on	  CSF	  immune	  response	  	  
Further	   analysis	   of	   ART	   effect	   on	   CSF	   immune	   response	   was	   conducted	   using	  
principal	  component	  analysis	  (PCA)	  (see	  section	  5.1.3	  for	  details	  of	  analysis	  method).	  
To	   allow	   a	   more	   complete	   assessment	   of	   the	   immune	   response,	   all	   the	   variables	  
described	   in	  the	  previous	  tables,	   reflecting	  both	  cellular	  and	  soluble	  aspects	  of	   the	  
immune	  response,	  were	  combined	  (total	  number	  of	  variables	  89).	  	  
	  
T-­‐tests	   were	   performed	   on	   transformed	   variables	   to	   identify	   those	   that	   differed	  
between	  subjects	  taking	  and	  not	  taking	  ART	  at	  enrolment;	  as	  previously	  described,	  
statistical	   significance	  was	  determined	  as	  a	  p-­‐value	  <0.05	  and	  a	  q-­‐value	  <0.1.	  Only	  
four	  variables	  were	  identified	  that	  met	  these	  criteria:	  CD4/CD8	  ratio,	  CD4	  T	  cells	  (%	  
total	  T	  cells),	  CD8	  cells	  (%	  CD45+	  cells)	  and	  CD8	  cells	  (%	  T	  cells)	  [Table	  5.10].	  	  
	  
Analyte	   p-­‐value	   q-­‐value	   Analyte	   p-­‐value	   q-­‐value	  
CD4+	  %T	   0.0023	   0.050	   CD8+	  %CD45	   0.0010	   0.043	  
CD4/CD8	  ratio	   0.0018	   0.050	   CD8+	  %T	   0.0005	   0.043	  
Table	  5.10	  –	  Variables	  that	  differed	  between	  subjects	  taking	  ART	  and	  not	  taking	  ART	  (PCA1).	  Red	  –	  
significantly	   increased	  with	  ART;	  green	  –	  significantly	  decreased	  with	  ART.	  P-­‐values	  refer	  to	  T-­‐tests	   ,	  
Q-­‐values	   generated	   using	   the	   Benjamini-­‐Hochberg	   procedure	   for	   multiple	   testing	   (Benjamini	   &	  
Hochberg	  1995)	  
These	   four	   variables	   were	   used	   to	   construct	   a	   PCA	   plot	   (PCA1)	   to	   illustrate	   the	  
effects	  of	  ART	  on	  CSF	  immune	  response	  [Figure	  5.16].	  This	  showed	  that	  while	  some	  
subjects	  taking	  ART	  (blue)	  clustered	  together	  near	  the	  top	  of	  the	  plot,	  others	  did	  not	  
and	   remained	  mixed	   together	   with	   non-­‐ART	   subjects	   (yellow)	   [Figure	   5.16a].	   This	  
same	  data	  is	  also	  displayed	  using	  a	  heat	  map	  [Figure	  5.17].	  Similar	  to	  the	  PCA	  some	  
subjects	  taking	  ART	  (blue)	  are	  seen	  to	  cluster	  together	  at	  the	  right	  of	  the	  plot,	  while	  




Figure	  5.16	  –	  PCA	  1	   –	   effect	  of	  ART	  on	  CSF	   immune	   response	  (a)	  PCA	  plot	  showing	  distribution	  of	  
subjects	  according	   to	  differences	   in	   their	  CSF	   immune	  response.	  Axes	  show	  the	   first	   three	  principal	  
components	  (PCs),	  values	  in	  parenthesis	  refer	  to	  the	  amount	  of	  overall	  sample	  variance	  they	  explain.	  
Half	  the	  subjects	  taking	  ART	  (blue)	  cluster	  at	  the	  top	  of	  the	  plot,	  but	  others	  appear	  no	  different	  from	  
subjects	  not	  on	  ART	  	  (yellow).	  Subject	  16	  (unmasking	  IRIS)	  is	  located	  as	  the	  most	  extreme	  point	  at	  the	  
top	  (marked).	  (b)	  The	  4	  variables	  that	  significantly	  differ	  between	  ART	  groups	  [Table	  5.10]	  are	  plotted	  
in	  the	  same	  axes	  to	  show	  their	  weighting	  to	  the	  first	  three	  principal	  components:	  red	  (increased	  with	  
ART),	  green	  (decreased	  with	  ART).	  Variables	  with	  more	  than	  80%	  correlation	  are	  connected.	  
	  
	  
Figure	  5.17	  Heat	  map	  for	  PCA	  1.	  Subjects	  (columns)	  are	  arranged	  according	  to	  hierarchical	  clustering,	  
a	  process	  which	  pairs	  them	  with	  their	  closest	  neighbours	  according	  to	  the	  relative	  expression	  of	  the	  4	  
variables	   (rows)	   that	   differed	   between	   ART	   groups	   [Table	   5.10]:	   red	   (variable	   increased),	   green	  
(variable	  decreased).	  Some	  subjects	   taking	  ART	   (marked	  blue	  above)	  cluster	  at	   the	  right	  side	  of	   the	  












5.6.2 Effect	  of	  effective	  ART	  on	  CSF	  immune	  response	  	  
As	   illustrated	   in	   chapter	   4	   (section	   4.2.4),	   participants	   taking	   ART	   were	   a	  
heterogeneous	  group,	  ranging	  from	  recent	  initiation	  of	  ART,	  to	  ART	  failure.	  Similar	  to	  
the	  analysis	  described	  in	  chapter	  4	  (section	  4.4.2),	  the	  PCA	  was	  repeated	  excluding	  
seven	   individuals	   who	   were	   clearly	   failing	   therapy	   (taking	   ART	   for	   more	   than	   6	  
months	   with	   detectable	   viral	   load)	   or	   in	   whom	   there	   were	   significant	   doubts	  
regarding	  adherence.	  Subjects	  were	  then	  re-­‐classified	  as	  effective-­‐ART	  (n=8)	  and	  no-­‐
ART	   (n=43)	   and	   immune	   response	   compared	   between	   these	   two	   groups	   to	  
determine	  the	  true	  effect	  of	  ART	  on	  CSF	  immune	  response	  [Table	  5.11].	  	  
	  
Analyte	   p-­‐value	   q-­‐value	   Analyte	   p-­‐value	   q-­‐value	  
CD4+	  %T	   0.0000	   0.001	   CD8+	  %CD45	   0.0001	   0.002	  
CD4/CD8	  ratio	   0.0000	   0.001	   CD8+	  %T	   0.0000	   0.001	  
CD4+	  %CD45	   0.0036	   0.040	   Large	  T	  %T	   0.0003	   0.005	  
CD206+	  %CD14-­‐	   0.0060	   0.053	   LargeT	  %CD45	   0.0018	   0.023	  
MFI	  CD16	  CD14-­‐	   0.0098	   0.073	   HLADR+	  %CD4	   0.0075	   0.060	  
MFI	  CD206	  CD14+	   0.0051	   0.050	   	   	   	  
MFI	  CD206	  CD14-­‐	   0.0016	   0.023	   	   	   	  
Table	  5.11	  –	  Variables	   that	  differed	  between	   subjects	   taking	  effective	   and	  no	  ART.	  Red	  shading	  –	  
variable	   increased	   in	   subjects	   taking	   effective	   ART;	   green	   shading	   –	   variable	   decreased	   in	   subjects	  
taking	   effective	   ART.	  MFI	   =	  median	   fluorescence	   intensity,	   CD14+	   and	   CD14-­‐	   refer	   to	  macrophage	  
populations.	  	  
Twelve	   variables	   were	   significantly	   different	   between	   these	   two	   groups	   including	  
four	   previously	   identified	   variables	   from	  PCA	   1	   [Table	   5.11].	   An	   additional	   four	   of	  
these	   variables	   reflected	   alterations	   in	   macrophage	   activation	   with	   subjects	   who	  
were	  taking	  effective-­‐ART	  having	  increased	  expression	  of	  CD206	  on	  both	  CD14+	  and	  
CD14-­‐	  MM	  (increased	  MFI),	   increased	  proportions	  of	  CD206	  expressing	  CD14-­‐	  MM,	  
and	  increased	  expression	  of	  CD16	  on	  CD14-­‐	  MM	  (MFI).	  Participants	  taking	  effective-­‐
ART	   also	   had	   significantly	   reduced	   HLA-­‐DR	   expression	   on	   CD4	   T	   cells	   (suggesting	  
decreased	  activation),	  and	  decreased	  relative	  frequency	  of	  “large	  T	  cells”	  (%	  T	  cells	  
or	  %	  CD45+	  cells)	  [Table	  5.11].	  	  
	  
These	  12	  variables	  were	  used	  to	  construct	  a	  PCA	  plot	  and	  heat	  map	  analysis	  (PCA	  2),	  
both	   of	   these	   showed	   significantly	   improved	   clustering	   of	   subjects	   taking	  effective	  
ART	  –	  almost	  a	  complete	  separation	  from	  subjects	  who	  were	  not	  taking	  ART	  [Figure	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5.18a,	   Figure	   5.19]).	   The	   influence	   of	   these	   12	   variables	   on	   the	   separation	   of	  
subjects	  was	  clearly	  demonstrated	  by	  the	  variable	  PCA	  plot,	  where	  similar	  variables	  
clustered	   closely	   together,	   often	   highly	   correlated	   (indicated	   by	   connections	  
between	  the	  points	  [Figure	  5.18b].	  
	  
	  
Figure	   5.18	   	   PCA	   2	   -­‐	   Effect	   of	   effective	   ART	   on	   CSF	   immune	   response:	   (a)	   PCA	   plot	   showing	  
distribution	   of	   subjects	   according	   to	   CSF	   immune	   response.	   Subjects	   taking	   effective-­‐ART	   (blue)	  
separate	   almost	   completely	   from	   subjects	   not	   taking	   ART	   (yellow),	   patient	   16	   is	   again	   at	   the	   top	  
(marked	   IICD16).	   (b)	   12	   variables	   from	   Table	   5.11	   that	   differ	   significantly	   between	   the	   two	   ART	  
groups.	  Their	  position	  in	  the	  PCA	  plot	  reflects	  their	  weightings	  in	  the	  three	  principal	  components:	  red	  
(higher	  with	  ART);	  green	  (lower	  with	  ART);	  variables	  correlated	  ≥80%	  are	  connected	  with	  lines.	  
	  
Figure	  5.19	  	  Heat	  map	  for	  PCA	  2.	  Subjects	  arranged	  by	  hierarchical	  clustering	  according	  to	  expression	  
of	  12	  variables	   (red	  –	   increased;	  green	  –	  decreased).	  Similar	   to	   the	  PCA	  plot	   [Figure	   5.18],	   subjects	  


































5.6.3 Effect	  of	  effective	  ART	  while	  adjusting	  for	  baseline	  factors	  
In	  chapter	  4	  it	  was	  also	  noted	  that	  individuals	  taking	  effective	  ART	  had	  significantly	  
higher	  peripheral	  CD4	  counts	  and	  significantly	  lower	  HIV-­‐1	  viral	  loads.	  To	  determine	  
whether	   the	   changes	   mentioned	   above	   were	   a	   direct	   effect	   of	   ART	   on	   the	   CSF	  
immune	   response	   or	   simply	   a	   reflection	   of	   changes	   in	   the	   blood,	   the	   PCA	   was	  
controlled	  for	  these	  baseline	  variables.	  Controlling	  for	  peripheral	  CD4	  count	  (PCA	  3)	  
resulted	   in	   a	   greater	   number	   of	   variables	   that	   differed	   significantly	   between	   the	  
groups,	   suggesting	   that	   the	  effects	  of	  ART	  were	   independent	   from	  changes	   in	  CD4	  
count	   [Table	   5.12].	   In	   addition	   to	   the	   previously	   identified	   variables	   from	   PCA	   2,	  
individuals	  taking	  effective	  ART	  also	  had	  significant	  increases	  in	  the	  frequency	  of	  CSF	  
neutrophils	  and	  significant	  decreases	   in	   the	  absolute	  counts	  of	  CD8	  T	  cells,	  double	  
negative	  T	  cells	  and	  large	  T	  cells	  in	  the	  CSF	  [Table	  5.12].	  	  	  
	  
Analyte	   p-­‐value	   q-­‐value	   Analyte	   p-­‐value	   q-­‐value	  
CD4+	  %T	   0.0001	   0.002	   CD8+	  %CD45	   <0.0001	   <0.001	  
CD4/CD8	  ratio	   0.0001	   0.002	   CD8+	  %T	   <0.0001	   <0.001	  
CD206+	  %CD14-­‐	   0.0044	   0.039	   CD8+/ml	   0.0007	   0.009	  
MFI	  CD16	  CD14-­‐	   0.0077	   0.056	   Large	  T	  %T	   0.0001	   0.002	  
MFI	  CD206	  CD14+	   0.0079	   0.056	   Large	  T/ml	   0.0014	   0.014	  
MFI	  CD206	  CD14-­‐	   0.0008	   0.009	   LargeT	  %CD45	   0.0001	   0.002	  
Neuts	  %CD45	   0.0111	   0.070	   CD4-­‐CD8-­‐/ml	   0.0082	   0.056	  
Table	  5.12	  	  Variables	  that	  differed	  significantly	  between	  individuals	  taking	  effective	  ART	  and	  those	  
who	  were	  not,	   adjusted	   for	   peripheral	   CD4	   count.	  Red	  shading	  –	   increased	  among	  subjects	   taking	  
ART;	   green	   shading	   –	   decreased	   among	   subjects	   taking	   ART.	  MFI	   =	  median	   fluorescence	   intensity,	  
CD14+	  and	  CD14-­‐	  refer	  to	  macrophage	  populations.	  Large	  T	  cells	  and	  CD4-­‐CD8-­‐	  T	  cells	  were	  described	  
in	  section	  5.2.5.	  	  	  
These	  14	  variables	  were	  used	  to	  construct	  a	  PCA	  plot	  and	  heat	  map	  analysis.	  Despite	  
the	   adjustment	   for	   CD4	   count,	   there	  was	   little	   change	   in	   appearance	   from	  PCA	   2;	  
individuals	  taking	  effective	  ART	  still	  clustered	  together	  on	  both	  the	  PCA	  plot	  and	  the	  
heatmap	  and	  were	  almost	  completely	  separated	  from	  those	  not	  taking	  ART	  [Figure	  
5.20a,	  5.21].	  The	  distribution	  and	  clustering	  of	  the	  variables	  in	  the	  PCA	  plot	  [Figure	  
5.20b]	  also	  remained	  similar	  to	  PCA	  2.	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Figure	  5.20	  	  PCA	  3.	  -­‐	  Effect	  of	  effective	  ART	  on	  CSF	  immune	  response	  (controlling	  for	  peripheral	  CD4	  
count).	   (a)	   Despite	   adjustment	   for	   peripheral	   CD4	   count,	   subjects	   taking	   effective	   ART	   (blue)	   still	  
clustered	  together	  and	  were	  almost	  separated	  completely	  from	  those	  not	  taking	  ART	  (yellow).	  (b)	  14	  
variables	  from	  [Table	  5.12]	  that	  contributing	  to	  the	  PCA;	  red	  shading	  –	  increased	  with	  effective	  ART,	  
green	  shading	  –	  decreased	  with	  effective	  ART;	  similar	  variables	  cluster	  together	  and	  are	  connected	  if	  
correlation	  >80%.	  	  
	  
Figure	  5.21	  	  Heat	  map	  for	  PCA	  3.	  Similar	  to	  the	  PCA	  plot	  above	  [Figure	  5.19a],	  hierarchical	  clustering	  
showed	  that	  subjects	  taking	  effective	  ART	  (blue)	  clustered	  together	  and	  were	  mainly	  separated	  from	  
those	  who	  were	   not	   taking	   ART	   (yellow).	   Variables	   contributing	   to	   this	   analysis	   are	   listed	   in	   Table	  








































The	  PCA	  was	  then	  altered	  to	  adjust	  for	  plasma	  HIV-­‐1	  viral	  load	  (but	  not	  CD4	  count).	  
The	  number	  of	  variables	  that	  significantly	  differed	  between	  ART	  groups,	  reduced	  to	  
just	  two:	  the	  frequency	  of	  CD4	  T	  cells	  and	  neutrophils	  in	  the	  CSF	  [Figure	  5.22].	  PCA	  
plot	  and	  heat	  map	  analysis	  showed	  no	  significant	  clustering	  or	  separation	  between	  
subjects	  according	  to	  ART	  status	  [Figure	  5.23a,	  5.24].	  	  
	  
Figure	  5.22	  	  Box	  plots	  showing	  effect	  of	  effective-­‐ART	  on	  CSF	  immune	  response	  when	  controlled	  for	  
HIV	   viral	   load.	   The	   only	   variables	   that	   differed	   significantly	   between	   subjects	   taking	   effective	   ART	  
(blue)	  and	  no	  ART	  (yellow)	  were	  the	  frequency	  of	  neutrophils	  (%CD45	  cells)	  and	  CD4	  T	  cells.	  Box-­‐plots	  
illustrate	   medians	   and	   interquartile	   ranges.	   Y-­‐axis	   is	   a	   standardized	   scale	   (variables	   are	   log-­‐
transformed	  and	  adjusted	  so	  that	  mean	  equals	  0	  and	  variance	  =1).	  	  
	  
Figure	   5.23	   	  PCA	   4	   –	  Effect	   of	  effective	  ART	   on	   CSF	   immune	   response	   (controlling	   for	  HIV-­‐1	   viral	  
load).	   (a)	  Subjects	  that	  are	  taking	  effective	  ART	  (blue)	  are	  no	  longer	  clearly	  separated	  from	  subjects	  
not	   taking	   ART	   (yellow).	   (b)	   Two	   variables	   remain	   significantly	   elevated	   (red)	   in	   subjects	   who	   are	  



















































Figure	  5.24	  	  Heat	  map	  for	  PCA	  4.	  Consistent	  with	  the	  PCA	  plot	  [figure	  5.23	  (a)],	  once	  an	  adjustment	  
for	  HIV-­‐1	  viral	  load	  is	  made,	  subjects	  no	  longer	  cluster	  according	  to	  ART	  status	  
To	  investigate	  this	  further,	  correlations	  between	  plasma	  HIV-­‐1	  viral	  load	  and	  all	  the	  
measured	   parameters	   of	   CSF	   immune	   response	   were	   examined;	   PCA	   plots	   were	  
constructed	   using	   only	   variables	   that	   were	   significantly	   correlated	   with	   viral	   load	  
(PCA	  5)	  (Pearson’s	  correlation,	  p<0.05	  q<0.1)	  [Table	  5.13,	  Figure	  5.25].	  	  
Analyte	   P	   Q	   R	   Analyte	   P	   Q	   R	  
CD8+	  %T	   0.0002	   0.007	   0.51	   CD4+	  %T	   0.0010	   0.018	   -­‐0.45	  
CD8+	  %CD45	   0.0027	   0.034	   0.42	   CD4/CD8	  ratio	   0.0003	   0.010	   -­‐0.49	  
Large	  T	  %T	   0.0007	   0.015	   0.46	   MFI	  CD206	  CD14+	   0.0000	   0.003	   -­‐0.55	  
LargeT	  %CD45	   0.0087	   0.077	   0.37	   CD206+	  %CD14+	   0.0055	   0.061	   -­‐0.39	  
HLADR+	  %CD4	   0.0125	   0.093	   0.35	   MFI	  CD206	  CD14-­‐	   0.0113	   0.092	   -­‐0.36	  
crypto	  FSC	   0.0065	   0.065	   0.38	   CD206+	  %CD14-­‐	   0.0024	   0.034	   -­‐0.42	  
Table	  5.13	   	  CSF	  variables	   that	   correlated	   significantly	  with	  plasma	  HIV-­‐1	  viral	   load.	  Red	  shading	  –	  
positively	  correlated,	  green	  shading	  –	  negatively	  correlated.	  	  
The	  variables	  identified,	  and	  the	  appearances	  of	  the	  PCA	  plot,	  were	  almost	  identical	  
to	   those	   in	  PCA	   2	   	   -­‐	   the	   effect	   of	   effective	  ART	   on	   CSF	   immune	   response	   [Figure	  
5.18].	   However,	   no	   variables	   were	   significantly	   correlated	   once	   adjusted	   for	   ART	  






























Figure	   5.25	   	   PCA	   5	   –	   Effect	   of	   HIV-­‐1	   viral	   load	   on	   CSF	   immune	   response.	   (a)	   PCA	   plot	   showing	  
differences	   in	   CSF	   immune	   response	   between	   individuals	   with	   high	   HIV-­‐1	   viral	   load	   (red	   ≈106	  
copies/mL)	  compared	  to	  low	  viral	  load	  (green	  ≈	  101copies/mL);	  appearances	  almost	  identical	  to	  PCA	  2	  
[figure	   5.18];	   (b)	   Variables	   that	   significantly	   correlated	   with	   HIV-­‐1	   viral	   load	   (q<0.1)	   were	   used	   to	  
construct	  PCA;	  colour	  of	  marker	  signifies	  direction	  of	  correlation	  (red	  –	  positive,	  green	  –	  negative).	  
This	   suggests	   that	   the	   observed	   effects	   of	   ART	   on	   CSF	   immune	   response	   are	  
mediated	  through	  changes	  in	  HIV-­‐1	  viral	  load,	  an	  entirely	  plausible	  hypothesis	  given	  
the	   known	   effect	   of	   ART	   on	   T	   cell	   populations	   in	   the	   blood	   (Battegay	   et	   al.	   2006;	  
Torti	  et	  al.	  2012).	  However,	  the	  effects	  of	  HIV-­‐1	  viral	  load	  on	  macrophage	  activation	  
are	   less	   well	   known.	   To	   try	   and	   separate	   these	   two	   connected	   effects,	   the	  
relationship	  between	  viral	   load	  and	  the	  expression	  of	  CD206	  on	  the	  surface	  of	  CSF	  
macrophages	  was	  examined	  among	  subjects	  who	  were	  not	  taking	  ART	  at	  enrolment.	  
This	  showed	  a	  clear	   inverse	  correlation	  between	  plasma	  HIV-­‐1	  viral	   load	   levels	  and	  
the	  expression	  of	  CD206	  on	  the	  surface	  of	  CD14+	  MM	  (Pearson’s	  r=-­‐0.59,	  p=0.0001)	  
[Figure	   5.26]	  but	  not	  CD206	  expression	  on	   the	   surface	  of	  CD14-­‐MM	   [Figure	   5.27].	  
This	  supports	  the	  hypothesis	  that	  ART	  induced	  changes	  in	  macrophage	  activation	  are	  
also	  mediated	  through	  alterations	   in	  HIV-­‐1	  viral	   load,	   rather	   than	  a	  direct	  effect	  of	  



















Figure	  5.26	  	  Relationship	  between	  plasma	  HIV	  viral	  load	  and	  the	  expression	  of	  CD206	  on	  CD14+	  
monocyte-­‐macrophages	  (MM)	  in	  the	  CSF	  of	  subjects	  with	  CM	  not	  taking	  ART.	  Expression	  of	  CD206	  is	  





Figure	  5.27	  	  Relationship	  between	  plasma	  HIV	  viral	  load	  and	  the	  expression	  of	  CD206	  on	  CD14-­‐	  
monocyte-­‐macrophages	  (MM)	  in	  the	  CSF	  of	  subjects	  with	  CM	  not	  taking	  ART.	  Expression	  of	  CD206	  is	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5.7 Markers	  of	  severe	  cryptococcal	  meningitis	  
5.7.1 Variables	  that	  correlate	  with	  fungal	  burden	  
The	   relationship	   between	   fungal	   burden	   and	   CSF	   immune	   response	   was	   explored	  
(PCA	  6).	  Fungal	  burden	  was	  assessed	  using	  CSF	  quantitative	  culture	  as	  described	  in	  
section	  3.4.11.	  Flow	  cytometry	  cryptococcal	  counts	  were	  removed	  from	  the	  analysis	  
due	   to	   the	   previously	   demonstrated	   close	   correlation	   with	   quantitative	   culture	  
[Figure	   5.7].	   Subjects	  were	   only	   included	   if	   a	   CSF	   sample	   had	   been	   taken	   prior	   to	  
receiving	  AmB	  (n=36).	  12	  variables	  were	  significantly	  correlated	  with	  fungal	  burden	  
[table	  5.14],	  these	  were	  used	  to	  create	  a	  PCA	  plot	  and	  heat	  map	  [Figures	  5.28,	  5.29].	  	  
	  	  
	   Analyte	   P	   Q	   R	   Analyte	   P	   Q	   R	  
PCA6	   CD14-­‐MM	  %CD45	  	   0.0017	   0.02	   0.50	   WCC/mL	   0.0044	   0.037	   -­‐0.46	  
	   	   	   	   lymph/ml	   0.0043	   0.037	   -­‐0.46	  
	   	   	   	   CD45+/ml	   0.0010	   0.017	   -­‐0.53	  
	   	   	   	   CD4+/ml	   0.0001	   0.003	   -­‐0.62	  
	   	   	   	   CD8+/ml	   0.0005	   0.010	   -­‐0.55	  
	   	   	   	   CD4-­‐CD8-­‐/ml	   0.0012	   0.017	   -­‐0.52	  
	   	   	   	   NK/ml	   0.0098	   0.075	   -­‐0.43	  
	   	   	   	   CD66	  MFI	   0.0141	   0.092	   -­‐0.41	  
	   	   	   	   	  G-­‐CSF	   0.0023	   0.025	   -­‐0.49	  
	   	   	   	   	  IL-­‐5	   0.0003	   0.009	   -­‐0.57	  
	   	   	   	   	  IL-­‐6	   0.0123	   0.087	   -­‐0.41	  
Table	   5.14	   	   Variables	   that	   correlated	   significantly	   with	   CSF	   fungal	   burden.	   Red	   shading	   (left)	   –
positive	   correlation;	   green	   shading	   (right)	   –	   negative	   correlation;	   also	   shown	   by	   Pearson’s	   R.	   All	  
variables	  ending	  with	  “/ml”	  are	  absolute	  counts.	  
Subjects	   clustered	   clearly	   by	   fungal	   burden.	   Individuals	   with	   high	   burden	   (red)	  
clustered	   at	   the	   bottom	   of	   the	   PCA	   plot	   while	   those	   with	   low	   burdens	   (green)	  
clustered	  near	  the	  top	  [Figure	  5.28a].	  A	  similar	  appearance	  was	  noted	  on	  the	  heat	  
map,	  those	  with	  high	  fungal	  burden	  clustering	  at	  the	  right	  side	  [Figure	  5.29].	  Analysis	  
of	  the	  variable	  plot	  showed	  that	  individuals	  with	  high	  fungal	  burden	  had	  significantly	  
fewer	   CSF	   CD4+	   T	   cells,	   CD8+	   T	   cells,	   CD4-­‐CD8-­‐	   T	   cells	   and	   NK	   cells,	   along	   with	  
reduced	  neutrophil	  CD66b	  expression	  (suggesting	  decreased	  activation),	  lower	  levels	  
of	  G-­‐CSF,	  IL-­‐5	  and	  IL-­‐6,	  and	  a	  greater	  relative	  frequency	  of	  CD14-­‐MM	  [Figure	  5.28b,	  
Table	   5.14].	   This	   is	   illustrated	   by	   the	   relationship	   between	  CSF	   fungal	   burden	   and	  
CSF	  CD4	  count	  at	  baseline	  [Figure	  5.30].	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Figure	  5.28	   	  PCA	  6	  –	  Relationship	  between	  CSF	   immune	  response	  and	   fungal	  burden.	  (a)	  PCA	  plot	  
illustrating	  clear	  differences	  in	  immune	  response	  between	  subjects	  with	  a	  high	  fungal	  burden	  (red	  ≈	  
106CFU/mL	  CSF)	  and	  low	  fungal	  burden	  (green	  ≈	  101CFU/mL	  CSF).	  Subjects	  with	  a	  high	  fungal	  burden	  
cluster	   together,	   further	   along	   the	   axis	   representing	   the	   1st	   principal	   component.	   (b)	   PCA	   plot	   of	  
variables	   significantly	   correlated	  with	   fungal	   burden,	   direction	  of	   correlation	   indicated	  by	   colour	   of	  
variable	  marker	  (red	  –	  positive	  correlation,	  green	  –	  negative	  correlation);	  closely	  correlated	  variables	  
cluster	  together	  on	  the	  plot.	  
	  
Figure	   5.29	   	  Heat	  map	   for	  PCA	  6.	  Hierarchal	   clustering	  according	   to	   the	  expression	  of	  12	  variables	  
found	   to	  be	   significantly	   correlated	  with	  HIV-­‐1	   viral	   load	   (listed	  on	   the	   right:	   red	   square	   increased,	  
green	  square	  decreased	  –	  see	  legend	  top	  left).	  Similar	  to	  the	  PCA	  plot	  above	  [figure	  5.28a],	  subjects	  
cluster	  by	  fungal	  burden:	  those	  with	  high	  fungal	  burden	  (red	  marking	  above	  heatmap)	  to	  the	  right	  of	  































Figure	  5.30	  	  Relationship	  between	  CSF	  fungal	  burden	  and	  CSF	  CD4	  count.	  Strong	  inverse	  correlation	  
demonstrated	   (Pearson’s	   R=-­‐0.689,	   p=0.0001).	   CSF	   fungal	   burden	   measured	   using	   quantitative	  
culture;	  CSF	  CD4	  count	  measured	  using	  flow	  cytometry.	  	  
The	  analysis	  was	  adjusted	   for	  HIV	  viral	   load	   (PCA	  7)	  and	  CD4	  count	   (PCA	  8)	   [Table	  
5.15].	   In	   contrast	   to	   the	   previous	   section,	   adjustment	   for	   HIV	   viral	   load	   led	   to	   an	  
increase	   in	   the	   number	   of	   significantly	   correlated	   variables.	   In	   addition	   to	   those	  
previously	  mentioned,	  subjects	  with	  high	  fungal	  burden	  also	  had	  significantly	  lower	  
CSF	  counts	  of	  CD14-­‐MM	  and	  CD14-­‐HLADR++	  cells,	  lower	  CSF	  concentrations	  of	  IFN-­‐γ	  
and	   VEGF,	   and	   increased	   frequency	   of	   CD163+CD14-­‐MM.	   The	   appearances	   of	   the	  
PCA	   plot	   were	   not	   significantly	   altered,	   with	   subjects	   still	   showing	   clustering	  
according	  to	  fungal	  burden	  [Appendix	  A,	   Figure	  A.1].	   In	  contrast,	  adjusting	  for	  CD4	  
count	  reduced	  the	  number	  of	  significantly	  associated	  variables	  to	  just	  2:	  numbers	  of	  
double	   negative	   T	   cells	   and	   IL-­‐5	   levels	   in	   the	   CSF.	   This	   resulted	   in	   decreased	  
clustering	  on	  PCA	  plot	  [appendix	  A,	  10.1.2,	  Figure	  A.2].	  In	  summary,	  individuals	  with	  
a	   high	   CSF	   fungal	   burden	   had	   significantly	   lower	   numbers	   of	   CD4,	   CD8,	   double	  
negative	  T	  cells,	  and	  NK	  cells	  in	  their	  CSF,	  and	  a	  reduced	  pro-­‐inflammatory	  cytokine	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   Analyte	   P	   Q	   R	   Analyte	   P	   Q	   R	  
PCA	  7	  
Adj	  VL	  
CD14-­‐	  %CD45	   0.002	   0.020	   0.50	   CSF	  WCC	   0.0019	   0.020	   -­‐0.51	  
CD163+	  %CD14-­‐	   0.018	   0.086	   0.41	   CSF_lymph	   0.0019	   0.020	   -­‐0.51	  
	   	   	   	   CD45/ml	   0.0002	   0.004	   -­‐0.60	  
	   	   	   	   CD4+/ml	   0.0000	   0.001	   -­‐0.65	  
	   	   	   	   CD8+/ml	   0.0000	   0.001	   -­‐0.65	  
	   	   	   	   CD4-­‐CD8-­‐/ml	   0.0001	   0.003	   -­‐0.62	  
	   	   	   	   Large	  T/ml	   0.0200	   0.094	   -­‐0.40	  
	   	   	   	   NK/ml	   0.0027	   0.021	   -­‐0.50	  
	   	   	   	   	   CD14-­‐/ml	   0.0100	   0.056	   -­‐0.44	  
	   	   	   	   	   CD14-­‐HLADR++/ml	   0.0106	   0.056	   -­‐0.43	  
	   	   	   	   	   CD66	  MFI	   0.0023	   0.020	   -­‐0.50	  
	   	   	   	   	   	  G-­‐CSF	   0.0012	   0.017	   -­‐0.53	  
	   	   	   	   	   	  IL-­‐5	   0.0003	   0.004	   -­‐0.59	  
	   	   	   	   	   	  IL-­‐6	   0.0097	   0.056	   -­‐0.44	  
	   	   	   	   	   	  IFN-­‐g	   0.0102	   0.056	   -­‐0.43	  
	   	   	   	   	   VEGF	   0.0101	   0.056	   -­‐0.44	  
PCA	  8	  
AdjCD4	  
	   	   	   	   CD4-­‐CD8-­‐/ml	   0.0022	   0.093	   -­‐0.51	  
	   	   	   	   	  IL-­‐5	   0.0006	   0.049	   -­‐0.56	  
Table	  5.15	  	  Variables	  that	  significantly	  correlated	  with	  CSF	  fungal	  burden	  following	  adjustment	  for	  
baseline	  viral	  load	  (PCA	  7),	  and	  CD4	  count	  (PCA	  8).	  	  
5.7.2 Decreased	  consciousness	  
As	   illustrated	   in	   chapter	   4,	   decreased	   consciousness	   is	   an	   important	   predictor	   of	  
poor	   outcome	   in	   CM.	   Participants	   with	   decreased	   consciousness	   at	   presentation	  
(GCS<15)	  were	  noted	  to	  have	  higher	  CSF	  concentrations	  of	  protein	  and	  GM-­‐CSF,	  and	  
lower	  frequency	  of	  CD14-­‐MM.	  However,	  these	  differences	  were	  not	  significant	  once	  
adjustment	  was	  made	  for	  multiple	  testing	  (q<0.1)	  [Table	  5.16,	  Figure	  5.31].	  	  
Analyte	   p-­‐value	   q-­‐value	   Analyte	   p-­‐value	   q-­‐value	  
Protein	   0.019	   0.943	   CD14-­‐	  %CD45	   0.036	   0.943	  
GM-­‐CSF	   0.034	   0.943	   	  	  
	   	  Table	  5.16	   	  Variables	   that	  differed	  between	  participants	  with	  altered	  or	  normal	   consciousness	   at	  
presentation.	   Altered	   consciousness	   defined	   as	   GCS<15.	   Red	   –	   increased	   if	   GCS<15;	   green	   –	  
decreased	  if	  GCS<15.	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Figure	   5.31	   	   Box	   plots	   showing	   variables	   that	   differed	   between	   subjects	   with	   altered	   or	   normal	  
consciousness	   at	   presentation.	   Altered	   consciousness	   defined	   as	   GCS<15	   (blue);	   GCS	   15	   (yellow).	  
Variables	  are	   log	   transformed	  and	  axis	   is	   standardized	   such	   that	  mean	  =	  0	  and	  variance	  =	  1.	  Boxes	  
show	  median	  with	  interquartile	  range.	  Whiskers	  set	  at	  1.5x	  the	  upper	  or	  lower	  box	  range	  respectively.	  
Outliers	  shown	  by	  points.	  
5.7.3 Raised	  intracranial	  pressure	  
Principal	   component	   analysis	   was	   also	   performed	   to	   examine	   the	   relationship	  
between	  baseline	   CSF	   immune	   response	   and	   the	   development	   of	   high	   intracranial	  
pressure	  (ICP)	  during	  hospitalization	  (CSF	  OP≥30cmH2O)	   (PCA	  9).	  12	  variables	  were	  
found	  to	  be	  significantly	  different	  (q<0.1)	  between	  subjects	  who	  developed	  and	  did	  
not	   develop	   high	   ICP	   [Table	   5.17].	   Individuals	   with	   high	   ICP	   had	   significantly	  
increased	   cryptococcal	   counts,	   increased	   cryptococcal	   size	   (crypto	   FSC),	   increased	  
frequency	   of	   “large”	   T	   cells	   and	   CD14-­‐MM	   in	   the	   CSF.	   They	   also	   had	   significantly	  
fewer	  CSF	  CD4	  T	  cells,	  double	  negative	  T	  cells	  and	  NK	  cells.	  These	  12	  variables	  were	  
used	   to	   construct	   a	   PCA	   plot	   and	   heat	   map,	   which	   showed	   marked	   clustering	   of	  
subjects	  with	  high	   ICP	   [Figures	   5.32,	   5.33].	  Adjusting	   the	  analysis	   for	  baseline	  CD4	  
count	  made	   very	   little	  difference	   to	   this	   (PCA	   10)	   [Table	   5.17;	  Appendix	  A,	   Figure	  
A.3].	  However,	  adjusting	  for	  baseline	  fungal	  burden	  (CFU)	  resulted	  in	  a	  reduction	  in	  
the	  number	  of	  variables	  and	  decreased	  clustering	  of	  subjects	  with	  high	  ICP	  (PCA	  11)	  
[Table	   5.17;	   Appendix	   A,	   Figure	   A.4].	   Despite	   this,	   increased	   cryptococcal	   count,	  
cryptococcal	  size	  and	  numbers	  of	  large	  T	  cells,	  along	  with	  decreased	  numbers	  of	  CSF	  
CD4	  T	  cells,	  all	  remained	  significantly	  associated	  with	  high	  ICP.	  	  


















Adjusted	   Analyte	   p-­‐value	   q-­‐value	   Analyte	   p-­‐value	   q-­‐value	  
PCA	  9	  
No	  adjust	  
Crypto	  %total	   0.0002	   0.001	   CD45+	  %total	   0.0002	   0.001	  
Crypto/ml	   0.0001	   0.001	   CSF	  WCC	   0.0079	   0.010	  
Crypto	  FSC	   0.0001	   0.001	   CSFlymph	   0.0079	   0.010	  
FSC	  crypto/CD4	   0.0060	   0.010	   CD4+/ml	   0.0011	   0.003	  
Large	  T	  %T	   0.0023	   0.005	   CD4-­‐CD8-­‐/ml	   0.0102	   0.012	  
CD14-­‐	  %CD45	   0.0127	   0.014	   NK/ml	   0.0172	   0.017	  
PCA	  10	  
CD4	  
Crypto	  %total	   0.0015	   0.006	   CD45+	  %total	   0.0022	   0.007	  
Crypto/ml	   0.0005	   0.004	   CSF	  WCC	   0.0395	   0.051	  
Crypto	  FSC	   0.0006	   0.004	   CSF_lymph	   0.0421	   0.051	  
FSC	  crypto/CD4	   0.0175	   0.030	   CD4+/ml	   0.0101	   0.020	  
Large	  T	  %T	   0.0038	   0.009	   CD4-­‐CD8-­‐/ml	   0.0420	   0.051	  
CD14-­‐	  %CD45	   0.0644	   0.070	   NK/ml	   0.0739	   0.074	  
PCA	  11	  
CFU	  
Crypto/ml	   0.0441	   0.116	   CD45+	  %total	   0.0485	   0.116	  
crypto	  FSC	   0.0327	   0.116	   CD4+/ml	   0.0342	   0.116	  
Large	  T	  %T	   0.0283	   0.116	   	   	   	  
Table	  5.17	   	  Variables	  that	  differ	  between	  participants	  with	  and	  without	  high	   ICP.	  Variables	  on	  the	  
left	  (red)	  are	  increased	  in	  participants	  with	  high	  ICP;	  those	  in	  the	  right	  (green)	  are	  decreased.	  Analyses	  
include	  unadjusted	  (PCA	  9),	  and	  adjusted	  for	  peripheral	  CD4	  count	  (PCA	  10)	  and	  CFU	  (PCA	  11).	  High	  
ICP	   is	   defined	   as	   CSF	  OP>30cmH2O.	   “%total”	   refers	   to	   the	   total	   CSF	   events	   (cells	   and	   cryptococci),	  
Crypto	  FSC	  refers	  to	  the	  forward	  scatter	  measurement	  of	  cryptococci	  –	  a	  measurement	  equivalent	  to	  
size.	  Crypto/CD4	  FSC	  is	  the	  ratio	  of	  cryptococcal	  size	  to	  that	  of	  CD4	  T	  cells.	  
	  
Figure	  5.32	  	  PCA	  9	  –	  Differences	  in	  CSF	  immune	  response	  between	  subjects	  who	  have	  high	  ICP	  and	  
those	   that	   do	   not.	   (a)	   Individuals	  with	   high	   ICP	   (blue)	   cluster	   together	   and	   broadly	   separate	   from	  
those	  who	   do	   not	   have	   high	   ICP	   (yellow).	   (b)	   Variables	   that	   significantly	   differed	   between	   the	   two	  
groups	  (red	  –	  increased	  in	  subjects	  with	  high	  ICP,	  green	  –	  decreased	  in	  subjects	  with	  high	  ICP).	  High	  



















Figure	  5.33	  	  Heat	  map	  for	  PCA	  9.	  Similar	  to	  the	  PCA	  plot	  [figure	  5.31],	  subjects	  with	  high	  ICP	  (blue),	  
cluster	  together	  at	  the	  right	  side	  of	  the	  plot	  according	  to	  the	  expression	  of	  12	  variables	  (right	  side:	  red	  
–	  increased,	  green	  –	  decreased).	  	  
In	  summary,	  individuals	  who	  developed	  significantly	  raised	  ICP	  during	  admission	  had	  
a	  greater	  fungal	  load	  and	  larger	  cryptococcal	  size,	  along	  with	  a	  paucity	  of	  CSF	  cellular	  
infiltrate,	  particularly	  CD4	  T	  cells.	  The	  first	  two	  of	  these	  variables	  are	  re-­‐emphasized	  
in	  Figures	  5.34	  and	  5.35.	  
	  















































Figure	  5.35	  	  Difference	  in	  cryptococcal	  size	  between	  individuals	  with	  and	  without	  high	  ICP	  during	  


































5.8.1 Microbiological	  outcome	  -­‐	  rate	  of	  CSF	  fungal	  clearance	  	  
The	   rate	   of	   clearance	   of	   cryptococci	   from	   the	   CSF	   is	   recognized	   as	   an	   important	  
surrogate	  marker	  of	  outcome	  in	  persons	  with	  cryptococcal	  meningitis	  (Bicanic	  et	  al.	  
2007).	  However,	  as	  discussed	  in	  chapter	  4,	  the	  data	  in	  this	  study	  is	  incomplete:	  EFAs	  
could	   only	   be	   calculated	   on	   47	   participants	   in	   the	   cohort	   and	   were	   subject	   to	   a	  
significant	   survival	  bias.	  With	   this	   caveat,	  baseline	  CSF	  variables	  were	  examined	   to	  
determine	   if	  any	  correlated	  significantly	  with	  EFA.	   Increased	  concentrations	  of	   IL-­‐7	  
and	  G-­‐CSF	  were	  observed	  among	  individuals	  with	  more	  rapid	  CSF	  clearance	  [Figure	  
5.36,	  5.37];	  however,	  these	  were	  not	  significant	  when	  adjusted	  for	  multiple	  testing	  
using	  a	  q-­‐value	  <0.1	  (q-­‐values	  0.8	  for	  both).	  	  	  
	  
	  
Figure	  5.36	   	  Relationship	  between	  EFA	  and	  baseline	  CSF	  G-­‐CSF	  concentration.	  EFA	  =	  early	  fungicial	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Figure	   5.37	   	   Relationship	   between	   EFA	   and	   baseline	   CSF	   IL-­‐7	   concentration.	   EFA	  =	   early	   fungicial	  
activity	  (rate	  of	  CSF	  clearance	  of	  cryptococci	  	  -­‐	  see	  section	  3.4.11	  for	  method),	  N=47	  
	  
5.8.2 Fatal	  outcome	  
To	  determine	  whether	  mortality	   in	  cryptococcal	  meningitis	  might	  be	  related	  to	  the	  
CSF	   immune	   response,	   the	   89	   variables	   measuring	   CSF	   immune	   response	   at	  
enrolment	  were	  compared	  between	  individuals	  who	  died	  or	  survived	  by	  day	  14	  and	  
by	  week	   12.	   No	   clear	   differences	  were	   noted	   in	   baseline	   immune	   response	  when	  
outcomes	   at	   day	   14	  were	   compared,	   but	   participants	  who	   died	   by	  week	   12	  were	  
noted	   to	   have	   reduced	   CSF	   concentrations	   of	   IFN-­‐γ	   and	   reduced	   frequencies	   of	  
double	  negative	  T	  cells	  (CD4-­‐CD8-­‐	  T	  cells,	  both	  as	  a	  proportion	  of	  CSF	  white	  cells	  and	  
CSF	  T	   cells)	   compared	   to	   subjects	  who	   survived.	  However,	  none	  of	   these	  variables	  
were	   significantly	   different	   when	   adjusted	   for	   multiple	   comparisons	   (all	   q-­‐values	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Figure	  5.38	  	  Differences	  in	  baseline	  CSF	  immune	  parameters	  between	  individuals	  who	  died	  and	  who	  
survived	  by	  week	  12	  of	  the	  study.	  Non-­‐survivors	  had	  lower	  frequency	  of	  CD4-­‐CD8-­‐	  T	  cells	  (DNT),	  both	  
as	   a	   proportion	   of	   all	   T	   cells	   and	   CSF	   white	   cells	   as	   a	   whole.	   Non-­‐survivors	   also	   had	   lower	   CSF	  
concentrations	  of	  IFN-­‐γ.	  However,	  differences	  were	  not	  significant	  using	  a	  q-­‐value	  <0.1	  to	  determine	  
statistical	  significance.	  Y-­‐axis	  is	  standardized	  scale,	  variables	  are	  log-­‐transformed	  and	  adjusted	  so	  that	  
mean	  equals	  0	  and	  variance	  =1.	  
	  
Despite	  this,	  a	  Cox	  proportional	  hazards	  model	  was	  created	  to	  examine	  whether	  any	  
components	  of	  the	  CSF	  immune	  response	  might	  improve	  on	  the	  predictive	  variables	  
identified	   in	   chapter	   4	   [section	   4.7].	   A	   univariate	   analysis	   was	   performed	   and	  
variables	   with	   a	   p-­‐value	   <0.2	   were	   carried	   forward	   into	   the	   multivariate	   model	  
[Table	  5.18].	  In	  the	  event	  of	  two	  very	  similar	  variables	  (e.g.	  DNT	  %T	  and	  DNT	  %WCC),	  
only	  one	  was	  taken	  forward	  to	  reduce	  problems	  with	  co-­‐linearity.	  A	  BASE	  model	  was	  
created	   using	   the	   variables	   “GCS<15”	   and	   “fungal	   burden”,	   these	   variables	   were	  
chosen	  based	  on	   the	   findings	   in	   chapter	   4	   [section	  4.7]	   and	   from	   larger	   published	  
cohorts	   (Jarvis	   et	   al	   2014).	   Variables	   identified	   from	   the	   univariate	   analysis	   were	  
individually	   added	   to	   the	   BASE	   model	   and	   their	   additional	   effect	   assessed	   by	  
comparing	  the	  two	  models	  with	  a	  likelihood-­‐ratio	  test	  (P<0.05).	  The	  only	  CSF	  variable	  
identified	   that	   did	   improve	   the	   predictive	   ability	   of	   the	   BASE	   model	   was	   the	  


























































	   UNIVARIATE	   MULTIVARIATE	  
HR	   P	   95%CI	   HR	   P	   95%CI	  
GCS<15	   4.29	   0.002	   1.87-­‐9.83	   3.43	   0.006	   1.29-­‐9.13	  
Fungal	  burden	  (log10CFU/ml)	   1.31	   0.058	   0.98-­‐1.76	   1.51	   0.008	   1.10-­‐2.09	  
Gaze	  palsy	   3.90	   0.011	   1.54-­‐9.89	   1.87	   0.286	   0.61-­‐5.79	  
Crypto/ml*	   1.18	   0.051	   0.99-­‐1.40	   1.14	   0.572	   0.72-­‐1.81	  
Crypto	  FSC*	   2.34	   0.125	   0.75-­‐7.35	   1.00	   0.917	   1.00-­‐1.00	  
CD14	  %CD45*	   1.34	   0.089	   0.95-­‐1.89	   1.31	   0.191	   0.87-­‐1.98	  
HLADR	  CD14	  (MFI)*	   0.52	   0.128	   0.22-­‐1.21	   0.48	   0.056	   0.22-­‐1.02	  
CD206	  CD14-­‐	  (MFI)*	   0.77	   0.220	   0.50-­‐1.19	   0.93	   0.771	   0.56-­‐1.53	  
HLADR	  CD14-­‐	  (MFI)*	   0.35	   0.066	   0.11-­‐1.10	   0.37	   0.097	   0.11-­‐1.22	  
HLADR++/ml*	   0.71	   0.016	   0.54-­‐0.94	   0.77	   0.103	   0.56-­‐1.05	  
HLADR	  CD14CD16	  (MFI)*	   0.49	   0.105	   0.21-­‐1.16	   0.42	   0.053	   0.18-­‐0.97	  
DNT	  %Tcells*	   0.46	   0.006	   0.28-­‐0.75	   0.87	   0.033	   0.77-­‐0.98	  
LargeT	  %Tcells*	   1.48	   0.025	   1.02-­‐2.16	   1.24	   0.315	   0.81-­‐1.89	  
LargeT/ml*	   1.13	   0.166	   0.95-­‐1.36	   1.18	   0.145	   0.94-­‐1.49	  
IL-­‐17*	   0.85	   0.074	   0.71-­‐1.02	   0.89	   0.216	   0.74-­‐1.07	  
IFNγ*	   0.82	   0.084	   0.67-­‐1.00	   1.04	   0.711	   0.83-­‐1.31	  
CD163*	   1.57	   0.051	   0.98-­‐2.52	   1.34	   0.206	   0.84-­‐2.14	  
CD14*	   2.24	   0.048	   0.97-­‐5.20	   1.99	   0.136	   0.78-­‐5.09	  
Table	  5.18	   	  Cox	  proportional	  hazards	  model	  examining	  components	  of	  CSF	   immune	  response	  that	  
predict	  fatal	  outcome	  from	  CM	  over	  24	  weeks.	  89	  variables	  were	  initially	  examined	  using	  a	  univariate	  
Cox	  regression	  analysis,	  18	  with	  P<0.2	  are	  included	  in	  the	  table	  above.	  All	  continuous	  variables	  are	  log	  
transformed	   to	   reduce	   skewing	   (*).	   Multivariate	   analysis	   was	   performed	   as	   described	   in	   the	   text.	  
Variables	   that	   remained	   significantly	  associated	  with	   fatal	  outcome	  are	  marked	  with	  a	  box.	  Altered	  
consciousness	  was	  defined	  as	  GCS<15;	  fungal	  burden	  was	  measured	  using	  quantitative	  culture	  (log10	  
CFU/ml).	  FSC	  =	  forward	  scatter	  (measurement	  of	  size);	  MFI	  =	  median	  fluorescence	  intensity;	  HLADR++	  




5.9 Immune	  reconstitution	  inflammatory	  syndrome	  (IRIS)	  
Finally,	  attempts	  were	  made	  to	  characterize	  both	  the	  baseline	  CSF	  immune	  response	  
predisposing	   to	   paradoxical	   IRIS,	   and	   the	   CSF	   immune	   response	   at	   the	   time	   of	  
paradoxical	   IRIS.	   Given	   the	   low	   numbers	   of	   subjects	   who	   developed	   this	  
complication	  in	  the	  cohort,	  this	  analysis	  should	  be	  considered	  exploratory	  only.	  
5.9.1 Susceptibility	  to	  IRIS	  
To	  determine	  whether	  a	  particular	  immune	  response	  during	  CM	  might	  predispose	  to	  
future	  paradoxical	   IRIS,	  baseline	  CSF	   immune	  parameters	  were	  compared	  between	  
individuals	  who	   developed	   IRIS	   after	   ART	   initiation	   and	   those	  who	   didn’t.	   Analysis	  
was	   restricted	   to	  28	   individuals	  who	   initiated	  ART	  during	   the	   study	  or	   switched	   to	  
second	  line	  from	  a	  failing	  regimen.	  Of	  these	  individuals,	  4	  developed	  a	  neurological	  
deterioration	  following	  ART	  initiation	  that	  met	  INSHI	  criteria	  for	  paradoxical	  IRIS	  (as	  
judged	  by	  members	  of	  the	  study	  team)	  (Haddow	  et	  al.	  2010).	  Seven	  variables	  were	  
identified	   that	   differed	   between	   these	   two	   groups	   [Table	   5.19].	   Individuals	   who	  
developed	   paradoxical	   IRIS	   during	   the	   study	   had	   increased	   baseline	   frequency	   of	  
large	  T	  cells	  and	  decreased	   frequency	  of	  CD4	  T	  cells	   in	   their	  CSF,	  along	  with	   lower	  
concentrations	  of	  VEGF,	  IL-­‐4,	  IL-­‐6,	  IFN-­‐α	  and	  MIP-­‐1β/CCL4.	  However,	  none	  of	  these	  
differences	   remained	   significant	   when	   adjusted	   for	   multiple	   testing	   (all	   q-­‐values	  
were	  greater	  than	  0.1).	  These	  seven	  variables	  were	  used	  to	  construct	  a	  PCA	  plot	  and	  
heat	  map	  (PCA	  12);	  subjects	  that	  developed	  paradoxical	  IRIS	  following	  ART	  initiation	  
were	  noted	  to	  cluster	  together	  [Figures	  5.39,	  5.40].	  	  
Analyte	   P	   Q	   R	   Analyte	   P	   Q	   R	  
Large	  T	  %T	   0.0326	   0.449	   0.40	   CD4+	  %CD45	   0.0380	   0.449	   -­‐0.39	  
	   	   	   	   VEGF	   0.0409	   0.449	   -­‐0.39	  
	   	   	   	   	  IL-­‐4	   0.0437	   0.449	   -­‐0.38	  
	   	   	   	   	  IL-­‐6	   0.0207	   0.449	   -­‐0.44	  
	   	   	   	   IFNα	   0.0242	   0.449	   -­‐0.42	  
	   	   	   	   MIP-­‐1β	   0.0499	   0.449	   -­‐0.37	  
Table	   5.19	   	   PCA	   12	   –	   CSF	   baseline	   variables	   that	   differed	   between	   individuals	   starting	   ART	  who	  
developed	  paradoxical	  IRIS	  and	  those	  who	  did	  not.	  Variables	  on	  the	  left	  (red	  shading)	  were	  higher	  at	  
baseline	  among	  persons	  who	  subsequently	  developed	   IRIS,	  while	   those	  on	  the	  right	   (shaded	  green)	  
were	   lower.	  Analysis	  was	  restricted	  to	  28	   individuals	  who	  either	  started	  ART	  or	  switched	  to	  2nd	   line	  
ART	   from	  a	   failing	   regimen.	  Diagnosis	   of	   paradoxical	   IRIS	  was	  made	  by	   study	   team	  based	  on	   INSHI	  
criteria	  (Haddow	  et	  al.	  2010).	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Figure	   5.39	   	  PCA	  12	   –	  Differences	   in	   baseline	   CSF	   immune	   response	  between	   individuals	   starting	  
ART	   who	   developed	   paradoxical	   IRIS	   (blue)	   and	   those	   who	   did	   not	   (yellow).	   (a)	   PCA	   plot	   shows	  
clustering	  of	  subjects	  who	  subsequently	  developed	   IRIS.	   (b)	  7	  variables	   found	  to	  differ	  between	  the	  
two	  groups	  and	  their	  weighting	  on	  the	  first	  three	  principal	  components	  (red	  –	  increased	  at	  baseline	  in	  
subjects	  who	  developed	  IRIS;	  green	  –	  decreased	  at	  baseline	  in	  subjects	  who	  developed	  IRIS).	  	  	  
	  
Figure	   5.40	   	   Heat	   map	   for	   PCA	   12.	   Similar	   to	   Figure	   5.38,	   subjects	   who	   subsequently	   developed	  
paradoxical	  IRIS	  (blue	  above)	  clustered	  at	  the	  right	  end	  of	  the	  plot,	  according	  to	  differing	  expression	  
of	  7	  variables	  (red	  –	  higher	  baseline	  levels,	  green	  –	  lower	  baseline	  levels).	  	  	  
5.9.2 The	  immune	  phenotype	  of	  cryptococcal	  IRIS	  
To	  better	  understand	  the	  immune	  phenotype	  of	  cryptococcal	  IRIS,	  the	  CSF	  immune	  
response	  was	  examined	  at	  the	  time	  of	  IRIS	  in	  four	  individuals	  (3	  from	  IICD	  cohort,	  1	  
enrolled	   separately).	   This	   was	   compared	   against	   the	   CSF	   immune	   response	   in	   a	  
variety	   of	   other	   scenarios	   where	   subjects	   in	   the	   study	   had	   an	   LP	   performed:	  
individuals	   at	   baseline	   with	   CM	   who	   were	   not	   taking	   ART	   (CM-­‐no	   ART;	   n=43);	  


















taking	  ART	  who	  developed	  cryptococcal	  relapse	  (CM-­‐relapse;	  n=3);	  individuals	  from	  
the	  cohort	  who	  had	  a	  LP	  after	  the	  initiation	  of	  ART	  but	  after	  clinical	  evaluation	  were	  
determined	   not	   to	   have	   any	   new	   serious	   CNS	   pathology	   (NAD;	   n=3).	   Summary	  
statistics	  for	  the	  five	  conditions	  are	  detailed	  in	  Table	  5.20.	  Groups	  were	  significantly	  
different	  terms	  of	  fungal	  burden	  and	  CD4	  count.	  
	  
	   CM-­‐no	  ART	   CM-­‐ART	   CM-­‐IRIS	   NAD	   CM-­‐relapse	   p	  
n	   43	   8	   4	   3	   3	   	  
CD4	  
	  
29	  (12-­‐67)	   65	  (45-­‐85)	   89	  (38-­‐172)	   97	  (56-­‐535)	   71	  (27-­‐328)	   0.03	  
Weeks	  ART	  
	  
0	   8	  (6-­‐12)	   9	  (5-­‐12)	   8	  (2-­‐8)	   11	  (8-­‐40)	   	  
CFU/ml	  log10	  
	  
4.7	  (3.5-­‐5.5)	   4.0	  (3.1-­‐6.1)	   0	   0	   4.7	  (3.5-­‐5.7)	   <0.01	  







































































































Table	   5.20	   –	   Summary	   characteristics	   of	   the	   different	   clinical	   groups	   undergoing	   LP	   during	   the	  
study.	  “CM	  No	  ART“	  =	  subjects	  with	  cryptococcal	  meningitis	  not	  taking	  ART;	  “CM-­‐ART”	  =	  subjects	  with	  
CM	  who	  are	  taking	  ART	  at	  baseline;	  “CM-­‐IRIS”	  –	  subjects	  at	  the	  time	  of	  paradoxical	  IRIS;	  “CM-­‐relapse”	  
=	  cryptococcal	  relapse;	  “NAD”	  –	  no	  abnormality	  detected/no	  significant	  new	  CNS	  pathology.	  P-­‐values	  
refer	  to	  Kruskall-­‐Wallis	  tests;	  p-­‐values	  ≤0.05	  are	  shaded;	  no	  post-­‐hoc	  testing	  was	  performed.	  
The	  CSF	  immune	  response	  at	  the	  time	  of	  paradoxical	  CM-­‐IRIS	  was	  first	  compared	  to	  
that	   of	   persons	   at	   baseline	   with	   CM	  who	   were	   not	   taking	   ART	   (CM-­‐no	   ART),	   this	  
included	  the	  baseline	  CSF	  of	  three	  of	  the	  four	  IRIS	  cases	  (PCA	  13).	  Six	  variables	  were	  
significantly	  different	  between	  these	  two	  groups	  (q<0.1)	  [Table	  5.21].	  Subjects	  with	  
CM-­‐IRIS	  were	  found	  to	  have	  a	  significantly	  higher	  CD4/CD8	  ratio,	  higher	  frequency	  of	  
CSF	  CD4	  T	   cells,	   lower	   frequency	  of	  CD8	  T	   cells,	   lower	  HLA-­‐DR	  expression	  on	  CD4-­‐
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CD8-­‐	  T	  cells,	  and	  lower	  CSF	  concentrations	  of	  MIP-­‐1β/CCL4.	  These	  six	  variables	  were	  
used	  to	  generate	  PCA	  plots.	  Subjects	  with	  paradoxical	  IRIS	  could	  be	  clearly	  separated	  
from	  those	  with	  CM-­‐no	  ART	  according	  to	  CSF	  immune	  response	  [Figure	  5.41].	  	  
	  
	  
Figure	   5.41	   	   PCA	   13	   –	   Differences	   in	   CSF	   immune	   response	   between	   participants	   at	   the	   time	   of	  
cryptococcal	   IRIS,	   and	   participants	   at	   baseline	  with	   cryptococcal	  meningitis	   (not	   taking	   ART).	   (a)	  
PCA	  plot	  showing	  distribution	  of	  subjects	  according	  to	  CSF	   immune	  response,	  subjects	  with	   IRIS	  are	  
clearly	  separated	  from	  individuals	  with	  CM-­‐no	  ART.	  (b)	  PCA	  variable	  plot	  illustrating	  the	  weighting	  of	  
the	  six	  differing	  variables	  on	  principal	  components	  1-­‐3.	  Variables	  marked	  in	  red	  are	  higher	  in	  persons	  
with	  IRIS,	  while	  those	  in	  green	  are	  lower	  in	  persons	  with	  IRIS;	  further	  details	  below	  [Table	  5.21].	  
Analyte	   p-­‐value	   q-­‐value	   Analyte	   p-­‐value	   q-­‐value	  
CD4/CD8	  ratio	   0.0001	   0.003	   HLADR+	  %CD4-­‐CD8-­‐	   0.0024	   0.035	  
CD4+	  %T	   0.0002	   0.005	   MIP-­‐1β/CCL4	   0.0017	   0.030	  
CD4+	  %CD45	   0.0007	   0.015	   CD8+	  %T	   0.0000	   0.000	  
Table	   5.21	   	   Variables	   from	   PCA	   13	   that	   differed	   significantly	   between	   CM-­‐IRIS	   and	   CM-­‐no	   ART.	  
Variables	  on	  the	  left	  (red	  shading)	  were	  increased	  in	  participants	  at	  the	  time	  of	  IRIS,	  those	  on	  the	  right	  
(green	  shading)	  were	  decreased	  [Figure	  5.41].	  
Finally,	  ANOVA	  was	  used	  to	  compare	  the	  CSF	  immune	  response	  between	  all	  five	  sub-­‐
groups	  described	  above	  [Table	  5.20].	  36	  variables	  were	   identified	  that	  significantly	  
differed	   between	   these	   groups	   (q-­‐value	   <0.1).	   These	   36	   variables	   were	   used	   to	  







Figure	  5.42	   	  PCA	  14	   -­‐	  Difference	   in	  CSF	   immune	  response	  according	   to	  clinical	  group.	   (a)	  PCA	  plot	  
illustrating	  differences	  between	   the	  5	   clinical	   groups	  according	   to	  CSF	   immune	   response	   (see	  Table	  
5.20	   for	   details)	   (b)	   Bar	   plots	   illustrating	   the	   variable	   weighting	   towards	   the	   first	   three	   principal	  









Figure	  5.43	   	  Heat	  map	  for	  PCA	  14.	  Similar	  to	  the	  PCA	  plot	  above	  [Figure	  5.42],	  individuals	  with	  CM-­‐
IRIS,	  CM-­‐ART	  and	  CM-­‐relapse	  all	  clustered	  together	  at	  the	  right	  of	  the	  plot.	  
Participants	   clustered	  according	   to	   clinical	   phenotype.	  Persons	  with	  CM	  not	   taking	  
ART	  (CM-­‐no	  ART,	  yellow)	  clustered	  near	  the	  centre	  of	  the	  plot	   [Figure	  5.42];	   those	  
taking	  ART	  but	  with	  no	  serious	  CNS	  pathology	  (NAD,	  turquoise)	  were	  situated	  at	  the	  
bottom	  with	  negative	  scores	  for	  principal	  component	  1	  (PC1)	  [Figure	  5.42];	  persons	  
with	  IRIS	  (CM-­‐IRIS,	  red),	  cryptococcal	  relapse	  (CM-­‐relapse,	  green),	  or	  with	  CM	  taking	  
ART	   at	   baseline	   (CM-­‐ART,	   blue),	   all	   clustered	   together	   in	   the	  direction	  of	   principal	  
component	  2	   (PC2)	   [Figure	   5.42].	   	  When	   the	  principal	   components	  were	  analysed,	  
the	   main	   variables	   that	   contributed	   to	   PC1	   were	   pro-­‐inflammatory	   cytokines	   and	  
neutrophil	   count	   –	   representing	   inflammation	   within	   the	   CSF.	   The	   main	   variables	  
contributing	  to	  PC2,	  were	  increased	  frequency	  of	  CD4	  T	  cells,	  decreased	  frequency	  of	  
CD8	   T	   cells,	   and	   increased	   macrophage	   expression	   of	   CD206	   –	   representing	   the	  
effects	   of	   ART	   (as	   demonstrated	   earlier	   in	   this	   chapter	   [section	   5.6.2]).	   	   Similar	  
clustering	  was	  noted	  on	  the	  heat	  map,	  with	  CM-­‐IRIS	  cases	  clustering	  to	  the	  right	  with	  
the	  other	  groups	  taking	  ART	  (CM-­‐ART,	  CM-­‐relapse	  and	  NAD)	  [Figure	  5.43].	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5.10 Discussion	  
In	   this	   chapter,	   data	   are	   presented	   concerning	   the	   CSF	   immune	   response	   in	  
individuals	  with	  HIV-­‐associated	  cryptococcal	  meningitis.	  In	  line	  with	  the	  aims	  stated	  
in	  chapter	  2,	  the	  immune	  response	  (including	  the	  activation	  state	  of	  CSF	  monocyte-­‐
macrophages)	   was	   characterized	   using	   flow	   cytometry	   and	   a	   variety	   of	   soluble	  
biomarkers.	  In	  addition,	  the	  effects	  of	  ART	  were	  studied	  and	  the	  immune	  correlates	  
of	  severe	  disease	  and	  poor	  clinical	  outcome	  were	  sought.	  	  
5.10.1 	  CSF	  flow	  cytometry	  
Although	   not	   frequently	   reported	   in	   the	   past,	   analysis	   of	   CSF	   cells	   using	   flow	  
cytometry	   is	  an	   increasingly	  popular	  technique.	   It	  has	  been	  used	  to	   investigate	  the	  
pathogenesis	  of	  neurological	  inflammatory	  disorders	  (such	  as	  multiple	  sclerosis)	  and	  
in	   the	   diagnosis	   of	   meningeal	   or	   central	   nervous	   system	   malignancy	   (especially	  
haematological	  malignancies)	  (Alvermann	  et	  al.	  2014;	  Kowarik	  et	  al.	  2014;	  Kleine	  et	  
al.	  1999;	  Han	  et	  al.	  2014;	  Illán	  et	  al.	  2014;	  Mitri	  et	  al.	  2014).	  There	  is	  one	  published	  
study	  to	  date	  where	  CSF	  flow	  cytometry	  was	  used	  to	  investigate	  subjects	  with	  CM-­‐
IRIS,	  it	  is	  discussed	  later	  in	  this	  chapter	  (Chang,	  Omarjee,	  et	  al.	  2013b).	  Despite	  initial	  
concerns	   regarding	   technical	   aspects,	   flow	   cytometry	   proved	   an	   effective	   and	  
reliable	   technique	   to	   characterize	   CSF	   cellular	   immune	   response.	   Sufficient	   cells	  
were	   obtained	   by	   centrifuging	   the	   large	   amounts	   of	   CSF	   drained	   for	   therapeutic	  
reasons.	  Maintaining	  CSF	  on	  ice	  immediately	  after	  LP	  and	  staining	  cells	  fresh	  –	  rather	  
than	  freezing	  to	  stain	  later	  –	  ensured	  viability	  remained	  high.	  	  
5.10.2 Identification	  of	  cryptococci	  
Initial	  pilot	  work	  identified	  a	  large	  population	  of	  cells	  in	  the	  CSF	  that	  did	  not	  express	  
the	  leukocyte	  marker	  CD45.	  Further	  analysis	  suggested	  these	  cells	  to	  be	  cryptococci,	  
given	  their	  large	  size	  (similar	  or	  larger	  than	  leukocytes)	  and	  relative	  abundance	  in	  the	  
CSF	  (often	  more	  frequent	  than	  leukocytes).	  This	  conclusion	  is	  supported	  by	  the	  very	  
close	  correlation	  between	  counts	  of	  CD45-­‐	  cells	   (as	  performed	  by	   flow	  cytometry),	  
and	  quantitative	  culture.	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Cryptococcal	   counts	   obtained	   from	   flow	   cytometry	   in	   this	   study	   are	   similar	   to	  
manual	  counts	  performed	  using	  microscopy	  reported	  in	  the	  literature.	  In	  a	  cohort	  of	  
98	  HIV-­‐infected	   individuals	   from	  Brazil	  with	  CM,	   the	   reported	  median	  cryptococcal	  
count	  was	  71	  yeasts/µL	  CSF	  (IQR	  3-­‐512)	  (Vidal	  et	  al.	  2012).	  Although	  the	  authors	  did	  
not	   report	   the	   ratio	   of	   cryptococci	   to	   leukocytes,	   they	   are	   of	   equal	   or	   possibly	  
greater	   magnitude	   to	   median	   CSF	   leukocyte	   counts	   reported	   from	   other	   cohorts	  
(median	  15	  cells/µl	  (IQR	  1-­‐57))	  (Jarvis	  et	  al.	  2014).	  In	  the	  IICD	  cohort,	  median	  counts	  
using	  flow	  cytometry	  were	  37	  yeasts/µl	  (IQR	  2-­‐160)	  and	  27	  leukocytes/µl	  (IQR	  8-­‐70).	  	  
	  
Given	   the	   inherent	   delays	   involved	   in	   obtaining	   quantitative	   culture	   results,	   flow	  
cytometry	  could	  potentially	  provide	  a	  fast,	  accurate,	  same	  day,	  method	  to	  measure	  
baseline	   cryptococcal	   burden	   in	   individuals	   with	   CM.	   Although	   in	   this	   format	   it	   is	  
unlikely	   to	   be	   a	   practical	   test	   in	   clinical	   practice,	   it	   could	   be	   utilized	   by	   research	  
studies,	   particularly	   as	   smaller	   flow	   cytometers	   become	   available.	   This	   approach	  
would	   be	   particularly	   useful	   if	   it	   could	   be	   combined	   with	   a	   cryptococcal	   viability	  
marker	  to	  differentiate	  live	  and	  dead	  cryptococci.	  	  
5.10.3 Cellular	  composition	  of	  CSF	  infiltrate	  	  
Following	  exclusion	  of	  cryptococci,	  it	  was	  possible	  to	  identify	  a	  variety	  of	  cell	  types	  in	  
the	   CSF	   including	   T	   cells,	   monocyte-­‐macrophages,	   and	   neutrophils.	   Although	  
significant	   variation	   was	   noted	   between	   individuals,	   CD8	   T	   cells	   were	   the	  
predominant	   cell	   type	   making	   up	   approximately	   half	   of	   all	   CSF	   cells,	   followed	   by	  
neutrophils,	  CD4	  T	  cells	  and	  monocyte-­‐macrophages.	  These	  findings	  are	  in	  contrast	  
to	  reports	  of	  CSF	  cell	  populations	  in	  healthy	  individuals,	  where	  CD4	  T	  cells	  are	  more	  
abundant,	   but	   broadly	   similar	   to	   other	   studies	   of	   asymptomatic	   HIV-­‐infected	  
individuals	  in	  the	  USA	  (median	  CD4>	  200)	  where	  a	  predominance	  of	  CD8	  T	  cells	  was	  
also	  reported	  (De	  Graaf	  et	  al.	  2011;	  Ho	  et	  al.	  2013).	  However,	  absolute	  cell	  counts	  in	  
the	  studies	  from	  the	  asymptomatic	  US	  cohorts	  were	  approximately	  5-­‐10	  fold	  lower	  
than	   counts	   reported	   in	   this	   cohort	   with	   cryptococcal	  meningitis,	   and	   neutrophils	  
were	  an	  uncommon	  finding	  in	  those	  studies.	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In	  addition	  to	  CD4+	  and	  CD8+	  T	  cell	  subsets,	  double	  negative	  and	  double	  positive	  T	  
cells	   were	   also	   seen	   (CD4-­‐CD8-­‐	   and	   CD4+CD8+	   respectively),	   the	   former	   being	   far	  
more	  frequent.	  NK	  cells	  were	   identified	   indirectly	  as	  non-­‐T	   lymphocytes	  expressing	  
CD16	   (after	   the	   exclusion	   of	   neutrophils	   and	  monocyte-­‐macrophages).	   Although	   a	  
reasonable	  approximation	  given	  the	  constraints	  of	  the	  antibody	  panel,	  this	  has	  to	  be	  
interpreted	   with	   some	   caution	   in	   the	   absence	   of	   CD56	   staining	   and	   may	  
underestimate	  NK	  cell	  numbers,	  as	  some	  CD56	  bright	  NK	  cells	  do	  not	  express	  CD16	  
(De	  Maria	  et	  al.	  2011).	  	  
	  
The	  double	  negative	  T	  cells	  (CD4-­‐CD8-­‐)	  are	  likely	  to	  be	  a	  mixture	  of	  γδ	  T	  cells	  and/or	  
invariant	  NK	  T	  cells,	  but	  further	  identification	  was	  also	  not	  possible.	  γδ	  T	  cells	  possess	  
a	  range	  of	  pattern	  recognition	  receptors	  and	  are	  considered	  a	  bridge	  between	  innate	  
and	   adaptive	   immunity	   (Martin	   et	   al.	   2009).	   They	   have	   been	   implicated	   in	   the	  
pathology	   of	   a	   number	   of	   autoimmune	   conditions	   and	   increased	   numbers	   are	  
reported	  in	  the	  CSF	  of	  patients	  with	  relapsing-­‐remitting	  multiple	  sclerosis	  (Schirmer	  
et	   al.	   2013).	   They	   are	   also	   reported	   in	   the	  CSF	  of	   children	  with	  mumps	  meningitis	  
(Bertotto	  et	  al.	  1995).	  Double	  positive	  T	  cells	  are	  occasionally	  described	  in	  blood,	  skin	  
and	  joints	  of	  individuals	  with	  auto-­‐immune	  disease	  and	  have	  also	  been	  reported	  to	  
be	   increased	   in	   individuals	  with	  HIV-­‐1	  and	  other	   viral	   infections	   (Parel	  &	  Chizzolini	  
2004;	  Chauhan	  et	  al.	  2012;	  Nascimbeni	  2004).	  Studies	  of	  multiple	  sclerosis	  have	  also	  
reported	  the	  presence	  of	  these	  cells	  the	  CSF	  (Waschbisch	  et	  al.	  2014).	  	  
	  
A	  peculiar	  phenomenon	  noticed	  in	  some	  subjects	  was	  the	  development	  of	  a	  sub-­‐set	  
of	   CD8	   T	   cells	   with	   a	   significantly	   increased	   forward	   and	   side	   scatter,	   indicating	  
increased	   size	   and	  granularity,	   referred	   to	   as	   “Large	  T	   cells”	   in	   this	   chapter.	   These	  
cells	   are	   most	   likely	   to	   be	   proliferating	   CD8	   T	   cells,	   due	   to	   either	   HIV-­‐1	   or	  
cryptococcal	   infection	  (Rathmell	  et	  al.	  2003).	  However,	   further	  study	   is	   required	  to	  
better	  characterize	  this	  cell	  sub-­‐set.	  	  
	  
In	  addition	  to	  the	  monocyte-­‐macrophage	  populations	  identified	  by	  expression	  of	  the	  
surface	  receptor	  CD14,	  a	  secondary	  population	  of	  cells	  was	  identified,	  also	  thought	  
to	   be	   monocyte-­‐macrophages	   (CD14-­‐MM).	   These	   cells	   were	   identified	   following	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exclusion	   of	   T	   cells,	   neutrophils	   and	   CD14+	   MM,	   and	   were	   CD4+CD3-­‐	   with	   high	  
expression	  of	  HLA-­‐DR.	  They	  had	  similar	  physical	  characteristics	  to	  CD14+	  monocyte-­‐
macrophages,	   similar	   CD68	   expression,	   and	   exhibited	   variable	   expression	   of	   the	  
macrophage	   activation	   markers	   CD206	   and	   CD163.	   	   In	   the	   literature,	   there	   are	   a	  
number	  of	  CD4+CD3-­‐	  cell	  populations	  described,	  including	  varieties	  of	  innate	  T	  cells	  
and	  dendritic-­‐like	  cells	  found	  mainly	  in	  lymphoid	  tissue	  (Bekiaris	  et	  al.	  2013;	  Lane	  et	  
al.	  2005).	  Whilst	  it	  is	  possible	  the	  cells	  identified	  in	  this	  study	  may	  also	  be	  dendritic	  in	  
origin,	   given	   the	   expression	   of	   the	   above	   markers,	   it	   seems	   more	   likely	   they	   are	  
monocytes	  or	  macrophages.	  Macrophage	  expression	  of	  CD4	   is	  well	  described,	  as	   is	  
the	  down-­‐regulation	  of	  CD14	  during	  their	  maturation	  from	  monocytes	  (Daigneault	  et	  
al.	   2010;	   Kazazi	   et	   al.	   1989).	   Further	   study	   is	   required	   to	   fully	   characterize	   this	  
subset.	  	  
5.10.4 Monocyte-­‐macrophages	  and	  their	  activation	  status	  
Expression	   of	   activation	   markers	   on	   the	   surface	   of	   CSF	   MM	   was	   not	   mutually	  
exclusive	  and	  co-­‐expression	  was	  common,	  particularly	  on	  CD14+MM.	  Furthermore,	  
it	  was	  noted	  that	  surface	  markers	  thought	  to	  indicate	  differing	  activation	  states	  were	  
often	  positively	  correlated.	  Although	  this	  finding	  is	  in	  contrast	  to	  the	  original	  dogma	  
regarding	   macrophage	   activation,	   it	   is	   in	   keeping	   with	   more	   recent	   thinking,	   that	  
activation	  of	  these	  cells	  should	  not	  be	  considered	  as	  dichotomous	  state	  but	  more	  a	  
diverse	   spectrum	   of	   responses	   (Gordon	   2003;	   Mosser	   &	   Edwards	   2008).	   This	   is	  
illustrated	   by	   recent	   studies	   of	   human	   tissue	   macrophages	   that	   express	   markers	  
both	  of	  classical	  and	  alternative	  activation	  (Helm	  et	  al.	  2014;	  Vogel	  et	  al.	  2013).	  	  
	  
Research	   published	   after	   the	   design	   of	   this	   study	   has	   examined	   the	   correlation	  
between	   gene	   and	   surface	   marker	   expression	   on	   human	   monocyte	   derived	  
macrophages	   polarized	   in-­‐vitro	   towards	   an	  M1	   or	  M2	   phenotype	   (incubation	  with	  
IFNγ,	   IL-­‐4	   and	   IL-­‐10	   for	   M1,	   M2	   and	   immune	   modulatory	   M2	   phenotypes	  
respectively)	  (Ambarus	  et	  al.	  2012).	  This	  showed	  that	  CD206	  was	  a	  good	  marker	  of	  
the	  M2	  alternatively	   activated	  phenotype	   (along	  with	  CD200)	   and	  CD163	  was	   also	  
shown	   to	   be	   a	   good	  marker	   of	   the	   immune	  modulatory	  M2	  phenotype.	  However,	  
rather	  than	  being	  associated	  with	  the	  M1	  classically	  activated	  phenotype	  CD16	  was	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found	   to	  be	  preferentially	   up-­‐regulated	   in	   the	  M2	   immune	  modulatory	  phenotype	  
(along	   with	   CD32),	   while	   HLA-­‐DR	   was	   highly	   expressed	   on	   both	   M1	   classically	  
activated	   and	  M2	   alternatively	   activated	  macrophages	   (as	   observed	   in	   this	   study).	  
CD64	   and	   CD80	   were	   both	   noted	   to	   be	   good	   markers	   for	   identification	   of	   M1	  
macrophages	  (Ambarus	  et	  al.	  2012).	  	  
5.10.5 Effect	  of	  ART	  on	  CSF	  immune	  response	  
The	  main	  effect	  of	  ART	  on	  CSF	  immune	  response	  was	  to	  alter	  the	  balance	  between	  
CD4	   and	   CD8	   T	   cells.	   Individuals	   with	   CM	   who	   were	   taking	   effective	   ART	   had	  
significantly	  increased	  CD4	  T	  cells	  and	  decreased	  CD8	  T	  cells	  (as	  a	  proportion	  of	  the	  
total	  CSF	  cellular	   infiltrate)	  compared	  to	  individuals	  not	  taking	  ART.	   	  These	  changes	  
appeared	  to	  be	  mainly	  due	  to	  a	  reduction	  in	  the	  numbers	  of	  CD8	  T	  cells	  rather	  than	  
an	  increase	  in	  CD4	  T	  cells.	  	  
	  
These	   findings	   are	   consistent	   with	   the	   well-­‐documented	   effects	   of	   ART	   on	   the	  
CD4/CD8	   balance	   in	   the	   blood	   (Battegay	   et	   al.	   2006)	   and	   also	  with	   recent	   studies	  
examining	  CSF	   cells	   among	   individuals	  with	  HIV-­‐1	   infection	   in	   the	  US	   (Leung	   et	   al.	  
2013;	  Ho	   et	   al.	   2013).	   Similar	   to	   findings	   presented	  here,	   those	   taking	  ART	  with	   a	  
suppressed	  viral	   load	  had	  significantly	   reduced	  CSF	  CD8	  counts,	  and	  an	   increase	   in	  
the	   CSF	   CD4/CD8	   ratio	   compared	   to	   those	   who	   were	   not	   taking	   ART.	   A	   greater	  
magnitude	  of	  change	   in	   the	  CD4/CD8	  ratio	  was	  also	  noted	   in	   the	  CSF	  compared	  to	  
the	   blood	   (Ho	   et	   al.	   2013).	   However,	   none	   of	   these	   individuals	   in	   the	   studies	  
mentioned	   above	   had	   a	   neurological	   opportunistic	   infection	   and	   the	  median	   CD4	  
count	  in	  all	  sub-­‐groups	  was	  >200/µL.	  The	  study	  presented	  here	  examines	  the	  effects	  
of	   ART	   on	   the	   CSF	   immune	   response	   during	   an	   opportunistic	   infection,	   a	   scenario	  
that	   has	   sparked	   much	   interest	   among	   researchers	   concerned	   with	   the	  
pathophysiology	   of	   IRIS.	   It	   is	   of	   anecdotal	   interest	   that	   the	   one	   individual	   in	   the	  
cohort	  who	  met	  clinical	  criteria	  for	  the	  diagnosis	  of	  unmasking-­‐IRIS	  had	  the	  highest	  
CSF	  CD4/CD8	  ratio	  of	  the	  cohort,	  and	  was	  seen	  clearly	  at	  the	  most	  extreme	  point	  on	  
the	  PCA	  plot	  [subject	  16,	  Figure	  5.17	  –	  see	  section	  4.4.3	  for	  clinical	  details].	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In	  addition	  to	  effects	  on	  the	  CD4/CD8	  ratio,	  effective	  ART	  was	  also	  associated	  with	  a	  
decrease	   in	   HLA-­‐DR	   expression	   on	   CD4	   T	   cells	   and	   a	   decrease	   in	   the	   relative	  
frequency	  of	   large	  T	  cells.	  This	   is	  consistent	  with	  an	  ART	   induced	  reduction	  of	  HIV-­‐
induced	   immune	   activation	   (Nakanjako	   et	   al.	   2011).	   With	   regard	   to	   monocyte-­‐
macrophage	   activation,	   persons	   taking	   effective	   ART	   had	   a	   significantly	   higher	  
expression	   of	   CD206	   on	   both	   CD14+	   and	   CD14-­‐	   MM	   (suggesting	   increased	  
alternative	  activation)	  and	  an	  increase	  in	  CD16	  expression	  on	  CD14-­‐MM.	  
	  
Increased	  numbers	  of	  CD16+	  monocytes	  have	  been	  previously	  reported	  in	  the	  CSF	  of	  
neurologically	   asymptomatic	  HIV-­‐infected	   individuals	   taking	  ART,	   particularly	   those	  
taking	  protease	   inhibitor	   (PI)	  based	   therapy	   (Neuenburg	  et	  al.	  2005).	  PI-­‐based	  ART	  
was	  uncommon	   in	   the	   IICD	  cohort	   (only	  one	  subject	  was	   taking	  at	  enrolment)	  and	  
exclusion	  of	  this	  person	  did	  not	  alter	  the	  results.	  Instead,	  the	  effects	  of	  ART	  on	  CSF	  
immune	  response	  in	  the	  IICD	  cohort	  were	  closely	  related	  to	  differences	  in	  HIV-­‐1	  viral	  
load.	  	  
	  
Given	   the	   clear	   interaction	   between	   ART	   and	   decreases	   in	   HIV-­‐1	   viral	   load,	   it	   is	  
difficult	  to	  examine	  their	  separate	  effects	  on	  CSF	  immune	  response.	  However,	  given	  
that	  changes	  in	  relative	  frequency	  of	  T	  cell	  subtypes	  were	  mainly	  driven	  by	  absolute	  
changes	   in	   CD8	   T	   cells	   as	   well	   as	   reduction	   of	   parameters	   associated	   with	   T	   cell	  
activation,	   it	   seems	   reasonable	   to	   conclude	   that	   ART	   influenced	   CSF	   immune	  
response	   in	   a	   large	   part	   through	   changes	   in	   in	   HIV-­‐1	   viral	   load.	   This	   is	   further	  
supported	   by	   the	   finding	   that	   HIV-­‐1	   viral	   load	   was	   negatively	   correlated	   with	  
CD14+MM	  expression	  of	  CD206,	  even	  among	  individuals	  not	  taking	  ART.	  	  
	  
These	  data	  suggest	  that	  CSF	  macrophages	  are	  driven	  towards	  classical	  activation	  by	  
ongoing	  HIV-­‐1	  replication	  and	  adopt	  a	  more	  alternatively	  activated	  phenotype	  when	  
viral	  load	  decreases.	  This	  is	  the	  opposite	  to	  the	  hypothesis	  presented	  in	  chapter	  2	  of	  
this	   thesis	   and	   contrary	   to	   review	   papers	   suggesting	   that	   as	   HIV-­‐1	   progresses,	  
macrophage	   activation	   moves	   from	   classical	   activation,	   through	   alternative	  
activation,	  to	  deactivation	  (Herbein	  &	  Varin	  2010).	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5.10.6 Relationship	  between	  CSF	  immune	  response	  and	  fungal	  burden	  	  
Increasing	   CSF	   fungal	   burden	  was	   clearly	   correlated	  with	   a	   paucity	   of	   CSF	   cellular	  
immune	  response.	  Individuals	  with	  high	  fungal	  burden	  had	  low	  numbers	  of	  NK,	  CD4,	  
CD8	  and	  double	  negative	  T	  cells	  in	  their	  CSF,	  along	  with	  decreased	  concentrations	  of	  
the	   IL-­‐5,	   IL-­‐6	   and	   G-­‐CSF.	   As	   previously	   discussed,	   a	   CSF	   cellular	   infiltrate	   and	   pro-­‐
inflammatory	   response	   was	   strongly	   associated	   with	   higher	   blood	   CD4	   counts,	  
adjustment	   for	  which	   removed	   the	   significance	   of	   the	  majority	   of	   variables	   in	   the	  
analysis.	   However,	   even	   following	   adjustment	   for	   peripheral	   CD4	   count,	   the	   CSF	  
counts	  of	  double	  negative	  T	  cells	  remained	  inversely	  correlated	  with	  fungal	  burden,	  
suggesting	  they	  may	  have	  an	  additional	  protective	  role.	  	  
	  
Previous	   studies	   have	   also	   reported	   an	   association	   between	   increased	   CSF	   fungal	  
burden	   and	   lack	   of	   immune	   response.	   A	   study	   conducted	   in	   Thailand	   reported	   an	  
increased	   fungal	   burden	   among	   individuals	   with	   low	   IL-­‐6,	   IFNγ	   and	   TNFα	  
concentrations	  in	  the	  CSF	  (Siddiqui	  et	  al.	  2005).	  Furthermore,	  studies	  in	  South	  Africa	  
showed	  that	  a	  peripheral	  blood	  antigen	  specific	  CD4	  T	  cells	  response	  characterized	  
by	  IFNγ	  and/or	  TNFα	  production	  was	  associated	  with	  increasing	  CSF	  cell	  counts	  and	  
lower	  fungal	  burden	  (Jarvis	  et	  al.	  2013).	  
5.10.7 Raised	  intracranial	  pressure	  
The	   relationship	   between	   peripheral	   CD4	   count,	   CSF	   cellular	   infiltrate	   and	   fungal	  
burden	   also	   appears	   important	   in	   the	   pathophysiology	   of	   CM-­‐associated	   raised	  
intracranial	   pressure.	   Individuals	   with	   high	   intracranial	   pressure	   (CSF	   opening	  
pressure	   >30cmH2O)	   were	   found	   to	   have	   significantly	   increased	   CSF	   cryptococcal	  
counts,	   increased	   size	  of	   cryptococci	  and	   significantly	  decreased	  CSF	  T	   cells	   counts	  
(CD4,	  CD8	  and	  double	  negative	  T	   cells).	   In	   contrast,	  persons	  with	  CSF	  OP	   that	  was	  
not	  high	  (<30cmH2O)	  had	  significantly	  lower	  cryptococcal	  counts,	  smaller	  cryptococci	  
and	  greater	  CSF	  cellular	   infiltrate.	  Adjusting	  for	  peripheral	  blood	  CD4	  count	  did	  not	  
significantly	  affect	   this	  analysis	  but	  adjusting	   for	   fungal	  burden	  did.	  However,	  even	  
following	   this,	   raised	   intracranial	   pressure	   remained	   significantly	   associated	   with	  
increased	  cryptococcal	  size,	  higher	  cryptococcal	  counts,	  and	  a	  lack	  of	  CSF	  CD4	  T	  cells.	  
There	   was	   little	   evidence	   to	   suggest	   that	   high	   ICP	   occurred	   as	   a	   result	   of	   a	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pathological	   inflammatory	   response.	   The	   only	   CSF	   immune	   factor	   that	   was	  
consistently	  raised	  among	  persons	  with	  high	  ICP	  was	  increased	  frequency	  of	  large	  T	  
cells	  in	  the	  CSF;	  further	  studies	  to	  better	  define	  these	  cells	  are	  warranted.	  	  
	  
In	   summary,	   these	   findings	   suggest	   that	   raised	   intracranial	   pressure	   in	   CM	   occurs	  
among	   individuals	   who	   have	   a	   state	   of	   profound	   immune	   deficiency,	   with	  
paucicellular	  CSF	  response,	  a	  high	  cryptococcal	  fungal	  burden	  and	  large	  cryptococcal	  
capsular	   size.	   These	   findings	   are	   consistent	   with	   previous	   studies	   that	   have	  
demonstrated	  similar	  associations	  between	  raised	  CSF	  opening	  pressure	  and	  greater	  
CSF	   fungal	   load	   (as	   measured	   by	   quantitative	   culture),	   and	   larger	   cryptococcal	  
capsular	  size,	  measured	  ex	  vivo	  using	  microscopy	  (Bicanic	  et	  al.	  2009a;	  Robertson	  et	  
al.	  2014).	  They	  provide	  further	  support	  to	  the	  theory	  that	  in	  CM,	  raised	  intracranial	  
pressure	  occurs	  due	  to	  obstruction	  of	  CSF	  drainage	  by	  the	  overwhelming	  organism	  
load	  (Loyse	  et	  al.	  2010).	  	  
5.10.8 Impaired	  consciousness	  	  
Although	   persons	   with	   impaired	   consciousness	   had	   increased	   concentrations	   of	  
protein	   and	   GM-­‐CSF	   in	   their	   CSF,	   along	   with	   decreased	   frequency	   of	   CD14-­‐MM,	  
these	   differences	   were	   not	   significant	   when	   adjusted	   for	   multiple	   comparisons.	  
Furthermore,	   no	   clear	   relationship	   was	   demonstrated	   between	   impaired	  
consciousness	   and	   raised	   intracranial	   pressure	   or	   fungal	   load.	   This	   is	   similar	   to	  
findings	  from	  a	  large	  multi-­‐centre	  cohort	  study	  where	  no	  significant	  association	  was	  
demonstrated	  between	  decreased	  consciousness	  and	  fungal	  burden,	  peripheral	  CD4	  
count	   or	   CSF	   cell	   count.	   In	   that	   study,	   altered	   consciousness	   was	   more	   common	  
among	  male	  patients	  and	  occurred	  more	  often	   in	   those	  with	  very	  high	   intracranial	  
pressure	   (ICP>30),	  but	  very	  high	   ICP	  did	  not	  appear	  contributory	   in	   the	  majority	  of	  
cases	  (Jarvis	  et	  al.	  2014).	  	  
5.10.9 Rate	  of	  fungal	  clearance	  
The	   rate	   of	   fungal	   clearance	   from	   the	   CSF	   was	   found	   to	   be	   correlated	   with	   CSF	  
concentrations	  of	  G-­‐CSF	  and	   IL-­‐7.	  G-­‐CSF	   is	  produced	  by	  a	  variety	  of	  cells	   (including	  
monocytes	   and	   macrophages)	   and	   stimulates	   the	   production	   and	   activation	   of	  
polymorphonuclear	   leukocytes	   (Page	  &	  Liles	  2008);	   in	  contrast,	   IL-­‐7	   is	  produced	  by	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cells	   in	   the	  bone	  marrow	  and	   thymus	  and	  acts	   to	   stimulated	   the	  proliferation	  and	  
maturation	   of	   T	   and	   B	   lymphocytes	   (Fry	   2002).	   Although	   not	   significant	   when	  
adjusted	   for	  multiple	   testing	   (q>0.1),	   this	   finding	   is	   consistent	  with	   the	   previously	  
mentioned	  study	  from	  Thailand,	  where	  rate	  of	  fungal	  clearance	  was	  also	  significantly	  
associated	  with	  the	  concentration	  of	  pro-­‐inflammatory	  cytokines	  (G-­‐CSF,	  IFN-­‐γ,	  TNF-­‐
α	  and	  IL-­‐6)	  (Siddiqui	  et	  al.	  2005).	  However,	  given	  the	  problems	  with	  incomplete	  data	  
and	   a	   strong	   survival	   bias	   for	   EFA	  measurement	   in	   the	   IICD	   cohort,	   these	   findings	  
should	  be	  interpreted	  with	  caution.	  
5.10.10 Mortality	  
Fatal	  outcome	  at	  week	  12	  was	  associated	  with	  significantly	  lower	  frequencies	  of	  CSF	  
double	  negative	  T	  cells	  and	  concentrations	  of	   IFN-­‐γ.	  Although	  these	  variables	  were	  
only	  significant	  using	  a	  cut-­‐off	  of	  p<0.05	  (rather	  than	  q<0.1),	  the	  frequency	  of	  double	  
negative	   T	   cells	   was	   found	   to	   be	   significantly	   associated	   with	   mortality	   in	   a	   Cox	  
regression	  (p<0.05)	  when	  adjusted	  for	  altered	  conscious	  level	  and	  fungal	  burden	  at	  
baseline.	  These	   findings	  are	   compatible	  with	  previous	   studies	   showing	   significantly	  
slower	   fungal	   clearance	   and	   reduced	   survival	   in	   individuals	   with	   lower	   CSF	   IFN-­‐γ	  
concentrations	  (Siddiqui	  et	  al.	  2005).	  Double	  negative	  T	  cells	  (likely	  comprising	  γδ	  T	  
cells	  and	   iNKT	  cells)	  are	  known	  to	  be	  significant	  producers	  of	   IFN-­‐γ	   and	  have	  been	  
reported	  in	  the	  lungs	  of	  mice	  infected	  with	  C.	  neoformans	  (Olson	  et	  al.	  2009;	  Cowley	  
et	   al.	   2010;	   Gao	   et	   al.	   2003;	   Uezu	   et	   al.	   2004).	   The	   results	   of	   experiments	   using	  
murine	  models	   of	   cryptococcosis,	   suggest	   that	   γδ	   T	   cells	   and	   iNKT	   cells	  may	   have	  
differing	  roles;	  while	  deletion	  of	  iNKT	  cells	  resulted	  in	  decreased	  Th1	  T	  cell	  responses	  
and	  decreased	  clearance	  of	  infection,	  deletion	  of	  γδ	  T	  cells	  resulted	  in	  increased	  Th1	  
responses	   and	   increased	   clearance	   of	   infection	   (Kawakami	   et	   al.	   2001;	  Uezu	   et	   al.	  
2004;	  Kawakami	  2004).	  This	   suggests	   that	   iNKT	  cells	  may	  have	  a	  pro-­‐inflammatory	  
role	  in	  the	  murine	  model	  of	  cryptococcosis,	  augmenting	  the	  host	  response,	  whilst	  γδ	  
T	   cells	  may	   have	   a	   regulatory	   role.	  However,	   the	   respective	   roles	   of	   these	   cells	   in	  
human	  immunity	  to	  cryptococcus	  are	  not	  established.	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5.10.11 Risk	  of	  Future	  IRIS	  
When	   the	   subjects	   who	   started	   ART	   (or	   switched	   to	   an	   active	   regimen)	   were	  
analysed,	   the	   risk	   of	   developing	   IRIS	   appeared	   to	   be	   associated	   with	   a	   particular	  
baseline	  CSF	  immune	  response.	  This	  comprised	  of	  a	  significantly	  increased	  frequency	  
of	  large	  T	  cells	  in	  the	  CSF,	  decreased	  frequency	  of	  CSF	  CD4	  cells,	  and	  lower	  levels	  of	  
IFNα,	  IL-­‐6,	  IL-­‐4,	  VEGF	  and	  MIP-­‐1β/CCL4.	  Although	  these	  findings	  were	  not	  significant	  
when	   adjusted	   for	   multiple	   corrections,	   subjects	   who	   went	   on	   to	   develop	   IRIS	  
following	   ART	   initiation	   did	   cluster	   together	   on	   heat	   map	   and	   PCA	   plot.	   These	  
findings	   are	   broadly	   in	   keeping	   with	   previous	   studies	   of	   cryptococcal	   IRIS	   from	  
Uganda	  that	  showed	  a	  link	  between	  a	  paucity	  of	  baseline	  CSF	  inflammatory	  response	  
and	  future	  IRIS	  risk	  (Boulware,	  Bonham,	  et	  al.	  2010a).	  	  
5.10.12 Immune	  phenotype	  of	  IRIS	  	  
Finally,	  to	  better	  characterize	  the	  phenotype	  of	  CM-­‐IRIS,	  the	  CSF	  immune	  response	  
in	   individuals	   who	   developed	   paradoxical	   CM-­‐IRIS	   following	   ART	   initiation,	   was	  
compared	   against	   a	   number	   of	   different	   control	   groups	  within	   the	   cohort	   (CM-­‐no	  
ART,	  CM-­‐ART,	  CM-­‐relapse	  (on	  ART)	  and	  no	  additional	  abnormality	  (on	  ART).	  
	  
When	   compared	   to	   individuals	   on	   ART	   who	   had	   no	   new	   neurological	   diagnosis,	  
participants	   with	   CM-­‐IRIS	   had	   evidence	   of	   increased	   CSF	   inflammation	   with	  
increased	  concentrations	  of	  CSF	  cytokines	  and	  increased	  CSF	  cellular	  infiltrate.	  This	  is	  
consistent	   with	   previous	   studies	   of	   CM-­‐IRIS,	   which	   have	   demonstrated	   increased	  
serum	  concentrations	  of	  IL-­‐2,	  IL-­‐6,	  IL-­‐8,	  IFN-­‐γ,	  G-­‐CSF,	  GM-­‐CSF	  and	  VEGF	  compared	  to	  
time-­‐matched	  controls,	  and	  studies	  of	  TB-­‐IRIS,	  in	  which	  serum	  concentrations	  of	  IL-­‐6,	  
IFN-­‐γ,	  and	  TNF-­‐α	  were	  also	  increased	  compared	  to	  time-­‐matched	  controls	  (Boulware,	  
Meya,	   et	   al.	   2010b;	   Tadokera	   et	   al.	   2011).	   In	   contrast,	   when	   the	   CSF	   immune	  
response	   in	   individuals	   with	   CM-­‐IRIS	   was	   compared	   to	   persons	   with	   cryptococcal	  
meningitis	   not	   taking	   ART,	   no	   difference	   in	   absolute	   CSF	   cell	   counts	   or	   cytokine	  
concentrations	   were	   evident.	   Instead,	   individuals	   with	   CM-­‐IRIS	   had	   increased	  
frequency	   of	   CD4	   T	   cells	   and	   decreased	   frequency	   of	   CD8	   T	   cells,	   along	   with	  
increased	  CD206	  expression	  on	  CSF	  MM,	  reflecting	  the	  effects	  of	  ART	  as	  previously	  
discussed.	   It	   is	   interesting	   to	  note	   that	   the	   cryptococcal	   count	  was	  not	   statistically	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different	  between	  these	  two	  groups,	  despite	  the	  participants	  with	  CM-­‐IRIS	  having	  a	  
negative	  fungal	  culture	  and	  those	  with	  CM	  having	  an	  active	  infection.	  This	  suggests	  
that	   individuals	  with	   CM-­‐IRIS	   still	   had	   a	   significant	   number	   of	   dead	   cryptococci	   in	  
their	   CSF.	   When	   analyzed	   together	   in	   a	   PCA	   plot,	   individuals	   at	   the	   time	   of	  
paradoxical	   cryptococcal	   IRIS	   did	   not	   appear	   to	   have	   a	   CSF	   immune	   response	   that	  
was	   substantially	   different	   to	   individuals	   with	   cryptococcal	   relapse	   and	   those	  
presenting	  with	  cryptococcal	  meningitis	  while	   taking	  ART.	  This	   is	   supportive	  of	   the	  
theory	   that	   CM-­‐IRIS	   occurs	   due	   to	   a	   persistence	   of	   cryptococcal	   antigen	   in	   the	  
context	   of	   increasing	   CD4	   cells,	   rather	   than	   a	   dysregulated	   immune	   response	  
(Boulware,	   Bonham,	   et	   al.	   2010a;	   Chang,	  Dorasamy,	   et	   al.	   2013a).	  However,	   given	  
the	   low	   numbers	   in	   this	   study,	   this	   data	   should	   be	   considered	   exploratory	   and	  
further	  research	  is	  required.	  	  
5.10.13 Limitations	  
This	  chapter	  provides	  a	  number	  of	  novel	   insights	   into	  the	  CSF	   immune	  response	   in	  
HIV-­‐associated	   cryptococcal	   meningitis.	   However,	   there	   were	   a	   number	   of	  
limitations	  to	  this	  work.	  
	  
The	   cohort	   was	   relatively	   small	   and	   participants	   exhibited	   a	   significant	   degree	   of	  
heterogeneity,	  particularly	  with	  regard	  to	  ART	  status.	  Although	  examining	  the	  effects	  
of	  taking	  ART	  at	  baseline	  was	  a	  specific	  aim	  of	  the	  study,	  the	  consequences	  of	  this	  
were	  a	  reduction	  in	  the	  number	  of	  subjects	  who	  were	  ART-­‐naïve/not	  taking	  ART	  and	  
as	  such	  the	  study	  was	  significantly	  underpowered	  to	  examine	  complications	  of	  ART	  
initiation	   such	   as	   paradoxical	   IRIS.	   Further	   studies	   are	   required,	   utilizing	   the	  
techniques	   developed	   here,	   to	   better	   characterize	   this	   important	   and	   poorly	  
understood	  complication.	  	  
	  
A	   further	   limitation	  was	   the	   significant	   proportion	   of	   subjects	   in	  whom	   it	  was	   not	  
possible	  to	  calculate	  the	  rate	  of	  CSF	  fungal	  clearance	  –	  a	  secondary	  end	  point	  for	  the	  
study.	   	   This	   was	   because	   lumbar	   punctures	   were	   only	   performed	   for	   clinical	  
indications,	  and	  not	  always	  by	  members	  of	  the	  study	  team.	  The	  assessment	  of	  fungal	  
clearance	  was	  also	  significantly	  affected	  by	  the	  high	  numbers	  of	  early	  deaths.	  Many	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of	   the	   participants	  who	  died	  whilst	   in	   hospital	   did	   not	   have	   a	   second	  quantitative	  
culture	  performed,	  and	  as	  such	  fungal	  clearance	  rates	  were	  not	  calculated	  leading	  to	  
survival	  bias.	  	  
	  
There	  were	  also	  a	  number	  of	  technical	   limitations	  to	  consider.	  Flow	  cytometry	  was	  
performed	   in	   real	   time,	  which	   led	   to	  both	  pros	  and	  cons.	  Although	   it	   removed	  the	  
effects	   of	   freezing	   on	   cell	   activation	   state	   (a	   major	   concern	   when	   assessing	  
macrophages	   and	   monocytes	   (Tippet	   et	   al,	   2011),	   it	   also	   meant	   that	   no	   repeat	  
measurements	  could	  be	  made	  if	  a	  technical	  problem	  arose	  on	  the	  first	  run	  (i.e.	  poor	  
staining	  of	  one	  fluorochrome)	  and	  occasionally	  this	  resulted	   in	  missing	  data.	   It	  also	  
meant	  that	  the	  acquisition	  of	  samples	  on	  the	  flow	  cytometer	  was	  made	  over	  a	  15-­‐
month	  period,	  raising	  the	  possibility	  that	  sample	  data	  could	  be	  vulnerable	  to	  changes	  
in	  the	  flow	  cytometer	  set	  up	  over	  time.	  To	  minimize	  this,	  application	  settings	  were	  
saved	   at	   the	   beginning	   of	   the	   study,	   and	   applied	   to	   each	   subsequent	   experiment.	  
During	   this	   period	   the	   machine	   was	   maintained	   optimally	   with	   regular	   quality	  
control.	  
	  
Ideally,	   the	   assessment	   of	   CSF	   immune	   response	   in	   CM	   would	   have	   been	   more	  
informative	   if	  there	  had	  been	  a	  comparison	  with	  CSF	  from	  healthy	  control	  subjects	  
and	  from	  HIV-­‐infected	  persons	  with	  no	  evidence	  of	  CNS	  pathology.	  However,	  there	  
are	  significant	  ethical	  issues	  around	  performing	  a	  lumbar	  puncture	  when	  there	  is	  no	  
clinical	   indication.	   It	   may	   have	   been	   possible	   to	   obtain	   such	   control	   samples	   by	  
examining	  all	  CSF	  being	  submitted	   to	   the	  hospital	   laboratory	   for	   investigation,	  and	  
later	   determining	   in	   whom	   there	   was	   no	   evidence	   of	   CNS	   pathology	   (e.g.	   benign	  
headache).	  However,	  it	  is	  unlikely	  that	  this	  method	  would	  have	  resulted	  in	  sufficient	  
CSF	  volume	  and	  cellular	  infiltrate	  to	  perform	  high	  quality	  flow	  cytometry	  analysis.	  	  
	  
Finally,	  methods	  to	  assess	  monocyte	  and	  macrophage	  activation	  were	  limited	  to	  the	  
assessment	  of	  surface	  markers	  by	  flow	  cytometry.	  Although	  some	  of	  these	  markers	  
do	   have	   good	   evidence	   base	   behind	   their	   use,	   further	   functional	   assays	  may	   have	  
been	  more	   informative.	   This	   approach	  was	   not	   adopted	  due	   to	   concerns	   over	   the	  
number	  of	  cells	  that	  could	  be	  obtained	  from	  CSF	  but	  this	  may	  be	  an	  option	  for	  future	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research.	  However,	  given	  that	  macrophage	  activation	  exhibits	  a	  degree	  of	  plasticity	  
and	  is	  strongly	  influenced	  by	  a	  variety	  of	  environmental	  factors,	  any	  technique	  that	  
involves	  prolonged	  ex	  vivo	  cell	  culture	  may	  result	  in	  findings	  that	  do	  not	  reflect	  the	  
pathological	  processes	  in	  vivo.	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CHAPTER	  6: HOST	  IMMUNE	  RESPONSE	  IN	  BLOOD	  
This	  chapter	  examines	  the	  blood	  immune	  response	  in	  individuals	  with	  HIV-­‐associated	  
cryptococcal	  meningitis.	   Cellular	   and	   soluble	   aspects	   of	   the	   immune	   response	   are	  
assessed	   using	   a	   number	   of	   techniques.	   Particular	   emphasis	   is	   given	   to	  monocyte	  
populations,	   their	   activation	   state	   and	   functional	   responses;	   information	   on	   T	   cell	  
populations	   is	   included	   but	   subsets	   were	   not	   examined	   in	   detail.	   In	   addition	   to	  
characterizing	   the	   monocyte	   phenotype,	   the	   effects	   of	   ART	   are	   assessed	   and	   the	  
relationship	   between	   blood	   immune	   response	   and	   CSF	   fungal	   burden	   examined.	  




6.1.1 Examination	  of	  peripheral	  blood	  using	  flow	  cytometry	  
The	  cellular	  composition	  of	  peripheral	  blood	  was	  assessed	  using	  flow	  cytometry;	  the	  
full	  staining	  protocol	  is	  detailed	  in	  chapter	  3	  [section	  3.4.3].	  All	  flow	  cytometry	  was	  
performed	   on	   fresh	   whole	   blood	   due	   to	   concerns	   about	   the	   effect	   of	   sample	  
processing	  on	  monocyte	  activation	  (Tippett	  et	  al.	  2011).	  Monocytes	  were	  identified	  
using	   CD14	   and	   HLA-­‐DR	   expression	   after	   gating-­‐out	   doublets,	   debris,	   antibody	  
aggregates,	  neutrophils,	  T	  cells	  and	  B	  cells	  [Figure	  6.1,	  6.2].	  	  
	  
Figure	  6.1	  Blood	  gating	  strategy	  1	   -­‐	   initial	  gating	  and	  “cleaning”	  of	  cells.	  (a)	  time	  gate	  was	  used	  to	  
remove	   any	   debris	   at	   the	   end	   of	   acquisition;	   (b)	   doublets	   were	   excluded;	   (c)	   &	   (d)	   antibody	  
aggregates	   removed	   (not	   evident	   in	   this	   example);	   (e)	   cellular	   debris	   removed;	   (f)	   resulting	   cells,	  
ready	  for	  analysis.	  
Monocytes	   were	   then	   categorized	   into	   classical	   (CD14++CD16-­‐),	   intermediate	  
(CD14++CD16+)	  and	  non-­‐classical	  (CD14-­‐CD16++)	  monocytes	  as	  previously	  described	  
[Figure	  6.2]	  (Ziegler-­‐Heitbrock	  et	  al.	  2010).	  Note	  was	  made	  of	  the	  overall	  frequency	  
of	  monocytes	  and	  monocyte	  subsets	  along	  with	  the	  expression	  of	  surface	  activation	  
markers	  HLA-­‐DR,	  CD163,	  CCR2,	  CCR5,	  CD11c	  and	  TLR4	  (measured	  in	  terms	  of	  median	  
fluorescent	  intensity)	  [Figure	  6.3].	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Figure	  6.2	   	  Blood	  gating	  strategy	  2	  -­‐	   identification	  of	  cell	  types.	  (a)	  Cells	  separated	  into	  neutrophils	  
and	  non-­‐neutrophils	  on	  basis	  of	  physical	  characterisitics;	  (b)	  neutrophils	  more	  accurately	  identified	  by	  
removing	   remaining	   CD14+	   monocytes;	   (c)	   CD16-­‐	   (apoptotic)	   neutrophils	   identified;	   (d)	   non-­‐
neutrophils	   split	   into	   T	   cells	   (CD3+)	   and	   non	   T	   cells	   (CD3-­‐);	   (e)	  monocytes	   broadly	   identified	   using	  
CD14+;	  (f)	  monocytes	  purified	  by	  removal	  of	  any	  remaining	  B	  cells;	  (g)	  monocytes	  purified	  by	  removal	  
of	  cells	  that	  are	  not	  CD14+	  or	  HLA-­‐DR+;	  (h)	  purified	  monocytes.	  	  
	  
	  
Figure	  6.3	  	  Blood	  gating	  strategy	  3	  -­‐	  monocyte	  subtypes	  and	  activation.	  (a)	  Monocytes	  are	  split	  into	  
classical	  (CD14++CD16-­‐)	  [red],	  intermediate	  (CD14++CD16+)	  [blue],	  and	  non-­‐classical	  (CD14+CD16++)	  
[green]	  subtypes	  (gates	  drawn	  using	  FMO);	  (b)	  histogram	  showing	  expression	  of	  HLA-­‐DR	  on	  the	  three	  
monocyte	  subsets;	  (c)	  histogram	  showing	  expression	  of	  CD163	  on	  the	  three	  monocyte	  subsets.	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T	   cell	   subsets	   were	   identified	   by	   surface	   expression	   of	   CD3,	   CD4	   and	   CD8;	   their	  
activation	  status	  was	  assessed	  through	  surface	  expression	  of	  HLA-­‐DR,	  CD38	  and	  PD-­‐1	  
(measured	  both	  in	  terms	  MFI	  and	  %	  of	  cells	  expressing	  the	  surface	  marker)	  [Figure	  
6.4].	  Gates	  were	  drawn	  using	  data	  from	  fluorescence	  minus	  one	  (FMO)	  experiments	  
(Herzenberg	  et	  al.	  2006).	  
	  
Figure	   6.4	   Blood	   gating	   strategy	   4	   -­‐	   T	   cell	   subsets	   and	   activation.	   (a)	   T	   cells	   and	   non-­‐T	   cells	  
differentiated	   by	   expression	   of	   CD3;	   (b)	   CD4/CD8	   T	   cell	   subsets;	   (c-­‐e)	   HLA-­‐DR,	   CD38	   and	   PD-­‐1	  
expression	  on	  CD4	  T	  cells;	  (f-­‐h)	  HLA-­‐DR,	  CD38	  and	  PD-­‐1	  expression	  on	  double	  negative	  (CD4-­‐CD8-­‐)	  T	  
cells;	  (i-­‐k)	  HLA-­‐DR,	  CD38	  and	  PD-­‐1	  expression	  on	  CD8	  T	  cells.	  NB	  Gating	  drawn	  using	  FMO.	  	  
IICD30 D0 bld1 redo Layout: T cells
1/8/14 18:29 Page 1 of 1 (FlowJo v9.5.3)









































































































































































































































6.1.2 Monocyte	  cytokine	  responses	  	  
Monocyte	   production	   of	   IL-­‐6,	   TNFα,	   IL-­‐10	   and	   IL-­‐12	   were	   assessed	   using	   flow	  
cytometry	   following	   fresh	   whole	   blood	   incubation	   with	   R848	   (imidazoquinoline	  
compound,	   TLR-­‐7/8	   agonist),	   LPS	   (lipopolysaccharide,	   TLR-­‐4	   agnoist),	   GXM	  
(glucuronoxylomannan)	   and	   CW	   (heat	   killed	   and	   mechanically	   disrupted	   C.	  
neoformans)	   [section	   3.4.6].	   After	   removal	   of	   doublets,	   debris	   and	   antibody	  
aggregates,	  a	  “dump	  channel”	  was	  used	  to	  exclude	  T	  cells	  (CD3),	  B	  cells	  (CD19)	  and	  
neutrophils	   (CD66a/c/e).	  Monocytes	  were	   identified	  from	  the	  remaining	  cells	  using	  
CD14	   and	   HLA-­‐DR	   expression	   [Figure	   6.5].	   Attempts	   to	   classify	   monocytes	   into	  
classical,	  intermediate	  and	  non-­‐classical	  sub-­‐types	  were	  abandoned	  after	  early	  pilot	  
work	  showed	  CD16+	  monocytes	  were	  not	  detectable	  following	  stimulation.	  
	  
Figure	   6.5	   	   WBASA-­‐1	   gating	   strategy	   1	   –	   monocyte	   intracellular	   cytokine	   production	   (a)	   Cellular	  
debris	  from	  end	  of	  acquisition	  removed;	  (b)	  doublets	  removed;	  (c)	  debris	  removed;	  (d)	  dump	  channel	  
used	  to	  remove	  T	  cells,	  B	  cells	  and	  neutrophils;	  (e)	  monocytes	  identified	  using	  CD14	  and	  HLA-­‐DR;	  (f)	  
expression	  of	  IL-­‐6	  and	  TNFα;	  (g)	  expression	  of	  IL-­‐12	  and	  IL-­‐10.	  NB	  gates	  in	  (f)	  and	  (g)	  drawn	  using	  the	  
un-­‐stimulated	  sample.	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Cytokine	   production	   was	   expressed	   as	   the	   percentage	   of	   monocytes	   that	   stained	  
positive	  for	  the	  respective	  cytokine;	  gates	  were	  drawn	  using	  un-­‐stimulated	  samples.	  
Due	  to	  unanticipated	  problems	  of	  cryptococcal	  antigen	  auto-­‐fluorescence,	  it	  was	  not	  
possible	   to	   examine	   intracellular	   IL-­‐12	   and	   IL-­‐10	   production	   following	   stimulation	  
with	   GXM	   and	   CW	   (glucuronoxylomannan	   and	   heat-­‐killed,	   mechanically	   disrupted	  
Cryptococcus	  neoformans	  respectively).	  	  
6.1.3 Neutrophil	  activation	  
Neutrophils	  were	  identified	  from	  the	  dump	  channel	  by	  differentiating	  from	  B	  and	  T	  
cells	  using	  forward	  and	  side	  scatter.	  Activation	  state	  was	  assessed	  by	  measuring	  the	  
surface	  expression	  of	  CD66(a/c/e)	  (MFI),	  and	  by	  loss	  of	  CD16-­‐	  expression.	  
6.1.4 Cytokine	  measurement	  
Cytokines	   concentrations	   were	   measured	   on	   stored	   samples	   of	   serum	   and	  
supernatants	   from	   24-­‐hour	   whole	   blood	   antigen	   stimulation	   experiments	   as	  
described	   in	   chapter	   3	   [section	   3.4.12].	   Although	   a	   30-­‐plex	   assay	   was	   used,	   four	  
analytes	   were	   excluded	   prior	   to	   analysis	   as	   they	   were	   felt	   to	   have	   no	   biological	  
relevance	  in	  CM	  (EGF,	  HGF,	  FDFb,	  eotaxin).	  Out	  of	  range	  low	  values	  were	  assigned	  a	  
zero	  value;	  out	  of	  range	  high	  values	  were	  assigned	  the	  highest	  value	  of	  the	  plate	  for	  
that	   analyte	  plus	  one.	  Values	   that	  were	  either	   above	  or	  below	   the	   standard	   curve	  
(and	   hence	   calculated	   by	   extrapolation)	   were	   used	   in	   the	   analysis	   provided	   the	  
standard	   curve	   results	   were	   within	   30%	   of	   expected.	   Eight	   analytes	   were	  
undetectable	  in	  serum	  samples	  and	  were	  excluded	  from	  the	  analysis	  (IL-­‐2,	  IL-­‐4,	  IL5,	  
IL-­‐13,	   IL-­‐17,	   GM-­‐CSF,	   IFNγ,	   TNFα).	   All	   analytes	   were	   detectable	   in	   stimulated	  
supernatants.	   Changes	   in	   cytokine	   concentration	   following	   stimulation	   were	  
calculated	  by	   subtracting	  unstimulated	  values	   from	  stimulated.	  To	  allow	   future	   log	  
transformation	   of	   data,	   any	   negative	   values	   were	   removed	   by	   adding	   the	   lowest	  
negative	  value	  plus	  one	  to	  all	  values	  of	  the	  respective	  analytes.	  	  	  	  
6.1.5 Transformation	  of	  variables	  
To	   allow	   parametric	   statistical	  modeling,	   variables	  were	   examined	   to	   see	  whether	  
they	  followed	  a	  normal	  distribution.	  This	  was	  done	  graphically	  (by	  plotting	  the	  values	  
on	   a	   histogram)	   and	   by	   using	   statistical	   tests	   (skewness	   and	   kurtosis	   test	   for	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normality).	   Appropriate	   transformations	   were	   applied	   to	   variables	   that	   did	   not	  
follow	  a	  normal	  distribution.	  Log	  transformations	  were	  performed	  on	  variables	  with	  
a	  marked	  positive	  skew	  (e.g.	  serum	  cytokine	  concentrations	  and	  MFI	  measurement	  
of	  cell	  surface	  marker	  expression).	  A	  constant	  was	  added	  prior	  to	  log	  transformation	  
to	  variables	  containing	  zero	  values.	  TNF-­‐α	  and	  IL-­‐6	  monocyte	  responses	  to	  LPS	  and	  
R848	  had	  a	  strong	  negative	  skew.	  Consequently,	  these	  variables	  were	  reflected	  and	  
expressed	  as	  the	  percentage	  of	  monocytes	  that	  were	  negative	  for	  the	  cytokine;	  the	  
resultant	  positively	  skew	  was	  then	  corrected	  using	  a	  log	  transformation.	  	  
6.1.6 Statistical	  analysis	  
Given	   the	   frequently	   skewed	   distributions	   of	   many	   variables,	   initial	   analyses	   in	  
section	   6.2	   were	   performed	   using	   non-­‐parametric	   testing	   (Wilcoxon	   rank	   sum,	  
Kruskal-­‐Wallis	  and	  Spearman’s	  correlation	  testing	  as	  appropriate).	  No	  adjustment	  for	  
multiple	   testing	   was	   performed	   apart	   from	   post-­‐hoc	   testing	   in	   Kruskal-­‐Wallis	   test	  
(adjusted	  p-­‐value	  of	  0.0125).	  In	  sections	  6.3	  and	  6.4,	  non-­‐parametric	  tests	  were	  used	  
to	   explore	   the	   data,	   but	   further	   principal	   component	   analysis	   and	  modeling	  were	  
performed	   using	   parametric	   tests	   on	   variables	   transformed	   as	   described	   above.	  
Given	   the	   large	   number	   of	   multiple	   comparisons	   associated	   with	   this	   analysis,	  
statistical	  significance	  was	  determined	  by	  a	  p-­‐value	  <0.05	  and	  a	  false	  discovery	  rate	  
(q-­‐value)	  of	  less	  than	  0.1	  (Benjamini	  &	  Hochberg	  1995).	  Compared	  to	  a	  “traditional”	  
method	  for	  multiple	  testing	  such	  as	  the	  Bonferroni	  correction	  (which	  can	  be	  overly	  
stringent),	   this	   method	   reduces	   the	   danger	   of	   a	   type	   II	   statistical	   error	   while	  
controlling	  the	  probability	  of	  a	  type	   I	  error	  at	  10%	  (for	  example,	   if	  10	  variables	  are	  
identified	  that	  significantly	  differ	  between	  two	  groups	  using	  a	  cut-­‐off	  of	  q<0.1,	  one	  is	  
likely	  to	  be	  a	  false	  positive).	  Data	  are	  presented	  in	  table	  and	  graph	  form,	  and	  also	  as	  
principal	   component	  and	  heat	  map	  plots	   as	  described	   in	   chapter	  5	   [section	  5.1.3].	  
For	   ease	   of	   presentation,	   only	   variables	   that	   were	   significantly	   different	   between	  
groups	   are	   presented	   in	   sections	   6.3	   and	   6.4.	   The	   preliminary	   analysis	   of	   all	   non-­‐
transformed	   variables	   using	   non-­‐parametric	   tests	   are	   included	   in	   appendix	   A	   for	  
completeness	  (section	  10.2).	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6.2 Characterization	  of	  blood	  immune	  phenotype	  	  
To	   better	   understand	   the	   immune	   response	   in	   subjects	   with	   CM	   and	   to	   provide	  
background	   information	   for	   subsequent	   analyses,	   the	   peripheral	   blood	   immune	  
response	  in	  individuals	  in	  the	  cohort	  was	  examined.	  This	  was	  compared	  to	  a	  group	  of	  
10	   healthy	   community	   controls	   (HC)	   and	   5	   individuals	  with	  HIV-­‐1	   infection	   (HIVC).	  
The	  group	  of	   individuals	  with	  HIV-­‐1	   infection	  all	  had	   low	  CD4	  counts	   (<200/µL),	  no	  
evidence	  of	  opportunistic	  infection,	   and	   were	   not	   taking	   ART;	   further	   details	   of	  
entry	  criteria	  are	  given	  in	  chapter	  3	  [Table	  3.2].	  	  
6.2.1 Monocyte	  phenotype	  in	  cryptococcal	  disease	  
Individuals	  with	  CM	  had	  a	  median	  of	  0.3x109/L	  circulating	  monocytes	  (IQR	  0.2-­‐0.5),	  
comprising	   a	   median	   of	   7.4%	   of	   circulating	   leukocytes	   (IQR	   5.4-­‐10.1)	   [Table	   6.1].	  
With	   regard	   to	   monocyte	   subsets,	   81%	   were	   classical	   monocytes	   (CD14++CD16-­‐),	  
10%	   intermediate	   (CD14++CD16+)	   and	   3%	   non-­‐classical	   (CD14+CD16++)	   (all	   values	  
medians)	   [Table	   6.1].	   There	   were	   no	   significant	   differences	   in	   absolute	  monocyte	  
counts	  or	  the	  relative	  frequency	  of	  monocytes	  between	  the	  three	  groups.	  However,	  
individuals	   with	   CM	   had	   a	   significantly	   greater	   proportion	   of	   non-­‐classical	  
(CD14+CD16++)	  monocytes	   compared	   to	   healthy	   controls	   (median	   3.0%	   (IQR,	   1.0-­‐
7.1)	  vs.	  1.0%	  (IQR,	  0.2-­‐2.5)	  respectively;	  p=0.010	  (p<0.0125	  significant))	  [Table	  6.1].	  
HIV-­‐infected	   controls	   also	   had	   a	   lower	   median	   percentage	   of	   non-­‐classical	  
monocytes	   compared	   to	   the	   CM	   group	   but	   this	   difference	   was	   not	   statistically	  
significant	  (0.6%	  (IQR	  0.2-­‐2.9)	  p=0.054).	  	  
	  
A	   number	   of	   differences	   in	   monocyte	   activation	   were	   noted	   between	   groups.	  
Individuals	   with	   CM	   had	   significantly	   lower	   HLA-­‐DR	   expression	   on	   classical	  
monocytes	   (CD14++CD16-­‐)	   compared	   to	   both	   healthy	   and	   HIV-­‐infected	   controls	  
(median	  HLA-­‐DR	  MFI	   (IQR):	   CM=878	   (576-­‐1570),	  HC=1660	   (1199-­‐2098),	  HIVC	   2210	  
(1856-­‐2855)	   MFI;	   p=0.002	   (overall),	   p=0.009	   (CM	   vs.	   HC)	   p=0.002	   (CM	   vs.	   HIVC))	  
[Table	   6.1].	   HLA-­‐DR	   expression	   was	   also	   significantly	   different	   on	   the	   monocyte	  
population	  as	  a	  whole,	  with	  the	  lowest	  expression	  again	  seen	  in	  the	  CM	  group	  and	  
highest	   expression	   in	   the	   HIVC	   group	   (median	   MFI	   (IQR):	   CM=1183	   (769-­‐2039),	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HC=1818	   (1239-­‐2273),	   HIVC=2936	   (2196-­‐3783);	   p=0.01)	   [Figure	   6.6].	   However,	   on	  
post-­‐hoc	   comparisons	   only	   the	   difference	   between	   CM	   and	   HIVC	   was	   statistically	  
significant	   (p=0.003,	   adjusted	   threshold	   for	   significance	   p<0.0125)	   [Table	   6.1].	  
Monocyte	   expression	   of	   CCR2	   and	   CCR5	   was	   also	   significantly	   lower	   among	  
individuals	  with	  CM	  compared	  to	  healthy	  controls,	  but	  was	  not	  significantly	  different	  
to	  HIV-­‐infected	  controls	  [Table	  6.1,	  Figure	  6.6].	  Similar	  findings	  of	  reduced	  CCR2	  and	  
CCR5	  among	  individuals	  with	  CM	  (compared	  to	  healthy	  controls)	  were	  noted	  for	  all	  
monocyte	   subsets	   except	   intermediate	  monocytes	   (CD14+CD16+)	  where	   only	   CCR2	  
was	  significantly	  reduced	  in	  the	  CM	  group	  [Table	  6.1].	  	  
	  
Table	  6.1	  	  Blood	  monocytes	  phenotype	  in	  CM,	  healthy	  and	  HIV-­‐infected	  controls.	  Values	  shown	  are	  
medians	   with	   interquartile	   range.	   Overall	   comparison	   is	   using	   the	   Kruskal-­‐Wallis	   test,	   post-­‐hoc	  
comparisons	  were	  performed	  using	  the	  Wilcoxon	  rank	  sum	  test	  (CM	  =	  1;	  HC	  =	  2;	  HIVC	  =	  3).	  P-­‐values	  
were	  considered	  significant	  if	  p<0.0125	  (α2=α1/2*(k-­‐1),	  where	  k=number	  of	  groups).	  	  Variables	  that	  
differed	  significantly	  between	  groups	  are	  marked	  in	  bold.	  	  
Population n Median IQR n Median IQR n Median IQR Overall 14vs42 14vs43
Monocyte4(%) WBC 59 7.37 5.35D10.1 10 5.76 5.01D7.12 5 5.69 5.14D5.79 0.184
Monocytes /mm3 60 0.30 0.19D0.47 10 0.26 0.18D0.29 5 0.28 0.20D0.30 0.674
HLA$DR'(MFI)' mono 56 1183 769$2039 10 1818 1239$2273 4 2936 2196$3783 0.010 0.057 0.003
CD1634(MFI) mono 57 6612 3829D9299 10 9017 8220D10819 5 5996 5512D6745 0.079
CCR2'(MFI) mono 55 1752 1176$2077 10 3183 3015$3884 5 1028 915$1695 0.000 0.000 0.095
CCR5'(MFI) mono 55 535 389$697 10 788 701$948 5 720 472$1236 0.016 0.003 0.132
TLR44(MFI) mono 33 260 196D376 10 338 289D369 5 232 153D276 0.365
CD804(MFI) mono 56 300 234D406 10 331 284D397 5 298 280D352 0.576
CD11c4(MFI) mono 55 486 381D738 10 522 387D592 5 430 318D486 0.416
CD14++CD16D4 mono 59 80.9 70.7D87 10 86.8 80.7D89.4 5 85.3 83.3D85.5 0.182
HLA$DR'(MFI) CD14++CD16D 56 878 578$1569.5 10 1660 1199$2098 4 2210 1856$2885 0.002 0.009 0.002
CD1634(MFI) CD14++CD16D 56 6374 4013D10651 10 9242 7934D10868 5 6246 5826D6954 0.164
CCR2'(MFI) CD14++CD16D 55 1905 1257$2441 10 3208 3035$3805 5 1075 952$2009 0.000 0.000 0.133
CCR5'(MFI) CD14++CD16D 55 630 506$872 10 879 795$993 5 785 585$1332 0.030 0.006 0.140
TLR44(MFI) CD14++CD16D 33 277 216D399 10 308 286D360 5 184 147D251 0.240
CD804(MFI) CD14++CD16D 56 276 224D352 10 322 264D354 5 303 247D336 0.432
CD11c4(MFI) CD14++CD16D 55 449 341D733 10 493 370D577 5 448 248D467 0.460
CD14++16+4(%) mono 59 10.3 5.07D17.3 10 8.1 6.36D13.2 5 14.1 8.35D14.3 0.822
HLADDR4(MFI) CD14++CD16+ 56 6207 3619D9262 10 7396 4984D10651 4 10163 9081D13733 0.073
CD1634(MFI) CD14++CD16+ 56 8348 5221D13641 10 10120 9233D12990 5 6239 5383D7675 0.109
CCR2'(MFI) CD14++CD16+ 55 1338 1097$1905 10 2919 2548$3927 5 914 803$1322 0.000 0.000 0.105
CCR54(MFI) CD14++CD16+ 55 887 726D1121 10 1127 968D1191 5 1006 775D1542 0.113
TLR4(MFI) CD14++CD16+ 33 445 265D695 10 435 241D617 5 337 206D448 0.460
CD804(MFI) CD14++CD16+ 56 687 538.5D963 10 620 539D869 5 509 467D593 0.462
CD11c4(MFI) CD14++CD16+ 55 1106 750D1334 10 1021 459D1387 5 544 521D883 0.143
CD14+16++'% mono 58 3 1.02$7.13 10 0.99 0.24$2.48 5 0.64 0.20$2.89 0.027 0.010 0.054
HLADDR4(MFI)4 CD14+CD16++ 54 4967 2969D6537 10 7642 2908D9855 4 10311 4699D17759 0.208
CD163'(MFI) CD14+CD16++ 54 1264 591$3235 10 2967 2442$4195 5 3527 1220$4461 0.047 0.013 0.094
CCR2'(MFI) CD14+CD16++ 55 903 757$1258 10 1453 1327$1659 5 723 532$992 0.003 0.001 0.169
CCR5'(MFI) CD14+CD16++ 55 508 361$747 10 867 769$939 5 568 356$999 0.016 0.002 0.295
TLR44(MFI) CD14+CD16++ 33 363 301D472 10 567 401D697 5 351 334D428 0.063
CD804(MFI) CD14+CD16++ 56 708 532D926 10 650 579D749 5 506 474D628 0.616




Figure	   6.6	  Box-­‐plot	   illustrating	  monocyte	   expression	   of	   HLA-­‐DR,	   CCR2	   and	   CCR5	   between	   clinical	  
groups.	  Box	  plots	  show	  the	  median	  and	  interquartile	  range	  of	  receptor	  MFI	  readings	  from	  the	  clinical	  
groups.	  Clinical	  groups	  comprise	  of	  HIV-­‐associated	  cryptococcal	  meningitis	  (Crypto),	  healthy	  controls,	  
and	  HIV-­‐infected	  controls.	  Broken	  arrows	  indicate	  differences	  for	  which	  p<0.0125.	  
CD163	   expression	   on	   non-­‐classical	   monocytes	   (CD14+CD16++)	   also	   differed	  
significantly	  between	  groups,	  being	  lowest	  in	  the	  CM	  group	  and	  highest	  in	  the	  HIVC	  
group;	   however,	   these	   inter-­‐group	   differences	   were	   not	   significant	   in	   post-­‐hoc	  
testing	   using	   the	   adjusted	   significance	   level	   of	   p<0.0125	   	   [Table	   6.1].	   CD163	  
expression	  did	  not	  differ	  significantly	  on	  the	  other	  monocyte	  subsets.	  
6.2.2 T	  cells	  and	  neutrophil	  phenotype	  in	  cryptococcal	  disease	  
With	  regard	  to	  non-­‐monocytes,	  a	  number	  of	  differences	  existed	  between	  the	  three	  
groups.	   Individuals	   with	   CM	   had	   a	   significantly	   increased	   relative	   frequency	   of	  
neutrophils	   compared	   to	   both	   healthy	   and	   HIV-­‐infected	   controls	   [Table	   6.2].	  
However,	  there	  was	  no	  significant	  difference	  in	  absolute	  neutrophil	  counts.	  	  
	  
As	  expected,	  the	  three	  groups	  differed	  significantly	  with	  regard	  to	  T	  cell	  populations.	  
CD4	  counts	  were	  significantly	  lower	  in	  the	  CM	  group	  compared	  to	  both	  healthy	  and	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relative	   frequency	   of	   CD8	   T	   cells	  was	   also	   significantly	   increased	   in	   the	   CM	   group	  
compared	   to	   healthy	   controls,	   but	   not	   when	   compared	   to	   HIV-­‐infected	   controls	  
[Table	   6.2].	   The	   relative	   frequency	   of	   double	   negative	   T	   cells	   (CD4-­‐CD8-­‐)	  was	   also	  
greater	   in	   the	  CM	  group	   compared	   to	   the	   two	   controls	   groups;	  however,	   only	   the	  
differences	   between	   the	   CM	   and	   HIVC	   groups	   were	   deemed	   significant	   using	   an	  




Table	  6.2	  	  Differences	  in	  T	  cells	  and	  neutrophils	  between	  clinical	  groups.	  Medians	  with	  interquartile	  
range	  shown.	  P-­‐values	  from	  Kruskal-­‐Wallis	  test	  with	  post-­‐hoc	  comparisons	  displayed	  (CM	  =	  1;	  HC	  =	  2;	  
HIVC	   =	   3).	   Statistical	   significance	   defined	   as	   overall	   p<0.05	   and	   p<0.0125	   for	   post-­‐hoc	   tests	  
(α2=α1/2*(k-­‐1),	  where	  k=number	  of	  groups).	  	  Variables	  that	  differed	  significantly	  between	  groups	  are	  




n Median IQR n Median IQR n* Median IQR overall 1*vs*2* 1*vs*3
neut% WBC 59 69 56-77 10 43 39-52 5 46.6 42.2-48.2 0.000 0.000 0.012
neut/mm3 59 3.1 1.8;4.1 10 1.7 1.3;3.2 5 2 1.7;2.7
CD16;*%neuts 59 1.01 0.48;2.06 10 0.933 0.65;1.6 5 1.13 0.605;2.25 0.923
CD4%count 60 35 13-76 10 632 594-712 5 120 114-149 0.000 0.000 0.008
CD4%T% T 57 5.5 1.9-10.7 10 52.6 45.4-62.1 5 5.68 5.62-13.1 0.000 0.000 0.173
CD4% WBC 57 0.34 0.16-1.05 10 15.55 12.9-17.9 5 2.21 1.59-2.62 0.000 0.000 0.010
HLA-DR%MFI%CD4%T 53 231 115-548 10 34 25-43 5 71.4 50.667-72 0.000 0.000 0.014
CD38*MFI*CD4*T 53 1684 1055;2629 10 1750 1400;2321 5 2595 1790;2935 0.532
PD-1%MFI%CD4%T 53 1155 821-1516 10 544.5 526.4-619 5 598 555-736 0.000 0.000 0.010
CD38+*%CD4*T 53 64.8 39.8;81.9 10 64.4 42.5;73.6 5 83 65.4;86.9 0.325
HLA-DR+% CD4%T 53 41.1 28.1-57.5 10 10.45 9.68-13.1 5 22 11.7-26.6 0.000 0.000 0.007
PD-1+% CD4%T 53 24.9 14.6-40.3 10 0.1595 0.13-0.49 5 2.24 1.96-3.07 0.000 0.000 0.002
CD8%T% T 57 83.9 77-88 10 38.05 34-46 5 89.8 81-91.4 0.000 0.000 0.197
CD8%T% WBC 57 8.05 4.2-12.7 10 11.04 8.1-13 5 25.6 16.2-25.8 0.004 0.117 0.001
HLA-DR%MFI%CD8%T 56 254 161-377 10 94.65 22-99 5 279 206-397 0.000 0.000 0.484
CD38%MFI%CD8%T 56 1230 622-2042 10 262.5 145-434 5 1241 1206-1992 0.000 0.000 0.243
PD-1%MFI%CD8%T 56 665.5 520-868 10 473.5 397-537 5 458 423-487 0.005 0.007 0.009
CD38+% CD8%T 56 85 68-94 10 48 44-64 5 83.8 79.1-93 0.002 0.000 0.373
HLA-DR+% CD8%T 56 36.1 24.5-50.5 10 13.6 8.17-19.5 5 39.2 30.1-52.9 0.000 0.000 0.468
PD-1+% %CD8 56 15.75 7-26.2 10 0.792 0.25-2.45 5 1.66 0.795-1.78 0.000 0.000 0.001
DNT% T 57 8.31 5.7-11.7 10 4.38 3.41-8.58 5 4.26 2.88-4.51 0.009 0.031 0.004
DNT% WBC 57 0.715 0.42-1.2 10 1.395 0.83-2.03 5 0.806 0.801-1.11 0.022 0.004 0.173
HLA-DR%MFI%DNT 56 211 147-281 10 123 111-144 5 165.7 138.8-277 0.002 0.000 0.344
CD38%MFI%DNT 56 816 228-1839 10 172 135-207 5 1451 1320-1794 0.001 0.000 0.091
PD-1%MFI%DNT 56 283.5 211.5-517 10 78.8 74.5-94.9 5 94.6 48.7-109 0.000 0.000 0.001
CD38+% DNT 56 68.4 40-82 10 35.1 30-40 5 77.2 71.8-80.5 0.010 0.003 0.198
HLA-DR+% DNT 56 33.2 21.1-45.3 10 19.1 13.9-21.5 5 28.7 15.7-41.5 0.015 0.002 0.281
PD-1% DNT 56 7.14 2.23-21 10 0.36 0.03-2.53 5 1.71 0.721-2.81 0.000 0.000 0.048
CD4CD8%ratio 57 0.06 0.02-0.13 10 1.34 1.05-1.86 5 0.06 0.06-0.16 0.000 0.000 0.204
HIV;infected*controlsHealthy*ControlsCryptococcal*meningitis p*value
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Regarding	   T	   cell	   activation,	   a	   number	   of	   differences	  were	   noted	   between	   groups.	  
With	  regard	  to	  CD4	  T	  cell	  activation,	  individuals	  with	  CM	  had	  significantly	  increased	  
proportion	  of	  cells	  expressing	  HLA-­‐DR	  and	  PD-­‐1	  compared	  to	  both	  healthy	  and	  HIV-­‐
infected	  controls	  [Table	  6.2,	  Figure	  6.7].	  With	  regard	  to	  CD8	  and	  double	  negative	  T	  
cells	   (CD4-­‐CD8-­‐)	   a	   similar	   pattern	   was	   seen:	   persons	   with	   CM	   had	   a	   significantly	  
increased	  proportion	  of	  cells	  expressing	  HLA-­‐DR,	  CD38	  or	  PD-­‐1	  compared	  to	  healthy	  
controls,	   and	   increased	   proportion	   of	   PD-­‐1	   expressing	   cells	   compared	   to	   HIV-­‐
infected	  controls	  [Table	  6.2;	  Figure	  6.8,	  6.9].	  	  
	  
	  
Figure	   6.7	   	   	  Differences	   in	   CD4	   T	   cell	   activation	   between	   clinical	   groups.	   	  Cryptococcal	  meningitis	  
(CM),	   healthy	   controls	   (HC)	   and	   HIV-­‐infected	   controls	   (HIVC).	   Plot	   shows	  median	   %	   of	   CD4	   T	   cells	  
expressing	   activation	   marker	   with	   interquartile	   range.	   Statistically	   significant	   differences	   (p<.0125)	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Figure	  6.8	  	  Differences	  in	  CD8	  T	  cell	  activation	  between	  clinical	  groups.	  Plot	  shows	  median	  %	  of	  CD8	  
T	   cells	   expressing	   activation	   marker	   with	   interquartile	   range.	   Statistically	   significant	   differences	  
(p<0.0125)	  are	  marked	  with	  a	  broken	  line.	  See	  Table	  6.2	  for	  exact	  p	  values.	  
	  
Figure	  6.9	  Differences	  in	  double	  negative	  (CD4-­‐CD8-­‐)	  T	  cell	  activation	  between	  clinical	  groups.	  Plot	  
shows	   median	   percentage	   of	   CD4	   T	   cells	   expressing	   activation	   marker	   with	   interquartile	   range.	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6.2.3 Serum	  cytokine	  concentrations	  in	  cryptococcal	  disease	  
The	  concentrations	  of	  20	  biomarkers	  were	  compared	  between	  groups	  [Table	  6.3].	  	  
	  
Table	   6.3	   	   Differences	   in	   serum	   biomarkers	   between	   CM,	   healthy	   controls	   and	   HIV-­‐	   controls.	  
Median	   serum	   concentrations	   of	   17	   biomarkers	   are	   displayed	   along	   with	   their	   interquartile	   range	  
(IQR).	  P-­‐values	  are	  for	  overall	  comparison	  (Kruskal-­‐Wallis	  test);	  post-­‐hoc	  comparisons	  also	  shown	  (CM	  
=	  1;	  HC	  =	  2;	  HIVC	  =	  3)	  using	  an	  adjusted	  p-­‐value	  for	  statistical	  significance	  (p<0.0125).	  	  
Almost	  all	  biomarkers	  were	  significantly	  raised	  in	  the	  CM	  group	  compared	  to	  healthy	  
controls	   [Table	   6.3].	   Compared	   to	  HIV-­‐infected	   controls,	   ten	   biomarkers	   remained	  
higher	   in	   CM	   individuals	   (VEGF,	   G-­‐CSF,	   IFNα,	   IL-­‐6,	   IL-­‐12,	   IL-­‐15,	   CCL4/MIP-­‐1β,	  
CXCL8/IL-­‐8,	   IL-­‐1β,	   and	   CRP),	   one	   was	   lower	   (CCL5/RANTES),	   and	   10	   showed	   no	  
statistical	  difference	  [Table	  6.3].	  
6.2.4 Monocyte	  functional	  responses	  in	  cryptococcal	  disease	  
Following	   a	   6-­‐hour	   stimulation,	   monocyte	   cytokine	   responses	   to	   cryptococcal	  
antigens,	   GXM	   and	   CW,	   were	   significantly	   lower	   than	   responses	   to	   LPS	   and	   R848	  
[Table	   6.4].	  When	   responses	  were	   compared	   between	   the	   three	   clinical	   groups,	   a	  
broadly	  similar	  pattern	  of	  response	  was	  observed.	  	  Following	  stimulation	  with	  R848	  
and	   LPS,	   the	   proportion	   of	   TNFα+	   or	   IL-­‐12+	  monocytes	   was	   significantly	   lower	   in	  
individuals	   with	   CM	   compared	   to	   HIV-­‐infected	   controls	   but	   was	   not	   different	   to	  
healthy	  controls	  [Table	  6.4;	  Figures	  6.10,	  6.11].	  Similarly,	  following	  stimulation	  with	  
GXM	   and	   CW,	   the	   proportion	   of	   IL-­‐6	   producing	   monocytes	   was	   also	   significantly	  
lower	   in	   the	  CM	  group	   compared	   to	  HIV-­‐infected	   controls	  but	  was	  no	  different	   to	  
n Median IQR n Median IQR n Median IQR overall 1/vs/2 1/vs/3
VEGF 59 1.42 0.61-2.29 10 0 0-0 5 0 0-0 0.000 0.000 0.001
GCSF 59 46 24-76 10 0 0-0 5 7 0-10 0.000 0.000 0.011
IFNa 59 216 164-276 10 16 11.1-19.3 5 22 12.3-522 0.000 0.000 0.000
IL6 59 34 13-66 10 1 0.38-1.08 5 2 1.45-2.2 0.000 0.000 0.001
IL12 59 364 276-532 10 99 91-109 5 194 137-219 0.000 0.000 0.005
CCL5 59 2816 2327-4727 10 31795 4443-69598 5 27231 19852-69599 0.000 0.000 0.000
IL15 59 166 115-268 10 0 0-0 5 4 0-53 0.000 0.000 0.005
CCL3 59 43 33.5-80.8 10 6 0.97-11.64 5 21 21.4-27.6 0.000 0.000 0.023
CCL4 59 93 56.7-166 10 68 39-117 5 31 3.9-31.5 0.004 0.117 0.001
CCL2 59 717 441-1391 10 356 219-449 5 440 258-1111 0.005 0.001 0.077
IL1RA 59 256 192-396 10 156 132-180 5 333 307-442 0.000 0.000 0.073
CXCL10 59 91 59.3-133 10 22 16.3-25.0 5 123 114-195 0.000 0.000 0.112
IL2R 59 462 265-794 10 197 108-221 5 924 735-1455 0.000 0.000 0.014
CXCL9 59 383 222-680 10 30 11.2-58.6 5 638 503-1683 0.000 0.000 0.051
CXCL8 59 70 26.9-124 10 0 0-5.68 5 0 0-0 0.000 0.000 0.001
IL-1b 59 5.5 3.3-9.5 10 0.0 0-0 5 0.0 0-0 0.000 0.000 0.002
IL87 59 0.0 081.8 10 0.0 080 5 0.0 080 0.240
IL810 59 7.0 2814.7 10 1.9 1.483 5 3.0 2.587.4 0.081
sCD163 59 1186 860-1570 10 593 362-801 5 2112 1281-3157 0.000 0.000 0.057
CRP 59 42.9 15.9-84.4 10 1.45 0-1.7 5 2.3 1.1-4.1 0.000 0.000 0.001
Cryptococcal/meningitis Healty/Controls HIV8infected/controls p/value
199	  	  
healthy	   controls.	   IL-­‐6	   production	   also	   differed	   significantly	   following	   R848	  
stimulation	  but	  post-­‐hoc	  testing	  was	  not	  statistically	  significant	  [Table	  6.4].	  	  
	  
	  
Table	   6.4	   	  Differences	   in	  monocyte	   responses	   following	  between	  CM,	  HC	  and	  HIVC.	  Whole	  blood	  
was	   stimulated	   for	   6	   hours	   with	   R848,	   LPS,	   GXM	   or	   CW.	   Responses	   were	   analysed	   using	   flow	  
cytometry.	   Cytokine	   gates	   were	   drawn	   using	   un-­‐stimulated	   sample.	   Relative	   frequencies	   of	  
monocytes	  and	  neutrophils	  (%mono	  and	  %neut)	  are	  expressed	  as	  a	  percentage	  of	  total	  leukocytes,	  all	  
other	   percentages	   refer	   to	   total	   monocyte	   population.	   HLA-­‐DR	   expression	   on	   monocytes	   (HLA-­‐DR	  
mono)	   and	   CD66	   expression	   on	   neutrophils	   (CD66	   neut)	   are	   expressed	   as	   median	   fluorescence	  
intensity	  (MFI);	  ratios	  both	  refer	  to	  the	  MFI	  of	  the	  stimulated	  sample	  divided	  by	  the	  un-­‐stimulated.	  P-­‐
values	  are	  shown	  for	  overall	  comparison	  (Kruskal-­‐Wallis	  test)	  and	  post-­‐hoc	  comparisons	  (CM	  =	  1;	  HC	  =	  
2;	  HIVC	   =	   3)	   using	   an	   adjusted	   p-­‐value	   for	   statistical	   significance	   (p<0.0125).	   Statistically	   significant	  
differences	  are	  marked	  in	  bold.	  
stim n Median n Median n Median Overall 1/vs/2 1/vs/3
%/mono R848 45 1.53 1.08 2.57 7 1.11 0.84 2.41 5 2.43 2.42 3.36 0.190 /
%"IL6+"mono R848 45 88 83 92 7 94 88 95 5 93 92 93 0.039 0.019 0.045
%"TNF+"mono R848 45 79 70 83 7 72 67 88 5 88 87 89 0.019 0.447 0.002
%/IL10+/mono R848 45 17 8 32 7 19 17 26 5 8 4 10 0.140
%"IL12+"mono R848 40 10 4 15 7 13 10 17 5 31 31 45 0.013 0.110 0.002
HLABDR//mono/ R848 45 5422 3645 7771 7 5140 4544 6038 5 12688 8827 12782 0.083
HLABDR/ratio R848 45 2.15 1.64 2.57 7 2.36 2.04 2.94 5 1.98 1.60 2.05 0.614
%"neut R848 45 77 58 85 7 51 41 71 5 53 41 54 0.001 0.004 0.003
CD66"neut R848 45 14149 9336 18695 7 7657 5937 10753 5 10861 9418 15316 0.038 0.005 0.438
CD66/ratio R848 45 2.02 1.56 2.43 7 2.06 1.68 2.44 5 2.04 1.99 2.45 0.966
%/mono LPS 48 3.42 2.24 4.41 10 3.59 2.42 4.47 5 2.15 1.74 3.74 0.570
%/IL6+/mono LPS 48 77 56 86 10 79 68 85 5 84 83 91 0.109
%"TNF+"mono LPS 48 42 21 55 10 39 35 46 5 66 62 72 0.019 0.446 0.002
%/IL10+/mono LPS 48 5.97 3.08 10.05 10 4.08 2.77 6.76 5 2.92 1.70 5.75 0.269
%"IL12+"mono LPS 43 1.26 0.32 3.09 10 2.09 1.02 3.23 5 10.46 6.63 16.73 0.001 0.164 0.000
HLABDR/mono LPS 46 5547 3281 7540 10 5729 4125 6463 5 10571 7341 12239 0.081
HLABDR/ratio LPS 46 1.87 1.68 2.74 10 2.24 1.41 2.71 5 1.71 1.65 2.15 0.856
%"neut LPS 47 78 61 87 10 53 48 70 5 55 44 61 0.001 0.002 0.005
CD66/neut LPS 47 10400 7346 13780 10 6992 5752 9091 5 11298 7411 11958 0.065
CD66/ratio LPS 47 1.60 1.37 1.87 10 1.61 1.23 2.06 5 1.74 1.74 2.07 0.625
%mono GXM 42 4.25 2.44 5.44 7 3.87 2.50 4.63 5 4.48 3.33 4.97 0.748
%"IL6+"mono GXM 42 1.37 0.38 3.14 7 2.88 1.23 5.68 5 6.96 5.71 8.46 0.002 0.115 0.000
%"TNF+"mono GXM 42 0.36 0.04 0.92 7 1.35 0.54 2.32 5 2.05 0.00 2.87 0.039 0.008 0.127
HLA>DR"mono GXM 42 3984 2417 5865 7 4461 3755 6966 5 7341 6707 7518 0.048 0.132 0.010
HLABDR/ratio GXM 42 1.43 1.22 2.06 7 2.04 1.88 2.34 5 1.51 1.15 1.75 0.137
%"neut GXM 42 60 43 71 7 34 32 45 5 35 35 40 0.007 0.003 0.026
CD66/neut GXM 42 14368 9653 19293 7 9443 5762 11373 5 14575 6088 14611 0.052
CD66/ratio GXM 42 2.01 1.69 2.50 7 2.29 1.32 2.76 5 1.55 1.43 2.29 0.529
%mono CW 41 4.73 3.10 6.81 6 3.73 3.36 3.93 5 4.50 3.30 5.06 0.533
%"IL6+"mono CW 41 1.04 0.04 2.33 6 0.28 0.15 0.41 5 7.49 3.84 8.71 0.002 0.197 0.001
%/TNF+/mono CW 41 0.95 0.21 1.87 6 0.40 0.13 0.53 5 3.51 0.60 4.71 0.109
HLA>DR"mono CW 41 2900 1806 3772 6 4046 3539 5022 5 5540 4797 5973 0.008 0.021 0.005
HLA>DR"ratio CW 41 1.01 0.75 1.35 6 1.66 1.46 1.87 5 1.22 1.00 1.23 0.027 0.004 0.478
%"neut CW 41 66 49 78 6 53 47 60 5 34 32 46.20 0.099
CD66/neut CW 41 16921 10560 20443 6 5704 4539 8721 5 15202 15089 25712 0.004 0.001 0.320






Figure	   6.10	   	   Differences	   in	  monocyte	   cytokine	   responses	   between	   clinical	   groups	   following	   R848	  
stimulation.	  Plot	  shows	  the	  differences	  in	  proportion	  of	  TNFα	  and	  IL-­‐12	  positive	  monocytes	  following	  
stimulation	  with	  R848,	  between	  clinical	  groups.	  Box	  plots	  display	  the	  median	  and	  interquartile	  range.	  
Statistically	  significant	  differences	  are	  marked	  with	  a	  broken	  arrow	  (p<0.0125).	  
	  
Figure	   6.11	   	   Differences	   in	   monocyte	   cytokine	   responses	   between	   clinical	   groups	   following	   LPS	  
stimulation.	  Plot	  shows	  the	  differences	  in	  proportion	  of	  TNFα	  and	  IL-­‐12	  positive	  monocytes	  following	  
stimulation	  with	  LPS,	  between	  clinical	  groups.	  Box	  plots	  display	  the	  median	  and	   interquartile	  range.	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Differences	   in	   peripheral	   blood	   neutrophils	   were	   also	   noted	   between	   the	   three	  
clinical	   groups.	   Following	   any	   of	   the	   four	   stimulations,	   relative	   neutrophil	   counts	  
(neutrophils	  measured	  as	  a	  percentage	  of	  total	  blood	  leukocytes)	  were	  significantly	  
higher	  in	  CM	  patients	  compared	  to	  both	  control	  groups	  [Table	  6.4].	  However,	  given	  
that	   neutrophil	   frequency	   (%WBC)	   prior	   to	   stimulation	  was	   higher	   in	   CM	   patients	  
anyway,	   it	   is	   likely	   that	   this	   result	   simply	   reflects	  baseline	  differences	  between	  the	  
groups	   rather	   than	   differing	   responses	   to	   whole	   blood	   stimulation.	   In	   addition,	  
following	   R848	   stimulation,	   the	   expression	   of	   the	   activation	  marker	   CD66a/c/e	   on	  
neutrophils	  was	  also	  significantly	  increased	  in	  individuals	  with	  CM	  compared	  to	  the	  
two	  control	   groups	   [Table	   6.4].	   	   Changes	   in	  CD66a/c/e	  expression	  were	  not	  noted	  
following	  other	  stimulations.	  	  	  
6.2.5 Whole	  blood	  cytokine	  responses	  in	  cryptococcal	  disease	  
Individuals	   with	   CM	   also	   appeared	   to	   have	   impaired	   cytokine	   responses	   in	   whole	  
blood	   supernatant	   following	   stimulation	   for	   24	   hours	   with	   the	   same	   four	  
compounds.	  In	  contrast	  to	  the	  monocyte	  intracellular	  cytokine	  responses,	  following	  
R848	   and	   LPS	   stimulation,	   patients	  with	   CM	  had	   significantly	   reduced	   IFN-­‐α,	   IL-­‐12	  
and	   IFN-­‐γ	   production	   compared	   to	   healthy	   controls,	   but	   were	   not	   different	   when	  




Figure	   6.12.	   Differences	   in	   whole	   blood	   cytokine	   response	   to	   R848	   stimulation	   between	   clinical	  
groups	   (Crypto=cryptococcal	   meningitis).	   Box-­‐plots	   show	   the	   median	   and	   interquartile	   range	   of	  
cytokine	  concentration	  in	  supernatant.	  Broken	  arrows	  indicate	  significant	  differences	  (p<0.0125).	  	  
	  
	  
Figure	   6.13	   Differences	   in	   whole	   blood	   cytokine	   response	   to	   LPS	   stimulation	   between	   clinical	  
groups	   (Crypto=cryptococcal	   meningitis).	   Box-­‐plots	   show	   the	   median	   and	   interquartile	   range	   of	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Table	   6.5	   	   Differences	   in	   whole	   blood	   cytokine	   response	   between	   clinical	   groups	   (R848/LPS	  
stimulation).	  Stimulation	  shown	  in	  column	  2.	  All	  values	  displayed	  are	  in	  pg/ml.	  P-­‐values	  are	  shown	  for	  
overall	  comparison	  (Kruskal-­‐Wallis	  test)	  and	  post-­‐hoc	  comparisons	  (CM	  =	  1,	  HC	  =	  2,	  HIVC	  =	  3)	  using	  an	  
adjusted	  p-­‐value	  for	  statistical	  significance	  (p<0.0125).	  Statistically	  significant	  differences	  are	  marked	  
in	  bold.	  	  
Differing	   responses	   were	   also	   seen	   following	   stimulation	   with	   the	   cryptococcal	  
preparations	  GXM	  and	  CW.	   IFN-­‐α	   concentrations	  were	   significantly	   higher	   in	  GXM	  
stimulated	  blood	   from	   individuals	  with	  CM	  compared	  to	  healthy	  controls	  but	  were	  
no	  different	  from	  HIV-­‐infected	  controls	  [Table	  6.6].	  Similar	  patterns	  were	  noted	  in	  IL-­‐
15	   and	   CXCL10/IP-­‐10	   (Interferon	   gamma	   induced	   Protein-­‐10)	   production	   following	  
GXM	  stimulation,	  and	  VEGF	  and	  IL-­‐1RA	  production	  following	  CW	  stimulation	  [Table	  
6.6].	  As	  with	  the	  monocyte	  responses,	  overall	  cytokine	  responses	  were	  much	  lower	  
following	   stimulation	   with	   the	   cryptococcal	   preparations	   compared	   to	   the	   TLR	  
agonists	  [Table	  6.5	  &	  6.6].	  	  
Cytokine stim n Median n Median n Median overall 12vs22 12vs23
VEGF R848 42 519 389 2485 10 342 319 430 5 1186 1041 2560 0.017 0.006 0.149
IL=1b R848 42 5382 1996 9329 10 5796 4131 8504 5 5289 3621 6462 0.931
G=CSF R848 42 781 575 1165 10 710 425 989 5 383 74 790 0.125
IL=10 R848 42 2226 1286 3703 10 2077 1857 2816 5 729 669 886 0.084
IFNa R848 42 2360 560 3605 10 8773 6730 9425 5 671 382 1204 0.000 0.000 0.183
IL=6 R848 42 43324 22881 88254 10 30908 25945 53469 5 24336 15511 30497 0.357
IL412 R848 42 7094 4168 11613 10 19018 13439 23212 5 7193 6600 9745 0.001 0.000 0.301
CCL5 R848 42 114831 26185 129783 10 117500 13636 119234 5 118455 112990 119670 0.690
IL=15 R848 42 3602 1942 5418 10 4071 3744 4480 5 4380 1537 5167 0.759
CCL3 R848 42 49468 23616 83441 10 66329 31261 75308 5 49909 25326 76283 0.794
CCL4 R848 42 80873 41530 124841 10 70455 65536 106962 5 67239 57823 93874 0.665
CCL2 R848 42 47622 31942 81744 10 57554 54196 75879 5 22092 20946 25717 0.020 0.164 0.007
IFNg R848 42 69 35 391 10 1173 633 4295 5 285 238 498 0.000 0.000 0.046
TNFa R848 42 14388 6798 22243 10 13245 11627 15381 5 12106 8057 20030 0.972
IL=1RA R848 42 14870 10691 24406 10 18263 15949 23163 5 16789 15805 32652 0.385
IL=7 R848 42 1308 985 1695 10 1612 1541 1732 5 1304 455 1331 0.070
CXCL10 R848 42 22997 21704 24307 10 22751 22137 23103 5 23914 23327 25506 0.164
IL=2R R848 42 5854 5032 6847 10 6867 6610 7199 5 6351 4194 6627 0.149
CXCL9 R848 42 7826 7715 7940 10 8172 8003 8323 5 7757 5878 7847 0.008 0.001 0.310
CXCL8 R848 41 92217 60422 185805 10 101433 84603 153307 5 51240 45799 70771 0.211
VEGF LPS 45 410 287 1952 10 362 283 402 5 1616 845 2476 0.098
IL41b LPS 45 1873 679 3906 10 3122 1847 6953 5 3251 3008 7723 0.039 0.030 0.025
G=CSF LPS 45 968 521 1181 10 894 722 1225 5 659 203 1314 0.732
IL=10 LPS 45 778 444 1421 10 719 566 1298 5 593 515 665 0.373
IFNa LPS 45 1160 343 2302 10 2389 2067 2780 5 209 146 592 0.005 0.004 0.056
IL=6 LPS 45 39880 21260 68483 10 39793 28857 51010 5 43116 34748 44920 0.959
IL412 LPS 45 2624 1679 3560 10 5449 3184 6915 5 3258 3041 6489 0.007 0.003 0.036
CCL5 LPS 45 118022 25823 137843 10 124497 55995 132971 5 133998 112669 140747 0.741
IL=15 LPS 45 1695 1070 3362 10 2673 1786 3161 5 3073 1537 3505 0.425
CCL3 LPS 45 30576 16856 55383 10 58150 29416 83393 5 38445 18750 54371 0.212
CCL4 LPS 45 56523 28232 83583 10 88184 58008 105667 5 63931 62751 66888 0.133
CCL2 LPS 45 31250 22287 47315 10 43605 37906 60047 5 13367 6511 26434 0.092
IFNg LPS 45 31 31 39 10 143 45 454 5 53 46 87 0.000 0.000 0.002
TNFa LPS 45 2881 1522 5318 10 3376 1805 5817 5 5675 5025 6653 0.370
IL=1RA LPS 45 11912 9096 18339 10 12332 10723 14009 5 21238 19203 27507 0.093
IL47 LPS 45 1288 880 1454 10 1682 1347 1805 5 1214 601 1466 0.039 0.007 0.397
CXCL10 LPS 45 21703 21324 22445 10 21506 21342 21803 5 23646 22416 23770 0.015 0.127 0.007
IL=2R LPS 45 5470 4813 6466 10 6437 6045 6932 5 5807 4324 6685 0.123
CXCL9 LPS 45 7707 7571 7833 10 7966 7682 8003 5 7813 6263 7890 0.060






Table	   6.6	   	   Differences	   in	   whole	   blood	   cytokine	   response	   between	   clinical	   groups	   (GXM/CW	  
stimulation).	  Stimulation	  shown	  in	  column	  2.	  All	  values	  displayed	  are	  in	  pg/ml.	  P-­‐values	  are	  shown	  for	  
overall	  comparison	  (Kruskal-­‐Wallis	  test)	  and	  post-­‐hoc	  comparisons	  (CM	  =	  1,	  HC	  =	  2,	  HIVC	  =	  3)	  using	  an	  
adjusted	  p-­‐value	  for	  statistical	  significance	  (p<0.0125).	  Statistically	  significant	  differences	  are	  marked	  
in	  bold.	  
Cytokine stim n Median n Median n Median overall 12vs22 12vs23
VEGF GXM 42 55 42 80 10 48 44 59 5 86 56 86 0.316
ILC1b GXM 42 11 7 66 10 63 20 282 5 18 12 23 0.096
GCCSF GXM 42 98 87 122 10 113 100 125 5 105 87 135 0.609
ILC10 GXM 42 118 115 124 10 118 117 126 5 117 117 119 0.431
IFNa GXM 42 172 152 197 10 93 38 167 5 168 168 170 0.010 0.001 0.331
ILC6 GXM 42 830 477 1762 10 1563 882 5047 5 835 547 1013 0.159
ILC12 GXM 42 140 120 161 10 152 109 170 5 128 124 149 0.853
CCL5 GXM 42 112130 105467 112130 10 111474 105921 112130 5 111851 107305 112131 0.330
IL115 GXM 42 598 555 652 10 499 376 548 5 560 537 588 0.001 0.000 0.125
CCL3 GXM 42 1473 408 5065 10 3785 2368 10058 5 2044 803 2136 0.224
CCL4 GXM 42 5120 3177 8093 10 4736 3371 6241 5 2980 2873 4087 0.454
CCL2 GXM 42 32708 24344 48548 10 51267 27376 64868 5 36137 28487 38339 0.395
IFNg GXM 42 33 31 44 10 32 31 37 5 33 31 33 0.520
TNFa GXM 42 28 16 163 10 176 30 365 5 16 15 23 0.098
ILC1RA GXM 42 2395 1639 3932 10 2344 1970 3197 5 2341 2266 2358 0.736
ILC7 GXM 42 130 103 162 10 145 129 221 5 137 125 157 0.316
CXCL10 GXM 42 21062 21039 21154 10 20996 20753 21043 5 21049 21020 21059 0.002 0.000 0.202
ILC2R GXM 42 3459 3326 3633 10 3530 3489 3573 5 3557 3502 3695 0.372
CXCL9 GXM 42 7626 7604 7764 10 7600 7564 7629 5 7626 7622 7677 0.224
CXCL8 GXM 42 45783 28232 72520 10 47774 24035 81281 5 53176 27579 88920 0.943
VEGF CW 42 64 41 77 10 40 39 47 5 79 58 114 0.007 0.007 0.055
ILC1b CW 42 18 7 165 10 13 8 15 5 89 18 227 0.261
GCCSF CW 42 106 87 162 10 104 87 116 5 141 97 156 0.395
ILC10 CW 42 118 115 150 10 116 116 120 5 119 117 121 0.843
IFNa CW 42 169 140 196 10 178 161 197 5 177 159 187 0.758
ILC6 CW 42 733 406 10536 10 697 580 1812 5 1042 998 1585 0.774
ILC12 CW 42 136 126 165 10 136 118 156 5 149 134 151 0.691
CCL5 CW 42 112130 99363 112130 10 111847 105793 112130 5 112130 111965 112131 0.468
ILC15 CW 42 586 545 628 10 598 581 640 5 590 573 599 0.686
CCL3 CW 42 3247 365 13839 10 796 283 1518 5 7019 4474 15280 0.065
CCL4 CW 42 4345 2664 7816 10 3329 2452 4624 5 5791 3766 5957 0.356
CCL2 CW 42 37044 25857 48616 10 43538 29115 46846 5 42708 36380 47769 0.696
IFNg CW 42 34 32 43 10 31 31 37 5 35 31 35 0.472
TNFa CW 42 98 18 1386 10 23 15 32 5 103 47 436 0.106
IL11RA CW 42 2444 1841 3672 10 1627 1442 1772 5 2273 2217 2708 0.007 0.001 0.422
ILC7 CW 42 138 97 179 10 146 120 167 5 141 132 186 0.765
CXCL10 CW 42 21045 21039 21095 10 21066 21053 21086 5 21051 21034 21070 0.388
ILC2R CW 42 3497 3390 3683 10 3407 3370 3478 5 3628 3489 3745 0.070
CXCL9 CW 42 7614 7584 7643 10 7656 7633 7809 5 7622 7602 7668 0.037 0.005 0.297
CXCL8 CW 42 43793 29283 73190 10 32036 26228 71767 5 62967 49154 945668 0.312
IQR IQR IQR
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6.3 Factors	  influencing	  host	  immune	  response	  	  	  
6.3.1 Effect	  of	  ART	  on	  host	  immune	  response	  
The	  effect	  of	  ART	  on	  blood	  immune	  response	  was	  assessed	  by	  comparing	  individuals	  
with	  CM	  who	  were	   taking	  effective	   ART	   (n=10)	   to	   those	  who	  were	  not	   taking	  ART	  
(n=43).	  Effective	  ART	  was	  defined	  as	  being	  on	  ART	  at	  admission	  with	  no	  evidence	  of	  
poor	   adherence	   or	   virological	   failure	   (detectable	   HIV	   viral	   after	   6	   months	   ART),	  
further	   details	   are	   given	   in	   chapter	   4	   [section	   4.4.2].	   Six	   variables	   were	   different	  
between	   groups	   using	   the	   cut-­‐off	   of	   p<0.05	   [Table	   6.7;	   Figure	   6.14].	   Individuals	  
taking	   ART	   had	   an	   increased	   frequency	   of	   CD4	   T	   cells,	   increased	   activation	   of	  
neutrophils	   following	   R848	   and	   LPS	   stimulation	   (increased	   CD66	   MFI),	   increased	  
production	   of	   the	   chemokines	   CCL2/MCP-­‐1	   (monocyte	   chemotactic	   protein	   1)	   and	  
CCL4/MIP-­‐1β	  (Macrophage	  Inflammatory	  Protein	  1-­‐β)	  following	  stimulation	  with	  CW	  
and	  GXM	  respectively,	  and	  reduced	  expression	  of	  CD163	  on	  non-­‐classical	  monocytes	  
(CD14+CD16++).	  However,	  none	  of	  these	  differences	  were	  significant	  when	  adjusting	  
for	  the	  multiple	  comparisons	  by	  using	  false	  discovery	  rates	  (FDR)	  <10%	  to	  determine	  
statistical	   significance	   (q<0.1)	   [Table	   6.7].	   	   For	   completeness,	   tables	   displaying	   the	  
non-­‐transformed	  values	  with	  full	  univariate	  analysis	  (non-­‐parametric)	  are	  included	  in	  
Appendix	  A	  [Tables	  A.2-­‐A.7].	  
	  
Analyte	   Pop	   Stim	   P	   Q	   Analyte	   Pop	   Stim	   P	   Q	  
%CD4*	   WBC	   	   0.007	   0.54	   CD163*	   14+16++	   	   0.008	   0.54	  
%CD4*	   T	  cells	   	   0.012	   0.54	   	   	   	   	   	  
CCL2	   	   CW	   0.007	   0.54	   	   	   	   	   	  
CD66*	   Neut	   R848	   0.020	   0.69	   	   	   	   	   	  
CD66*	   Neut	   LPS	   0.018	   0.64	   	   	   	   	   	  
Table	  6.7	   	  Variables	   that	  differed	  between	   individuals	   taking	  and	  not	   taking	  effective	  ART.	  Red	  –	  
increased	  with	  ART;	  green	  –	  decreased	  with	  ART.	  Cell	  populations	  and	  stimulation	  are	  listed,	  as	  are	  p	  




Figure	   6.14	   	   Variables	   that	   differed	   between	   no	   ART	   and	   effective	   ART	   groups.	   The	   six	   variables	  
detailed	   in	   Table	   6.7	   are	   displayed	   graphically	   [yellow	   –	   no	   ART;	   blue	   –	   ART].	   Variables	   are	  
standardized	   such	   that	   the	   mean	   equals	   0	   and	   variance	   1,	   y-­‐axis	   scale	   not	   included	   for	   graphical	  
clarity.	  	  
6.3.2 Relationship	  between	  CD4	  count	  and	  immune	  response	  	  
The	   possible	   influence	   of	   CD4	   count	   on	   host	   immune	   response	   was	   assessed	   by	  
examining	   correlations	   between	   CD4	   count	   and	   the	   variables	   listed	   in	   section	   6.2.	  
The	  frequency	  of	  CD4	  T	  cells	  measured	  by	  flow	  cytometry	  (both	  as	  a	  proportion	  of	  
WBC	  and	  T	  cells)	  were	  removed	  from	  this	  analysis.	  Five	  variables	  were	  significantly	  
correlated	  with	  absolute	  CD4	  count	  following	  the	  methods	  described	  earlier	  [section	  
6.1.6].	   Participants	   with	   an	   increased	   peripheral	   CD4	   count	   were	   found	   to	   have	  
increased	   frequencies	   of	   CD8	   cells,	   increased	   frequency	   of	   monocytes	   following	  
incubation	   with	   GXM,	   decreased	   frequency	   of	   double	   negative	   T	   cells	   (CD4-­‐CD8-­‐)	  
and	   decreased	   frequency	   of	   circulating	   neutrophils	   (%WBC)	   following	   stimulation	  
with	  R848	  or	  LPS	  [Table	  6.8;	  Figure	  6.15].	  	  
	  
Analyte	   Pop	   Stim	   R	   P	   Q	   Analyte	   Pop	   Stim	   R	   P	   Q	  
%CD8*	   WBC	   	   0.39	   0.002	   0.095	   %DNT	   T	   	   -­‐0.39	   0.002	   0.095	  
%mono	   WBC	   GXM	   0.39	   0.002	   0.095	   %neut	   WBC	   R848	   -­‐0.41	   0.001	   0.095	  
	   	   	   	   	   	   %neut	   WBC	   LPS	   -­‐0.46	   <0.001	   0.054	  
Table	   6.8	   Variables	   that	   showed	   significant	   correlation	   with	   CD4	   count.	   Five	   variables	   that	  
significantly	   correlated	   with	   CD4	   count	   are	   shown	   (red	   –	   positive	   correlation;	   green	   –	   negative	  
correlation].	  Populations	  for	  which	  percentages	  refer	  are	  displayed,	  as	  are	  stimulations.	  P	  values,	  q-­‐
values	  and	  Pearson’s	  r	  values	  are	  all	  listed.	  Variables	  marked	  *	  are	  log2	  transformed.	  
+" +"(CD14+CD16 +)"
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These	   five	  variables	  were	  used	   to	  construct	  a	  PCA	  plot	   to	   illustrate	  how	  the	  blood	  
immune	   response	   among	   subjects	   with	   higher	   CD4	   counts	   differed	   from	   that	   of	  
individuals	  with	   lower	  CD4	  counts.	   Individuals	  with	  a	  higher	  CD4	  count	   (marked	   in	  
red)	  had	  higher	  values	  for	  principal	  components	  1	  and	  were	  located	  towards	  the	  top	  
of	  the	  plot;	  whilst	  those	  with	  lower	  CD4	  counts	  had	  are	  marked	  in	  green	  and	  located	  
at	  the	  bottom	  (lower	  values	  for	  principal	  component	  1)	  [Figure	  6.15a].	  Examining	  the	  
PCA-­‐variable	   plot	   [Figure	   6.15b]	   shows	   the	   influence	   of	   the	   variables	   on	   the	   PCA:	  
frequency	   of	   CD8	   cells	   and	   frequency	   of	   monocytes	   after	   incubation	   with	   GXM	  
contributed	   positively	   to	   principal	   components	   1	   (PC1);	   frequency	   of	   neutrophils	  
(following	   either	   R848	   or	   LPS	   stimulation)	   and	   CD4-­‐CD8-­‐	   T	   cells	   contributed	  
negatively	   to	   PC1	   [Figure	   6.16b].	   Figure	   6.16	   further	   demonstrates	   the	   inverse	  
correlation	  between	  peripheral	  CD4	  count	  and	  frequency	  of	  circulating	  neutrophils.	  
	  
	  
Figure	   6.15	   	   Relationship	   between	   CD4	   count	   and	   blood	   immune	   response	   in	   CM.	   (a)	   PCA	   plot	  
showing	   distribution	   of	   study	   subjects	   according	   to	   the	   five	   variables	   listed	   in	   Table	   6.8.	   Subjects	  
coloured	   according	   to	   CD4	   count	   (red	   –	   higher	   CD4;	   green	   –	   lower	   CD4).	   (b)	   five	   variables	   that	  
significantly	   correlated	  with	   absolute	   count	   of	   blood	   CD4	   cells	   (red	   –	   positive	   correlation,	   green	   –	  













Figure	   6.16	   	   Relationship	   between	   peripheral	   CD4	   count	   and	   frequency	   of	   blood	   neutrophils.	  
(pearson’s	  r=-­‐0.49,	  p<0.0001).	  
6.3.3 Relationship	  between	  blood	  immune	  response	  and	  fungal	  burden	  
Variables	  were	  then	  assessed	  to	  determine	  whether	  they	  correlated	  with	  CSF	  fungal	  
burden.	  Similar	  to	  the	  analysis	  performed	  in	  chapter	  5,	  only	  individuals	  who	  had	  not	  
received	   amphotericin	   at	   enrolment	  were	   included	   (n=35).	   CSF	   fungal	   burden	  was	  
positively	  correlated	  with	  frequency	  of	  blood	  neutrophils	  and	  negatively	  correlated	  
with	  whole	  blood	   IFN-­‐γ	   responses	   to	  LPS	  and	  GXM	  [Table	   6.9;	   Figures	   6.17,	   6.18].	  
However,	  given	  that	  the	  false	  discovery	  rate	  in	  these	  analyses	  was	  greater	  than	  10%,	  
the	  findings	  should	  be	   interpreted	  with	  a	  degree	  of	  caution.	  For	  completeness,	  the	  
full	  univariate	  non-­‐parametric	  analysis	   is	   included	   in	  Appendix	  A	   [Tables	  A.8-­‐A.10].	  
The	   relationship	   between	   blood	   CD4	   count	   and	   CSF	   fungal	   burden	   was	   also	  
examined;	  a	  clear	  inverse	  correlation	  was	  demonstrated	  [Figure	  6.19].	  	  
	  
Analyte	   Pop	   Stim	   R	   P	   Q	   Analyte	   Pop	   Stim	   R	   P	   Q	  
%Neut	   WBC	   	   0.53	   0.001	   0.115	   IFN-­‐γ*	   	   LPS	   -­‐0.56	   0.001	   0.104	  
	   	   	   	   	   	   IFN-­‐γ*	   	   GXM	   -­‐0.50	   0.002	   0.147	  
Table	  6.9	  	  Variables	  that	  showed	  correlation	  with	  CSF	  fungal	  burden.	  Three	  variables	  that	  correlated	  
with	   fungal	   burden	  are	   show	   (red	  –	  positive	   correlation;	   green	  –	  negative	   correlation).	   Populations	  
and	  stimulation	  are	  included	  as	  before.	  Pearson’s	  r,	  p-­‐values	  and	  q-­‐values	  are	  also	  listed.	  NB.	  Q-­‐values	  




















Figure	  6.17	  	  Relationship	  between	  blood	  neutrophils	  and	  CSF	  fungal	  burden	  in	  CM	  [Table	  6.9]	  
	  
Figure	   6.18	   	   Relationship	   between	   whole	   blood	   IFNγ 	   response	   to	   LPS	   and	   CSF	   fungal	   burden	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Figure	   6.19	   	   Relationship	   between	   peripheral	   blood	   CD4	   count	   and	   CSF	   fungal	   burden	   (n=35).	  
Significant	   inverse	   correlation	   observed	   (Pearsons’s	   r=-­‐0.51,	   p=0.002).	   Analysis	   limited	   to	   subjects	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6.4 Clinical	  Outcome	  
6.4.1 Day	  14	  outcome	  
Baseline	  immune	  response	  was	  compared	  between	  subjects	  who	  survived	  or	  died	  by	  
day	  14.	  To	  account	  for	  multiple	  comparisons,	  a	  false	  discovery	  rate	  (FDR)	  of	  less	  than	  
10%	  (q<0.1)	  was	  used	  to	  determine	  statistical	  significance.	  Variables	  that	  met	  these	  
criteria	   are	   listed	   below	   [Table	   6.10].	   For	   completeness,	   the	   full	   univariate	   non-­‐
parametric	  analysis	  is	  included	  in	  Appendix	  A	  [Tables	  A.11-­‐A.16].	  
	  
Analyte	   Pop	   Stim	   P	   Q	   Analyte	   Pop	   Stim	   P	   Q	  
HLADR	  ratio*	   mono	   R848	   0.000	   0.000	   HLADR*	   mono	   	   0.009	   0.097	  
HLADR	  ratio*	   mono	   LPS	   0.000	   0.000	   HLADR*	   14+16-­‐	   	   0.002	   0.057	  
HLADR	  ratio*	   mono	   GXM	   0.000	   0.000	   HLADR*	   14+16+	   	   0.003	   0.058	  
HLADR	  ratio*	   mono	   CW	   0.001	   0.030	   HLADR	   mono	   R848	   0.009	   0.097	  
%neut	   wbc	   GXM	   0.003	   0.058	   HLADR	   mono	   LPS	   0.003	   0.058	  
%neut	   wbc	   CW	   0.003	   0.058	   HLADR	   mono	   GXM	   0.001	   0.028	  
%neut	   wbc	   	   0.006	   0.088	   HLADR	   mono	   CW	   0.002	   0.057	  
%TNF-­‐ve*	   mono	   LPS	   0.003	   0.058	   IFNg*	   	   R848	   0.011	   0.099	  
CXCL10/IP10*	   	   	   0.009	   0.097	   IL12*	   	   R848	   0.010	   0.099	  
IL6*	   	   	   0.009	   0.097	   IFNg*	   	   LPS	   0.009	   0.097	  
IL10*	   	   	   0.001	   0.030	   IL12*	   	   LPS	   0.009	   0.097	  
	   	   	   	   	   %mono	   wbc	   GXM	   0.006	   0.093	  
Table	  6.10	   	  Variables	  that	  differed	  significantly	  between	  subjects	  who	  died	  or	  survived	  by	  day	  14.	  
Those	   shaded	   red	  are	  higher	  among	  persons	  who	  died	  by	  day	  14,	   those	   shaded	  green	  were	   lower.	  
Variables	   marked	   *	   are	   log2	   transformed.	   “Pop”	   =	   cell	   population	   on	   which	   the	   measurement	   is	  
taken;	   “stim”	   (stimulation	   of	   the	   cells);	   “HLA-­‐DR	   ratio”	   (HLA-­‐DR	   MFI	   stimulated/HLA-­‐DR	   MFI	  
unstimulated);	  14+16-­‐	  (CD14++CD16-­‐	  monocytes);	  14+16+	  (CD14++CD16+	  monocytes).	  
Compared	   to	   survivors,	   non-­‐survivors	   had	   significantly	   reduced	  HLA-­‐DR	   expression	  
on	   circulating	   monocytes,	   including	   the	   classical	   monocyte	   (CD14++CD16-­‐)	   and	  
intermediate	  monocyte	   (CD14++CD16+)	  subsets	   [Table	   6.10].	  Although	  the	  relative	  
increase	   in	   HLA-­‐DR	   expression	   between	   un-­‐stimulated	   and	   stimulated	   samples	  
(“HLA-­‐DR	   ratio”)	   was	   significantly	   higher	   in	   non-­‐survivors,	   absolute	   expression	   of	  
HLA-­‐DR	   remained	   significantly	   lower	   following	   all	   four	   of	   the	   stimulations.	   Non-­‐
survivors	   also	   had	   an	   a	   greater	   frequency	   of	   circulating	   neutrophils	   (%WBC),	   a	  
greater	  proportion	  of	  neutrophils	  in	  whole	  blood	  following	  stimulation	  with	  either	  of	  
the	  two	  cryptococcal	  antigens	  –	  GXM	  and	  CW;	  significantly	  higher	  concentrations	  of	  
serum	   IL-­‐6,	   IL-­‐10	   and	   CXCL10/IP-­‐10;	   a	   reduced	   monocyte	   TNF-­‐α	   response	   to	   LPS	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(increased	  proportion	  of	  TNFα-­‐ve	  monocytes);	  and	  decreased	  IFN-­‐γ	  and	  IL-­‐12p40/70	  
supernatant	   concentrations	   following	   whole	   blood	   stimulation	   with	   R848	   or	   LPS	  
[Table	  6.10;	  Figure	  6.20b].	   	  These	  differences	  between	  survivors	  and	  non-­‐survivors	  
were	   explored	   using	   principal	   component	   analysis	   (PCA).	   The	   first	   three	   principal	  
components	   were	   found	   to	   account	   for	   64%	   of	   the	   variance	   in	   the	   23	   variables	  
[Figure	   6.20].	   Examination	   of	   the	   PCA	   plot	   showed	   that	   non-­‐survivors	   (blue)	  
appeared	  to	  cluster	  together,	  and	  were	  largely	  separated	  from	  the	  survivors	  (yellow)	  
[Figure	   6.20a].	   A	   similar	   pattern	  was	   also	  observed	   in	   the	  unsupervised	  hierarchal	  
heat	  map	  analysis,	  with	  individuals	  who	  died	  before	  day	  14	  clustering	  together	  at	  the	  
far	  right	  side	  of	  the	  plot	  [Figure	  6.21].	  
	  
	  
Figure	  6.20	  	  PCA	  examining	  the	  relationship	  between	  blood	  immune	  response	  and	  day	  14	  outcome	  
(a)	  Distribution	  of	   subjects	  according	   to	  baseline	  blood	   immune	   response.	  Subjects	   that	  died	   (blue)	  
clustered	   together	   and	   were	   largely	   separated	   from	   those	   who	   survived	   (yellow).	   (b)	   Baseline	  
variables	  that	  differed	  significantly	  between	  the	  two	  groups	  (red	  –	  increased	  in	  non-­‐survivors;	  green	  –	  
decreased	  in	  non-­‐survivors).	  The	  position	  of	  variables	  in	  the	  plot	  indicates	  their	  weighting	  towards	  the	  
first	  three	  principal	  components.	  Stimulating	  agents	  are	  listed	  in	  brackets.	  
Adjusting	   the	  analysis	   for	  baseline	   fungal	   load	   resulted	   in	   very	   little	   change	   to	   the	  
analysis	  and	   little	  change	   to	   the	  plots.	  20	  variables	   remained	  significantly	  different	  
between	   survivors	   and	   non-­‐survivors	   (q<0.1)	   but	   frequency	   of	   neutrophils	  was	   no	  
longer	   significant	   [Table	   6.11].	   PCA	   plot	   and	   heat	   map	   showed	   similar	   clustering,	  
with	  non-­‐survivors	  located	  at	  the	  top	  of	  the	  PCA	  plot	  separating	  from	  the	  survivors	  






























Figure	  6.21	   	  Heat	  map	  illustrating	  relationship	  between	  baseline	  blood	  immune	  response	  and	  day	  
14	   outcome	   (hierarchal	   clustering).	   Subjects	   who	   died	   by	   day	   14	   (marked	   blue	   above)	   grouped	  
together	  according	  to	  the	  baseline	  expression	  of	  23	  variables	  (marked	  on	  right	  and	  table	  6.10;	  red	  –	  
variable	  increased,	  green	  –	  variable	  decreased).	  
Analyte	   Pop	   Stim	   P	   Q	   Analyte	   Pop	   Stim	   P	   Q	  
HLADR	  ratio*	   mono	   R848	   <0.001	   0.001	   HLADR	   mono	   R848	   0.006	   0.079	  
HLADR	  ratio*	   mono	   LPS	   <0.001	   0.001	   HLADR	   mono	   LPS	   0.002	   0.069	  
HLADR	  ratio*	   mono	   GXM	   <0.001	   0.001	   HLADR	   mono	   GXM	   0.001	   0.035	  
HLADR	  ratio*	   mono	   CW	   0.001	   0.052	   HLADR	   mono	   CW	   0.003	   0.072	  
%TNF-­‐ve*	   mono	   LPS	   0.003	   0.072	   HLADR	   14+16-­‐	   	   0.002	   0.069	  
%neut	   wbc	   GXM	   0.006	   0.079	   HLADR	   14+16+	   	   0.006	   0.079	  
%neut	   wbc	   CW	   0.008	   0.092	   IL-­‐12*	   	   R848	   0.007	   0.092	  
IL-­‐6*	   	   	   0.004	   0.074	   IL-­‐12*	   	   LPS	   0.005	   0.079	  
CRP*	   	   	   0.004	   0.074	   IFNg*	   	   LPS	   0.009	   0.092	  
IL-­‐10*	   	   	   0.003	   0.072	   IL-­‐1RA*	   	   LPS	   0.008	   0.092	  
Table	  6.11	  Variables	  that	  differed	  significantly	  (q<0.1)	  between	  survivors	  and	  non-­‐survivors	  at	  day	  
14	   following	   adjustment	   for	   baseline	   fungal	   burden.	   Those	   shaded	   in	   red	   are	   increased	   in	   non-­‐
survivors,	  those	  in	  green	  are	  reduced	  in	  non-­‐survivors.	  Variables	  marked	  *	  are	  log	  transformed.	  Other	  






























Figure	   6.22	   	   PCA	   examining	   relationship	   between	   blood	   immune	   response	   and	   day	   14	   outcome	  
(adjusted	   for	   baseline	   fungal	   load).	   (a)	   PCA	   plot	   showing	   distribution	   of	   subjects	   according	   to	  
baseline	   blood	   immune	   response.	   Subjects	   that	   died	   (blue)	   clustered	   together	   and	   were	   largely	  
separated	   from	   those	   who	   survived	   (yellow).	   (b)	   Distribution	   of	   the	   variables	   according	   to	   their	  
contribution	  to	  the	  first	  three	  components	  (red	  –	  increased	  in	  subjects	  who	  died;	  green	  –	  decreased	  
in	  subjects	  who	  died).	  
	  
Figure	  6.23	   	  Heat	  map	  illustrating	  relationship	  between	  baseline	  blood	  immune	  response	  and	  day	  
14	  outcome	  (adjusted	  for	   fungal	  burden).	  Non-­‐survivors	  (blue	  above)	  grouped	  together	  at	  the	  right	  
of	   the	   plot	   according	   to	   expression	   of	   20	   variables	   (red–	   increased	   expression;	   green	   –	   decreased;	  

















































6.4.2 Week	  4	  outcome	  
The	   differences	   in	   baseline	   immune	   response	   between	   individuals	   who	   died	   or	  
survived	  by	  week	  4	  were	  broadly	  similar	  to	  the	  results	  at	  day	  14	  [Table	  6.12].	  As	  with	  
day	  14	  outcome,	   the	   relative	  change	   in	  HLA-­‐DR	  expression	  between	  un-­‐stimulated	  
and	  stimulated	  blood	  was	  significantly	  higher	   in	  non-­‐survivors	   following	  any	  of	   the	  
four	   stimulations.	   In	   addition,	   individuals	   who	   died	   by	   week	   4	   had	   decreased	  
circulating	  monocytes	   and	  decreased	  monocyte	  HLA-­‐DR	   expression	   following	  GXM	  
stimulation.	   Furthermore,	  non-­‐survivors	  had	   reduced	   IL-­‐1RA	  and	   IL-­‐1β	   response	   to	  
LPS	   stimulation	   and	   reduced	   monocyte	   production	   of	   TNF-­‐α	   [Table	   6.12].	   For	  
completeness,	  the	  full	  univariate	  non-­‐parametric	  analysis	   is	   included	  in	  Appendix	  A	  
[Tables	   A.17-­‐A.22].	   PCA	   and	   heat	   map	   analysis	   showed	   a	   similar	   clustering	   of	  
subjects	  according	  to	  outcome	  [Figures	  6.24,	  6.25].	  
	  
Analyte	   Pop	   Stim	   P	   Q	   Analyte	   Pop	   Stim	   P	   Q	  
HLADR	  ratio*	   mono	   R848	   0.001	   0.037	   HLADR	   mono	   GXM	   0.002	   0.089	  
HLADR	  ratio*	   mono	   LPS	   0.000	   0.027	   %mono	   wbc	   GXM	   0.004	   0.092	  
HLADR	  ratio*	   mono	   GXM	   0.000	   0.027	   IL-­‐1RA*	   	   LPS	   0.003	   0.089	  
HLADR	  ratio*	   mono	   CW	   0.003	   0.089	   IL-­‐1b*	   	   LPS	   0.003	   0.089	  
%TNF-­‐ve*	   mono	   LPS	   0.001	   0.037	   	   	   	   	   	  
Table	  6.12	  	  Baseline	  differences	  between	  subjects	  who	  died	  or	  survived	  by	  week	  4.	  Red	  –	  increased	  
in	   individuals	   who	   died;	   green	   –	   decreased	   in	   individuals	   who	   died.	   Abbreviations	   are	   identical	   to	  
previous	  tables.	  	  
	  
Figure	  6.24	  	  PCA	  examining	  relationship	  between	  baseline	  blood	  immune	  response	  and	  outcome	  at	  
week	  4.	  (a)	  PCA	  plot	  shows	  clustering	  of	  survivors	  (yellow)	  and	  non-­‐survivors	  (blue).	  (b)	  Variables	  that	  














Figure	  6.25	  	  Heatmap	  illustrating	  relationship	  between	  baseline	  blood	  immune	  response	  and	  
outcome	  at	  week	  4.	  Hierarchal	  clustering	  is	  performed	  according	  to	  the	  expression	  of	  nine	  variables	  
(red	  –	  increased;	  green	  –	  decreased);	  subjects	  who	  died	  (blue)	  are	  seen	  to	  cluster	  together	  at	  the	  
right.	  
Adjustment	  for	  CSF	  fungal	  burden	  resulted	  in	  very	   little	  change	  to	  the	  analysis:	  the	  
number	  of	  variables	  that	  differed	  between	  groups	  was	  reduced	  from	  nine	  to	  seven,	  
and	   the	   appearances	   of	   the	   PCA	   plot	   remained	   relatively	   unchanged	   [Table	   6.13;	  
Figures	  6.26,	  6.27].	  	  
	  
Analyte	   Pop	   Stim	   P	   Q	   Analyte	   Pop	   Stim	   P	   Q	  
HLADR	  ratio*	   mono	   R848	   0.002	   0.075	   HLADR	   mono	   GXM	   0.003	   0.087	  
HLADR	  ratio*	   mono	   LPS	   0.001	   0.047	   IL-­‐1b*	   	   LPS	   0.002	   0.084	  
HLADR	  ratio*	   mono	   GXM	   <0.001	   0.047	   IL-­‐1RA*	   	   LPS	   0.001	   0.068	  
%TNF-­‐ve*	   mono	   LPS	   0.001	   0.047	   	   	   	   	   	  
Table	  6.13	   	  Baseline	  differences	  between	  subjects	  who	  died	  or	   survived	  by	  week	  4.	   (adjusted	   for	  
CFU).	   Red	   –	   increased	   in	   non-­‐survivors;	   green	   –	   decreased	   in	   non-­‐survivors.	   Abbreviations	   are	  















Figure	  6.26	  	  Relationship	  between	  baseline	  blood	  immune	  response	  and	  week	  4	  outcome	  adjusted	  
for	  CSF	  fungal	  burden.	  (a)	  PCA	  plot	  showing	  distribution	  of	  subjects	  according	  baseline	  blood	  immune	  
response.	  Subjects	  that	  died	  (blue)	  are	  seen	  to	  cluster	  together	  and	  are	  largely	  separate	  from	  subjects	  
who	  survived	  (yellow).	  (b)	  Variables	  that	  differed	  significantly	  between	  these	  two	  groups.	  
	  
Figure	   6.27	   	   Heatmap	   of	   outcome	   at	   week	   4	   adjusted	   for	   baseline	   fungal	   burden.	   Hierarchal	  
clustering	   is	   performed	   according	   to	   the	   expression	   of	   nine	   variables	   (red	   –	   increased;	   green	   –	  
decreased);	  subjects	  who	  died	  (blue)	  are	  seen	  to	  cluster	  together	  at	  the	  right.	  
Although	  similar	  differences	  in	  baseline	  variables	  to	  those	  mentioned	  in	  the	  previous	  
two	  sections	  were	  observed	  among	  individuals	  who	  died	  before	  week	  12	  compared	  
to	   survivors,	   none	   of	   these	   differences	   were	   significant	   using	   the	   q-­‐value	   cut-­‐off	  



















6.4.3 	  Predictive	  model	  for	  14-­‐day	  survival	  	  
To	  demonstrate	   the	  benefit	   of	   the	   immune	   signature	  described	   in	   section	  6.4.1	   in	  
predicting	   mortality	   within	   the	   first	   14	   days	   in	   the	   IICD	   cohort,	   the	   first	   principal	  
component	   (PC1)	   from	   that	   analysis	   (“the	   relationship	   between	   blood	   immune	  
response	   and	   day	   14	   outcome”	   [Table	   6.10;	   Figure	   6.20])	   was	   incorporated	   as	   a	  
single	  summative	  variable	   into	  a	   logistic	   regression	  model	   to	  predict	   fatal	  outcome	  
by	   day	   14.	   Analysis	   was	   restricted	   to	   37	   individuals	   in	   the	   cohort	   in	   whom	   full	  
immunological	  data	  was	  available	  for	  these	  variables.	  Variables	  that	  contributed	  to	  
PC1	  are	  listed	  below,	  including	  their	  relative	  weightings	  for	  reference	  [Table	  6.14].	  
	  	  
Variable	   PC1	  loading	  
mono	  HLADR	   -­‐0.221	  
HLADR	  	  CD14+CD16-­‐	   -­‐0.250	  
HLADR	  CD14+CD16+	  	   -­‐0.172	  
%Neut	   0.270	  
lL-­‐6	  (serum)	   0.271	  
CXCL10/IP-­‐10	  (serum)	   0.117	  
CRP	  (serum)	   0.195	  
IFN-­‐g	  (R848)	   -­‐0.180	  
IL-­‐12	  (R848)	   -­‐0.174	  
IL-­‐12	  (LPS)	   -­‐0.118	  
IFN-­‐g	  (LPS)	   -­‐0.177	  
TNF-­‐a	  -­‐ve	  mono	  (LPS)	   0.195	  
%mono	  (GXM)	   -­‐0.200	  
%neut	  (GXM)	   0.240	  
%neut	  (CW)	   0.263	  
mono	  HLADR	  (R848)	   -­‐0.260	  
mono	  HLADR	  (LPS)	   -­‐0.276	  
mono	  HLADR	  (GXM)	   -­‐0.280	  
mono	  HLADR	  (CW)	   -­‐0.260	  
mono	  HLADR	  ratio	  (R848)	   0.118	  
mono	  HLADR	  ratio	  (LPS)	   0.112	  
mono	  HLADR	  ratio	  (GXM)	   -­‐0.024	  
mono	  HLADR	  ratio	  (CW)	   0.058	  
IL-­‐10	  (serum)	   0.170	  
Table	  6.14	  Variables	  that	  contributed	  to	  PC1	  [Figure	  6.19]	  and	  their	  respective	  loadings.	  Values	  are	  
co-­‐efficients	   with	   range	   -­‐1	   to	   +1	   and	   illustrate	   relative	   loading	   to	   PC1.	   The	   five	   variables	   with	   the	  
largest	  contribution	  to	  PC1	  are	  highlighted;	  stimulating	  agent	  detailed	  in	  brackets	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Conscious	   level	  at	  presentation	  and	  CSF	  fungal	  burden	  were	  used	  to	  create	  a	  BASE	  
model	   (due	   to	   their	   previously	   demonstrated	   importance	   in	   predicting	   poor	  
outcome,	   [section	  4.7]	   (Jarvis	  et	  al.	  2014)).	  The	  addition	  of	  PC1	  to	  the	  BASE	  model	  
(PC1	  model)	  was	  shown	  to	  significantly	  improve	  the	  overall	  model	  fit,	  demonstrated	  
by	   a	   likelihood	   ratio	   test	   p=0.0001	   comparing	   the	   two	   models	   [Table	   6.15].	  
Furthermore,	   following	   the	   addition	   of	   PC1,	   the	   two	   base	   variables	   no	   longer	  
appeared	   to	   influence	  model	   fit	   to	   the	   same	  extent	   (p-­‐values	   from	   likelihood	   ratio	  
tests	  removing	  these	  variables	  were	  0.152	  and	  0.141	  for	  altered	  consciousness	  and	  
fungal	  burden	  respectively).	  
	  
Adjusted	  
Odds	  Ratio	   P-­‐value	   95%CI	  
GCS<15	  at	  presentation	   6.39	   0.152	   0.45-­‐90	  
CSF	  Fungal	  burden	  (log10CFU/mL)*	   2.09*	   0.141	   0.65-­‐6.66	  
Principal	  Component	  1†	  	   2.02†	   <0.001	   1.19-­‐3.43	  
Table	  6.15	   	   Logistic	   regression	  model	   to	  predict	  mortality	  at	  day	  14	   in	  CM	  –	  PC1	  model.	  Principal	  
component	  1	  from	  the	  analysis	  in	  Figure	  6.20	  was	  added	  to	  the	  BASE	  model	  of	  altered	  consciousness	  
and	   fungal	   burden.	   Analysis	   restricted	   to	   37	   individuals	   for	   which	   full	   immunological	   data	   was	  
available.	  *OR	  per	  log10	  increase	  in	  fungal	  burden;	  †OR	  per	  unit	  increase	  of	  PC1.	  	  
	  
Figure	   6.28	   –	   Receiver	   operating	   curves	   comparing	   predictive	   performance	   of	   the	   BASE	   and	   PC1	  
logistic	   regression	  models	   in	  predicting	   fatal	  outcome	  by	  day	  14	   (n=37).	  BASE	  model:	  GCS<15,	  CSF	  
fungal	  burden;	  PC1	  model:	  GCS<15,	  CSF	  fungal	  burden,	  PC1.	  Calculated	  areas	  under	  the	  ROC	  curves	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Receiver	   operating	   curves	   generated	   for	   these	   two	  models	   showed	   that	   the	   area	  
under	  the	  curve	  (AUC)	  for	  the	  PC1	  model	  was	  0.89,	  compared	  to	  0.71	  for	  the	  BASE	  
model	   [Figure	   6.28].	   However,	   this	   difference	   did	   not	   reach	   statistical	   significance	  
(p=0.107),	   this	   is	   likely	   to	   be	   a	   consequence	   of	   the	   low	   numbers	   of	   participants	  
involved	  in	  the	  analysis.	  	  
	  
The	   same	   principal	   component	   analysis	  was	   repeated	   but	   excluding	   variables	   that	  
were	   derived	   from	   whole	   blood	   antigen	   stimulation	   assays	   (the	   main	   reason	   for	  
missing	  data).	  This	  resulted	   in	  the	  following	  variables	  being	  used	  for	  a	   limited	  PCA:	  
neutrophil	  frequency	  (%);	  serum	  concentration	  of	  CRP,	  IL-­‐6,	  IL-­‐10	  and	  CXCL10/IP-­‐10;	  
HLA-­‐DR	   expression	   (MFI)	   on	   CD14++CD16-­‐	   monocytes,	   CD14++CD16+	   monocytes,	  
and	  total	  monocytes.	  Data	  were	  available	  for	  55	  subjects	  in	  the	  cohort.	  The	  PC1	  from	  
this	   analysis	   (Limited	   PC1)	   was	   similarly	   entered	   as	   a	   summative	   variable	   into	   a	  
logistic	   regression	  model	  along	  with	  altered	  consciousness	  and	  baseline	  CSF	   fungal	  
burden	   (Limited	   PC1	   model	   [Table	   6.16]).	   The	   addition	   of	   Limited	   PC1	   also	  
significantly	  improved	  the	  fit	  of	  the	  model	  (likelihood	  ratio	  test	  p<0.0001	  compared	  
to	  BASE	  model).	  When	  the	  performance	  of	  the	  two	  models	  was	  assessed	  for	  the	  55	  
individuals	  who	  had	  data	   to	   generate	  PC1,	   the	   areas	  under	   the	   receiver	   operating	  
curves	  were	  0.90	  and	  0.77	  for	  the	  Limited	  PC1	  model	  and	  BASE	  model	  respectively	  
[Figure	   6.29].	   However,	   this	   difference	   also	   did	   not	   reach	   statistical	   significance	  
(p=0.074).	  
	  
	   Adjusted	  Odds	  Ratio	   P-­‐value	   95%	  CI	  
GCS<15	  at	  presentation	   20.6	   0.012	   1.35-­‐314	  
CSF	  Fungal	  burden	  (log10CFU/mL)	   2.37*	   0.034	   0.89-­‐6.3	  
Principal	  Component	  1	  (limited)	   2.89†	   <0.001	   1.45-­‐5.75	  
Table	   6.16	   Logistic	   regression	  model	   to	   predict	  mortality	   at	   day	   14	   in	   CM	   –	   Limited	   PC1	  model.	  
Limited	   principal	   component	   1	   has	   been	   added	   to	   the	   BASE	   regression	   model	   described	   above.	  
Analysis	  restricted	  to	  55	  individuals	  for	  which	  immunological	  data	  was	  available.	  *Per	  1	  log10	  increase	  




Figure	  6.29	  -­‐	  Receiver	  operating	  curves	  comparing	  predictive	  performance	  of	  the	  BASE	  and	  Limited	  
PC1	   logistic	  regression	  models	   in	  predicting	  fatal	  outcome	  by	  day	  14	  (n=55).	  BASE	  model:	  GCS<15,	  
CSF	   fungal	   burden;	   Limited	   PC1	   model:	   GCS<15,	   CSF	   fungal	   burden,	   limited	   PC1.	   Calculated	   areas	  
under	  the	  two	  ROC	  curves	  are	  shown	  in	  the	  plot	  legend;	  no	  significant	  difference	  was	  noted	  between	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6.5 Discussion	  
In	  this	  chapter,	  the	  immune	  response	  in	  the	  blood	  of	  individuals	  with	  HIV-­‐associated	  
cryptococcal	  meningitis	  is	  characterized	  using	  a	  variety	  of	  techniques.	  The	  influence	  
of	   ART	   and	   CD4	   count	   are	   assessed,	   the	   relationship	   between	   blood	   immune	  
response	  and	  CSF	  fungal	   load	   is	  explored,	  and	   immune	  correlates	  of	   fatal	  outcome	  
are	  identified.	  Emphasis	  is	  placed	  on	  the	  activation	  of	  monocytes	  and	  their	  cytokine	  
responses	  but	  information	  on	  T	  cells,	  neutrophils	  and	  overall	  cytokine	  response	  are	  
also	  analysed.	  
6.5.1 Immune	  phenotype	  of	  cryptococcal	  meningitis	  
Monocyte	  phenotype	  in	  cryptococcal	  meningitis	  
Monocyte	   counts	   in	   individuals	   with	   HIV-­‐associated	   cryptococcal	   meningitis	   were	  
within	  normal	  laboratory	  limits	  and	  did	  not	  significantly	  differ	  from	  counts	  measured	  
in	  healthy	  or	  HIV-­‐infected	  controls.	  However,	  individuals	  with	  HIV-­‐associated	  CM	  did	  
have	   a	   significant	   expansion	   of	   the	   non-­‐classical	   (CD14+CD16++)	  monocyte	   subset	  
compared	   to	  healthy	  controls.	  Both	   intermediate	   (CD14++CD16+)	  and	  non-­‐classical	  
(CD14+CD16++)	  monocytes	  have	  a	  more	  pro-­‐inflammatory	  phenotype	  compared	  to	  
classical	   monocytes	   (CD14++CD16-­‐)	   and	   are	   characterized	   by	   increased	   antigen	  
presentation	  and	  pro-­‐inflammatory	  cytokine	  production	   (Belge	  et	  al.	  2002;	  Ziegler-­‐
Heitbrock	   2006).	   Expansion	   of	   these	   two	  monocyte	   subsets	   have	   been	   previously	  
described	   in	  a	  number	  of	   inflammatory	  conditions	   including	  HIV-­‐1	   infection,	  where	  
increases	   in	   the	   intermediate	  monocyte	  population	  appear	   to	  be	  closely	   related	  to	  
the	  degree	  of	  viraemia	  (Ziegler-­‐Heitbrock	  2006;	  Ansari	  et	  al.	  2012;	  Funderburg	  et	  al.	  
2012;	  Han	  et	  al.	  2009).	  In	  this	  study,	  although	  the	  median	  frequency	  of	  intermediate	  
monocytes	   was	   higher	   in	   individuals	   with	   CM	   compared	   to	   healthy	   controls,	   this	  
difference	   was	   not	   statistically	   significant.	   This	   may	   be	   due	   to	   methodological	  
differences,	  a	  lack	  of	  statistical	  power,	  or	  differences	  in	  the	  degree	  of	  HIV-­‐1	  disease	  
between	  the	  study	  populations.	  	  
	  
Individuals	  with	  CM	  were	  also	  noted	  to	  have	  significantly	  reduced	  expression	  of	  the	  
chemokine	   receptors	  CCR2	  and	  CCR5	  on	  circulating	  blood	  monocytes	  compared	   to	  
healthy	  controls	  but	  not	  when	  compared	  with	  HIV-­‐infected	  controls.	  This	  was	  noted	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on	  the	  classical	  and	  non-­‐classical	  monocyte	  subsets,	  and	  the	  monocyte	  population	  as	  
a	  whole.	  CCR2/MCP-­‐1	  and	  CCR5/RANTES	  are	  integral	  to	  the	  migration	  of	  monocytes	  
to	  the	  tissues	  (CCR2	  binds	  CCL2/MCP-­‐1;	  CCR5	  binds	  CCL3/MIP-­‐1α,	  CCL4/MIP-­‐1β	  and	  
CCL5/RANTES)	  (Matsushima	  et	  al.	  1989;	  Samson	  et	  al.	  1996;	  Hsieh	  et	  al.	  2014).	  CCR5	  
is	  also	  a	  co-­‐receptor	  for	  HIV-­‐1	  viral	  entry,	  the	  blocking	  of	  which	  (with	  agents	  such	  as	  
maraviroc)	   is	   now	   a	   component	   of	   anti-­‐retroviral	   therapy	   (Alkhatib	   et	   al.	   1996;	  
Fätkenheuer	  et	  al.	  2005).	  Although	  the	  down	  regulation	  of	  CCR5	  expression	  may	  be	  
beneficial	   in	   reducing	   cellular	   infection	  with	  HIV-­‐1,	   it	   is	   likely	   to	   result	   in	   impaired	  
monocyte	   migration	   to	   sites	   of	   infection	   or	   inflammation	   similar	   to	   that	   seen	  
following	   pharmacologic	   blockade	   of	   the	   receptor	   (Rossi	   et	   al.	   2011).	   The	   down	  
regulation	  of	  chemokine	  receptors	  in	  CM	  is	  in	  contrast	  to	  studies	  that	  have	  analyzed	  
monocyte	  gene	  expression	  profiles	  from	  HIV-­‐1	  infected	  individuals	  that	  have	  shown	  
increased	  expression	  of	  both	  CCR2	  and	  CCR5	  (Pulliam	  et	  al.	  2004).	  These	  contrasting	  
findings	   are	   most	   likely	   to	   be	   due	   to	   differences	   in	   the	   severity	   of	   HIV-­‐1	   disease	  
between	  the	  study	  populations	  (CD4	  count	  was	  significantly	  lower	  in	  this	  study	  and	  
subjects	   had	   an	   active	   opportunistic	   infection).	   Of	   note,	   novel	   populations	   of	  
CD14++CD16-­‐	  monocytes	  with	   reduced	  expression	  of	  CCR2	  have	  been	  described	   in	  
both	   HIV-­‐1	   infected	   adults	   and	   rhesus	   macaques	   with	   acute	   SIV	   infection;	  
transcriptome	   analysis	   of	   such	   cells	   suggest	   a	   cellular	   phenotype	   similar	   to	  
monocytic	  myeloid-­‐derived	  suppressor	  cells	  with	  reduced	  pro-­‐inflammatory	  cytokine	  
production	  (Gama	  et	  al.	  2012).	   It	   is	  not	  possible	  to	  determine	  whether	  similar	  cells	  
were	  present	  among	  subjects	  in	  this	  study	  due	  to	  the	  confines	  of	  the	  flow	  cytometry	  
panel	  used.	  
	  
No	  convincing	  differences	   in	  monocyte	  activation	  state	  or	  cytokine	  responses	  were	  
noted	  between	   individuals	  with	  HIV-­‐associated	  CM	  and	  healthy	  controls.	  However,	  
compared	  to	  HIV-­‐infected	  controls,	   individuals	  with	  CM	  had	  significantly	  decreased	  
expression	   of	   HLA-­‐DR	   on	   the	   surface	   of	   circulating	   monocytes	   and	   significantly	  
reduced	  proportions	  of	  TNF-­‐α	  producing	  monocytes	  or	   IL-­‐12	  producing	  monocytes	  
following	  LPS	  (TLR4)	  or	  R848	  (TLR7/8)	  stimulation.	  In	  addition,	  the	  proportion	  of	  IL-­‐6	  
producing	   monocytes	   following	   exposure	   to	   either	   of	   the	   two	   cryptococcal	  
preparations	  was	  also	  reduced	  among	  individuals	  with	  CM	  compared	  to	  HIV-­‐infected	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controls.	   Previous	   studies	   have	   shown	   HIV-­‐1	   infection	   to	   be	   associated	   with	   an	  
increase	  in	  both	  monocyte	  and	  macrophage	  responses	  to	  LPS	  (Dutertre	  et	  al.	  2012;	  
Bergamini	   et	   al.	   1999;	   Baqui	   et	   al.	   2000).	   	   The	   fact	   that	   this	   did	   not	   occur	   in	  
individuals	   with	   CM	   suggests	   a	   relative	   down	   regulation	   of	   monocyte	   activation	  
compared	  to	  HIV-­‐infected	  controls.	  It	  is	  possible	  this	  could	  be	  a	  consequence	  of	  the	  
lower	  CD4	  count	  and	  more	  advanced	  HIV-­‐1	  disease	  seen	  in	  this	  group	  of	  individuals.	  
However,	   it	   is	  also	  possible	   it	  could	  be	  a	  direct	  anti-­‐inflammatory	  effect	  of	  GXM	  as	  
previously	  described	  with	  other	   aspects	  of	   the	   immune	   response	   (Ellerbroek	  et	   al.	  
2002;	   Yauch	   et	   al.	   2006).	   Given	   the	   low	   numbers	   of	   HIV-­‐infected	   controls	   in	   this	  
study,	  these	  findings	  should	  be	  interpreted	  with	  caution.	  	  
	  
Whole	  blood	  cytokine	  responses	  in	  cryptococcal	  meningitis	  
In	   contrast	   to	   the	   monocyte	   cytokine	   responses	   described	   above,	   whole	   blood	  
cytokine	   responses	   did	   show	   significant	   differences	   between	   individuals	   with	   CM	  
and	   healthy	   controls.	   However,	   unlike	   in	   vivo	   studies	   that	   have	   demonstrated	   an	  
increase	  in	  pro-­‐inflammatory	  cytokine	  response	  to	  LPS	  with	  HIV-­‐1	  infection	  (da	  Silva	  
et	  al.	  1999),	  individuals	  with	  CM	  had	  a	  significantly	  reduced	  ex	  vivo	  IFN-­‐α,	  IL-­‐12	  and	  
IFNγ	  production	  following	  TLR4	  or	  TLR7/8	  stimulation.	  It	  is	  possible	  that	  these	  results	  
may	   reflect	   the	   differing	   degree	   of	   CD4	   cell	   depletion	   between	   HIV-­‐infected	  
individuals	   in	   the	   two	   studies.	   However,	   given	   the	   neutrophilia	   and	   significantly	  
increased	   concentration	   of	   pro-­‐inflammatory	   cytokines	   in	   individuals	   with	   CM	  
compared	   to	   both	   control	   groups,	   it	   is	   also	   possible	   that	   the	   decreased	   cytokine	  
responses	   are	   due	   to	   down	   regulation	   related	   to	   negative	   feedback	   through	  
regulatory	  components	  of	  the	  immune	  response.	  	  
	  
T	  cell	  phenotype	  in	  cryptococcal	  meningitis	  
Compared	  to	  healthy	  controls,	   individuals	  with	  HIV-­‐associated	  CM	  had	  significantly	  
lower	  CD4	  counts,	  significantly	  increased	  HLA-­‐DR	  and	  PD-­‐1	  expression	  on	  CD4	  T	  cells,	  
and	  significantly	   increased	  HLA-­‐DR,	  CD38,	  and	  PD-­‐1	  expression	  on	  CD8	  and	  double	  
negative	  T	   cells.	  When	   compared	   to	  HIV-­‐infected	   controls,	  HLA-­‐DR	  expression	  was	  
increased	  on	  CD4	  cells	  among	   individuals	  with	  CM	  but	  not	  on	   the	  other	   two	  T	  cell	  
subsets.	  However,	  individuals	  with	  CM	  had	  significantly	  increased	  expression	  of	  PD-­‐1	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on	   all	   T	   cells	   subsets	   compared	   to	   HIV-­‐infected	   controls.	   Taken	   together	   these	  
findings	  are	  suggestive	  of	  a	  T	  cell	  phenotype	  in	  CM	  that	  is	  characterized	  by	  increased	  
cellular	   activation	   but	   also	   increased	   cellular	   exhaustion.	   This	   is	   consistent	   with	  
previous	  studies	  that	  have	  shown	  these	  two	  processes	  to	  be	  important	  components	  
of	  HIV-­‐1	  pathogenesis	  (Hazenberg	  et	  al.	  2003;	  Biancotto	  et	  al.	  2008;	  Day	  et	  al.	  2006;	  
Porichis	  et	  al.	  2011).	  
	  
In	  summary,	  when	  compared	  to	  healthy	  controls,	  individuals	  with	  HIV-­‐associated	  CM	  
had	   a	   blood	   immune	   phenotype	   characterized	   by	   CD4	   cell	   depletion,	   increased	  
inflammation,	  decreased	  monocyte	  chemokine	  expression	  and	  immune	  exhaustion;	  
when	  compared	  to	  HIV-­‐infected	  controls	  with	  no	  opportunistic	  infection,	  individuals	  
with	   CM	   had	   decreased	   monocyte	   activation,	   decreased	   monocyte	   cytokine	  
responses	  following	  TLR	  4	  or	  7/8	  stimulation,	  and	  evidence	  of	  T	  cell	  exhaustion.	  	  
	  
6.5.2 Factors	  influencing	  immune	  response	  
Effect	  of	  ART	  on	  immune	  response	  in	  blood.	  	  
Although	  individuals	  taking	  effective	  ART	  did	  have	  increased	  frequency	  of	  circulating	  
CD4	   T	   cells	   compared	   to	   those	   not	   taking	   ART,	   these	   differences	   were	   no	   longer	  
significant	   when	   adjusted	   for	   multiple	   testing	   (q<0.1);	   furthermore,	   ART	   had	   no	  
effect	  on	  monocyte	  populations,	  activation	  or	  ex-­‐vivo	  functional	  responses.	  This	  is	  in	  
contrast	  to	  the	  findings	  in	  the	  CSF,	  where	  clear	  differences	  in	  the	  CD4/CD8	  ratio	  and	  
the	  activation	  state	  of	  monocyte-­‐macrophages	  were	  noted	  [section	  5.6.2].	  Although	  
it	   is	   possible	   that	   the	   increased	   numbers	   of	   variables	   examined	   in	   blood	   assays	  
affected	   the	   statistical	   power	   of	   the	   analysis	   after	   correction	   for	   multiple	  
comparisons	  (resulting	  in	  increased	  q-­‐values),	  the	  lack	  of	  findings	  suggests	  that	  ART	  
has	  a	  more	  dramatic	  effect	  on	   immune	  response	  at	   the	  site	  of	  disease	   than	   in	   the	  
blood.	   Compartmentalization	   of	   immune	   response	   has	   previously	   been	  
demonstrated	   in	   both	   cryptococcal	   and	   tuberculous	   meningitis	   with	   increased	  
inflammation	  seen	  in	  the	  CSF	  compared	  to	  blood	  (Naranbhai	  et	  al.	  2014;	  Marais	  et	  al.	  
2014).	  However,	  the	  differing	  effect	  of	  ART	  on	  the	  two	  compartments	  has	  not	  been	  
widely	  studied.	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Relationship	  between	  fungal	  burden,	  CD4	  count	  and	  immune	  response	  	  
An	   interconnected	   relationship	   between	   CD4	   count,	   immune	   response	   and	   fungal	  
burden	   was	   demonstrated.	   Increased	   CSF	   fungal	   load	   was	   associated	   with	   an	  
decreased	  peripheral	  CD4	  count	  and	  increased	  frequency	  of	  blood	  neutrophils,	  along	  
with	  decreased	  whole	  blood	  IFN-­‐γ	  responses	  to	  both	  LPS	  and	  GXM.	  This	  is	  consistent	  
with	   previous	   studies	   that	   have	   shown	   increased	   fungal	   burden	   to	   be	   associated	  
with	  reduced	  IFN-­‐γ	  concentrations	  in	  the	  CSF	  and	  a	  peripheral	  blood	  antigen	  specific	  
CD4	  phenotype	  characterised	  by	  increased	  MIP-­‐1α/CCL3	  production	  and	  decreased	  
IFN-­‐γ	   and/or	   TNF-­‐α	   production	   (Jarvis	   et	   al.	   2013;	   Siddiqui	   et	   al.	   2005).	   Taken	  
together,	   these	   findings	   suggest	   that	   high	   CSF	   fungal	   burdens	   occur	   among	  
individuals	   with	   low	   CD4	   counts	   and	   decreased	   Th1	   responses.	   The	   observed	  
neutrophilia	   is	   likely	   to	   reflect	  an	   ineffective	   response	   to	   the	  uncontrolled	   invasive	  
fungal	  infection.	  
6.5.3 Immune	  correlates	  of	  fatal	  outcome	  
Fatal	   cases	   of	   HIV-­‐asscociated	   cryptococcal	   meninigitis	   were	   observed	   to	   have	   a	  
particular	   immune	   signature,	   characterised	   by	   increased	   frequency	   of	   neutrophils,	  
increased	  soluble	  markers	  of	  immune	  activation	  (IL-­‐6,	  CRP,	  CXCL10/IP-­‐10),	  increased	  
anti-­‐inflammatory	   mediators	   (IL-­‐10),	   reduced	   whole	   blood	   pro-­‐inflammatory	  
cytokine	  production	  following	  TLR4	  or	  TLR7/8	  stimulation	  (IFNγ,	   IL-­‐12,	   IL-­‐1β	  and	   IL-­‐
1RA),	  decreased	  HLA-­‐DR	  expression	  on	  circulating	  monocytes	   (both	  stimulated	  and	  
unstimulated),	   and	   decreased	   monocyte	   production	   of	   TNF-­‐α	   following	   LPS	  
stimulation	   [Figure	   6.19].	   Given	   the	   significant	   multicollinearity	   of	   the	   variables,	  
principal	  component	  analysis	  was	  used	  to	  analyze	  the	  data.	  64%	  of	  variance	  in	  these	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  variables	  could	  be	  summarized	  by	  just	  the	  first	  three	  principal	  components;	  when	  
entered	  into	  a	  regression	  model,	  principal	  component	  1	  (PC1),	  summarizing	  41%	  of	  
total	   sample	   variance,	   was	   found	   to	   be	   significantly	   associated	   with	   increased	  
probability	  of	  mortality	  within	  the	  first	  2	  weeks	  of	  the	  study	  even	  when	  adjusted	  for	  
conscious	  level	  and	  baseline	  fungal	  burden.	  This	  suggests	  that	  dysfunctional	  immune	  
response	  may	  be	  an	  important	  determinant	  of	  poor	  outcome	  in	  CM.	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One	  of	  the	  main	  aspects	  of	  this	  immune	  signature	  was	  the	  decreased	  expression	  of	  
HLA-­‐DR	  on	  circulating	  monocytes.	  HLA-­‐DR	  is	  a	  glycosylated	  transmembrane	  protein	  
expressed	  on	  the	  surface	  of	  monocytes,	  macrophages,	  B	  cells	  and	  dendritic	  cells.	  As	  
a	  MHC	  class	  II	  molecule,	  it	  plays	  a	  major	  role	  in	  antigen	  presentation	  to	  CD4	  T	  cells	  
(Cheadle	   1993).	   Reduced	   expression	   of	   HLA-­‐DR	   on	   the	   surface	   of	   monocytes	   has	  
been	   reported	   in	   a	   variety	   of	   infective	   and	   inflammatory	   conditions;	   possible	  
mechanisms	  include	  increased	  surface	  shedding,	  decreased	  cellular	  transcription	  and	  
post-­‐translational	  inhibition	  of	  expression	  (Monneret,	  et	  al.	  2004;	  Perry	  et	  al.	  2004).	  
As	  observed	   in	   this	   study,	  decreased	  monocyte	  expression	  of	  HLA-­‐DR	   is	   frequently	  
associated	   with	   reduced	   TNF-­‐α	   response	   following	   stimulation	   with	   LPS,	   the	  
combination	  of	  these	  two	  features	  is	  described	  as	  “monocyte	  anergy”	  (Williams	  et	  al.	  
1998;	  Döcke	  et	  al.	  1997;	  Monneret,	  et	  al.	  2004).	  Although	  most	  frequently	  studied	  in	  
the	  context	  of	  bacterial	   sepsis,	  monocyte	  anergy	  has	  been	  reported	   in	  a	  variety	  of	  
other	  conditions	  including	  acute	  pancreatitis,	  multiple	  trauma,	  hepatic	  cirrhosis,	  and	  
in	  premature	  infants	  (Kylanpaa	  et	  al.	  2005;	  Williams	  et	  al.	  1998;	  West	  &	  Mold	  2012)	  
(Birle	  et	  al.	  2003;	  Palojärvi	  et	  al.	  2013;	  Antoniades	  et	  al.	  2005).	  In	  addition	  to	  being	  a	  
feature	   of	   these	   conditions,	   monocyte	   anergy	   has	   frequently	   been	   found	   to	   be	  
associated	   with	   a	   worse	   prognosis,	   such	   as	   increased	   mortality	   from	   sepsis	   and	  
increased	   susceptibility	   to	   infections	   in	   severe	   trauma	   (Lekkou	   et	   al.	   2004;	  
Muehlstedt	  et	  al.	  2002).	  	  
	  
Monocyte	   anergy	   forms	   a	   central	   component	   of	   the	   compensatory	   anti-­‐
inflammatory	   response	   syndrome	   (CARS),	   a	   profound	   down	   regulation	   of	   the	  
immune	  response	  following	  major	  pro-­‐inflammatory	   insult	   (Bone	  1996;	  Ward	  et	  al.	  
2008).	   In	   addition	   to	   the	   features	   of	   monocyte	   anergy,	   CARS	   is	   characterized	   by	  
increased	  lymphocyte	  apoptosis,	  reduced	  T	  cell	  proliferative	  and	  cytokine	  responses,	  
and	  cutaneous	  anergy	  (Ward	  et	  al.	  2008;	  Bone	  1996).	  Although	  T	  cell	  responses	  were	  
not	  examined	  specifically	   in	  this	  study,	  subjects	  who	  died	  by	  day	  14	  had	  decreased	  
concentrations	  of	  IL-­‐12	  and	  IFN-­‐γ	  in	  the	  supernatant	  of	  LPS	  or	  R848	  stimulated	  whole	  
blood,	   suggesting	   additional	   impairment	   of	   adaptive	   immune	   responses.	   IL-­‐12	   is	  
produced	  by	  monocytes,	  macrophages	  and	  dendritic	  cells,	  and	  acts	  (alongside	  IL-­‐15	  
and	   IL-­‐18)	   to	  promote	   IFN-­‐γ	   production	  by	  NK	  and	  CD4	  T	   cells	   (Varma	  et	  al.	   2001;	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Varma	   et	   al.	   2002;	   Kanevskiy	   et	   al.	   2013;	   Schroder	   2003).	   IFN-­‐γ	   is	   known	   to	   be	  
integral	   to	   the	   host	   defence	   against	   C.	   neoformans:	   observational	   studies	   have	  
demonstrated	  an	  association	  between	  low	  CSF	  levels	  and	  fatal	  outcome	  (Siddiqui	  et	  
al.	   2005);	   a	   clinical	   trial	   has	   demonstrated	   the	   benefits	   of	   adjunctive	   IFN-­‐γ	   in	  
improving	  the	  rate	  of	  fungal	  clearance	  (Jarvis	  et	  al.	  2012);	  and	  fatal	  outcome	  in	  CM	  
has	  been	  shown	  to	  be	  associated	  with	  a	  CD4	  T	  cell	  phenotype	  characterised	  by	  a	  lack	  
of	   IFN-­‐γ	   and	  TNF-­‐α	   production	   (Jarvis	   et	   al.	   2013).	   These	   findings	   suggest	   that	   the	  
impaired	   IFN-­‐γ	   responses	   observed	   among	   individuals	   with	   CM	   who	   have	   a	   fatal	  
outcome	   may	   be	   due	   to	   reduced	   antigen	   presentation	   and	   IL-­‐12	   production	   by	  
anergic	  monocytes.	  	  
	  
Studies	   in	   bacterial	   sepsis	   have	   suggested	   that	   the	   development	   of	   CARS	   is	  
dependent	  on	  the	  actions	  of	   IL-­‐10	  (Muehlstedt	  et	  al.	  2002;	  Monneret,	  et	  al.	  2004).	  
Increased	  plasma	   levels	  of	   IL-­‐10	  were	  observed	  among	  non-­‐survivors	   in	   this	   study,	  
and	   may	   explain	   the	   alterations	   in	   immune	   parameters	   described	   above.	   In-­‐vitro	  
studies	   have	   shown	   that	   the	   presence	   of	   IL-­‐10	   directly	   inhibits	   pro-­‐inflammatory	  
cytokine	  responses	  of	  macrophages	  and	  their	  ability	  to	  present	  antigen,	  resulting	  in	  
additional	  impairment	  of	  CD4	  T	  cell	  IFN-­‐γ	  production	  (Fiorentino,	  Zlotnik,	  Mosmann,	  
et	   al.	   1991a;	   Fiorentino,	   Zlotnik,	   Vieira,	   et	   al.	   1991b).	   Murine	   studies	   have	   also	  
shown	  that	  significantly	  impaired	  T	  cell	  responses	  (decreased	  proliferation	  and	  IFN-­‐γ	  
production)	  occur	  	  when	  monocyte	  anergy	  is	  induced	  through	  pre-­‐exposure	  to	  LPS,	  a	  
phenomenon	   known	   as	   endotoxin	   tolerance;	   this	   process	   was	   also	   shown	   to	   be	  
dependent	  on	  the	  presence	  of	  IL-­‐10	  (Varma	  et	  al.	  2001;	  Wolk	  et	  al.	  2000;	  Draisma	  et	  
al.	  2009).	  	  
	  
Although	  the	  evidence	  for	  a	  CARS-­‐like	  immune	  response	  among	  individuals	  with	  fatal	  
HIV-­‐associated	   CM	   in	   this	   study	   is	   compelling,	   the	   reasons	   why	   these	   individuals	  
developed	  the	  condition	  are	  not	  immediately	  apparent,	  and	  were	  not	  simply	  related	  
to	   low	  CD4	  count.	   It	   is	  possible	   that	   the	  condition	  may	  have	  developed	  as	  a	  direct	  
result	  of	  invasive	  infection	  with	  C.	  neoformans,	  especially	  as	  the	  major	  component	  of	  
the	   cryptococcal	   capsule	   glucuronoxylomannan	   (GXM)	   is	   known	   to	   have	   anti-­‐
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inflammatory	  properties	  (Yauch	  et	  al.	  2006;	  Ellerbroek	  et	  al.	  2002).	  Alternatively,	  it	  is	  
possible	   that	  participants	   in	   this	   study	  may	  have	  died	   from	  unrecognised	  bacterial	  
sepsis.	   As	   described	   above,	   this	   is	   a	   well-­‐recognized	   cause	   for	   CARS	   (Ward	   et	   al.	  
2008);	  however,	  baseline	  blood	  cultures	  were	  perfomed	  at	  enrolment	   in	  46	  out	  of	  
the	  60	  participants	  and	  identified	  no	  significant	  bacterial	  pathogens.	  
	  
A	   final	   explanation	   for	   the	   development	   of	   a	   CARS-­‐like	   immune	   response	   in	   fatal	  
cases	   of	   cryptococcal	   meningitis	   is	   HIV-­‐1	   infection	   itself.	   Persistant	   immune	  
activation	   is	   a	   central	   component	   of	   HIV-­‐1	   pathophysiology	   and	   is	   thought	   to	   be	  
driven	   either	   directly	   by	   persistent	   viral	   replication	   and	   the	   production	   of	   viral	  
proteins,	   or	   indirectly	   through	   translocation	   of	   microbial	   products	   through	   the	  
intestinal	  wall	  (Brenchley	  et	  al.	  2006;	  Hazenberg	  et	  al.	  2003;	  Appay	  &	  Sauce	  2008).	  It	  
is	   possible	   that	   this	   persistant	   immune	  activation	  over	  many	   years	  may	  eventually	  
result	  in	  a	  downregulation	  of	  immune	  responses	  leading	  to	  the	  features	  of	  CARS	  as	  
described	   above.	   Increased	   IL-­‐10	   levels	   have	   been	   reported	   among	   HIV-­‐infected	  
individuals	   as	   disease	   progresses	   and	   increased	   markers	   of	   systemic	   immune	  
activation	  such	  as	   IL-­‐6	  and	  CRP	  have	  been	  repeatedly	  shown	  to	  be	  associated	  with	  
fatal	   outcome	   in	   cohort	   studies	   (Stylianou	   et	   al.	   1999;	   Boulware	   et	   al.	   2010b;	  
Boulware	   et	   al.	   2011;	   Rautonen	   et	   al.	   1991;	   Breen	   et	   al.	   1990;	   Birx	   et	   al.	   1990).	  
Furthermore,	   IL-­‐6	   has	   also	   been	   shown	   to	   have	   anti-­‐inflammatory	   actions	   and	   in	  
murine	  experiments	  results	  in	  impaired	  macrophage	  cytokine	  responses	  to	  LPS	  and	  a	  
M2	  macrophage	  phenotype	  (Mauer	  et	  al.	  2014).	  Both	  IL-­‐10	  and	  IL-­‐6	  are	  produced	  by	  
monocytes	   following	   stimulation	   with	   HIV-­‐1	   viral	   proteins	   (Ji	   et	   al.	   2005);	   the	  
elevated	  concentrations	  among	  non-­‐survivors	  observed	  in	  this	  study	  suggest	  that	  the	  
monocytes	  of	  these	   individuals	  were	  excessively	  activated,	  possibly	  resulting	   in	  the	  
development	  of	  anergy.	  	  
	  
The	  role	  monocytes	  play	  in	  the	  pathophysiology	  of	  other	  HIV-­‐associated	  conditions,	  
such	  as	  cardiac	  disease	  and	  HIV-­‐associated	  neurocognative	  disorder,	   is	   increasingly	  
recognized	   (Wilson	   et	   al.	   2014;	   Kedzierska	  &	  Crowe	  2002;	   K.	   C.	  Williams	  &	  Hickey	  
2002;	  Burdo	  et	   al.	   2011b).	   The	   findings	   in	   this	   chapter	   suggest	   that	   they	  may	  also	  
play	  an	  important	  role	  in	  determining	  outcome	  from	  opportunistic	  infections	  among	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persons	  with	  AIDS.	  The	  anergic	  state	  of	  circulating	  monocytes	  among	  persons	  who	  
died	   from	   cryptococcal	   meningitis	   appeared	   to	   result	   not	   only	   in	   impairment	   of	  
innate	   immunity,	   but	   also	   a	   possible	   impairment	   of	   T	   cell	   function,	   and	   down	  
regulation	  of	   the	   immune	  responses	  as	  a	  whole.	  Although	  this	   study	   is	  not	  able	   to	  
demonstrate	   causality,	   the	   actions	   of	   IL-­‐10	   are	   well	   described	   and	   the	   effects	   of	  
anergic	   monocytes	   on	   adaptive	   immunity	   have	   previouisly	   been	   demonstrated	   in	  
vitro	   and	   and	   in	   murine	   models.	   It	   therefore	   seems	   logical	   that	   monocyte	  
dysfunction	  may	   not	   simply	   be	   a	  marker	   of	   poor	   outcome	   but	   could	   also	   explain	  
some	   of	   the	   mechanisms	   involved	   in	   the	   poor	   outcome	   of	   persons	   with	   HIV-­‐
associated	  cryptococcal	  meningitis.	  	  
6.5.4 Limitiations	  
The	  analyses	  presented	  in	  this	  chapter	  have	  a	  number	  of	  limitations.	  The	  study	  was	  
small	   and	   underpowered,	   particularly	   the	   comparisons	   between	   individuals	   with	  
cryptococcal	   meningitis,	   healthy	   controls	   and	   HIV-­‐infected	   controls	   [section	   6.2].	  
This	   was	   mainly	   due	   to	   the	   difficulty	   in	   selecting	   suitable	   HIV-­‐infected	   control	  
patients	   with	   a	   sufficiently	   low	   CD4	   count	   but	   no	   evidence	   of	   an	   opportunistic	  
infection.	   Out	   of	   ten	   individuals	   originally	   identified	   to	   be	   enrolled	   in	   this	   group,	  
three	  had	  symptoms	  suggestive	  of	  TB	  and	  were	  not	  enrolled,	  and	  two	  were	  enrolled	  
but	   later	  excluded	  as	  a	  diagnosis	  of	  TB	  was	  made	  on	  sputum	  culture.	  Furthermore,	  
no	   significant	   effort	   was	   made	   to	   adjust	   for	   multiple	   comparisons.	   However,	   the	  
main	  aim	  of	  this	  part	  of	  the	  chapter	  was	  simply	  to	  provide	  background	  information	  
on	   which	   to	   base	   the	   interpretion	   of	   subsequent	   immunological	   analysis;	   in	   this	  
respect	   it	   remains	   useful.	   In	   the	   main	   cohort,	   the	   number	   of	   subjects	   were	   still	  
relatively	  low,	  there	  was	  significant	  inter-­‐subject	  heterogeneity	  and	  a	  large	  number	  
of	  variables	  were	  measured.	  This	  is	  a	  consequence	  of	  the	  study	  design	  (primarily	  an	  
exploratory	  study)	  but	   is	  an	  increasing	  feature	  of	  biological	  and	  particularly	  genetic	  
research.	   Efforts	   were	  made	   to	   control	   for	   the	   risk	   of	   a	   type	   I	   statistical	   error	   by	  
using	   the	   false	   discovery	   rate	   (q-­‐value)	   to	   determine	   statistical	   significance.	   By	  
definition	  this	  will	  not	  eliminate	  the	  risk	  of	  type	  I	  error	  but	  control	  it	  such	  that	  10%	  of	  
variables	  determined	  to	  be	  statistically	   significant	  will	  be	   false	  positives;	  compared	  
to	  more	   stringent	  methods	   of	   adjusting	   for	   statistical	   testing	   (such	   as	   Bonferroni)	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using	   the	   false	   discovery	   rate	   results	   in	   a	   significantly	   reduced	   chance	   of	   a	   type	   II	  
statistical	   error.	   In	   contrast	   to	   p-­‐values,	   there	   is	   less	   consensus	   in	   what	   q-­‐value	  
should	  be	  labelled	  as	  statistically	  significant	  and	  values	  of	  0.05	  to	  0.1	  have	  been	  used	  
elsewhere	  (Coussens	  et	  al.	  2012;	  Duffy	  et	  al.	  2014));	  due	  to	  the	  exploratory	  nature	  of	  
this	  study	  0.1	  has	  been	  consistently	  reported.	  Consequently,	  greater	  emphasis	  was	  
placed	  on	  the	  interpretation	  of	  variables	  in	  which	  a	  number	  of	  similar	  measurements	  
had	   been	   made	   (e.g.	   in	   non-­‐survivors,	   HLA-­‐DR	   expression	   was	   reduced	   both	   on	  
resting	  and	  all	  four	  types	  of	  stimulated	  monocytes).	  	  
With	  regard	  to	  technical	  issues,	  flow	  cytometry	  was	  performed	  in	  real-­‐time	  on	  fresh	  
whole	  blood	  (rather	  than	  frozen	  peripheral	  blood	  mononuclear	  cells).	  Although	  this	  
reduced	   the	   possibility	   that	   processing	   and	   handling	   of	   blood	   could	   alter	   the	  
monocyte	  activation	  state	  (Tippett	  et	  al.	  2011),	  it	  did	  make	  the	  assays	  vulnerable	  to	  
time-­‐related	  changes	  in	  flow	  cytometer	  set-­‐up.	  To	  avoid	  this,	  assays	  were	  performed	  
to	   a	   standard	   protocol	   and	   application	   settings	   were	   saved	   in	   FACS	   diva.	   An	  
additional	  consequence	  of	  not	  saving	  cells	  was	  that	  assays	  could	  not	  be	  repeated	  in	  
the	   event	   of	   a	   technical	   problem.	   One	   such	   problem	   was	   the	   suspected	  
contamination	   of	   a	   batch	   of	   sodium	   heparin	   blood	   collection	   tubes	  with	   LPS.	   This	  
was	  rapidly	  identified	  and	  rectified	  but	  resulted	  in	  a	  number	  of	  subjects	  having	  data	  
from	   whole	   blood	   antigen	   stimulation	   assays	   removed	   from	   the	   analysis.	   Finally,	  
although	   the	  models	  used	   to	  predict	   fatal	  outcome	  performed	  well	  on	   this	  cohort,	  
no	  attempt	  was	  made	  to	  split	  the	  cohort	  into	  training	  and	  testing	  sets	  due	  to	  the	  low	  
numbers	  of	  participants.	  As	  such,	  these	  results	  need	  to	  be	  validated	  on	  other	  cohorts	  
of	  patients	  with	  HIV-­‐associated	  cryptococcal	  meningitis	  .	  	  
Despite	   these	   limitations,	   this	   chapter	   presents	   novel	   findings	  with	   respect	   to	   the	  
immunology	  of	  HIV-­‐associated	  cryptococcal	  meningitis.	  In	  contrast	  to	  the	  findings	  in	  
the	  CSF	  (chapter	  5),	  ART	  appeared	  not	  have	  a	  dramatic	  effect	  on	  the	  blood	  immune	  
response;	   however,	   a	   clear	   immune	   signature	   was	   identified	   at	   baseline	   among	  
subjects	   who	   died	   during	   their	   2-­‐week	   admission,	   suggestive	   of	  monocyte	   anergy	  
and	  other	  features	  of	  the	  compensatory	  anti-­‐inflammatory	  response	  syndrome.	  The	  
cause	   of	   this	   down-­‐regulation	   of	   immune	   response	   remains	   to	   be	   defined,	   but	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persistant	  HIV-­‐associated	   immune	   activation	   or	   the	   immune	  modulating	   effects	   of	  
shed	  cryptococcal	  capsular	  components,	  are	  likely	  possibilities.	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CHAPTER	  7: EARLY	  ART	  INITIATION	  IN	  CRYPTOCOCCOSIS	  
This	   chapter	   further	   explores	   the	   effects	   of	   ART	   on	   the	   immune	   response	   in	  
cryptococcal	   meningitis.	   Soluble	   biomarkers	   were	   measured	   in	   CSF	   and	   serum	  
samples	   collected	  during	  a	   clinical	   trial	  designed	   to	  determine	   the	  optimal	   time	   to	  
start	   ART	   in	   persons	   with	   CM.	   In	   this	   trial,	   early	   ART	   initiation	   (after	   1-­‐2	   weeks	  
amphotericin	   B	   therapy)	   was	   associated	   with	   increased	   mortality	   compared	   to	  
deferred	  initiation	  (after	  5	  weeks).	  In	  addition	  to	  assessing	  the	  effects	  of	  ART	  on	  the	  
immune	  response,	  this	  chapter	  also	  examines	  whether	  there	  is	  supportive	  evidence	  
to	   suggest	   ART-­‐associated	   immune	   pathology	   may	   have	   been	   the	   cause	   of	   these	  





7.1 The	  COAT	  trial	  
The	  results	  of	  the	  COAT	  trial	  are	  reported	  elsewhere	  (Boulware	  et	  al.	  2014a).	  Briefly,	  
earlier	  ART	   initiation	   (7-­‐13	  days	  after	  CM	  diagnosis)	  was	  associated	  with	   increased	  
mortality	  compared	  to	  deferred	  ART	  initiation	  after	  5	  weeks	  (26-­‐week	  mortality,	  45%	  
vs.	   30%	   respectively;	   HR=1.73,	   95%	   CI	   1.06-­‐2.82,	   n=177,	   p=0.03)	   (Boulware	   et	   al.	  
2014a).	   These	  excess	  deaths	  occurred	  primarily	  within	   the	   first	   2	   to	  5	  weeks	   after	  
cryptococcal	   meningitis	   diagnosis	   (1-­‐4	   weeks	   after	   ART	   initiation	   in	   the	   early	   ART	  
arm)	   and	   were	   mainly	   driven	   by	   increased	   mortality	   among	   the	   sub-­‐group	   of	  
participants	  with	  a	  paucicellular	  CSF	  white	  cell	  count	  (WCC<5/µL)	  at	  randomization	  	  	  
(HR	   3.87,	   95%	   CI	   1.41-­‐10.58,	   n=64,	   p=0.008).	   In	   contrast,	   there	  was	   no	   significant	  
difference	  in	  mortality	  between	  the	  treatment	  arms	  in	  the	  sub-­‐group	  with	  CSF	  WCC	  
≥5/µL	   (HR	   0.88,	   95%CI	   0.46-­‐1.71,	   n=100,	   p=0.71)	   (Boulware	   et	   al.	   2014a).	   When	  
results	   were	   analyzed	   by	   study	   site,	   earlier	   ART	   initiation	   was	   associated	   with	  
significantly	   increased	   mortality	   in	   Kampala	   (HR	   1.83,	   95%CI	   1.01-­‐3.32,	   n=115,	  
p=0.045)	  and	  a	  non-­‐significant	  trend	  towards	  increased	  mortality	  among	  subjects	  in	  
Mbarara	   (HR	   2.65,	   95%CI	   0.78-­‐4.22,	   n=35,	   p=0.112).	   However,	   no	   increase	   in	  
mortality	  was	   associated	  with	   earlier	  ART	   initiation	   among	  participants	   enrolled	   in	  
Cape	  Town	   (HR=0.80,	  95%CI	  0.20-­‐3.22,	  n=27,	  p=0.758).	  With	   regard	   to	  paradoxical	  
cryptococcal	   IRIS,	   there	  were	   increased	  cases	  observed	   in	   the	  earlier	  ART	  arm,	  but	  
this	   difference	   did	   not	   reach	   statistical	   significance	   (cumulative	   incidence	   20%	   vs.	  
13%,	  p=0.32,	  early	  vs.	  deferred	  ART	  respectively).	  	  
	  
The	  findings	  of	  the	  COAT	  trial	  are	  consistent	  with	  a	  previous	  study	  of	  ART	  timing	  in	  
CM	   conducted	   in	   Zimbabwe	   using	   fluconazole	   as	   induction	   antifungal	   therapy	  
[section	   1.8.5]	   (Makadzange	   et	   al.	   2010).	   This	   chapter	   examines	   whether	   ART-­‐
associated	  immune	  pathology	  could	  have	  been	  the	  cause	  of	  the	  excess	  deaths	  in	  the	  
COAT	  trial,	  despite	  the	  absence	  of	  an	  excess	  of	  overt,	  clinically	  recognized	  IRIS.	  To	  do	  
this,	  the	  effects	  of	  ART	  on	  host	  immune	  response	  were	  examined	  by	  comparing	  CSF	  
and	  serum	  biomarkers	  between	   the	   two	   treatment	  arms	  at	  equivalent	   time	  points	  
during	  the	   first	  21	  days	  of	  anti-­‐fungal	   therapy,	  and	  the	  relationship	  between	  these	  
biomarkers	  and	  fatal	  outcome	  are	  explored.	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7.2 Additional	  Methodology	  
7.2.1 COAT	  immunology	  sub-­‐study	  design	  
Full	   details	   of	   the	   COAT	   trial	   study	   design	   including	   entry	   criteria	   are	   detailed	   in	  
chapter	  3	  [section	  3.3]	  and	  elsewhere	  (Boulware	  et	  al.	  2014a).	  As	  per	  trial	  protocol	  
samples	   of	   CSF	   and	   serum	   were	   taken	   at	   1,	   8,	   and	   14	   days	   following	   CM	  
diagnosis/initiation	   of	   amphotericin	   B;	   further	   serum	   samples	   were	   also	   taken	   21	  
days	   following	   CM	  diagnosis	   [Figure	   7.1].	   Samples	   of	   serum	  and	  CSF	   supernatants	  
were	   cryopreserved	   at	   -­‐80°C,	   transported	   to	   the	   University	   of	   Minnesota	   and	  
defrosted	  in	  batches	  for	  biomarker	  analysis	  [section	  7.7.2].	  	  
	  
	  
Figure	  7.1	  	  Flow	  diagram	  detailing	  the	  sample	  time	  points	  of	  CSF	  and	  serum	  during	  the	  COAT	  trial.	  



















7.2.2 Biomarker	  analysis	  
Luminex	  magnetic	   bead	   technology	   (Bio-­‐Rad	   Laboratories,	   Hercules,	   CA,	   USA)	  was	  
used	  to	  analyze	  the	  concentration	  of	  19	  cytokines	  and	  chemokines	  (G-­‐CSF,	  GM-­‐CSF,	  
IFN-­‐γ,	   TNF-­‐α,	   IL-­‐1β,	   IL-­‐2,	   IL-­‐4,	   IL-­‐5,	   IL-­‐6,	   IL-­‐7,	   IL-­‐8,	   IL-­‐10,	   IL-­‐12,	   IL-­‐13,	   IL-­‐17,	   MCP-­‐
1/CCL2,	  MIP-­‐1α/CCL3,	  MIP-­‐1β/CCL4,	  VEGF)	   in	   cryopreserved	  CSF	  and	  serum	  at	   the	  
time	   points	   detailed	   above	   [Figure	   7.1].	   In	   addition,	   three	   soluble	   markers	   of	  
macrophage	   activation	   (soluble	   CD14,	   soluble	   CD163	   and	   CCL22/MDC)	   were	  
measured	  using	  commercial	  ELISA	  kits	   (DC140,	  DC1630,	  and	  DMD00,	  R&D	  Systems	  
Inc,	   MN,	   USA).	   Manufacturers	   protocols	   were	   followed	   for	   both;	   full	   details	   of	  
laboratory	   method	   are	   included	   in	   sections	   3.4.12	   and	   3.4.13.	   These	   data	   were	  
combined	  with	   the	  CSF	  cell	   count	  obtained	  by	  microscopy	   (WCC)	  at	  clinical	   service	  
laboratories	  that	  partake	  in	  external	  quality	  assurance	  programmes.	  	  
7.2.3 Data	  processing	  and	  data	  analysis	  
Out	   of	   range	   values	   that	   were	   below	   the	   standard	   curve	   were	   arbitrarily	   given	   a	  
value	  half	  way	  between	  the	  manufacturers	  published	  lower	  limit	  of	  detection	  (LLOD)	  
and	  0.	  Biomarkers	  with	  substantial	  proportions	  of	  undetectable	  values	  (≥50%)	  were	  
analyzed	  as	  categorical	  variables:	  “detectable”	  (≥LLOD)	  vs.	  “non-­‐detectable	  (<LLOD)	  
(e.g.	  IL-­‐2,	  IL-­‐1,	  IL-­‐5,	  CCL22/MDC).	  CSF	  white	  cell	  count	  (WCC)	  was	  analysed	  in	  terms	  
of	  absolute	  values,	  and	  also	  as	  a	  categorical	  variable	  classified	  as	  “raised”	  vs.	  “not-­‐
raised”	   (≥5	   or	   <5	   cells/µL	   respectively).	   Biomarker	   concentrations	   were	   log2	  
transformed	   to	   normalize	   their	   frequently	   skewed	   distributions	   and	   comparisons	  
made	  between	  study	  arms	  at	  equivalent	  time	  points.	  Parametric	  and	  non-­‐parametric	  
tests	  were	  performed	  as	  appropriate;	  transformed	  values	  were	  converted	  back	  and	  
presented	  as	  geometric	  means.	  Statistical	  analysis	  was	  performed	  using	  SAS	  version	  
9.3	  (SAS	  Institute,	  Cary,	  NC)	  and	  Stata	  version	  12.0	  (Stata	  Corp,	  Texas,	  USA).	  Principal	  
component	   analysis	   (PCA)	   was	   performed	   using	   Qlucore	   Omics	   explorer	   (Lund,	  
Sweden)	  as	  described	  in	  chapter	  5	  [section	  5.1.3].	  	  
	  
For	  the	  purposes	  of	  the	  immunological	  sub-­‐analysis	  of	  the	  COAT	  trial	  presented	  here,	  
clinical	   outcome	   was	   assessed	   5	   weeks	   post	   CM	   diagnosis.	   At	   this	   time	   point,	  
individuals	   in	   the	   early	  ART	   arm	  had	   received	  ART	   for	   4	  weeks	  while	   the	  deferred	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ART	  arm	  had	  not	  yet	  started	  ART.	  This	  time	  point	  was	  selected	  because	  it	  captured	  
the	  majority	  of	  the	  excess	  mortality	  observed	  in	  the	  trial.	  Biomarkers	  associated	  with	  
fatal	   outcome	   were	   examined	   using	   a	   univariate	   logistic	   regression	   and	   a	  
multivariate	   model	   was	   constructed	   adjusting	   for	   important	   clinical	   prognostic	  
markers	  using	  a	  forward	  stepwise	  approach.	  Principal	  component	  analysis	  (PCA)	  was	  
also	   used	   to	   examine	   the	   clustering	   of	   survivors	   and	   non-­‐survivors	   according	   to	  
immune	  response.	  Logistic	   regression	  analysis	  was	  also	  performed	  adding	  principal	  
components	   to	   the	   base	   model	   (instead	   of	   individual	   variables),	   in	   a	   forwards	  
stepwise	  approach.	  	  
7.2.4 Acknowledgement	  of	  additional	  contribution	  to	  this	  work	  	  
The	  work	   presented	   in	   this	   chapter	   is	   a	   collaboration	   between	   researchers	   at	   the	  
University	   of	   Cape	   Town	   (South	   Africa),	   University	   of	  Minnesota	   (USA),	  Makerere	  
University	   (Uganda),	   and	   Mbarara	   University	   of	   Science	   &	   Technology	   (Uganda).	  
Samples	  were	  obtained	  from	  subjects	  enrolled	  in	  the	  COAT	  trial	  by	  members	  of	  the	  
COAT	   trial	   team	   as	   described	   in	   chapter	   3.	   Laboratory	   work	   was	   carried	   out	   at	  
laboratories	   in	   the	   University	   of	  Minnesota	   (USA)	   by	  Maximillian	   von	   Hohenberg,	  
Grace	   Linder,	   Josh	   Rhein	   and	   myself	   under	   the	   scientific	   guidance	   of	   Associate	  
Professor	   David	   Boulware	   (principal	   investigator	   for	   the	   COAT	   trial).	   Dr	   Kathy	  
Huppler-­‐Hussiek	   (University	   of	   Minnesota)	   provided	   additional	   statistical	   analysis	  
and	  generated	  the	  plots	  in	  section	  7.4.	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7.3 Results:	  overview	  	  
7.3.1 Numbers	  of	  samples	  
177	  persons	  were	  enrolled	  in	  the	  COAT	  trial;	  155	  (87.6%)	  were	  alive	  and	  still	  enrolled	  
in	   the	   study	   at	   day	   14.	   CSF	   WCCs	   results	   were	   available	   for	   166,	   146	   and	   120	  
participants	  at	  1,	  8	  and	  14	  days	  after	  commencing	  amphotericin	  respectively,	  while	  
stored	   CSF	   specimens	   were	   available	   for	   167,	   115,	   and	   121	   (Figure	   7.2).	   Stored	  
serum	  was	  available	  for	  168,	  161	  and	  151	  trial	  participants	  at	  the	  same	  time	  points,	  a	  
further	  136	  subjects	  had	  serum	  available	  at	  21	  days	  after	  diagnosis	  (median	  12	  days	  
of	  early	  ART).	  Due	  to	  the	   low	  volume	  of	  stored	  CSF	  at	  the	  Mbarara	  site,	   it	  was	  not	  
possible	  to	  measure	  concentrations	  of	  the	  three	  macrophage-­‐specific	  biomarkers	  in	  
this	  group	  of	  individuals	  (sCD163,	  sCD14,	  CCL22/MDC).	  	  
	  
	  
Figure	   7.2	   Flow	   diagram	   illustrating	   COAT	   subject	   numbers	   and	   available	   CSF	   samples	   at	   CM	  
diagnosis	  (D1)	  and	  COAT	  day	  14	  (D14).	  	  
	  
Cryptococcal meningitis,  
HIV-infected, ART naïve  
n=177 enrolled  
Early ART  
(1-2 weeks) 
6 month mortality 45%  
Enrolled  = 88 
CSF at Day 0  = 81 
In trial at Day 14  = 73 
CSF at Day 14  = 57 
Deferred ART  
(5 weeks) 
6 month mortality 30% 
Enrolled  = 89 
CSF at Day 0  = 86  
In trial at Day 14  = 82 
CSF at Day 14  = 64 
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7.3.2 Participant	  characteristics	  at	  enrolment	  
A	  brief	  summary	  of	  participants	  for	  whom	  samples	  were	  available	  is	  included	  below	  
[Table	   7.1];	   median	   CD4	   count	   was	   28	   cells/µL	   and	   HIV	   viral	   load	   was	   5.5	   log10	  
copies/ml.	   There	   were	   no	   significant	   differences	   between	   study	   arms	   in	   baseline	  
demographics	  or	  markers	  of	  CM	  severity	  (e.g.	  GCS	  and	  fungal	  burden).	  	  
	  
Characteristic	   Early	  ART	  (n=81)	   Deferred	  ART	  (n=86)	  
Age	  (years)	   35	  (28,	  40)	   36	  (30,	  40)	  
Male	  gender	   40	  (49%)	   45	  (52%)	  
Weight	  (kg)	   53.0	  (46.5,	  59.0)	   54.1	  (48.0,	  60.7)	  
Glasgow	  Coma	  Scale	  <	  15	   21	  (26%)	   26	  (30%)	  
CSF	  Opening	  Pressure	  (cmH2O)	   29	  (19,	  36)	   26	  (18,	  42)	  
CSF	  Quantitative	  Culture	  (log10CFU/mL)	   5.3	  (4.3,	  5.7)	   4.8	  (3.8,	  5.4)	  
CSF	  Cryptococcal	  Antigen	  Titer	   8000	  (2000,	  16000)	   4000	  (1000,	  16000)	  
CSF	  White	  Cells	  (cells/μL)	   10	  (4,	  85)	   29	  (4,	  110)	  
CSF	  Protein	  (mg/dL)	   110	  (50,	  188)	   111	  (64,	  182)	  
On	  TB	  treatment	   21	  (26%)	   18	  (21%)	  
CD4	  Count	  (cells/μL)	   28	  (10,	  70)	   29	  (11,	  76)	  
HIV	  RNA	  (log10copies/mL)	   5.5	  (5.2,	  5.8)	   5.5	  (5.3,	  5.8)	  
Table	   7.1	   	   Background	   characteristics	   by	   trial	   arm	   for	   participants	   in	   COAT	   trial	   in	   whom	   CSF	  
biomarkers	   were	   measured	   at	   CM	   diagnosis.	   No	   significant	   differences	  were	   noted	   between	   trial	  
arms.	  Data	  are	  median	  and	  IQR,	  or	  number	  and	  percentage.	  CRAG	  titres	  refer	  to	  the	  maximal	  dilution	  
of	  the	  sample	  for	  which	  a	  cryptococcal	  antigen	  test	  remained	  positive.	  	  
7.3.3 Differences	  between	  study	  sites	  
A	  number	  of	  baseline	  differences	  were	  noted	  between	  study	  sites,	  including	  median	  
CD4	   count	   (Kampala	   17	   cells/µL,	  Mbarara	   36	   cells/µL	   and	   Cape	   Town	   67	   cells/µL,	  
p<0.0001),	  median	  CSF	  white	  cell	  count	  (Kampala	  30	  cells/µL,	  Mbarara	  5	  cells/µL	  and	  
Cape	   Town	   82	   cells/µL;	   p=0.001)	   and	   median	   CSF	   GXM	   titre	   (Kampala	   1:4000,	  
Mbarara	   1:320,	   Cape	   Town	   1:400;	   p<0.0001)	   [Table	   7.2].	   A	   greater	   proportion	   of	  
participants	   in	   Kampala	   and	   Mbarara	   had	   decreased	   consciousness	   compared	   to	  
Cape	   Town	   (30%,	   29%	   and	   11%	   respectively),	   but	   this	   did	   not	   reach	   statistical	  
significance	   (p=0.142).	   There	  were	   also	   significant	   differences	   in	   the	   proportion	   of	  
subjects	   with	   CSF	   cell	   count	   ≥5	   cells/µL	   at	   all	   three	   time	   points.	   Mortality	   also	  
differed	   significantly	  between	   sites	   at	  days	  14	  and	  30	  and	  was	  highest	   in	  Kampala	  
[Table	  7.2].	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At	  Cryptococcal	  Meningitis	  
Diagnosis	  
	  	   	  	   	  	   	  	  
CD4	  cells/mL	   17	  (7,	  69)	   36	  (14,	  74)	   67	  (43,	  88)	   <0.001	  
HIV	  VL	  log10	  copies/mL	   5.5	  (5.3,	  5.7)	   5.5	  (5.2,	  5.9)	   5.5	  (5.1,	  5.9)	   0.68	  
GCS	  <	  15	   34	  (30%)	   10	  (29%)	   3	  (11%)	   0.14	  
log10CFU/mL	  CSF	   5.0	  (3.9,	  5.5)	   5.2	  (4.3,	  5.6)	   4.8	  (2.8,	  6.0)	   0.58	  
CSF	  White	  Cells,	  Day	  1	   30	  (4,	  108)	   5	  (0,	  10)	   82	  (17,	  313)	   <0.001	  
GXM	  titre	   4000	  (1024-­‐8192)	   320	  (160-­‐1280)	   4000	  (1000-­‐8000)	   <0.001	  
CSF	  White	  Cells	  ≥5	  cells/mL	   	  	   	  	   	  	   	  	  
Amphotericin	  Day	  1	   61	  (56.5%)	   20	  (62.5%)	   22	  (85%)	   0.03	  
Amphotericin	  Day	  8	   47	  (49%)	   9	  (53%)	   23	  (92%)	   <0.001	  
Amphotericin	  Day	  14	   24	  (33%)	   11	  (50%)	   23	  (92%)	   <0.001	  
Sterile	  CSF	  at	  Day	  14	   39	  (48%)	   13	  (59%)	   16	  (67%)	   0.24	  
Mortality	   	  	   	  	   	  	   	  	  
Day	  14	  	   20	  (17%)	   2	  (5.7%)	   0	  (0.0%)	   0.02	  
Day	  30	  	   32	  (28%)	   7	  (20%)	   1	  (3.7%)	   0.02	  
Anytime	  	   49	  (43%)	   13	  (37%)	   8	  (30%)	   0.44	  
Table	  7.2	  	  Differences	  in	  baseline	  characteristics	  between	  COAT	  study	  sites.	  Data	  are	  median	  (IQR),	  
or	  N	  (%).	  P-­‐values	  are	  from	  Kruskal-­‐Wallis	  or	  Chi-­‐squared	  tests	  as	  appropriate.	  GCS	  =	  Glasgow	  coma	  
scale,	  Log10CFU/mL	  CSF	  refers	  to	  CSF	  fungal	  burden,	  mortality	  timepoints	  refer	  to	  days	  following	  CM	  
diagnosis.	  Variables	  that	  significantly	  differ	  between	  groups	  are	  shaded	  in	  red.	  	  
Further	   comparison	   between	   study	   sites,	   showed	   that	   15	   CSF	   and	   7	   serum	  
biomarkers	   were	   significantly	   different	   between	   the	   three	   study	   sites	   at	   day	   1	  
[Tables	   7.3	   and	   7.4	   respectively].	   Differences	   between	   study	   sites	   were	   also	  
demonstrated	  using	  PCA	  plots	  [Figures	  7.3,	  7.4].	  When	  CSF	  biomarker	  profiles	  were	  
analysed,	  participants	  clearly	  clustered	   together	  by	  study	  site	  both	  at	  baseline	  and	  
later	   time	   points	   prior	   to	   any	   variable	   filtering	   [Figure	   7.3].	   Clustering	   was	   not	  
altered	  by	  adjustment	  for	  CD4	  count	  or	  fungal	  burden,	  or	  by	  removing	  the	  variables	  
sCD163,	   sCD14	   and	   CCL22/MDC	   (which	   had	   not	   been	   measured	   in	   subjects	   from	  
Mbarara).	   In	   contrast	   to	   CSF	   biomarkers,	   PCA	   plots	   of	   subjects	   serum	   biomarker	  
profiles	  concentrations	  did	  not	  produce	  such	  clear	  differences	  between	  sites	  [Figure	  
7.4].	  Given	  these	  observed	  differences,	  a	  decision	  was	  made	  to	  analyze	  the	  cohort	  as	  




Variable	   Kampala	  (n=115)	   Mbarara	  (n=35)	   CapeTown	  (n=27)	   P	  
n	   Mdn	   IQR	  or	  %	   n	   Mdn	   IQR	  or	  %	   n	   Mdn	   	  
sCD14	   98	   592	   357-­‐961	   0	   	   	   26	   833	   459-­‐1076	   0.165	  
sCD163	   98	   449	   233-­‐818	   0	   	   	   26	   1006	   396-­‐1876	   0.002	  
CCL22	   98	   117	   106-­‐297	   0	   	   	   26	   412	   179-­‐936	   0.001	  
GCSF	   107	   58	   34-­‐127	   34	   99	   45-­‐202	   26	   69	   40-­‐143	   0.054	  
GMCSF	   107	   370	   282-­‐507	   34	   290	   253-­‐352	   26	   191	   140-­‐294	   0.000	  
IFNγ	   107	   45	   22-­‐92	   34	   42	   7.8-­‐96	   26	   21	   7.3-­‐63	   0.057	  
TNFα	   107	   8.6	   5.1-­‐14.4	   34	   145	   69-­‐253	   26	   9.3	   6.0-­‐13.1	   0.000	  
IL-­‐10	   107	   9.4	   5.6-­‐15.9	   34	   5.4	   3-­‐12	   26	   7.4	   3.6-­‐10.5	   0.010	  
IL-­‐12	   107	   9.2	   5.1-­‐16.6	   34	   15	   9.1-­‐25.1	   26	   6.2	   1.3-­‐15.0	   0.003	  
IL-­‐13	   107	   11.1	   1.9-­‐60	   34	   91	   13.7-­‐278	   26	   85	   36-­‐192	   0.000	  
IL-­‐17	   107	   20	   8.4-­‐31	   34	   32	   12.8-­‐42	   26	   1.2	   0.35-­‐6.5	   0.000	  
IL-­‐1β	   107	   0.63	   0.4-­‐1.3	   34	   0.43	   0.4-­‐2.2	   26	   0.4	   0.4-­‐0.4	   0.044	  
IL-­‐2	   107	   2.1	   0.55-­‐6.3	   34	   0.55	   0.6-­‐3.9	   26	   1.76	   0.55-­‐1.76	   0.104	  
IL-­‐4	   107	   0.95	   0.55-­‐1.87	   34	   0.25	   0.25-­‐1.21	   26	   0.44	   0.25-­‐0.76	   0.000	  
IL-­‐5	   107	   0.82	   0.4-­‐1.75	   34	   0.42	   0.4-­‐1.06	   26	   0.46	   0.4-­‐1.04	   0.250	  
IL-­‐6	   107	   128	   31-­‐574	   34	   322	   45-­‐2456	   26	   98	   35-­‐550	   0.238	  
IL-­‐7	   107	   3.6	   2.1-­‐5.7	   34	   7.3	   3.4-­‐18	   26	   8.1	   4.9-­‐59	   0.000	  
IL-­‐8	   107	   670	   322-­‐1203	   34	   858	   377-­‐2583	   26	   325	   191-­‐1086	   0.033	  
MCP-­‐1	   107	   393	   207-­‐1600	   34	   850	   232-­‐1762	   26	   497	   210-­‐903	   0.275	  
MIP-­‐1α	   21	   9.3	   4.4-­‐14.9	   34	   99.9	   66-­‐149	   26	   7	   3.8-­‐9.8	   0.000	  
MIP-­‐1β	   107	   105	   60-­‐167	   34	   10.8	   4.8-­‐26.4	   26	   102	   81-­‐124	   0.000	  
VEGF	   58	   80	   36-­‐113	   34	   8.7	   3.6-­‐20	   26	   35	   2.8-­‐86	   0.000	  
Table	  7.3	  	  Differences	  in	  CSF	  biomarkers	  between	  study	  sites	  at	  enrolment	  (day	  1).	  P-­‐values	  are	  calculated	  using	  
the	  Kruskal-­‐Wallis	  test.	  P<0.05	  are	  marked	  in	  bold.	  
Variable	   Kampala	  (n=110)	   Mbarara	  (n=32)	   Cape	  Town	  (n=26)	   P	  
Mdn	   IQR	   Mdn	   IQR	   Mdn	   IQR	  
CRP	   36.3	   15-­‐67	   61.5	   37-­‐199	   61.4	   26-­‐85	   0.001	  
GCSF	   49.2	   28-­‐100	   60.9	   42-­‐89	   68.6	   36-­‐117	   0.362	  
GMCSF	   6.9	   1.7-­‐16.8	   30.9	   16-­‐31	   0.86	   0.9-­‐0.9	   <0.001	  
IFNγ	   248	   162-­‐383	   266	   173-­‐374	   322	   153-­‐406	   0.405	  
TNFα 	   13.9	   5-­‐29	   23	   15.2-­‐31	   25.2	   4-­‐53	   0.020	  
IL10	   4.2	   0.6-­‐12.6	   4.8	   1.3-­‐9.4	   7.11	   1-­‐19	   0.805	  
IL12	   14.8	   5.4-­‐37.3	   14.3	   7.5-­‐38	   18.5	   4.9-­‐50	   0.908	  
IL13	   5.1	   2-­‐9.5	   4.6	   2.3-­‐7.8	   5.25	   2.6-­‐8.9	   0.796	  
IL17	   2.85	   1.8-­‐35.4	   4.4	   1-­‐47	   1.18	   0.8-­‐80	   0.65	  
IL1b	   1.42	   0.88-­‐2.3	   1.41	   0.7-­‐2.3	   2.58	   2-­‐5.2	   <0.001	  
IL2	   1.14	   0.6-­‐7.7	   7.51	   4.3-­‐7.5	   0.55	   0.6-­‐0.6	   <0.001	  
IL4	   2.56	   1.7-­‐4.1	   3.65	   1.9-­‐4.8	   4.82	   2.5-­‐7.5	   0.005	  
IL5	   2.92	   1.6-­‐5.1	   2.98	   1.6-­‐5	   5.23	   3.1-­‐7.4	   0.005	  
IL6	   21	   9.3-­‐44	   19.8	   10.3-­‐44	   22.7	   12.3-­‐74	   0.717	  
IL7	   14.7	   10.2-­‐23	   16.3	   9.8-­‐21	   15.6	   13.2-­‐30	   0.236	  
IL8	   65	   44-­‐124	   60.8	   38-­‐89	   106	   55-­‐173	   0.164	  
MCP1	   37	   18-­‐105	   44.7	   27-­‐99	   41	   26-­‐108	   0.583	  
MIP1α	   14	   8.4-­‐28	   15.2	   5.1-­‐27	   13.5	   4.3-­‐51	   0.345	  
MIP1β	   275	   199-­‐413	   212	   141-­‐352	   286	   179-­‐825	   0.097	  
VEGF	   380	   158-­‐735	   425	   232-­‐959	   340	   199-­‐901	   0.671	  
sCD14	   2.3	   1.9-­‐3	   2.65	   2.3-­‐3.4	   	   	   0.109	  
sCD163	   838	   612-­‐1277	   794	   638-­‐1339	   	   	   0.817	  
Table	  7.4	  	  Differences	  in	  serum	  biomarkers	  between	  study	  sites	  at	  enrolment	  (day	  1).	  P-­‐values	  are	  generated	  by	  
Kruskall-­‐Wallis	  test,	  p	  values	  <0.05	  are	  marked	  in	  bold.	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Figure	  7.3	   	  Differences	   in	  CSF	   immune	   response	  between	   sites	   at	  D1.	  PCA	  showing	  distribution	  of	  
subjects	   according	   to	   CSF	   cytokine	   profile	   from	   amphotericin	   days	   1,	   adjusted	   for	   CD4	   count	   and	  
fungal	   burden.	   Subjects	   are	   coloured	   according	   to	   study	   site	   as	   per	   legend.	   Clear	   separation	   and	  
clustering	  of	  subjects	  by	  study	  site	  demonstrated.	  Variables	  and	  their	  respective	  contribution	  to	  the	  
three	   principal	   components	   from	   the	   top	   plot	   are	   shown	   graphically	   below	   (red	   bar	   –	   positive	  
weighting;	  green	  bar	  –	  negative	  weighting).	  
COAT%CSF%D0%site%diﬀ%adj%CD4%CFU%
no%CD14/CD163/MDC%









































































































































Figure	   7.4	   	   	   Differences	   in	   serum	   immune	   response	   between	   sites.	   PCA	   showing	   distribution	   of	  
subjects	  according	  to	  serum	  cytokine	  profile	   from	  amphotericin	  days	  1,	  adjusted	  for	  CD4	  count	  and	  
fungal	  burden.	  Subjects	  are	  coloured	  according	  to	  study	  site	  as	  per	  legend.	   In	  contrast	  to	  Figure	  7.3.	  
no	   clear	   separation	   or	   clustering	   of	   subjects	   by	   study	   site	   is	   demonstrated.	   Variables	   and	   their	  
respective	   contribution	   to	   the	   three	  principal	   components	   from	   the	   top	  plot	   are	   shown	  graphically	  
below	  (red	  bar	  –	  positive	  weighting;	  green	  bar	  –	  negative	  weighting).	  
	  








































































7.4 Effect	  of	  ART	  on	  immune	  response	  
7.4.1 Effect	  of	  ART	  on	  CSF	  leukocyte	  count	  
The	  effect	  of	  early	  ART	  on	  CSF	  cellular	  infiltrate	  was	  explored.	  At	  amphotericin	  day	  1	  
and	   at	   amphotericin	   day	   8	   (COAT	   randomization),	   there	   were	   no	   differences	  
between	  study	  arms	  in	  terms	  of	  median	  CSF	  WCC,	  or	  the	  proportion	  of	  participants	  
with	   a	   raised	   CSF	  WCC	   (≥5	   cells/µL).	   However,	   at	   amphotericin	   day	   14	   (median	   6	  
days	   ART	   in	   the	   early	   ART	   group)	   there	  were	   significantly	  more	   individuals	   in	   the	  
early	  ART	  group	  with	  a	  raised	  CSF	  WCC	  (≥5	  cells/µL)	  compared	  to	  the	  deferred	  ART	  
group	   (58%	  vs.	  40%,	   respectively,	  p=0.047;	   [Figure	  7.5,	   7.6]).	  Differences	   in	  day-­‐14	  
CSF	  WCC	  were	  predominantly	  driven	  by	  increasing	  cell	  counts	  in	  those	  with	  CSF	  WCC	  
<5	   cells/µL	   at	   day	   1;	   this	   occurred	   in	   28%	   of	   such	   persons	   in	   the	   early	   ART	   arm	  
(10/36)	  but	  in	  0%	  in	  the	  deferred	  arm	  (0/27)	  (p=0.001)	  [Figure	  7.7].	  
	  
Figure	  7.5	   	  Differences	  in	  CSF	  WCC	  between	  COAT	  trial	  arms	  during	  over	  time.	   	  WCC	  are	  shown	  as	  
dots,	  diamonds	   show	   the	  geometric	  mean	  along	  with	  95%	  CI;	   red	   (early	  ART),	  blue	   (deferred	  ART).	  
Percentage	  of	  participants	  with	  CSF	  WCC	  <5/µL	  are	  shown	  at	  the	  bottom	  of	  the	  plot,	  with	  p-­‐values.	  
Total	  numbers	  of	  CSF	  samples	  available	  at	  each	  time	  point	  are	  listed	  at	  the	  bottom.	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Figure	  7.6	  	  Proportions	  of	  individuals	  with	  CSF	  WCC≥5/µL	  at	  the	  three	  COAT	  time	  points.	  Red	  –	  early	  
ART;	  blue	  –	  deferred	  ART.	  Chi2	  p-­‐values	  are	  shown	  above.	  	  
	  
Figure	  7.7	  	  Changes	  in	  CSF	  WCC	  in	  individuals	  with	  WCC<5/µL	  at	  presentation.	  Numbers	  of	  subjects	  
with	   CSF	   WCC<5µL	   at	   presentation	   are	   shown	   on	   the	   left;	   numbers	   (and	   percentages)	   with	   CSF	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7.4.2 Effect	  of	  ART	  on	  CSF	  biomarkers	  –	  whole	  cohort	  
To	  further	  characterize	  the	  effect	  of	  early	  ART	  on	  the	  immune	  response	  at	  the	  site	  of	  
disease,	  differences	  in	  the	  22	  CSF	  biomarkers	  were	  analyzed	  at	  days	  1,	  8	  and	  14.	  No	  
significant	  differences	  were	  noted	  in	  the	  concentration	  of	  any	  of	  the	  biomarkers	  at	  
any	  of	  the	  three	  time	  points;	  results	  for	  day	  14	  are	  shown	  below	  [Table	  7.5].	  
	  
	  CSF	  Biomarker	  
Early	  ART	   Deferred	  ART	  
P-­‐value	  
N	   Mean	  (95%	  CI)	   N	   Mean	  (95%	  CI)	  
WCC	  (cells/μL)	   57	   14.0	  (9.8	  -­‐	  20.0)	   63	   9.9	  (6.6	  -­‐	  14.7)	   0.20	  
G-­‐CSF	   57	   59.0	  (44.4	  -­‐	  78.4)	   64	   61.2	  (45.6	  -­‐	  82.1)	   0.86	  
GM-­‐CSF	   57	   256	  (195	  -­‐	  337)	   64	   253	  (190	  -­‐	  337)	   0.95	  
IFN-­‐γ	   57	   19.3	  (14.1	  -­‐	  26.5)	   64	   20.7	  (15.2	  -­‐	  28.2)	   0.75	  
TNF-­‐α	   57	   5.3	  (4.4	  -­‐	  6.5)	   64	   5.5	  (4.4	  -­‐	  6.9)	   0.79	  
VEGF	   57	   57.5	  (38.0	  -­‐	  86.9)	   64	   57.4	  (39.4	  -­‐	  83.5)	   0.99	  
IL-­‐4	   57	   0.5	  (0.4	  -­‐	  0.5)	   64	   0.5	  (0.4	  -­‐	  0.6)	   0.43	  
IL-­‐6	   57	   41.7	  (28.3	  -­‐	  61.5)	   64	   35.5	  (21.5	  -­‐	  58.4)	   0.62	  
IL-­‐7	   57	   6.3	  (4.5	  -­‐	  8.8)	   64	   5.4	  (3.8	  -­‐	  7.7)	   0.55	  
IL-­‐8	   57	   228	  (171	  -­‐	  305)	   64	   211	  (160	  -­‐	  279)	   0.70	  
IL-­‐10	   57	   6.1	  (5.2	  -­‐	  7.2)	   64	   5.5	  (4.3	  -­‐	  7.0)	   0.50	  
IL-­‐12	   57	   9.8	  (7.8	  -­‐	  12.3)	   64	   8.9	  (6.9	  -­‐	  11.6)	   0.61	  
IL-­‐13	   57	   24.7	  (15.3	  -­‐	  40.0)	   64	   14.5	  (8.5	  -­‐	  24.7)	   0.15	  
IL-­‐17	   57	   4.6	  (3.0	  -­‐	  7.1)	   64	   4.1	  (2.7	  -­‐	  6.4)	   0.71	  
CCL2/MCP-­‐1	   57	   408	  (288	  -­‐	  578)	   64	   420	  (295	  -­‐	  599)	   0.90	  
CCL3/MIP-­‐1α	   48	   6.1	  (4.6	  -­‐	  8.1)	   51	   5.6	  (4.3	  -­‐	  7.3)	   0.66	  
CCL4/MIP-­‐1b	   57	   92.8	  (77.4	  -­‐	  111)	   64	   86.2	  (70.5	  -­‐	  106)	   0.60	  
sCD14	  (ng/mL)	   39	   706	  (586	  -­‐	  849)	   48	   597	  (479	  -­‐	  745)	   0.27	  
sCD163	  (ng/mL)	   39	   479	  (369	  -­‐	  623)	   48	   428	  (332	  -­‐	  551)	   0.55	  
	   	  	   N	  (%)	  Detectable	   	  	   N	  (%)	  Detectable	   	  	  
IL-­‐1β	   57	   17	  (30%)	   64	   17	  (27%)	   0.69	  
IL-­‐2	   57	   33	  (58%)	   64	   46	  (72%)	   0.11	  
IL-­‐5	   57	   23	  (40%)	   64	   30	  (47%)	   0.47	  
CCL22	  /	  MDC	   39	   26	  (67%)	   48	   31	  (65%)	   0.84	  
Table	  7.5	  	  Differences	  in	  CSF	  biomarkers	  between	  trial	  arms	  at	  day	  14	  (whole	  cohort).	  No	  significant	  
differences	  are	  noted	  between	  early	  and	  deferred	  ART.	  Biomarker	  values	  are	  geometric	  mean	  values	  
from	   log2	   transformation.	   P-­‐values	   are	   from	   linear	   regression	  or	  Chi-­‐square	   tests.	  Unless	   specified,	  





7.4.3 Effect	  of	  ART	  on	  CSF	  biomarkers	  -­‐	  Kampala	  
When	  the	  analysis	  was	  restricted	  to	  subjects	  recruited	  in	  Kampala	  with	  available	  CSF	  
at	  day	  14	  (n=77);	  IL-­‐13,	  CCL3/MIP-­‐1α,	  sCD14	  and	  sCD163	  were	  all	  significantly	  higher	  
among	  individuals	  receiving	  early	  ART	  compared	  to	  participants	  in	  the	  deferred	  ART	  
arm	   [Table	   7.6,	   Figure	   7.8].	   In	  addition,	   at	  day	  14,	  CSF	   IL-­‐2	  was	  also	  detectable	   in	  
significantly	   fewer	   individuals	   in	   the	  early	  ART	  arm	  compared	   to	   the	  deferred	  ART	  
arm	  (Chi2	  p=0.020).	  
	  
	  CSF	  Biomarker	  
Early	  ART	   Deferred	  ART	  
P-­‐value	  
N	   Mean	  (95%	  CI)	   N	   Mean	  (95%	  CI)	  
WCC,	  cells/μL	   35	   12.3	  (8.3	  -­‐	  18.2)	   38	   8.2	  (5.8	  -­‐	  11.4)	   0.12	  
G-­‐CSF	   36	   51.7	  (37.7	  -­‐	  71.0)	   41	   50.3	  (34.0	  -­‐	  74.5)	   0.92	  
GM-­‐CSF	   36	   252	  (201	  -­‐	  315)	   41	   290	  (256	  -­‐	  330)	   0.27	  
IFN-­‐γ	   36	   18.3	  (13.1	  -­‐	  25.6)	   41	   13.4	  (9.5	  -­‐	  18.7)	   0.20	  
TNF-­‐α	   36	   4.2	  (3.3	  -­‐	  5.3)	   41	   3.7	  (2.9	  -­‐	  4.7)	   0.48	  
VEGF	   36	   66.1	  (41.9	  -­‐	  104.3)	   41	   68.9	  (50.6	  -­‐	  93.8)	   0.88	  
IL-­‐4	   36	   0.5	  (0.4	  -­‐	  0.5)	   41	   0.4	  (0.3	  -­‐	  0.5)	   0.28	  
IL-­‐6	   36	   38.9	  (23.4	  -­‐	  64.7)	   41	   20.7	  (11.8	  -­‐	  36.4)	   0.11	  
IL-­‐7	   36	   4.5	  (3.3	  -­‐	  6.2)	   41	   3.5	  (2.4	  -­‐	  5.3)	   0.37	  
IL-­‐8	   36	   207	  (142	  -­‐	  302)	   41	   164	  (121.9	  -­‐	  222)	   0.34	  
IL-­‐10	   36	   5.5	  (4.5	  -­‐	  6.7)	   41	   4.3	  (3.3	  -­‐	  5.7)	   0.20	  
IL-­‐12	   36	   10.6	  (8.5	  -­‐	  13.3)	   41	   8.0	  (5.9	  -­‐	  10.8)	   0.15	  
IL-­‐13	   36	   22.4	  (12.8	  -­‐	  39.3)	   41	   8.9	  (4.6	  -­‐	  17.3)	   0.04	  
IL-­‐17	   36	   5.4	  (3.4	  -­‐	  8.5)	   41	   3.8	  (2.2	  -­‐	  6.4)	   0.34	  
CCL2	  /	  MCP-­‐1	   36	   382	  (246	  -­‐	  594)	   41	   342	  (217	  -­‐	  539)	   0.74	  
CCL3	  /	  MIP-­‐1α	   27	   6.3	  (4.7	  -­‐	  8.5)	   28	   3.7	  (2.7	  -­‐	  5.0)	   0.02	  
CCL4	  /	  MIP-­‐1b	   36	   94.3	  (73.7	  -­‐	  121)	   41	   74.5	  (59.1	  -­‐	  93.9)	   0.18	  
sCD14,	  ng/mL	   29	   748.5	  (597	  -­‐	  938)	   35	   510.5	  (388	  -­‐	  671)	   0.04	  
sCD163,	  ng/mL	   29	   476	  (353	  -­‐	  642)	   35	   299	  (234	  -­‐	  381)	   0.02	  
	   	  	   N	  (%)	  Detectable	   	  	   N	  (%)	  Detectable	   	  	  
IL-­‐1β	   36	   15	  (42%)	   41	   9	  (22%)	   0.06	  
IL-­‐2	   36	   18	  (50%)	   41	   31	  (76%)	   0.02	  
IL-­‐5	   36	   14	  (39%)	   41	   16	  (39%)	   0.99	  
CCL22	  /	  MDC	   29	   17	  (59%)	   35	   19	  (54%)	   0.73	  
Table	  7.6	  	  Differences	  in	  CSF	  biomarkers	  between	  trial	  arms	  at	  day	  14	  (Kampala).	  Mean	  IL-­‐13,	  sCD14	  
and	   sCD163	  were	   significantly	   higher	   in	   the	   early	   ART	   group	   at	   day	   14	   compared	   to	   deferred	   ART	  
among	   subjects	   enrolled	   in	   Kampala.	   Also,	   significantly	   fewer	   subjects	   receiving	   early	   ART	   had	  
detectable	   CSF	   IL-­‐2.	   No	   significant	   differences	   were	   noted	   in	   the	   other	   cytokines	   and	   chemokines	  
measured.	  Biomarker	  values	  are	  geometric	  mean	  values	  from	  log2	  transformation.	  P-­‐values	  are	  from	  




Figure	   7.8	   	   Differences	   in	   CSF	   biomarkers	   between	   trial	   arms	   at	   day	   14	   (Kampala)	   Significantly	  
increased	   concentration	   of	   IL-­‐13,	   sCD14,	   sCD163	   and	   CCL3/MIP-­‐1α	   were	   noted	   at	   day	   14	   in	  
participants	   in	   the	   early	  ART	   group	   (red)	   compared	   to	   deferred	  ART	   group	   (blue)	   in	   Kampala.	  Dots	  
represent	  individual	  values,	  diamonds	  illustrate	  the	  geometric	  mean	  and	  95%	  CI.	  Y-­‐axis	  is	  log-­‐scaled.	  
P-­‐values	  from	  linear	  regression	  models.	  CSF	  IL-­‐13	  was	  undetectable	  in	  8%	  (3/36)	  in	  the	  early	  ART	  and	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7.4.4 Effect	  of	  ART	  on	  CSF	  biomarkers	  –	  Cape	  Town	  
A	  similar	  analysis	  was	  performed	  examining	  subjects	  enrolled	  in	  Cape	  Town	  (n=23).	  	  
Three	  variables	  were	  found	  to	  significantly	  differ	  between	  treatment	  arms	  at	  day	  14:	  
sCD14,	  sCD163	  and	  IL-­‐4	  [Table	  7.7;	  Figure	  7.9].	  However,	  contrary	  to	  the	  findings	  in	  
Kampala	  where	  early	  ART	  was	  associated	  with	  higher	  concentrations	  of	  macrophage	  
activation	   markers,	   individuals	   in	   Cape	   Town	   who	   received	   early	   ART	   had	  
significantly	  lower	  concentrations	  of	  sCD163	  and	  sCD14	  [Figure	  7.9].	  	  
	  
	  	   Early	  ART	   Deferred	  ART	   	  
CSF	  Biomarker	   N	   Mean	  (95%	  CI)	   N	   Mean	  (95%	  CI)	   P-­‐value	  
WCC	  (cells/μL)	   12	   46.9	  (24.1	  -­‐	  91.3)	   13	   66.4	  (26.1	  -­‐	  168.6)	   0.56	  
G-­‐CSF	   10	   70.7	  (27.7	  -­‐	  181.0)	   12	   60.7	  (37.8	  -­‐	  97.3)	   0.77	  
GM-­‐CSF	   10	   186.1	  (126.1	  -­‐	  274.7)	   12	   206.8	  (137.3	  -­‐	  311.4)	   0.72	  
IFN-­‐γ	   10	   12.0	  (3.7	  -­‐	  38.5)	   12	   39.5	  (20.4	  -­‐	  76.2)	   0.08	  
TNF-­‐α	   10	   10.2	  (6.6	  -­‐	  15.9)	   12	   11.5	  (8.3	  -­‐	  15.9)	   0.68	  
VEGF	   10	   16.1	  (4.4	  -­‐	  58.7)	   12	   12.9	  (3.7	  -­‐	  44.8)	   0.81	  
IL-­‐4	   10	   0.3	  (0.3	  -­‐	  0.4)	   12	   0.8	  (0.4	  -­‐	  1.3)	   0.02	  
IL-­‐6	   10	   123.1	  (58.7	  -­‐	  258.1)	   12	   169.6	  (54.4	  -­‐	  528.7)	   0.66	  
IL-­‐7	   10	   16.3	  (5.4	  -­‐	  49.1)	   12	   8.4	  (3.7	  -­‐	  19.2)	   0.35	  
IL-­‐8	   10	   388.2	  (195.7	  -­‐	  770.1)	   12	   455.1	  (220.9	  -­‐	  937.5)	   0.76	  
IL-­‐10	   10	   6.1	  (3.9	  -­‐	  9.6)	   12	   7.5	  (4.0	  -­‐	  13.8)	   0.63	  
IL-­‐12	   10	   5.7	  (3.2	  -­‐	  10.0)	   12	   6.5	  (3.5	  -­‐	  12.3)	   0.76	  
IL-­‐13	   10	   104.4	  (48.8	  -­‐	  223.2)	   12	   59.0	  (21.1	  -­‐	  165.4)	   0.41	  
IL-­‐17	   10	   1.4	  (0.6	  -­‐	  3.3)	   12	   4.4	  (1.4	  -­‐	  13.7)	   0.13	  
CCL2/MCP-­‐1	   10	   320.6	  (163.8	  -­‐	  627.7)	   12	   642.1	  (317.3	  -­‐	  1299.2)	   0.18	  
CCL3/MIP-­‐1α	   10	   3.7	  (1.8	  -­‐	  7.3)	   12	   7.6	  (4.3	  -­‐	  13.2)	   0.12	  
CCL4/MIP-­‐1b	   10	   88.1	  (71.2	  -­‐	  109.0)	   12	   127.1	  (87.8	  -­‐	  184.2)	   0.13	  
sCD14	  (ng/mL)	   10	   594.7	  (440.1	  -­‐	  803.6)	   13	   911.9	  (722.3	  -­‐	  1151.2)	   0.04	  
sCD163	  (ng/mL)	   10	   487.7	  (275.9	  -­‐	  862.3)	   13	   1129	  (887	  -­‐	  1439)	   <.01	  
	   	   N	  (%)	  Detectable	   	   N	  (%)	  Detectable	   	  
IL-­‐1β	   10	   1	  (10.0%)	   12	   4	  (33.3%)	   0.20	  
IL-­‐2	   10	   6	  (60.0%)	   12	   8	  (66.7%)	   0.75	  
IL-­‐5,	  	   10	   4	  (40.0%)	   12	   7	  (58.3%)	   0.40	  
CCL22/MDC	   10	   9	  (90.0%)	   13	   12	  (92.3%)	   0.85	  
Table	  7.7	  	  Differences	  in	  CSF	  WCC	  and	  biomarkers	  between	  COAT	  trial	  arms	  at	  day	  14	  (Cape	  Town	  
only	  n=22)	  Geometric	  means	  displayed	  with	  95%	  CI,	  or	  numbers	  with	  percentage	  as	  appropriate.	  P-­‐
values	   from	   linear	   regression	   and	   chi-­‐squared	   tests.	   Significant	   variables	   are	   highlighted.	   Unless	  
specified,	  biomarkers	  are	  measured	  in	  pg/mL.	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Figure	  7.9	   	  Differences	   in	  CSF	  biomarkers	  between	   trial	   arms	  at	  day	  14	   (Cape	  Town)	   (n=22).	  Dots	  
represent	  individual	  values,	  diamonds	  illustrate	  the	  geometric	  mean	  and	  95%	  CI.	  Y-­‐axis	  is	  log-­‐scaled.	  
P-­‐values	  from	  linear	  regression	  models	  
7.4.5 Effect	  of	  ART	  on	  CSF	  biomarkers	  –	  Mbarara	  
No	   variables	   were	   significantly	   different	   between	   study	   arms	   among	   individuals	  
recruited	  in	  Mbarara,	  Uganda	  (data	  not	  shown).	  	  
7.4.6 Effect	  of	  ART	  on	  serum	  biomarkers	  –	  whole	  cohort	  
To	  examine	   the	  effects	  of	  ART	   initiation	  on	   the	   systemic	   immune	   response,	   serum	  
biomarker	  concentrations	  were	  compared	  between	  treatment	  arms	  at	  days	  1,	  8,	  14	  
and	   21.	   No	   differences	   were	   noted	   between	   study	   arms	   at	   days	   1	   and	   8	   (CM	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(who	   had	   received	   ART	   for	   a	   median	   of	   6	   days)	   were	   found	   to	   have	   significantly	  
lower	   serum	   C-­‐reactive	   protein	   (CRP)	   compared	   to	   those	   in	   the	   deferred	   arm	  
(geometric	  mean	  89	  (95%CI	  73-­‐109)	  vs.	  123	  (95%	  CI	  105-­‐145)	  mg/L,	  p=0.0141,	  early	  
vs.	  deferred	  respectively)	  [Table	  7.8].	  However,	  at	  study	  day	  21	  (when	  the	  early	  arm	  
had	   received	   ART	   for	   a	   median	   of	   13	   days)	   mean	   CRP	   in	   the	   early	   arm	   was	  
significantly	  higher	  than	  that	  of	  the	  deferred	  arm	  (geometric	  mean	  51	  (95%CI	  39-­‐69)	  
vs.	  33	  (95%CI	  25-­‐45)	  mg/L,	  p=0.0353,	  early	  vs.	  deferred	  respectively)	  [Table	  7.9].	  	  
	  
Serum	  Biomarker	   Early	  ART	   Deferred	  ART	   P-­‐value	  
N	   Mean	  (95%	  CI)	   N	   Mean	  (95%	  CI)	  
G-­‐CSF	   73	   13.6	  (10.9,	  16.8)	   78	   17.5	  (13.6,	  22.4)	   0.13	  
GM-­‐CSF	   73	   2.4	  (1.7,	  3.3)	   78	   2.4	  (1.7,	  3.2)	   0.99	  
IFN-­‐γ	   73	   41.3	  (31.6,	  54.1)	   78	   45.9	  (34.0,	  62.0)	   0.61	  
TNF-­‐α	   73	   12.6	  (9.0,	  17.7)	   78	   18.2	  (12.8,	  26.0)	   0.15	  
VEGF	   73	   245	  (169,	  353)	   78	   160	  (118,	  218)	   0.08	  
IL-­‐1β	   73	   0.9	  (0.8,	  1.1)	   78	   1.1	  (0.9,	  1.3)	   0.27	  
IL-­‐2	   73	   0.7	  (0.6,	  0.8)	   78	   0.8	  (0.7,	  1.1)	   0.19	  
IL-­‐4	   73	   0.8	  (0.6,	  0.9)	   78	   0.9	  (0.7,	  1.1)	   0.42	  
IL-­‐5	   73	   1.3	  (1.1,	  1.6)	   78	   1.5	  (1.2,	  1.9)	   0.29	  
IL-­‐6	   73	   36.1	  (25.1,	  51.9)	   78	   47.3	  (34.9,	  64.2)	   0.26	  
IL-­‐7	   73	   9.8	  (8.4,	  11.4)	   78	   9.8	  (8.5,	  11.3)	   0.99	  
IL-­‐8	   73	   49.0	  (40.3,	  59.5)	   78	   39.4	  (31.7,	  48.9)	   0.15	  
IL-­‐10	   73	   3.0	  (2.3,	  3.9)	   78	   3.5	  (2.5,	  5.1)	   0.47	  
IL-­‐12	   73	   10.9	  (9.1,	  13.1)	   78	   13.3	  (11.2,	  15.8)	   0.13	  
IL-­‐13	   73	   3.1	  (2.5,	  3.7)	   78	   3.2	  (2.6,	  4.0)	   0.69	  
IL-­‐17	   73	   5.2	  (3.3,	  8.3)	   78	   5.5	  (3.4,	  8.7)	   0.89	  
CCL2	  /	  MCP-­‐1	   73	   47.4	  (36.3,	  61.8)	   78	   60.5	  (46.9,	  78.2)	   0.20	  
CCL3	  /	  MIP-­‐1α	   73	   12.6	  (8.4,	  19.0)	   78	   10.9	  (7.6,	  15.7)	   0.60	  
CCL4	  /	  MIP-­‐1β	   73	   200	  (147,	  271)	   78	   187	  (138,	  253)	   0.76	  
sCD14	  (ng/mL)	   73	   4.6	  (4.2,	  5.1)	   78	   4.8	  (4.4,	  5.3)	   0.56	  
sCD163	  (ng/mL)	   73	   1014	  (869,	  1184)	   78	   1141	  (984,	  1323)	   0.28	  
CRP	  (mg/L)	   73	   89.0	  (72.7,	  109)	   80	   123	  (105,	  145)	   0.01	  
Table	   7.8	   Differences	   in	   serum	   biomarkers	   between	   trial	   arms	   at	   day	   14	   (whole	   cohort).	   No	  
significant	  differences	  are	  noted	   in	   the	   concentration	  of	   serum	  cytokines	  and	  chemokines	  between	  
early	  and	  deferred	  ART	  groups	  at	  day	  14.	  However,	  CRP	  was	  significantly	  lower	  in	  the	  early	  ART	  group.	  
Biomarker	   values	   are	   geometric	   mean	   values	   from	   log2	   transformation.	   P-­‐values	   are	   from	   linear	  





Serum	  Biomarker	   Early	  ART	   Deferred	  ART	   P-­‐value	  
N	   Mean	  (95%	  CI)	   N	   Mean	  (95%	  CI)	  
G-­‐CSF	   63	   14.3	  (10.6,	  19.3)	   73	   10.9	  (8.2,	  14.5)	   0.20	  
GM-­‐CSF	   63	   1.7	  (1.2,	  2.4)	   73	   1.4	  (1.0,	  1.8)	   0.39	  
IFN-­‐γ	   63	   21.5	  (14.0,	  33.0)	   73	   14.5	  (9.8,	  21.4)	   0.18	  
TNF-­‐α	   63	   11.8	  (7.8,	  17.8)	   73	   9.2	  (6.4,	  13.2)	   0.37	  
VEGF	   63	   152	  (93.8,	  245)	   73	   124	  (82.1,	  188)	   0.54	  
IL-­‐1β	   63	   1.3	  (1.1,	  1.5)	   73	   1.1	  (0.9,	  1.2)	   0.16	  
IL-­‐2	   63	   0.7	  (0.6,	  0.8)	   73	   0.7	  (0.6,	  0.9)	   0.69	  
IL-­‐4,	  	   63	   0.9	  (0.7,	  1.1)	   73	   0.8	  (0.7,	  1.0)	   0.57	  
IL-­‐5	   63	   2.0	  (1.6,	  2.5)	   73	   1.5	  (1.3,	  1.8)	   0.07	  
IL-­‐6	   63	   18.8	  (12.9,	  27.3)	   73	   19.9	  (13.3,	  29.9)	   0.83	  
IL-­‐7	   63	   8.3	  (6.8,	  10.3)	   73	   8.0	  (6.8,	  9.4)	   0.78	  
IL-­‐8	   63	   44.7	  (35.7,	  56.0)	   73	   37.9	  (30.9,	  46.6)	   0.29	  
IL-­‐10	   63	   2.0	  (1.5,	  2.7)	   73	   1.9	  (1.3,	  2.8)	   0.91	  
IL-­‐12	   63	   8.7	  (6.4,	  11.9)	   73	   6.9	  (4.9,	  9.7)	   0.33	  
IL-­‐13	   63	   2.5	  (2.1,	  3.1)	   73	   2.6	  (2.1,	  3.1)	   0.92	  
IL-­‐17	   63	   1.4	  (0.9,	  2.4)	   73	   1.3	  (0.8,	  2.1)	   0.77	  
CCL2	  /	  MCP-­‐1	   63	   41.9	  (32.9,	  53.4)	   73	   41.8	  (32.2,	  54.3)	   0.99	  
CCL3	  /	  MIP-­‐1α	   63	   9.6	  (6.3,	  14.8)	   73	   9.4	  (6.4,	  14.0)	   0.94	  
CCL4	  /	  MIP-­‐1β	   63	   164	  (123,	  218)	   73	   173	  (132,	  226)	   0.77	  
sCD14	  (ng/mL)	   63	   4.4	  (4.0,	  4.9)	   73	   4.2	  (3.7,	  4.6)	   0.45	  
sCD163	  (ng/mL)	   63	   799	  (700,	  912)	   73	   1010	  (890,	  1146)	   0.01	  
CRP	  (mg/L)	   58	   51.2	  (39.3,	  66.8)	   67	   33.4	  (25.1,	  44.5)	   0.04	  
Table	   7.9	   	   Differences	   in	   serum	   biomarkers	   between	   trial	   arms	   at	   day	   21	   (whole	   cohort).	   	   No	  
significant	  differences	  are	  noted	   in	   the	   concentration	  of	   serum	  cytokines	  and	  chemokines	  between	  
early	   and	   deferred	  ART	   groups	   at	   day	   21.	   CRP	  was	   significantly	   higher	   in	   the	   early	   ART	   group,	   but	  
sCD163	  was	  significantly	  lower.	  Values	  are	  geometric	  mean	  values	  from	  log2	  transformation.	  P-­‐values	  
are	  from	  linear	  regression.	  Unless	  specified,	  biomarkers	  are	  measured	  in	  pg/mL	  
These	   differences	   can	   be	   visualized	   when	   displayed	   graphically	   over	   time	   [Figure	  
7.10].	   In	  subjects	  who	  did	  not	  receive	  ART,	  CRP	  gradually	  increased	  throughout	  the	  
14	  days	  of	  amphotericin	  treatment,	  falling	  rapidly	  afterwards.	  However,	  in	  the	  early	  
ART	   group,	   CRP	   appeared	   to	   plateau	   after	   ART	   was	   initiated	   at	   day	   8,	   returning	  
slowly	  to	  baseline	  values.	  In	  addition,	  at	  day	  21,	  the	  early	  ART	  group	  had	  significantly	  
lower	  serum	  sCD163	  concentration	  compared	  to	  the	  deferred	  ART	  group	  (geometric	  
mean	  799	  (95%	  CI	  700-­‐912)	  vs.	  1010	  (95%	  CI	  890-­‐1146)	  ng/mL,	  p=0.0135,	  early	  vs.	  
deferred	  ART	   respectively)	   [Table	   7.9].	   In	   contrast,	   no	   significant	   differences	  were	  




Figure	  7.10	  Differences	  in	  serum	  CRP	  between	  trial	  arms	  over	  time	  during	  COAT	  trial.	  Participants’	  
CRP	   values	   are	   shown	   as	   dots.	   Diamonds	   represent	   geometric	   mean	   and	   95%	   CI.	   Numbers	   of	  
participants	   per	   group	   are	   shown	   below.	   CRP	   levels	   increased	   during	   the	   14	   days	   of	   amphotericin	  
therapy	   and	   declined	   afterwards.	   In	   the	   group	   that	   received	   early	   ART	   initiation	   (red),	   CRP	   was	  






7.4.7 	   Profile	  of	  biomarkers	  in	  individuals	  with	  WCC	  <	  5/µL	  CSF	  
As	  detailed	   in	   section	  7.1	  and	  elsewhere	   (Boulware	  et	  al.	  2014a),	   the	  difference	   in	  
survival	  between	  early	  and	  deferred	  ART	  was	  particularly	  marked	  in	  individuals	  with	  
CSF	  WCC	  <5/µL	  at	  randomization	  (amphotericin	  day	  8).	  To	  further	  characterize	  this	  
immune	   phenotype,	   CSF	   and	   serum	   biomarker	   concentrations	   were	   compared	  
between	  participants	  with	  normal	  (<5/µL)	  and	  elevated	  (≥5/µL)	  CSF	  WCC	  at	  this	  time	  
point.	  	  
	  
	  CSF	  Biomarker	  
CSF	  White	  Cells	  <	  5/µL	   CSF	  White	  Cells	  ≥	  5/µL	   P-­‐
value	  N	  
Mean	  (95%	  CI)	  	  
N	  (%)	  detectable	  
N	  
Mean	  (95%	  CI)	  
	  N	  (%)	  detectable	  
G-­‐CSF	   47	   40.0	  (31.0,	  51.7)	   62	   42.2	  (33.2,	  53.7)	   0.77	  
GM-­‐CSF	   47	   330	  (294,	  369)	   62	   219	  (174,	  276)	   <.01	  
IFN-­‐γ	   47	   27.4	  (18.7,	  39.9)	   62	   24.1	  (16.6,	  34.9)	   0.64	  
TNF-­‐α	   47	   5.9	  (4.4,	  7.8)	   62	   6.8	  (5.4,	  8.6)	   0.43	  
VEGF	   27	   29.5	  (18.0,	  48.2)	   37	   25.3	  (14.3,	  44.9)	   0.71	  
IL-­‐4	   47	   0.7	  (0.6,	  0.9)	   62	   0.7	  (0.6,	  0.9)	   0.91	  
IL-­‐6	   47	   79.2	  (43.7,	  144)	   62	   138	  (83.5,	  229)	   0.16	  
IL-­‐7	   47	   3.9	  (2.9,	  5.3)	   62	   4.0	  (3.1,	  5.1)	   0.92	  
IL-­‐8	   47	   406	  (291,	  566)	   62	   477	  (352,	  646)	   0.49	  
IL-­‐10	   47	   8.5	  (6.8,	  10.6)	   62	   7.5	  (6.0,	  9.4)	   0.47	  
IL-­‐12	   47	   5.7	  (3.9,	  8.2)	   62	   6.1	  (4.6,	  7.9)	   0.78	  
IL-­‐13	   47	   14.3	  (8.7,	  23.5)	   62	   18.7	  (11.9,	  29.3)	   0.44	  
IL-­‐17	   47	   6.3	  (4.0,	  9.8)	   62	   5.1	  (3.3,	  7.7)	   0.51	  
CCL2	  /	  MCP-­‐1	   47	   593	  (382,	  920)	   62	   455	  (320,	  646)	   0.35	  
CCL3	  /	  MIP-­‐1α	   6	   8.7	  (6.7,	  11.2)	   26	   5.4	  (3.4,	  8.6)	   0.36	  
CCL4	  /	  MIP-­‐1b	   47	   108.5	  (91.2,	  129)	   62	   103.5	  (86.5,	  124)	   0.72	  
sCD14	  (ng/mL)	   43	   524	  (372,	  737)	   59	   800	  (639,	  1002)	   0.04	  
sCD163	  (ng/mL)	   43	   427	  (305,	  599)	   59	   676	  (505,	  905)	   0.05	  
IL-­‐1β	   47	   23	  (49%)	   62	   27	  (44%)	   0.58	  
IL-­‐2	   47	   18	  (38%)	   62	   32	  (52%)	   0.17	  
IL-­‐5	   47	   25	  (53%)	   62	   34	  (55%)	   0.87	  
CCL22	  /	  MDC	   43	   27	  (63%)	   59	   48	  (81%)	   0.04	  
Table	   7.10	   Differences	   in	   CSF	   biomarkers	   at	   randomization	   (amphotericin	   day	   8)	   between	  
individuals	  with	  CSF	  White	  Cells	  <5	  and	  ≥5	  cells/µL.	  Individuals	  with	  CSF	  WCC	  <5/µL	  had	  significantly	  
higher	  CSF	  GM-­‐CSF,	   and	   significantly	   reduced	   sCD14	   and	   sCD163	   compared	   to	   individuals	  with	  CSF	  
WCC	   ≥5/µL.	   Biomarker	   values	   are	   geometric	   mean	   values	   from	   log2	   transformation.	   P-­‐values	   are	  
from	  linear	  regression	  of	  biomarker	  on	  CSF	  white	  cell	  count	  at	  randomization	  group.	  Unless	  specified,	  
biomarkers	  are	  measured	  in	  pg/mL	  
255	  	  
Participants	  with	  WCC	  <5/µL	  at	  day	  8	  were	  significantly	  less	  likely	  to	  have	  detectable	  
CCL22/MDC	   in	   their	   CSF	   compared	   to	   those	   with	   WCC	   ≥5/µL	   (63%	   vs.	   81%	  
respectively,	  P=.04),	   they	   also	   had	   significantly	   increased	   CSF	   GM-­‐CSF	   (P<.01)	   and	  
significantly	  lower	  CSF	  concentrations	  of	  the	  macrophage	  activation	  markers	  sCD14	  
(P=.05)	   and	   sCD163	   (P=.04)	   [Table	   7.10;	   Figure	   7.11].	   Participants	   with	   CSF	   WCC	  
<5/mL	   at	   day	   8	   also	   had	   increased	   serum	   concentrations	   of	   both	   IL-­‐4	   and	   IL-­‐17	  
(P=.05	   for	  each)	   (Table	   7.11;	   Figure	   7.11).	  Despite	   these	  differences	  prior	   to	  COAT	  
randomization,	  there	  were	  no	  significant	  CSF	  or	  serum	  biomarker	  differences	  at	  day	  
14	  in	  the	  early	  ART	  arm	  between	  subjects	  with	  normal	  or	  raised	  day	  8	  CSF	  WCC.	  
	  
Serum	  Biomarker	   CSF	  White	  Cells	  <5/µL	   CSF	  White	  Cells	  ≥5/µL	   P-­‐value	  
N	   Mean	  (95%	  CI)	   N	   Mean	  (95%	  CI)	  
G-­‐CSF	   61	   17.5	  (12.6,	  24.2)	   72	   15.2	  (11.7,	  19.7)	   0.51	  
GM-­‐CSF	   61	   5.2	  (3.6,	  7.4)	   72	   4.2	  (2.8,	  6.1)	   0.42	  
IFN-­‐γ	   61	   56.2	  (34.9,	  90.3)	   72	   32.8	  (22.7,	  47.4)	   0.08	  
TNF-­‐α	   61	   8.4	  (6.2,	  11.3)	   72	   8.2	  (6.4,	  10.5)	   0.91	  
VEGF	   61	   177	  (120,	  260)	   72	   141	  (98.2,	  202)	   0.40	  
IL-­‐1β	   61	   1.2	  (0.9,	  1.4)	   72	   0.9	  (0.8,	  1.1)	   0.11	  
IL-­‐2	   61	   2.0	  (1.2,	  3.3)	   72	   1.7	  (1.1,	  2.6)	   0.64	  
IL-­‐4	   61	   1.5	  (1.2,	  2.0)	   72	   1.1	  (0.9,	  1.3)	   0.05	  
IL-­‐5	   61	   2.0	  (1.5,	  2.7)	   72	   1.6	  (1.3,	  2.0)	   0.20	  
IL-­‐6	   61	   38.8	  (24.9,	  60.6)	   72	   32.6	  (23.6,	  45.1)	   0.53	  
IL-­‐7	   61	   9.8	  (8.1,	  12.0)	   72	   8.9	  (7.7,	  10.4)	   0.44	  
IL-­‐8	   61	   49.3	  (38.4,	  63.2)	   72	   49.8	  (39.6,	  62.5)	   0.95	  
IL-­‐10	   61	   3.0	  (1.9,	  4.7)	   72	   2.1	  (1.5,	  3.0)	   0.24	  
IL-­‐12	   61	   14.2	  (10.9,	  18.6)	   72	   10.9	  (8.4,	  14.1)	   0.16	  
IL-­‐13	   61	   2.5	  (1.8,	  3.3)	   72	   3.0	  (2.3,	  4.0)	   0.32	  
IL-­‐17	   61	   9.1	  (5.4,	  15.3)	   72	   4.4	  (2.7,	  7.2)	   0.05	  
CCL2	  /	  MCP-­‐1	   61	   72.8	  (53.2,	  99.7)	   72	   58.1	  (43.2,	  78.3)	   0.31	  
CCL4	  /	  MIP-­‐1β	   61	   361	  (291,	  449)	   72	   278	  (227,	  341)	   0.09	  
CRP	  (mg/L)	   61	   84.0	  (67.3,	  105)	   72	   91.5	  (75.2,	  111)	   0.57	  
Table	   7.11	   Differences	   in	   serum	   biomarkers	   at	   randomization	   (amphotericin	   day	   8)	   between	  
individuals	  with	  CSF	  white	  cell	  counts	  (WCC)	  <5	  and	  ≥5	  cells/µL.	  Individuals	  with	  CSF	  WCC	  <5/µL	  had	  
significantly	  higher	  serum	  IL-­‐4	  and	  IL-­‐17	  concentrations	  compared	  to	  individuals	  with	  CSF	  WCC	  ≥5/µL.	  
Biomarker	   values	   are	   geometric	   mean	   values	   from	   log2	   transformation.	   P-­‐values	   are	   from	   linear	  




Figure	  7.11	  Differences	   in	  serum	  and	  CSF	  biomarkers	  between	  subjects	  with	  normal	  or	  raised	  CSF	  
White	   Cell	   Count	   at	   COAT	   randomization	   (median	   amphotericin	   day	   8).	   	   Participants	   who	   had	   a	  
normal	  CSF	  white	  cell	   count	   (<5/µL)	  at	   randomization	  had	  significantly	  higher	   serum	   IL-­‐4,	   IL-­‐17	  and	  
CSF	   GM-­‐CSF	   levels,	   but	   significantly	   lower	   CSF	   sCD14	   and	   sCD163	   levels,	   compared	   to	   participants	  
with	  raised	  CSF	  white	  cell	  count	  (≥5/µL).	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7.5 Associations	  with	  mortality	  
7.5.1 CSF	  biomarkers	  and	  fatal	  outcome	  
No	  CSF	  biomarkers	  at	  day	  1,	  8	  or	  14	  were	  found	  to	  be	  associated	  with	  fatal	  outcome	  
during	   the	   5	  weeks	   following	   CM	   diagnosis	   	   (corresponding	   to	   the	   time	   period	   in	  
which	   the	   excess	   COAT	  deaths	   occurred	   (Boulware	   et	   al.	   2014a)).	   Data	   for	   day	   14	  
biomarkers	  are	  shown	  below	  [Table	  7.12].	  	  
	   Odds	  Ratio	  (OR)	   P	   95%CI	  
WCC	  (cells/µL)	   1.02	   0.864	   0.80-­‐1.30	  
GXM	  titre	  	   1.11	   0.438	   0.85-­‐1.45	  
sCD14	  (ng/mL)	   2.07	   0.126	   0.82-­‐5.23	  
sCD163	  (ng/mL)	   1.15	   0.658	   0.62-­‐2.14	  
GCSF	  	   1.06	   0.759	   0.73-­‐1.54	  
GMCSF	  	   1.44	   0.227	   0.80-­‐2.62	  
IFN-­‐γ	  	   1.12	   0.543	   0.78-­‐1.59	  
TNF-­‐α	  	   0.80	   0.405	   0.48-­‐1.35	  
IL-­‐10	  	   1.01	   0.960	   0.61-­‐1.68	  
IL-­‐12	  	   0.82	   0.375	   0.53-­‐1.27	  
IL-­‐13	   0.93	   0.495	   0.75-­‐1.15	  
IL-­‐17	   1.11	   0.416	   0.86-­‐1.43	  
IL-­‐1β	  	   0.78	   0.586	   0.32-­‐1.91	  
IL-­‐2	  	   1.31	   0.136	   0.92-­‐1.87	  
IL-­‐4	  	   1.07	   0.837	   0.58-­‐1.97	  
IL-­‐5	  	   0.79	   0.436	   0.44-­‐1.43	  
IL-­‐6	   0.94	   0.644	   0.74-­‐1.20	  
IL-­‐7	  	   0.84	   0.311	   0.60-­‐1.17	  
IL-­‐8	  	   1.04	   0.837	   0.71-­‐1.52	  
MCP-­‐1/CCL2	  	   1.04	   0.823	   0.76-­‐1.41	  
MIP-­‐1α	  /CCL3	   1.03	   0.904	   0.63-­‐1.70	  
MIP-­‐1β/CCL4	   0.88	   0.664	   0.50-­‐1.56	  
VEGF	  	   1.30	   0.128	   0.93-­‐0.83	  
Table	   7.12	   	   Associations	   between	   day	   14	   CSF	   biomarker	   and	   5-­‐week	   mortality	   (n=121).	   All	  
biomarkers	   measured	   in	   pg/mL	   and	   log2	   transformed	   unless	   specified.	   OR	   per	   log2	   increase	   in	  
biomarker,	  from	  univariate	  logistic	  regression.	  No	  significant	  associations	  noted.	  
7.5.2 Serum	  biomarkers	  and	  fatal	  outcome	  (day	  1	  &	  day	  8)	  
No	  serum	  biomarkers	  at	  day	  1	  were	  significantly	  associated	  with	  5-­‐week	  mortality.	  
However,	  non-­‐survivors	  had	  significantly	  increased	  concentrations	  of	  serum	  IL-­‐6	  and	  
CRP	   at	   day	   8	   (COAT	   trial	   randomization)	   compared	   to	   survivors	   (OR	   1.26,	   (95%	   CI	  
1.07-­‐1.49),	   p=0.006;	  OR	   1.50,	   (1.07-­‐2.1),	   p=0.015;	  OR	  per	   log2	   increase	   in	   IL-­‐6	   and	  
CRP	  respectively).	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7.5.3 Serum	  biomarkers	  and	  mortality	  	  (day	  14)	  
At	   day	   14,	   9	   serum	   biomarkers	   were	   identified	   that	   were	   significantly	   increased	  
among	  individuals	  who	  had	  a	  fatal	  outcome	  by	  week	  5	  [Table	  7.13].	  When	  adjusted	  
for	  baseline	  GCS	  and	  COAT	  trial	  arm	  in	  a	  logistic	  regression	  model,	  only	  three	  day-­‐14	  
biomarkers	  remained	  significantly	  associated	  with	  mortality:	  CRP,	  GM-­‐CSF	  and	  IL-­‐17.	  
Baseline	  fungal	  burden	  was	  initially	  incorporated	  into	  the	  multivariate	  model	  despite	  
lack	   of	   clear	   association	   with	   mortality	   in	   the	   univariate	   analysis	   due	   to	   its	  
demonstrated	   importance	   in	   previous	   studies	   (Jarvis,	   et	   al.	   2014).	   However,	   it	   did	  
not	  add	  to	  the	  final	  model	  and	  was	  consequently	  removed.	  
	   UNIVARIATE	   MULTIVARIATE	  MODEL	  
	   UOR	   p	   95%	  CI	   AOR	   P	   95%	  CI	  
GCS<15	  (D0)	   2.23	   0.061	   0.96-­‐5.17	   3.07	   0.027	   1.14-­‐8.31	  
Early	  ART	   2.46	   0.030	   1.09-­‐5.55	   3.85	   0.004	   1.48-­‐10.0	  
CFU/ml	  (D0)	   1.23	   0.200	   0.90-­‐1.69	   1.05	   0.783	   0.73-­‐1.53	  
CRP	  	   1.76	   0.004	   1.20-­‐2.58	   1.96	   0.001	   1.29-­‐2.98	  
G-­‐CSF	  	   1.22	   0.154	   0.93-­‐1.61	   	   	   	  
GM-­‐CSF	  	   1.47	   0.001	   1.18-­‐1.84	   1.43	   0.007	   1.11-­‐1.85	  
IFN-­‐γ	  	   1.33	   0.029	   1.03-­‐1.71	   1.07	   0.730	   0.74-­‐1.55	  
TNF-­‐α	  	   1.08	   0.431	   0.90-­‐1.29	   	   	   	  
IL-­‐10	  	   1.28	   0.034	   1.02-­‐1.62	   1.16	   0.446	   0.79-­‐1.70	  
IL-­‐12	  	   1.30	   0.195	   0.87-­‐1.93	   	   	   	  
IL-­‐13	  	   1.60	   0.011	   1.11-­‐2.29	   1.17	   0.166	   0.72-­‐1.90	  
IL-­‐17	  	   1.26	   0.018	   1.04-­‐1.53	   1.32	   0.016	   1.04-­‐1.66	  
IL-­‐1β	  	   2.12	   0.012	   1.18-­‐3.82	   1.96	   0.171	   0.75-­‐5.12	  
IL-­‐2	  	   0.93	   0.767	   0.58-­‐1.49	   	   	   	  
IL-­‐4	  	   1.25	   0.419	   0.72-­‐2.17	   	   	   	  
IL-­‐5	  	   1.33	   0.253	   0.82-­‐2.16	   	   	   	  
IL-­‐6	  	   1.22	   0.038	   1.01-­‐1.47	   0.88	   0.467	   0.63-­‐1.24	  
IL-­‐7	  	   1.42	   0.147	   0.88-­‐2.27	   	   	   	  
IL-­‐8	  	   1.32	   0.056	   0.99-­‐1.76	   	   	   	  
MCP-­‐1	  	   1.23	   0.083	   0.97-­‐1.55	   	   	   	  
MIP-­‐1α	  	   1.04	   0.614	   0.88-­‐1.24	   	   	   	  
MIP-­‐1β	  	   1.00	   0.992	   0.81-­‐1.23	   	   	   	  
VEGF	  	   1.13	   0.249	   0.92-­‐1.38	   	   	   	  
sCD14	  	   2.55	   0.016	   1.19-­‐5.46	   1.02	   0.974	   0.33-­‐3.18	  
sCD163	  	   1.15	   0.501	   0.77-­‐1.72	   	   	   	  
Table	   7.13	   	   Association	   between	   day	   14	   serum	   biomarkers	   and	   5-­‐week	   mortality	   (n=149).	   All	  
biomarkers	   measured	   in	   pg/mL	   (apart	   from	   CD14	   and	   CD163	   (ng/mL)	   and	   CRP	   (mg/L))	   and	   log2	  
transformed	   prior	   to	   inclusion	   in	   model	   (CFU	   log10	   transformed	   as	   per	   convention).	   	   Logistic	  
regression	   used	   to	   calculate	   unadjusted	   and	   adjusted	   odds	   ratios	   (UOR	   and	   AOR)	   per	   log2/log10	  
increase	   in	   biomarker.	   Variables	   significantly	   associated	   with	   fatal	   outcome	   in	   univariate	   analysis	  
(p<0.05)	  were	  entered	  into	  a	  multivariate	  model,	  adjusting	  for	  baseline	  conscious	  level	  and	  trial	  arm.	  
Biomarkers	   showing	   significant	   association	   with	   mortality	   are	   shaded.	   Variables	   in	   final	   model	  
outlined	  in	  bold.	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  The	  relationship	  between	  day-­‐14	  serum	  biomarkers	  and	  fatal	  outcome	  was	  further	  
explored	  using	  principal	  component	  analysis	  [Figure	  7.12].	  When	  day	  14	  biomarkers	  
were	  filtered	  for	  those	  significantly	  associated	  with	  5-­‐week	  mortality	  (p-­‐value	  <0.05	  
and	  q-­‐value	  <0.1),	  the	  same	  9	  variables	  were	  identified.	  The	  contribution	  of	  each	  of	  
these	  nine	  variables	  to	  the	  first	  three	  principal	  components	  is	  shown	  in	  Figure	  7.12b	  
and	  Table	  7.14.	  Examination	  of	  the	  PCA	  plot	  showed	  that	  some,	  but	  not	  all,	  of	  the	  
participants	  with	  fatal	  outcome	  clustered	  together	  [Figure	  7.12a].	  	  
	  
Figure	  7.12	  	  PCA	  of	  day	  14	  serum	  biomarkers	  and	  5-­‐week	  mortality.	  (a)	  PCA	  plot	  shows	  clustering	  of	  
some,	   but	   not	   all,	   subjects	   with	   fatal	   outcome	   according	   to	   d14	   serum	   biomarkers.	   (b)	   Variable	  
loading	  of	   the	  9	   serum	  biomarkers	  at	  day	  14	   that	   significantly	  differed	  between	  survivors	  and	  non-­‐
survivors	   (q-­‐value	   <0.1)	   to	   the	   first	   three	   principal	   components.	   All	   biomarkers	   were	   significantly	  
increased	  at	  d14	  in	  subjects	  who	  died.	  See	  also	  table	  7.14	  below.	  
Variable	   PC1	   PC2	   PC3	  
CRP	   0.095	   -­‐0.680	   0.126	  
GM-­‐CSF	   0.343	   0.111	   0.555	  
IFN-­‐γ	   0.355	   0.169	   0.122	  
IL-­‐10	   0.416	   -­‐0.006	   -­‐0.249	  
IL-­‐13	   0.351	   0.074	   0.508	  
IL-­‐17	   0.342	   0.297	   -­‐0.122	  
IL-­‐1b	   0.394	   0.012	   -­‐0.274	  
IL-­‐6	   0.384	   -­‐0.136	   -­‐0.491	  
CD14	   0.178	   -­‐0.621	   0.101	  
Table	  7.14	  	  Variable	  loadings	  for	  the	  first	  three	  principal	  components	  (PC1,	  PC2,	  PC3).	  Values	  are	  co-­‐
efficients	   with	   range	   -­‐1	   to	   +1.	   All	   variables	   were	   log2	   transformed	   to	   reduced	   skewing.	   Principals	  
components	   correspond	   to	  Figure	   7.12	   above.	   The	   three	   variables	  with	   the	   largest	   contribution	   to	  






Many	  of	   the	  biomarkers	  were	  noted	   to	  be	   in	  close	  proximity	   to	  each	  other	  on	   the	  
PCA	   variable	   plot,	   suggesting	   close	   correlation	   between	   these	   variables	   [Figure	  
7.12b].	  To	  better	   reflect	   the	  predictive	  effect	  of	   the	  overall	  biomarker	   signature	   in	  
COAT	   subjects,	   the	   first	   three	  principal	   components	   from	   the	  principal	   component	  
analysis	   were	   entered	   into	   the	   logistic	   regression	   model	   instead	   of	   individual	  
biomarkers.	  	  
	   UNIVARIATE	   MULTIVARIATE	  MODEL	  
	   UOR	   p	   95%	  CI	   AOR	   p	   95%	  CI	  
GCS<15	  (D0)	   2.23	   0.061	   0.96-­‐5.17	   2.91	   0.031	   1.11-­‐7.67	  
Early	  ART	   2.46	   0.030	   1.09-­‐5.55	   3.69	   0.005	   1.43-­‐9.51	  
CFU/ml	  (D0)	   1.23	   0.200	   0.90-­‐1.69	   1.15	   0.463	   0.78-­‐1.68	  
PC1	   1.57	   <0.001	   1.24-­‐1.99	   1.82	   <0.001	   1.73-­‐2.43	  
PC2	   1.33	   0.088	   0.96-­‐1.84	   1.34	   0.117	   0.93-­‐1.94	  
PC3	   1.35	   0.135	   0.91-­‐2.01	   1.34	   0.160	   0.89-­‐2.00	  
Table	   7.15	  Association	   between	   principal	   components	   1-­‐3	   and	   5-­‐week	  mortality	   (n=149).	   Logistic	  
regression	  model	  used	  to	  examine	  associations	  between	  principal	  components	  1-­‐3	  and	  fatal	  outcome	  
by	   week	   5	   (as	   shown	   in	   Figure	   7.12	   and	   Table	   7.14).	   PC1	   was	   significantly	   associated	   with	   fatal	  
outcome	  in	  both	  univariate	  and	  multivariate	  analysis	  (adjusting	  for	  baseline	  conscious	  level	  and	  COAT	  
trial	  arm).	  PC	  =	  principal	  component.	  UOR	  =	  unadjusted	  odds	  ratio;	  AOR	  =	  adjusted	  odds	  ratio.	  	  
	  
Univariate	   analysis	   showed	   that	   principal	   component	   1	   (PC1)	   was	   significantly	  
associated	   with	   death	   by	   week	   5	   while	   principal	   components	   2	   and	   3	   (PC2,	   PC3)	  
showed	   only	   a	   non-­‐significant	   trend	   [Table	   7.15].	   When	   adjusted	   for	   baseline	  
conscious	  level	  and	  COAT	  trial	  arm,	  PC1	  remained	  significantly	  associated	  with	  fatal	  
outcome	  by	  week	  5.	  The	  effect	  of	  adding	  PC1	  to	  the	  baseline	  clinical	  variables	  was	  
demonstrated	  by	  plotting	  the	  receiver	  operating	  curves	  for	  the	  two	  models,	  with	  the	  
PRINCIPAL	  COMPONENT	  model	  (GCS,	  COAT	  trial	  arm	  and	  PC1)	  showing	  a	  significantly	  
increased	   area	   under	   the	   curve	   (AUC)	   compared	   to	   the	   CLINICAL	  model	   (GCS	   and	  
COAT	  trial	  arm)	  (0.81	  vs.	  0.65,	  p=0.003)	  [Figure	  7.13].	  No	  significant	  interaction	  was	  
noted	  between	  any	  of	  the	  principal	  components	  and	  the	  COAT	  trial	  arm.	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Figure	  7.13	  Receiver	  operating	  curves	   illustrating	   the	  additional	  benefit	  of	  day	  14	  biomarker	  data	  
on	  predicting	  5-­‐week	  mortality	  (n=149).	  Two	  logistic	  regression	  models	  to	  predictive	  mortality	  at	  CM	  
week	  5	  were	  compared:	  CLINICAL	  model	  (GCS<15	  +	  COAT	  trial	  arm)	  and	  PRINCIPAL	  COMPONENT	  (PC)	  
model	  (GCS	  +	  COAT	  trial	  arm	  +	  PC1).	  The	  PRINCIPAL	  COMPONENT	  model	  had	  a	  significantly	  increased	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7.6 Discussion	  
This	  chapter	  further	  explores	  the	  effects	  of	  ART	  on	  the	  host	  immune	  response	  during	  
HIV-­‐associated	   cryptococcal	   meningitis.	   In	   contrast	   to	   previous	   chapters,	   which	  
examined	  the	  differences	  in	  immune	  response	  between	  persons	  who	  are	  taking	  ART	  
or	   not	   taking	   ART	   at	   presentation	   with	   CM,	   this	   chapter	   examined	   the	   effects	   of	  
initiation	   of	   ART	   during	   anti-­‐fungal	   treatment	   for	   cryptococcal	   meningitis.	   It	   also	  
attempts	  to	  determine	  whether	  the	  excess	  early	  mortality	  observed	  in	  the	  COAT	  trial	  
among	  participants	  with	  CM	  who	  started	  ART	  after	  only	  1-­‐2	  weeks	  of	  amphotericin	  B	  
based	   therapy	   (45%	  mortality	   at	   6-­‐months	   compared	   to	   30%	  with	   deferred	   ART),	  
was	   immunologically	  mediated:	  an	  “IRIS-­‐like”	  complication	  (Boulware	  et	  al.	  2014a).	  
This	  was	  done	  by	  examining	  CSF	  and	   serum	   immune	   responses	  during	   the	   first	   14	  
days	   of	   anti-­‐fungal	   therapy	   (21	   days	   for	   serum),	   and	   comparing	   the	   immune	  
responses	   between	   the	   two	   arms	   of	   the	   COAT	   trial	   (early	   vs.	   deferred	   ART).	  
Furthermore,	   the	   chapter	   examines	  whether	   any	   biomarkers	   at	   these	   time	   points	  
were	  associated	  with	  mortality	  during	  the	  first	  5	  weeks	  following	  CM	  diagnosis	  (the	  
time	  period	  in	  which	  the	  excess	  mortality	  during	  the	  COAT	  trial	  occurred).	  Additional	  
sub-­‐analyses	   were	   performed	   for	   CSF	   biomarkers	   by	   study	   site	   due	   to	   significant	  
differences	   in	   host	   immune	   response	  of	   participants	   enrolled	   at	   them.	  Biomarkers	  
differences	  between	  study	  site	  may	  have	  been	  due	  to	  a	  variety	  of	  factors	   including	  
severity	  of	  HIV-­‐1	  disease,	  variations	  in	  host	  genetics,	  infecting	  fungal	  strain,	  level	  of	  
neurological	   impairment	   on	   presentation	   to	   hospital,	   and	   differences	   in	   sample	  
collection	  and	  handling.	  
7.6.1 Effect	  of	  earlier	  ART	  initiation	  on	  CSF	  immune	  response	  
Earlier	   ART	   initiation	   was	   found	   to	   be	   associated	   with	   an	   increased	   CSF	   cellular	  
infiltrate.	  At	  day	  14,	  there	  were	  significantly	  more	  participants	  in	  the	  early	  ART	  arm	  
who	  had	  raised	  CSF	  white	  cell	  count	  (≥5/µL)	  compared	  with	  the	  deferred	  ART	  arm;	  at	  
this	  time	  point	  persons	  in	  the	  early	  ART	  arm	  had	  received	  a	  median	  of	  6	  days	  ART.	  	  
This	  occurred	  mainly	  among	  individuals	  who	  had	  a	  paucity	  of	  CSF	  white	  cell	  response	  
at	   their	   initial	   presentation	   with	   CM	   (CSF	   WCC	   <5/µL).	   By	   day	   14,	   28%	   of	   such	  
participants	  in	  the	  early	  ART	  arm	  had	  developed	  a	  CSF	  cellular	  infiltrate	  and	  19%	  had	  
died,	   compared	   to	  0%	  with	  cellular	   infiltrate	   in	   the	  deferred	  ART	  arm	  and	  only	  4%	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mortality.	   This	   is	   particularly	   relevant	   as	   the	   majority	   of	   the	   early-­‐ART-­‐associated	  
mortality	   in	   the	   COAT	   trial	   occurred	   among	   persons	   with	   a	   paucity	   of	   CSF	   WCC	  
response	   prior	   to	   ART	   initiation,	   and	   it	   was	   this	   same	   group	  who	   have	   previously	  
been	   shown	   to	   be	   at	   increased	   risk	   of	   CM-­‐IRIS	   in	   cohort	   studies	   (Boulware	   et	   al.	  
2014a;	  Chang,	  Dorasamy,	  et	  al.	  2013a;	  Boulware	  et	  al.	  2010a).	  Further	  examination	  
of	  participants	  in	  this	  study	  with	  a	  paucicellular	  CSF	  response	  prior	  to	  ART	  initiation	  
showed	   they	   also	   had	   significantly	   greater	   CSF	   concentrations	   of	   GM-­‐CSF	   and	  
significantly	   lower	  CSF	  concentrations	  of	  sCD14	  and	  sCD163.	  This	  suggests	  reduced	  
CNS	  macrophage	  activation,	  and	  further	   illustrates	  the	  paucity	  of	  CSF	   inflammation	  
in	  such	  individuals	  (beyond	  their	  lower	  white	  cell	  counts)	  (Moller	  2012).	  Participants	  
with	   CSF	  WCC<5/µL	   at	   day	   8	   also	   had	   significantly	   increased	   serum	   IL-­‐4	   and	   IL-­‐17	  
concentrations,	   suggesting	  a	  Th2	  and	  Th17	  skew	  to	   their	   immune	  response.	  This	   is	  
notable	   as	   pre-­‐ART	   elevations	   in	   IL-­‐4	   and	   IL-­‐17	   have	   previously	   been	   reported	   in	  
persons	   who	   developed	   CM-­‐IRIS	   in	   cohort	   studies	   (Boulware	   et	   al.	   2010b);	   it	   is	  
possible	  this	  group	  in	  the	  COAT	  trial	  may	  have	  responded	  similarly	  on	  commencing	  
ART.	  	  
	  
At	   day	   14,	   persons	   receiving	   earlier	   ART	   in	   Kampala	   also	   had	   increased	   CSF	  
concentrations	   of	   sCD14,	   sCD163,	   macrophage	   inflammatory	   protein-­‐1α	   (MIP-­‐
1α/CCL3)	   and	   IL-­‐13.	   These	   findings	   are	   consistent	   with	   increased	   macrophage	  
activation	   in	   the	   central	   nervous	   system	   (CNS)	   and	   a	   Th2	   skew	   to	   the	   immune	  
response	   (Moller	   2012;	   Muraille	   &	   Leo	   1998).	   Th2	   immune	   responses	   have	   been	  
shown	   to	   be	   detrimental	   during	   infection	   with	   intra-­‐cellular	   organisms	   such	   as	  
Cryptococcus	   neoformans	   (Jain	   et	   al.	   2009;	   Müller	   et	   al.	   2007).	   Macrophage	  
activation	   is	   also	   known	   to	   be	   central	   to	   the	   host	   immune	   response	   against	  
cryptococci,	   with	   M1	   macrophages	   (classically	   activated)	   demonstrating	   anti-­‐
cryptococcal	   activity	   but	  M2	  macrophages	   (alternatively	   activated)	   being	   relatively	  
permissive	   to	   infection	   (Stenzel	   et	   al.	   2009;	   Voelz	   et	   al.	   2010).	   CD163	   is	   a	  
haptoglobin-­‐haemoglobin	   scavenging	   receptor	   found	   on	   monocytes	   and	  
macrophages	  and	   is	  cleaved	  from	  the	  cell	   surface	   in	  response	  to	  cellular	  activation	  
(Moller	   2012).	  Measurement	  of	   soluble	  CD163	   (sCD163)	   is	   considered	   an	   accurate	  
reflection	   of	   macrophage	   and	   monocyte	   activation	   and	   has	   been	   proposed	   as	   a	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diagnostic	   and	   prognostic	   marker	   in	   a	   variety	   of	   infective	   and	   inflammatory	  
conditions	  (e.g.	  haemophagocytic	  syndrome,	  acute	  liver	  failure,	  bacterial	  sepsis	  and	  
tuberculosis)	   (Moller	   2012;	   Su	   et	   al.	   2013;	   Feng	   et	   al.	   2012;	   Møller	   et	   al.	   2006;	  
Knudsen	  et	  al.	  2005).	  	  Soluble	  CD163	  is	  raised	  in	  HIV-­‐1	  infection	  and	  reflects	  disease	  
activity,	  being	  positively	  correlated	  with	  HIV	  viral	  load	  and	  negatively	  correlated	  with	  
CD4	   count;	   levels	   typically	   fall	   following	   ART	   initiation	   (Burdo	   et	   al.	   2011a).	  
Macrophage	   activation	   has	   been	   implicated	   in	   the	   pathophysiology	   of	   TB-­‐IRIS	   in	  
cytokine,	  gene	  expression,	  and	  post-­‐mortem	  studies	  (Tadokera	  et	  al.	  2011;	  Tran	  et	  al.	  
2014;	   Lawn	  et	  al.	   2009).	   It	   is	  possible	   that	   increased	  macrophage	  activation	   in	   the	  
central	   nervous	   system	   of	   individuals	   in	   the	   COAT	   trial	   may	   also	   represent	   a	  
detrimental	  IRIS-­‐like	  pathology	  that	  contributed	  to	  mortality.	  
	  
CD14	  is	  also	  found	  on	  monocytes	  and	  macrophages	  and	  functions	  as	  a	  receptor	  for	  
lipopolysaccharide	  (LPS)	  (Ziegler-­‐Heitbrock	  &	  Ulevitch	  1993).	  It	  can	  also	  be	  released	  
from	   the	   cell	   surface	   in	   response	   to	   a	   range	   of	   stimuli	   and	   is	   also	   regarded	   as	   a	  
marker	   of	   monocyte-­‐macrophage	   activation	   (Ziegler-­‐Heitbrock	   &	   Ulevitch	   1993).	  
Serum	  concentrations	  are	  elevated	  in	  HIV-­‐1	  infection	  –	  possibly	  related	  to	  microbial	  
translocation	  –	  and	  have	  been	   shown	   to	  be	  associated	  with	   increased	  mortality	   in	  
HIV	   cohort	   studies	   (Sandler	   et	   al.	   2011).	   Raised	   CSF	   sCD14	   has	   been	   reported	   in	  
bacterial	  meningitis	  both	  in	  hospitalized	  patients	  and	  mouse	  models	  (Nockher	  et	  al.	  
1999;	  Cauwels	  et	  al.	  1999).	  Evidence	  suggests	  this	  is	  a	  result	  of	  increased	  intrathecal	  
production	  by	  infiltrating	  blood	  leukocytes	  rather	  than	  diffusion	  of	  the	  protein	  across	  
the	  blood-­‐brain	  barrier	  (Nockher	  et	  al.	  1999;	  Cauwels	  et	  al.	  1999).	  Not	  only	  is	  sCD14	  
a	  marker	  of	  monocyte-­‐macrophage	  activation,	  but	  also	  has	  biological	  activity	  and	  in	  
murine	  models	  has	  been	  shown	  to	  augment	  the	  host	  immune	  response	  resulting	  in	  
significantly	   increased	   concentrations	   of	   the	   pro-­‐inflammatory	   cytokines	   IL-­‐6	   and	  
TNF-­‐α	   (Cauwels	  et	  al.	   1999).	   Elevated	  MIP-­‐1α/CCL3	  has	  also	  been	  observed	   in	   the	  
CSF	  of	  persons	  with	  bacterial	  and	  TB	  meningitis	  (Inaba	  et	  al.	  1997;	  Mastroianni	  et	  al.	  
1998),	   	   and	   an	   increased	   CCL3:CXCL10	   ratio	   prior	   to	   ART	   initiation	   is	   reported	   in	  
persons	  who	  develop	  cryptococcal-­‐IRIS	  (Chang,	  Omarjee,	  et	  al.	  2013b).	  In	  addition	  to	  
its	   chemotactic	   activities,	   MIP-­‐1α/CCL3	   is	   also	   reported	   to	   modulate	   the	   immune	  
response	  by	  stimulating	  pro-­‐inflammatory	  cytokine	  production	  from	  a	  variety	  of	  cells	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(O’Grady	  et	  al.	  1999).	  It	  is	  possible	  that	  sCD14	  and	  MIP-­‐1α/CCL3	  may	  have	  played	  a	  
similar	   role	   following	  ART	   initiation	   in	   the	  COAT	   trial:	  not	  only	   reflecting	   increased	  
macrophage	   activation	  within	   the	   CNS	   but	   driving	   a	   detrimental	   pro-­‐inflammatory	  
immune	  response.	  
	  
Given	   these	   findings,	   it	   is	   somewhat	   surprising	   that	   early	   ART	   initiation	   was	   not	  
associated	   with	   any	   significant	   increase	   in	   paradoxical	   CM-­‐IRIS	   in	   the	   COAT	   trial	  
(Boulware	   et	   al.	   2014a).	   This	   is	   in	   contrast	   to	   studies	   of	   ART	   timing	   in	   HIV-­‐1-­‐
associated	   TB,	   where	   a	   clear	   increase	   in	   IRIS	   was	   demonstrated	   with	   earlier	   ART	  
initiation	   (Naidoo	   et	   al.	   2012;	   Luetkemeyer	   et	   al.	   2014;	   Laureillard	   et	   al.	   2013).	  
However,	   the	   case	   definition	   of	   paradoxical	   CM-­‐IRIS	   specifies	   that	   persons	   must	  
undergo	  a	  biphasic	  clinic	  course:	  initial	  clinical	  improvement	  on	  anti-­‐fungal	  therapy,	  
then	  an	  ART-­‐associated	  clinical	  deterioration	  (Haddow	  et	  al.	  2010).	  In	  the	  COAT	  trial,	  
individuals	   in	   the	   early	   ART	   group	   often	   initiated	   ART	   prior	   to	   the	   resolution	   of	  
meningitis	   symptoms,	   making	   it	   difficult	   to	   differentiate	   this	   secondary	   clinical	  
deterioration	   from	   their	   initial	   presentation.	   In	   previous	   cohort	   studies,	   persons	  
developing	   CM-­‐IRIS	   have	   demonstrated	   significant	   elevations	   in	   a	   variety	   of	   pro-­‐
inflammatory	  cytokines	  in	  their	  CSF	  (TNFα,	  IFNγ,	  G-­‐CSF,	  IL-­‐6)	  (Boulware	  et	  al.	  2010a).	  
No	  similar	   increase	   in	  CSF	  pro-­‐inflammatory	  cytokines	  was	  noted	  with	  early	  ART	   in	  
this	  trial.	  However,	  CSF	  samples	  were	  only	  available	  up	  to	  6	  days	  after	  the	  initiation	  
of	   ART.	   It	   is	   possible	   that	   had	   later	   samples	   been	   available,	   an	   evolution	   in	   CNS	  
immune	   response	   may	   have	   been	   demonstrated:	   from	   cellular	   infiltrate	   and	  
increased	   macrophage	   activation,	   to	   widespread	   elevation	   of	   inflammatory	  
cytokines,	  possibly	  potentiated	  by	  the	  effects	  of	  sCD14	  and	  MIP-­‐1α/CCL3.	  
	  
Compared	  to	  participants	  enrolled	  in	  Kampala,	  earlier	  ART	  initiation	  among	  subjects	  
enrolled	   in	   Cape	   Town	   appeared	   to	   have	   the	   opposite	   effect	   on	   the	   CSF	   immune	  
response.	  Cape	  Town	  subjects	  in	  the	  early	  ART	  arm	  were	  found	  to	  have	  significantly	  
reduced	   concentrations	   of	   sCD163,	   sCD14	   and	   IL-­‐4	   compared	   to	   the	   deferred	  ART	  
arm,	   implying	   decreased	   macrophage	   activation.	   Although	   the	   Cape	   Town	   data	  
should	   be	   interpreted	   with	   caution	   due	   to	   the	   low	   number	   of	   subjects	   enrolled	  
there,	  it	  is	  notable	  that	  these	  differing	  effects	  of	  ART	  on	  CSF	  macrophage	  activation	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during	   treatment	   for	   CM	   (promoting	   resolution	   of	   inflammation	   in	   Cape	   Town	  
subjects	   but	   augmenting	   CSF	   inflammation	   in	   Kampala	   subjects)	   mirrored	   the	  
differing	   clinical	   effects	   of	   earlier	   ART	   initiation	   at	   the	   two	   sites:	   no	   difference	   in	  
mortality	   with	   earlier	   ART	   initiation	   in	   Cape	   Town	   but	   a	   significant	   increase	   in	  
mortality	   in	   Kampala.	   These	   differing	   immune	   responses	   between	   the	   two	   study	  
sites	  could	  be	  explained	  by	  a	  number	  of	   inherent	  differences	  between	  participants	  
recruited	  there.	  	  Individuals	  in	  Kampala	  had	  significantly	  lower	  peripheral	  blood	  CD4	  
counts	   and	   significantly	   lower	   CSF	   leukocyte	   counts	   at	   enrolment	   compared	   to	  
individuals	   in	   Cape	   Town.	   Furthermore,	   individuals	   in	   Kampala	   were	   significantly	  
more	   likely	   to	   have	   a	   paucicellular	   CSF	   response	   at	   randomization	   (cell	   count	   <5	  
cells/µL),	  a	  sub-­‐group	  identified	  from	  the	  COAT	  trial	  to	  be	  at	  particularly	  high	  risk	  of	  
mortality	   from	   early	   ART	   (Boulware	   et	   al.	   2014a).	   The	   finding	   that	   subjects	   from	  
Kampala	   (where	   the	   majority	   of	   mortality	   in	   the	   trial	   occurred)	   had	   evidence	   of	  
increased	  macrophage	  activation	  in	  the	  central	  nervous	  system	  after	  only	  6	  days	  of	  
ART,	   is	   supportive	   of	   the	   hypothesis	   that	   the	   increased	  mortality	   associated	   with	  
early	  ART	  in	  the	  COAT	  trial	  may	  have	  been	  caused	  by	  immunopathology,	  despite	  the	  
absence	  of	  clinically	  recognized	  IRIS.	  	  
7.6.2 Effect	  of	  ART	  on	  immune	  response	  in	  blood	  
In	  contrast	  to	  the	  effects	  of	  ART	  on	  CSF	  immune	  response	  there	  was	  no	  evidence	  to	  
suggest	   ART	   initiation	   lead	   to	   increased	   systemic	   inflammatory	   response;	   cytokine	  
and	  chemokine	  concentrations	  were	  not	  elevated	  and	  there	  was	  a	  decrease	  in	  serum	  
CRP.	  However,	  CRP	  is	  a	  relatively	  non-­‐specific	  marker	  and	  was	  already	  considerably	  
elevated	   in	   the	   majority	   of	   individuals	   at	   the	   time	   of	   randomization.	   Indeed,	  
compartmentalization	  of	  immune	  response	  has	  been	  clearly	  demonstrated	  in	  studies	  
of	   TBM-­‐IRIS	  where	  after	   2	  weeks	  of	  ART,	   individuals	  who	  went	  on	   to	  develop	   IRIS	  
had	   marked	   elevation	   in	   CSF	   pro-­‐inflammatory	   cytokines	   but	   little	   change	   in	   the	  
serum	  (Marais	  et	  al.	  2014).	  	  
7.6.3 Biomarkers	  predicting	  fatal	  outcome	  
In	  contrast	  to	  the	  results	  above,	  where	  early	  ART	  initiation	  appeared	  to	  alter	  the	  CSF	  
immune	   response	   significantly	   more	   than	   that	   of	   the	   blood,	   when	   immune	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correlates	  of	   fatal	   outcome	  were	   sought,	   no	  CSF	  biomarkers	  were	   identified	  but	   a	  
clear	  immune	  signature	  was	  noted	  in	  serum.	  This	  showed	  that	  subjects	  who	  died	  by	  
week	   5	   had	   significantly	   increased	   day	   14	   concentrations	   of	   serum	   CRP,	   GM-­‐CSF,	  
IFN-­‐γ,	  IL-­‐10,	  IL-­‐13,	  IL-­‐17,	  IL-­‐1β,	  IL-­‐6	  and	  sCD14	  compared	  to	  those	  who	  survived.	  This	  
suggests	  that	   individuals	  who	  died	  had	  increased	  systemic	   inflammation	  at	  the	  end	  
of	  amphotericin	  B	  therapy,	  compared	  to	  those	  who	  survived.	  The	  influence	  of	  these	  
day-­‐14	   serum	   biomarkers	   on	   5-­‐week	   mortality	   was	   illustrated	   by	   the	   significant	  
improvement	  seen	  in	  the	  logistic	  regression	  model	  when	  principal	  component	  1	  was	  
added	   to	   the	   clinical	   variables	   of	   baseline	  GCS	   and	   COAT	   trial	   arm.	   However,	   it	   is	  
important	   to	   note	   that	   none	   of	   these	   biomarkers	   were	   elevated	   in	   the	   serum	   of	  
individuals	   in	   the	   early	   ART	   arm,	   suggesting	   that	   this	   biomarker	   signature	   of	   fatal	  
outcome	   was	   not	   driven	   by	   early	   ART	   initiation.	   Indeed,	   given	   the	   high	   rates	   of	  
bacteraemia	  reported	  in	  this	  cohort	  it	   is	  possible	  this	  association	  between	  systemic	  
inflammation	   and	   mortality	   may	   reflect	   sepsis	   rather	   than	   fatal	   ART	   related	  
immunopathology	   (Rajasingham	   et	   al.	   2014).	   It	   is	   also	   possible	   it	   may	   reflect	   the	  
generalized	  systemic	  inflammation	  associated	  with	  HIV-­‐infection,	  shown	  in	  previous	  
studies	   to	  be	  a	   strong	  predictors	  of	  mortality	   (Sandler	   et	   al.	   2011;	  Boulware	  et	   al.	  
2011;	  Appay	  &	  Sauce	  2008).	  
7.6.4 Limitations	  and	  summary	  	  
Due	  to	  the	  COAT	  trial	  being	  halted	  prematurely	  by	  the	  data	  safety	  monitoring	  board,	  
these	   immunological	   analyses	   are	   underpowered.	   Reported	   associations	   are	  
significant	  in	  terms	  of	  the	  calculated	  p-­‐value,	  but	  most	  analyses	  (bar	  the	  associations	  
with	  fatal	  outcome)	  have	  not	  been	  adjusted	  for	  multiple	  comparisons,	  this	  is	  due	  to	  
the	   exploratory	   nature	   of	   the	   work.	   Furthermore,	   some	   of	   the	   reported	   findings	  
were	  from	  sub-­‐group	  analyses.	  However,	  this	  was	  considered	  appropriate	  given	  the	  
significant	   heterogeneity	   in	   CSF	   immune	   response	   between	   the	   three	   sites	   even	  
when	   adjusted	   for	   CD4	   count	   and	   fungal	   burden.	   The	   CSF	   findings	   may	   also	   be	  
subject	  to	  a	  degree	  of	  sample	  bias,	  as	  CSF	  was	  not	  available	  for	  all	  study	  subjects	  at	  
day	  14	  (due	  to	  early	  mortality	  or	  refusal	  of	  LP).	  In	  addition,	  as	  the	  timing	  of	  LPs	  was	  
set	  by	  the	  trial	  protocol,	  it	  was	  only	  possible	  to	  assess	  the	  effect	  of	  ART	  on	  the	  CSF	  
immune	   response	   for	   the	   first	   week	   of	   therapy.	   Finally,	   care	   must	   be	   taken	   in	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extrapolating	  the	  findings	  of	  the	  survival	  analysis	  in	  section	  7.5.3	  to	  other	  cohorts	  of	  
patients	  with	  CM.	  This	   is	  because	  the	  COAT	  trial	  only	  enrolled	   individuals	  who	  had	  
survived	  the	  first	  week	  of	  anti-­‐fungal	  therapy	  and	  as	  such	  is	  subject	  to	  an	  element	  of	  
survival	  bias.	  	  
	  
Despite	   these	   limitations,	   this	   chapter	  gives	  a	  unique	   insight	   into	   the	   immunologic	  
changes	  that	  result	  from	  ART	  initiation	  at	  the	  site	  of	  disease	  during	  an	  opportunistic	  
infection.	  It	  provides	  evidence	  that	  ART	  leads	  to	  alterations	  in	  host	  immunity	  within	  
the	   first	   week	   of	   initiation,	   and	   provides	   supportive	   evidence	   to	   suggest	   that	   the	  
increase	   in	   mortality	   associated	   with	   early	   ART	   in	   the	   COAT	   trial	   may	   have	   been	  
immunologically	  mediated.	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CHAPTER	  8: DISCUSSION	  AND	  CONCLUSIONS	  
In	   the	   final	   chapter	   the	   main	   findings	   of	   the	   four	   results	   chapters	   are	   brought	  
together	  to	  address	  the	  three	  main	  aims	  of	  the	  thesis.	  The	  findings	  of	  the	  thesis	  are	  
put	   in	   context	   of	   the	   current	   literature,	   limitations	   of	   the	   study	   are	   discussed	   and	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8.1 Addressing	  the	  central	  aims	  of	  the	  thesis	  
8.1.1 AIM	  1:	  To	  characterize	  the	  activation	  state	  of	  macrophages	  and	  monocytes	  
This	  aim	  was	  addressed	  in	  chapters	  5	  and	  6	  (IICD	  study,	  CSF	  immune	  responses	  and	  
blood	  immune	  responses	  respectively).	  Although	  largely	  descriptive,	  given	  the	  lack	  of	  
prior	  human	  studies	  examining	  this	  aspect	  of	  cryptococcal	  immunity	  it	  is	  considered	  
novel	  work.	  Additional	  observations	  on	  other	  aspects	  of	  the	  immune	  response	  were	  
also	  included.	  
	  
CSF	  immune	  response	  
In	   chapter	   5,	   the	   CSF	   immune	   response	   in	   HIV-­‐associated	   CM	   was	   shown	   to	   be	  
relatively	   paucicellular.	   This	   is	   consistent	   with	   previous	   studies	   of	   CM	   and	   is	   in	  
contrast	   to	   bacterial	   or	   TB	   meningitis	   where	   CSF	   white	   cell	   counts	   are	   often	  
significantly	   raised	   (Bicanic	  &	  Harrison	  2004;	   Jarvis	   et	   al.	   2014;	  Marais	   et	   al.	   2010;	  
Peltola	  et	  al.	  2007).	  While	  neutrophils	  are	  the	  most	  common	  infiltrating	  cell	  type	  in	  
bacterial	   meningitis,	   and	   CD4	   T	   cells	   the	   most	   common	   in	   other	  
infective/inflammatory	  CNS	  disorders,	  CD8	  T	  cells	  were	   the	  most	   common	  CSF	  cell	  
among	   persons	   in	   this	   study	   with	   HIV-­‐associated	   CM	   (followed	   by	   neutrophils,	  
monocyte-­‐macrophages,	  CD4	  T	  cells	  and	  NK	  cells)	  (Ichiyama	  et	  al.	  2009;	  Kowarik	  et	  al.	  
2014).	  It	  is	  likely	  that	  the	  findings	  observed	  here	  reflect,	  in	  a	  large	  part,	  ongoing	  HIV-­‐
1	  replication	  rather	  than	  an	  anti-­‐fungal	   response	  by	  CD8	  T	  cells.	   In	  addition,	   it	  was	  
noticed	  that	  some	  individuals	  had	  a	  distinct,	  secondary	  population	  of	  CD8	  T	  cells	  that	  
were	   significantly	   larger	   than	   normal	   CD8	   T	   cells.	   Given	   the	   positive	   correlation	  
between	  the	  frequency	  of	  these	  cells	  and	  HIV-­‐1	  viral	  load,	  it	  is	  possible	  they	  are	  also	  




Data	  presented	   in	   chapter	  5	  also	   showed	   that	  monocyte-­‐macrophages	   (MM)	  were	  
easily	   identified	   in	   the	   CSF	   using	   the	   surface	  marker	   CD14.	   However,	   a	   secondary	  
population	  of	  CD14	  negative	  CSF	  cells	  were	  identified	  that	  also	  appeared	  to	  be	  MM;	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an	  equivalent	  population	  was	  not	  found	  in	  circulating	  blood.	  These	  cells	  were	  HLA-­‐
DR,	   CD4	   and	   CD68	   positive,	   had	   similar	   physical	   characteristics	   to	   CD14+MM	  
(forward	   and	   side	   scatter),	   and	   frequently	   expressed	   the	   macrophage	   markers	  
CD206	  and	  CD163.	  Further	  characterization	  was	  not	  possible	  within	  the	  limits	  of	  the	  
antibody	   panel	   used;	   however,	   given	   that	   CD14	   is	   often	   lost	   during	   macrophage	  
maturation,	   it	   is	   possible	   that	   these	   cells	  may	   be	   a	  more	  mature	  MM	   population	  
(Daigneault	  et	  al.	  2010).	  	  
	  
Examination	  of	  the	  activation	  state	  of	  CSF	  monocyte-­‐macrophages	  showed	  frequent	  
expression	   of	   markers	   associated	   with	   a	   M2	   macrophage	   phenotype	   (CD206	   and	  
CD163)	   on	   both	   CD14+MM	   and	   CD14-­‐MM.	   However,	   surface	   markers	   were	  
frequently	  co-­‐expressed	  and	  closely	  co-­‐correlated,	  even	  those	  indicating	  apparently	  
opposite	   activation	   states	   (e.g.	   CD206,	   CD16	   and	   HLA-­‐DR)	   (Biswas	   &	   Mantovani	  
2010).	   These	   findings	   are	   in	   contrast	   to	   the	   traditional	   M1	   vs.	   M2	   dogma	   but	   in	  
keeping	   with	   more	   recent	   thinking,	   that	   macrophage	   activation	   resembles	   a	  
continuous	   spectrum	   rather	   than	   a	   dichotomous	   state	   (Gordon	   2003;	   Mosser	   &	  
Edwards	  2008).	  	  
	  
Monocyte	  populations	  
Circulating	   monocyte	   populations	   in	   blood	   among	   individuals	   with	   HIV-­‐associated	  
CM	  were	  examined	  in	  chapter	  6,	  and	  comparisons	  made	  with	  those	  of	  healthy	  and	  
HIV-­‐infected	  controls.	  Although	  comparisons	  were	  clearly	  underpowered,	  a	  number	  
of	   interesting	   observations	   were	   noted.	   	   Persons	   with	   CM	   had	   an	   increased	  
proportion	   of	   non-­‐classical	   monocytes	   (CD14+CD16++),	   decreased	   expression	   of	  
HLA-­‐DR	   on	   the	   classical	   subset	   (CD14++CD16-­‐),	   and	   decreased	   expression	   of	   the	  
chemokine	   receptors	   CCR2	   and	   CCR5.	   In	   summary	   this	   suggests	   a	   monocyte	  
phenotype	   characterized	   by	   increased	   potential	   for	   cytokine	   production	   but	  
decreased	  antigen	  presentation	  and	  reduced	  ability	  to	  migrate	  to	  the	  site	  of	  disease	  
(Ziegler-­‐Heitbrock	   2006;	   Rossi	   et	   al.	   2011).	   When	   stimulated	   with	   TLR	   ligands,	  
monocyte	   cytokine	   production	   was	   no	   different	   between	   persons	   with	   CM	   and	  
healthy	   controls	   but	   was	   significantly	   increased	   in	   HIV-­‐infected	   controls.	   This	  
suggests	   that	   although	   HIV-­‐1	   infection	   may	   initially	   potentiate	   pro-­‐inflammatory	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monocyte	  responses,	  by	  the	  time	  an	   individual	  develops	  advanced	  HIV	  disease	  and	  
cryptococcosis	   this	   effect	   has	   waned.	   	   This	   is	   consistent	   with	   the	   theory	   that	  
although	  HIV-­‐1	  infection	  is	  associated	  with	  immune	  activation,	  it	  ultimately	  leads	  to	  
immune	  exhaustion	  (Khaitan	  &	  Unutmaz	  2010).	  However,	   it	   is	  equally	  possible	  that	  
infection	   with	   C.	   neoformans	   results	   directly	   in	   a	   down-­‐regulation	   of	   immune	  
response.	  
8.1.2 AIM	  2:	  To	  assess	  the	  effects	  of	  ART	  on	  immune	  response	  during	  CM	  
This	   aim	   was	   addressed	   in	   two	   ways.	   In	   the	   IICD	   study	   [chapters	   5	   and	   6],	   the	  
immune	  responses	  in	  CSF	  and	  blood	  were	  compared	  between	  persons	  with	  CM	  who	  
were	   taking	   ART	  at	   presentation,	   and	   those	   who	   were	   not.	   In	   the	   COAT	   trial	  
immunology	  study	  [chapter	  7],	  CSF	  and	  serum	  immune	  responses	  in	  individuals	  with	  
CM	  were	  measured	  during	  the	  first	  3	  weeks	  of	  anti-­‐fungal	  therapy,	  and	  comparisons	  
made	  between	  subjects	   in	  the	  early	  ART	  arm	  (who	  started	  ART	  a	  median	  of	  8	  days	  
after	   CM	  diagnosis),	   and	   those	   in	   the	   deferred	  ART	   arm	   (who	  did	   not	   initiate	  ART	  
until	  5	  weeks	  after	  CM	  diagnosis).	  	  
	  
In	   chapter	  5,	   subjects	  with	  CM	   in	   the	   IICD	   study	  who	  were	   taking	  effective	  ART	  at	  
presentation	   were	   noted	   to	   have	   a	   significantly	   increased	   CSF	   CD4/CD8	   ratio	  
compared	  to	  those	  who	  were	  not	  taking	  ART.	  Effective	  ART	  was	  also	  associated	  with	  
decreased	  activation	  of	  CSF	  CD4	  T	  cells,	  decreased	  frequency	  of	  “large”	  T	  cells	  in	  the	  
CSF,	   increased	  expression	  of	  CD16	  on	  CSF	  CD14-­‐	  MM,	  and	   increased	  expression	  of	  
CD206	   on	   CD14+	   and	   CD14-­‐	   CSF	   macrophages	   –	   suggesting	   a	   M2	   macrophage	  
phenotype.	   This	   switch	   towards	   a	   M2	   phenotype	   was	   closely	   associated	   with	  
decreases	  in	  HIV-­‐1	  viral	  load	  in	  peripheral	  blood.	  Indeed,	  even	  in	  subjects	  not	  taking	  
ART	   there	  was	  an	   inverse	  correlation	  between	  plasma	  viral	   load	  and	  expression	  of	  
CD206	  on	  CSF	  CD14+	  MM.	  In	  contrast,	  data	  presented	  in	  chapter	  6	  showed	  that	  the	  
effects	   of	   ART	   on	   the	   immune	   response	   in	   blood	  were	   not	   as	   clear-­‐cut.	   Although	  
there	  was	  an	  increased	  frequency	  of	  circulating	  CD4	  T	  cells	  among	  individuals	  taking	  
ART	  and	  an	  increased	  activation	  of	  neutrophils	  after	  stimulation	  with	  LPS	  and	  R848,	  
these	  differences	  were	  not	  significant	  once	  adjusted	  for	  multiple	  comparisons.	  ART	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also	  appeared	  to	  have	  no	  significant	  effect	  on	  serum	  cytokine	  concentrations,	  or	  the	  
cytokine	  response	  of	  monocytes	  and	  whole	  blood	  to	  the	  various	  stimulations.	  	  
	  
In	   chapter	   7,	   earlier	   ART	   initiation	   among	   participants	   in	   the	   COAT	   trial	   also	  
appeared	  to	  have	  a	  greater	  effect	  on	  the	  immune	  response	  in	  the	  CSF	  compared	  to	  
the	   blood.	   In	   blood,	   ART	   initiation	  was	   associated	  with	   a	   plateauing	   of	   CRP	   levels	  
during	  the	  second	  week	  of	  amphotericin	  B	  therapy	  (rather	  than	  the	  steady	  rise	  seen	  
in	  the	  deferred	  ART	  arm),	  and	  lower	  serum	  markers	  of	  macrophage	  activation	  at	  day	  
21	  (sCD163).	  	  In	  contrast,	  at	  day	  14,	  significantly	  more	  subjects	  in	  the	  early	  ART	  arm	  
had	  an	  elevated	  CSF	  WCC	  (≥5/µL)	  when	  compared	  to	  the	  deferred	  ART	  arm;	  this	  was	  
after	   just	   six	   days	   of	   ART.	   The	   differences	   in	   day	   14	  WCC	  were	  mainly	   due	   to	   the	  
development	  of	  a	  cellular	   infiltrate	  among	  participants	   in	   the	  earlier	  ART	  arm	  who	  
had	  a	  paucity	  of	  CSF	  white	  cells	  at	  baseline.	  	  In	  contrast,	  none	  of	  the	  participants	  in	  
the	   deferred	  ART	   group	  with	   an	   initial	   paucity	   of	   CSF	  white	   cells	   developed	   a	   CSF	  
cellular	  infiltrate	  by	  day	  14.	  Given	  the	  excess	  mortality	  associated	  with	  early	  ART	  in	  
the	  COAT	  trial,	  especially	  among	  subjects	  with	  a	   low	  CSF	  WCC	  at	   randomization,	   it	  
seems	  plausible	  that	  these	  changes	   in	  CSF	  WCC	  may	  represent	  a	  detrimental,	  ART-­‐
driven,	   immune	   response.	   	  Unfortunately,	   this	   cellular	   infiltrate	  was	  not	   examined	  
further	   using	   flow	   cytometry.	   As	   such,	   the	   nature	   of	   the	   cellular	   infiltrate	   and	   the	  
activation	  state	  of	  these	  cells	  cannot	  be	  fully	  determined.	  	  
Data	   presented	   in	   chapter	   7	   also	   showed	   that	   among	   COAT	   subjects	   in	   Kampala,	  
early	  ART	  initiation	  was	  associated	  with	  significantly	  increased	  CSF	  concentrations	  of	  
sCD14,	   sCD163,	   MIP-­‐1α/CCL3	   and	   IL-­‐13,	   and	   a	   lower	   proportion	   of	   subjects	   with	  
detectable	  CSF	   IL-­‐2	   levels.	  This	  suggests	  that	  ART	   initiation	  resulted	   in	  macrophage	  
activation	  within	  the	  CNS,	  and	  a	  possible	  detrimental	  Th2	  skew	  to	  the	  T	  cell	  response	  
(Müller	   et	   al.	   2007;	   Stenzel	   et	   al.	   2009).	   This	   is	   potentially	   significant	   given	   that	  
Kampala	  was	  the	  largest	  site	  in	  the	  COAT	  trial	  and	  where	  the	  largest	  number	  of	  trial	  
deaths	   occurred.	   It	   is	   also	   consistent	   with	   studies	   of	   HIV-­‐associated	   TB	   where	  
paradoxical	  IRIS	  has	  been	  linked	  with	  increased	  serum	  concentrations	  of	  sCD163	  and	  
sCD14	   (Andrade	   et	   al.	   2014).	   In	   contrast,	   subjects	   in	   Cape	   Town	  had	   the	   opposite	  
response,	   early	  ART	  was	   associated	  with	   lower	   concentrations	  of	   CSF	   IL-­‐4,	   sCD163	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and	  sCD14	  suggesting	  reduced	  CNS	  macrophage	  activation.	  Given	  the	  low	  numbers	  
of	  subjects	  enrolled	  in	  Cape	  Town	  it	  is	  difficult	  to	  draw	  robust	  conclusions	  from	  these	  
findings	   but	   it	   is	   interesting	   to	   observe	   that	   while	   earlier	   ART	   initiation	   was	  
associated	  with	  a	  clear	   increase	   in	  mortality	   in	  the	  Kampala	  cohort,	  no	  detrimental	  
effect	  was	  observed	  in	  Cape	  Town.	  There	  are	  a	  variety	  of	  possible	  reasons	  for	  these	  
contrasting	   responses.	   Compared	   to	   subjects	   in	   Kampala,	   those	   enrolled	   in	   Cape	  
Town	  had	  significantly	  higher	  CD4	  counts	  and	  a	  greater	  proportion	  had	  a	  CSF	  white	  
cell	   count	  ≥5/µL.	   It	   is	   also	  possible	   that	  differences	   in	  host	   and	  pathogen	  genetics	  
may	  also	  have	  played	  a	  role.	  
Both	  of	  these	  studies	  suggest	  that	  ART	  has	  a	  more	  profound	  effect	  on	  host	  immune	  
response	  at	  the	  site	  of	  disease	  compared	  to	  the	  blood.	  However,	  the	  effects	  of	  ART	  
on	   CSF	   macrophage	   activation	   in	   the	   two	   studies	   appear	   to	   be	   contradictory.	   In	  
chapter	   5	   (IICD	   cohort),	   ART	   was	   associated	   with	   a	   M2	   macrophage	   phenotype,	  
considered	  a	  more	  anti-­‐inflammatory	  state	  (Gordon	  2003),	  but	  in	  chapter	  7,	  among	  
Kampala	   subjects	   in	   the	   COAT	   trial,	   ART	   was	   associated	   with	   increased	  
concentrations	  of	  sCD14	  and	  sCD163,	  suggesting	  a	  more	  pro-­‐inflammatory	  response	  
(Moller	   2012).	   In	   both	   of	   these	   scenarios,	   subjects	   had	   active	   infection	   with	   C.	  
neoformans	  and	  were	  taking	  ART.	  However,	  in	  the	  IICD	  study,	  macrophage	  activation	  
was	   assessed	   after	   several	   weeks	   of	   ART	   (when	   the	   HIV	   viral	   load	   was	   often	  
undetectable)	  whereas	   in	  the	  COAT	  trial	  macrophage	  activation	  was	  assessed	  after	  
only	  a	  few	  days	  of	  ART.	  Furthermore,	  subjects	  in	  the	  IICD	  study	  started	  ART	  prior	  to	  
the	   development	   of	   CM	   symptoms	  when	   the	  CSF	   fungal	   burden	  would	   have	   been	  
low	   (or	   not	   present);	   in	   contrast,	   subjects	   in	   the	   early	   arm	   of	   the	   COAT	   study	  
initiated	  ART	  during	   the	  second	  week	  of	  anti-­‐fungal	   therapy,	  when	  antigen	  burden	  
was	  high.	  This	  is	  particularly	  relevant	  given	  that	  increased	  antigen	  burden	  at	  the	  time	  
of	   ART	   initiation	   has	   been	   associated	   with	   increased	   risk	   of	   IRIS	   in	   a	   number	   of	  
studies	  (Jarvis	  et	  al.	  2014;	  Chang	  et	  al.	  2013;	  Boulware	  et	  al.	  2010b).	  	  
In	   conclusion,	   these	   studies	   suggest	   that	   ART	   has	   a	   greater	   effect	   on	   the	   immune	  
response	  at	   the	  site	  of	  disease	  compared	  to	  the	  blood.	  Among	  persons	  developing	  
cryptococcal	  meningitis	  while	  taking	  ART,	  it	  was	  associated	  with	  a	  switch	  towards	  a	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M2	   macrophage	   phenotype,	   possibly	   through	   alterations	   in	   HIV-­‐1	   viral	   load.	  
However,	   when	   ART	   was	   initiated	   during	   an	   active	   infection	   with	   C.	   neoformans,	  
when	   fungal	   burden	   was	   high,	   it	   was	   associated	   with	   a	   potentially	   detrimental	  
inflammatory	  response	  characterized	  by	  macrophage	  activation.	  
8.1.3 AIM	  3:	  To	  explore	  immune	  correlates	  of	  disease	  severity	  and	  poor	  outcome	  
This	  forms	  the	  central	  aspect	  of	  the	  thesis	  and	  is	  addressed	  in	  chapters	  4-­‐7.	  Disease	  
severity	   is	   assessed	   in	   terms	   of	   fungal	   burden,	   raised	   intracranial	   pressure	   and	  
decreased	   consciousness;	   poor	   outcome	   is	   assessed	   in	   terms	   of	   rate	   of	   fungal	  
clearance	  and	  death.	  	  
	  
Fungal	  burden	  [chapters	  5	  &	  6]	  
In	  chapter	  5,	  an	  association	  was	  demonstrated	  between	  increased	  CSF	  fungal	  burden	  
and	  a	  paucity	  of	  CSF	  inflammation,	  characterized	  by	  reduced	  numbers	  of	  CD4	  T	  cells,	  
CD8	   T	   cells,	   double	   negative	   T	   cells	   and	  NK	   cells	   in	   the	  CSF,	   along	  with	   decreased	  
concentrations	  of	  the	  pro-­‐inflammatory	  cytokines	  IL-­‐6	  and	  G-­‐CSF.	  Fungal	  burden	  was	  
also	   inversely	   correlated	   with	   peripheral	   blood	   CD4	   count	   and	   whole	   blood	   IFN-­‐γ	  
response	   to	   LPS,	   and	   demonstrated	   a	   positive	   correlation	   with	   circulating	   blood	  
neutrophils.	   These	   findings	   are	   consistent	   with	   previous	   studies	   that	   have	  
demonstrated	  associations	  between	  high	  CSF	  fungal	  burden	  and	  low	  peripheral	  CD4	  
count,	   impaired	  peripheral	  blood	  IFN-­‐γ	  responses,	  and	  a	  paucity	  of	   inflammation	  in	  
the	  CSF	  (low	  IFNγ	  concentrations	  and	  low	  CSF	  WCC)	  (Siddiqui	  et	  al.	  2005;	  Jarvis	  et	  al.	  
2013;	   Jarvis	   et	   al.	   2014).	   However,	   the	   findings	   presented	   in	   chapter	   5	   further	  
characterize	   the	   nature	   of	   the	   CSF	   infiltrate.	   Contrary	   to	   the	   hypothesis	   stated	   in	  
chapter	  2,	  there	  was	  no	  association	  between	  CSF	  fungal	  burden	  and	  the	  presence	  of	  
a	  CSF	  macrophage	  M2	  phenotype.	  
	  
Raised	  intracranial	  pressure	  [chapter	  5]	  
Chapter	   5	   also	   examined	   factors	   associated	   with	   raised	   intracranial	   pressure.	   The	  
development	   of	   high	   CSF	   opening	   pressure	   (>30cm	   H2O)	   during	   admission	   was	  
associated	   with	   a	   significantly	   higher	   baseline	   fungal	   burden/cryptococcal	   count,	  
larger	  cryptococcal	  size	  and	  lower	  CSF	  cell	  counts	  (CD4,	  CD8,	  double	  negative	  T	  cells	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and	   NK	   cells).	   Although	   individuals	   with	   raised	   ICP	   were	   noted	   to	   have	   increased	  
relative	   frequencies	   of	   CD14-­‐MM	   and	   large	   T	   cells	   in	   the	   CSF,	   there	   was	   no	  
convincing	   evidence	   to	   suggest	   that	   raised	   ICP	   occurred	   as	   a	   result	   of	   a	   pro-­‐
inflammatory	  immune	  response,	  and	  no	  evidence	  to	  suggest	  it	  was	  associated	  with	  
ART	  use.	  Instead,	  raised	  ICP	  appeared	  to	  occur	  in	  individuals	  with	  a	  profound	  lack	  of	  
immune	   response	   in	   the	   CSF	   and	   was	   closely	   associated	   with	   increased	   fungal	  
burden	  and	  capsule	  size.	  This	  is	  consistent	  with	  the	  hypothesis	  that	  raised	  ICP	  in	  CM	  
occurs	   due	   to	   obstruction	   of	   CSF	   drainage	   by	   the	   overwhelming	   organism	   load	  
(particularly	   capsular	   material),	   and	   is	   consistent	   with	   previous	   studies	   that	   have	  
shown	  both	  fungal	  burden	  and	  capsular	  size	  to	  be	  significantly	  associated	  with	  raised	  
intracranial	  pressure	  (Bicanic	  et	  al.	  2009a;	  Robertson	  et	  al.	  2014;	  Loyse	  et	  al.	  2010).	  	  
	  
Decreased	  consciousness	  [chapter	  5]	  
Associations	  between	  the	  CSF	  immune	  response	  and	  decreased	  consciousness	  were	  
also	   examined	   in	   chapter	   5.	   Individuals	   with	   altered	   consciousness	   did	   not	   have	  
significantly	   increased	   intracranial	   pressure	   nor	   did	   they	   have	   increased	   fungal	  
burden.	   Once	   adjusted	   for	   multiple	   comparisons,	   there	   were	   also	   no	   immune	  
parameters	  associated	  with	  decreased	  consciousness.	  	  
	  
Rate	  of	  fungal	  clearance	  [chapter	  5]	  
Despite	   its	   frequent	  use	  as	  a	  surrogate	  endpoint	   in	  phase	  2	  drug	   trials,	   the	  rate	  of	  
fungal	   clearance	   was	   not	   found	   to	   be	   a	   useful	   endpoint	   in	   this	   study	   due	   to	  
incomplete	  data.	  Study	  subjects	  who	  died	  within	  the	  first	  few	  days	  after	  enrolment	  
frequently	  did	  not	  have	  a	  second	  quantitative	  culture	  performed,	  making	  calculation	  
of	  fungal	  clearance	  rate	  impossible	  and	  resulting	  in	  a	  significant	  survival	  bias	  in	  this	  
measurement.	  Although	  a	  positive	  association	  was	  noted	  between	  the	  rate	  of	  fungal	  
clearance	  and	  CSF	  concentrations	  of	  the	  pro-­‐inflammatory	  cytokines	  G-­‐CSF	  and	  IL-­‐7,	  
this	  was	  not	  significant	  following	  adjustment	  for	  multiple	  comparisons.	  However,	  it	  is	  
in	   keeping	   with	   previous	   studies	   suggesting	   a	   pro-­‐inflammatory	   CSF	   response	  
(particularly	  increased	  IFN-­‐γ	  concentration)	  improves	  fungal	  clearance	  (Siddiqui	  et	  al.	  
2005;	  Jarvis	  et	  al.	  2012).	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Fatal	  outcome	  [chapters	  5,	  6	  and	  7]	  
This	  was	   examined	   in	   both	   the	   IICD	   cohort	   and	   the	   COAT	   trial.	   In	   the	   IICD	   cohort	  
[Chapters	  5	  &	  6],	  CSF	  and	  serum	   immune	  responses	  of	   subjects	  were	  examined	  at	  
baseline,	  and	  comparisons	  made	  between	  those	  who	  survived	  and	  who	  died	  during	  
study	  follow	  up	  (at	  day	  14,	  week	  12	  and	  over	  the	  24	  weeks	  of	  follow	  up).	  In	  the	  COAT	  
trial,	  biomarker	  concentrations	  in	  CSF	  and	  serum	  at	  the	  end	  of	  amphotericin	  therapy	  
were	  examined,	  and	  associations	  sought	  with	  mortality	  over	  the	  next	  3	  weeks,	   the	  
time	   period	   in	   which	   the	   majority	   of	   excess	   mortality	   in	   the	   COAT	   trial	   occurred	  
[chapter	  7].	  	  
	  
In	   chapter	   5,	   subjects	  who	  died	  by	  week	  12	   in	   the	   IICD	   study	  were	   found	   to	  have	  
lower	  concentrations	  of	  CSF	   IFN-­‐γ	   and	   fewer	  double	  negative	   (CD4-­‐CD8-­‐)	  T	   cells	   in	  
the	  CSF	  compared	  to	  subjects	  who	  survived.	  Although	  this	  was	  not	  significant	  when	  
adjusted	   for	  multiple	  comparisons	   (using	  a	  q-­‐value	  of	  0.1),	  decreased	   frequency	  of	  
double	   negative	   T	   cells	   did	   remain	   associated	   with	   mortality	   in	   a	   Cox	   regression	  
model	  when	  adjusted	  for	  conscious	  level	  and	  baseline	  fungal	  burden.	  	  These	  findings	  
are	   consistent	   with	   previously	   published	   studies	   reporting	   low	   levels	   of	   CSF	   pro-­‐
inflammatory	  cytokines	  in	  non-­‐survivors	  (IFNγ,	  TNFα,	  IL-­‐6	  and	  IL-­‐8)	  and	  clinical	  trials	  
demonstrating	   the	   therapeutic	   benefits	   of	   adjunctive	   IFN-­‐γ	   (Siddiqui	   et	   al.	   2005;	  
Jarvis	  et	  al.	  2012).	   It	   is	  also	  biologically	  plausible,	  given	  that	  a	  number	  of	  cells	   that	  
make	  up	  the	  double	  negative	  T	  cell	  population	  are	  avid	  producers	  of	  IFN-­‐γ	  (iNKT	  cells	  
and	  γδ	  T	  cells)	   (Olson	  et	  al.	  2009;	  Kawakami	  2004).	  Further	  studies	  are	  required	  to	  
clarify	  the	  role	  of	  these	  cells	  in	  the	  human	  host	  response	  against	  C.	  neoformans.	  
	  
In	   chapter	   6,	   a	   clear	   immune	   signature	   was	   noted	   at	   enrolment	   in	   the	   blood	   of	  
subjects	  in	  the	  IICD	  cohort	  who	  died	  during	  the	  first	  2	  weeks	  of	  therapy.	  Monocytes	  
from	   non-­‐survivors	   exhibited	   features	   of	   monocyte	   anergy	   characterized	   by	  
significantly	   reduced	   HLA-­‐DR	   expression	   and	   impaired	   TNF-­‐α	   response	   to	   LPS	  
stimulation	  (Williams	  et	  al.	  1998;	  Kylanpaa	  et	  al.	  2005).	  This	  was	  accompanied	  by	  a	  
distinctive	   immune	   phenotype	   of	   increased	   immune	   activation	   (greater	  
concentrations	   of	   IL-­‐6,	   CXCL10/IP-­‐10	   and	   increased	   frequency	   of	   circulating	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neutrophils),	   increased	   anti-­‐inflammatory	   markers	   (IL-­‐10),	   and	   decreased	   whole	  
blood	  Th1	  responses	  (decreased	  IL-­‐12	  and	  IFN-­‐γ	  production	  when	  whole	  blood	  was	  
stimulated	   with	   TLR	   ligands).	   These	   findings	   closely	   resemble	   features	   of	   the	  
compensatory	   anti-­‐inflammatory	   response	   syndrome	   (CARS),	   a	   down-­‐regulation	   of	  
immune	  responses	  following	  significant	  pro-­‐inflammatory	  insult	  (Bone	  1996).	  CARS	  is	  
well	   recognized	   in	   severe	   sepsis	   and	   polytrauma	   and	   is	   thought	   to	   be	   mediated	  
through	  the	  effects	  of	  IL-­‐10	  (Ward	  et	  al.	  2008),	  elevations	  of	  which	  were	  also	  noted	  
among	  non-­‐survivors	   in	   the	   IICD	   cohort.	   Impaired	  T	   cell	   responses	  are	  also	  a	  well-­‐
recognized	  component	  of	  CARS,	  possibly	  due	  to	  decreased	  antigen	  presentation	  and	  
decreased	   co-­‐stimulatory	   cytokine	   production	   by	   anergic	   monocytes	   (Ward	   et	   al.	  
2008).	  This	  provides	  a	  possible	  explanation	   for	   the	  previously	  observed	  association	  
between	   impaired	   cryptococcus	   specific	   CD4	   T	   cell	   pro-­‐inflammatory	   cytokine	  
responses	   and	   fatal	   outcome	   in	   cryptococcal	   meningitis	   (Jarvis	   et	   al.	   2013).	   The	  
importance	   of	   this	   immune	   signature	   in	   determining	   fatal	   outcome	   was	   clearly	  
demonstrated	  in	  the	  IICD	  cohort,	  when	  the	  first	  principal	  component	  (PC1)	  from	  the	  
principal	   component	   analysis	   was	   added	   to	   a	   logistic	   regression	   model.	   	   In	   this	  
model,	   PC1	   remained	   significantly	   associated	   with	   14-­‐day	   mortality	   even	   when	  
adjusted	   for	   conscious	   level	   and	   baseline	   fungal	   burden,	   suggesting	   that	  
dysfunctional	   host	   immune	   response	   may	   be	   an	   important	   factor	   in	   determining	  
fatal	  outcome	  in	  HIV-­‐associated	  cryptococcal	  disease.	  The	  reasons	  why	  individuals	  in	  
the	   IICD	   study	   developed	   a	   CARS-­‐like	   immune	   response	   were	   not	   specifically	  
examined	   in	   this	   study.	   Possibilities	   include	   a	   direct	   effect	   of	   C.	   neoformans	  
infection,	   immune	  exhaustion	  due	   to	  end-­‐stage	  HIV-­‐1	   infection,	  or	  occult	  bacterial	  
sepsis	   (although	   no	   blood	   cultures	   performed	   identified	   bacteraemia	   at	   baseline).	  
Further	  studies	  are	  required	  to	  verify	  this	  observation	  and	  investigate	  the	  underlying	  
mechanisms.	  	  
	  
In	  chapter	  7,	  no	  association	  was	  noted	  between	  fatal	  outcome	  in	  the	  COAT	  trial	  and	  
CSF	   immune	   response	   at	   any	   of	   the	   time	   points	   examined.	   This	   was	   despite	   the	  
previously	   described	   differences	   at	   day	   14	   between	   the	   two	   arms	   of	   the	   trial.	  
However,	   unlike	   the	   IICD	   study,	   no	   flow	   cytometry	  was	   performed	   to	   analyze	   the	  
nature	  of	  the	  CSF	  cellular	  infiltrate.	  Given	  that	  many	  of	  the	  apparent	  effects	  of	  ART	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on	   CSF	   immune	   response	   in	   the	   IICD	   study	   related	   to	   cellular	   rather	   than	   soluble	  
components	  of	  the	  immune	  response,	  it	  is	  possible	  that	  a	  study	  using	  flow	  cytometry	  
may	  have	  been	  more	  informative.	  With	  regard	  to	  the	  immune	  response	  measured	  in	  
the	  blood,	  in	  contrast	  to	  the	  findings	  of	  the	  IICD	  study	  no	  baseline	  measurements	  of	  
immune	   function	   were	   found	   to	   be	   associated	   with	   fatal	   outcome	   among	  
participants	  in	  the	  COAT	  trial.	  However,	  the	  findings	  of	  the	  IICD	  study	  were	  strongly	  
influenced	  by	  early	  mortality,	  with	  almost	  50%	  of	  deaths	  occurring	  during	   the	   first	  
week	  of	  antifungal	  therapy.	  As	  COAT	  trial	  enrollment	  did	  not	  occur	  until	  day	  8,	  such	  
individuals	   were	   not	   included	   in	   the	   trial,	   resulting	   in	   survival	   bias	   in	   any	  
measurement	  taken	  prior	  to	  this	  point.	  Data	  from	  the	  COAT	  trial	  did	  identify	  a	  large	  
number	  of	  serum	  biomarkers	  at	  day	  14	  that	  were	  significantly	  higher	  in	  participants	  
who	  died	  during	  the	  next	  3	  weeks	  (i.e.	  5	  weeks	  following	  CM	  diagnosis	  and	  4	  weeks	  
following	  ART	  initiation	  in	  the	  early	  ART	  arm	  –	  the	  time	  period	  in	  which	  the	  excess	  
mortality	   in	   the	  COAT	   trial	   occurred).	   This	   included	   elevated	  CRP,	   sCD14,	  GM-­‐CSF,	  
IFN-­‐γ,	   IL-­‐1β,	   IL-­‐6,	   IL-­‐10,	   IL-­‐13,	   and	   IL-­‐17,	   suggesting	   that	   an	   increased	   systemic	  
inflammatory	  response	  was	  associated	  with	  poor	  outcome.	  However,	  none	  of	  these	  
markers	   were	   significantly	   increased	   in	   the	   early	   ART	   arm	   at	   this	   time	   point	  
suggesting	  that	  the	  immune	  signature	  was	  not	  driven	  by	  the	  initiation	  of	  early	  ART.	  It	  
is	   possible	   that	   these	   observations	   may	   instead	   reflect	   either	   bacterial	   sepsis,	   or	  
generalized	  systemic	  inflammation	  associated	  with	  HIV-­‐infection,	  shown	  in	  previous	  
studies	   to	   be	   a	   strong	   predictor	   of	  mortality	   (Sandler	   et	   al.	   2011;	   Boulware	   et	   al.	  
2011;	  Appay	  &	  Sauce	  2008).	  	  
	  
In	   summary,	   data	   from	   this	   thesis	   suggests	   that	   fatal	   outcome	   in	   CM	   occurs	   as	   a	  
result	  of	  widespread	  systemic	   immune	  activation	   resulting	   in	  a	  down	  regulation	  of	  




8.2 Analysis	  of	  findings	  and	  limitations	  of	  the	  work	  
This	   thesis	   is	   one	   of	   the	   most	   in-­‐depth	   studies	   of	   the	   immune	   response	   among	  
persons	   with	   HIV-­‐associated	   cryptococcal	   meningitis.	   It	   makes	   a	   number	   of	   novel	  
findings,	   particularly	   with	   respect	   to	   the	   role	   of	   monocyte	   and	   macrophage	  
activation.	  The	  role	  of	  macrophage	  activation	  has	  been	  studied	  extensively	  in	  murine	  
and	   cell	   culture	   models	   of	   cryptococcosis	   where	   alternatively	   activated	   (M2)	  
macrophages	   have	   been	   associated	   with	   higher	   fungal	   burden	   and	   worse	   clinical	  
outcome	  (Stenzel	  et	  al.	  2009).	  However,	  in	  this	  study,	  the	  presence	  of	  CSF	  monocyte-­‐
macrophages	  displaying	  CD206	  –	  the	  most	  widely	  recognized	  marker	  of	  alternative	  
activation	  –	  did	  not	  appear	  to	  impact	  on	  fungal	  burden,	  rate	  of	  fungal	  clearance	  or	  
overall	  survival.	  	  
	  
This	  contrast	  in	  findings	  between	  human	  and	  animal	  studies	  illustrates	  an	  important	  
point.	   It	   emphasizes	   the	   importance	   of	   studying	   the	   immune	   response	   in	   humans	  
and	  cautions	  against	  an	  over	  reliance	  on	  animal	  models.	  Although	  animal	  models	  are	  
undoubtedly	   useful,	   enabling	   experiments	   that	   are	   simply	   impossible	   in	   humans,	  
there	  are	  important	  caveats	  to	  their	  use.	  The	  first	  is	  that	  there	  are	  clearly	  differences	  
between	   the	  biology	  of	   the	  hosts.	  This	   is	  not	  at	  all	   surprising	  given	   that	   significant	  
differences	   in	   immune	   response	   even	   exist	   between	   different	   breeds	   of	  
experimental	   mice	   (Chen	   et	   al.	   2008).	   The	   anti-­‐microbial	   activity	   of	   macrophages	  
clearly	   varies	   between	   species	   as	   demonstrated	   by	   deletion	   experiments	   prior	   to	  
cryptococcal	   challenge.	  Whilst	  macrophage	  deletion	   in	   rats	   resulted	   in	   significantly	  
increased	   fungal	   loads,	   in	   mice	   fungal	   load	   decreased	   (Shao	   et	   al.	   2005).	   This	  
suggests	   that	   rat	   macrophages	   have	   an	   inherent	   anti-­‐fungal	   activity	   but	   murine	  
macrophages	  are	  permissive	  to	  infection.	  Furthermore,	  although	  the	  Th1/Th2/Th17	  
paradigm	  is	  well	  characterized	  in	  mice,	  evidence	  that	  it	  is	  relevant	  in	  humans	  is	  not	  
so	  clear	   (Rook	  2001).	  Animal	  models	  of	  cryptococcosis	  also	  do	  not	  account	   for	   the	  
effect	   of	   chronic	   infection	   with	   HIV-­‐1,	   which	   is	   clearly	   associated	   with	   significant	  
changes	  in	  host	  immune	  response	  not	  simply	  limited	  to	  CD4	  cell	  depletion	  (Cadogan	  
et	   al.	   2008).	   	   In	   addition	   to	   differences	   in	   the	   host	   biology,	   there	   may	   also	   be	  
differences	  between	  the	  infecting	  strains	  of	  C.	  neoformans.	  People	  are	  infected	  with	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a	  variety	  of	  strains,	  some	  of	  which	  are	  known	  to	  be	  associated	  with	  worse	  outcome	  
(Wiesner	   et	   al.	   2012).	   However,	   animal	   experiments	   frequently	   use	   identical	  
laboratory	  strains	  (Wozniak	  et	  al.	  2011).	  Finally,	  the	  timing	  and	  site	  of	  infection	  may	  
also	   be	   an	   important	   consideration.	   Murine	   experiments	   are	   typically	   conducted	  
days	  or	  weeks	  after	  infection	  and	  often	  involve	  a	  pulmonary	  challenge	  (Muller	  et	  al.	  
2013).	   In	  contrast,	  people	  may	  be	   latently	   infected	  for	  years,	  with	  disease	  typically	  
occurring	   in	   the	   immune	   privileged	   site	   of	   the	   central	   nervous	   system	   (Garcia-­‐
Hermoso	   et	   al.	   1999).	   Given	   these	   factors,	   further	   research	   is	   required	   to	   better	  
understand	   the	   human	   immune	   response	   both	   to	   Cryptococcus	   neoformans	   and	  
many	  other	  important	  human	  pathogens.	  
	  
There	  are	  a	  number	  of	  limitations	  to	  this	  work,	  further	  details	  of	  which	  are	  included	  
in	   the	   discussion	   sections	   of	   chapters	   4-­‐7.	   In	   general,	   the	   main	   IICD	   cohort	   was	  
relatively	   small,	   exhibited	   a	   significant	   degree	   of	   the	   heterogeneity	   and	  
complications	   such	  as	   IRIS	  were	   rare.	   Furthermore,	  no	  CSF	   samples	  were	  available	  
from	  healthy	  or	  HIV-­‐infected	  controls.	  	  
	  
With	   regard	   to	   technical	   issues,	   CSF	   macrophage	   activation	   was	   assessed	   mainly	  
through	   surface	   marker	   expression,	   due	   to	   concerns	   regarding	   more	   complicated	  
functional	   assays	   (antigen	   stimulation	   and	   intracellular	   cytokine	   production).	  
Although	   functional	   responses	  were	  examined	   in	   the	  blood,	   it	  was	  not	  possible	   to	  
obtain	  a	  purified	  form	  of	  the	  cryptococcal	  antigen	  mannoprotein,	  necessitating	  the	  
use	  of	  crude	  preparations	  of	  heat-­‐killed,	  mechanically-­‐disrupted	  C.	  neoformans	  and	  
purified	  preparations	  of	  GXM.	  Whilst	  the	  decision	  not	  to	  freeze	  cells	  and	  to	  perform	  
all	  flow	  cytometry	  on	  fresh	  samples	  did	  minimize	  cell	  manipulation	  prior	  to	  staining,	  
it	   also	   made	   it	   impossible	   to	   repeat	   any	   assay	   in	   the	   event	   of	   a	   technical	   error.	  
Future	  studies	  in	  this	  area	  will	  have	  to	  consider	  both	  of	  these	  issues.	  	  
	  
Despite	  these	  problems,	  the	  main	  objectives	  of	  the	  study	  were	  achieved.	  However,	  
the	  effects	  of	  ART	  initiation	  on	  the	  immune	  response	  and	  the	  characterization	  of	  the	  
immune	  phenotype	  of	  CM-­‐IRIS	  were	  limited	  by	  the	  early	  cessation	  of	  the	  COAT	  trial.	  
The	  original	  intention	  had	  been	  to	  nest	  the	  IICD	  study	  within	  the	  COAT	  trial	  to	  enable	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a	   detailed	   examination	   of	   the	   effects	   of	   ART	   initiation	   on	   both	   the	   cellular	   and	  
soluble	  aspects	  of	  the	  immune	  response.	  However,	  the	  COAT	  trial	  was	  halted	  by	  the	  
DSMB	   in	   the	   same	   month	   that	   the	   IICD	   study	   started	   enrolling.	   It	   was	   therefore	  
necessary	  to	  enroll	  a	  separate	  observational	  cohort	  for	  the	  IICD	  study	  while	  analysis	  
of	  the	  effects	  of	  ART	  initiation	  in	  the	  COAT	  trial	  were	  limited	  to	  the	  measurement	  of	  
soluble	  biomarkers	  on	  cryopreserved	  samples	  of	  CSF	  and	  serum.	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8.3 Future	  directions	  
8.3.1 Further	  characterization	  of	  immune	  response	  
There	  remain	  a	  number	  of	  unanswered	  questions	  with	  respect	  to	  the	  host	  immune	  
response	   in	   in	   HIV-­‐associated	   cryptococcal	   meningitis	   that	   warrant	   further	  
investigation.	   The	   functional	   response	   of	   cells	   in	   the	   CSF	   (cytokine	   production	   or	  
proliferation)	   was	   not	   examined	   in	   this	   study.	   Provided	   sufficient	   volumes	   of	   CSF	  
were	  obtained,	  it	  would	  be	  relatively	  easy	  to	  study	  antigen	  specific	  responses	  in	  CD4	  
T	   cells	   following	   stimulation	   with	   cryptococcal	   mannoprotein.	   In	   addition,	   further	  
targeted	   flow	  cytometry	   studies	  are	  warranted	   to	   fully	  understand	   the	  nature	  and	  
function	   of	   some	   unusual	   cellular	   populations	   observed	   in	   the	   CSF.	   These	   include	  
large	  CD8	  T	  cells,	  the	  CD4-­‐CD8-­‐	  T	  cell	  population	  (possibly	  made	  up	  from	  iNKT	  cells,	  
γδ	   T	   cells,	   and	   other	   innate	   T	   cells),	   and	   the	   CD3-­‐CD4+CD14-­‐	   cell	   population,	  
concluded	   to	   be	   CD14-­‐	  monocyte-­‐macrophages.	   In	   addition,	   examination	   of	   blood	  
and	  CSF	  gene	  expression	  signatures	  with	  microarray	  analysis	  could	  also	  be	  used	  to	  
provide	  additional	   information	  about	  the	  activation	  state	  of	   the	   immune	  system	   in	  
these	   two	   compartments.	   Although	   studying	   the	   immune	   response	   in	   the	   CSF	  
provides	   potentially	   more	   information	   than	   the	   blood,	   studies	   examining	   the	  
activation	  state	  of	  macrophages	  and	  microglial	  cells	  within	  brain	  tissue	  itself	  would	  
be	   immensely	   useful.	   Possible	  ways	   to	   do	   this	  would	   be	   to	   examine	   post	  mortem	  
brain	   specimens	   using	   immunohistochemistry	   or	   microarray	   gene	   expression	  
analysis.	  	  
	  
With	   respect	   to	   the	   immune	   response	   in	   blood,	   further	   study	   is	   also	   required	   to	  
clarify	   the	   relationship	   between	   monocyte	   anergy	   and	   T	   cells	   responses,	   and	   to	  
determine	  the	  underlying	  cause	  of	  the	  CARS-­‐like	  immune	  signature	  among	  patients	  
with	  CM.	  Taking	  blood	  cultures	  prior	   to	   the	  use	  of	  any	  antibiotics,	  or	  by	  using	  16S	  
ribosomal	   PCR	   would	   better	   answer	   the	   question	   of	   occult	   bacterial	   infection.	  
Furthermore,	  prospectively	  collecting	  plasma	  in	  EDTA	  tubes	  would	  enable	  LPS	  levels	  
to	  be	  accurately	  measured	  to	  assess	  the	  degree	  of	  bacterial	  translocation	  that	  may	  
contribute	  to	  immune	  activation.	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8.3.2 The	  development	  of	  prognostic	  scores	  in	  cryptococcal	  meningitis	  
One	  area	  of	  further	  study	  would	  be	  to	  use	  the	  measurement	  of	  immune	  parameters,	  
along	   with	   clinical	   and	   microbiological	   parameters,	   to	   help	   inform	   an	   individual’s	  
prognosis.	   Possible	   applications	   of	   this	  would	   be	   the	   ability	   to	   identify	   patients	   at	  
presentation	   to	   hospital	  who	  were	   at	   the	   highest	   risk	   of	  mortality	   and	   to	   identify	  
patients	   starting	   ART	  who	  were	   at	   the	   highest	   risk	   of	   developing	   IRIS.	   This	   would	  
enable	   the	   targeting	   of	  more	   potent	   anti-­‐fungal	   drug	   therapies	   to	   those	  with	   the	  
greatest	  need	  or	  possibly	  the	  use	  of	  immunotherapy	  [section	  8.3.3].	  It	  could	  also	  be	  
used	  to	  inform	  optimal	  ART	  initiation	  strategies	  (e.g.	   in	  patients	  at	  high	  risk	  of	  IRIS,	  
ART	  initiation	  might	  be	  delayed	  until	  the	  CSF	  is	  confirmed	  to	  be	  sterile).	  Techniques	  
such	  as	  support	  vector	  machine	  learning	  and	  decision	  tree	  analyses	  can	  be	  useful	  in	  
identifying	  important	  parameters	  (Jarvis	  JN,	  et	  al.	  2015).	  However,	  to	  be	  any	  benefit	  
in	   practical	   terms,	   the	   tests	   involved	  would	  have	   to	  be	   relatively	   easy	   to	  perform,	  
have	   a	   rapid	   turn	   around	   time	   and	   be	   validated	   on	   multiple	   cohorts.	   Although	   a	  
daunting	   challenge,	   there	   are	   now	   commercial	   kits	   available	   that	   could	   be	   useful,	  
such	   as	   those	   able	   to	   measure	   monocyte	   HLA-­‐DR	   expression	   using	   standard	  
laboratory	   CD4	   analyzers	   (van	   der	   Meer	   et	   al.	   2006).	   If	   this	   could	   be	   effectively	  
combined	  with	  other	  more	  easily	  measurable	  parameters	   (such	  as	  CSF	  CRAG	   titre,	  
CSF	   white	   cell	   count,	   blood	   neutrophil	   count	   and	   serum	   CRP	   concentration)	   an	  
immune	  prediction	  score	  could	  be	  feasible	  within	  the	  setting	  of	  a	  suitably	  equipped	  
hospital	  laboratory.	  	  
8.3.3 Adjunctive	  immunotherapy	  
The	   identification	   of	   an	   immune	   signature	   in	   CM	   closely	   associated	   with	   fatal	  
outcome	  raises	  the	  question	  of	  whether	  an	   intervention	  could	  be	  used	  to	  alter	  the	  
clinical	   course.	   The	   reversal	   of	   immune	   suppression	   associated	   with	   CARS	   is	   a	  
frequently	  discussed	  subject	  in	  sepsis	  literature	  (Hotchkiss	  &	  Opal	  2010).	  In	  vitro	  and	  
ex	   vivo	   studies	   have	   shown	   that	   incubating	   cells	  with	   interferon	   gamma	   (IFN-­‐γ)	   or	  
granulocyte	  macrophage	  colony	  stimulating	  factor	  (GM-­‐CSF)	  can	  potentiate	  the	  pro-­‐
inflammatory	   cytokine	   response	   to	   LPS	   and	   reverse	   the	   decrease	   in	   cytokine	  
production	   seen	   in	   monocyte	   anergy	   (Hayes	   et	   al.	   1995;	   Kylanpaa	   et	   al.	   2005;	  
Williams	  et	  al.	  1998).	  Further	  studies	  in	  bacterial	  sepsis,	  have	  also	  shown	  that	  either	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of	  these	  two	  molecules	  will	  reverse	  markers	  of	  monocyte	  anergy	   in	  vivo,	   leading	  to	  
increased	  monocyte	  HLA-­‐DR	  expression	  and	  increased	  TNF-­‐α	  response	  to	  LPS	  (Döcke	  
et	   al.	   1997;	   Drossou-­‐Agakidou	   et	   al.	   2002).	   Although	   no	   clear	   survival	  benefit	   has	  
been	  shown	  with	  their	  use,	  both	  GM-­‐CSF	  and	  G-­‐CSF	  (granulocyte	  colony	  stimulating	  
factor)	   have	   been	   associated	   with	   a	   significant	   improvement	   in	   the	   resolution	   of	  
infection	  when	   used	   as	   an	   adjunctive	   treatment	   in	   severe	   sepsis	   (Bo	   et	   al.	   2011).	  
Subsequent	   studies	   have	   examined	   the	   effects	   of	   refining	   this	   approach	   with	  
targeted	   therapy,	  by	   giving	  GM-­‐CSF	   to	   individuals	  with	   severe	   sepsis	   in	  whom	   low	  
monocyte	   HLA-­‐DR	   expression	   has	   been	   observed.	   In	   a	   small,	   double-­‐blind,	  
randomized	  control	  trial	  (n=38),	  the	  use	  of	  targeted	  GM-­‐CSF	  therapy	  in	  this	  way	  was	  
associated	   with	   significantly	   improved	   APACHE-­‐II	   disease	   severity	   scores,	   reduced	  
time	   on	   mechanical	   ventilation,	   decreased	   length	   of	   intensive	   care	   stay,	   and	  
decreased	  overall	  length	  of	  hospitalization	  (Meisel	  et	  al.	  2009).	  Mortality	  at	  28	  days	  
in	  this	  study	  was	  lower	  in	  the	  GM-­‐CSF	  group	  (16%	  vs.	  21%)	  but	  this	  finding	  was	  not	  
statistically	  significant.	  Further	  large-­‐scale	  studies	  are	  planned.	  
	  
The	  concept	  of	  using	  immune	  therapy	  in	  cryptococcal	  meningitis	  is	  not	  new.	  In	  a	  trial	  
conducted	  in	  South	  Africa,	  the	  use	  of	  adjunctive	  IFN-­‐γ	  (in	  addition	  to	  amphotericin	  B	  
and	  flucytosine	  therapy)	  resulted	  in	  a	  significantly	  increased	  rate	  of	  fungal	  clearance	  
with	   no	   significant	   complications	   (Jarvis	   et	   al.	   2012).	   Although	   the	   study	   did	   not	  
detect	   any	   difference	   in	   survival,	   it	   was	   not	   powered	   to	   do	   so.	   The	   rationale	   for	  
trialing	   IFN-­‐γ	   in	  CM	  patients	  had	  been	  based	  on	  data	   from	  animal	  studies,	  and	  the	  
observation	  in	  humans,	  that	  non-­‐survivors	  had	  low	  levels	  of	  the	  cytokine	  in	  their	  CSF	  
(Hardison	  et	  al.	  2010;	  Zhou	  et	  al.	  2007;	  Siddiqui	  et	  al.	  2005).	   Judging	  by	   the	  sepsis	  
data	   discussed	   above,	   IFN-­‐γ	   and	   GM-­‐CSF	   may	   have	   additional	   benefit	   in	   CM	   by	  
reversing	  monocyte	  anergy.	  Furthermore,	  in	  vitro	  studies	  have	  also	  shown	  additional	  
benefits	   of	   GM-­‐CSF	   in	   potentiating	   the	   anti-­‐cryptococcal	   activity	   of	   neutrophils,	  
monocytes	   and	   macrophages,	   especially	   when	   used	   alongside	   anti-­‐fungal	   therapy	  
(Tascini	   et	   al.	   1999;	   Meisel	   et	   al.	   2009;	   Chiller	   et	   al.	   2002).	   Given	   the	   apparent	  
benefits	  of	  targeted	  immune	  therapy	  in	  sepsis,	  a	  similar	  approach	  may	  be	  beneficial	  
in	   HIV-­‐associated	   cryptococcal	   meningitis	   and	   consideration	   should	   be	   given	   to	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clinical	   trials.	   Persons	   who	   may	   potentially	   benefit	   could	   be	   identified	   using	   a	  
predictive	   scoring	   system	  as	  discussed	   above	   [section	  8.3.2]	   and	   targeted	   immune	  
therapy	   (possibly	   using	   a	   combination	   of	   both	   IFNγ	   and	   GM-­‐CSF)	   could	   then	   be	  
administered	  given	  alongside	  anti-­‐fungal	  therapy.	  	  
	  
Although	  there	  would	  undoubtedly	  be	  many	  challenges	  to	  its	  use	  in	  clinical	  practice,	  
if	   relatively	   simple	   tests	   could	   be	   used	   to	   identify	   patients	   likely	   to	   benefit,	   and	   if	  
immune	   modulatory	   agents	   could	   be	   acquired	   at	   a	   reasonable	   cost,	   adjunctive	  
immune	   therapy	   could	   prove	   both	   effective	   and	   feasible	   in	   certain	   settings.	  Given	  
the	  unacceptably	  high	  mortality	  rate	  of	  HIV-­‐associated	  cryptococcal	  meningitis	  even	  
when	  potent	  anti-­‐fungal	  therapy	  is	  available,	  further	  research	  into	  better	  treatment	  
strategies	  remains	  a	  priority.	  Such	  an	  approach	  could	  also	  pave	  the	  way	  for	  studies	  
of	  targeted	  immune	  modulating	  therapy	  in	  the	  treatment	  of	  other	  infections.	  Given	  
the	  recent	  advances	  of	  immune	  therapy	  in	  oncology	  (Larkin	  J,	  et	  al,	  2015)	  and	  rapid	  
rise	   of	   anti-­‐microbial	   resistance	   worldwide	   (WHO,	   2014),	   this	   strategy	   could	  
potentially	  become	  an	  important	  component	  of	  anti-­‐infection	  therapy	  in	  the	  future.	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8.4 Concluding	  remarks	  
This	   thesis	   constitutes	   one	   of	   the	   most	   detailed	   examinations	   of	   the	   immune	  
response	   among	   persons	   with	   HIV-­‐associated	   cryptococcal	   meningitis	   to	   date.	  
Extensive	  characterization	  of	  both	  CSF	  and	  blood	  immune	  response	  was	  performed,	  
with	  a	  focus	  on	  the	  activation	  status	  of	  monocytes	  and	  macrophages.	  In	  addition	  to	  
its	  relevance	  in	  cryptococcal	  meningitis,	  the	  findings	  presented	  in	  this	  thesis	  are	  also	  
relevant	   to	  macrophage	   biology	   as	   a	  whole.	   Although	   the	   concept	   of	  macrophage	  
activation	   has	   been	   well	   studied	   in	   animals	   and	   cell	   culture	   models,	   research	   is	  
limited	  in	  humans,	  especially	  in	  specific	  disease	  states	  and	  within	  the	  central	  nervous	  
system.	  This	  thesis	  has	  specifically	  addressed	  these	  gaps	  in	  knowledge.	  	  
	  
A	  number	  of	  novel	  observations	   regarding	   the	   immune	   response	   in	  HIV-­‐associated	  
cryptococcal	   meningitis	   have	   been	  made,	   particularly	   regarding	   the	   nature	   of	   the	  
CSF	   cellular	   infiltrate,	   the	   activation	   state	   of	   macrophages	   within	   the	   CSF,	   and	  
associations	  with	  clinical	  outcome.	  The	  effect	  of	  ART	  on	  the	   immune	  response	  was	  
examined	   both	   in	   persons	  with	   CM	  who	   initiated	   ART,	   and	   in	   persons	   taking	   ART	  
who	   developed	   CM,	   in	   both	   the	   CSF	   and	   blood.	   Given	   the	   increased	   mortality	  
associated	  with	  early	  ART	   initiation	   in	   the	  COAT	   trial,	   the	   findings	   in	   chapter	  7	  are	  
particularly	   relevant.	  Finally,	  novel	  observations	  were	  made	   identifying	  an	   immune	  
phenotype	  at	  presentation	  that	  was	  associated	  with	  fatal	  outcome,	  characterized	  by	  
monocyte	   anergy	   and	   a	   CARS-­‐like	   immune	   response.	   Further	   research	   in	   this	   area	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Additional	  tables	  from	  chapter	  5	  
Sample	  compensation	  matrix	  for	  CSF	  flow	  cytometry	  
	   AF488	   AF700	   Am	  	  
Cyan	  














1.000	   0.000	   0.006	   0.001	   0.000	   0.000	   0.003	   0.000	   0.009	   0.001	   0.000	  
AF700	  
	  
0.004	   1.000	   0.003	   0.020	   0.267	   0.001	   0.001	   0.085	   0.026	   0.001	   0.006	  
Am	  
Cyan	  
0.013	   0.000	   1.000	   0.000	   0.000	   0.103	   0.000	   0.000	   0.000	   0.218	   0.047	  
APC	  
	  
0.000	   0.152	   0.000	   1.000	   0.041	   0.000	   0.000	   0.016	   0.010	   0.000	   0.045	  
APC-­‐H7	  
	  
0.001	   0.056	   0.005	   0.032	   1.000	   0.003	   0.000	   0.352	   0.000	   0.000	   0.002	  
Pacific	  
Blue	  
0.003	   0.001	   0.415	   0.002	   0.006	   1.000	   0.000	   0.002	   0.000	   0.020	   0.004	  
PE	  
	  
0.001	   0.002	   0.000	   0.001	   0.001	   0.000	   1.000	   0.017	   0.110	   0.030	   0.009	  
PE-­‐Cy7	  
	  
0.000	   0.002	   0.001	   0.001	   0.018	   0.001	   0.018	   1.000	   0.003	   0.001	   0.000	  
PerCP-­‐
Cy5.5	  
0.001	   0.081	   0.000	   0.027	   0.029	   0.000	   0.000	   0.215	   1.000	   0.000	   0.135	  
Qdot	  
605	  
0.001	   0.001	   0.002	   0.002	   0.002	   0.002	   0.025	   0.001	   0.002	   1.000	   0.012	  
Qdot	  
655	  
0.000	   0.008	   0.000	   0.300	   0.000	   0.000	   0.000	   0.007	   0.541	   0.043	   1.000	  
Table	   A.1	   -­‐	   Sample	   compensation	   matrix	   for	   CSF	   flow	   cytometry.	   	   This	   specifies	   the	   amount	   of	  
spillover	  (proportion)	  from	  the	  row’s	  primary	  fluorochrome	  into	  the	  column’s	  detector.	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CSF	  immune	  response	  and	  fungal	  burden	  	  
	  
Figure	  A.1	  –	  PCA	  7	   	   -­‐	  Relationship	  between	  CSF	  fungal	  burden	  and	   immune	  response	  adjusted	  for	  
plasma	   HIV	   viral	   load.	   Left	   side	   shows	   how	   CSF	   immune	   response	   varies	   according	   to	   CSF	   fungal	  
burden.	   Right	   side	   shows	   the	   variables	   that	   are	   significantly	   correlated	   to	   log10CFU/mlCSF	   (q<0.1):	  
red	  –	  positive	  correlation;	  green	  –	  negative	  correlation.	  Corresponds	  to	  table	  5.15	  
	  
	  
Figure	  A.2	  –	  PCA	  8	   -­‐	  Relationship	  between	  CSF	   fungal	  burden	  and	   immune	   response	  adjusted	   for	  
peripheral	  CD4	  count.	  Variables	  on	  right	  are	  significantly	  negatively	  correlated	  with	  log10CFU	  (q<0.1).	  
































CSF	  immune	  response	  and	  raised	  intracranial	  pressure	  
	  
	  
Figure	  A.3	  –	  PCA	  10	  -­‐	  Differences	  in	  CSF	  immune	  response	  between	  subjects	  who	  had	  high	  ICP	  (CSF	  




















Figure	  A.4	  –	  PCA	  11	  -­‐	  Differences	  in	  CSF	  immune	  response	  between	  subjects	  who	  had	  high	  ICP	  (CSF	  










Additional	  tables	  from	  chapter	  6	  
Effect	  of	  effective	  ART	  on	  blood	  immune	  response	  
	  
Table	   A.2	   –	   Differences	   in	   blood	  monocytes	   phenotype	   between	   individuals	   with	   CM	  who	  were	  
taking	   and	   not	   taking	   ART.	   Medians	   compared	   using	   rank-­‐sum	   tests.	   No	   adjustment	   made	   for	  
multiple	  comparisons.	  
Population n Median IQR n Median IQR p
%Mono WBC 44 7.31 5.26<9.43 10 6 5.35<8.18 0.404
Mono /mm3 45 0.28 0.17<0.48 10 0.32 0.28<0.45 0.571
HLA<DRFMFIF mono 42 1096 750<2073 9 1114 865<1373 0.902
CD163FMFI mono 43 6615 3829<9305 9 4583 3478<7798 0.271
CCR2FMFI mono 42 1753 1153<2070 8 1519 1157<2141 0.958
CCR5FMFI mono 42 562 416<697 8 408 370<486 0.112
TLR4%MFI mono 27 276 2060376 3 159 1490219 0.035
CD80FMFI mono 43 306 233<385 8 237 206<294 0.143
CD11cFMFI mono 42 490 351<732 8 392 374<496 0.278
%CD14++CD16< mono 44 81 72<86 10 85.5 77<89 0.157
HLA<DRFMFI CD14++CD16< 42 875 530<1587 9 860 774<1285 0.902
CD163FMFI CD14++CD16< 42 6825 3821<10677 9 5094 4205<7865 0.277
CCR2FMFI CD14++CD16< 42 1889 1285<2276 8 2063 1289<2459 0.751
CCR5FMFIF CD14++CD16< 42 633 511<779 8 496 468<751 0.266
TLR4MFI CD14++CD16< 27 277 211<396 3 216 150<577 0.604
CD80MFI CD14++CD16< 43 278 225<338 8 218 198<274 0.103
CD11cMFI CD14++CD16< 42 449 341<688 8 370 306<470 0.234
%CD14++16+ mono 44 9.8 5.1<17.3 10 8.55 3.38<12.2 0.167
HLA<DRFMFI CD14++CD16+ 42 6206.5 3949<8393 9 5874 2833<9174 0.521
CD163FMFI CD14++CD16+ 42 8885 5639<13829 9 4633 4402<8572 0.098
CCR2%MFI CD14++CD16+ 42 1264.5 101501781 8 1953 124802373 0.049
CCR5FMFI CD14++CD16+ 42 881.5 749<1066 8 709 682<1267 0.412
TLR4MFI CD14++CD16+ 27 430 263<593 3 346 78<4207 0.863
CD80FMFI CD14++CD16+ 43 682 538<960 8 556 507<742 0.393
CD11cMFI CD14++CD16+ 42 1074.5 750<1299 8 1033 646<1139 0.606
%CD14+16++ mono 43 3.5 1.46<7.13 10 0.93 0.57<10.3 0.317
HLA<DRFMFI CD14+CD16++ 40 4481.5 2957<6427 9 5173 3314<9125 0.699
CD163%MFI CD14+CD16++ 40 1716.5 75003267 9 309 2690741 0.006
CCR2FMFI CD14+CD16++ 42 897.5 757<1258 8 878 698<1034 0.751
CCR5FMFI CD14+CD16++ 42 522.5 368<747 8 355 327<501 0.135
TLR4FMFI CD14+CD16++ 27 380 301<472 3 298 296<308 0.137
CD80FMFI CD14+CD16++ 43 746 524<958 8 601 388<685 0.070




Table	  A.3	  –	  Differences	   in	  blood	  T	   cell	  phenotype	  between	   individuals	  with	  CM	  who	  were	   taking	  
and	   not	   taking	   ART.	  Medians	   compared	   using	   rank-­‐sum	   tests.	   No	   adjustment	   made	   for	   multiple	  
comparisons	  
	  
Table	  A.4	   –	  Differences	   in	   serum	  cytokine	   concentration	  between	   individuals	  with	  CM	  who	  were	  
taking	   and	   not	   taking	   ART.	   Medians	   compared	   using	   rank-­‐sum	   tests.	   No	   adjustment	   made	   for	  
multiple	  comparisons.	  
n median IQR n median IQR p
neut-%WBC 44 67 55.6776.6 10 75.8 70.7780.2 0.114
neut/mm3 44 3 1.774.3 10 3.8 3.174.9 0.119
CD167-%neuts 44 1 0.4971.94 10 0.6 0.3371.44 0.533
CD4$T$%T 43 3.9 1.42,10 9 11 7.43,14.5 0.013
CD4$%WBC 43 0.28 0.14,0.97 9 1.12 0.66,3.01 0.017
HLA7DR-MFI-CD4-T 40 191 1037542 9 316 14771034 0.366
CD38-MFI-CD4-T 40 2123 1113.573065 9 1408 89171684 0.148
PD71-MFI-CD4-T 40 1047 792.571536 9 1167 100171263 0.959
CD38+-%CD4-T 40 66 38785 9 59 35769 0.296
HLA7DR+-%CD4-T 40 41 27755 9 41 30775 0.394
PD71+-%CD4-T 40 24 12.4740.3 9 16.4 10741.6 0.796
CD8-T-%T 43 84.4 75.5788.6 9 82.8 8079.2 0.241
CD8-T-%WBC 43 8.3 4.7713.9 9 7.3 3.4710.4 0.885
HLA7DR-MFI-CD8-T 42 263 1807373 9 239 1567297 0.843
CD38-MFI-CD8-T 42 1230 54572009 9 1158 58371355 0.604
PD71-MFI-CD8-T 42 651 5197854 9 651 4127761 0.674
CD38+-%CD8-T 42 85 67795 9 82 74789 0.902
HLA7DR+-%CD8-T 42 36.7 25.2750.4 9 32.6 29.5742.4 0.729
PD71+-%-CD8 42 14.4 5.9723.8 9 19.2 6.0720.9 0.980
DNT-%T 43 8.31 5.96711.7 9 6.33 5.378.424 0.241
DNT-%WBC 43 0.7 0.4271.26 9 1.01 0.4071.03 0.699
HLA7DR-MFI-DNT 42 201 146.27266 9 239 1507297 0.444
CD38-MFI-DNT 42 810 22871971 9 476 20971158 0.354
PD71-MFI-DNT 42 281 1687530 9 262 2417377 0.834
CD38+-%DNT 42 68 36782 9 69 40774 0.961
HLA7DR+-%DNT 42 34 21745 9 33 30745 0.824
PD71-%DNT 42 6.5 2.75720 9 2.13 1.54720.9 0.630
CD4/CD8$ratio 43 0.05 0.01,0.13 9 0.13 0.09,0.18 0.014
No-ART Effective-ART
n Median IQR n Median IQR p
VEGF 44 1.41 0.6142.26 10 1.72 1.0842.19 0.824
GCSF 44 46 26472 10 57 184102 0.553
IFNa 44 218 1684279 10 164 1464211 0.077
IL6 44 29 28095 10 37 18461 0.456
IL12 44 354 2794523 10 437 3574555 0.338
CCL5 44 2861 242844727 10 2619 220943711 0.689
EOTAXIN 44 83 544135 10 61 51496 0.322
IL15 44 161 1004268 10 209 1404337 0.385
CCL3 44 45 34469 10 40 34491 0.850
CCL4 44 89 564167 10 104 924318 0.442
CCL2 44 736 49241453 10 552 32741059 0.217
IL1RA 44 240 1874351 10 299 22441197 0.391
CXCL10 44 100 574139 10 73 654106 0.947
IL2R 44 420 2524720 10 709 31641324 0.251
CXCL9 44 338 2204648 10 425 2224782 0.632
CXCL8 44 70 254102 10 73 464199 0.338
sCD14 44 3263 288344328 10 3418 296342891 0.894
sCD163 44 1039 85841535 10 1367 107442531 0.174
CRP 44 35 12482 10 78 45485 0.109
IL41b 44 6.02 3.349.7 10 4.91 4.147 0.772
IL#7 44 0 0#26.6 10 20.6 0#55.1 0.028




Table	   A.5	   –	   Differences	   in	  monocyte	   responses	   in	   individuals	  with	   CM	  who	  were	   taking	   and	   not	  
taking	  ART.	  Medians	  compared	  using	  rank-­‐sum	  tests.	  No	  adjustment	  made	  for	  multiple	  comparisons.	  
	  
Response stim n Median n Median p
%.mono R848 32 1.49 1.02 2.54 8 1.54 1.33 2.00 0.919
%"IL6+"mono R848 32 88.07 85.10 91.64 8 89.72 82.17 94.58 0.685
%"TNF+"mono R848 32 79.69 61.40 83.25 8 79.02 53.64 82.15 0.685
%.IL10+.mono R848 32 15.65 7.31 32.26 8 21.83 15.60 39.35 0.279
%"IL12+"mono R848 30 9.96 4.63 15.36 6 11.68 4.27 13.97 0.966
HLA?DR..mono. R848 32 5360 3264 7790 8 5422 4345 8082 0.710
HLA?DR.ratio R848 32 2.18 1.66 2.50 8 2.03 1.59 2.47 0.660
%"neut R848 32 75.35 56.90 84.55 8 76.20 61.60 83.75 0.879
CD66"neut R848 32 13240 8213 18319 8 18358 13134 24581 0.063
CD66.ratio R848 32 2.04 1.69 2.56 8 1.87 1.52 2.49 0.589
%.mono LPS 34 3.54 1.90 4.89 9 3.30 2.58 3.85 0.893
%.IL6+.mono LPS 34 75.45 55.78 84.59 9 79.95 56.70 88.24 0.551
%"TNF+"mono LPS 34 41.06 23.44 54.62 9 41.88 10.86 48.03 0.456
%.IL10+.mono LPS 34 4.41 2.59 10.03 9 8.82 8.23 10.06 0.078
%.IL12+.mono LPS 32 1.11 0.31 2.80 7 2.04 0.31 3.09 0.486
HLA?DR.mono LPS 33 5155 3173 7540 8 5752 3711 7564 0.622
HLA?DR.ratio LPS 33 1.86 1.71 2.21 8 1.81 1.54 2.64 0.831
%"neut LPS 33 76.80 59.60 85.50 9 77.40 71.70 81.00 0.878
CD66.neut LPS 33 10145 7325 12766 9 13841 10287 19928 0.064
CD66.ratio LPS 33 1.62 1.43 1.87 9 1.41 1.34 1.66 0.283
%mono GXM 29 4.32 1.94 5.35 8 3.87 3.51 5.60 0.645
%"IL6+"mono GXM 29 1.33 0.38 2.94 8 2.11 1.26 4.14 0.356
%"TNF+"mono GXM 29 0.37 0.00 0.88 8 0.32 0.27 0.67 0.796
HLA6DR"mono GXM 29 3957 2251 5865 8 4366 2937 5644 0.580
HLA?DR.ratio GXM 29 1.39 1.22 1.82 8 1.44 1.22 2.15 1.000
%"neut GXM 29 62.10 42.30 71.40 8 59.00 50.00 70.65 0.927
CD66.neut GXM 29 12256 9534 17943 8 18189 11884 24060 0.223
CD66.ratio GXM 29 2.23 1.69 2.66 8 1.85 1.46 2.00 0.068
%mono CW 28 4.33 2.05 7.06 8 5.06 3.84 6.66 0.470
%"IL6+"mono CW 28 1.06 0.00 2.62 8 0.46 0.26 1.42 0.848
%.TNF+.mono CW 28 1.03 0.00 1.90 8 0.38 0.32 0.70 0.467
HLA6DR"mono CW 28 2730 1516 3719 8 3573 2447 3833 0.435
HLA6DR"ratio CW 28 1.03 0.73 1.35 8 1.04 0.78 1.44 0.879
%"neut CW 28 66.30 47.45 79.55 8 65.70 57.00 83.10 0.704
CD66.neut CW 28 16240 9958 20655 8 17823 13728 22976 0.403





Table	  A.6	  –	  Differences	   in	  whole	  blood	  cytokine	  responses	  (to	  R848	  and	  LPS)	  between	   individuals	  
with	   CM	   who	   were	   taking	   and	   not	   taking	   ART.	   Medians	   compared	   using	   rank-­‐sum	   tests.	   No	  
adjustment	  made	  for	  multiple	  comparisons	  
	  
Cytokine Stim
n Median n Median p
VEGF R848 30 556 399 2485 8 467 285 2622 0.591
IL:1b R848 30 5144 1862 10139 8 6633 3126 7583 0.667
G:CSF R848 30 734 575 1003 8 1121 799 1459 0.092
IL:10 R848 30 2226 1286 3704 8 1656 1190 3231 0.519
IFNa R848 30 2261 504 3122 8 2443 850 4001 0.496
IL:6 R848 30 39244 18617 88204 8 43197 28846 119767 0.474
IL:12 R848 30 6385 4168 11514 8 6009 3288 8469 0.543
CCL5 R848 30 115133 26185 129783 8 121909 22724 130572 0.943
IL:15 R848 30 3424 1837 4516 8 4622 2591 7692 0.252
CCL3 R848 30 47229 21475 85205 8 47154 26215 72672 0.971
CCL4 R848 30 80873 45803 126211 8 66705 40842 148776 1.000
CCL2 R848 30 47622 31942 69269 8 78437 34553 107499 0.371
IFNg R848 30 69 34 391 8 60 39 506 1.000
TNFa R848 30 13946 5510 22034 8 12508 7860 21217 0.915
IL:1RA R848 30 16500 10691 24406 8 14363 10649 24140 0.720
IL7 R848 30 1210 959 1653 8 1431 956 1817 0.591
CXCL10 R848 30 22918 21685 24274 8 24085 21974 25553 0.210
IL:2R R848 30 5956 5109 6847 8 5693 4845 7660 0.720
CXCL9 R848 30 7834 7726 7940 8 7790 7637 7955 0.667
CXCL8 R848 30 84780 60422 151410 7 192138 92733 208546 0.088
VEGF LPS 32 396 287 1975 8 441 277 2296 0.735
IL:1b LPS 32 1872 531 2775 8 2330 1476 3913 0.344
G:CSF LPS 32 797 443 1140 8 1015 799 2235 0.141
IL:10 LPS 32 780 488 1278 8 710 344 2209 0.973
IFNa LPS 32 1148 324 2240 8 1294 490 2572 0.660
IL:6 LPS 32 36892 19220 50957 8 53121 24483 158670 0.344
IL:12 LPS 32 2570 1613 3427 8 2336 1679 3364 0.813
CCL5 LPS 32 120575 28224 137689 8 112936 23975 137716 0.748
IL:15 LPS 32 1658 1139 3185 8 1954 914 4635 0.761
CCL3 LPS 32 28033 15422 46193 8 45542 17866 71838 0.310
CCL4 LPS 32 53959 30017 79080 8 61624 31618 139056 0.565
CCL2 LPS 32 31564 21484 50573 8 32460 22907 53860 0.946
IFNg LPS 32 31 31 39 8 36 30 40 0.658
TNFa LPS 32 2735 1521 4749 8 2779 1518 5395 0.946
IL:1RA LPS 32 11441 8670 17952 8 11778 8607 19648 0.813
IL7 LPS 32 1139 829 1437 8 1315 1036 1663 0.457
CXCL10 LPS 32 21699 21344 22437 8 21860 21312 22534 0.735
IL:2R LPS 32 5321 4844 6402 8 5592 4449 7722 0.813
CXCL9 LPS 32 7711 7566 7840 8 7714 7613 7788 0.892





Table	  A.7	   -­‐	  Differences	   in	  whole	  blood	  cytokine	   responses	   (to	  GXM	  and	  CW)	  between	   individuals	  
with	   CM	   who	   were	   taking	   and	   not	   taking	   ART.	   Medians	   compared	   using	   rank-­‐sum	   tests.	   No	  
adjustment	  made	  for	  multiple	  comparisons	  
	   	  
Cytokine Stim
n Median n Median p
VEGF GXM 29 56 44 74 8 43 37 107 0.555
IL:1b GXM 29 11 7 66 8 13 6 140 1.000
G:CSF GXM 29 102 87 110 8 103 91 122 0.868
IL:10 GXM 29 118 115 128 8 118 115 121 0.555
IFNa GXM 29 171 152 195 8 189 161 206 0.376
IL:6 GXM 29 676 477 3874 8 1017 444 1370 0.912
IL:12 GXM 29 139 118 161 8 143 121 152 1.000
CCL5 GXM 29 112130 111046 112130 8 111333 44701 112130 0.258
IL:15 GXM 29 593 555 635 8 659 584 778 0.196
CCL3 GXM 29 1551 457 4980 8 1167 319 10099 0.941
CCL4 GXM 29 4725 3290 8063 8 4685 3272 17976 0.632
CCL2 GXM 29 30878 23424 48548 8 38077 30359 71432 0.197
IFNg GXM 29 33 31 44 8 34 32 63 0.366
TNFa GXM 29 23 17 212 8 48 11 117 0.712
IL:1RA GXM 29 2323 1639 3569 8 3118 1856 4191 0.658
IL7 GXM 29 129 104 168 8 113 97 143 0.223
CXCL10 GXM 29 21065 21039 21137 8 21055 21044 21295 0.796
IL:2R GXM 29 3487 3326 3741 8 3459 3204 3615 0.417
CXCL9 GXM 29 7624 7594 7734 8 7649 7574 7726 0.912
CXCL8 GXM 29 46877 32076 72520 8 27240 23562 85244 0.302
VEGF CW 29 63 42 77 8 59 40 83 0.883
IL:1b CW 29 18 7 438 8 21 7 58 0.868
G:CSF CW 29 110 93 176 8 102 83 142 0.427
IL:10 CW 29 118 115 159 8 118 114 122 0.529
IFNa CW 29 161 140 193 8 175 121 197 0.971
IL:6 CW 29 600 404 13430 8 758 522 1021 0.825
IL:12 CW 29 136 127 165 8 134 113 141 0.483
CCL5 CW 29 112130 5683 112130 8 111258 97041 112130 0.550
IL:15 CW 29 588 553 624 8 593 540 849 0.825
CCL3 CW 29 4453 344 12508 8 1335 719 9351 0.796
CCL4 CW 29 4342 2568 7816 8 4921 2963 5908 0.912
CCL2 CW 29 30213 25428 44928 8 47222 43628 108443 0.009
IFNg CW 29 33 32 42 8 36 32 64 0.438
TNFa CW 29 168 15 1386 8 32 23 477 0.796
IL:1RA CW 29 2456 1659 3748 8 2404 1969 3024 0.768
IL7 CW 29 137 92 179 8 120 97 154 0.580
CXCL10 CW 29 21044 21039 21055 8 21080 21052 21197 0.055
IL:2R CW 29 3490 3350 3683 8 3565 3451 3722 0.531
CXCL9 CW 29 7615 7585 7643 8 7605 7539 7729 0.883




Associations	  between	  CSF	  fungal	  burden	  and	  blood	  immune	  response	  	  
	  
Table	  A.8	  –	  Correlation	  between	  CSF	   fungal	   load	  and	  phenotype	  of	  blood	  monocytes	   (left)	   and	  T	  
cells	   (right)	   in	   individuals	   with	   CM.	   Correlations	   performed	   using	   Spearman’s	   correlation.	   No	  
adjustment	  for	  multiple	  testing	  
	  
Table	  A.9	   –	   Spearman’s	   Correlation	   between	   CSF	   fungal	   load	   and	   serum	   cytokine	   concentrations	  
among	  individuals	  with	  CM.	  Correlations	  performed	  using	  Spearman’s	  correlation.	  No	  adjustment	  for	  
multiple	  testing.	  
Measurment Population r p Measurment population r p
WBC /mm3 0.13 0.311 neut/% WBC 0.38 0.003
Monocyte1(%) WBC 50.10 0.454 neut/mm3 0.25 0.057
Monocytes /mm3 50.04 0.741 CD1651% neuts 50.01 0.933
HLA5DR1(MFI)1 mono 50.18 0.180 CD41T1% T1cells 50.19 0.168
CD1631(MFI) mono 0.10 0.443 CD41% WBC 50.20 0.136
CCR21(MFI) mono 0.18 0.181 HLA5DR1MFI CD41T 0.03 0.833
CCR51(MFI) mono 0.17 0.214 CD381MFI CD41T 0.23 0.103
TLR41(MFI) mono 50.19 0.300 PD91/MFI/ CD41T 0.43 0.001
CD801(MFI) mono 50.21 0.124 CD38+1% CD41T 0.21 0.126
CD11c1(MFI) mono 50.13 0.358 HLA5DR+1% CD41T 0.09 0.502
CD14++CD1651 mono 0.04 0.790 PD91+/% CD41T 0.34 0.012
HLA5DR1(MFI) CD14++CD165 50.20 0.149 CD81T1% T1cells 0.14 0.302
CD1631(MFI) CD14++CD165 0.02 0.862 CD81T1% WBC 50.25 0.063
CCR21(MFI) CD14++CD165 0.03 0.840 HLA5DR1MFI CD81T 50.20 0.142
CCR51(MFI) CD14++CD165 0.11 0.438 CD381MFI CD81T 0.04 0.753
TLR41(MFI) CD14++CD165 50.33 0.062 PD91/MFI CD8/T 0.39 0.003
CD801(MFI) CD14++CD165 50.17 0.218 CD38+1% CD81T 0.04 0.751
CD11c1(MFI) CD14++CD165 50.07 0.606 HLA5DR+1% CD81T 50.10 0.444
CD14+16+1(%) mono 50.03 0.795 PD51+1% CD81T 0.24 0.077
HLA5DR1(MFI) CD14++CD16+ 50.19 0.152 DNT1%T T1cells 0.14 0.290
CD1631(MFI) CD14++CD16+ 0.06 0.657 DNT1% WBC 50.15 0.272
CCR21(MFI) CD14++CD16+ 0.18 0.187 HLA5DR1MFI DNT 0.01 0.935
CCR51(MFI) CD14++CD16+ 0.15 0.273 CD381MFI DNT 0.17 0.212
TLR/(MFI) CD14++CD16+ 90.43 0.012 PD511MFI DNT 0.26 0.051
CD801(MFI) CD14++CD16+ 50.12 0.385 CD38+1% DNT 0.18 0.183
CD11c1(MFI) CD14++CD16+ 50.21 0.119 HLA5DR+1% DNT 0.09 0.488
CD14516+1% mono 50.04 0.793 PD91/% DNT 0.27 0.048
HLA5DR1(MFI)1 CD14+CD16++ 50.12 0.371 CD4CD81ratio 50.17 0.198
CD1631(MFI) CD14+CD16++ 0.06 0.680
CCR21(MFI) CD14+CD16++ 0.18 0.177
CCR51(MFI) CD14+CD16++ 0.22 0.101
TLR41(MFI) CD14+CD16++ 50.27 0.134
CD801(MFI) CD14+CD16++ 0.10 0.480

























Table	  A.10	  –	  Correlation	  between	  CSF	  fungal	  burden	  (log10	  CFU/ml	  CSF)	  and	  whole	  blood	  cytokine	  
response	   (left	   and	   middle),	   and	   monocyte	   responses	   (right).	   Correlations	   performed	   using	  
Spearman’s	  correlation.	  No	  adjustment	  for	  multiple	  testing.	  
	   	  
Cytokine stim r p Cytokine stim r p Measurement stim r p
VEGF R848 (0.09 0.575 VEGF GXM (0.25 0.116 %1mono R848 (0.14 0.347
IL(1b R848 (0.21 0.179 IL41b GXM 40.39 0.012 %8IL6+8mono R848 0.12 0.425
G(CSF R848 (0.25 0.104 G(CSF GXM (0.23 0.140 %8TNF+8mono R848 0.15 0.332
IL(10 R848 (0.16 0.318 IL(10 GXM (0.15 0.329 %8IL10+8mono R848 (0.07 0.654
IFNa R848 (0.01 0.951 IFNa GXM (0.09 0.557 %8IL12+8mono R848 0.17 0.293
IL(6 R848 (0.11 0.486 IL(6 GXM (0.25 0.109 HLA4DR11mono1 R848 0.07 0.633
IL(12 R848 (0.02 0.888 IL(12 GXM (0.18 0.253 HLA4DR1ratio R848 0.45 0.002
CCL5 R848 0.08 0.609 CCL5 GXM 0.14 0.369 %8neut R848 0.26 0.084
IL(15 R848 (0.08 0.627 IL(15 GXM (0.23 0.144 CD668neut R848 (0.26 0.084
CCL3 R848 (0.20 0.203 CCL3 GXM 40.42 0.006 CD668ratio R848 0.05 0.720
CCL4 R848 40.45 0.003 CCL4 GXM 40.41 0.007 %8mono LPS 0.00 0.979
CCL2 R848 (0.04 0.787 CCL2 GXM (0.23 0.146 %8IL6+8mono LPS (0.09 0.524
IFNg R848 (0.17 0.274 IFNg GXM 40.39 0.010 %1TNF+1mono LPS (0.11 0.475
TNFa R848 (0.13 0.417 TNFa GXM (0.29 0.060 %8IL10+8mono LPS (0.07 0.628
IL(1RA R848 (0.08 0.603 IL(1RA GXM (0.20 0.211 %8IL12+8mono LPS 0.16 0.299
IL7 R848 (0.07 0.642 IL7 GXM (0.30 0.053 HLA4DR1mono LPS 0.04 0.793
CXCL10 R848 (0.08 0.607 CXCL10 GXM (0.15 0.338 HLA4DR1ratio LPS 0.41 0.004
IL(2R R848 (0.06 0.712 IL(2R GXM (0.18 0.252 %8neut LPS 0.26 0.080
CXCL9 R848 40.34 0.027 CXCL9 GXM (0.01 0.926 CD668neut LPS (0.23 0.119
CXCL8 R848 (0.15 0.348 CXCL8 GXM 0.01 0.965 CD668ratio LPS 0.11 0.478
VEGF LPS (0.14 0.348 VEGF CW 40.51 0.001 %mono GXM (0.29 0.058
IL(1b LPS (0.22 0.146 IL41b CW 40.35 0.025 %8IL6+8mono GXM (0.13 0.404
G(CSF LPS (0.21 0.158 G4CSF CW 40.36 0.021 %8TNF+8mono GXM (0.14 0.366
IL(10 LPS (0.16 0.279 IL(10 CW (0.21 0.189 HLA4DR1mono GXM (0.08 0.602
IFNa LPS (0.06 0.701 IFNa CW 0.14 0.383 HLA4DR1ratio GXM 0.32 0.040
IL(6 LPS (0.22 0.154 IL46 CW 40.32 0.040 %1neut GXM 0.17 0.286
IL(12 LPS 0.05 0.742 IL(12 CW (0.06 0.709 CD668neut GXM (0.21 0.182
CCL5 LPS 0.14 0.345 CCL5 CW 0.18 0.257 CD668ratio GXM 0.09 0.577
IL415 LPS (0.05 0.763 IL415 CW 40.34 0.026 %mono CW (0.19 0.231
CCL3 LPS (0.19 0.201 CCL3 CW (0.16 0.297 %8IL6+8mono CW 0.02 0.885
CCL4 LPS (0.20 0.195 CCL4 CW (0.15 0.328 %8TNF+8mono CW 0.11 0.507
CCL2 LPS 0.03 0.856 CCL2 CW (0.16 0.325 HLA(DR8mono CW (0.19 0.236
IFNg LPS (0.14 0.375 IFNg CW (0.26 0.100 HLA4DR1ratio CW 0.19 0.242
TNFa LPS (0.07 0.632 TNFa CW (0.26 0.098 %8neut CW 0.20 0.200
IL(1RA LPS (0.03 0.841 IL(1RA CW (0.11 0.469 CD668neut CW 40.31 0.050
IL7 LPS (0.02 0.921 IL7 CW (0.10 0.550 CD668ratio CW (0.01 0.947
CXCL10 LPS (0.06 0.684 CXCL10 CW (0.20 0.209
IL(2R LPS (0.14 0.344 IL(2R CW (0.18 0.251
CXCL9 LPS (0.08 0.607 CXCL9 CW 40.34 0.027
CXCL8 LPS (0.18 0.247 CXCL8 CW (0.10 0.535
335	  	  
Differences	  in	  immune	  response	  between	  survivors	  and	  non-­‐survivors	  
	  
Table	  A.11	  –	  Baseline	  differences	   in	  monocyte	  phenotype	  between	  survivors	  and	  non-­‐survivors	  at	  
14	  days.	  Medians	  compared	  using	  rank-­‐sum	  tests.	  No	  adjustment	  made	  for	  multiple	  comparisons	  
	  
Day$14$outcome
Population n Median IQR n Median IQR p
Monocyte2(%) WBC 46 7.61 5.36@10.3 13 5.56 3.07@6.31 0.065
Monocytes /mm3 46 0.32 0.22@0.48 14 0.25 0.10@0.38 0.190
HLA0DR$(MFI)$ mono 43 1373 80702073 13 865 3760995 0.043
CD1632(MFI) mono 44 6524 3637@9069 13 8025 4585@9305 0.323
CCR22(MFI) mono 42 1615 1113@2070 13 1831 1578@2576 0.109
CCR52(MFI) mono 42 557 362@725 13 519 476@577 0.751
TLR42(MFI) mono 25 255 174@336 8 390 226@539 0.153
CD802(MFI) mono 43 306 233@385 13 261 235@430 0.930
CD11c2(MFI) mono 42 486 384@746 13 497 326@707 0.663
CD14++CD16@2 mono 46 82.4 73.5@88.2 13 78.7 67.7@82.9 0.191
HLA0DR$(MFI) CD14++CD16@ 43 1113 67501591 13 518 3510896 0.015
CD1632(MFI) CD14++CD16@ 43 6100 3821@9576 13 6730 4813@13644 0.421
CCR2$(MFI) CD14++CD16@ 42 1832 118602260 13 2194 171703214 0.050
CCR52(MFI) CD14++CD16@ 42 645 481@919 13 583 542@722 0.937
TLR42(MFI) CD14++CD16@ 25 248 216@332 8 408 290@568.5 0.081
CD802(MFI) CD14++CD16@ 43 278 223@338 13 266 225.4@371 0.907
CD11c2(MFI) CD14++CD16@ 42 449 368@688 13 409 293@744 0.649
CD14++16+2(%) mono 46 8.9 4.77@17.3 13 14 10.4@16.6 0.224
HLA0DR$(MFI) CD14++CD16+ 43 6723 535709860 13 3491 262306966 0.011
CD1632(MFI) CD14++CD16+ 43 8123 5096@11978 13 11506 6249@30020 0.118
CCR22(MFI) CD14++CD16+ 42 1299 1037@1848 13 1436 1140@1905 0.559
CCR52(MFI) CD14++CD16+ 42 897 696@1121 13 865 779@1057 0.649
TLR2(MFI) CD14++CD16+ 25 430 283@935 8 485 247.5@620.5 0.867
CD802(MFI) CD14++CD16+ 43 709 538@966 13 682 555@896 0.734
CD11c2(MFI) CD14++CD16+ 42 1115 750@1499 13 867 709@1299 0.312
CD14+16++2% mono 45 2.63 1.02@6.6 13 4.14 1.46@8.39 0.461
HLA@DR2(MFI)2 CD14+CD16++ 41 5028 3292@7716 13 4058 2969@5646 0.754
CD163$(MFI) CD14+CD16++ 41 1204 591@2674 13 1837 769@3409 0.448
CCR22(MFI) CD14+CD16++ 42 907.5 779@1146 13 826 757@1632 0.843
CCR52(MFI) CD14+CD16++ 42 491 361@747 13 512 385@680 0.707
TLR42(MFI) CD14+CD16++ 25 337 298@486 8 401 323.5@456 0.737
CD802(MFI) CD14+CD16++ 43 746 524@924 13 633 542@982 0.778




Table	  A.12	  –	  Baseline	  differences	  in	  T	  cells	  and	  neutrophils	  between	  survivors	  and	  non-­‐survivors	  by	  
day	  14.	  Medians	  compared	  using	  rank-­‐sum	  tests.	  No	  adjustment	  made	  for	  multiple	  comparisons	  
	  
Table	  A.13	  –	  Baseline	  differences	   in	  serum	  cytokines	  between	  survivors	  and	  non-­‐survivors	  by	  day	  
14.	  Medians	  compared	  using	  rank-­‐sum	  tests.	  No	  adjustment	  made	  for	  multiple	  comparisons	  
Day$14$outcome
n Median IQR n Median IQR p
neut$%WBC 46 67.45 54.6675.8 13 76.8 68.8682.6 0.007
neut/mm3 46 2.89 1.6664.03 13 4.03 2.9665.16 0.027
CD16/0%neuts 46 1.3 0.53/2.14 13 0.5 0.252/1.11 0.056
CD40T0%T 44 6.8 2.125/10.85 13 3.75 0.76/7.1 0.203
CD40%WBC 44 0.42 0.15/1.54 13 0.25 0.17/0.31 0.098
HLA/DR0MFI0CD40T 42 269.5 129.7/557 11 145.3 80.7/378 0.254
CD380MFI0CD40T 42 1679 993/2453 11 2404 1500/3944 0.241
PD/10MFI0CD40T 42 1036 767/1454 11 1461 1155/2685 0.054
CD38+0%CD40T 42 62.2 39.8/79.7 11 65.6 31.2/83.3 0.792
HLA/DR+0%CD40T 42 42.65 30.3/58.2 11 29.5 26.8/48.1 0.181
PD/1+0%CD40T 42 19.15 10.2/40.3 11 37.8 24.9/75 0.133
CD8$T$%T 44 82.7 75.9687.6 13 88.1 84691 0.025
CD80T0%WBC 44 8.3 3.8/14.3 13 6.7 4.7/10.4 0.568
HLA/DR0MFI0CD80T 43 258 150.8/373 13 239 208/513 0.621
CD380MFI0CD80T 43 1154 582/1649 13 1624 876/2298 0.248
PD/10MFI0CD80T 43 708 476/873 13 603 538/863 0.691
CD38+0%CD80T 43 85.1 68.3/93.5 13 78.9 68.1/93.6 0.946
HLA/DR+0%CD80T 43 36.3 23.7/50.4 13 35.6 27/53.8 0.923
PD/1+0%0CD8 43 14.9 5.75/27.9 13 22.3 9.72/26.1 0.479
DNT0%T 44 8.42 5.81/13.2 13 8.19 4.11/8.9 0.287
DNT0%WBC 44 0.89 0.43/1.2 13 0.47 0.31/0.72 0.060
HLA6DR$MFI$DNT 43 177.9 141.56266 13 241 2086332 0.031
CD38$MFI$DNT 43 678 20861317 13 1355 85062554 0.043
PD/10MFI0DNT 43 301 228/539 13 229 173/262 0.130
CD38+0%DNT 43 62.8 35.5/81.8 13 77.3 66.9/81.9 0.197
HLA/DR+0%DNT 43 33.1 20.9/44.9 13 36 27.1/48.2 0.286
PD/10%DNT 43 6.11 1.78/17.5 13 20.9 3.7/26.6 0.109
CD4CD8ratio 44 0.08 0.02/0.13 13 0.04 0.01/0.10 0.196
Survived Died
Day$14$outcome
n Median' IQR n Median IQR p
VEGF 45 1.4 0.6872.22 14 1.85 0.6175.05 0.373
GCSF 45 46 28767 14 56 0786 0.610
IFNa 45 216 1517270 14 202 1737309 0.359
IL6 45 27 13457 14 85 184170 0.033
IL12 45 371 2857545 14 308 2277444 0.240
CCL5 45 2816 242975403 14 2822 192973711 0.402
EOTAXIN 45 74 517127 14 97 687143 0.247
IL15 45 161 1007239 14 253 1337511 0.053
CCL3 45 40 34771 14 45 407110 0.243
CCL4 45 101 577153 14 82 637207 0.722
CCL2 45 643 43371331 14 1274 61175570 0.078
IL1RA 45 254 2017334 14 331 18271369 0.193
CXCL10 45 76 584126 14 127 794272 0.039
IL2R 45 379 2394636 14 801 37241324 0.023
CXCL9 45 326 2227628 14 464 22271126 0.181
CXCL8 45 64 287102 14 86 22.67197 0.433
sCD14 45 3284 293173893 14 3834 293175183 0.383
sCD163 45 1057 79741511 14 1410 119641856 0.026
CRP 45 33 13468 14 85 474115 0.011
IL71b 45 4.9 3.379.5 14 7.1 4.979.5 0.459
IL77 45 0 23.8 14 0 0736.5 0.805




Table	  A.14	  –	  Baseline	  differences	   in	  monocyte	  responses	  between	  survivors	  and	  non-­‐survivors	  by	  




stim n Median n Median p
%$mono R848 32 1.89 1.23 2.86 13 1.24 0.82 1.52 0.039
%/IL6+/mono R848 32 88 83 91 13 91 83 94 0.468
%/TNF+/mono R848 32 80 76 84 13 71 51 80 0.057
%/IL10+/mono R848 32 17.6 8.9 30.3 13 12.5 6.5 37.5 0.617
%/IL12+/mono R848 27 10.3 6.3 15.1 13 4.6 3.1 16.3 0.279
HLA:DR$$mono$ R848 32 5880 4027 8257 13 3495 1775 5694 0.016
HLA:DR$ratio R848 32 1.85 1.5 2.25 13 2.95 2.47 4.51 0.000
%/neut R848 32 73.2 56.9 82.3 13 85.2 71 87.8 0.052
CD66/neut R848 32 13240 8646 17335 13 15187 11328 24641 0.168
CD66/ratio R848 32 2 1.53 2.35 13 2.29 1.7 3.21 0.354
%$mono LPS 35 3.54 2.5 4.92 13 1.85 1.28 3.85 0.041
%/IL6+/mono LPS 35 80 65 86 13 57 53 86 0.372
%$TNF+$mono LPS 35 48 37 58 13 14 10 41 0.010
%/IL10+/mono LPS 35 7.1 2.9 10.5 13 3.7 3.2 7.6 0.291
%/IL12+/mono LPS 30 1.48 0.86 3.22 13 0.53 0.3 2.05 0.076
HLA:DR$mono LPS 33 5648 4356 7730 13 3173 2058 5881 0.013
HLA:DR$ratio LPS 33 1.75 1.47 2.02 13 3.59 2.12 4.81 0.000
%/neut LPS 34 75.5 59.6 85.2 13 83.4 73.4 89.8 0.065
CD66/neut LPS 34 10387 6867 13467 13 12038 9633 15869 0.216
CD66/ratio LPS 34 1.6 1.37 1.7 13 1.62 1.43 1.9 0.353
%mono GXM 31 4.86 3.14 5.76 11 2.98 0.91 4.35 0.007
%/IL6+/mono GXM 31 1.4 0.84 3.136 11 1.329 0.15 4.27 0.852
%/TNF+/mono GXM 31 0.43 0.25 0.97 11 0.04 0 0.92 0.182
HLA:DR$mono GXM 31 4360 3754 6179 11 2033 1352 5254 0.005
HLA:DR$ratio GXM 31 1.35 1.16 1.56 11 2.47 1.64 3.34 0.000
%$neut GXM 31 54.2 39.6 65.5 11 70.8 68.5 73.6 0.006
CD66/neut GXM 31 14019 9534 19293 11 14546 11230 23962 0.786
CD66/ratio GXM 31 2.01 1.69 2.54 11 2 1.55 2.43 0.721
%mono CW 30 5.11 3.56 7.61 11 3.13 1.24 5.06 0.017
%/IL6+/mono CW 30 1.13 0.19 2.48 11 0.07 0 2.26 0.203
%/TNF+/mono CW 30 1.02 0.34 1.87 11 0.43 0 2.08 0.184
HLA:DR$mono CW 30 3181 2367 3974 11 1115 551 3470 0.019
HLA:DR$ratio CW 30 0.94 0.67 1.16 11 1.59 1.19 2.21 0.002
%$neut CW 30 54.1 44.9 70.8 11 75 65.1 88.7 0.011
CD66/neut CW 30 16239.5 10560 20350 11 17083 9104 25226 0.680






Table	  A.15	   –	   Baseline	   differences	   in	  whole	   blood	   cytokine	   responses	   (to	   R848	   and	   LPS)	   between	  
survivors	   and	   non-­‐survivors	   by	   day	   14.	  Medians	   compared	   using	   rank-­‐sum	   tests.	   No	   adjustment	  
made	  for	  multiple	  comparisons	  
Cytokine Stimulation n Median n Median p
VEGF R848 31 502 399 2824 11 537 349 1822 0.658
ILC1b R848 31 6256 3263 10139 11 2825 886 7286 0.133
GCCSF R848 31 804 575 1176 11 734 569 1165 1.000
ILC10 R848 31 2348 1333 3704 11 1543 1143 2444 0.259
IFNa R848 31 2773 562 4416 11 2305 335 3438 0.224
ILC6 R848 31 44140 21671 119300 11 41379 22881 62592 0.539
IL#12 R848 31 7829 4802 12571 11 4168 2951 9368 0.047
CCL5 R848 31 118536 27417 134446 11 112260 16646 126199 0.383
IL#15 R848 31 4074 2315 6213 11 2210 1691 3834 0.033
CCL3 R848 31 50140 28815 85205 11 39816 17697 54508 0.399
CCL4 R848 31 98114 45803 126211 11 60239 39143 92363 0.213
CCL2 R848 31 42624 31205 81744 11 68154 41973 95610 0.149
IFNg R848 31 85 35 469 11 43 31 67 0.052
TNFa R848 31 18172 7774 23209 11 7753 3696 14255 0.050
ILC1RA R848 31 15629 11946 27436 11 13777 9933 21171 0.353
IL7 R848 31 1327 1082 1772 11 1289 782 1653 0.324
CXCL10 R848 31 23156 21704 24332 11 22163 21664 23646 0.310
ILC2R R848 31 5873 5109 8166 11 5835 4816 6248 0.432
CXCL9 R848 31 7837 7728 7987 11 7726 7689 7855 0.235
CXCL8 R848 30 84780 53489 154495 11 92733 65162 202093 0.346
VEGF LPS 32 452 295 2067 13 383 256 431 0.220
ILC1b LPS 32 2106 1131 3412 13 680 129 4309 0.176
GCCSF LPS 32 909 607 1374 13 1003 490 1089 0.608
ILC10 LPS 32 804 601 1735 13 583 229 1216 0.084
IFNa LPS 32 1291 420 2309 13 1078 286 2275 0.249
ILC6 LPS 32 43724 22397 78055 13 28860 16603 66542 0.282
IL#12 LPS 32 2783 1953 3975 13 2204 1112 2867 0.051
CCL5 LPS 32 121995 29889 137996 13 114489 8804 119959 0.201
IL#15 LPS 32 1856 1354 3746 13 1055 690 2277 0.031
CCL3 LPS 32 37331 22152 62054 13 15214 13398 42642 0.031
CCL4 LPS 32 68692 41402 102417 13 38247 21779 52791 0.038
CCL2 LPS 32 31061 22437 45132 13 38748 20381 75852 0.409
IFNg LPS 32 32 31 43 13 31 30 37 0.182
TNFa LPS 32 3883 1866 5588 13 2192 875 3419 0.054
ILC1RA LPS 32 13486 9521 21016 13 10215 6658 13430 0.080
IL7 LPS 32 1309 891 1483 13 1143 740 1421 0.341
CXCL10 LPS 32 21756 21368 22586 13 21374 21312 21824 0.104
ILC2R LPS 32 5484 4971 6657 13 5470 4270 5967 0.260
CXCL9 LPS 32 7719 7552 7848 13 7682 7577 7733 0.617





Cytokine Stimulation n Median n Median p
VEGF GXM 31 54 42 80 11 56 36 64 0.383
ILA1b GXM 31 12 7 87 11 9 5 36 0.202
GACSF GXM 31 97 87 123 11 99 65 109 0.218
ILA10 GXM 31 119 116 126 11 116 113 123 0.224
IFNa GXM 31 173 137 208 11 167 152 188 0.432
ILA6 GXM 31 999 501 1940 11 561 366 1393 0.165
IL#12 GXM 31 146 123 167 11 135 112 140 0.089
CCL5 GXM 31 112130 110883 112130 11 111920 3298 112130 0.377
ILA15 GXM 31 603 555 687 11 593 555 652 0.519
CCL3 GXM 31 1581 484 6148 11 408 224 3911 0.050
CCL4 GXM 31 5742 3366 11928 11 3177 2486 6248 0.025
CCL2 GXM 31 35383 24703 52411 11 27834 21872 48548 0.126
IFNg GXM 31 34 32 61 11 32 29 34 0.024
TNFa GXM 31 34 17 212 11 22 10 94 0.153
ILA1RA GXM 31 3069 1771 4088 11 2261 1390 2733 0.074
IL7 GXM 31 137 112 165 11 104 85 162 0.050
CXCL10 GXM 31 21060 21038 21258 11 21065 21042 21154 0.989
ILA2R GXM 31 3487 3358 3688 11 3410 3130 3587 0.310
CXCL9 GXM 31 7626 7613 7809 11 7594 7539 7718 0.149
CXCL8 GXM 31 53693 32076 107259 11 28232 21789 53089 0.017
VEGF CW 31 71 42 77 11 48 37 74 0.224
ILA1b CW 31 19 7 227 11 8 3 76 0.174
GACSF CW 31 105 87 176 11 110 99 127 0.977
ILA10 CW 31 118 115 150 11 116 115 162 0.557
IFNa CW 31 177 140 204 11 156 138 169 0.310
ILA6 CW 31 831 519 13430 11 406 363 1254 0.054
ILA12 CW 31 136 127 175 11 135 115 140 0.213
CCL5 CW 31 112130 107481 112130 11 112098 1013 112130 0.473
ILA15 CW 31 590 541 641 11 584 560 602 0.898
CCL3 CW 31 4453 365 15149 11 1074 276 10477 0.224
CCL4 CW 31 4348 2751 12273 11 3174 2260 5924 0.259
CCL2 CW 31 38124 26482 62740 11 30213 21692 46327 0.283
IFNg CW 31 34 32 46 11 34 31 35 0.208
TNFa CW 31 168 18 1386 11 30 10 1387 0.271
ILA1RA CW 31 2432 1659 3850 11 2652 2169 3006 0.830
IL7 CW 31 143 98 179 11 107 85 195 0.203
CXCL10 CW 31 21045 21034 21109 11 21046 21043 21095 0.548
ILA2R CW 31 3491 3350 3799 11 3502 3398 3644 0.742
CXCL9 CW 31 7615 7585 7648 11 7596 7537 7625 0.224
CXCL8 CW 31 50266 29283 91550 11 38945 26679 56376 0.193
Day9149outcome Survived Died
IQR IQR
Table	   A.16	   -­‐	   Baseline	   differences	   in	   whole	   blood	   cytokine	   responses	   (to	   GXM	   and	   CW)	  
between	  survivors	  and	  non-­‐survivors	  by	  day	  14.	  Medians	  compared	  using	  rank-­‐sum	  tests.	  No	  
adjustment	  made	  for	  multiple	  comparisons	  
340	  	  
	  
Table	  A.17	  –	  Baseline	  differences	  in	  monocyte	  phenotype	  between	  survivors	  and	  non-­‐survivors	  by	  









Population no Median IQR yes Median IQR p
Monocyte$(%) WBC 40 7.88 5.55610.45 18 5.5 2.766.6 0.024
Monocytes /mm3 40 0.38 0.22>0.52 19 0.26 0.13>0.36 0.089
HLA>DRG(MFI)G mono 38 1420 807>2073 17 882 526>1227 0.069
CD163G(MFI) mono 39 6521 3478>8839 17 8025 4517>11056 0.203
CCR2G(MFI) mono 37 1659 1153>2070 17 1826 1470>2150 0.244
CCR5G(MFI) mono 37 556 362>786 17 519 436>583 0.978
TLR4G(MFI) mono 24 252 168>335 9 420 256>507 0.082
CD80G(MFI) mono 38 300 233>376 17 261 235>430 0.841
CD11cG(MFI) mono 37 485 384>808 17 486 363>672 0.609
CD14++CD16>G mono 40 82.4 74.25>88 18 80.1 70.7>83.6 0.455
HLA6DR$(MFI) CD14++CD16> 38 1071 67561587 17 774 4176904 0.050
CD163G(MFI) CD14++CD16> 38 6374 3821>9437 17 6730 4813>17712 0.237
CCR2$(MFI) CD14++CD16> 37 1837 1186>2276 17 2052 1533>2860 0.189
CCR5G(MFI) CD14++CD16> 37 634 481>929 17 583 516>677 0.662
TLR4G(MFI) CD14++CD16> 24 244 214>329 9 399 396>557 0.052
CD80G(MFI) CD14++CD16> 38 275.5 230>338 17 266 210.3>371 0.906
CD11cG(MFI) CD14++CD16> 37 449 368>733 17 449 319>630 0.576
CD14++16+G(%) mono 40 8.9 4.7>17.6 18 11.9 6.9>16.5 0.444
HLA6DR$(MFI) CD14++CD16+ 38 6813 541269860 17 3949 290366966 0.010
CD163G(MFI) CD14++CD16+ 38 8012 5096>11489 17 11506 5639>30375 0.097
CCR2G(MFI) CD14++CD16+ 37 1426 1037>1979 17 1338 1120>1901 0.896
CCR5G(MFI) CD14++CD16+ 37 901 682>1121 17 865 775>1057 0.773
TLRG(MFI) CD14++CD16+ 24 437.5 273>987.5 9 475 265>593 0.746
CD80G(MFI) CD14++CD16+ 38 701 538>960 17 682 555>966 1.000
CD11cG(MFI) CD14++CD16+ 37 1117 821>1499 17 867 664>1299 0.180
CD14+16++G% mono 39 2.35 0.825>6.6 18 3.92 1.46>8.39 0.391
HLA>DRG(MFI)G CD14+CD16++ 36 5101 2458>7858.5 17 4058 3045>5646 0.939
CD163G(MFI) CD14+CD16++ 36 1231 593>2888 17 1800 573>3298 0.775
CCR2G(MFI) CD14+CD16++ 37 912 779>1258 17 890 757>978 0.675
CCR5G(MFI) CD14+CD16++ 37 508 349>753 17 512 385>680 0.682
TLR4G(MFI) CD14+CD16++ 24 330 297>505.5 9 416 346>440 0.599
CD80G(MFI) CD14+CD16++ 38 728 500>924 17 707 578>958 0.729





Table	  A.18.	  –	  Baseline	  differences	  in	  neutrophils	  and	  T	  cells	  between	  survivors	  and	  non-­‐survivors	  by	  
week	  4.	  Medians	  compared	  using	  rank-­‐sum	  tests.	  No	  adjustment	  made	  for	  multiple	  comparisons	  
Week$4$outcome
n Median IQR n Median IQR p
neut$%WBC 40 67.5 52.35675.2 18 76.5 66.3681 0.028
neut/mm3 40 2.85 1.7264.05 18 3.73 2.9665.16 0.039
CD166$%neuts 40 1.36 0.6162.7 18 0.7 0.3161.3 0.046
CD4.T.%T 39 4.67 1.65810.7 17 6.38 3.36810 0.965
CD4.%WBC 39 0.35 0.1481.0 17 0.258 0.17881.12 0.624
HLA8DR.MFI.CD4.T 37 314 1418673 15 146.7 858378 0.167
CD38.MFI.CD4.T 37 1674 98182453 15 2120 150083519 0.303
PD81.MFI.CD4.T 37 1028 76781454 15 1422 101081715 0.096
CD38+.%CD4.T 37 59.3 36.9881.9 15 65.6 39.8883.3 0.694
HLA8DR+.%CD4.T 37 44.6 26.3868.1 15 33.5 28.1848.1 0.222
PD81+.%CD4.T 37 20 9.96840.3 15 37.8 16.3845 0.152
CD8.T.%T 39 83 76888 17 87 77891 0.203
CD8.T.%WBC 39 8.2 3.4814.7 17 6.7 4.7811.3 0.689
HLA8DR.MFI.CD8.T 38 246 1518373 17 295 2088414 0.393
CD38.MFI.CD8.T 38 1071 58281649 17 1491 87682298 0.222
PD81.MFI.CD8.T 38 689 4878873 17 609 5388863 0.743
CD38+.%CD8.T 38 84 68893 17 86 68896 0.623
HLA8DR+.%CD8.T 38 35.25 23.7846.7 17 43.8 27853.4 0.554
PD81+.%.CD8 38 15.75 5.59827.9 17 20.9 9.72826.1 0.591
DNT.%T 39 8.5 6.3813 17 8.2 4.189.0 0.229
DNT$%WBC 39 0.96 0.4361.26 17 0.47 0.3160.72 0.049
HLA8DR.MFI.DNT 38 183 1428266 17 239 1558332 0.111
CD38.MFI.DNT 38 697 22881317 17 1237 42682075 0.259
PD81.MFI.DNT 38 295.5 2288539 17 241 2048426 0.321
CD38+.%DNT 38 68 35.6881.8 17 72.5 42.1881.9 0.623
HLA8DR+.%DNT 38 33.2 21844.9 17 32.6 26.8848.2 0.506
PD81.%DNT 38 6.81 2.13818.1 17 13.1 2.83823.8 0.548




Table	  A.19	   –	   Baseline	   differences	   in	   serum	   cytokines	   concentrations	   between	   survivors	   and	  non-­‐
survivors	   by	   week	   4.	  Medians	   compared	   using	   rank-­‐sum	   tests.	   No	   adjustment	   made	   for	   multiple	  
comparisons	  
Week$4$outcome
n Median IQR n Median IQR p
VEGF 39 1.42 0.7582.29 19 1.54 0.5884.8 0.697
GCSF 39 46 28867 19 56 0899 0.449
IFNa 39 216 1468282 19 185 1738247 0.980
IL6 39 27 14857 19 63 138170 0.079
IL12 39 364 2848532 19 311 2278545 0.545
CCL5 39 3103 257446583 19 2558 192943143 0.041
EOTAXIN 39 75 518129 19 96 54.58140 0.613
IL15 39 162 1128260 19 212 1268346 0.172
CCL3 39 40 34871 19 43 40891 0.393
CCL4 39 101 488166 19 83 638189 0.791
CCL2 39 717 46181331 19 1256 41781675 0.316
IL1RA 39 256 1928368 19 310 18281206 0.260
CXCL10 39 87 588130 19 108 618207 0.125
IL2R 39 372 2138646 19 502 35781067 0.059
CXCL9 39 309 2188628 19 448 2228964 0.085
CXCL8 39 70 288102 19 82 278199 0.380
sCD14 39 3271 284483893 19 3807 293185684 0.243
sCD163 39 1057 79741450 19 1417 102042425 0.019
CRP 39 33 13468 19 79 334115 0.020
IL81b 39 5.5 3.3810.0 19 5.4 3.388.6 0.747
IL87 39 0 0831.7 19 0 0836.5 0.842




Table	  A.20	  –	  Baseline	  differences	   in	  monocyte	  responses	  between	  survivors	  and	  non-­‐survivors	  by	  
week	  4.	  Medians	  compared	  using	  rank-­‐sum	  tests.	  No	  adjustment	  made	  for	  multiple	  comparisons	  
	  
Week$4$outcome
stim n Median n Median p
%$mono R848 28 1.89 1.35 2.92 16 1.19 0.85 1.82 0.023
%/IL6+/mono R848 28 88 82 92 16 89 83 93 0.558
%/TNF+/mono R848 28 80 74 85 16 77 51 80 0.083
%/IL10+/mono R848 28 18 8 29 16 14 8 40 0.884
%/IL12+/mono R848 23 10.1 6.3 14 16 7.2 3 20.5 0.549
HLA9DR$$mono$ R848 28 5880 4027 8257 16 3640 1947 5914 0.019
HLA9DR$ratio R848 28 1.97 1.62 2.32 16 2.53 2.26 4.35 0.004
%/neut R848 28 74 58 82 16 83 66 88 0.154
CD66/neut R848 28 13676 8646 18319 16 14668 10462 22706 0.341
CD66/ratio R848 28 2 1.52 2.38 16 1.94 1.6 2.94 0.617
%/mono LPS 30 3.54 2.5 4.59 17 3.31 1.57 3.88 0.160
%/IL6+/mono LPS 30 80 69 86 17 57 48 85 0.101
%$TNF+$mono LPS 30 49 40 61 17 23 10 41 0.002
%/IL10+/mono LPS 30 6.7 2.9 10 17 4.1 3.2 8.8 0.740
%/IL12+/mono LPS 25 1.42 1.05 2.68 17 0.53 0 2.22 0.108
HLA9DR$mono LPS 29 5648 4356 7540 16 3632 2159 5902 0.029
HLA9DR$ratio LPS 29 1.75 1.47 2.05 16 2.63 1.83 4.34 0.001
%/neut LPS 29 76.8 61.9 85.2 17 81.1 71.7 89.7 0.255
CD66/neut LPS 29 10374 6867 13780 17 11124 9551 12957 0.432
CD66/ratio LPS 29 1.6 1.41 1.69 17 1.6 1.37 1.87 0.873
%mono GXM 27 4.88 3.14 5.76 14 3.22 1.11 4.35 0.004
%/IL6+/mono GXM 27 1.4 0.4 3.14 14 1.3295 0.29 3.821 0.783
%/TNF+/mono GXM 27 0.43 0.05 1 14 0.3 0 0.92 0.270
HLA9DR$mono GXM 27 4098 3754 6179 14 2685 1513 5254 0.018
HLA9DR$ratio GXM 27 1.36 1.16 1.59 14 2.03 1.47 3.19 0.002
%$neut GXM 27 57.2 41.5 65.5 14 69.5 53.5 72.6 0.046
CD66/neut GXM 27 16355 7448 21036 14 13077 10193 15053 0.805
CD66/ratio GXM 27 2.01 1.69 2.5 14 1.94 1.55 2.43 0.545
%mono CW 27 5.07 3.56 7.67 13 3.13 1.4 5.06 0.015
%/IL6+/mono CW 27 1.07 0.19 2.91 13 0.14 0 2.26 0.263
%/TNF+/mono CW 27 0.95 0.34 1.87 13 0.43 0 1.93 0.229
HLAKDR/mono CW 27 3156 2056 3772 13 1897 688 3470 0.081
HLA9DR$ratio CW 27 0.92 0.67 1.28 13 1.35 1.06 1.89 0.005
%/neut CW 27 61.2 45.8 77.6 13 71.7 60.1 86.8 0.122
CD66/neut CW 27 15760 10476 20350 13 17083 14546 22505 0.444





Table	   A.21	   –	   Baseline	   differences	   in	   whole	   blood	   cytokine	   response	   to	   R848	   and	   LPS	   between	  
survivors	   and	   non-­‐survivors	   by	   week	   4.	  Medians	   compared	   using	   rank-­‐sum	   tests.	   No	   adjustment	  
made	  for	  multiple	  comparisons	  
	  
Cytokine Stim n Median yes Median p
VEGF R848 27 557 460 3009 14 424 349 983 0.094
ILB1b R848 27 6642 3413 10139 14 3670 1053 7286 0.187
GBCSF R848 27 838 593 1194 14 729 569 1157 0.450
ILB10 R848 27 2532 1333 4047 14 1639 1286 2376 0.125
IFNa R848 27 2217 523 4835 14 2429 560 3147 0.545
ILB6 R848 27 45016 26498 127105 14 38680 22881 54426 0.260
ILB12 R848 27 8039 4802 12872 14 4811 3501 9368 0.062
CCL5 R848 27 118536 27417 134446 14 114831 26185 126199 0.762
IL#15 R848 27 4484 2315 6745 14 2780 1837 3834 0.023
CCL3 R848 27 50735 28815 85205 14 42739 17697 54508 0.350
CCL4 R848 27 98114 40153 126211 14 70743 41530 93619 0.509
CCL2 R848 27 44225 31205 82418 14 58060 34712 80893 0.601
IFNg R848 27 112 35 713 14 45 31 84 0.029
TNFa R848 27 18172 8704 25169 14 9872 3911 18689 0.045
ILB1RA R848 27 17371 13432 32956 14 13028 9933 20392 0.066
IL7 R848 27 1327 985 1805 14 1333 830 1653 0.527
CXCL10 R848 27 23834 21813 24561 14 21998 21664 22953 0.062
ILB2R R848 27 5873 5109 8166 14 5937 4839 6248 0.492
CXCL9 R848 27 7843 7745 7991 14 7728 7689 7855 0.079
CXCL8 R848 26 107426 60074 185805 14 92070 62585 192377 0.932
VEGF LPS 28 485 360 2145 16 338 222 412 0.016
IL#1b LPS 28 2275 1600 3913 16 679 99 3134 0.025
GBCSF LPS 28 992 700 1493 16 808 349 1085 0.157
IL#10 LPS 28 861 633 2109 16 514 229 1027 0.026
IFNa LPS 28 897 371 2441 16 1242 303 2289 0.450
ILB6 LPS 28 47965 25496 118674 16 28738 8425 57513 0.079
IL#12 LPS 28 2913 1953 4953 16 2193 1231 3074 0.043
CCL5 LPS 28 121995 29889 137996 16 115100 17313 134003 0.392
IL#15 LPS 28 2521 1367 4143 16 1319 689 2016 0.011
CCL3 LPS 28 38002 25111 68054 16 16035 10169 45079 0.012
CCL4 LPS 28 67612 41402 119857 16 41475 20468 76813 0.054
CCL2 LPS 28 31061 22437 45132 16 37056 22430 72412 0.393
IFNg LPS 28 34 31 46 16 31 30 37 0.072
TNFa LPS 28 3883 1908 5895 16 2042 530 3637 0.040
IL#1RA LPS 28 15668 10482 22466 16 9237 6504 12671 0.005
IL7 LPS 28 1309 891 1509 16 1133 603 1467 0.213
CXCL10 LPS 28 21865 21503 22710 16 21368 21278 21776 0.014
ILB2R LPS 28 5484 4971 7034 16 5480 4269 6216 0.262
CXCL9 LPS 28 7758 7626 7859 16 7665 7559 7729 0.130





Table	   A.22	   –	   Baseline	   differences	   in	   whole	   blood	   cytokine	   response	   to	   GXM	   and	   CW	   between	  
survivors	   and	   non-­‐survivors	   by	   week	   4.	  Medians	   compared	   using	   rank-­‐sum	   tests.	   No	   adjustment	  
made	  for	  multiple	  comparisons	  
	  
	  
Cytokine Stim n Median yes Median p
VEGF GXM 27 60 42 82 14 52 39 64 0.272
ILB1b GXM 27 12 7 87 14 11 5 36 0.527
GBCSF GXM 27 97 90 123 14 101 78 109 0.349
ILB10 GXM 27 119 116 126 14 117 115 123 0.545
IFNa GXM 27 172 137 202 14 167 152 188 0.660
ILB6 GXM 27 999 477 1762 14 618 395 1393 0.322
IL#12 GXM 27 145 123 167 14 137 112 148 0.206
CCL5 GXM 27 112130 110883 112130 14 111960 3705 112130 0.324
IL#15 GXM 27 603 559 687 14 590 552 652 0.283
CCL3 GXM 27 1551 480 8225 14 742 240 3911 0.138
CCL4 GXM 27 5668 3355 11928 14 3387 2534 7086 0.153
CCL2 GXM 27 35383 29200 47230 14 26553 22324 48548 0.094
IFNg GXM 27 33 32 61 14 33 31 38 0.156
TNFa GXM 27 32 16 212 14 22 12 94 0.433
IL#1RA GXM 27 3081 1854 4374 14 2181 1488 2733 0.048
IL7 GXM 27 131 105 155 14 117 85 162 0.336
CXCL10 GXM 27 21060 21038 21258 14 21061 21042 21154 0.956
ILB2R GXM 27 3455 3326 3633 14 3436 3322 3741 0.762
CXCL9 GXM 27 7626 7613 7809 14 7607 7539 7718 0.196
CXCL8 GXM 27 45167 31971 107259 14 41884 23253 61268 0.216
VEGF CW 27 72 43 77 14 53 41 74 0.196
ILB1b CW 27 19 7 165 14 13 5 227 0.527
GBCSF CW 27 103 87 162 14 116 102 222 0.441
ILB10 CW 27 118 115 128 14 116 115 162 0.945
IFNa CW 27 185 147 204 14 153 135 169 0.131
ILB6 CW 27 831 497 10536 14 540 383 21175 0.309
IL#12 CW 27 136 129 175 14 135 115 144 0.350
CCL5 CW 27 112130 110553 112130 14 111921 2904 112130 0.338
IL#15 CW 27 595 535 744 14 583 555 602 0.721
CCL3 CW 27 3553 344 15149 14 1639 470 10477 0.564
CCL4 CW 27 4348 2751 12273 14 3819 2273 5924 0.350
CCL2 CW 27 39473 25857 62740 14 32819 22741 46327 0.410
IFNg CW 27 33 32 48 14 34 32 38 0.601
TNFa CW 27 130 18 1386 14 49 12 1387 0.700
ILB1RA CW 27 2432 1659 3994 14 2675 2169 3006 0.826
IL7 CW 27 140 98 179 14 116 85 195 0.322
CXCL10 CW 27 21050 21039 21138 14 21045 21042 21064 0.826
ILB2R CW 27 3529 3350 3799 14 3496 3419 3644 0.805
CXCL9 CW 27 7621 7585 7655 14 7596 7537 7625 0.070





Table	  A.23	  –	  Baseline	  difference	   in	  monocyte	  phenotype	  between	  survivors	  and	  non-­‐survivors	  by	  
week	  12.	  Medians	  compared	  using	  rank-­‐sum	  tests.	  No	  adjustment	  made	  for	  multiple	  comparisons	  
	  
Week$12$outcome
Population n Median IQR n Median IQR p
Monocyte2(%) WBC 35 7.6 5.36>10.3 21 5.89 3.07>9.03 0.134
Monocytes /mm3 35 0.4 0.22>0.52 22 0.26 0.15>0.38 0.085
HLA>DR2(MFI)2 mono 33 1373 807>1958 20 936 616>1802 0.137
CD1632(MFI) mono 34 6071.5 3478>8581 20 7438 4377>10181 0.275
CCR22(MFI) mono 32 1600.5 1065>2074 20 1816 1383>2033 0.251
CCR52(MFI) mono 32 512.5 360>823 20 545 456>616 0.560
TLR42(MFI) mono 21 255 174>336 11 323 196>507 0.275
CD802(MFI) mono 33 294 223.4>348 20 303 236.5>451 0.369
CD11c2(MFI) mono 32 475 366>813 20 495 375>690 0.925
CD14++CD16>2 mono 35 82.4 75>88.3 21 79.3 70.7>83.6 0.379
HLA>DR2(MFI) CD14++CD16> 33 1121 675>1587 20 796 464>1034 0.088
CD1632(MFI) CD14++CD16> 33 6030 3821>8701 20 6415 4281>15678 0.331
CCR22(MFI) CD14++CD16> 32 1813 1186>2415 20 2051 1395>2680 0.319
CCR52(MFI) CD14++CD16> 32 630 457>965 20 617 529>735 0.821
TLR42(MFI) CD14++CD16> 21 253 211>332 11 396 230>557 0.148
CD802(MFI) CD14++CD16> 33 278 223>323 20 277 218>373 0.680
CD11c2(MFI) CD14++CD16> 32 436 348>750 20 452 330>687 0.918
CD14++16+2(%) mono 35 8.6 4.3>17.3 21 11.6 6.9>16.5 0.407
HLA/DR$(MFI) CD14++CD16+ 33 6559 5412/9860 20 5066 3066/7213 0.037
CD1632(MFI) CD14++CD16+ 33 7900 4414>11485 20 9456 5944>30198 0.088
CCR22(MFI) CD14++CD16+ 32 1366 982>1991.5 20 1387 1130>1903 0.756
CCR52(MFI) CD14++CD16+ 32 859 674>1108 20 881.5 777>1103 0.328
TLR2(MFI) CD14++CD16+ 21 401 263>935 11 475 265>648 0.736
CD802(MFI) CD14++CD16+ 33 653 523>809 20 686.5 556>1062 0.331
CD11c2(MFI) CD14++CD16+ 32 1114.5 750>1464 20 936.5 687>1301 0.510
CD14+16++2% mono 34 2.49 0.825>6.6 21 3.7 1.46>8.39 0.478
HLA>DR2(MFI)2 CD14+CD16++ 31 4339 2414>6410 20 4677.5 3169>6489 0.537
CD1632(MFI) CD14+CD16++ 31 906 487>2019 20 1818.5 671>4093 0.203
CCR22(MFI) CD14+CD16++ 32 979 701>1286 20 898 762>1170 0.895
CCR52(MFI) CD14+CD16++ 32 462.5 327>799.5 20 522.5 409>712 0.516
TLR42(MFI) CD14+CD16++ 21 322 296>525 11 416 323>472 0.394
CD802(MFI) CD14+CD16++ 33 658 446>927 20 718 600>927 0.582




Table	  A.24	  –	  Baseline	  differences	  in	  neutrophils	  and	  T	  cells	  between	  survivors	  and	  non-­‐survivors	  by	  
week	  12.	  Medians	  compared	  using	  rank-­‐sum	  tests.	  No	  adjustment	  made	  for	  multiple	  comparisons	  
	  
Table	   A.25	   –	   Baseline	   differences	   in	   serum	   cytokine	   concentration	   between	   survivors	   and	   non-­‐
survivors	   by	  week	   12.	  Medians	   compared	   using	   rank-­‐sum	   tests.	  No	   adjustment	  made	   for	  multiple	  
comparisons	  
Week$12$outcome
n Median IQR n Median IQR p
neut-%WBC 35 70.7 49.2:76.7 21 75.1 65.8:78.1 0.190
neut/mm3 35 290 178:409 21 355 290:487 0.201
CD16:-%neuts 35 1.34 0.53:2.14 21 0.91 0.46:1.27 0.150
CD4-T-%T 34 6.1 1.9:11 20 5.5 3.4:9.9 0.788
CD4-%WBC 34 0.36 0.14:1.0 20 0.3 0.20:1.18 0.761
HLA:DR-MFI-CD4-T 32 315 146:736 18 151 85:378 0.130
CD38-MFI-CD4-T 32 1677 967:2971 18 1902 1500:2817 0.332
PD:1-MFI-CD4-T 32 1070 761:1536 18 1187 1010:1603 0.249
CD38+-%CD4-T 32 60 35.7:87 18 65.2 44.6:79.7 0.832
HLA:DR+-%CD4-T 32 44.9 29:68.9 18 36.3 28.1:48.1 0.203
PD:1+-%CD4-T 32 24.4 9.8:41.6 18 30 16.3:41.6 0.473
CD8-T-%T 34 82 75.4:87.8 20 86.5 79.7:90.5 0.113
CD8-T-%WBC 34 7.5 2.9:14.7 20 7.7 4.8:12.0 0.844
HLA:DR-MFI-CD8-T 33 241 151:373 20 281 214:463 0.313
CD38$MFI$CD8$T 33 869 54581274 20 1558 105082360 0.037
PD:1-MFI-CD8-T 33 709 487:873 20 618 535.5:803.5 0.545
CD38+-%CD8-T 33 81.1 68.2:91.1 20 89.85 70.3:96.75 0.147
HLA:DR+-%CD8-T 33 33.1 23.7:46.7 20 43.95 29.25:53.6 0.354
PD:1+-%-CD8 33 16.6 5.59:28.2 20 12.9 7.025:25.2 0.790
DNT-%T 34 8.4 6.4:13 20 8 4.2:9.0 0.223
DNT-%WBC 34 0.78 0.42:1.22 20 0.54 0.36:0.91 0.237
HLA:DR-MFI-DNT 33 178 142:266 20 240 152:373 0.112
CD38-MFI-DNT 33 678 228:1133 20 1296 318:2553 0.137
PD:1-MFI-DNT 33 301 231:539 20 247 189:445 0.283
CD38+-%DNT 33 67.7 35.6:78.3 20 74.9 41:86 0.389
HLA:DR+-%DNT 33 33.1 21.2:44.2 20 34.3 23.9:51.2 0.374
PD:1-%DNT 33 6.1 2.3:20 20 10.3 2.2:22.4 0.883
CD4CD8ratio 34 0.07 0.02:0.13 20 0.06 0.04:0.12 0.788
Survived Died
Week$4$outcome
n Median IQR n Median IQR p
VEGF 39 1.42 0.7582.29 19 1.54 0.5884.8 0.697
GCSF 39 46 28867 19 56 0899 0.449
IFNa 39 216 1468282 19 185 1738247 0.980
IL6 39 27 14857 19 63 138170 0.079
IL12 39 364 2848532 19 311 2278545 0.545
CCL5 39 3103 257446583 19 2558 192943143 0.041
EOTAXIN 39 75 518129 19 96 54.58140 0.613
IL15 39 162 1128260 19 212 1268346 0.172
CCL3 39 40 34871 19 43 40891 0.393
CCL4 39 101 488166 19 83 638189 0.791
CCL2 39 717 46181331 19 1256 41781675 0.316
IL1RA 39 256 1928368 19 310 18281206 0.260
CXCL10 39 87 588130 19 108 618207 0.125
IL2R 39 372 2138646 19 502 35781067 0.059
CXCL9 39 309 2188628 19 448 2228964 0.085
CXCL8 39 70 288102 19 82 278199 0.380
sCD14 39 3271 284483893 19 3807 293185684 0.243
sCD163 39 1057 79741450 19 1417 102042425 0.019
CRP 39 33 13468 19 79 334115 0.020
IL81b 39 5.5 3.3810.0 19 5.4 3.388.6 0.459
IL87 39 0 0831.7 19 0 0836.5 0.805






Table	  A.26	  –	  Baseline	  differences	   in	  monocyte	  responses	  between	  survivors	  and	  non-­‐survivors	  by	  




stim n Median n Median p
%$mono R848 25 1.93 1.39 2.92 18 1.28 0.87 2.12 0.065
%8IL6+8mono R848 25 88.43 85.06 91.80 18 87.64 80.90 92.72 0.806
%8TNF+8mono R848 25 80.28 75.39 85.01 18 77.10 50.62 79.56 0.046
%8IL10+8mono R848 25 18.23 9.73 28.36 18 12.90 6.54 37.50 0.460
%8IL12+8mono R848 21 10.13 6.30 12.13 17 8.89 3.13 17.19 0.547
HLA:DR$$mono$ R848 25 5858 3955 7538 18 3911 2118 6133 0.065
HLA:DR$ratio R848 25 1.98 1.64 2.36 18 2.48 1.82 4.18 0.036
%8neut R848 25 76.60 58.90 82.90 18 80.10 64.30 87.70 0.498
CD668neut R848 25 14816 8664 18330 18 13597 9814 20771 0.640
CD668ratio R848 25 2.05 1.56 2.43 18 1.80 1.50 2.66 0.806
%8mono LPS 27 3.53 2.47 4.23 19 3.67 1.57 4.89 0.608
%8IL6+8mono LPS 27 79.95 66.53 86.63 19 63.20 48.40 84.59 0.177
%$TNF+$mono LPS 27 44.84 38.96 58.08 19 27.40 9.67 50.13 0.031
%8IL10+8mono LPS 27 7.13 2.68 10.06 19 4.07 3.21 8.82 0.569
%8IL12+8mono LPS 23 1.41 0.86 2.68 18 0.55 0.00 3.41 0.258
HLA:DR$mono LPS 26 5635 3938 7415 18 4456 2260 5922 0.081
HLA:DR$ratio LPS 26 1.78 1.50 2.11 18 2.17 1.79 3.86 0.016
%8neut LPS 26 77.60 64.00 85.50 19 81.00 59.00 89.70 0.646
CD668neut LPS 26 10263 6867 13841 19 11828 9551 13467 0.370
CD668ratio LPS 26 1.60 1.39 1.83 19 1.60 1.37 1.87 0.909
%mono GXM 24 4.87 2.84 5.70 16 3.57 1.13 4.66 0.040
%8IL6+8mono GXM 24 1.94 0.34 3.27 16 1.33 0.34 3.04 0.678
%8TNF+8mono GXM 24 0.34 0.05 0.81 16 0.34 0.00 1.00 0.803
HLA:DR$mono GXM 24 4042 3344 6009 16 3007 1548 5275 0.064
HLA:DR$ratio GXM 24 1.38 1.17 1.76 16 1.73 1.36 2.92 0.024
%$neut GXM 24 58.20 44.00 66.60 16 68.85 46.75 72.00 0.301
CD668neut GXM 24 15187 8491 20165 16 14368 10712 20338 0.934
CD668ratio GXM 24 2.00 1.68 2.40 16 2.07 1.65 2.55 0.956
%mono CW 24 5.06 3.39 7.61 15 3.72 1.40 6.57 0.145
%8IL6+8mono CW 24 1.24 0.26 2.69 15 0.07 0.00 2.26 0.076
%8TNF+8mono CW 24 1.12 0.36 2.40 15 0.43 0.00 1.93 0.101
HLAKDR8mono CW 24 3076 2212 3679 15 1897 688 3940 0.133
HLA:DR$ratio CW 24 0.98 0.79 1.30 15 1.27 0.97 1.89 0.071
%8neut CW 24 63.45 46.05 77.95 15 66.60 53.00 86.80 0.286
CD668neut CW 24 15908 11565 20397 15 16921 9104 22505 0.977





Table	   A.27	   –	   Baseline	   differences	   in	   whole	   blood	   cytokine	   response	   to	   R848	   and	   LPS	   between	  
survivors	   and	   non-­‐survivors	   by	  week	   12.	  Medians	   compared	  using	   rank-­‐sum	   tests.	  No	   adjustment	  
made	  for	  multiple	  comparisons	  
	  
Cytokine stim n Median n Median p
VEGF R848 24 556 467 2916 16 493 351 1698 0.294
ILA1b R848 24 6520 3338 10294 16 4479 1343 8288 0.270
GACSF R848 24 860 657 1221 16 729 572 1161 0.415
ILA10 R848 24 2645 1641 4143 16 1639 1215 2410 0.087
IFNa R848 24 2295 543 4626 16 2326 509 3080 0.294
ILA6 R848 24 46122 27572 132716 16 38680 19079 58509 0.176
ILA12 R848 24 8175 5088 12722 16 4811 3554 10441 0.098
CCL5 R848 24 120138 25707 133330 16 113463 28711 125054 0.600
IL#15 R848 24 4486 2566 7178 16 2780 1764 4066 0.016
CCL3 R848 24 51933 28960 90638 16 42739 18086 68975 0.320
CCL4 R848 24 99397 52201 150401 16 70743 40337 109161 0.294
CCL2 R848 24 59931 33224 84332 16 47318 29724 78012 0.659
IFNg R848 24 99 35 591 16 48 33 117 0.163
TNFa R848 24 19133 8761 26090 16 9872 4249 18889 0.031
ILA1RA R848 24 18698 14194 30196 16 13028 9950 20781 0.116
IL7 R848 24 1287 1033 1853 16 1333 827 1653 0.499
CXCL10 R848 24 23849 22099 24630 16 21998 21612 23299 0.031
ILA2R R848 24 6131 5050 8515 16 5822 4936 6239 0.362
CXCL9 R848 24 7848 7736 8001 16 7734 7702 7850 0.098
CXCL8 R848 23 130208 61513 192138 16 79712 56555 153370 0.304
VEGF LPS 25 466 364 2102 18 368 247 1741 0.089
ILA1b LPS 25 2355 1570 3906 18 844 129 4309 0.069
GACSF LPS 25 1016 770 1445 18 841 444 1089 0.176
IL#10 LPS 25 896 604 2198 18 595 229 1216 0.049
IFNa LPS 25 1160 385 2316 18 1107 320 2275 0.325
ILA6 LPS 25 48361 30934 87627 18 28738 12093 66542 0.099
ILA12 LPS 25 2946 2007 4125 18 2193 1350 3280 0.085
CCL5 LPS 25 122205 30625 137843 18 114666 18688 123420 0.246
IL#15 LPS 25 2589 1415 4388 18 1319 687 2277 0.008
CCL3 LPS 25 38772 27777 68606 18 17118 13398 47516 0.025
CCL4 LPS 25 68500 48447 113355 18 41475 21779 78152 0.055
CCL2 LPS 25 31877 23526 45191 18 31187 19842 68972 0.922
IFNg LPS 25 35 31 44 18 31 30 38 0.080
TNFa LPS 25 4098 1973 5472 18 2042 875 3856 0.069
IL#1RA LPS 25 14855 10624 22094 18 9797 6658 15485 0.034
IL7 LPS 25 1296 901 1454 18 1133 740 1421 0.184
CXCL10 LPS 25 21948 21614 22647 18 21373 21312 21824 0.030
ILA2R LPS 25 5627 4981 7299 18 5480 4270 5967 0.228
CXCL9 LPS 25 7776 7635 7869 18 7665 7571 7725 0.069






Table	   A.28	   –	   Baseline	   differences	   in	   whole	   blood	   cytokine	   response	   to	   GXM	   and	   CW	   between	  
survivors	   and	   non-­‐survivors	   by	  week	   12.	  Medians	   compared	  using	   rank-­‐sum	   tests.	  No	   adjustment	  
made	  for	  multiple	  comparisons	  
Cytokine stim n Median n Median p
VEGF GXM 24 63 42 81 16 53 39 69 0.408
IL@1b GXM 24 14 6 132 16 11 6 33 0.423
G@CSF GXM 24 100 91 123 16 98 82 107 0.281
IL@10 GXM 24 119 115 127 16 118 115 123 0.639
IFNa GXM 24 173 126 198 16 167 153 186 0.679
IL@6 GXM 24 1001 457 2771 16 618 436 1577 0.334
IL@12 GXM 24 146 122 165 16 136 116 144 0.204
CCL5 GXM 24 112130 108175 112130 16 112065 51947 112130 0.671
IL@15 GXM 24 606 560 758 16 590 554 644 0.189
CCL3 GXM 24 1473 473 9172 16 951 260 4214 0.214
CCL4 GXM 24 5705 3328 12470 16 3415 2627 7118 0.185
CCL2 GXM 24 35890 29603 46840 16 26553 22564 39713 0.053
IFNg GXM 24 33 32 63 16 34 31 39 0.240
TNFa GXM 24 31 16 248 16 22 14 77 0.448
IL#1RA GXM 24 3292 1905 4513 16 2181 1498 2968 0.050
IL7 GXM 24 130 104 155 16 121 88 155 0.423
CXCL10 GXM 24 21064 21039 21303 16 21055 21040 21112 0.740
IL@2R GXM 24 3471 3325 3624 16 3423 3345 3664 0.740
CXCL9 GXM 24 7628 7617 7793 16 7611 7541 7697 0.129
CXCL8 GXM 24 44353 30900 70602 16 41884 24095 73957 0.440
VEGF CW 24 73 42 79 16 53 41 75 0.235
IL@1b CW 24 22 7 301 16 8 6 152 0.258
G@CSF CW 24 103 87 169 16 112 100 175 0.543
IL@10 CW 24 119 115 139 16 116 115 161 0.751
IFNa CW 24 187 147 205 16 159 137 173 0.122
IL@6 CW 24 848 508 11983 16 540 384 11214 0.214
IL#12 CW 24 139 130 180 16 134 115 142 0.143
CCL5 CW 24 112130 109017 112130 16 112114 51134 112130 0.496
IL#15 CW 24 592 533 766 16 586 558 616 0.890
CCL3 CW 24 10456 342 18752 16 1120 480 10005 0.408
CCL4 CW 24 5018 2823 13288 16 3300 2346 5837 0.214
CCL2 CW 24 39963 26170 63876 16 30732 22734 44926 0.235
IFNg CW 24 33 32 49 16 34 32 38 0.553
TNFa CW 24 204 16 1786 16 30 15 831 0.423
IL@1RA CW 24 2444 1807 4194 16 2542 2005 2997 0.562
IL7 CW 24 141 97 196 16 119 88 178 0.246
CXCL10 CW 24 21050 21036 21150 16 21045 21042 21060 0.825
IL@2R CW 24 3578 3398 3815 16 3480 3374 3596 0.307
CXCL9 CW 24 7626 7586 7669 16 7603 7560 7620 0.068
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IICD	  Patient	  information	  and	  consent	  sheet	  
	  
Introduction	  
You	   are	   being	   invited	   to	   take	   part	   in	   a	   research	   study.	   Before	   you	   decide	   it	   is	  
important	   for	   you	   to	   understand	  why	   the	   research	   is	   being	   done	   and	  what	   it	  will	  
involve.	  Please	   take	   time	   to	   read	   the	   following	   information	  carefully	  and	  discuss	   it	  
with	  friends	  and	  relatives.	  	  Ask	  us	  if	  there	  is	  anything	  that	  is	  not	  clear	  or	  if	  you	  would	  
like	  more	  information.	  	  
	  
Why	  are	  you	  asking	  me?	  
Based	   on	   your	   current	   symptoms	   the	   doctors	   think	   you	   may	   have	   an	   infection	  
around	   the	  brain	   called	   cryptococcal	  meningitis	   .	   This	   is	   the	   condition	  we	  want	   to	  
study.	  
	  
What	  is	  cryptococcal	  meningitis?	  
Cryptococcal	  meningitis	  is	  an	  infection	  of	  the	  brain	  with	  the	  bug	  cryptococcus.	  It	  only	  
affects	   people	   who	   have	   a	   weakened	   immune	   system	   and	   causes	   a	   very	   severe	  
headache	  and	  drowsiness.	  This	  is	  a	  life	  threatening	  infection	  but	  is	  treatable	  with	  the	  
correct	   medicine.	   However,	   there	   are	   other	   causes	   of	   meningitis	   that	   require	   a	  
different	  medicine.	  The	  doctors	  need	  to	  know	  the	  type	  of	  infection	  you	  have	  in	  order	  
to	  give	  you	  the	  best	  medicine.	  For	  people	  with	  your	  symptoms	  the	  standard	  medical	  
procedure	  to	  find	  out	  what	  is	  causing	  the	  problem	  is	  a	  lumbar	  puncture.	  	  
	  
What	  is	  a	  lumbar	  puncture	  test?	  
The	   lumbar	   puncture	   (or	   LP)	   test	   is	   when	   the	   doctor	   puts	   a	   needle	   between	   the	  
bones	  in	  your	  lower	  back	  and	  takes	  a	  sample	  of	  the	  fluid	  that	  bathes	  the	  brain	  and	  
the	  spine	  (spinal	  fluid).	  This	  takes	  about	  20	  minutes.	  The	  spinal	  fluid	  is	  tested	  in	  the	  
laboratory	  to	  see	  if	  there	  are	  signs	  of	  infection.	  LPs	  are	  a	  very	  important	  test	  to	  do	  in	  
patients	  who	  might	  have	  meningitis	  and	  are	  part	  of	  the	  standard	  treatment.	  It	  helps	  
the	   doctors	   find	   out	   exactly	   what	   is	   wrong	   with	   you	   and	   can	   lower	   the	   pressure	  
inside	  the	  brain,	  making	  your	  headache	  better.	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Even	  if	  you	  do	  not	  want	  to	  be	  in	  the	  study,	  it	  is	  strongly	  recommended	  that	  you	  have	  
a	   lumbar	   puncture	   now.	   If	   your	   headache	   persists	   you	  may	   require	   further	   lumbar	  
punctures	  over	  the	  next	  few	  weeks.	  
	  
Are	  there	  any	  risks	  of	  having	  a	  lumbar	  puncture	  test?	  
Lumbar	   punctures	   (LPs)	   are	   a	   safe	   procedure,	   however	   they	   can	   be	   a	   bit	  
uncomfortable.	   You	   will	   feel	   a	   sharp	   pain	   in	   your	   back	   when	   they	   first	   start	   but	  
during	  the	  procedure	  you	  usually	  just	  feel	  pushing.	  Afterwards	  your	  back	  can	  be	  a	  bit	  
sore	  but	  often	  your	  headache	  is	  a	  lot	  better.	  There	  can	  be	  some	  bleeding	  afterwards,	  
and	  occasionally	  an	  infection	  can	  develop	  where	  the	  needle	  was	  placed.	  The	  doctor	  
will	  use	  sterilised	  equipment	  to	  reduce	  the	  risk	  of	  this	  happening.	  
	  
What	  is	  the	  Study	  and	  why	  is	  it	  being	  done?	  
The	  Innate	  Immunity	  in	  Cryptococcal	  Disease	  (IICD)	  study	  is	  a	  medical	  study	  designed	  
to	   examine	   the	  body’s	   responses	   to	   cryptococcal	  meningitis.	  We	  want	   to	   examine	  
whether	  differences	  in	  some	  people’s	  immune	  systems	  help	  them	  to	  recover	  faster	  
from	  cryptococcal	  meningitis	  than	  other	  people.	  By	  understanding	  more	  clearly	  how	  
the	  body	  fights	  cryptococcal	  disease	  we	  hope	  to	   improve	  the	  ways	  we	  can	  treat	   it,	  
and	  better	  predict	  those	  patients	  who	  may	  develop	  complications	  in	  the	  future	  
	  
What	  will	  happen	  if	  i	  agree	  to	  take	  part?	  
If	  you	  would	  like	  to	  be	  part	  of	  the	  study,	  and	  are	  happy	  that	  we	  have	  answered	  all	  
your	  questions,	  we	  will	  ask	  you	  to	  sign	  this	   informed	  consent	  form.	  The	  doctor	  will	  
examine	   you	   and	   record	   some	   of	   your	  medical	   details.	   You	  will	   have	   some	   blood	  
taken,	  and	  a	   lumbar	  puncture	   test	  will	  be	  performed.	  This	   lumbar	  puncture	   test	   is	  
part	  of	  the	  standard	  treatment	  of	  cryptococcal	  meningitis	  –	  to	  confirm	  the	  diagnosis,	  
and	   reduce	   the	  pressure	   in	  your	  head	   (by	  draining	  off	   some	  spinal	   fluid).	  The	   fluid	  
that	  is	  drained	  off	  is	  normally	  thrown	  away;	  we	  would	  like	  to	  use	  this	  for	  our	  study.	  
You	  will	  receive	  treatment	  for	  cryptococcal	  meningitis	  in	  hospital	  (daily	  injections	  for	  
14	  days).	  If	  the	  pressure	  inside	  your	  head	  becomes	  too	  high,	  we	  will	  need	  to	  do	  more	  
lumbar	   puncture	   tests	   to	   drain	   off	   the	   fluid.	   After	   the	   14-­‐day	   period	   we	   will	   do	  
another	   lumbar	  puncture	  to	  see	   if	   the	   infection	  has	  gone	  and	  the	  pressure	  back	  to	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normal.	  These	  extra	  lumbar	  puncture	  tests	  are	  all	  part	  of	  the	  standard	  treatment	  for	  
cryptococcal	  meningitis.	  If	  you	  do	  have	  these	  extra	  LPs	  performed	  we	  would	  like	  to	  
ask	  your	  permission	  to	  store	  some	  of	  this	  spinal	   fluid	  to	  do	  study	   investigations	  on	  
too.	  Very	  occasionally,	  patients	  require	  operations	  whilst	  in	  hospital.	  If	  you	  do	  have	  
an	  operation	  and	  the	  doctors	  take	  any	  tissue	  samples,	  we	  would	  like	  to	  store	  these	  
and	  do	  some	  tests	  on	  them	  too.	  	  
	  
What	  will	  happen	  to	  my	  samples?	  
We	  will	  send	  the	  samples	  to	  our	  laboratory	  in	  the	  University	  of	  Cape	  Town,	  and	  will	  
test	  how	  strongly	  your	  body	   is	   fighting	   the	   infection.	   If	  you	  give	  us	  permission,	  we	  
will	   store	  excess	   fluid	   in	   the	   lab	   for	   further	   tests.	  We	  will	  not	   sell	  any	  samples	  but	  
may	  share	  them	  will	  other	  universities	  or	  institutions	  for	  further	  testing.	  This	  may	  be	  
in	  South	  Africa,	  or	  overseas	  (UK	  or	  USA).	  	  
	  
Who	  will	  see	  the	  information	  that	  is	  collected?	  
The	   personal	   information	   that	  we	   collect	   from	   this	   study	  will	   only	   be	   seen	   by	   the	  
study	  doctors.	  When	  we	  send	  samples	  to	  the	  lab	  we	  put	  a	  number	  on	  the	  sample	  not	  
your	   name.	   Your	   personal	   information	   or	   identity	   will	   not	   be	   disclosed	   in	   any	  
published	  reports	  or	  presentations.	  	  
	  
What	  happens	  after	  I	  go	  home?	  
After	  your	  hospital	  treatment	  is	  finished	  you	  will	  go	  home	  but	  will	  still	  need	  to	  take	  
tablets	  to	  stop	  the	  infection	  coming	  back.	  You	  will	  need	  to	  be	  seen	  regularly	   in	  the	  
clinic	  to	  make	  sure	  you	  are	  OK.	  This	  will	  mainly	  be	  a	  local	  clinic	  but	  we	  may	  also	  ask	  
you	  to	  also	  come	  to	  our	  clinic	  here	  in	  the	  hospital.	  If	  you	  come	  to	  our	  clinic	  we	  may	  
ask	  you	  if	  we	  can	  perform	  blood	  tests	  for	  the	  purpose	  of	  the	  study.	  We	  also	  request	  
permission	  to	  contact	  your	  clinic,	  or	  yourself	  directly,	  to	  enquire	  about	  your	  state	  of	  
health	   for	   the	  6	  months	  after	  your	  hospital	   admission.	   If	   you	  become	  unwell	   after	  
you	  have	  gone	  home	  you	  must	  contact	  us	  directly	  or	  come	  back	  to	  hospital.	  We	  will	  
assess	  you	  in	  clinic	  or	  the	  ward,	  we	  may	  need	  to	  repeat	  the	  lumbar	  puncture	  test	  to	  
make	  sure	  the	  cryptococcus	  is	  not	  back.	  If	  we	  have	  extra	  spinal	  fluid	  after	  these	  tests	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have	  been	  performed,	  we	  would	   like	  your	  permission	  to	  store	  this	  and	  use	  this	   for	  
research	  projects.	  	  
	  
Will	  I	  receive	  any	  payment	  for	  being	  in	  the	  study?	  
We	  do	  not	  pay	  people	  to	  be	  in	  the	  study,	  however	  we	  will	  give	  you	  some	  money	  to	  
cover	  your	  travel	  expenses	  if	  you	  have	  to	  come	  to	  see	  us	  in	  clinic	  (R50).	  
	  
What	  are	  the	  benefits	  of	  being	  involved?	  
There	  are	  no	  direct	  benefits	  for	  you	  being	  involved	  in	  this	  study	  but	  we	  hope	  that	  the	  
findings	   from	   this	   study	   will	   help	   improve	   the	   treatment	   of	   other	   people	   with	  
cryptococcal	  meningitis	  in	  the	  future.	  	  	  
	  
Will	  I	  get	  my	  results?	  
Any	   information	   relevant	   to	   your	   care	   will	   be	   shared	   with	   you	   and	   your	   doctors.	  
Other	  results	  will	  be	  collected	  along	  with	  those	  of	  other	  patients	  and	  published	  as	  a	  
report	   in	   a	  medical	   journal.	   If	   you	  would	   like	   a	   copy	   of	   this	  we	   can	   give	   it	   to	   you	  
when	   it	   is	  published.	  Alternatively	   if	  you	  would	  prefer,	  one	  of	  the	  study	  doctors	  or	  
nurses	  can	  explain	  the	  findings	  to	  you	  later.	  
	  
Are	  there	  any	  risks	  of	  being	  involved?	  
There	   are	   no	   significant	   additional	   risks	   of	   being	   involved	   in	   this	   study	   as	   the	  
treatment	   you	   receive	   and	   procedures	   you	   undergo	   are	   all	   part	   of	   the	   normal	  
treatment.	  Even	  if	  you	  are	  not	   in	  the	  trial	  you	  will	  require	  regular	   lumbar	  puncture	  
tests.	  The	  main	  difference	  of	  being	  in	  the	  study	  is	  that	  you	  have	  to	  come	  back	  to	  the	  
hospital	   more	   frequently	   over	   the	   next	   6	  months	   and	   will	   have	   extra	   blood	   tests	  
during	  this	  time.	  However,	  this	  means	  the	  doctors	  will	  be	  able	  to	  keep	  a	  closer	  eye	  
on	  you.	  	  
	  
What	  if	  Something	  Goes	  Wrong?	  
The	  University	  of	  Cape	  Town	  (UCT)	  undertakes	  that	  in	  the	  event	  of	  you	  suffering	  any	  
significant	  deterioration	   in	  health	  or	  well-­‐being,	  or	  from	  any	  unexpected	  sensitivity	  
or	  toxicity,	  that	  is	  caused	  by	  your	  participation	  in	  the	  study,	  it	  will	  provide	  immediate	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medical	   care.	  UCT	  has	   appropriate	   insurance	   cover	   to	  provide	  prompt	  payment	  of	  
compensation	  for	  any	  trial-­‐related	  injury.	  An	  injury	  is	  considered	  trial-­‐related	  if,	  and	  
to	  the	  extent	  that,	  it	   is	  caused	  by	  study	  activities.	  You	  must	  notify	  the	  study	  doctor	  
immediately	   of	   any	   side	   effects	   and/or	   injuries	   during	   the	   trial,	   whether	   they	   are	  
research-­‐related	  or	  other	  related	  complications.	  
	  
`	  
Do	  I	  have	  to	  be	  involved?	  
No.	  You	  are	  under	  no	  obligation	  to	  be	  involved	  in	  this	  study.	  If	  you	  decide	  not	  to	  be	  
involved	   in	   the	   study	   you	   will	   still	   be	   cared	   for	   by	   the	   doctors	   here	   at	   GF	   Jooste	  
hospital.	  They	  will	  still	  do	  blood	  tests	  and	  lumbar	  punctures	  and	  you	  will	  receive	  the	  
same	  treatment.	  	  
	  
What	  if	  i	  change	  my	  mind?	  
If	  you	  do	  agree	  to	  take	  part	  in	  the	  study	  you	  are	  still	  allowed	  to	  change	  your	  mind	  at	  
any	  time	  and	  withdraw	  from	  the	  study.	  You	  do	  not	  have	  to	  tell	  us	  why,	  and	  it	  will	  not	  
affect	  your	  treatment.	  
	  
Who	  do	  I	  speak	  to	  if	  I	  have	  any	  questions?	  
If	  you	  have	  any	  further	  questions	  you	  can	  speak	  to	  the	  study	  counsellor,	  study	  nurse	  
or	  any	  of	  the	  study	  team.	  
	  
Doctors:	  	   James	  Scriven	  (0736	  842563)	  
Charlotte	  Schutz	  	  
Graeme	  Meintjes	  (021	  406	  6797)	  
Friedrich	  Thienemann	  
	  
Study	  nurse:	   Brian	  Memela	  (0732051899)	  
	  
Counsellor:	   Monica	  Magwayi	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Please	   circle	   “Yes”	   or	   “No”	   to	   confirm	   that	   you	   agree	   or	   do	   not	   agree	  with	   the	  
statements	  below	  
I	  have	  read	  the	  patient	  information	  sheet	  	   Yes	   No	  
I	  have	  had	  the	  chance	  to	  ask	  questions	  and	  I	  am	  satisfied	  by	  the	  
answers	  
Yes	   No	  
I	  agree	  to	  take	  part	  in	  the	  study	  but	  understand	  I	  can	  change	  my	  
mind	  at	  any	  time	  
Yes	   No	  
I	  agree	  that	  my	  personal	  information,	  blood,	  and	  spinal	  fluid	  can	  
be	  stored	  and	  used	  for	  the	  purpose	  of	  this	  study	  
Yes	   No	  
I	  agree	  that	   if	   I	  have	  an	  operation	  any	  tissue	  samples	  taken	  can	  
also	  be	  used	  for	  the	  purpose	  of	  this	  study	  
Yes	   No	  
I	  agree	   that	  any	  of	  my	  samples	  may	  be	  stored	   for	  use	   in	   future	  
research	  projects	  related	  to	  cryptococcal	  disease	  
Yes	   No	  
	  
Name	  of	  participant	  
	  
Signature	  	   Date	  
	   	  
	  
Name	  of	  family	  representative	  (if	  patient	  unable	  to	  give	  consent	  as	  too	  drowsy)	  
	  
Signature	  	   Date	  
	   	  
	  
Member	  of	  study	  team	  taking	  consent	  
	  
Signature	  	   Date	  




IICD	  contorls	  -­‐	  information	  sheet	  
	  
Introduction	  
You	   are	   being	   invited	   to	   take	   part	   in	   a	   research	   study.	   Before	   you	   decide	   it	   is	  
important	   for	   you	   to	   understand	  why	   the	   research	   is	   being	   done	   and	  what	   it	  will	  
involve.	  Please	   take	   time	   to	   read	   the	   following	   information	  carefully	  and	  discuss	   it	  
with	  friends	  and	  relatives.	  	  Ask	  us	  if	  there	  is	  anything	  that	  is	  not	  clear	  or	  if	  you	  would	  
like	  more	  information.	  	  
	  
What	  is	  the	  Study	  and	  why	  is	  it	  being	  done?	  
Innate	   Immunity	   in	   Cryptococcal	   Disease	   (IICD)	   is	   a	   medical	   study	   designed	   to	  
examine	  how	  the	  body’s	   immune	  system	  reacts	   to	  an	   infection	  called	  cryptococcal	  
meningitis.	   It	   is	   a	   study	  mainly	  based	   in	  GF	   Jooste,	  Khayelitsha	  and	  Mitchells	  Plain	  
hospitals.	  
	  
Why	  are	  you	  asking	  me?	  
To	  understand	  how	  a	  person’s	  immune	  system	  responds	  to	  cryptococcal	  meningitis	  
we	  need	  to	  examine	  the	  immune	  response	  in	  people	  who	  do	  not	  have	  the	  infection.	  
This	  is	  why	  we	  are	  asking	  you.	  	  
	  
	  
What	  will	  happen	  if	  i	  agree	  to	  take	  part?	  
If	  you	  would	  like	  to	  be	  part	  of	  the	  study,	  and	  are	  happy	  that	  we	  have	  answered	  all	  
your	  questions,	  we	  will	  ask	  you	  to	  sign	  this	  informed	  consent	  form	  and	  complete	  the	  
symptom	  questionnaire.	  You	  will	  have	  blood	  taken	  (30mls)	  and	  be	  asked	  to	  supply	  a	  
sputum	   sample	   -­‐	   this	   is	   so	   we	   can	   check	   you	   definitely	   do	   not	   have	   cryptococcal	  
infection	  or	  TB.	  To	  help	  us	  understand	  the	  results	  better	  we	  also	  need	  to	  know	  your	  
HIV	  status.	  If	  you	  have	  not	  had	  an	  HIV	  test	  in	  the	  last	  month	  we	  will	  ask	  you	  to	  visit	  




What	  will	  happen	  to	  my	  samples?	  
We	  will	  send	  the	  samples	  to	  our	  laboratory	  in	  the	  University	  of	  Cape	  Town,	  and	  will	  
measure	  how	  strong	  your	  immune	  system	  is.	  If	  you	  give	  us	  permission,	  we	  will	  store	  
excess	  fluid	  in	  the	  lab	  for	  further	  tests.	  We	  will	  not	  sell	  any	  samples	  but	  may	  share	  
them	  will	  other	  universities	  or	   institutions	  for	  further	  testing.	  This	  may	  be	   in	  South	  
Africa,	  or	  overseas	  (UK	  or	  USA).	  	  
	  
Who	  will	  see	  the	  information	  that	  is	  collected?	  
The	   information	   that	   we	   collect	   from	   this	   study	   will	   only	   be	   seen	   by	   the	   study	  
doctors.	  When	  we	  send	  samples	  to	  the	  lab	  we	  put	  a	  number	  on	  the	  sample	  not	  your	  
name.	  Your	  personal	   information	  or	   identity	  will	  not	  be	  disclosed	   in	  any	  published	  
reports	  or	  presentations.	  	  
	  
What	  are	  the	  benefits	  of	  being	  involved?	  
There	  are	  no	  direct	  benefits	  for	  you	  being	  involved	  in	  this	  study	  but	  we	  hope	  that	  the	  
findings	  from	  this	  study	  will	  help	  improve	  the	  treatment	  of	  people	  with	  cryptococcal	  
meningitis	  in	  the	  future.	  	  	  
	  
Are	  there	  any	  risks	  of	  being	  involved?	  
There	  are	  no	  significant	  additional	  risks	  of	  being	  involved	  in	  this	  study	  apart	  from	  the	  
pain	  of	  having	  blood	  taken.	  The	  amount	  of	  blood	  taken	  is	  not	  large.	  	  	  
	  
What	  if	  Something	  Goes	  Wrong?	  
The	  University	  of	  Cape	  Town	  (UCT)	  undertakes	  that	  in	  the	  event	  of	  you	  suffering	  any	  
significant	  deterioration	   in	  health	  or	  well-­‐being,	  or	  from	  any	  unexpected	  sensitivity	  
or	  toxicity,	  that	  is	  caused	  by	  your	  participation	  in	  the	  study,	  it	  will	  provide	  immediate	  
medical	   care.	  UCT	  has	   appropriate	   insurance	   cover	   to	  provide	  prompt	  payment	  of	  
compensation	  for	  any	  trial-­‐related	  injury.	  An	  injury	  is	  considered	  trial-­‐related	  if,	  and	  
to	  the	  extent	  that,	  it	   is	  caused	  by	  study	  activities.	  You	  must	  notify	  the	  study	  doctor	  
immediately	   of	   any	   side	   effects	   and/or	   injuries	   during	   the	   trial,	   whether	   they	   are	  




If	  you	  have	  any	  further	  questions	  you	  can	  speak	  to	  the	  study	  counsellor,	  study	  nurse	  
or	  any	  of	  the	  study	  team.	  
	  
Doctors:	  	   James	  Scriven	  (0736	  842563)	  
Charlotte	  Schutz	  	  
Graeme	  Meintjes	  (021	  406	  6797)	  
	  
Counsellor:	   Monica	  Magwayi	  
	  
Study	  nurse:	   Yolisa	  Sigila	  (0790901009)	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Please	   circle	   “Yes”	   or	   “No”	   to	   confirm	   that	   you	   agree	   or	   do	   not	   agree	   with	   the	  
statements	  below	  
I	  have	  read	  the	  patient	  information	  sheet	  	   Yes	   No	  
I	  have	  had	  the	  chance	  to	  ask	  questions	  and	  I	  am	  satisfied	  by	  the	  
answers	  
Yes	   No	  
I	  agree	  to	  take	  part	  in	  the	  study	  but	  understand	  I	  can	  change	  my	  
mind	  at	  any	  time	  
Yes	   No	  
I	   agree	   that	  my	   personal	   information	   and	   blood	   can	   be	   stored	  
and	  used	  for	  the	  purpose	  of	  this	  study	  
Yes	   No	  
I	  agree	   that	  any	  of	  my	  samples	  may	  be	  stored	   for	  use	   in	   future	  
research	  projects	  	  
Yes	   No	  
	  
	  
Name	  of	  participant	  
	  
Signature	  	   Date	  
	   	  
	  
	  
Member	  of	  study	  team	  taking	  consent	  
	  
Signature	  	   Date	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Consent	  for	  post	  mortem	  
	  
Figure	  B.1	  –	  Consent	  for	  post-­‐mortem	  examination	  (part	  1)	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Figure	  B.2	  –	  Consent	  for	  post-­‐mortem	  examination	  (part	  2)	  
